Microinjection	O
of	O
ritanserin	B-ChemicalEntity
into	O
the	O
CA1	O
region	O
of	O
hippocampus	O
improves	O
scopolamine	B-ChemicalEntity
-	O
induced	O
amnesia	B-DiseaseOrPhenotypicFeature
in	O
adult	O
male	O
rats	B-OrganismTaxon
.	O

The	O
effect	O
of	O
ritanserin	B-ChemicalEntity
(	O
5	B-GeneOrGeneProduct
-	O
HT2	I-GeneOrGeneProduct
antagonist	O
)	O
on	O
scopolamine	B-ChemicalEntity
(	O
muscarinic	B-GeneOrGeneProduct
cholinergic	I-GeneOrGeneProduct
antagonist	O
)	O
-	O
induced	O
amnesia	B-DiseaseOrPhenotypicFeature
in	O
Morris	O
water	O
maze	O
(	O
MWM	O
)	O
was	O
investigated	O
.	O

Rats	B-OrganismTaxon
were	O
divided	O
into	O
eight	O
groups	O
and	O
bilaterally	O
cannulated	O
into	O
CA1	O
region	O
of	O
the	O
hippocampus	O
.	O

One	O
week	O
later	O
,	O
they	O
received	O
repeatedly	O
vehicles	O
(	O
saline	O
,	O
DMSO	B-ChemicalEntity
,	O
saline	O
+	O
DMSO	B-ChemicalEntity
)	O
,	O
scopolamine	B-ChemicalEntity
(	O
2	O
microg	O
/	O
0	O
.	O
5	O
microl	O
saline	O
/	O
side	O
;	O
30	O
min	O
before	O
training	O
)	O
,	O
ritanserin	B-ChemicalEntity
(	O
2	O
,	O
4	O
and	O
8	O
microg	O
/	O
0	O
.	O
5	O
microl	O
DMSO	B-ChemicalEntity
/	O
side	O
;	O
20	O
min	O
before	O
training	O
)	O
and	O
scopolamine	B-ChemicalEntity
(	O
2	O
microg	O
/	O
0	O
.	O
5	O
microl	O
;	O
30	O
min	O
before	O
ritanserin	B-ChemicalEntity
injection	O
)	O
+	O
ritanserin	B-ChemicalEntity
(	O
4	O
microg	O
/	O
0	O
.	O
5	O
microl	O
DMSO	B-ChemicalEntity
)	O
through	O
cannulae	O
each	O
day	O
.	O

Animals	O
were	O
tested	O
for	O
four	O
consecutive	O
days	O
(	O
4	O
trial	O
/	O
day	O
)	O
in	O
MWM	O
during	O
which	O
the	O
position	O
of	O
hidden	O
platform	O
was	O
unchanged	O
.	O

In	O
the	O
fifth	O
day	O
,	O
the	O
platform	O
was	O
elevated	O
above	O
the	O
water	O
surface	O
in	O
another	O
position	O
to	O
evaluate	O
the	O
function	O
of	O
motor	O
,	O
motivational	O
and	O
visual	O
systems	O
.	O

The	O
results	O
showed	O
a	O
significant	O
increase	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
to	O
find	O
platform	O
in	O
scopolamine	B-ChemicalEntity
-	O
treated	O
group	O
as	O
compared	O
to	O
saline	O
group	O
.	O

Ritanserin	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
(	O
4	O
microg	O
/	O
0	O
.	O
5	O
microl	O
/	O
side	O
)	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
mentioned	O
parameters	O
as	O
compared	O
to	O
DMSO	B-ChemicalEntity
-	O
treated	O
group	O
.	O

However	O
,	O
scopolamine	B-ChemicalEntity
and	O
ritanserin	B-ChemicalEntity
co	O
-	O
administration	O
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
escape	O
latencies	O
and	O
traveled	O
distances	O
as	O
compared	O
to	O
the	O
scopolamine	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
.	O

Our	O
findings	O
show	O
that	O
microinjection	O
of	O
ritanserin	B-ChemicalEntity
into	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
improves	O
the	O
scopolamine	B-ChemicalEntity
-	O
induced	O
amnesia	B-DiseaseOrPhenotypicFeature
.	O
P2RX7	B-GeneOrGeneProduct
:	O
A	O
bipolar	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
unipolar	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
candidate	O
susceptibility	O
gene?	O
The	O
chromosomal	O
region	O
12q24	O
has	O
been	O
previously	O
implicated	O
by	O
linkage	O
studies	O
of	O
both	O
bipolar	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
and	O
unipolar	B-DiseaseOrPhenotypicFeature
mood	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
and	O
we	O
have	O
reported	O
two	O
pedigrees	O
segregating	O
both	O
bipolar	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
and	O
Darier	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
that	O
show	O
linkage	O
across	O
this	O
region	O
.	O

The	O
gene	O
P2RX7	B-GeneOrGeneProduct
is	O
located	O
in	O
this	O
chromosomal	O
region	O
and	O
has	O
been	O
recently	O
reported	O
as	O
a	O
susceptibility	O
gene	O
for	O
bipolar	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
and	O
unipolar	B-DiseaseOrPhenotypicFeature
depression	I-DiseaseOrPhenotypicFeature
.	O

The	O
non	O
-	O
synonymous	O
SNP	O
rs2230912	B-SequenceVariant
(	O
resulting	O
in	O
amino	O
-	O
acid	O
polymorphism	O
Q460R	B-SequenceVariant
)	O
showed	O
the	O
strongest	O
association	O
and	O
has	O
been	O
postulated	O
to	O
be	O
pathogenically	O
relevant	O
.	O

We	O
have	O
investigated	O
this	O
gene	O
in	O
a	O
large	O
UK	O
case	O
-	O
control	O
sample	O
(	O
bipolar	B-DiseaseOrPhenotypicFeature
I	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
N	O
=	O
687	O
,	O
unipolar	B-DiseaseOrPhenotypicFeature
recurrent	I-DiseaseOrPhenotypicFeature
major	I-DiseaseOrPhenotypicFeature
depression	I-DiseaseOrPhenotypicFeature
N	O
=	O
1	O
,	O
036	O
,	O
controls	O
N	O
=	O
1	O
,	O
204	O
)	O
.	O

Neither	O
rs2230912	B-SequenceVariant
nor	O
any	O
of	O
8	O
other	O
SNPs	O
genotyped	O
across	O
P2RX7	B-GeneOrGeneProduct
was	O
found	O
to	O
be	O
associated	O
with	O
mood	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
in	O
general	O
,	O
nor	O
specifically	O
with	O
bipolar	B-DiseaseOrPhenotypicFeature
or	I-DiseaseOrPhenotypicFeature
unipolar	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
.	O

Further	O
,	O
sequencing	O
of	O
our	O
two	O
chromosome	O
12	O
-	O
linked	O
bipolar	O
-	O
Darier	O
families	O
showed	O
no	O
evidence	O
of	O
rare	O
variants	O
at	O
P2RX7	B-GeneOrGeneProduct
that	O
could	O
explain	O
the	O
linkage	O
.	O

Our	O
data	O
do	O
not	O
provide	O
support	O
for	O
rs2230912	B-SequenceVariant
or	O
the	O
other	O
polymorphisms	O
studied	O
within	O
the	O
P2RX7	B-GeneOrGeneProduct
locus	O
,	O
being	O
involved	O
in	O
susceptibility	O
to	O
mood	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
.	O
Pilocarpine	B-ChemicalEntity
seizures	B-DiseaseOrPhenotypicFeature
cause	O
age	O
-	O
dependent	O
impairment	B-DiseaseOrPhenotypicFeature
in	I-DiseaseOrPhenotypicFeature
auditory	I-DiseaseOrPhenotypicFeature
location	I-DiseaseOrPhenotypicFeature
discrimination	I-DiseaseOrPhenotypicFeature
.	O

Children	O
who	O
have	O
status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
have	O
continuous	O
or	O
rapidly	O
repeating	O
seizures	B-DiseaseOrPhenotypicFeature
that	O
may	O
be	O
life	O
-	O
threatening	O
and	O
may	O
cause	O
life	O
-	O
long	O
changes	O
in	O
brain	O
and	O
behavior	O
.	O

The	O
extent	O
to	O
which	O
status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
causes	O
deficits	B-DiseaseOrPhenotypicFeature
in	I-DiseaseOrPhenotypicFeature
auditory	I-DiseaseOrPhenotypicFeature
discrimination	I-DiseaseOrPhenotypicFeature
is	O
unknown	O
.	O

A	O
naturalistic	O
auditory	O
location	O
discrimination	O
method	O
was	O
used	O
to	O
evaluate	O
this	O
question	O
using	O
an	O
animal	O
model	O
of	O
status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	B-OrganismTaxon
were	O
injected	O
with	O
saline	O
on	O
postnatal	O
day	O
(	O
P	O
)	O
20	O
,	O
or	O
a	O
convulsant	O
dose	O
of	O
pilocarpine	B-ChemicalEntity
on	O
P20	O
or	O
P45	O
.	O

Pilocarpine	B-ChemicalEntity
on	O
either	O
day	O
induced	O
status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
;	O
status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
at	O
P45	O
resulted	O
in	O
CA3	B-CellLine
cell	O
loss	O
and	O
spontaneous	O
seizures	B-DiseaseOrPhenotypicFeature
,	O
whereas	O
P20	O
rats	B-OrganismTaxon
had	O
no	O
cell	O
loss	O
or	O
spontaneous	O
seizures	B-DiseaseOrPhenotypicFeature
.	O

Mature	O
rats	B-OrganismTaxon
were	O
trained	O
with	O
sound	O
-	O
source	O
location	O
and	O
sound	O
-	O
silence	O
discriminations	O
.	O

Control	O
(	O
saline	O
P20	O
)	O
rats	B-OrganismTaxon
acquired	O
both	O
discriminations	O
immediately	O
.	O

In	O
status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
(	O
P20	O
)	O
rats	B-OrganismTaxon
,	O
acquisition	O
of	O
the	O
sound	O
-	O
source	O
location	O
discrimination	O
was	O
moderately	O
impaired	O
.	O

Status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
(	O
P45	O
)	O
rats	B-OrganismTaxon
failed	O
to	O
acquire	O
either	O
sound	O
-	O
source	O
location	O
or	O
sound	O
-	O
silence	O
discriminations	O
.	O

Status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
in	O
rat	B-OrganismTaxon
causes	O
an	O
age	O
-	O
dependent	O
,	O
long	O
-	O
term	O
impairment	B-DiseaseOrPhenotypicFeature
in	I-DiseaseOrPhenotypicFeature
auditory	I-DiseaseOrPhenotypicFeature
discrimination	I-DiseaseOrPhenotypicFeature
.	O

This	O
impairment	O
may	O
explain	O
one	O
cause	O
of	O
impaired	B-DiseaseOrPhenotypicFeature
auditory	I-DiseaseOrPhenotypicFeature
location	I-DiseaseOrPhenotypicFeature
discrimination	I-DiseaseOrPhenotypicFeature
in	O
humans	B-OrganismTaxon
.	O
The	O
first	O
founder	O
DGUOK	B-GeneOrGeneProduct
mutation	O
associated	O
with	O
hepatocerebral	B-DiseaseOrPhenotypicFeature
mitochondrial	I-DiseaseOrPhenotypicFeature
DNA	I-DiseaseOrPhenotypicFeature
depletion	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Deoxyguanosine	B-DiseaseOrPhenotypicFeature
kinase	I-DiseaseOrPhenotypicFeature
(	O
dGK	I-DiseaseOrPhenotypicFeature
)	O
deficiency	I-DiseaseOrPhenotypicFeature
is	O
a	O
frequent	O
cause	O
of	O
mitochondrial	B-DiseaseOrPhenotypicFeature
DNA	I-DiseaseOrPhenotypicFeature
depletion	I-DiseaseOrPhenotypicFeature
associated	O
with	O
a	O
hepatocerebral	O
phenotype	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
splice	O
site	O
mutation	O
in	O
the	O
DGUOK	B-GeneOrGeneProduct
gene	O
and	O
the	O
clinical	O
,	O
radiologic	O
,	O
and	O
genetic	O
features	O
of	O
these	O
DGUOK	B-GeneOrGeneProduct
patients	B-OrganismTaxon
.	O

This	O
new	O
DGUOK	B-GeneOrGeneProduct
homozygous	O
mutation	O
(	O
c	B-SequenceVariant
.	O
444	I-SequenceVariant
-	O
62C	I-SequenceVariant
>	O
A	I-SequenceVariant
)	O
was	O
identified	O
in	O
three	O
patients	B-OrganismTaxon
from	O
two	O
North	O
-	O
African	O
consanguineous	O
families	O
with	O
combined	O
respiratory	B-DiseaseOrPhenotypicFeature
chain	I-DiseaseOrPhenotypicFeature
deficiencies	I-DiseaseOrPhenotypicFeature
and	O
mitochondrial	B-DiseaseOrPhenotypicFeature
DNA	I-DiseaseOrPhenotypicFeature
depletion	I-DiseaseOrPhenotypicFeature
in	O
the	O
liver	O
.	O

Brain	O
MRIs	O
are	O
normal	O
in	O
DGUOK	B-GeneOrGeneProduct
patients	B-OrganismTaxon
in	O
the	O
literature	O
.	O

Interestingly	O
,	O
we	O
found	O
subtentorial	B-DiseaseOrPhenotypicFeature
abnormal	I-DiseaseOrPhenotypicFeature
myelination	I-DiseaseOrPhenotypicFeature
and	O
moderate	B-DiseaseOrPhenotypicFeature
hyperintensity	I-DiseaseOrPhenotypicFeature
in	O
the	O
bilateral	O
pallidi	O
in	O
our	O
patients	B-OrganismTaxon
.	O

This	O
new	O
mutation	O
creates	O
a	O
cryptic	O
splice	O
site	O
in	O
intron	O
3	O
(	O
in	O
position	O
-	O
62	O
)	O
and	O
is	O
predicted	O
to	O
result	O
in	O
a	O
larger	O
protein	O
with	O
an	O
in	O
-	O
frame	O
insertion	O
of	O
20	O
amino	O
acids	O
.	O

In	O
silico	O
analysis	O
of	O
the	O
putative	O
impact	O
of	O
the	O
insertion	O
shows	O
serious	O
clashes	O
in	O
protein	O
conformation	O
:	O
this	O
insertion	O
disrupts	O
the	O
alpha5	O
helix	O
of	O
the	O
dGK	B-GeneOrGeneProduct
kinase	O
domain	O
,	O
rendering	O
the	O
protein	O
unable	O
to	O
bind	O
purine	O
deoxyribonucleosides	B-ChemicalEntity
.	O

In	O
addition	O
,	O
a	O
common	O
haplotype	O
that	O
segregated	O
with	O
the	O
disease	O
in	O
both	O
families	O
was	O
detected	O
by	O
haplotype	O
reconstruction	O
with	O
10	O
markers	O
(	O
microsatellites	O
and	O
SNPs	O
)	O
,	O
which	O
span	O
4	O
.	O
6	O
Mb	O
of	O
DNA	O
covering	O
the	O
DGUOK	B-GeneOrGeneProduct
locus	O
.	O

In	O
conclusion	O
,	O
we	O
report	O
a	O
new	O
DGUOK	B-GeneOrGeneProduct
splice	O
site	O
mutation	O
that	O
provide	O
insight	O
into	O
a	O
critical	O
protein	O
domain	O
(	O
dGK	B-GeneOrGeneProduct
kinase	O
domain	O
)	O
and	O
the	O
first	O
founder	O
mutation	O
in	O
a	O
North	O
-	O
African	O
population	O
.	O
Atypical	O
GH	B-DiseaseOrPhenotypicFeature
insensitivity	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
and	O
severe	O
insulin	B-DiseaseOrPhenotypicFeature
-	O
like	I-DiseaseOrPhenotypicFeature
growth	I-DiseaseOrPhenotypicFeature
factor	I-DiseaseOrPhenotypicFeature
-	O
I	I-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
resulting	O
from	O
compound	O
heterozygous	O
mutations	O
of	O
the	O
GH	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
,	O
including	O
a	O
novel	O
frameshift	O
mutation	O
affecting	O
the	O
intracellular	O
domain	O
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
GH	B-DiseaseOrPhenotypicFeature
insensitivity	I-DiseaseOrPhenotypicFeature
and	O
IGF	B-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
may	O
result	O
from	O
aberrations	O
of	O
the	O
GH	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
GHR	B-GeneOrGeneProduct
)	O
.	O

We	O
describe	O
a	O
4	O
-	O
year	O
-	O
old	O
child	O
with	O
modest	O
growth	B-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
and	O
normal	O
serum	O
concentrations	O
of	O
GH	B-GeneOrGeneProduct
-	O
binding	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
GHBP	B-GeneOrGeneProduct
)	O
,	O
but	O
clinical	O
evidence	O
of	O
GH	B-DiseaseOrPhenotypicFeature
insensitivity	I-DiseaseOrPhenotypicFeature
.	O

METHOD	O
:	O
Serum	O
and	O
DNA	O
samples	O
from	O
the	O
proband	O
and	O
his	O
parents	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
The	O
child	O
had	O
a	O
height	O
of	O
-	O
4	O
SD	O
,	O
elevated	O
serum	O
GH	B-GeneOrGeneProduct
concentrations	O
,	O
abnormally	O
low	O
serum	O
IGF	B-GeneOrGeneProduct
-	O
I	I-GeneOrGeneProduct
and	O
IGFBP	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
concentrations	O
and	O
normal	O
GHBP	B-GeneOrGeneProduct
concentrations	O
.	O

DNA	O
analysis	O
revealed	O
compound	O
heterozygosity	O
for	O
mutations	O
of	O
GHR	B-GeneOrGeneProduct
,	O
including	O
a	O
previously	O
reported	O
R211H	B-SequenceVariant
mutation	O
and	O
a	O
novel	O
duplication	O
of	O
a	O
nucleotide	O
in	O
exon	O
9	O
(	O
899dupC	B-SequenceVariant
)	O
,	O
the	O
latter	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
stop	O
codon	O
.	O

Treatment	O
with	O
recombinant	O
DNA	O
-	O
derived	O
IGF	B-GeneOrGeneProduct
-	O
I	I-GeneOrGeneProduct
resulted	O
in	O
growth	O
acceleration	O
.	O

CONCLUSION	O
:	O
Mutations	O
affecting	O
the	O
intracellular	O
domain	O
of	O
the	O
GHR	B-GeneOrGeneProduct
can	O
result	O
in	O
GH	B-DiseaseOrPhenotypicFeature
insensitivity	I-DiseaseOrPhenotypicFeature
and	O
IGF	B-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
,	O
despite	O
normal	O
serum	O
concentrations	O
of	O
GHBP	B-GeneOrGeneProduct
.	O

The	O
presence	O
of	O
clinical	O
and	O
biochemical	O
evidence	O
of	O
GH	B-GeneOrGeneProduct
resistance	O
is	O
sufficient	O
to	O
consider	O
the	O
possibility	O
of	O
aberrations	O
of	O
the	O
GHR	B-GeneOrGeneProduct
,	O
even	O
in	O
the	O
presence	O
of	O
normal	O
serum	O
GHBP	B-GeneOrGeneProduct
concentrations	O
.	O
Safety	O
of	O
capecitabine	B-ChemicalEntity
:	O
a	O
review	O
.	O

IMPORTANCE	O
OF	O
THE	O
FIELD	O
:	O
Fluoropyrimidines	B-ChemicalEntity
,	O
in	O
particular	O
5	B-ChemicalEntity
-	O
fluorouracil	I-ChemicalEntity
(	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
)	O
,	O
have	O
been	O
the	O
mainstay	O
of	O
treatment	O
for	O
several	O
solid	O
tumors	B-DiseaseOrPhenotypicFeature
,	O
including	O
colorectal	B-DiseaseOrPhenotypicFeature
,	O
breast	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
head	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
neck	I-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
,	O
for	O
>	O
40	O
years	O
.	O

AREAS	O
COVERED	O
IN	O
THIS	O
REVIEW	O
:	O
This	O
article	O
reviews	O
the	O
pharmacology	O
and	O
efficacy	O
of	O
capecitabine	B-ChemicalEntity
with	O
a	O
special	O
emphasis	O
on	O
its	O
safety	O
.	O

WHAT	O
THE	O
READER	O
WILL	O
GAIN	O
:	O
The	O
reader	O
will	O
gain	O
better	O
insight	O
into	O
the	O
safety	O
of	O
capecitabine	B-ChemicalEntity
in	O
special	O
populations	O
such	O
as	O
patients	B-OrganismTaxon
with	O
advanced	O
age	O
,	O
renal	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
kidney	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

We	O
also	O
explore	O
different	O
dosing	O
and	O
schedules	O
of	O
capecitabine	B-ChemicalEntity
administration	O
.	O

TAKE	O
HOME	O
MESSAGE	O
:	O
Capecitabine	B-ChemicalEntity
is	O
an	O
oral	O
prodrug	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
and	O
was	O
developed	O
to	O
fulfill	O
the	O
need	O
for	O
a	O
more	O
convenient	O
therapy	O
and	O
provide	O
an	O
improved	O
safety	O
/	O
efficacy	O
profile	O
.	O

It	O
has	O
shown	O
promising	O
results	O
alone	O
or	O
in	O
combination	O
with	O
other	O
chemotherapeutic	O
agents	O
in	O
colorectal	B-DiseaseOrPhenotypicFeature
,	O
breast	I-DiseaseOrPhenotypicFeature
,	O
pancreaticobiliary	I-DiseaseOrPhenotypicFeature
,	O
gastric	I-DiseaseOrPhenotypicFeature
,	O
renal	I-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
head	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
neck	I-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
.	O

The	O
most	O
commonly	O
reported	O
toxic	O
effects	O
of	O
capecitabine	B-ChemicalEntity
are	O
diarrhea	B-DiseaseOrPhenotypicFeature
,	O
nausea	B-DiseaseOrPhenotypicFeature
,	O
vomiting	B-DiseaseOrPhenotypicFeature
,	O
stomatitis	B-DiseaseOrPhenotypicFeature
and	O
hand	B-DiseaseOrPhenotypicFeature
-	O
foot	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Capecitabine	B-ChemicalEntity
has	O
a	O
well	O
-	O
established	O
safety	O
profile	O
and	O
can	O
be	O
given	O
safely	O
to	O
patients	B-OrganismTaxon
with	O
advanced	O
age	O
,	O
hepatic	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
dysfunctions	I-DiseaseOrPhenotypicFeature
.	O
Fluoxetine	B-ChemicalEntity
improves	O
the	O
memory	B-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
caused	O
by	O
the	O
chemotherapy	O
agent	O
5	B-ChemicalEntity
-	O
fluorouracil	I-ChemicalEntity
.	O

Cancer	B-DiseaseOrPhenotypicFeature
patients	O
who	O
have	O
been	O
treated	O
with	O
systemic	O
adjuvant	O
chemotherapy	O
have	O
described	O
experiencing	O
deteriorations	O
in	O
cognition	O
.	O

A	O
widely	O
used	O
chemotherapeutic	O
agent	O
,	O
5	B-ChemicalEntity
-	O
fluorouracil	I-ChemicalEntity
(	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
)	O
,	O
readily	O
crosses	O
the	O
blood	O
-	O
brain	O
barrier	O
and	O
so	O
could	O
have	O
a	O
direct	O
effect	O
on	O
brain	O
function	O
.	O

In	O
particular	O
this	O
anti	O
mitotic	O
drug	O
could	O
reduce	O
cell	O
proliferation	O
in	O
the	O
neurogenic	O
regions	O
of	O
the	O
adult	O
brain	O
.	O

In	O
contrast	O
reports	O
indicate	O
that	O
hippocampal	O
dependent	O
neurogenesis	O
and	O
cognition	O
are	O
enhanced	O
by	O
the	O
SSRI	B-ChemicalEntity
antidepressant	O
Fluoxetine	B-ChemicalEntity
.	O

In	O
this	O
investigation	O
the	O
behavioural	O
effects	O
of	O
chronic	O
(	O
two	O
week	O
)	O
treatment	O
with	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
and	O
(	O
three	O
weeks	O
)	O
with	O
Fluoxetine	B-ChemicalEntity
either	O
separately	O
or	O
in	O
combination	O
with	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
were	O
tested	O
on	O
adult	O
Lister	O
hooded	O
rats	B-OrganismTaxon
.	O

Behavioural	O
effects	O
were	O
tested	O
using	O
a	O
context	O
dependent	O
conditioned	O
emotional	O
response	O
test	O
(	O
CER	O
)	O
which	O
showed	O
that	O
animals	O
treated	O
with	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
had	O
a	O
significant	O
reduction	O
in	O
freezing	O
time	O
compared	O
to	O
controls	O
.	O

A	O
separate	O
group	O
of	O
animals	O
was	O
tested	O
using	O
a	O
hippocampal	O
dependent	O
spatial	O
working	O
memory	O
test	O
,	O
the	O
object	O
location	O
recognition	O
test	O
(	O
OLR	O
)	O
.	O

Animals	O
treated	O
only	O
with	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
showed	O
significant	O
deficits	O
in	O
their	O
ability	O
to	O
carry	O
out	O
the	O
OLR	O
task	O
but	O
co	O
administration	O
of	O
Fluoxetine	B-ChemicalEntity
improved	O
their	O
performance	O
.	O

5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
chemotherapy	O
caused	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
proliferating	O
cells	O
in	O
the	O
sub	O
granular	O
zone	O
of	O
the	O
dentate	O
gyrus	O
compared	O
to	O
controls	O
.	O

This	O
reduction	O
was	O
eliminated	O
when	O
Fluoxetine	B-ChemicalEntity
was	O
co	O
administered	O
with	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
.	O

Fluoxetine	B-ChemicalEntity
on	O
its	O
own	O
had	O
no	O
effect	O
on	O
proliferating	O
cell	O
number	O
or	O
behaviour	O
.	O

These	O
findings	O
suggest	O
that	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
can	O
negatively	O
affect	O
both	O
cell	O
proliferation	O
and	O
hippocampal	O
dependent	O
working	O
memory	O
and	O
that	O
these	O
deficits	O
can	O
be	O
reversed	O
by	O
the	O
simultaneous	O
administration	O
of	O
the	O
antidepressant	O
Fluoxetine	B-ChemicalEntity
.	O
TIEG1	B-GeneOrGeneProduct
deficiency	O
confers	O
enhanced	O
myocardial	O
protection	O
in	O
the	O
infarcted	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
by	O
mediating	O
the	O
Pten	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
signalling	O
pathway	O
.	O

The	O
transforming	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
TGF	I-GeneOrGeneProduct
)	O
-	O
b	I-GeneOrGeneProduct
-	O
inducible	I-GeneOrGeneProduct
early	I-GeneOrGeneProduct
gene	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
TIEG1	B-GeneOrGeneProduct
)	O
plays	O
a	O
crucial	O
role	O
in	O
modulating	O
cell	O
apoptosis	O
and	O
proliferation	O
in	O
a	O
number	O
of	O
diseases	O
,	O
including	O
pancreatic	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
,	O
leukaemia	B-DiseaseOrPhenotypicFeature
and	O
osteoporosis	B-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
the	O
functional	O
role	O
of	O
TIEG1	B-GeneOrGeneProduct
in	O
the	O
heart	O
has	O
not	O
been	O
fully	O
defined	O
.	O

In	O
this	O
study	O
,	O
we	O
first	O
investigated	O
the	O
role	O
of	O
TIEG1	B-GeneOrGeneProduct
in	O
ischaemic	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

For	O
in	O
vitro	O
experiments	O
,	O
cardiomyocytes	O
were	O
isolated	O
from	O
both	O
TIEG1	B-GeneOrGeneProduct
knockout	O
(	O
KO	O
)	O
and	O
wile	O
-	O
type	O
(	O
WT	O
)	O
mice	B-OrganismTaxon
,	O
and	O
the	O
apoptotic	O
ratios	O
were	O
evaluated	O
after	O
a	O
48	O
-	O
h	O
ischaemic	O
insult	O
.	O

A	O
cell	O
proliferation	O
assay	O
was	O
performed	O
after	O
7	O
days	O
of	O
incubation	O
under	O
normoxic	O
conditions	O
.	O

In	O
addition	O
,	O
the	O
angiogenic	O
capacity	O
of	O
endothelial	O
cells	O
was	O
determined	O
by	O
tube	O
formation	O
assay	O
.	O

For	O
in	O
vivo	O
experiments	O
,	O
a	O
model	O
of	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
(	O
MI	B-DiseaseOrPhenotypicFeature
)	O
was	O
established	O
using	O
both	O
TIEG1	B-GeneOrGeneProduct
KO	O
and	O
WT	O
mice	B-OrganismTaxon
.	O

Echocardiography	O
was	O
performed	O
at	O
3	O
and	O
28	O
days	O
post	O
-	O
MI	B-DiseaseOrPhenotypicFeature
,	O
whereas	O
the	O
haemodynamics	O
test	O
was	O
performed	O
28	O
days	O
post	O
-	O
MI	B-DiseaseOrPhenotypicFeature
.	O

Histological	O
analyses	O
of	O
apoptosis	O
,	O
proliferation	O
,	O
angiogenesis	O
and	O
infarct	B-DiseaseOrPhenotypicFeature
zone	O
assessments	O
were	O
performed	O
using	O
terminal	B-GeneOrGeneProduct
deoxynucleotidyltransferase	I-GeneOrGeneProduct
-	O
mediated	O
dUTP	B-ChemicalEntity
nick	O
-	O
end	O
labelling	O
(	O
TUNEL	O
)	O
staining	O
,	O
BrdU	O
immunostaining	O
,	O
a	B-GeneOrGeneProduct
-	O
smooth	I-GeneOrGeneProduct
muscle	I-GeneOrGeneProduct
actin	I-GeneOrGeneProduct
(	O
a	B-GeneOrGeneProduct
-	O
SMA	I-GeneOrGeneProduct
)	O
/	O
CD31	B-GeneOrGeneProduct
immunostaining	O
and	O
Masson	O
'	O
s	O
trichrome	O
staining	O
,	O
respectively	O
.	O

Changes	O
in	O
the	O
expression	O
of	O
related	O
proteins	O
caused	O
by	O
TIEG1	B-GeneOrGeneProduct
deficiency	O
were	O
confirmed	O
using	O
both	O
reverse	O
transcription	O
-	O
quantitative	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
qPCR	O
)	O
and	O
western	O
blot	O
analysis	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
absence	O
of	O
TIEG1	B-GeneOrGeneProduct
prevented	O
cardiomyocytes	O
from	O
undergoing	O
apoptosis	O
and	O
promoted	O
higher	O
proliferation	O
;	O
it	O
stimulated	O
the	O
proliferation	O
of	O
endothelial	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Improved	O
cardiac	O
function	O
and	O
less	O
scar	O
formation	O
were	O
observed	O
in	O
TIEG1	B-GeneOrGeneProduct
KO	O
mice	B-OrganismTaxon
,	O
and	O
we	O
also	O
observed	O
the	O
altered	O
expression	O
of	O
phosphatase	B-GeneOrGeneProduct
and	I-GeneOrGeneProduct
tensin	I-GeneOrGeneProduct
homolog	I-GeneOrGeneProduct
(	O
Pten	B-GeneOrGeneProduct
)	O
,	O
Akt	B-GeneOrGeneProduct
and	O
Bcl	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
/	O
Bax	B-GeneOrGeneProduct
,	O
as	O
well	O
as	O
vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
VEGF	B-GeneOrGeneProduct
)	O
.	O

On	O
the	O
whole	O
,	O
our	O
findings	O
indicate	O
that	O
the	O
absence	O
of	O
TIEG1	B-GeneOrGeneProduct
plays	O
a	O
cardioprotective	O
role	O
in	O
ischaemic	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
by	O
promoting	O
changes	O
in	O
Pten	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
signalling	O
.	O
Long	O
-	O
Lived	O
CD4	B-GeneOrGeneProduct
+	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
+	O
T	O
Cells	O
rather	O
than	O
Short	O
-	O
Lived	O
CD4	B-GeneOrGeneProduct
+	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
+	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
+	O
T	O
Cells	O
Initiate	O
Rapid	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
Production	O
To	O
Suppress	O
Anamnestic	O
T	O
Cell	O
Responses	O
during	O
Secondary	O
Malaria	B-DiseaseOrPhenotypicFeature
Infection	I-DiseaseOrPhenotypicFeature
.	O

CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
T	O
cells	O
that	O
produce	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
are	O
the	O
source	O
of	O
host	O
-	O
protective	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
during	O
primary	O
infection	B-DiseaseOrPhenotypicFeature
with	O
a	O
number	O
of	O
different	O
pathogens	O
,	O
including	O
Plasmodium	O
spp	O
.	O

The	O
fate	O
of	O
these	O
CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
(	O
+	O
)	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
(	O
+	O
)	O
T	O
cells	O
following	O
clearance	O
of	O
primary	O
infection	B-DiseaseOrPhenotypicFeature
and	O
their	O
subsequent	O
influence	O
on	O
the	O
course	O
of	O
repeated	O
infections	O
is	O
,	O
however	O
,	O
presently	O
unknown	O
.	O

In	O
this	O
study	O
,	O
utilizing	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
-	O
yellow	O
fluorescent	O
protein	O
(	O
YFP	O
)	O
and	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
-	O
GFP	O
dual	O
reporter	O
mice	B-OrganismTaxon
,	O
we	O
show	O
that	O
primary	O
malaria	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
-	O
induced	O
CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
+	O
)	O
T	O
cells	O
have	O
limited	O
memory	O
potential	O
,	O
do	O
not	O
stably	O
express	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
,	O
and	O
are	O
disproportionately	O
lost	O
from	O
the	O
Ag	O
-	O
experienced	O
CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
T	O
cell	O
memory	O
population	O
during	O
the	O
maintenance	O
phase	O
postinfection	O
.	O

CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
+	O
)	O
T	O
cells	O
generally	O
exhibited	O
a	O
short	O
-	O
lived	O
effector	O
rather	O
than	O
effector	O
memory	O
T	O
cell	O
phenotype	O
postinfection	O
and	O
expressed	O
high	O
levels	O
of	O
PD	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
,	O
Lag	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
,	O
and	O
TIGIT	B-GeneOrGeneProduct
,	O
indicative	O
of	O
cellular	O
exhaustion	O
.	O

Consistently	O
,	O
the	O
surviving	O
CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
+	O
)	O
T	O
cell	O
-	O
derived	O
cells	O
were	O
unresponsive	O
and	O
failed	O
to	O
proliferate	O
during	O
the	O
early	O
phase	O
of	O
secondary	O
infection	B-DiseaseOrPhenotypicFeature
.	O

In	O
contrast	O
,	O
CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
YFP	O
(	O
+	O
)	O
GFP	O
(	O
-	O
)	O
T	O
cell	O
-	O
derived	O
cells	O
expanded	O
rapidly	O
and	O
upregulated	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
expression	O
during	O
secondary	O
infection	B-DiseaseOrPhenotypicFeature
.	O

Correspondingly	O
,	O
CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
T	O
cells	O
were	O
the	O
major	O
producers	O
within	O
an	O
accelerated	O
and	O
amplified	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
response	O
during	O
the	O
early	O
stage	O
of	O
secondary	O
malaria	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

Notably	O
,	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
exerted	O
quantitatively	O
stronger	O
regulatory	O
effects	O
on	O
innate	O
and	O
CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
T	O
cell	O
responses	O
during	O
primary	O
and	O
secondary	O
infections	O
,	O
respectively	O
.	O

The	O
results	O
in	O
this	O
study	O
significantly	O
improve	O
our	O
understanding	O
of	O
the	O
durability	O
of	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
-	O
producing	O
CD4	B-GeneOrGeneProduct
(	O
+	O
)	O
T	O
cells	O
postinfection	O
and	O
provide	O
information	O
on	O
how	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
may	O
contribute	O
to	O
optimized	O
parasite	O
control	O
and	O
prevention	O
of	O
immune	O
-	O
mediated	O
pathology	O
during	O
repeated	O
malaria	B-DiseaseOrPhenotypicFeature
infections	I-DiseaseOrPhenotypicFeature
.	O
Chloroacetaldehyde	B-ChemicalEntity
as	O
a	O
sulfhydryl	B-ChemicalEntity
reagent	I-ChemicalEntity
:	O
the	O
role	O
of	O
critical	O
thiol	B-ChemicalEntity
groups	O
in	O
ifosfamide	B-ChemicalEntity
nephropathy	B-DiseaseOrPhenotypicFeature
.	O

Chloroacetaldehyde	B-ChemicalEntity
(	O
CAA	B-ChemicalEntity
)	O
is	O
a	O
metabolite	O
of	O
the	O
alkylating	B-ChemicalEntity
agent	I-ChemicalEntity
ifosfamide	B-ChemicalEntity
(	O
IFO	B-ChemicalEntity
)	O
and	O
putatively	O
responsible	O
for	O
renal	B-DiseaseOrPhenotypicFeature
damage	I-DiseaseOrPhenotypicFeature
following	O
anti	O
-	O
tumor	B-DiseaseOrPhenotypicFeature
therapy	O
with	O
IFO	B-ChemicalEntity
.	O

Depletion	O
of	O
sulfhydryl	B-ChemicalEntity
(	O
SH	B-ChemicalEntity
)	O
groups	O
has	O
been	O
reported	O
from	O
cell	O
culture	O
,	O
animal	O
and	O
clinical	O
studies	O
.	O

In	O
this	O
work	O
the	O
effect	O
of	O
CAA	B-ChemicalEntity
on	O
human	B-OrganismTaxon
proximal	O
tubule	O
cells	O
in	O
primary	O
culture	O
(	O
hRPTEC	B-CellLine
)	O
was	O
investigated	O
.	O

Toxicity	B-DiseaseOrPhenotypicFeature
of	O
CAA	B-ChemicalEntity
was	O
determined	O
by	O
protein	O
content	O
,	O
cell	O
number	O
,	O
LDH	B-ChemicalEntity
release	O
,	O
trypan	B-ChemicalEntity
blue	I-ChemicalEntity
exclusion	O
assay	O
and	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
activity	O
.	O

Free	O
thiols	B-ChemicalEntity
were	O
measured	O
by	O
the	O
method	O
of	O
Ellman	O
.	O

CAA	B-ChemicalEntity
reduced	O
hRPTEC	B-CellLine
cell	O
number	O
and	O
protein	O
,	O
induced	O
a	O
loss	O
in	O
free	O
intracellular	O
thiols	B-ChemicalEntity
and	O
an	O
increase	O
in	O
necrosis	B-DiseaseOrPhenotypicFeature
markers	O
.	O

CAA	B-ChemicalEntity
but	O
not	O
acrolein	B-ChemicalEntity
inhibited	O
the	O
cysteine	B-GeneOrGeneProduct
proteases	I-GeneOrGeneProduct
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
,	O
caspase	B-GeneOrGeneProduct
-	O
8	I-GeneOrGeneProduct
and	O
cathepsin	B-GeneOrGeneProduct
B	I-GeneOrGeneProduct
.	O

Caspase	B-GeneOrGeneProduct
activation	O
by	O
cisplatin	B-ChemicalEntity
was	O
inhibited	O
by	O
CAA	B-ChemicalEntity
.	O

In	O
cells	O
stained	O
with	O
fluorescent	O
dyes	O
targeting	O
lysosomes	O
,	O
CAA	B-ChemicalEntity
induced	O
an	O
increase	O
in	O
lysosomal	O
size	O
and	O
lysosomal	O
leakage	O
.	O

The	O
effects	O
of	O
CAA	B-ChemicalEntity
on	O
cysteine	B-GeneOrGeneProduct
protease	I-GeneOrGeneProduct
activities	O
and	O
thiols	B-ChemicalEntity
could	O
be	O
reproduced	O
in	O
cell	O
lysate	O
.	O

Acidification	O
,	O
which	O
slowed	O
the	O
reaction	O
of	O
CAA	B-ChemicalEntity
with	O
thiol	B-ChemicalEntity
donors	O
,	O
could	O
also	O
attenuate	O
effects	O
of	O
CAA	B-ChemicalEntity
on	O
necrosis	B-DiseaseOrPhenotypicFeature
markers	O
,	O
thiol	B-ChemicalEntity
depletion	O
and	O
cysteine	B-GeneOrGeneProduct
protease	I-GeneOrGeneProduct
inhibition	O
in	O
living	O
cells	O
.	O

Thus	O
,	O
CAA	B-ChemicalEntity
directly	O
reacts	O
with	O
cellular	O
protein	O
and	O
non	O
-	O
protein	O
thiols	B-ChemicalEntity
,	O
mediating	O
its	O
toxicity	B-DiseaseOrPhenotypicFeature
on	O
hRPTEC	B-CellLine
.	O

This	O
effect	O
can	O
be	O
reduced	O
by	O
acidification	O
.	O

Therefore	O
,	O
urinary	O
acidification	O
could	O
be	O
an	O
option	O
to	O
prevent	O
IFO	B-ChemicalEntity
nephropathy	B-DiseaseOrPhenotypicFeature
in	O
patients	B-OrganismTaxon
.	O
Absence	O
of	O
PKC	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
attenuates	O
lithium	B-ChemicalEntity
-	O
induced	O
nephrogenic	B-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
insipidus	I-DiseaseOrPhenotypicFeature
.	O

Lithium	B-ChemicalEntity
,	O
an	O
effective	O
antipsychotic	O
,	O
induces	O
nephrogenic	B-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
insipidus	I-DiseaseOrPhenotypicFeature
(	O
NDI	B-DiseaseOrPhenotypicFeature
)	O
in	O
40%	O
of	O
patients	B-OrganismTaxon
.	O

The	O
decreased	O
capacity	O
to	O
concentrate	O
urine	O
is	O
likely	O
due	O
to	O
lithium	B-ChemicalEntity
acutely	O
disrupting	O
the	O
cAMP	B-ChemicalEntity
pathway	O
and	O
chronically	O
reducing	O
urea	B-GeneOrGeneProduct
transporter	I-GeneOrGeneProduct
(	O
UT	B-GeneOrGeneProduct
-	O
A1	I-GeneOrGeneProduct
)	O
and	O
water	O
channel	O
(	O
AQP2	B-GeneOrGeneProduct
)	O
expression	O
in	O
the	O
inner	O
medulla	O
.	O

Targeting	O
an	O
alternative	O
signaling	O
pathway	O
,	O
such	O
as	O
PKC	B-GeneOrGeneProduct
-	O
mediated	O
signaling	O
,	O
may	O
be	O
an	O
effective	O
method	O
of	O
treating	O
lithium	B-ChemicalEntity
-	O
induced	O
polyuria	B-DiseaseOrPhenotypicFeature
.	O

PKC	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
null	O
mice	B-OrganismTaxon
(	O
PKCa	B-GeneOrGeneProduct
KO	O
)	O
and	O
strain	O
-	O
matched	O
wild	O
type	O
(	O
WT	O
)	O
controls	O
were	O
treated	O
with	O
lithium	B-ChemicalEntity
for	O
0	O
,	O
3	O
or	O
5	O
days	O
.	O

WT	O
mice	B-OrganismTaxon
had	O
increased	O
urine	O
output	O
and	O
lowered	O
urine	O
osmolality	O
after	O
3	O
and	O
5	O
days	O
of	O
treatment	O
whereas	O
PKCa	B-GeneOrGeneProduct
KO	O
mice	B-OrganismTaxon
had	O
no	O
change	O
in	O
urine	O
output	O
or	O
concentration	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
AQP2	B-GeneOrGeneProduct
expression	O
in	O
medullary	O
tissues	O
was	O
lowered	O
after	O
3	O
and	O
5	O
days	O
in	O
WT	O
mice	B-OrganismTaxon
;	O
however	O
,	O
AQP2	B-GeneOrGeneProduct
was	O
unchanged	O
in	O
PKCa	B-GeneOrGeneProduct
KO	O
.	O

Similar	O
results	O
were	O
observed	O
with	O
UT	B-GeneOrGeneProduct
-	O
A1	I-GeneOrGeneProduct
expression	O
.	O

Animals	O
were	O
also	O
treated	O
with	O
lithium	B-ChemicalEntity
for	O
6	O
weeks	O
.	O

Lithium	B-ChemicalEntity
-	O
treated	O
WT	O
mice	B-OrganismTaxon
had	O
19	O
-	O
fold	O
increased	O
urine	O
output	O
whereas	O
treated	O
PKCa	B-GeneOrGeneProduct
KO	O
animals	O
had	O
a	O
4	O
-	O
fold	O
increase	O
in	O
output	O
.	O

AQP2	B-GeneOrGeneProduct
and	O
UT	B-GeneOrGeneProduct
-	O
A1	I-GeneOrGeneProduct
expression	O
was	O
lowered	O
in	O
6	O
week	O
lithium	B-ChemicalEntity
-	O
treated	O
WT	O
animals	O
whereas	O
in	O
treated	O
PKCa	B-GeneOrGeneProduct
KO	O
mice	B-OrganismTaxon
,	O
AQP2	B-GeneOrGeneProduct
was	O
only	O
reduced	O
by	O
2	O
-	O
fold	O
and	O
UT	B-GeneOrGeneProduct
-	O
A1	I-GeneOrGeneProduct
expression	O
was	O
unaffected	O
.	O

Urinary	O
sodium	B-ChemicalEntity
,	O
potassium	B-ChemicalEntity
and	O
calcium	B-ChemicalEntity
were	O
elevated	O
in	O
lithium	B-ChemicalEntity
-	O
fed	O
WT	O
but	O
not	O
in	O
lithium	B-ChemicalEntity
-	O
fed	O
PKCa	B-GeneOrGeneProduct
KO	O
mice	B-OrganismTaxon
.	O

Our	O
data	O
show	O
that	O
ablation	O
of	O
PKCa	B-GeneOrGeneProduct
preserves	O
AQP2	B-GeneOrGeneProduct
and	O
UT	B-GeneOrGeneProduct
-	O
A1	I-GeneOrGeneProduct
protein	O
expression	O
and	O
localization	O
in	O
lithium	B-ChemicalEntity
-	O
induced	O
NDI	B-DiseaseOrPhenotypicFeature
,	O
and	O
prevents	O
the	O
development	O
of	O
the	O
severe	O
polyuria	B-DiseaseOrPhenotypicFeature
associated	O
with	O
lithium	B-ChemicalEntity
therapy	O
.	O
H3	B-GeneOrGeneProduct
histamine	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
mediated	O
activation	O
of	O
protein	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
Calpha	I-GeneOrGeneProduct
inhibits	O
the	O
growth	O
of	O
cholangiocarcinoma	B-DiseaseOrPhenotypicFeature
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Histamine	B-ChemicalEntity
regulates	O
functions	O
via	O
four	O
receptors	O
(	O
HRH1	B-GeneOrGeneProduct
,	O
HRH2	B-GeneOrGeneProduct
,	O
HRH3	B-GeneOrGeneProduct
,	O
and	O
HRH4	B-GeneOrGeneProduct
)	O
.	O

The	O
d	B-ChemicalEntity
-	O
myo	I-ChemicalEntity
-	O
inositol	I-ChemicalEntity
1	I-ChemicalEntity
,	O
4	I-ChemicalEntity
,	O
5	I-ChemicalEntity
-	O
trisphosphate	I-ChemicalEntity
(	O
IP	B-ChemicalEntity
(	O
3	I-ChemicalEntity
)	O
)	O
/	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
/	O
protein	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
C	I-GeneOrGeneProduct
(	O
PKC	B-GeneOrGeneProduct
)	O
/	O
mitogen	B-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
pathway	O
regulates	O
cholangiocarcinoma	B-DiseaseOrPhenotypicFeature
growth	O
.	O

We	O
evaluated	O
the	O
role	O
of	O
HRH3	B-GeneOrGeneProduct
in	O
the	O
regulation	O
of	O
cholangiocarcinoma	B-DiseaseOrPhenotypicFeature
growth	O
.	O

Expression	O
of	O
HRH3	B-GeneOrGeneProduct
in	O
intrahepatic	O
and	O
extrahepatic	O
cell	O
lines	O
,	O
normal	O
cholangiocytes	O
,	O
and	O
human	B-OrganismTaxon
tissue	O
arrays	O
was	O
measured	O
.	O

In	O
Mz	B-CellLine
-	O
ChA	I-CellLine
-	O
1	I-CellLine
cells	O
stimulated	O
with	O
(	O
R	I-ChemicalEntity
)	O
-	O
(	O
alpha	I-ChemicalEntity
)	O
-	O
(	O
-	O
)	O
-	O
methylhistamine	I-ChemicalEntity
dihydrobromide	I-ChemicalEntity
(	O
RAMH	B-ChemicalEntity
)	O
,	O
we	O
measured	O
(	O
a	O
)	O
cell	O
growth	O
,	O
(	O
b	O
)	O
IP	B-ChemicalEntity
(	O
3	I-ChemicalEntity
)	O
and	O
cyclic	B-ChemicalEntity
AMP	I-ChemicalEntity
levels	O
,	O
and	O
(	O
c	O
)	O
phosphorylation	O
of	O
PKC	B-GeneOrGeneProduct
and	O
mitogen	B-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
isoforms	O
.	O

Localization	O
of	O
PKCalpha	B-GeneOrGeneProduct
was	O
visualized	O
by	O
immunofluorescence	O
in	O
cell	O
smears	O
and	O
immunoblotting	O
for	O
PKCalpha	B-GeneOrGeneProduct
in	O
cytosol	O
and	O
membrane	O
fractions	O
.	O

Following	O
knockdown	O
of	O
PKCalpha	B-GeneOrGeneProduct
,	O
Mz	B-CellLine
-	O
ChA	I-CellLine
-	O
1	I-CellLine
cells	O
were	O
stimulated	O
with	O
RAMH	B-ChemicalEntity
before	O
evaluating	O
cell	O
growth	O
and	O
extracellular	B-GeneOrGeneProduct
signal	I-GeneOrGeneProduct
-	O
regulated	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
(	O
ERK	I-GeneOrGeneProduct
)	O
-	O
1	I-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
phosphorylation	O
.	O

In	O
vivo	O
experiments	O
were	O
done	O
in	O
BALB	B-CellLine
/	O
c	I-CellLine
nude	O
mice	B-OrganismTaxon
.	O

Mice	B-OrganismTaxon
were	O
treated	O
with	O
saline	O
or	O
RAMH	B-ChemicalEntity
for	O
44	O
days	O
and	O
tumor	B-DiseaseOrPhenotypicFeature
volume	O
was	O
measured	O
.	O

Tumors	B-DiseaseOrPhenotypicFeature
were	O
excised	O
and	O
evaluated	O
for	O
proliferation	O
,	O
apoptosis	O
,	O
and	O
expression	O
of	O
PKCalpha	B-GeneOrGeneProduct
,	O
vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
VEGF	I-GeneOrGeneProduct
)	O
-	O
A	I-GeneOrGeneProduct
,	O
VEGF	B-GeneOrGeneProduct
-	O
C	I-GeneOrGeneProduct
,	O
VEGF	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
,	O
and	O
VEGF	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
3	I-GeneOrGeneProduct
.	O

HRH3	B-GeneOrGeneProduct
expression	O
was	O
found	O
in	O
all	O
cells	O
.	O

RAMH	B-ChemicalEntity
inhibited	O
the	O
growth	O
of	O
cholangiocarcinoma	B-DiseaseOrPhenotypicFeature
cells	O
.	O

RAMH	B-ChemicalEntity
increased	O
IP	B-ChemicalEntity
(	O
3	I-ChemicalEntity
)	O
levels	O
and	O
PKCalpha	B-GeneOrGeneProduct
phosphorylation	O
and	O
decreased	O
ERK1	B-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
phosphorylation	O
.	O

RAMH	B-ChemicalEntity
induced	O
a	O
shift	O
in	O
the	O
localization	O
of	O
PKCalpha	B-GeneOrGeneProduct
expression	O
from	O
the	O
cytosolic	O
domain	O
into	O
the	O
membrane	O
region	O
of	O
Mz	B-CellLine
-	O
ChA	I-CellLine
-	O
1	I-CellLine
cells	O
.	O

Silencing	O
of	O
PKCalpha	B-GeneOrGeneProduct
prevented	O
RAMH	B-ChemicalEntity
inhibition	O
of	O
Mz	B-CellLine
-	O
ChA	I-CellLine
-	O
1	I-CellLine
cell	O
growth	O
and	O
ablated	O
RAMH	B-ChemicalEntity
effects	O
on	O
ERK1	B-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
phosphorylation	O
.	O

In	O
vivo	O
,	O
RAMH	B-ChemicalEntity
decreased	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
and	O
expression	O
of	O
VEGF	B-GeneOrGeneProduct
and	O
its	O
receptors	O
;	O
PKCalpha	B-GeneOrGeneProduct
expression	O
was	O
increased	O
.	O

RAMH	B-ChemicalEntity
inhibits	O
cholangiocarcinoma	B-DiseaseOrPhenotypicFeature
growth	O
by	O
PKCalpha	B-GeneOrGeneProduct
-	O
dependent	O
ERK1	B-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
dephosphorylation	O
.	O

Modulation	O
of	O
PKCalpha	B-GeneOrGeneProduct
by	O
histamine	B-GeneOrGeneProduct
receptors	I-GeneOrGeneProduct
may	O
be	O
important	O
in	O
regulating	O
cholangiocarcinoma	B-DiseaseOrPhenotypicFeature
growth	O
.	O
The	O
G51S	B-SequenceVariant
purine	B-GeneOrGeneProduct
nucleoside	I-GeneOrGeneProduct
phosphorylase	I-GeneOrGeneProduct
polymorphism	O
is	O
associated	O
with	O
cognitive	B-DiseaseOrPhenotypicFeature
decline	I-DiseaseOrPhenotypicFeature
in	O
Alzheimer	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

Alzheimer	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
AD	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
polygenic	O
and	O
multifactorial	O
complex	O
disease	O
,	O
whose	O
etiopathology	O
is	O
still	O
unclear	O
,	O
however	O
several	O
genetic	O
factors	O
have	O
shown	O
to	O
increase	O
the	O
risk	O
of	O
developing	O
the	O
disease	O
.	O

Purine	O
nucleotides	O
and	O
nucleosides	O
play	O
an	O
important	O
role	O
in	O
the	O
brain	O
.	O

Besides	O
their	O
role	O
in	O
neurotransmission	O
and	O
neuromodulation	O
,	O
they	O
are	O
involved	O
in	O
trophic	O
factor	O
release	O
,	O
apoptosis	O
,	O
and	O
inflammatory	B-DiseaseOrPhenotypicFeature
responses	O
.	O

These	O
mediators	O
may	O
also	O
have	O
a	O
pivotal	O
role	O
in	O
the	O
control	O
of	O
neurodegenerative	O
processes	O
associated	O
with	O
AD	B-DiseaseOrPhenotypicFeature
.	O

In	O
this	O
report	O
the	O
distribution	O
of	O
the	O
exonic	O
G	B-SequenceVariant
/	O
A	I-SequenceVariant
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
purine	B-GeneOrGeneProduct
nucleoside	I-GeneOrGeneProduct
phosphorylase	I-GeneOrGeneProduct
(	O
PNP	B-GeneOrGeneProduct
)	O
gene	O
,	O
resulting	O
in	O
the	O
amino	O
acid	O
substitution	O
serine	B-SequenceVariant
to	I-SequenceVariant
glycine	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
51	I-SequenceVariant
(	O
G51S	B-SequenceVariant
)	O
,	O
was	O
investigated	O
in	O
a	O
large	O
population	O
of	O
AD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
(	O
n	O
=	O
321	O
)	O
and	O
non	O
-	O
demented	O
control	O
(	O
n	O
=	O
208	O
)	O
.	O

The	O
PNP	B-GeneOrGeneProduct
polymorphism	O
distribution	O
was	O
not	O
different	O
between	O
patients	B-OrganismTaxon
and	O
controls	O
.	O

The	O
polymorphism	O
distribution	O
was	O
also	O
analyzed	O
in	O
AD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
stratified	O
according	O
to	O
differential	O
progressive	O
rate	O
of	O
cognitive	B-DiseaseOrPhenotypicFeature
decline	I-DiseaseOrPhenotypicFeature
during	O
a	O
2	O
-	O
year	O
follow	O
-	O
up	O
.	O

An	O
increased	O
representation	O
of	O
the	O
PNP	B-GeneOrGeneProduct
AA	O
genotype	O
was	O
observed	O
in	O
AD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
fast	O
cognitive	B-DiseaseOrPhenotypicFeature
deterioration	I-DiseaseOrPhenotypicFeature
in	O
comparison	O
with	O
that	O
from	O
patients	B-OrganismTaxon
with	O
slow	O
deterioration	O
rate	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
G51S	B-SequenceVariant
PNP	B-GeneOrGeneProduct
polymorphism	O
is	O
associated	O
with	O
a	O
faster	O
rate	O
of	O
cognitive	B-DiseaseOrPhenotypicFeature
decline	I-DiseaseOrPhenotypicFeature
in	O
AD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
highlighting	O
the	O
important	O
role	O
of	O
purine	O
metabolism	O
in	O
the	O
progression	O
of	O
this	O
neurodegenerative	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
.	O
Antithrombotic	B-ChemicalEntity
drug	I-ChemicalEntity
use	O
,	O
cerebral	B-DiseaseOrPhenotypicFeature
microbleeds	I-DiseaseOrPhenotypicFeature
,	O
and	O
intracerebral	B-DiseaseOrPhenotypicFeature
hemorrhage	I-DiseaseOrPhenotypicFeature
:	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
studies	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
Cerebral	B-DiseaseOrPhenotypicFeature
microbleeds	I-DiseaseOrPhenotypicFeature
(	O
MB	B-DiseaseOrPhenotypicFeature
)	O
are	O
potential	O
risk	O
factors	O
for	O
intracerebral	B-DiseaseOrPhenotypicFeature
hemorrhage	I-DiseaseOrPhenotypicFeature
(	O
ICH	B-DiseaseOrPhenotypicFeature
)	O
,	O
but	O
it	O
is	O
unclear	O
if	O
they	O
are	O
a	O
contraindication	O
to	O
using	O
antithrombotic	B-ChemicalEntity
drugs	I-ChemicalEntity
.	O

Insights	O
could	O
be	O
gained	O
by	O
pooling	O
data	O
on	O
MB	B-DiseaseOrPhenotypicFeature
frequency	O
stratified	O
by	O
antithrombotic	O
use	O
in	O
cohorts	O
with	O
ICH	B-DiseaseOrPhenotypicFeature
and	O
ischemic	B-DiseaseOrPhenotypicFeature
stroke	I-DiseaseOrPhenotypicFeature
(	O
IS	B-DiseaseOrPhenotypicFeature
)	O
/	O
transient	B-DiseaseOrPhenotypicFeature
ischemic	I-DiseaseOrPhenotypicFeature
attack	I-DiseaseOrPhenotypicFeature
(	O
TIA	B-DiseaseOrPhenotypicFeature
)	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
review	O
of	O
published	O
and	O
unpublished	O
data	O
from	O
cohorts	O
with	O
stroke	B-DiseaseOrPhenotypicFeature
or	O
TIA	B-DiseaseOrPhenotypicFeature
to	O
compare	O
the	O
presence	O
of	O
MB	B-DiseaseOrPhenotypicFeature
in	O
:	O
(	O
1	O
)	O
antithrombotic	O
users	O
vs	O
nonantithrombotic	O
users	O
with	O
ICH	B-DiseaseOrPhenotypicFeature
;	O
(	O
2	O
)	O
antithrombotic	O
users	O
vs	O
nonusers	O
with	O
IS	B-DiseaseOrPhenotypicFeature
/	O
TIA	B-DiseaseOrPhenotypicFeature
;	O
and	O
(	O
3	O
)	O
ICH	B-DiseaseOrPhenotypicFeature
vs	O
ischemic	B-DiseaseOrPhenotypicFeature
events	O
stratified	O
by	O
antithrombotic	O
use	O
.	O

We	O
also	O
analyzed	O
published	O
and	O
unpublished	O
follow	O
-	O
up	O
data	O
to	O
determine	O
the	O
risk	O
of	O
ICH	B-DiseaseOrPhenotypicFeature
in	O
antithrombotic	O
users	O
with	O
MB	B-DiseaseOrPhenotypicFeature
.	O

RESULTS	O
:	O
In	O
a	O
pooled	O
analysis	O
of	O
1460	O
ICH	B-DiseaseOrPhenotypicFeature
and	O
3817	O
IS	B-DiseaseOrPhenotypicFeature
/	O
TIA	B-DiseaseOrPhenotypicFeature
,	O
MB	B-DiseaseOrPhenotypicFeature
were	O
more	O
frequent	O
in	O
ICH	B-DiseaseOrPhenotypicFeature
vs	O
IS	B-DiseaseOrPhenotypicFeature
/	O
TIA	B-DiseaseOrPhenotypicFeature
in	O
all	O
treatment	O
groups	O
,	O
but	O
the	O
excess	O
increased	O
from	O
2	O
.	O
8	O
(	O
odds	O
ratio	O
;	O
range	O
,	O
2	O
.	O
3	O
-	O
3	O
.	O
5	O
)	O
in	O
nonantithrombotic	O
users	O
to	O
5	O
.	O
7	O
(	O
range	O
,	O
3	O
.	O
4	O
-	O
9	O
.	O
7	O
)	O
in	O
antiplatelet	O
users	O
and	O
8	O
.	O
0	O
(	O
range	O
,	O
3	O
.	O
5	O
-	O
17	O
.	O
8	O
)	O
in	O
warfarin	B-ChemicalEntity
users	O
(	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
also	O
an	O
excess	O
of	O
MB	B-DiseaseOrPhenotypicFeature
in	O
warfarin	B-ChemicalEntity
users	O
vs	O
nonusers	O
with	O
ICH	B-DiseaseOrPhenotypicFeature
(	O
OR	O
,	O
2	O
.	O
7	O
;	O
95%	O
CI	O
,	O
1	O
.	O
6	O
-	O
4	O
.	O
4	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
none	O
in	O
warfarin	B-ChemicalEntity
users	O
with	O
IS	B-DiseaseOrPhenotypicFeature
/	O
TIA	B-DiseaseOrPhenotypicFeature
(	O
OR	O
,	O
1	O
.	O
3	O
;	O
95%	O
CI	O
,	O
0	O
.	O
9	O
-	O
1	O
.	O
7	O
;	O
P	O
=	O
0	O
.	O
33	O
;	O
P	O
difference	O
=	O
0	O
.	O
01	O
)	O
.	O

There	O
was	O
a	O
smaller	O
excess	O
of	O
MB	B-DiseaseOrPhenotypicFeature
in	O
antiplatelet	O
users	O
vs	O
nonusers	O
with	O
ICH	B-DiseaseOrPhenotypicFeature
(	O
OR	O
,	O
1	O
.	O
7	O
;	O
95%	O
CI	O
,	O
1	O
.	O
3	O
-	O
2	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
findings	O
were	O
similar	O
for	O
antiplatelet	O
users	O
with	O
IS	B-DiseaseOrPhenotypicFeature
/	O
TIA	B-DiseaseOrPhenotypicFeature
(	O
OR	O
,	O
1	O
.	O
4	O
;	O
95%	O
CI	O
,	O
1	O
.	O
2	O
-	O
1	O
.	O
7	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
P	O
difference	O
=	O
0	O
.	O
25	O
)	O
.	O

In	O
pooled	O
follow	O
-	O
up	O
data	O
for	O
768	O
antithrombotic	O
users	O
,	O
presence	O
of	O
MB	B-DiseaseOrPhenotypicFeature
at	O
baseline	O
was	O
associated	O
with	O
a	O
substantially	O
increased	O
risk	O
of	O
subsequent	O
ICH	B-DiseaseOrPhenotypicFeature
(	O
OR	O
,	O
12	O
.	O
1	O
;	O
95%	O
CI	O
,	O
3	O
.	O
4	O
-	O
42	O
.	O
5	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
excess	O
of	O
MB	B-DiseaseOrPhenotypicFeature
in	O
warfarin	B-ChemicalEntity
users	O
with	O
ICH	B-DiseaseOrPhenotypicFeature
compared	O
to	O
other	O
groups	O
suggests	O
that	O
MB	B-DiseaseOrPhenotypicFeature
increase	O
the	O
risk	O
of	O
warfarin	B-ChemicalEntity
-	O
associated	O
ICH	B-DiseaseOrPhenotypicFeature
.	O

Limited	O
prospective	O
data	O
corroborate	O
these	O
findings	O
,	O
but	O
larger	O
prospective	O
studies	O
are	O
urgently	O
required	O
.	O
Efficacy	O
of	O
everolimus	B-ChemicalEntity
(	O
RAD001	B-ChemicalEntity
)	O
in	O
patients	B-OrganismTaxon
with	O
advanced	O
NSCLC	B-DiseaseOrPhenotypicFeature
previously	O
treated	O
with	O
chemotherapy	O
alone	O
or	O
with	O
chemotherapy	O
and	O
EGFR	B-GeneOrGeneProduct
inhibitors	O
.	O

BACKGROUND	O
:	O
Treatment	O
options	O
are	O
scarce	O
in	O
pretreated	O
advanced	O
non	B-DiseaseOrPhenotypicFeature
-	O
small	I-DiseaseOrPhenotypicFeature
-	O
cell	I-DiseaseOrPhenotypicFeature
lung	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
NSCLC	B-DiseaseOrPhenotypicFeature
)	O
patients	B-OrganismTaxon
.	O

RAD001	B-ChemicalEntity
,	O
an	O
oral	O
inhibitor	O
of	O
the	O
mammalian	B-GeneOrGeneProduct
target	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
rapamycin	I-GeneOrGeneProduct
(	O
mTOR	B-GeneOrGeneProduct
)	O
,	O
has	O
shown	O
phase	O
I	O
efficacy	O
in	O
NSCLC	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
Stage	O
IIIb	O
or	O
IV	O
NSCLC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
with	O
two	O
or	O
fewer	O
prior	O
chemotherapy	O
regimens	O
,	O
one	O
platinum	B-ChemicalEntity
based	O
(	O
stratum	O
1	O
)	O
or	O
both	O
chemotherapy	O
and	O
epidermal	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
tyrosine	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
inhibitors	O
(	O
stratum	O
2	O
)	O
,	O
received	O
RAD001	B-ChemicalEntity
10	O
mg	O
/	O
day	O
until	O
progression	O
or	O
unacceptable	O
toxicity	B-DiseaseOrPhenotypicFeature
.	O

Primary	O
objective	O
was	O
overall	O
response	O
rate	O
(	O
ORR	O
)	O
.	O

Analyses	O
of	O
markers	O
associated	O
with	O
the	O
mTOR	B-GeneOrGeneProduct
pathway	O
were	O
carried	O
out	O
on	O
archival	O
tumor	B-DiseaseOrPhenotypicFeature
from	O
a	O
subgroup	O
using	O
immunohistochemistry	O
(	O
IHC	O
)	O
and	O
direct	O
mutation	O
sequencing	O
.	O

RESULTS	O
:	O
Eighty	O
-	O
five	O
patients	B-OrganismTaxon
were	O
enrolled	O
,	O
42	O
in	O
stratum	O
1	O
and	O
43	O
in	O
stratum	O
.	O

ORR	O
was	O
4	O
.	O
7%	O
(	O
7	O
.	O
1%	O
stratum	O
1	O
;	O
2	O
.	O
3%	O
stratum	O
2	O
)	O
.	O

Overall	O
disease	O
control	O
rate	O
was	O
47	O
.	O
1%	O
.	O

Median	O
progression	O
-	O
free	O
survivals	O
(	O
PFSs	O
)	O
were	O
2	O
.	O
6	O
(	O
stratum	O
1	O
)	O
and	O
2	O
.	O
7	O
months	O
(	O
stratum	O
2	O
)	O
.	O

Common	O
>	O
or	O
=	O
grade	O
3	O
events	O
were	O
fatigue	B-DiseaseOrPhenotypicFeature
,	O
dyspnea	B-DiseaseOrPhenotypicFeature
,	O
stomatitis	B-DiseaseOrPhenotypicFeature
,	O
anemia	B-DiseaseOrPhenotypicFeature
,	O
and	O
thrombocytopenia	B-DiseaseOrPhenotypicFeature
.	O

Pneumonitis	B-DiseaseOrPhenotypicFeature
,	O
probably	O
or	O
possibly	O
related	O
,	O
mainly	O
grade	O
1	O
/	O
2	O
,	O
occurred	O
in	O
25%	O
.	O

Cox	O
regression	O
analysis	O
of	O
IHC	O
scores	O
found	O
that	O
only	O
phospho	O
AKT	B-GeneOrGeneProduct
(	O
pAKT	B-GeneOrGeneProduct
)	O
was	O
a	O
significant	O
independent	O
predictor	O
of	O
worse	O
PFS	O
.	O

CONCLUSIONS	O
:	O
RAD001	B-ChemicalEntity
10	O
mg	O
/	O
day	O
was	O
well	O
tolerated	O
,	O
showing	O
modest	O
clinical	O
activity	O
in	O
pretreated	O
NSCLC	B-DiseaseOrPhenotypicFeature
.	O

Evaluation	O
of	O
RAD001	B-ChemicalEntity
plus	O
standard	O
therapy	O
for	O
metastatic	O
NSCLC	B-DiseaseOrPhenotypicFeature
continues	O
.	O
Decreased	O
Whole	O
-	O
Body	O
Fat	O
Mass	O
Produced	O
by	O
Chronic	O
Alcohol	B-ChemicalEntity
Consumption	O
is	O
Associated	O
with	O
Activation	O
of	O
S6K1	B-GeneOrGeneProduct
-	O
Mediated	O
Protein	O
Synthesis	O
and	O
Increased	O
Autophagy	O
in	O
Epididymal	O
White	O
Adipose	O
Tissue	O
.	O

BACKGROUND	O
:	O
Chronic	O
alcohol	B-ChemicalEntity
consumption	O
leads	O
to	O
a	O
loss	O
of	O
white	O
adipose	O
tissue	O
(	O
WAT	O
)	O
but	O
the	O
underlying	O
mechanisms	O
for	O
this	O
lipodystrophy	B-DiseaseOrPhenotypicFeature
are	O
not	O
fully	O
elucidated	O
.	O

This	O
study	O
tested	O
the	O
hypothesis	O
that	O
the	O
reduction	O
in	O
WAT	O
mass	O
in	O
chronic	O
alcohol	B-ChemicalEntity
-	O
fed	O
mice	B-OrganismTaxon
is	O
associated	O
with	O
a	O
decreased	O
protein	O
synthesis	O
specifically	O
related	O
to	O
impaired	O
function	O
of	O
mammalian	B-GeneOrGeneProduct
target	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
rapamycin	I-GeneOrGeneProduct
(	O
mTOR	B-GeneOrGeneProduct
)	O
.	O

METHODS	O
:	O
Adult	O
male	O
mice	B-OrganismTaxon
were	O
provided	O
an	O
alcohol	B-ChemicalEntity
-	O
containing	O
liquid	O
diet	O
for	O
24	O
weeks	O
or	O
an	O
isonitrogenous	O
isocaloric	O
control	O
diet	O
.	O

In	O
vivo	O
protein	O
synthesis	O
was	O
determined	O
at	O
this	O
time	O
and	O
thereafter	O
epididymal	O
WAT	O
(	O
eWAT	O
)	O
was	O
excised	O
for	O
analysis	O
of	O
signal	O
transduction	O
pathways	O
central	O
to	O
controling	O
protein	O
synthesis	O
and	O
degradation	O
.	O

RESULTS	O
:	O
While	O
chronic	O
alcohol	B-ChemicalEntity
feeding	O
decreased	O
whole	O
-	O
body	O
and	O
eWAT	O
mass	O
,	O
this	O
was	O
associated	O
with	O
a	O
discordant	O
increase	O
in	O
protein	O
synthesis	O
in	O
eWAT	O
.	O

This	O
increase	O
was	O
not	O
associated	O
with	O
a	O
change	O
in	O
mTOR	B-GeneOrGeneProduct
,	O
4E	B-GeneOrGeneProduct
-	O
BP1	I-GeneOrGeneProduct
,	O
Akt	B-GeneOrGeneProduct
,	O
or	O
PRAS40	B-GeneOrGeneProduct
phosphorylation	O
.	O

Instead	O
,	O
a	O
selective	O
increase	O
in	O
phosphorylation	O
of	O
S6K1	B-GeneOrGeneProduct
and	O
its	O
downstream	O
substrates	O
,	O
S6	B-GeneOrGeneProduct
and	O
eIF4B	B-GeneOrGeneProduct
was	O
detected	O
in	O
alcohol	B-ChemicalEntity
-	O
fed	O
mice	B-OrganismTaxon
.	O

Alcohol	B-ChemicalEntity
also	O
increased	O
eEF2K	B-GeneOrGeneProduct
phosphorylation	O
and	O
decreased	O
eEF2	B-GeneOrGeneProduct
phosphorylation	O
consistent	O
with	O
increased	O
translation	O
elongation	O
.	O

Alcohol	B-ChemicalEntity
increased	O
Atg12	B-GeneOrGeneProduct
-	O
5	I-GeneOrGeneProduct
,	O
LC3B	B-GeneOrGeneProduct
-	O
I	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
-	O
II	I-GeneOrGeneProduct
,	O
and	O
ULK1	B-GeneOrGeneProduct
S555	B-SequenceVariant
phosphorylation	O
,	O
suggesting	O
increased	O
autophagy	O
,	O
while	O
markers	O
of	O
apoptosis	O
(	O
cleaved	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
,	O
and	O
PARP	B-GeneOrGeneProduct
)	O
were	O
unchanged	O
.	O

Lipolytic	O
enzymes	O
(	O
ATGL	B-GeneOrGeneProduct
and	O
HSL	B-GeneOrGeneProduct
phosphorylation	O
)	O
were	O
increased	O
and	O
lipogenic	O
regulators	O
(	O
PPARgamma	B-GeneOrGeneProduct
and	O
C	B-GeneOrGeneProduct
/	O
EBPalpha	I-GeneOrGeneProduct
)	O
were	O
decreased	O
in	O
eWAT	O
by	O
alcohol	B-ChemicalEntity
.	O

Although	O
alcohol	B-ChemicalEntity
increased	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
,	O
and	O
IL	B-GeneOrGeneProduct
-	O
1beta	I-GeneOrGeneProduct
mRNA	O
,	O
no	O
change	O
in	O
key	O
components	O
of	O
the	O
NLRP3	B-GeneOrGeneProduct
inflammasome	O
(	O
NLRP3	B-GeneOrGeneProduct
,	O
ACS	B-GeneOrGeneProduct
,	O
and	O
cleaved	O
caspase	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
was	O
detected	O
suggesting	O
alcohol	B-ChemicalEntity
did	O
not	O
increase	O
pyroptosis	O
.	O

Plasma	O
insulin	B-GeneOrGeneProduct
did	O
not	O
differ	O
between	O
groups	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
demonstrate	O
that	O
the	O
alcohol	B-ChemicalEntity
-	O
induced	O
decrease	O
in	O
whole	O
-	O
body	O
fat	O
mass	O
resulted	O
in	O
part	O
from	O
activation	O
of	O
autophagy	O
in	O
eWAT	O
as	O
protein	O
synthesis	O
was	O
increased	O
and	O
mediated	O
by	O
the	O
specific	O
increase	O
in	O
the	O
activity	O
of	O
S6K1	B-GeneOrGeneProduct
.	O
A	O
potential	O
regulatory	O
single	O
nucleotide	O
polymorphism	O
in	O
the	O
promoter	O
of	O
the	O
Klotho	B-GeneOrGeneProduct
gene	O
may	O
be	O
associated	O
with	O
essential	B-DiseaseOrPhenotypicFeature
hypertension	I-DiseaseOrPhenotypicFeature
in	O
the	O
Chinese	O
Han	O
population	O
.	O

BACKGROUND	O
:	O
Mice	B-OrganismTaxon
with	O
defects	O
in	O
the	O
Klotho	B-GeneOrGeneProduct
gene	O
exhibit	O
multiple	O
aging	O
phenotypes	O
including	O
arteriosclerosis	B-DiseaseOrPhenotypicFeature
.	O

We	O
hypothesised	O
that	O
the	O
G	B-SequenceVariant
-	O
395A	I-SequenceVariant
polymorphism	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	B-OrganismTaxon
Klotho	B-GeneOrGeneProduct
gene	O
may	O
contribute	O
to	O
the	O
prevalence	O
of	O
Essential	B-DiseaseOrPhenotypicFeature
Hypertension	I-DiseaseOrPhenotypicFeature
(	O
EH	B-DiseaseOrPhenotypicFeature
)	O
.	O

METHODS	O
:	O
We	O
investigate	O
whether	O
the	O
G	B-SequenceVariant
-	O
395A	I-SequenceVariant
polymorphism	O
of	O
Klotho	B-GeneOrGeneProduct
is	O
associated	O
with	O
EH	B-DiseaseOrPhenotypicFeature
in	O
a	O
population	O
consisting	O
of	O
215	O
patients	B-OrganismTaxon
with	O
EH	B-DiseaseOrPhenotypicFeature
and	O
220	O
non	O
-	O
hypertensive	B-DiseaseOrPhenotypicFeature
subjects	O
.	O

We	O
also	O
tested	O
whether	O
a	O
G	B-SequenceVariant
/	O
A	I-SequenceVariant
substitution	O
at	O
the	O
G	B-SequenceVariant
-	O
395A	I-SequenceVariant
site	O
affected	O
the	O
transcription	O
level	O
in	O
vitro	O
through	O
the	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
.	O

RESULTS	O
:	O
Differences	O
in	O
the	O
genotype	O
distributions	O
of	O
the	O
G	B-SequenceVariant
-	O
395A	I-SequenceVariant
polymorphism	O
between	O
the	O
EH	B-DiseaseOrPhenotypicFeature
and	O
non	O
-	O
hypertension	B-DiseaseOrPhenotypicFeature
groups	O
are	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
032	O
)	O
.	O

There	O
are	O
differential	O
effects	O
of	O
age	O
,	O
gender	O
and	O
smoking	O
status	O
on	O
the	O
association	O
of	O
the	O
G	B-SequenceVariant
-	O
395A	I-SequenceVariant
polymorphism	O
with	O
EH	B-DiseaseOrPhenotypicFeature
;	O
the	O
G	B-SequenceVariant
-	O
395A	I-SequenceVariant
polymorphism	O
is	O
significantly	O
associated	O
with	O
EH	B-DiseaseOrPhenotypicFeature
in	O
subjects	O
over	O
60years	O
old	O
,	O
in	O
females	O
and	O
in	O
nonsmokers	O
.	O

A	O
multiple	O
logistic	O
regression	O
analysis	O
indicated	O
that	O
the	O
odds	O
ratio	O
for	O
EH	B-DiseaseOrPhenotypicFeature
in	O
the	O
-	O
395A	I-SequenceVariant
allele	O
carriers	O
as	O
compared	O
with	O
the	O
control	O
group	O
was	O
0	O
.	O
593	O
(	O
P	O
=	O
0	O
.	O
024	O
)	O
after	O
adjusting	O
for	O
current	O
traditional	O
risk	O
factors	O
.	O

The	O
dual	O
-	O
luciferase	O
reporter	O
assay	O
revealed	O
that	O
the	O
-	O
395A	I-SequenceVariant
carrier	O
of	O
a	O
498	O
-	O
bp	O
DNA	O
fragment	O
(	O
containing	O
the	O
G	B-SequenceVariant
-	O
395A	I-SequenceVariant
site	O
)	O
upstream	O
of	O
the	O
Klotho	B-GeneOrGeneProduct
gene	O
has	O
higher	O
relative	O
luciferase	O
activity	O
than	O
the	O
-	O
395G	I-SequenceVariant
carrier	O
.	O

CONCLUSIONS	O
:	O
The	O
G	B-SequenceVariant
-	O
395A	I-SequenceVariant
polymorphism	O
of	O
the	O
human	B-OrganismTaxon
Klotho	B-GeneOrGeneProduct
gene	O
is	O
associated	O
with	O
EH	B-DiseaseOrPhenotypicFeature
and	O
may	O
be	O
a	O
potential	O
regulatory	O
site	O
.	O
Protective	O
effects	O
of	O
antithrombin	B-ChemicalEntity
on	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
nephrosis	B-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
.	O

We	O
investigated	O
the	O
effects	O
of	O
antithrombin	B-ChemicalEntity
,	O
a	O
plasma	O
inhibitor	O
of	O
coagulation	O
factors	O
,	O
in	O
rats	B-OrganismTaxon
with	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
-	O
induced	O
nephrosis	B-DiseaseOrPhenotypicFeature
,	O
which	O
is	O
an	O
experimental	O
model	O
of	O
human	B-OrganismTaxon
nephrotic	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Antithrombin	B-ChemicalEntity
(	O
50	O
or	O
500	O
IU	O
/	O
kg	O
/	O
i	O
.	O
v	O
.	O
)	O
was	O
administered	O
to	O
rats	B-OrganismTaxon
once	O
a	O
day	O
for	O
10	O
days	O
immediately	O
after	O
the	O
injection	O
of	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
(	O
50	O
mg	O
/	O
kg	O
/	O
i	O
.	O
v	O
.	O
)	O
.	O

Treatment	O
with	O
antithrombin	B-ChemicalEntity
attenuated	O
the	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
-	O
induced	O
hematological	B-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
.	O

Puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
-	O
induced	O
renal	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
and	O
hyperlipidemia	B-DiseaseOrPhenotypicFeature
were	O
also	O
suppressed	O
.	O

Histopathological	O
examination	O
revealed	O
severe	O
renal	B-DiseaseOrPhenotypicFeature
damage	I-DiseaseOrPhenotypicFeature
such	O
as	O
proteinaceous	O
casts	O
in	O
tubuli	O
and	O
tubular	O
expansion	O
in	O
the	O
kidney	O
of	O
control	O
rats	B-OrganismTaxon
,	O
while	O
an	O
improvement	O
of	O
the	O
damage	O
was	O
seen	O
in	O
antithrombin	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
.	O

In	O
addition	O
,	O
antithrombin	B-ChemicalEntity
treatment	O
markedly	O
suppressed	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
-	O
induced	O
apoptosis	O
of	O
renal	O
tubular	O
epithelial	O
cells	O
.	O

Furthermore	O
,	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
-	O
induced	O
increases	O
in	O
renal	O
cytokine	O
content	O
were	O
also	O
decreased	O
.	O

These	O
findings	O
suggest	O
that	O
thrombin	B-GeneOrGeneProduct
plays	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
-	O
induced	O
nephrotic	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Treatment	O
with	O
antithrombin	B-ChemicalEntity
may	O
be	O
clinically	O
effective	O
in	O
patients	B-OrganismTaxon
with	O
nephrotic	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O
A	O
single	O
amino	O
acid	O
substitution	O
confers	O
B	O
-	O
cell	O
clonogenic	O
activity	O
to	O
the	O
HIV	B-OrganismTaxon
-	O
1	I-OrganismTaxon
matrix	O
protein	O
p17	B-GeneOrGeneProduct
.	O

Recent	O
data	O
highlight	O
the	O
presence	O
,	O
in	O
HIV	B-DiseaseOrPhenotypicFeature
-	O
1	I-DiseaseOrPhenotypicFeature
-	O
seropositive	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
lymphoma	B-DiseaseOrPhenotypicFeature
,	O
of	O
p17	B-GeneOrGeneProduct
variants	O
(	O
vp17s	O
)	O
endowed	O
with	O
B	O
-	O
cell	O
clonogenicity	O
,	O
suggesting	O
a	O
role	O
of	O
vp17s	O
in	O
lymphomagenesis	B-DiseaseOrPhenotypicFeature
.	O

We	O
investigated	O
the	O
mechanisms	O
responsible	O
for	O
the	O
functional	O
disparity	O
on	O
B	O
cells	O
between	O
a	O
wild	O
-	O
type	O
p17	B-GeneOrGeneProduct
(	O
refp17	O
)	O
and	O
a	O
vp17	O
named	O
S75X	B-SequenceVariant
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
single	O
Arginine	B-SequenceVariant
(	O
R	I-SequenceVariant
)	O
to	I-SequenceVariant
Glycine	I-SequenceVariant
(	O
G	I-SequenceVariant
)	O
mutation	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
76	I-SequenceVariant
in	O
the	O
refp17	O
backbone	O
(	O
p17R76G	B-GeneOrGeneProduct
)	O
,	O
as	O
in	O
the	O
S75X	B-SequenceVariant
variant	O
,	O
is	O
per	O
se	O
sufficient	O
to	O
confer	O
a	O
B	O
-	O
cell	O
clonogenic	O
potential	O
to	O
the	O
viral	O
protein	O
and	O
modulate	O
,	O
through	O
activation	O
of	O
the	O
PTEN	B-GeneOrGeneProduct
/	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
signaling	O
pathway	O
,	O
different	O
molecules	O
involved	O
in	O
apoptosis	O
inhibition	O
(	O
CASP	B-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
,	O
CASP	B-GeneOrGeneProduct
-	O
7	I-GeneOrGeneProduct
,	O
DFF	B-GeneOrGeneProduct
-	O
45	I-GeneOrGeneProduct
,	O
NPM	B-GeneOrGeneProduct
,	O
YWHAZ	B-GeneOrGeneProduct
,	O
Src	B-GeneOrGeneProduct
,	O
PAX2	B-GeneOrGeneProduct
,	O
MAPK8	B-GeneOrGeneProduct
)	O
,	O
cell	O
cycle	O
promotion	O
and	O
cancer	B-DiseaseOrPhenotypicFeature
progression	O
(	O
CDK1	B-GeneOrGeneProduct
,	O
CDK2	B-GeneOrGeneProduct
,	O
CDK8	B-GeneOrGeneProduct
,	O
CHEK1	B-GeneOrGeneProduct
,	O
CHEK2	B-GeneOrGeneProduct
,	O
GSK	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
,	O
NPM	B-GeneOrGeneProduct
,	O
PAK1	B-GeneOrGeneProduct
,	O
PP2C	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
)	O
.	O

Moreover	O
,	O
the	O
only	O
R	B-SequenceVariant
to	I-SequenceVariant
G	I-SequenceVariant
mutation	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
76	I-SequenceVariant
was	O
found	O
to	O
strongly	O
impact	O
on	O
protein	O
folding	O
and	O
oligomerization	O
by	O
altering	O
the	O
hydrogen	O
bond	O
network	O
.	O

This	O
generates	O
a	O
conformational	O
shift	O
in	O
the	O
p17	B-GeneOrGeneProduct
R76G	B-SequenceVariant
mutant	O
which	O
enables	O
a	O
functional	O
epitope	O
(	O
s	O
)	O
,	O
masked	O
in	O
refp17	O
,	O
to	O
elicit	O
B	O
-	O
cell	O
growth	O
-	O
promoting	O
signals	O
after	O
its	O
interaction	O
with	O
a	O
still	O
unknown	O
receptor	O
(	O
s	O
)	O
.	O

Our	O
findings	O
offer	O
new	O
opportunities	O
to	O
understand	O
the	O
molecular	O
mechanisms	O
accounting	O
for	O
the	O
B	O
-	O
cell	O
growth	O
-	O
promoting	O
activity	O
of	O
vp17s	O
.	O
Mutation	O
analysis	O
of	O
CHRNA1	B-GeneOrGeneProduct
,	O
CHRNB1	B-GeneOrGeneProduct
,	O
CHRND	B-GeneOrGeneProduct
,	O
and	O
RAPSN	B-GeneOrGeneProduct
genes	O
in	O
multiple	B-DiseaseOrPhenotypicFeature
pterygium	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
/	O
fetal	B-DiseaseOrPhenotypicFeature
akinesia	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

Multiple	B-DiseaseOrPhenotypicFeature
pterygium	I-DiseaseOrPhenotypicFeature
syndromes	I-DiseaseOrPhenotypicFeature
(	O
MPS	B-DiseaseOrPhenotypicFeature
)	O
comprise	O
a	O
group	O
of	O
multiple	O
congenital	B-DiseaseOrPhenotypicFeature
anomaly	I-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
characterized	O
by	O
webbing	O
(	O
pterygia	O
)	O
of	O
the	O
neck	O
,	O
elbows	O
,	O
and	O
/	O
or	O
knees	O
and	O
joint	B-DiseaseOrPhenotypicFeature
contractures	I-DiseaseOrPhenotypicFeature
(	O
arthrogryposis	B-DiseaseOrPhenotypicFeature
)	O
.	O

MPS	B-DiseaseOrPhenotypicFeature
are	O
phenotypically	O
and	O
genetically	O
heterogeneous	O
but	O
are	O
traditionally	O
divided	O
into	O
prenatally	O
lethal	O
and	O
nonlethal	O
(	O
Escobar	O
)	O
types	O
.	O

Previously	O
,	O
we	O
and	O
others	O
reported	O
that	O
recessive	O
mutations	O
in	O
the	O
embryonal	B-GeneOrGeneProduct
acetylcholine	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
g	I-GeneOrGeneProduct
subunit	I-GeneOrGeneProduct
(	O
CHRNG	B-GeneOrGeneProduct
)	O
can	O
cause	O
both	O
lethal	O
and	O
nonlethal	O
MPS	B-DiseaseOrPhenotypicFeature
,	O
thus	O
demonstrating	O
that	O
pterygia	O
resulted	O
from	O
fetal	B-DiseaseOrPhenotypicFeature
akinesia	I-DiseaseOrPhenotypicFeature
.	O

We	O
hypothesized	O
that	O
mutations	O
in	O
acetylcholine	O
receptor	O
-	O
related	O
genes	O
might	O
also	O
result	O
in	O
a	O
MPS	B-DiseaseOrPhenotypicFeature
/	O
fetal	B-DiseaseOrPhenotypicFeature
akinesia	I-DiseaseOrPhenotypicFeature
phenotype	O
and	O
so	O
we	O
analyzed	O
15	O
cases	O
of	O
lethal	O
MPS	B-DiseaseOrPhenotypicFeature
/	O
fetal	B-DiseaseOrPhenotypicFeature
akinesia	I-DiseaseOrPhenotypicFeature
without	O
CHRNG	B-GeneOrGeneProduct
mutations	O
for	O
mutations	O
in	O
the	O
CHRNA1	B-GeneOrGeneProduct
,	O
CHRNB1	B-GeneOrGeneProduct
,	O
CHRND	B-GeneOrGeneProduct
,	O
and	O
rapsyn	B-GeneOrGeneProduct
(	O
RAPSN	B-GeneOrGeneProduct
)	O
genes	O
.	O

No	O
CHRNA1	B-GeneOrGeneProduct
,	O
CHRNB1	B-GeneOrGeneProduct
,	O
or	O
CHRND	B-GeneOrGeneProduct
mutations	O
were	O
detected	O
,	O
but	O
a	O
homozygous	O
RAPSN	B-GeneOrGeneProduct
frameshift	O
mutation	O
,	O
c	B-SequenceVariant
.	O
1177	I-SequenceVariant
-	O
1178delAA	I-SequenceVariant
,	O
was	O
identified	O
in	O
a	O
family	O
with	O
three	O
children	O
affected	O
with	O
lethal	O
fetal	B-DiseaseOrPhenotypicFeature
akinesia	I-DiseaseOrPhenotypicFeature
sequence	I-DiseaseOrPhenotypicFeature
.	O

Previously	O
,	O
RAPSN	B-GeneOrGeneProduct
mutations	O
have	O
been	O
reported	O
in	O
congenital	B-DiseaseOrPhenotypicFeature
myasthenia	I-DiseaseOrPhenotypicFeature
.	O

Functional	O
studies	O
were	O
consistent	O
with	O
the	O
hypothesis	O
that	O
whereas	O
incomplete	O
loss	O
of	O
rapsyn	B-GeneOrGeneProduct
function	O
may	O
cause	O
congenital	B-DiseaseOrPhenotypicFeature
myasthenia	I-DiseaseOrPhenotypicFeature
,	O
more	O
severe	O
loss	O
of	O
function	O
can	O
result	O
in	O
a	O
lethal	O
fetal	B-DiseaseOrPhenotypicFeature
akinesia	I-DiseaseOrPhenotypicFeature
phenotype	O
.	O
Comparison	O
of	O
sequential	O
cytomegalovirus	B-OrganismTaxon
isolates	O
in	O
a	O
patient	B-OrganismTaxon
with	O
lymphoma	B-DiseaseOrPhenotypicFeature
and	O
failing	O
antiviral	O
therapy	O
.	O

BACKGROUND	O
:	O
Long	B-DiseaseOrPhenotypicFeature
-	O
term	I-DiseaseOrPhenotypicFeature
anti	I-DiseaseOrPhenotypicFeature
-	O
cytomegalovirus	I-DiseaseOrPhenotypicFeature
(	O
CMV	B-DiseaseOrPhenotypicFeature
)	O
treatments	O
in	O
immunocompromised	O
patients	B-OrganismTaxon
are	O
hampered	O
by	O
resistance	O
to	O
antiviral	O
drugs	O
.	O

Longitudinal	O
changes	O
in	O
the	O
resistance	O
genotype	O
may	O
depend	O
on	O
changes	O
in	O
selective	O
pressure	O
and	O
the	O
complexity	O
of	O
CMV	B-DiseaseOrPhenotypicFeature
isolates	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
longitudinal	O
changes	O
in	O
the	O
CMV	B-DiseaseOrPhenotypicFeature
resistance	O
genotype	O
and	O
phenotype	O
along	O
with	O
strain	O
-	O
specific	O
variability	O
in	O
a	O
patient	B-OrganismTaxon
with	O
non	B-DiseaseOrPhenotypicFeature
-	O
Hodgkin	I-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
in	O
whom	O
successive	O
anti	O
-	O
CMV	B-DiseaseOrPhenotypicFeature
treatments	O
failed	O
.	O

STUDY	O
DESIGN	O
:	O
The	O
resistance	O
phenotype	O
and	O
genotype	O
of	O
seven	O
CMV	B-DiseaseOrPhenotypicFeature
isolates	O
collected	O
from	O
one	O
patient	B-OrganismTaxon
during	O
a	O
2	O
-	O
year	O
follow	O
-	O
up	O
period	O
were	O
retrospectively	O
analysed	O
.	O

In	O
parallel	O
,	O
we	O
used	O
glycoprotein	B-GeneOrGeneProduct
B	I-GeneOrGeneProduct
(	O
gB	B-GeneOrGeneProduct
)	O
genotyping	O
,	O
and	O
a	O
-	O
and	O
UL10	O
-	O
13	O
-	O
sequence	O
analysis	O
to	O
study	O
CMV	B-DiseaseOrPhenotypicFeature
interstrain	O
variability	O
.	O

RESULTS	O
:	O
The	O
patient	B-OrganismTaxon
was	O
infected	O
by	O
at	O
least	O
three	O
CMV	B-DiseaseOrPhenotypicFeature
strains	O
plus	O
variants	O
of	O
the	O
parental	O
strains	O
.	O

Resistance	O
to	O
ganciclovir	B-ChemicalEntity
,	O
cidofovir	B-ChemicalEntity
and	O
foscarnet	B-ChemicalEntity
was	O
successively	O
detected	O
during	O
the	O
follow	O
-	O
up	O
period	O
.	O

UL97	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
changes	O
responsible	O
for	O
resistance	O
to	O
ganciclovir	B-ChemicalEntity
were	O
initially	O
detected	O
at	O
residues	O
591	O
and	O
592	O
,	O
and	O
then	O
at	O
position	O
594	O
.	O

Decreased	O
sensitivity	O
to	O
foscarnet	B-ChemicalEntity
coincided	O
with	O
the	O
appearance	O
of	O
amino	O
acid	O
substitution	O
N495K	B-SequenceVariant
in	O
DNA	O
polymerase	O
,	O
whereas	O
cross	O
-	O
resistance	O
to	O
ganciclovir	B-ChemicalEntity
and	O
cidofovir	B-ChemicalEntity
was	O
due	O
to	O
the	O
L501I	B-SequenceVariant
substitution	O
.	O

CONCLUSIONS	O
:	O
The	O
CMV	B-DiseaseOrPhenotypicFeature
isolates	O
obtained	O
from	O
our	O
patient	B-OrganismTaxon
were	O
complex	O
mixtures	O
of	O
strains	O
.	O

Changes	O
in	O
resistance	O
genotypes	O
depended	O
on	O
resistance	O
selective	O
pressure	O
and	O
were	O
not	O
linked	O
to	O
interstrain	O
variation	O
.	O
Bortezomib	B-ChemicalEntity
and	O
dexamethasone	B-ChemicalEntity
as	O
salvage	O
therapy	O
in	O
patients	B-OrganismTaxon
with	O
relapsed	O
/	O
refractory	O
multiple	B-DiseaseOrPhenotypicFeature
myeloma	I-DiseaseOrPhenotypicFeature
:	O
analysis	O
of	O
long	O
-	O
term	O
clinical	O
outcomes	O
.	O

Bortezomib	B-ChemicalEntity
(	O
bort	B-ChemicalEntity
)	O
-	O
dexamethasone	B-ChemicalEntity
(	O
dex	B-ChemicalEntity
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
(	O
R	O
/	O
R	O
)	O
multiple	B-DiseaseOrPhenotypicFeature
myeloma	I-DiseaseOrPhenotypicFeature
(	O
MM	B-DiseaseOrPhenotypicFeature
)	O
.	O

This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	B-ChemicalEntity
(	O
1	O
.	O
3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	B-ChemicalEntity
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
bort	B-ChemicalEntity
)	O
as	O
salvage	O
treatment	O
in	O
85	O
patients	B-OrganismTaxon
with	O
R	O
/	O
R	O
MM	B-DiseaseOrPhenotypicFeature
after	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
or	O
conventional	O
chemotherapy	O
.	O

The	O
median	O
number	O
of	O
prior	O
lines	O
of	O
therapy	O
was	O
2	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
patients	B-OrganismTaxon
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort	B-ChemicalEntity
-	O
dex	B-ChemicalEntity
.	O

The	O
median	O
number	O
of	O
bort	B-ChemicalEntity
-	O
dex	B-ChemicalEntity
cycles	O
was	O
6	O
,	O
up	O
to	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O

On	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
,	O
55	O
%	O
of	O
the	O
patients	B-OrganismTaxon
achieved	O
at	O
least	O
partial	O
response	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
partial	O
response	O
.	O

Median	O
durations	O
of	O
response	O
,	O
time	O
to	O
next	O
therapy	O
and	O
treatment	O
-	O
free	O
interval	O
were	O
8	O
,	O
11	O
.	O
2	O
,	O
and	O
5	O
.	O
1	O
months	O
,	O
respectively	O
.	O

The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	B-DiseaseOrPhenotypicFeature
neuropathy	I-DiseaseOrPhenotypicFeature
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patients	B-OrganismTaxon
(	O
grade	O
II	O
,	O
38	O
%	O
;	O
grade	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatment	O
discontinuation	O
in	O
6	O
%	O
.	O

With	O
a	O
median	O
follow	O
up	O
of	O
22	O
months	O
,	O
median	O
time	O
to	O
progression	O
,	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
8	O
.	O
9	O
,	O
8	O
.	O
7	O
,	O
and	O
22	O
months	O
,	O
respectively	O
.	O

Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	B-OrganismTaxon
achieving	O
CR	O
and	O
receiving	O
bort	B-ChemicalEntity
-	O
dex	B-ChemicalEntity
a	O
single	O
line	O
of	O
prior	O
therapy	O
.	O

Bort	B-ChemicalEntity
-	O
dex	B-ChemicalEntity
was	O
an	O
effective	O
salvage	O
treatment	O
for	O
MM	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
particularly	O
for	O
those	O
in	O
first	O
relapse	O
.	O
Adenosine	B-GeneOrGeneProduct
A	I-GeneOrGeneProduct
(	O
2A	I-GeneOrGeneProduct
)	O
receptor	I-GeneOrGeneProduct
gene	O
(	O
ADORA2A	B-GeneOrGeneProduct
)	O
variants	O
may	O
increase	O
autistic	B-DiseaseOrPhenotypicFeature
symptoms	I-DiseaseOrPhenotypicFeature
and	O
anxiety	B-DiseaseOrPhenotypicFeature
in	O
autism	B-DiseaseOrPhenotypicFeature
spectrum	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
.	O

Autism	B-DiseaseOrPhenotypicFeature
spectrum	I-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
(	O
ASDs	B-DiseaseOrPhenotypicFeature
)	O
are	O
heterogeneous	O
disorders	O
presenting	O
with	O
increased	O
rates	O
of	O
anxiety	B-DiseaseOrPhenotypicFeature
.	O

The	O
adenosine	B-GeneOrGeneProduct
A	I-GeneOrGeneProduct
(	O
2A	I-GeneOrGeneProduct
)	O
receptor	I-GeneOrGeneProduct
gene	O
(	O
ADORA2A	B-GeneOrGeneProduct
)	O
is	O
associated	O
with	O
panic	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
and	O
is	O
located	O
on	O
chromosome	O
22q11	O
.	O
23	O
.	O

Its	O
gene	O
product	O
,	O
the	O
adenosine	B-GeneOrGeneProduct
A	I-GeneOrGeneProduct
(	O
2A	I-GeneOrGeneProduct
)	O
receptor	I-GeneOrGeneProduct
,	O
is	O
strongly	O
expressed	O
in	O
the	O
caudate	O
nucleus	O
,	O
which	O
also	O
is	O
involved	O
in	O
ASD	B-DiseaseOrPhenotypicFeature
.	O

As	O
autistic	B-DiseaseOrPhenotypicFeature
symptoms	I-DiseaseOrPhenotypicFeature
are	O
increased	O
in	O
individuals	O
with	O
22q11	B-DiseaseOrPhenotypicFeature
.	O
2	I-DiseaseOrPhenotypicFeature
deletion	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
,	O
and	O
large	O
22q11	B-DiseaseOrPhenotypicFeature
.	O
2	I-DiseaseOrPhenotypicFeature
deletions	I-DiseaseOrPhenotypicFeature
and	O
duplications	O
have	O
been	O
observed	O
in	O
ASD	B-DiseaseOrPhenotypicFeature
individuals	O
,	O
in	O
this	O
study	O
,	O
98	O
individuals	O
with	O
ASD	B-DiseaseOrPhenotypicFeature
and	O
234	O
control	O
individuals	O
were	O
genotyped	O
for	O
eight	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
ADORA2A	B-GeneOrGeneProduct
.	O

Nominal	O
association	O
with	O
the	O
disorder	O
was	O
observed	O
for	O
rs2236624	B-SequenceVariant
-	O
CC	O
,	O
and	O
phenotypic	O
variability	O
in	O
ASD	B-DiseaseOrPhenotypicFeature
symptoms	O
was	O
influenced	O
by	O
rs3761422	B-SequenceVariant
,	O
rs5751876	B-SequenceVariant
and	O
rs35320474	B-SequenceVariant
.	O

In	O
addition	O
,	O
association	O
of	O
ADORA2A	B-GeneOrGeneProduct
variants	O
with	O
anxiety	B-DiseaseOrPhenotypicFeature
was	O
replicated	O
for	O
individuals	O
with	O
ASD	B-DiseaseOrPhenotypicFeature
.	O

Findings	O
point	O
toward	O
a	O
possible	O
mediating	O
role	O
of	O
ADORA2A	B-GeneOrGeneProduct
variants	O
on	O
phenotypic	O
expression	O
in	O
ASD	B-DiseaseOrPhenotypicFeature
that	O
need	O
to	O
be	O
replicated	O
in	O
a	O
larger	O
sample	O
.	O
Hypoxia	B-DiseaseOrPhenotypicFeature
in	O
renal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
with	O
proteinuria	B-DiseaseOrPhenotypicFeature
and	O
/	O
or	O
glomerular	O
hypertension	B-DiseaseOrPhenotypicFeature
.	O

Despite	O
the	O
increasing	O
need	O
to	O
identify	O
and	O
quantify	O
tissue	O
oxygenation	O
at	O
the	O
cellular	O
level	O
,	O
relatively	O
few	O
methods	O
have	O
been	O
available	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
a	O
new	O
hypoxia	B-DiseaseOrPhenotypicFeature
-	O
responsive	O
reporter	O
vector	O
using	O
a	O
hypoxia	B-DiseaseOrPhenotypicFeature
-	O
responsive	O
element	O
of	O
the	O
5	O
'	O
vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
untranslated	O
region	O
and	O
generated	O
a	O
novel	O
hypoxia	B-DiseaseOrPhenotypicFeature
-	O
sensing	O
transgenic	O
rat	B-OrganismTaxon
.	O

We	O
then	O
applied	O
this	O
animal	O
model	O
to	O
the	O
detection	O
of	O
tubulointerstitial	O
hypoxia	B-DiseaseOrPhenotypicFeature
in	O
the	O
diseased	B-DiseaseOrPhenotypicFeature
kidney	I-DiseaseOrPhenotypicFeature
.	O

With	O
this	O
model	O
,	O
we	O
were	O
able	O
to	O
identify	O
diffuse	O
cortical	O
hypoxia	B-DiseaseOrPhenotypicFeature
in	O
the	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
-	O
induced	O
nephrotic	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
and	O
focal	O
and	O
segmental	O
hypoxia	B-DiseaseOrPhenotypicFeature
in	O
the	O
remnant	O
kidney	O
model	O
.	O

Expression	O
of	O
the	O
hypoxia	B-DiseaseOrPhenotypicFeature
-	O
responsive	O
transgene	O
increased	O
throughout	O
the	O
observation	O
period	O
,	O
reaching	O
2	O
.	O
2	O
-	O
fold	O
at	O
2	O
weeks	O
in	O
the	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
model	O
and	O
2	O
.	O
6	O
-	O
fold	O
at	O
4	O
weeks	O
in	O
the	O
remnant	O
kidney	O
model	O
,	O
whereas	O
that	O
of	O
vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
showed	O
a	O
mild	O
decrease	O
,	O
reflecting	O
distinct	O
behaviors	O
of	O
the	O
two	O
genes	O
.	O

The	O
degree	O
of	O
hypoxia	B-DiseaseOrPhenotypicFeature
showed	O
a	O
positive	O
correlation	O
with	O
microscopic	O
tubulointerstitial	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
in	O
both	O
models	O
.	O

Finally	O
,	O
we	O
identified	O
the	O
localization	O
of	O
proliferating	O
cell	O
nuclear	O
antigen	O
-	O
positive	O
,	O
ED	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
-	O
positive	O
,	O
and	O
terminal	O
dUTP	B-ChemicalEntity
nick	O
-	O
end	O
labeled	O
-	O
positive	O
cells	O
in	O
the	O
hypoxic	B-DiseaseOrPhenotypicFeature
cortical	O
area	O
in	O
the	O
remnant	O
kidney	O
model	O
.	O

We	O
propose	O
here	O
a	O
possible	O
pathological	O
tie	O
between	O
chronic	O
tubulointerstitial	O
hypoxia	B-DiseaseOrPhenotypicFeature
and	O
progressive	O
glomerular	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
.	O
Anxiogenic	B-DiseaseOrPhenotypicFeature
potential	O
of	O
ciprofloxacin	B-ChemicalEntity
and	O
norfloxacin	B-ChemicalEntity
in	O
rats	B-OrganismTaxon
.	O

INTRODUCTION	O
:	O
The	O
possible	O
anxiogenic	B-DiseaseOrPhenotypicFeature
effects	O
of	O
fluoroquinolones	B-ChemicalEntity
,	O
namely	O
ciprofloxacin	B-ChemicalEntity
and	O
norfloxacin	B-ChemicalEntity
,	O
were	O
investigated	O
in	O
adult	O
Charles	O
Foster	O
albino	O
rats	B-OrganismTaxon
of	O
either	O
sex	O
,	O
weighing	O
150	O
-	O
200	O
g	O
.	O

METHODS	O
:	O
The	O
drugs	O
were	O
given	O
orally	O
,	O
in	O
doses	O
of	O
50	O
mg	O
/	O
kg	O
for	O
five	O
consecutive	O
days	O
and	O
the	O
experiments	O
were	O
performed	O
on	O
the	O
fifth	O
day	O
.	O

The	O
tests	O
included	O
open	O
-	O
field	O
exploratory	O
behaviour	O
,	O
elevated	O
plus	O
maze	O
and	O
elevated	O
zero	O
maze	O
,	O
social	O
interaction	O
and	O
novelty	O
-	O
suppressed	O
feeding	O
latency	O
behaviour	O
.	O

RESULTS	O
:	O
The	O
results	O
indicate	O
that	O
ciprofloxacin	B-ChemicalEntity
-	O
and	O
norfloxacin	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
showed	O
anxious	B-DiseaseOrPhenotypicFeature
behaviour	I-DiseaseOrPhenotypicFeature
in	O
comparison	O
to	O
control	O
rats	B-OrganismTaxon
in	O
all	O
the	O
parameters	O
studied	O
.	O

However	O
,	O
ciprofloxacin	B-ChemicalEntity
-	O
and	O
norfloxacin	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
did	O
not	O
differ	O
significantly	O
from	O
each	O
other	O
in	O
various	O
behavioural	O
parameters	O
.	O

CONCLUSION	O
:	O
The	O
present	O
experimental	O
findings	O
substantiate	O
the	O
clinically	O
observed	O
anxiogenic	B-DiseaseOrPhenotypicFeature
potential	O
of	O
ciprofloxacin	B-ChemicalEntity
and	O
norfloxacin	B-ChemicalEntity
.	O
Cytochrome	B-GeneOrGeneProduct
p4501A1	I-GeneOrGeneProduct
gene	O
variants	O
as	O
susceptibility	O
marker	O
for	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

CYP1A1	B-GeneOrGeneProduct
activates	O
environmental	O
procarcinogens	O
and	O
catalyzes	O
oxidative	O
metabolism	O
of	O
estrogens	O
and	O
is	O
likely	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
etiology	O
of	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

To	O
evaluate	O
this	O
phenomenon	O
,	O
the	O
association	O
between	O
two	O
single	O
nucleotide	O
polymorphisms	O
(	O
A	B-SequenceVariant
to	I-SequenceVariant
G	I-SequenceVariant
transition	O
in	O
exon7	O
leading	O
to	O
amino	O
acid	O
substitution	O
Ile462Val	B-SequenceVariant
and	O
T3801C	B-SequenceVariant
at	O
3	O
'	O
UTR	O
)	O
of	O
CYP1A1	B-GeneOrGeneProduct
gene	O
in	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
were	O
analyzed	O
in	O
a	O
case	O
-	O
control	O
study	O
of	O
100	O
individuals	O
in	O
South	O
Indian	O
population	O
.	O

The	O
estimated	O
relative	O
risk	O
was	O
significantly	O
high	O
for	O
individuals	O
with	O
w1	O
/	O
m1	O
genotype	O
at	O
3	O
'	O
UTR	O
of	O
CYP1A1	B-GeneOrGeneProduct
gene	O
(	O
OR	O
-	O
4	O
.	O
64	O
;	O
95%CI	O
=	O
1	O
.	O
51	O
-	O
14	O
.	O
86	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
whereas	O
the	O
CYP1A1	B-GeneOrGeneProduct
Ile	B-SequenceVariant
/	O
Val	I-SequenceVariant
genotype	O
(	O
w2	O
/	O
m2	O
)	O
on	O
exon	O
7	O
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
decreased	O
risk	O
for	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
OR	O
-	O
0	O
.	O
17	O
;	O
95%CI	O
=	O
0	O
.	O
02	O
-	O
0	O
.	O
89	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

A	O
Stratified	O
analysis	O
of	O
the	O
genotypes	O
with	O
age	O
of	O
onset	O
and	O
tumor	B-DiseaseOrPhenotypicFeature
grade	O
showed	O
the	O
w1	O
/	O
m1	O
genotype	O
to	O
be	O
significantly	O
associated	O
with	O
an	O
early	O
age	O
of	O
onset	O
;	O
however	O
the	O
tumor	B-DiseaseOrPhenotypicFeature
grades	O
did	O
not	O
have	O
significant	O
association	O
with	O
the	O
variant	O
genotypes	O
.	O

Thus	O
the	O
present	O
study	O
indicates	O
that	O
individuals	O
with	O
the	O
variant	O
w1	O
/	O
m1	O
genotype	O
exhibit	O
an	O
increased	O
risk	O
while	O
those	O
with	O
w2	O
/	O
m2	O
genotype	O
exhibit	O
a	O
decreased	O
risk	O
for	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O
Four	O
novel	O
mutations	O
in	O
the	O
thiazide	B-ChemicalEntity
-	O
sensitive	O
Na	B-GeneOrGeneProduct
-	O
Cl	I-GeneOrGeneProduct
co	I-GeneOrGeneProduct
-	O
transporter	I-GeneOrGeneProduct
gene	O
in	O
Japanese	O
patients	B-OrganismTaxon
with	O
Gitelman	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Gitelman	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
GS	B-DiseaseOrPhenotypicFeature
)	O
is	O
an	O
autosomal	B-DiseaseOrPhenotypicFeature
recessive	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
resulting	O
from	O
inactivating	O
mutations	O
in	O
the	O
thiazide	B-ChemicalEntity
-	O
sensitive	O
Na	B-GeneOrGeneProduct
-	O
Cl	I-GeneOrGeneProduct
co	I-GeneOrGeneProduct
-	O
transporter	I-GeneOrGeneProduct
(	O
NCCT	B-GeneOrGeneProduct
)	O
gene	O
.	O

To	O
date	O
,	O
almost	O
90	O
mutations	O
have	O
been	O
identified	O
.	O

It	O
is	O
possible	O
that	O
there	O
is	O
a	O
population	O
-	O
specific	O
distribution	O
of	O
mutations	O
.	O

In	O
this	O
study	O
,	O
we	O
analysed	O
mutations	O
in	O
the	O
NCCT	B-GeneOrGeneProduct
gene	O
of	O
seven	O
Japanese	O
patients	B-OrganismTaxon
with	O
GS	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
Peripheral	O
blood	O
mononuclear	O
cells	O
were	O
isolated	O
from	O
patients	B-OrganismTaxon
with	O
GS	B-DiseaseOrPhenotypicFeature
,	O
their	O
family	O
members	O
and	O
healthy	O
control	O
subjects	O
.	O

A	O
mutation	O
analysis	O
of	O
the	O
NCCT	B-GeneOrGeneProduct
gene	O
was	O
performed	O
completely	O
by	O
direct	O
automated	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
-	O
amplified	O
DNA	O
products	O
.	O

In	O
patients	B-OrganismTaxon
with	O
a	O
deletion	O
or	O
splice	O
site	O
mutation	O
,	O
we	O
undertook	O
cDNA	O
sequence	O
analysis	O
.	O

RESULTS	O
:	O
We	O
identified	O
nine	O
mutations	O
.	O

Five	O
of	O
them	O
[	O
c	B-SequenceVariant
.	O
185C	I-SequenceVariant
>	O
T	I-SequenceVariant
(	O
Thr60Met	B-SequenceVariant
)	O
,	O
c	B-SequenceVariant
.	O
1712C	I-SequenceVariant
>	O
T	I-SequenceVariant
(	O
Ala569Val	B-SequenceVariant
)	O
,	O
c	B-SequenceVariant
.	O
1930C	I-SequenceVariant
>	O
T	I-SequenceVariant
(	O
Arg642Cys	B-SequenceVariant
)	O
,	O
c	B-SequenceVariant
.	O
2552T	I-SequenceVariant
>	O
A	I-SequenceVariant
(	O
Leu849His	B-SequenceVariant
)	O
and	O
c	B-SequenceVariant
.	O
1932delC	I-SequenceVariant
]	O
have	O
been	O
reported	O
in	O
Japanese	O
patients	B-OrganismTaxon
,	O
but	O
not	O
in	O
GS	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
from	O
other	O
ethnic	O
groups	O
.	O

The	O
remaining	O
four	O
mutations	O
[	O
c	B-SequenceVariant
.	O
7A	I-SequenceVariant
>	O
T	I-SequenceVariant
(	O
Met1Leu	B-SequenceVariant
)	O
,	O
c	B-SequenceVariant
.	O
1181_1186	I-SequenceVariant
+	O
20del26	I-SequenceVariant
,	O
c	B-SequenceVariant
.	O
1811_1812delAT	I-SequenceVariant
and	O
IVS16	B-SequenceVariant
+	O
1G	I-SequenceVariant
>	O
A	I-SequenceVariant
]	O
were	O
novel	O
.	O

In	O
cDNA	O
derived	O
from	O
a	O
patient	B-OrganismTaxon
with	O
c	B-SequenceVariant
.	O
1181_1186	I-SequenceVariant
+	O
20del26	I-SequenceVariant
,	O
a	O
deletion	O
of	O
exon	O
9	O
and	O
a	O
frameshift	O
at	O
the	O
start	O
of	O
exon	O
10	O
were	O
observed	O
.	O

In	O
cDNA	O
derived	O
from	O
patients	B-OrganismTaxon
with	O
IVS16	B-SequenceVariant
+	O
1G	I-SequenceVariant
>	O
A	I-SequenceVariant
,	O
an	O
additional	O
96	B-SequenceVariant
bp	I-SequenceVariant
insertion	I-SequenceVariant
between	O
exons	O
16	O
and	O
17	O
was	O
observed	O
.	O

Six	O
out	O
of	O
seven	O
patients	B-OrganismTaxon
were	O
compound	O
heterozygotes	O
,	O
and	O
the	O
remaining	O
one	O
carried	O
a	O
single	O
heterozygous	O
mutation	O
.	O

CONCLUSIONS	O
:	O
We	O
found	O
four	O
novel	O
mutations	O
in	O
the	O
NCCT	B-GeneOrGeneProduct
gene	O
in	O
seven	O
Japanese	O
patients	B-OrganismTaxon
with	O
GS	B-DiseaseOrPhenotypicFeature
.	O

Moreover	O
,	O
our	O
study	O
suggests	O
that	O
the	O
distribution	O
of	O
mutations	O
in	O
the	O
NCCT	B-GeneOrGeneProduct
gene	O
in	O
Japanese	O
GS	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
potentially	O
differs	O
from	O
that	O
in	O
other	O
populations	O
.	O
Autosomal	O
dominant	O
mutation	O
in	O
the	O
signal	O
peptide	O
of	O
renin	B-GeneOrGeneProduct
in	O
a	O
kindred	O
with	O
anemia	B-DiseaseOrPhenotypicFeature
,	O
hyperuricemia	B-DiseaseOrPhenotypicFeature
,	O
and	O
CKD	B-DiseaseOrPhenotypicFeature
.	O

Homozygous	O
or	O
compound	O
heterozygous	O
mutations	O
in	O
renin	B-GeneOrGeneProduct
(	O
REN	B-GeneOrGeneProduct
)	O
cause	O
renal	B-DiseaseOrPhenotypicFeature
tubular	I-DiseaseOrPhenotypicFeature
dysgenesis	I-DiseaseOrPhenotypicFeature
,	O
which	O
is	O
characterized	O
by	O
death	B-DiseaseOrPhenotypicFeature
in	O
utero	O
due	O
to	O
kidney	B-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
and	O
pulmonary	B-DiseaseOrPhenotypicFeature
hypoplasia	I-DiseaseOrPhenotypicFeature
.	O

The	O
phenotype	O
resembles	O
the	O
fetopathy	B-DiseaseOrPhenotypicFeature
caused	O
by	O
angiotensin	B-ChemicalEntity
-	O
converting	I-ChemicalEntity
enzyme	I-ChemicalEntity
inhibitor	I-ChemicalEntity
or	O
angiotensin	B-ChemicalEntity
receptor	I-ChemicalEntity
blocker	I-ChemicalEntity
intake	O
during	O
pregnancy	O
.	O

Recently	O
,	O
heterozygous	O
REN	B-GeneOrGeneProduct
mutations	O
were	O
shown	O
to	O
result	O
in	O
early	O
-	O
onset	O
hyperuricemia	B-DiseaseOrPhenotypicFeature
,	O
anemia	B-DiseaseOrPhenotypicFeature
,	O
and	O
chronic	B-DiseaseOrPhenotypicFeature
kidney	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
CKD	B-DiseaseOrPhenotypicFeature
)	O
.	O

To	O
date	O
,	O
only	O
3	O
different	O
heterozygous	O
REN	B-GeneOrGeneProduct
mutations	O
have	O
been	O
published	O
.	O

We	O
report	O
mutation	O
analysis	O
of	O
the	O
REN	B-GeneOrGeneProduct
gene	O
in	O
39	O
kindreds	O
with	O
hyperuricemia	B-DiseaseOrPhenotypicFeature
and	O
CKD	B-DiseaseOrPhenotypicFeature
who	O
previously	O
tested	O
negative	O
for	O
mutations	O
in	O
the	O
UMOD	B-GeneOrGeneProduct
(	O
uromodulin	B-GeneOrGeneProduct
)	O
and	O
HNF1B	B-GeneOrGeneProduct
(	O
hepatocyte	B-GeneOrGeneProduct
nuclear	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
1b	I-GeneOrGeneProduct
)	O
genes	O
.	O

We	O
identified	O
one	O
kindred	O
with	O
a	O
novel	O
thymidine	B-SequenceVariant
to	I-SequenceVariant
cytosine	I-SequenceVariant
mutation	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
28	I-SequenceVariant
in	O
the	O
REN	B-GeneOrGeneProduct
complementary	O
DNA	O
,	O
corresponding	O
to	O
a	O
tryptophan	B-SequenceVariant
to	I-SequenceVariant
arginine	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
10	I-SequenceVariant
,	O
which	O
is	O
found	O
within	O
the	O
signal	O
sequence	O
(	O
c	B-SequenceVariant
.	O
28T	I-SequenceVariant
>	O
C	I-SequenceVariant
;	O
p	B-SequenceVariant
.	O
W10R	I-SequenceVariant
)	O
.	O

On	O
this	O
basis	O
,	O
we	O
conclude	O
that	O
REN	B-GeneOrGeneProduct
mutations	O
are	O
rare	O
events	O
in	O
patients	B-OrganismTaxon
with	O
CKD	B-DiseaseOrPhenotypicFeature
.	O

Within	O
the	O
kindred	O
,	O
we	O
found	O
affected	O
individuals	O
over	O
4	O
generations	O
who	O
carried	O
the	O
novel	O
REN	B-GeneOrGeneProduct
mutation	O
and	O
were	O
characterized	O
by	O
significant	O
anemia	B-DiseaseOrPhenotypicFeature
,	O
hyperuricemia	B-DiseaseOrPhenotypicFeature
,	O
and	O
CKD	B-DiseaseOrPhenotypicFeature
.	O

Anemia	B-DiseaseOrPhenotypicFeature
was	O
severe	O
and	O
disproportional	O
to	O
the	O
degree	O
of	O
decreased	O
kidney	O
function	O
.	O

Because	O
all	O
heterozygous	O
REN	B-GeneOrGeneProduct
mutations	O
that	O
have	O
been	O
described	O
are	O
localized	O
in	O
the	O
signal	O
sequence	O
,	O
screening	O
of	O
the	O
REN	B-GeneOrGeneProduct
gene	O
for	O
patients	B-OrganismTaxon
with	O
CKD	B-DiseaseOrPhenotypicFeature
with	O
hyperuricemia	B-DiseaseOrPhenotypicFeature
and	O
anemia	B-DiseaseOrPhenotypicFeature
may	O
best	O
be	O
focused	O
on	O
sequencing	O
of	O
exon	O
1	O
,	O
which	O
encodes	O
the	O
signal	O
peptide	O
.	O
A	O
Critical	O
Role	O
for	O
the	O
Type	B-GeneOrGeneProduct
I	I-GeneOrGeneProduct
Interferon	I-GeneOrGeneProduct
Receptor	I-GeneOrGeneProduct
in	O
Virus	O
-	O
Induced	O
Autoimmune	B-DiseaseOrPhenotypicFeature
Diabetes	I-DiseaseOrPhenotypicFeature
in	O
Rats	B-OrganismTaxon
.	O

The	O
pathogenesis	O
of	O
human	B-OrganismTaxon
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
,	O
characterized	O
by	O
immune	O
-	O
mediated	O
damage	O
of	O
insulin	B-GeneOrGeneProduct
-	O
producing	O
b	O
-	O
cells	O
of	O
pancreatic	O
islets	O
,	O
may	O
involve	O
viral	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

Essential	O
components	O
of	O
the	O
innate	O
immune	O
antiviral	O
response	O
,	O
including	O
type	B-GeneOrGeneProduct
I	I-GeneOrGeneProduct
interferon	I-GeneOrGeneProduct
(	O
IFN	B-GeneOrGeneProduct
)	O
and	O
IFN	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
mediated	O
signaling	O
pathways	O
,	O
are	O
candidates	O
for	O
determining	O
susceptibility	O
to	O
human	B-OrganismTaxon
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
.	O

Numerous	O
aspects	O
of	O
human	B-OrganismTaxon
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
pathogenesis	O
are	O
recapitulated	O
in	O
the	O
LEW	O
.	O
1WR1	O
rat	B-OrganismTaxon
model	O
.	O

Diabetes	B-DiseaseOrPhenotypicFeature
can	O
be	O
induced	O
in	O
LEW	O
.	O
1WR1	O
weanling	O
rats	B-OrganismTaxon
challenged	O
with	O
virus	O
or	O
with	O
the	O
viral	O
mimetic	O
polyinosinic	B-ChemicalEntity
:	O
polycytidylic	I-ChemicalEntity
acid	I-ChemicalEntity
(	O
poly	B-ChemicalEntity
I	I-ChemicalEntity
:	O
C	I-ChemicalEntity
)	O
.	O

We	O
hypothesized	O
that	O
disrupting	O
the	O
cognate	O
type	B-GeneOrGeneProduct
I	I-GeneOrGeneProduct
IFN	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
type	B-GeneOrGeneProduct
I	I-GeneOrGeneProduct
IFN	I-GeneOrGeneProduct
a	I-GeneOrGeneProduct
/	O
b	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
[	O
IFNAR	B-GeneOrGeneProduct
]	O
)	O
to	O
interrupt	O
IFN	B-GeneOrGeneProduct
signaling	O
would	O
prevent	O
or	O
delay	O
the	O
development	O
of	O
virus	O
-	O
induced	O
diabetes	B-DiseaseOrPhenotypicFeature
.	O

We	O
generated	O
IFNAR1	B-GeneOrGeneProduct
subunit	O
-	O
deficient	O
LEW	O
.	O
1WR1	O
rats	B-OrganismTaxon
using	O
CRISPR	O
-	O
Cas9	O
(	O
clustered	O
regularly	O
interspaced	O
short	O
palindromic	O
repeats	O
-	O
associated	O
protein	O
9	O
)	O
genome	O
editing	O
and	O
confirmed	O
functional	O
disruption	O
of	O
the	O
Ifnar1	B-GeneOrGeneProduct
gene	O
.	O

IFNAR1	B-GeneOrGeneProduct
deficiency	O
significantly	O
delayed	O
the	O
onset	O
and	O
frequency	O
of	O
diabetes	B-DiseaseOrPhenotypicFeature
and	O
greatly	O
reduced	O
the	O
intensity	O
of	O
insulitis	B-DiseaseOrPhenotypicFeature
after	O
poly	B-ChemicalEntity
I	I-ChemicalEntity
:	O
C	I-ChemicalEntity
treatment	O
.	O

The	O
occurrence	O
of	O
Kilham	B-OrganismTaxon
rat	I-OrganismTaxon
virus	I-OrganismTaxon
-	O
induced	O
diabetes	B-DiseaseOrPhenotypicFeature
was	O
also	O
diminished	O
in	O
IFNAR1	B-GeneOrGeneProduct
-	O
deficient	O
animals	O
.	O

These	O
findings	O
firmly	O
establish	O
that	O
alterations	O
in	O
innate	O
immunity	O
influence	O
the	O
course	O
of	O
autoimmune	B-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
and	O
support	O
the	O
use	O
of	O
targeted	O
strategies	O
to	O
limit	O
or	O
prevent	O
the	O
development	O
of	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
.	O
Anticonvulsant	O
effect	O
of	O
eslicarbazepine	B-ChemicalEntity
acetate	I-ChemicalEntity
(	O
BIA	B-ChemicalEntity
2	I-ChemicalEntity
-	O
093	I-ChemicalEntity
)	O
on	O
seizures	B-DiseaseOrPhenotypicFeature
induced	O
by	O
microperfusion	O
of	O
picrotoxin	B-ChemicalEntity
in	O
the	O
hippocampus	O
of	O
freely	O
moving	O
rats	B-OrganismTaxon
.	O

Eslicarbazepine	B-ChemicalEntity
acetate	I-ChemicalEntity
(	O
BIA	B-ChemicalEntity
2	I-ChemicalEntity
-	O
093	I-ChemicalEntity
,	O
S	B-ChemicalEntity
-	O
(	O
-	O
)	O
-	O
10	I-ChemicalEntity
-	O
acetoxy	I-ChemicalEntity
-	O
10	I-ChemicalEntity
,	O
11	I-ChemicalEntity
-	O
dihydro	I-ChemicalEntity
-	O
5H	I-ChemicalEntity
-	O
dibenzo	I-ChemicalEntity
/	O
b	I-ChemicalEntity
,	O
f	I-ChemicalEntity
/	O
azepine	I-ChemicalEntity
-	O
5	I-ChemicalEntity
-	O
carboxamide	I-ChemicalEntity
)	O
is	O
a	O
novel	O
antiepileptic	B-ChemicalEntity
drug	I-ChemicalEntity
,	O
now	O
in	O
Phase	O
III	O
clinical	O
trials	O
,	O
designed	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
and	O
safety	O
in	O
comparison	O
with	O
the	O
structurally	O
related	O
drugs	O
carbamazepine	B-ChemicalEntity
(	O
CBZ	B-ChemicalEntity
)	O
and	O
oxcarbazepine	B-ChemicalEntity
(	O
OXC	B-ChemicalEntity
)	O
.	O

We	O
have	O
studied	O
the	O
effects	O
of	O
oral	O
treatment	O
with	O
eslicarbazepine	B-ChemicalEntity
acetate	I-ChemicalEntity
on	O
a	O
whole	O
-	O
animal	O
model	O
in	O
which	O
partial	O
seizures	B-DiseaseOrPhenotypicFeature
can	O
be	O
elicited	O
repeatedly	O
on	O
different	O
days	O
without	O
changes	O
in	O
threshold	O
or	O
seizure	B-DiseaseOrPhenotypicFeature
patterns	O
.	O

In	O
the	O
animals	O
treated	O
with	O
threshold	O
doses	O
of	O
picrotoxin	B-ChemicalEntity
,	O
the	O
average	O
number	O
of	O
seizures	B-DiseaseOrPhenotypicFeature
was	O
2	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
2	O
,	O
and	O
average	O
seizure	B-DiseaseOrPhenotypicFeature
duration	O
was	O
39	O
.	O
5	O
+	O
/	O
-	O
8	O
.	O
4s	O
.	O

Pre	O
-	O
treatment	O
with	O
a	O
dose	O
of	O
30	O
mg	O
/	O
kg	O
2h	O
before	O
picrotoxin	B-ChemicalEntity
microperfusion	O
prevented	O
seizures	B-DiseaseOrPhenotypicFeature
in	O
the	O
75%	O
of	O
the	O
rats	B-OrganismTaxon
.	O

Lower	O
doses	O
(	O
3	O
and	O
10mg	O
/	O
kg	O
)	O
did	O
not	O
suppress	O
seizures	B-DiseaseOrPhenotypicFeature
,	O
however	O
,	O
after	O
administration	O
of	O
10mg	O
/	O
kg	O
,	O
significant	O
reductions	O
in	O
seizures	B-DiseaseOrPhenotypicFeature
duration	O
(	O
24	O
.	O
3	O
+	O
/	O
-	O
6	O
.	O
8s	O
)	O
and	O
seizure	B-DiseaseOrPhenotypicFeature
number	O
(	O
1	O
.	O
6	O
+	O
/	O
-	O
0	O
.	O
34	O
)	O
were	O
found	O
.	O

No	O
adverse	O
effects	O
of	O
eslicarbazepine	B-ChemicalEntity
acetate	I-ChemicalEntity
were	O
observed	O
in	O
the	O
behavioral	O
/	O
EEG	O
patterns	O
studied	O
,	O
including	O
sleep	O
/	O
wakefulness	O
cycle	O
,	O
at	O
the	O
doses	O
studied	O
.	O
Hypomorphic	O
mutations	O
in	O
meckelin	B-GeneOrGeneProduct
(	O
MKS3	B-GeneOrGeneProduct
/	O
TMEM67	B-GeneOrGeneProduct
)	O
cause	O
nephronophthisis	B-DiseaseOrPhenotypicFeature
with	I-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
(	O
NPHP11	B-DiseaseOrPhenotypicFeature
)	O
.	O

BACKGROUND	O
:	O
Nephronophthisis	B-DiseaseOrPhenotypicFeature
(	O
NPHP	B-DiseaseOrPhenotypicFeature
)	O
,	O
a	O
rare	O
recessive	O
cystic	B-DiseaseOrPhenotypicFeature
kidney	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
,	O
is	O
the	O
most	O
frequent	O
genetic	O
cause	O
of	O
chronic	B-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
in	O
children	O
and	O
young	O
adults	O
.	O

Mutations	O
in	O
nine	O
genes	O
(	O
NPHP1	B-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
)	O
have	O
been	O
identified	O
.	O

NPHP	B-DiseaseOrPhenotypicFeature
can	O
be	O
associated	O
with	O
retinal	B-DiseaseOrPhenotypicFeature
degeneration	I-DiseaseOrPhenotypicFeature
(	O
Senior	B-DiseaseOrPhenotypicFeature
-	O
Loken	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
)	O
,	O
brainstem	O
and	O
cerebellar	B-DiseaseOrPhenotypicFeature
anomalies	I-DiseaseOrPhenotypicFeature
(	O
Joubert	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
)	O
,	O
or	O
liver	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
To	O
identify	O
a	O
causative	O
gene	O
for	O
the	O
subset	O
of	O
patients	B-OrganismTaxon
with	O
associated	O
liver	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
,	O
the	O
authors	O
performed	O
a	O
genome	O
wide	O
linkage	O
search	O
in	O
a	O
consanguineous	O
family	O
with	O
three	O
affected	O
patients	B-OrganismTaxon
using	O
50K	O
SNP	O
microarrays	O
and	O
homozygosity	O
mapping	O
.	O

RESULTS	O
:	O
The	O
authors	O
obtained	O
a	O
significant	O
maximum	O
parametric	O
LOD	O
(	O
logarithm	O
of	O
odds	O
)	O
score	O
of	O
Z	O
(	O
max	O
)	O
=	O
3	O
.	O
72	O
on	O
chromosome	O
8q22	O
and	O
identified	O
a	O
homozygous	O
missense	O
mutation	O
in	O
the	O
gene	O
MKS3	B-GeneOrGeneProduct
/	O
TMEM67	B-GeneOrGeneProduct
.	O

When	O
examining	O
a	O
worldwide	O
cohort	O
of	O
62	O
independent	O
patients	B-OrganismTaxon
with	O
NPHP	B-DiseaseOrPhenotypicFeature
and	O
associated	O
liver	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
we	O
identified	O
altogether	O
four	O
novel	O
mutations	O
(	O
p	B-SequenceVariant
.	O
W290L	I-SequenceVariant
,	O
p	B-SequenceVariant
.	O
C615R	I-SequenceVariant
,	O
p	B-SequenceVariant
.	O
G821S	I-SequenceVariant
,	O
and	O
p	B-SequenceVariant
.	O
G821R	I-SequenceVariant
)	O
in	O
five	O
of	O
them	O
.	O

Mutations	O
of	O
MKS3	B-GeneOrGeneProduct
/	O
TMEM67	B-GeneOrGeneProduct
,	O
found	O
recently	O
in	O
Meckel	B-DiseaseOrPhenotypicFeature
-	O
Gruber	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
MKS	I-DiseaseOrPhenotypicFeature
)	O
type	I-DiseaseOrPhenotypicFeature
3	I-DiseaseOrPhenotypicFeature
and	O
Joubert	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
JBTS	I-DiseaseOrPhenotypicFeature
)	O
type	I-DiseaseOrPhenotypicFeature
6	I-DiseaseOrPhenotypicFeature
,	O
are	O
predominantly	O
truncating	O
mutations	O
.	O

In	O
contrast	O
,	O
the	O
mutations	O
detected	O
here	O
in	O
patients	B-OrganismTaxon
with	O
NPHP	B-DiseaseOrPhenotypicFeature
and	O
associated	O
liver	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
are	O
exclusively	O
missense	O
mutations	O
.	O

This	O
suggests	O
that	O
they	O
may	O
represent	O
hypomorphic	O
alleles	O
,	O
leading	O
to	O
a	O
milder	O
phenotype	O
compared	O
with	O
the	O
more	O
severe	O
MKS	B-DiseaseOrPhenotypicFeature
or	O
JBTS	B-DiseaseOrPhenotypicFeature
phenotype	O
.	O

Additionally	O
,	O
mutation	O
analysis	O
for	O
MKS3	B-GeneOrGeneProduct
/	O
TMEM67	B-GeneOrGeneProduct
in	O
120	O
patients	B-OrganismTaxon
with	O
JBTS	B-DiseaseOrPhenotypicFeature
yielded	O
seven	O
different	O
(	O
four	O
novel	O
)	O
mutations	O
in	O
five	O
patients	B-OrganismTaxon
,	O
four	O
of	O
whom	O
also	O
presented	O
with	O
congenital	O
liver	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
.	O

CONCLUSIONS	O
:	O
Hypomorphic	O
MKS3	B-GeneOrGeneProduct
/	O
TMEM67	B-GeneOrGeneProduct
mutations	O
cause	O
NPHP	B-DiseaseOrPhenotypicFeature
with	I-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
(	O
NPHP11	B-DiseaseOrPhenotypicFeature
)	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
MKS3	B-GeneOrGeneProduct
mutations	O
in	O
patients	B-OrganismTaxon
with	O
no	O
vermian	O
agenesis	O
and	O
without	O
neurological	O
signs	O
.	O

Thus	O
NPHP	B-DiseaseOrPhenotypicFeature
,	O
JBTS	B-DiseaseOrPhenotypicFeature
,	O
and	O
MKS	B-DiseaseOrPhenotypicFeature
represent	O
allelic	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
.	O
Genetic	O
variants	O
of	O
the	O
T	B-GeneOrGeneProduct
-	O
cell	I-GeneOrGeneProduct
immunoglobulin	I-GeneOrGeneProduct
mucin	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
but	O
not	O
the	O
T	B-GeneOrGeneProduct
-	O
cell	I-GeneOrGeneProduct
immunoglobulin	I-GeneOrGeneProduct
mucin	I-GeneOrGeneProduct
3	I-GeneOrGeneProduct
gene	O
are	O
associated	O
with	O
asthma	B-DiseaseOrPhenotypicFeature
in	O
an	O
African	O
American	O
population	O
.	O

BACKGROUND	O
:	O
The	O
T	B-GeneOrGeneProduct
-	O
cell	I-GeneOrGeneProduct
immunoglobulin	I-GeneOrGeneProduct
mucin	I-GeneOrGeneProduct
(	O
TIM	B-GeneOrGeneProduct
)	O
proteins	O
and	O
their	O
genetic	O
variants	O
have	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
regulating	O
allergic	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
.	O

OBJECTIVE	O
:	O
Genetic	O
association	O
of	O
the	O
sequence	O
variants	O
for	O
TIM	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
and	O
TIM	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
genes	O
with	O
asthma	B-DiseaseOrPhenotypicFeature
in	O
an	O
African	O
American	O
population	O
was	O
investigated	O
.	O

METHODS	O
:	O
Both	O
case	O
-	O
control	O
and	O
family	O
-	O
based	O
association	O
analyses	O
were	O
performed	O
for	O
a	O
total	O
of	O
7	O
polymorphisms	O
,	O
including	O
3	O
single	O
nucleotide	O
polymorphism	O
(	O
SNPs	O
)	O
and	O
1	O
insertion	O
/	O
deletion	O
polymorphism	O
in	O
the	O
TIM	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
3	I-GeneOrGeneProduct
SNPs	O
in	O
the	O
TIM	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
genes	O
.	O

The	O
exposure	O
to	O
hepatitis	B-OrganismTaxon
A	I-OrganismTaxon
virus	I-OrganismTaxon
as	O
judged	O
by	O
seropositivity	O
was	O
also	O
examined	O
.	O

RESULTS	O
:	O
In	O
the	O
case	O
-	O
control	O
design	O
,	O
the	O
frequencies	O
of	O
the	O
TT	O
genotype	O
for	O
SNP	O
rs2277025	B-SequenceVariant
and	O
the	O
homozygous	O
deletion	O
variant	O
(	O
157delMTTTVP	B-SequenceVariant
)	O
in	O
the	O
fourth	O
exon	O
of	O
the	O
TIM	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
gene	O
were	O
higher	O
among	O
patients	B-OrganismTaxon
with	O
patients	B-OrganismTaxon
with	O
asthma	B-DiseaseOrPhenotypicFeature
compared	O
with	O
the	O
controls	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
2	O
.	O
779	O
,	O
P	O
=	O
.	O
016	O
;	O
and	O
OR	O
,	O
3	O
.	O
09	O
,	O
P	O
=	O
.	O
022	O
,	O
respectively	O
)	O
.	O

This	O
association	O
was	O
substantiated	O
by	O
haplotype	O
analysis	O
of	O
these	O
and	O
2	O
additional	O
SNPs	O
(	O
OR	O
,	O
2	O
.	O
48	O
;	O
P	O
=	O
.	O
004	O
)	O
,	O
and	O
also	O
by	O
family	O
-	O
based	O
tests	O
for	O
the	O
allele	O
and	O
haplotype	O
carrying	O
157delMTTTVP	B-SequenceVariant
(	O
P	O
=	O
.	O
009	O
and	O
P	O
=	O
.	O
048	O
,	O
respectively	O
)	O
.	O

Furthermore	O
,	O
this	O
association	O
seems	O
to	O
exist	O
even	O
in	O
the	O
hepatitis	B-OrganismTaxon
A	I-OrganismTaxon
virus	I-OrganismTaxon
-	O
seronegative	O
subjects	O
in	O
our	O
data	O
.	O

None	O
of	O
the	O
3	O
variants	O
in	O
TIM	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
genes	O
yielded	O
significant	O
association	O
with	O
either	O
asthma	B-DiseaseOrPhenotypicFeature
or	O
asthma	B-DiseaseOrPhenotypicFeature
-	O
related	O
phenotypes	O
.	O

CONCLUSION	O
:	O
Our	O
findings	O
suggest	O
that	O
the	O
genetic	O
variants	O
of	O
the	O
TIM	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
but	O
not	O
the	O
TIM	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
gene	O
contribute	O
to	O
asthma	B-DiseaseOrPhenotypicFeature
susceptibility	O
in	O
this	O
African	O
-	O
American	O
population	O
.	O
Identification	O
of	O
a	O
gain	O
-	O
of	O
-	O
function	O
mutation	O
of	O
the	O
prolactin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
in	O
women	B-OrganismTaxon
with	O
benign	B-DiseaseOrPhenotypicFeature
breast	I-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
.	O

There	O
is	O
currently	O
no	O
known	O
genetic	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
linked	O
to	O
prolactin	B-GeneOrGeneProduct
(	O
Prl	B-GeneOrGeneProduct
)	O
or	O
its	O
receptor	O
(	O
PrlR	B-GeneOrGeneProduct
)	O
in	O
humans	B-OrganismTaxon
.	O

Given	O
the	O
essential	O
role	O
of	O
this	O
hormonal	O
system	O
in	O
breast	O
physiology	O
,	O
we	O
reasoned	O
that	O
genetic	O
anomalies	O
of	O
Prl	B-GeneOrGeneProduct
/	O
PrlR	B-GeneOrGeneProduct
genes	O
may	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
breast	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
with	O
high	O
proliferative	O
potential	O
.	O

Multiple	B-DiseaseOrPhenotypicFeature
fibroadenomas	I-DiseaseOrPhenotypicFeature
(	O
MFA	B-DiseaseOrPhenotypicFeature
)	O
are	O
benign	B-DiseaseOrPhenotypicFeature
breast	I-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
which	O
appear	O
most	O
frequently	O
in	O
young	O
women	B-OrganismTaxon
,	O
including	O
at	O
puberty	O
,	O
when	O
Prl	B-GeneOrGeneProduct
has	O
well	O
-	O
recognized	O
proliferative	O
actions	O
on	O
the	O
breast	O
.	O

In	O
a	O
prospective	O
study	O
involving	O
74	O
MFA	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
170	O
control	O
subjects	O
,	O
we	O
identified	O
four	O
patients	B-OrganismTaxon
harboring	O
a	O
heterozygous	O
single	O
nucleotide	O
polymorphism	O
in	O
exon	O
6	O
of	O
the	O
PrlR	B-GeneOrGeneProduct
gene	O
,	O
encoding	O
Ile	B-SequenceVariant
(	O
146	I-SequenceVariant
)	O
-	O
-	O
>	O
Leu	I-SequenceVariant
substitution	O
in	O
its	O
extracellular	O
domain	O
.	O

This	O
sole	O
substitution	O
was	O
sufficient	O
to	O
confer	O
constitutive	O
activity	O
to	O
the	O
receptor	O
variant	O
(	O
PrlR	B-GeneOrGeneProduct
(	O
I146L	B-SequenceVariant
)	O
)	O
,	O
as	O
assessed	O
in	O
three	O
reconstituted	O
cell	O
models	O
(	O
Ba	B-CellLine
/	O
F3	I-CellLine
,	O
HEK293	B-CellLine
and	O
MCF	B-CellLine
-	O
7	I-CellLine
cells	O
)	O
by	O
Prl	B-GeneOrGeneProduct
-	O
independent	O
(	O
i	O
)	O
PrlR	B-GeneOrGeneProduct
tyrosine	O
phosphorylation	O
,	O
(	O
ii	O
)	O
activation	O
of	O
signal	B-GeneOrGeneProduct
transducer	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
activator	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
transcription	I-GeneOrGeneProduct
5	I-GeneOrGeneProduct
(	O
STAT5	B-GeneOrGeneProduct
)	O
signaling	O
,	O
(	O
iii	O
)	O
transcriptional	O
activity	O
toward	O
a	O
Prl	B-GeneOrGeneProduct
-	O
responsive	O
reporter	O
gene	O
,	O
and	O
(	O
iv	O
)	O
cell	O
proliferation	O
and	O
protection	O
from	O
cell	O
death	O
.	O

Constitutive	O
activity	O
of	O
PrlR	B-GeneOrGeneProduct
(	O
I146L	B-SequenceVariant
)	O
in	O
the	O
breast	O
sample	O
from	O
a	O
patient	B-OrganismTaxon
was	O
supported	O
by	O
increased	O
STAT5	B-GeneOrGeneProduct
signaling	O
.	O

This	O
is	O
a	O
unique	O
description	O
of	O
a	O
functional	O
mutation	O
of	O
the	O
PrlR	B-GeneOrGeneProduct
associated	O
with	O
a	O
human	B-OrganismTaxon
disease	O
.	O

Hallmarks	O
of	O
constitutive	O
activity	O
were	O
all	O
reversed	O
by	O
a	O
specific	O
PrlR	B-ChemicalEntity
antagonist	I-ChemicalEntity
,	O
which	O
opens	O
potential	O
therapeutic	O
approaches	O
for	O
MFA	B-DiseaseOrPhenotypicFeature
,	O
or	O
any	O
other	O
disease	O
that	O
could	O
be	O
associated	O
with	O
this	O
mutation	O
in	O
future	O
.	O
Polymorphic	O
Alu	O
insertions	O
and	O
the	O
genetic	O
structure	O
of	O
Iberian	O
Basques	O
.	O

Eight	O
Alu	O
sequences	O
(	O
ACE	B-GeneOrGeneProduct
,	O
TPA25	B-GeneOrGeneProduct
,	O
PV92	B-GeneOrGeneProduct
,	O
APO	B-GeneOrGeneProduct
,	O
FXIIIB	B-GeneOrGeneProduct
,	O
D1	B-GeneOrGeneProduct
,	O
A25	B-GeneOrGeneProduct
and	O
B65	B-GeneOrGeneProduct
)	O
were	O
analyzed	O
in	O
two	O
samples	O
from	O
Navarre	O
and	O
Guipuzcoa	O
provinces	O
(	O
Basque	O
Country	O
,	O
Spain	O
)	O
.	O

Alu	O
data	O
for	O
other	O
European	O
,	O
Caucasus	O
and	O
North	O
African	O
populations	O
were	O
compiled	O
from	O
the	O
literature	O
for	O
comparison	O
purposes	O
to	O
assess	O
the	O
genetic	O
relationships	O
of	O
the	O
Basques	O
in	O
a	O
broader	O
geographic	O
context	O
.	O

Results	O
of	O
both	O
MDS	O
plot	O
and	O
AMOVA	O
revealed	O
spatial	O
heterogeneity	O
among	O
these	O
three	O
population	O
clusters	O
clearly	O
defined	O
by	O
geography	O
.	O

On	O
the	O
contrary	O
,	O
no	O
substantial	O
genetic	O
heterogeneity	O
was	O
found	O
between	O
the	O
Basque	O
samples	O
,	O
or	O
between	O
Basques	O
and	O
other	O
Europeans	O
(	O
excluding	O
Caucasus	O
populations	O
)	O
.	O

Moreover	O
,	O
the	O
genetic	O
information	O
obtained	O
from	O
Alu	O
data	O
conflicts	O
with	O
hypotheses	O
linking	O
the	O
origin	O
of	O
Basques	O
with	O
populations	O
from	O
North	O
Africa	O
(	O
Berbers	O
)	O
or	O
from	O
the	O
Caucasus	O
region	O
(	O
Georgia	O
)	O
.	O

In	O
order	O
to	O
explain	O
the	O
reduced	O
genetic	O
heterogeneity	O
detected	O
by	O
Alu	O
insertions	O
among	O
Basque	O
subpopulations	O
,	O
values	O
of	O
the	O
Wright	O
'	O
s	O
F	O
(	O
ST	O
)	O
statistic	O
were	O
estimated	O
for	O
both	O
Alu	O
markers	O
and	O
a	O
set	O
of	O
short	O
tandem	O
repeats	O
(	O
STRs	O
)	O
in	O
terms	O
of	O
two	O
geographical	O
scales	O
:	O
(	O
1	O
)	O
the	O
Basque	O
Country	O
,	O
(	O
2	O
)	O
Europe	O
(	O
including	O
Basques	O
)	O
.	O

In	O
the	O
Basque	O
area	O
,	O
estimates	O
of	O
Wahlund	O
'	O
s	O
effect	O
for	O
both	O
genetic	O
markers	O
showed	O
no	O
statistical	O
difference	O
between	O
Basque	O
subpopulations	O
.	O

However	O
,	O
when	O
this	O
analysis	O
was	O
performed	O
on	O
a	O
European	O
scale	O
,	O
F	O
(	O
ST	O
)	O
values	O
were	O
significantly	O
higher	O
for	O
Alu	O
insertions	O
than	O
for	O
STR	O
alleles	O
.	O

From	O
these	O
results	O
,	O
we	O
suggest	O
that	O
the	O
spatial	O
heterogeneity	O
of	O
the	O
Basque	O
gene	O
pool	O
identified	O
in	O
previous	O
polymorphism	O
studies	O
is	O
relatively	O
recent	O
and	O
probably	O
caused	O
by	O
a	O
differential	O
process	O
of	O
genetic	O
admixture	O
with	O
non	O
-	O
Basque	O
neighboring	O
populations	O
modulated	O
by	O
the	O
effect	O
of	O
a	O
linguistic	O
barrier	O
to	O
random	O
mating	O
.	O
Phosphatidylinositol	B-GeneOrGeneProduct
4	I-GeneOrGeneProduct
-	O
kinase	I-GeneOrGeneProduct
IIb	I-GeneOrGeneProduct
negatively	O
regulates	O
invadopodia	O
formation	O
and	O
suppresses	O
an	O
invasive	O
cellular	O
phenotype	O
.	O

The	O
type	B-GeneOrGeneProduct
II	I-GeneOrGeneProduct
phosphatidylinositol	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
-	O
kinase	I-GeneOrGeneProduct
(	O
PI4KII	B-GeneOrGeneProduct
)	O
enzymes	O
synthesize	O
the	O
lipid	B-ChemicalEntity
phosphatidylinositol	B-ChemicalEntity
4	I-ChemicalEntity
-	O
phosphate	I-ChemicalEntity
(	O
PI	B-ChemicalEntity
(	O
4	I-ChemicalEntity
)	O
P	I-ChemicalEntity
)	O
,	O
which	O
has	O
been	O
detected	O
at	O
the	O
Golgi	O
complex	O
and	O
endosomal	O
compartments	O
and	O
recruits	O
clathrin	B-GeneOrGeneProduct
adaptors	O
.	O

Despite	O
common	O
mechanistic	O
similarities	O
between	O
the	O
isoforms	O
,	O
the	O
extent	O
of	O
their	O
redundancy	O
is	O
unclear	O
.	O

We	O
found	O
that	O
depletion	O
of	O
PI4KIIa	B-GeneOrGeneProduct
and	O
PI4KIIb	B-GeneOrGeneProduct
using	O
small	O
interfering	O
RNA	O
led	O
to	O
actin	B-GeneOrGeneProduct
remodeling	O
.	O

Depletion	O
of	O
PI4KIIb	B-GeneOrGeneProduct
also	O
induced	O
the	O
formation	O
of	O
invadopodia	O
containing	O
membrane	B-GeneOrGeneProduct
type	I-GeneOrGeneProduct
I	I-GeneOrGeneProduct
matrix	I-GeneOrGeneProduct
metalloproteinase	I-GeneOrGeneProduct
(	O
MT1	B-GeneOrGeneProduct
-	O
MMP	I-GeneOrGeneProduct
)	O
.	O

Depletion	O
of	O
PI4KII	B-GeneOrGeneProduct
isoforms	O
also	O
differentially	O
affected	O
trans	O
-	O
Golgi	O
network	O
(	O
TGN	O
)	O
pools	O
of	O
PI	B-ChemicalEntity
(	O
4	I-ChemicalEntity
)	O
P	I-ChemicalEntity
and	O
post	O
-	O
TGN	O
traffic	O
.	O

PI4KIIb	B-GeneOrGeneProduct
depletion	O
caused	O
increased	O
MT1	B-GeneOrGeneProduct
-	O
MMP	I-GeneOrGeneProduct
trafficking	O
to	O
invasive	O
structures	O
at	O
the	O
plasma	O
membrane	O
and	O
was	O
accompanied	O
by	O
reduced	O
colocalization	O
of	O
MT1	B-GeneOrGeneProduct
-	O
MMP	I-GeneOrGeneProduct
with	O
membranes	O
containing	O
the	O
endosomal	O
markers	O
Rab5	B-GeneOrGeneProduct
and	O
Rab7	B-GeneOrGeneProduct
but	O
increased	O
localization	O
with	O
the	O
exocytic	O
Rab8	B-GeneOrGeneProduct
.	O

Depletion	O
of	O
PI4KIIb	B-GeneOrGeneProduct
was	O
sufficient	O
to	O
confer	O
an	O
aggressive	O
invasive	O
phenotype	O
on	O
minimally	O
invasive	O
HeLa	B-CellLine
and	O
MCF	B-CellLine
-	O
7	I-CellLine
cell	O
lines	O
.	O

Mining	O
oncogenomic	O
databases	O
revealed	O
that	O
loss	O
of	O
the	O
PI4K2B	B-GeneOrGeneProduct
allele	O
and	O
underexpression	O
of	O
PI4KIIb	B-GeneOrGeneProduct
mRNA	O
are	O
associated	O
with	O
human	B-OrganismTaxon
cancers	B-DiseaseOrPhenotypicFeature
.	O

This	O
finding	O
supports	O
the	O
cell	O
data	O
and	O
suggests	O
that	O
PI4KIIb	B-GeneOrGeneProduct
may	O
be	O
a	O
clinically	O
significant	O
suppressor	O
of	O
invasion	O
.	O

We	O
propose	O
that	O
PI4KIIb	B-GeneOrGeneProduct
synthesizes	O
a	O
pool	O
of	O
PI	B-ChemicalEntity
(	O
4	I-ChemicalEntity
)	O
P	I-ChemicalEntity
that	O
maintains	O
MT1	B-GeneOrGeneProduct
-	O
MMP	I-GeneOrGeneProduct
traffic	O
in	O
the	O
degradative	O
pathway	O
and	O
suppresses	O
the	O
formation	O
of	O
invadopodia	O
.	O
Common	O
germline	O
genetic	O
variation	O
in	O
antioxidant	O
defense	O
genes	O
and	O
survival	O
after	O
diagnosis	O
of	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

PURPOSE	O
:	O
The	O
prognosis	O
of	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
varies	O
considerably	O
among	O
individuals	O
,	O
and	O
inherited	O
genetic	O
factors	O
may	O
help	O
explain	O
this	O
variability	O
.	O

Of	O
particular	O
interest	O
are	O
genes	O
involved	O
in	O
defense	O
against	O
reactive	B-ChemicalEntity
oxygen	I-ChemicalEntity
species	I-ChemicalEntity
(	O
ROS	B-ChemicalEntity
)	O
because	O
ROS	B-ChemicalEntity
are	O
thought	O
to	O
cause	O
DNA	O
damage	O
and	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
.	O

PATIENTS	B-OrganismTaxon
AND	O
METHODS	O
:	O
We	O
examined	O
associations	O
between	O
54	O
polymorphisms	O
that	O
tag	O
the	O
known	O
common	O
variants	O
(	O
minor	O
allele	O
frequency	O
>	O
0	O
.	O
05	O
)	O
in	O
10	O
genes	O
involved	O
in	O
oxidative	O
damage	O
repair	O
(	O
CAT	B-GeneOrGeneProduct
,	O
SOD1	B-GeneOrGeneProduct
,	O
SOD2	B-GeneOrGeneProduct
,	O
GPX1	B-GeneOrGeneProduct
,	O
GPX4	B-GeneOrGeneProduct
,	O
GSR	B-GeneOrGeneProduct
,	O
TXN	B-GeneOrGeneProduct
,	O
TXN2	B-GeneOrGeneProduct
,	O
TXNRD1	B-GeneOrGeneProduct
,	O
and	O
TXNRD2	B-GeneOrGeneProduct
)	O
and	O
survival	O
in	O
4	O
,	O
470	O
women	B-OrganismTaxon
with	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

RESULTS	O
:	O
Two	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
GPX4	B-GeneOrGeneProduct
(	O
rs713041	B-SequenceVariant
and	O
rs757229	B-SequenceVariant
)	O
were	O
associated	O
with	O
all	O
-	O
cause	O
mortality	O
even	O
after	O
adjusting	O
for	O
multiple	O
hypothesis	O
testing	O
(	O
adjusted	O
P	O
=	O
.	O
0041	O
and	O
P	O
=	O
.	O
0035	O
)	O
.	O

These	O
SNPs	O
are	O
correlated	O
with	O
each	O
other	O
(	O
r2	O
=	O
0	O
.	O
61	O
)	O
.	O

GPX4	B-GeneOrGeneProduct
rs713041	B-SequenceVariant
is	O
located	O
near	O
the	O
selenocysteine	B-ChemicalEntity
insertion	O
sequence	O
element	O
in	O
the	O
GPX4	B-GeneOrGeneProduct
3	O
'	O
untranslated	O
region	O
,	O
and	O
the	O
rare	O
allele	O
of	O
this	O
SNP	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	B-DiseaseOrPhenotypicFeature
,	O
with	O
a	O
hazard	O
ratio	O
of	O
1	O
.	O
27	O
per	O
rare	O
allele	O
carried	O
(	O
95%	O
CI	O
,	O
1	O
.	O
13	O
to	O
11	O
.	O
43	O
)	O
.	O

This	O
effect	O
was	O
not	O
attenuated	O
after	O
adjusting	O
for	O
tumor	B-DiseaseOrPhenotypicFeature
stage	O
,	O
grade	O
,	O
or	O
estrogen	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
status	O
.	O

We	O
found	O
that	O
the	O
common	O
allele	O
is	O
preferentially	O
expressed	O
in	O
normal	O
lymphocytes	O
,	O
normal	O
breast	O
,	O
and	O
breast	B-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
compared	O
with	O
the	O
rare	O
allele	O
,	O
but	O
there	O
were	O
no	O
differences	O
in	O
total	O
levels	O
of	O
GPX4	B-GeneOrGeneProduct
mRNA	O
across	O
genotypes	O
.	O

CONCLUSION	O
:	O
These	O
data	O
provide	O
strong	O
support	O
for	O
the	O
hypothesis	O
that	O
common	O
variation	O
in	O
GPX4	B-GeneOrGeneProduct
is	O
associated	O
with	O
prognosis	O
after	O
a	O
diagnosis	O
of	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O
A	O
novel	O
IRF6	B-GeneOrGeneProduct
nonsense	O
mutation	O
(	O
Y67X	B-SequenceVariant
)	O
in	O
a	O
German	O
family	O
with	O
Van	B-DiseaseOrPhenotypicFeature
der	I-DiseaseOrPhenotypicFeature
Woude	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Van	B-DiseaseOrPhenotypicFeature
der	I-DiseaseOrPhenotypicFeature
Woude	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
VWS	B-DiseaseOrPhenotypicFeature
)	O
is	O
the	O
most	O
common	O
type	O
of	O
syndromic	B-DiseaseOrPhenotypicFeature
orofacial	I-DiseaseOrPhenotypicFeature
cleft	I-DiseaseOrPhenotypicFeature
,	O
which	O
accounts	O
for	O
approximately	O
2%	O
of	O
all	O
cleft	B-DiseaseOrPhenotypicFeature
lip	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
palate	I-DiseaseOrPhenotypicFeature
cases	O
.	O

It	O
is	O
characterised	O
by	O
variable	O
association	O
of	O
lower	O
lip	B-DiseaseOrPhenotypicFeature
pits	I-DiseaseOrPhenotypicFeature
,	O
cleft	B-DiseaseOrPhenotypicFeature
lip	I-DiseaseOrPhenotypicFeature
and	O
cleft	B-DiseaseOrPhenotypicFeature
palate	I-DiseaseOrPhenotypicFeature
,	O
and	O
hypodontia	B-DiseaseOrPhenotypicFeature
.	O

VWS	B-DiseaseOrPhenotypicFeature
arises	O
as	O
the	O
result	O
of	O
mutations	O
in	O
the	O
gene	O
encoding	O
interferon	B-GeneOrGeneProduct
regulatory	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
6	I-GeneOrGeneProduct
(	O
IRF6	B-GeneOrGeneProduct
)	O
.	O

The	O
disorder	O
is	O
transmitted	O
in	O
an	O
autosomal	O
dominant	O
manner	O
,	O
with	O
high	O
penetrance	O
and	O
variable	O
expressivity	O
.	O

Very	O
recently	O
,	O
mutations	O
of	O
the	O
IRF6	B-GeneOrGeneProduct
gene	O
in	O
exons	O
2	O
-	O
9	O
have	O
been	O
found	O
in	O
VWS	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
suggesting	O
that	O
this	O
gene	O
plays	O
an	O
important	O
role	O
in	O
orofacial	O
development	O
.	O

We	O
report	O
a	O
novel	O
mutation	O
of	O
the	O
IRF6	B-GeneOrGeneProduct
gene	O
in	O
a	O
German	O
family	O
.	O

Five	O
out	O
of	O
the	O
12	O
persons	O
affected	O
were	O
able	O
to	O
be	O
investigated	O
.	O

The	O
mutation	O
produced	O
a	O
stop	O
codon	O
within	O
exon	O
4	O
of	O
the	O
IRF6	B-GeneOrGeneProduct
gene	O
.	O

All	O
5	O
patients	B-OrganismTaxon
were	O
heterozygous	O
for	O
a	O
base	O
substitution	O
c	B-SequenceVariant
.	O
201C	I-SequenceVariant
>	O
A	I-SequenceVariant
changing	O
the	O
tyrosine	B-SequenceVariant
codon	I-SequenceVariant
at	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
position	I-SequenceVariant
67	I-SequenceVariant
into	I-SequenceVariant
a	I-SequenceVariant
stop	I-SequenceVariant
codon	O
(	O
p	B-SequenceVariant
.	O
Y67X	I-SequenceVariant
)	O
in	O
exon	O
4	O
.	O

The	O
premature	O
stop	O
codon	O
was	O
responsible	O
for	O
a	O
truncated	O
protein	O
lacking	O
parts	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
and	O
the	O
complete	O
Smad	B-GeneOrGeneProduct
-	O
interferon	B-GeneOrGeneProduct
regulatory	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
binding	O
domain	O
probably	O
essential	O
for	O
interactions	O
with	O
the	O
Smad	B-GeneOrGeneProduct
transcription	O
factors	O
.	O
Late	O
-	O
onset	O
metachromatic	B-DiseaseOrPhenotypicFeature
leukodystrophy	I-DiseaseOrPhenotypicFeature
:	O
molecular	O
pathology	O
in	O
two	O
siblings	O
.	O

We	O
report	O
on	O
a	O
new	O
allele	O
at	O
the	O
arylsulfatase	B-GeneOrGeneProduct
A	I-GeneOrGeneProduct
(	O
ARSA	B-GeneOrGeneProduct
)	O
locus	O
causing	O
late	O
-	O
onset	O
metachromatic	B-DiseaseOrPhenotypicFeature
leukodystrophy	I-DiseaseOrPhenotypicFeature
(	O
MLD	B-DiseaseOrPhenotypicFeature
)	O
.	O

In	O
that	O
allele	O
arginine84	B-SequenceVariant
,	O
a	O
residue	O
that	O
is	O
highly	O
conserved	O
in	O
the	O
arylsulfatase	B-GeneOrGeneProduct
gene	O
family	O
,	O
is	O
replaced	O
by	O
glutamine	O
.	O

In	O
contrast	O
to	O
alleles	O
that	O
cause	O
early	O
-	O
onset	O
MLD	B-DiseaseOrPhenotypicFeature
,	O
the	O
arginine84	B-SequenceVariant
to	I-SequenceVariant
glutamine	I-SequenceVariant
substitution	O
is	O
associated	O
with	O
some	O
residual	O
ARSA	B-GeneOrGeneProduct
activity	O
.	O

A	O
comparison	O
of	O
genotypes	O
,	O
ARSA	B-GeneOrGeneProduct
activities	O
,	O
and	O
clinical	O
data	O
on	O
4	O
individuals	O
carrying	O
the	O
allele	O
of	O
81	O
patients	B-OrganismTaxon
with	O
MLD	B-DiseaseOrPhenotypicFeature
examined	O
,	O
further	O
validates	O
the	O
concept	O
that	O
different	O
degrees	O
of	O
residual	O
ARSA	B-GeneOrGeneProduct
activity	O
are	O
the	O
basis	O
of	O
phenotypical	O
variation	O
in	O
MLD	B-DiseaseOrPhenotypicFeature
.	O
Families	O
with	O
the	O
risk	O
allele	O
of	O
DISC1	B-GeneOrGeneProduct
reveal	O
a	O
link	O
between	O
schizophrenia	B-DiseaseOrPhenotypicFeature
and	O
another	O
component	O
of	O
the	O
same	O
molecular	O
pathway	O
,	O
NDE1	B-GeneOrGeneProduct
.	O

We	O
have	O
previously	O
reported	O
a	O
robust	O
association	O
between	O
an	O
allelic	O
haplotype	O
of	O
'	O
Disrupted	B-GeneOrGeneProduct
in	I-GeneOrGeneProduct
Schizophrenia	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
'	O
(	O
DISC1	B-GeneOrGeneProduct
)	O
and	O
schizophrenia	B-DiseaseOrPhenotypicFeature
in	O
a	O
nationwide	O
collection	O
of	O
Finnish	O
schizophrenia	B-DiseaseOrPhenotypicFeature
families	O
.	O

This	O
specific	O
DISC1	B-GeneOrGeneProduct
allele	O
was	O
later	O
identified	O
to	O
associate	O
with	O
visual	O
working	O
memory	O
,	O
selectively	O
in	O
males	O
.	O

DISC1	B-GeneOrGeneProduct
association	O
to	O
schizophrenia	B-DiseaseOrPhenotypicFeature
has	O
since	O
been	O
replicated	O
in	O
multiple	O
independent	O
study	O
samples	O
from	O
different	O
populations	O
.	O

In	O
this	O
study	O
,	O
we	O
conditioned	O
our	O
sample	O
of	O
Finnish	O
families	O
for	O
the	O
presence	O
of	O
the	O
Finnish	O
tentative	O
risk	O
allele	O
for	O
DISC1	B-GeneOrGeneProduct
and	O
re	O
-	O
analyzed	O
our	O
genome	O
-	O
wide	O
scan	O
data	O
of	O
443	O
markers	O
on	O
the	O
basis	O
of	O
this	O
stratification	O
.	O

Two	O
additional	O
loci	O
displayed	O
an	O
evidence	O
of	O
linkage	O
(	O
LOD	O
>	O
3	O
)	O
and	O
included	O
a	O
locus	O
on	O
16p13	O
,	O
proximal	O
to	O
the	O
gene	O
encoding	O
NDE1	B-GeneOrGeneProduct
,	O
which	O
has	O
been	O
shown	O
to	O
biologically	O
interact	O
with	O
DISC1	B-GeneOrGeneProduct
.	O

Although	O
none	O
of	O
the	O
observed	O
linkages	O
remained	O
significant	O
after	O
multiple	O
test	O
correction	O
through	O
simulation	O
,	O
further	O
analysis	O
of	O
NDE1	B-GeneOrGeneProduct
revealed	O
an	O
association	O
between	O
a	O
tag	O
-	O
haplotype	O
and	O
schizophrenia	B-DiseaseOrPhenotypicFeature
(	O
P	O
=	O
0	O
.	O
00046	O
)	O
specific	O
to	O
females	O
,	O
which	O
proved	O
to	O
be	O
significant	O
(	O
P	O
=	O
0	O
.	O
011	O
)	O
after	O
multiple	O
test	O
correction	O
.	O

Our	O
finding	O
would	O
support	O
the	O
concept	O
that	O
initial	O
gene	O
findings	O
in	O
multifactorial	O
diseases	O
will	O
assist	O
in	O
the	O
identification	O
of	O
other	O
components	O
of	O
complex	O
genetic	O
etiology	O
.	O

Notably	O
,	O
this	O
and	O
other	O
converging	O
lines	O
of	O
evidence	O
underline	O
the	O
importance	O
of	O
DISC1	B-GeneOrGeneProduct
-	O
related	O
functional	O
pathways	O
in	O
the	O
etiology	O
of	O
schizophrenia	B-DiseaseOrPhenotypicFeature
.	O
CenpH	B-GeneOrGeneProduct
regulates	O
meiotic	O
G2	O
/	O
M	O
transition	O
by	O
modulating	O
the	O
APC	B-GeneOrGeneProduct
/	O
CCdh1	I-GeneOrGeneProduct
-	O
cyclin	B-GeneOrGeneProduct
B1	I-GeneOrGeneProduct
pathway	O
in	O
oocytes	O
.	O

Meiotic	O
resumption	O
(	O
G2	O
/	O
M	O
transition	O
)	O
and	O
progression	O
through	O
meiosis	O
I	O
(	O
MI	O
)	O
are	O
two	O
key	O
stages	O
for	O
producing	O
fertilization	O
-	O
competent	O
eggs	O
.	O

Here	O
,	O
we	O
report	O
that	O
CenpH	B-GeneOrGeneProduct
,	O
a	O
component	O
of	O
the	O
kinetochore	O
inner	O
plate	O
,	O
is	O
responsible	O
for	O
G2	O
/	O
M	O
transition	O
in	O
meiotic	O
mouse	B-OrganismTaxon
oocytes	O
.	O

Depletion	O
of	O
CenpH	B-GeneOrGeneProduct
by	O
morpholino	B-ChemicalEntity
injection	O
decreased	O
cyclin	B-GeneOrGeneProduct
B1	I-GeneOrGeneProduct
levels	O
,	O
resulting	O
in	O
attenuation	O
of	O
maturation	B-GeneOrGeneProduct
-	O
promoting	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
MPF	B-GeneOrGeneProduct
)	O
activation	O
,	O
and	O
severely	O
compromised	O
meiotic	O
resumption	O
.	O

CenpH	B-GeneOrGeneProduct
protects	O
cyclin	B-GeneOrGeneProduct
B1	I-GeneOrGeneProduct
from	O
destruction	O
by	O
competing	O
with	O
the	O
action	O
of	O
APC	B-GeneOrGeneProduct
/	O
C	I-GeneOrGeneProduct
(	O
Cdh1	B-GeneOrGeneProduct
)	O
Impaired	O
G2	O
/	O
M	O
transition	O
after	O
CenpH	B-GeneOrGeneProduct
depletion	O
could	O
be	O
rescued	O
by	O
expression	O
of	O
exogenous	O
cyclin	B-GeneOrGeneProduct
B1	I-GeneOrGeneProduct
.	O

Unexpectedly	O
,	O
blocking	O
CenpH	B-GeneOrGeneProduct
did	O
not	O
affect	O
spindle	O
organization	O
and	O
meiotic	O
cell	O
cycle	O
progression	O
after	O
germinal	O
vesicle	O
breakdown	O
.	O

Our	O
findings	O
reveal	O
a	O
novel	O
role	O
of	O
CenpH	B-GeneOrGeneProduct
in	O
regulating	O
meiotic	O
G2	O
/	O
M	O
transition	O
by	O
acting	O
via	O
the	O
APC	B-GeneOrGeneProduct
/	O
C	I-GeneOrGeneProduct
(	O
Cdh1	B-GeneOrGeneProduct
)	O
-	O
cyclin	B-GeneOrGeneProduct
B1	I-GeneOrGeneProduct
pathway	O
.	O
The	O
fibrinogen	B-GeneOrGeneProduct
gamma	I-GeneOrGeneProduct
10034C	B-SequenceVariant
>	O
T	I-SequenceVariant
polymorphism	O
is	O
not	O
associated	O
with	O
Peripheral	B-DiseaseOrPhenotypicFeature
Arterial	I-DiseaseOrPhenotypicFeature
Disease	I-DiseaseOrPhenotypicFeature
.	O

Conversion	O
of	O
fibrinogen	B-GeneOrGeneProduct
to	O
fibrin	B-GeneOrGeneProduct
plays	O
an	O
essential	O
role	O
in	O
hemostasis	O
and	O
results	O
in	O
stabilization	O
of	O
the	O
fibrin	B-GeneOrGeneProduct
clot	O
.	O

Fibrinogen	B-GeneOrGeneProduct
consists	O
of	O
three	O
pairs	O
of	O
non	O
-	O
identical	O
polypeptide	O
chains	O
,	O
encoded	O
by	O
different	O
genes	O
(	O
fibrinogen	B-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
[	O
FGA	B-GeneOrGeneProduct
]	O
,	O
fibrinogen	B-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
[	O
FGB	B-GeneOrGeneProduct
]	O
and	O
fibrinogen	B-GeneOrGeneProduct
gamma	I-GeneOrGeneProduct
[	O
FGG	B-GeneOrGeneProduct
]	O
)	O
.	O

A	O
functional	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
the	O
FGG	B-GeneOrGeneProduct
gene	O
(	O
FGG	B-GeneOrGeneProduct
10034C	B-SequenceVariant
>	O
T	I-SequenceVariant
,	O
rs2066865	B-SequenceVariant
)	O
has	O
been	O
associated	O
with	O
deep	B-DiseaseOrPhenotypicFeature
venous	I-DiseaseOrPhenotypicFeature
thrombosis	I-DiseaseOrPhenotypicFeature
and	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
.	O

Aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyze	O
the	O
role	O
of	O
this	O
polymorphism	O
in	O
peripheral	B-DiseaseOrPhenotypicFeature
arterial	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
PAD	B-DiseaseOrPhenotypicFeature
)	O
.	O

The	O
study	O
was	O
designed	O
as	O
case	O
-	O
control	O
study	O
including	O
891	O
patients	B-OrganismTaxon
with	O
documented	O
PAD	B-DiseaseOrPhenotypicFeature
and	O
777	O
control	O
subjects	O
.	O

FGG	B-GeneOrGeneProduct
genotypes	O
were	O
determined	O
by	O
exonuclease	O
(	O
TaqMan	O
)	O
assays	O
.	O

FGG	B-GeneOrGeneProduct
genotype	O
frequencies	O
were	O
not	O
significantly	O
different	O
between	O
PAD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
(	O
CC	O
:	O
57	O
.	O
3%	O
,	O
CT	O
:	O
36	O
.	O
7%	O
,	O
TT	O
:	O
5	O
.	O
8%	O
)	O
and	O
control	O
subjects	O
(	O
CC	O
:	O
60	O
.	O
9%	O
,	O
CT	O
:	O
33	O
.	O
5%	O
,	O
TT	O
5	O
.	O
6%	O
;	O
p	O
=	O
0	O
.	O
35	O
)	O
.	O

In	O
a	O
multivariate	O
logistic	O
regression	O
analysis	O
including	O
age	O
,	O
sex	O
,	O
smoking	O
,	O
diabetes	B-DiseaseOrPhenotypicFeature
,	O
arterial	O
hypertension	B-DiseaseOrPhenotypicFeature
and	O
hypercholesterolemia	B-DiseaseOrPhenotypicFeature
,	O
the	O
FGG	B-GeneOrGeneProduct
10034	B-SequenceVariant
T	I-SequenceVariant
variant	O
was	O
not	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
PAD	B-DiseaseOrPhenotypicFeature
(	O
Odds	O
ratio	O
1	O
.	O
07	O
,	O
95%	O
confidence	O
interval	O
0	O
.	O
84	O
-	O
1	O
.	O
37	O
;	O
p	O
=	O
0	O
.	O
60	O
)	O
.	O

The	O
FGG	B-GeneOrGeneProduct
10034C	B-SequenceVariant
>	O
T	I-SequenceVariant
polymorphism	O
was	O
furthermore	O
not	O
associated	O
with	O
age	O
at	O
onset	O
of	O
PAD	B-DiseaseOrPhenotypicFeature
.	O

We	O
conclude	O
that	O
the	O
thrombophilic	O
FGG	B-GeneOrGeneProduct
10034	B-SequenceVariant
T	I-SequenceVariant
gene	O
variant	O
does	O
not	O
contribute	O
to	O
the	O
genetic	O
susceptibility	O
to	O
PAD	B-DiseaseOrPhenotypicFeature
.	O
Concordance	O
between	O
PIK3CA	B-GeneOrGeneProduct
mutations	O
in	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
of	O
esophageal	B-DiseaseOrPhenotypicFeature
squamous	I-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
PIK3CA	B-GeneOrGeneProduct
mutations	O
are	O
expected	O
to	O
be	O
potential	O
therapeutic	O
targets	O
for	O
esophageal	B-DiseaseOrPhenotypicFeature
squamous	I-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
(	O
ESCC	B-DiseaseOrPhenotypicFeature
)	O
.	O

We	O
aimed	O
to	O
clarify	O
the	O
concordance	O
between	O
PIK3CA	B-GeneOrGeneProduct
mutations	O
detected	O
in	O
endoscopic	O
biopsy	O
specimens	O
and	O
corresponding	O
surgically	O
resected	O
specimens	O
.	O

METHODS	O
:	O
We	O
examined	O
five	O
hotspot	O
mutations	O
in	O
the	O
PIK3CA	B-GeneOrGeneProduct
gene	O
(	O
E542K	B-SequenceVariant
,	O
E545K	B-SequenceVariant
,	O
E546K	B-SequenceVariant
,	O
H1047R	B-SequenceVariant
,	O
and	O
H1047L	B-SequenceVariant
)	O
in	O
formalin	B-ChemicalEntity
-	O
fixed	O
and	O
paraffin	B-ChemicalEntity
-	O
embedded	O
tissue	O
sections	O
of	O
paired	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
from	O
181	O
patients	B-OrganismTaxon
undergoing	O
curative	O
resection	O
for	O
ESCC	B-DiseaseOrPhenotypicFeature
between	O
2000	O
and	O
2011	O
using	O
a	O
Luminex	O
technology	O
-	O
based	O
multiplex	O
gene	O
mutation	O
detection	O
kit	O
.	O

RESULTS	O
:	O
Mutation	O
analyses	O
were	O
successfully	O
performed	O
for	O
both	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
in	O
all	O
the	O
cases	O
.	O

A	O
PIK3CA	B-GeneOrGeneProduct
mutation	O
was	O
detected	O
in	O
either	O
type	O
of	O
specimen	O
in	O
13	O
cases	O
(	O
7	O
.	O
2%	O
,	O
95%	O
confidence	O
interval	O
:	O
3	O
.	O
9	O
-	O
12	O
.	O
0	O
)	O
.	O

The	O
overall	O
concordance	O
rate	O
,	O
positive	O
predictive	O
value	O
,	O
and	O
negative	O
predictive	O
value	O
were	O
98	O
.	O
3%	O
(	O
178	O
/	O
181	O
)	O
,	O
90	O
.	O
9%	O
(	O
10	O
/	O
11	O
)	O
,	O
and	O
98	O
.	O
8%	O
(	O
168	O
/	O
170	O
)	O
,	O
respectively	O
.	O

Among	O
patients	B-OrganismTaxon
with	O
a	O
PIK3CA	B-GeneOrGeneProduct
mutation	O
detected	O
in	O
both	O
types	O
of	O
specimens	O
,	O
the	O
concordance	O
between	O
PIK3CA	B-GeneOrGeneProduct
mutation	O
genotypes	O
was	O
100%	O
.	O

There	O
were	O
three	O
cases	O
with	O
a	O
discordant	O
mutation	O
status	O
between	O
the	O
types	O
of	O
specimens	O
(	O
PIK3CA	B-GeneOrGeneProduct
mutation	O
in	O
surgically	O
resected	O
specimen	O
and	O
wild	O
-	O
type	O
in	O
biopsy	O
specimen	O
in	O
two	O
cases	O
,	O
and	O
the	O
opposite	O
pattern	O
in	O
one	O
case	O
)	O
,	O
suggesting	O
possible	O
intratumoral	O
heterogeneity	O
in	O
the	O
PIK3CA	B-GeneOrGeneProduct
mutation	O
status	O
.	O

CONCLUSIONS	O
:	O
The	O
PIK3CA	B-GeneOrGeneProduct
mutation	O
status	O
was	O
highly	O
concordant	O
between	O
endoscopic	O
biopsy	O
and	O
surgically	O
resected	O
specimens	O
from	O
the	O
same	O
patient	B-OrganismTaxon
,	O
suggesting	O
that	O
endoscopic	O
biopsy	O
specimens	O
can	O
be	O
clinically	O
used	O
to	O
detect	O
PIK3CA	B-GeneOrGeneProduct
mutations	O
in	O
patients	B-OrganismTaxon
with	O
ESCC	B-DiseaseOrPhenotypicFeature
.	O
Paraoxonase	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
polymorphisms	O
and	O
survival	O
.	O

The	O
antioxidant	O
enzyme	O
paraoxonase	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
PON1	B-GeneOrGeneProduct
)	O
has	O
previously	O
been	O
suggested	O
to	O
confer	O
protection	O
against	O
coronary	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
CHD	B-DiseaseOrPhenotypicFeature
)	O
,	O
one	O
of	O
the	O
main	O
causes	O
of	O
death	B-DiseaseOrPhenotypicFeature
in	O
the	O
Western	O
world	O
.	O

Two	O
coding	O
polymorphisms	O
,	O
55M	B-SequenceVariant
/	O
L	I-SequenceVariant
and	O
192Q	B-SequenceVariant
/	O
R	I-SequenceVariant
,	O
and	O
a	O
promoter	O
variant	O
,	O
-	O
107C	I-SequenceVariant
/	O
T	I-SequenceVariant
,	O
has	O
been	O
extensively	O
studied	O
with	O
respect	O
to	O
susceptibility	O
to	O
CHD	B-DiseaseOrPhenotypicFeature
.	O

In	O
this	O
study	O
,	O
we	O
have	O
investigated	O
the	O
impact	O
of	O
these	O
three	O
polymorphisms	O
on	O
mortality	O
using	O
a	O
sample	O
of	O
1932	O
Danish	O
individuals	O
aged	O
47	O
-	O
93	O
years	O
,	O
previously	O
used	O
in	O
gene	O
-	O
longevity	O
studies	O
.	O

A	O
cross	O
-	O
sectional	O
study	O
comparing	O
the	O
genotype	O
distribution	O
of	O
the	O
three	O
polymorphisms	O
separately	O
as	O
well	O
as	O
the	O
haplotype	O
distribution	O
in	O
different	O
age	O
groups	O
did	O
not	O
reveal	O
any	O
difference	O
.	O

However	O
,	O
a	O
longitudinal	O
follow	O
-	O
up	O
study	O
on	O
survival	O
in	O
the	O
same	O
sample	O
indicated	O
that	O
192RR	B-SequenceVariant
homozygotes	O
have	O
a	O
poorer	O
survival	O
compared	O
to	O
QQ	O
homozygotes	O
(	O
hazard	O
rate	O
:	O
1	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

We	O
hereafter	O
used	O
an	O
independent	O
sample	O
of	O
541	O
Danish	O
individuals	O
from	O
the	O
oldest	O
cohort	O
and	O
confirmed	O
the	O
initial	O
findings	O
(	O
hazard	O
rate	O
:	O
1	O
.	O
38	O
,	O
P	O
=	O
0	O
.	O
09	O
)	O
.	O

In	O
both	O
samples	O
,	O
the	O
effect	O
was	O
most	O
pronounced	O
in	O
women	B-OrganismTaxon
.	O

Using	O
self	O
-	O
reported	O
data	O
on	O
ischemic	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
to	O
evaluate	O
the	O
impact	O
of	O
the	O
PON	B-GeneOrGeneProduct
192Q	B-SequenceVariant
/	O
R	I-SequenceVariant
polymorphism	O
on	O
susceptibility	O
to	O
CHD	B-DiseaseOrPhenotypicFeature
,	O
we	O
found	O
only	O
a	O
nonsignificant	O
trend	O
of	O
192RR	B-SequenceVariant
homozygosity	O
in	O
women	B-OrganismTaxon
being	O
a	O
risk	O
factor	O
.	O

Our	O
results	O
thus	O
indicates	O
that	O
PON1	B-GeneOrGeneProduct
192RR	B-SequenceVariant
homozygosity	O
is	O
associated	O
with	O
increased	O
mortality	O
in	O
women	B-OrganismTaxon
in	O
the	O
second	O
half	O
of	O
life	O
and	O
that	O
this	O
increased	O
mortality	O
is	O
possibly	O
related	O
to	O
CHD	B-DiseaseOrPhenotypicFeature
severity	O
and	O
survival	O
after	O
CHD	B-DiseaseOrPhenotypicFeature
rather	O
than	O
susceptibility	O
to	O
development	O
of	O
CHD	B-DiseaseOrPhenotypicFeature
.	O
The	O
antiarrhythmic	O
effect	O
and	O
possible	O
ionic	O
mechanisms	O
of	O
pilocarpine	B-ChemicalEntity
on	O
animal	O
models	O
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
effects	O
of	O
pilocarpine	B-ChemicalEntity
and	O
explore	O
the	O
underlying	O
ionic	O
mechanism	O
,	O
using	O
both	O
aconitine	B-ChemicalEntity
-	O
induced	O
rat	B-OrganismTaxon
and	O
ouabain	B-ChemicalEntity
-	O
induced	O
guinea	B-OrganismTaxon
pig	I-OrganismTaxon
arrhythmia	B-DiseaseOrPhenotypicFeature
models	O
.	O

Confocal	O
microscopy	O
was	O
used	O
to	O
measure	O
intracellular	O
free	O
-	O
calcium	B-ChemicalEntity
concentrations	O
(	O
[	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
]	O
(	O
i	O
)	O
)	O
in	O
isolated	O
myocytes	O
.	O

The	O
current	O
data	O
showed	O
that	O
pilocarpine	B-ChemicalEntity
significantly	O
delayed	O
onset	O
of	O
arrhythmias	B-DiseaseOrPhenotypicFeature
,	O
decreased	O
the	O
time	O
course	O
of	O
ventricular	B-DiseaseOrPhenotypicFeature
tachycardia	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
fibrillation	I-DiseaseOrPhenotypicFeature
,	O
reduced	O
arrhythmia	B-DiseaseOrPhenotypicFeature
score	O
,	O
and	O
increased	O
the	O
survival	O
time	O
of	O
arrhythmic	B-DiseaseOrPhenotypicFeature
rats	B-OrganismTaxon
and	O
guinea	B-OrganismTaxon
pigs	I-OrganismTaxon
.	O

[	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
]	O
(	O
i	O
)	O
overload	O
induced	O
by	O
aconitine	B-ChemicalEntity
or	O
ouabain	B-ChemicalEntity
was	O
reduced	O
in	O
isolated	O
myocytes	O
pretreated	O
with	O
pilocarpine	B-ChemicalEntity
.	O

Moreover	O
,	O
M	B-GeneOrGeneProduct
(	O
3	I-GeneOrGeneProduct
)	O
-	O
muscarinic	I-GeneOrGeneProduct
acetylcholine	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
mAChR	B-GeneOrGeneProduct
)	O
antagonist	O
4	B-ChemicalEntity
-	O
DAMP	I-ChemicalEntity
(	O
4	B-ChemicalEntity
-	O
diphenylacetoxy	I-ChemicalEntity
-	O
N	I-ChemicalEntity
-	O
methylpiperidine	I-ChemicalEntity
-	O
methiodide	I-ChemicalEntity
)	O
partially	O
abolished	O
the	O
beneficial	O
effects	O
of	O
pilocarpine	B-ChemicalEntity
.	O

These	O
data	O
suggest	O
that	O
pilocarpine	B-ChemicalEntity
produced	O
antiarrhythmic	O
actions	O
on	O
arrhythmic	B-DiseaseOrPhenotypicFeature
rat	B-OrganismTaxon
and	O
guinea	B-OrganismTaxon
pig	I-OrganismTaxon
models	O
induced	O
by	O
aconitine	B-ChemicalEntity
or	O
ouabain	B-ChemicalEntity
via	O
stimulating	O
the	O
cardiac	O
M	B-GeneOrGeneProduct
(	O
3	I-GeneOrGeneProduct
)	O
-	O
mAChR	I-GeneOrGeneProduct
.	O

The	O
mechanism	O
may	O
be	O
related	O
to	O
the	O
improvement	O
of	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
handling	O
.	O
Arginase	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
deletion	O
in	O
myeloid	O
cells	O
affects	O
the	O
inflammatory	B-DiseaseOrPhenotypicFeature
response	O
in	O
allergic	O
asthma	B-DiseaseOrPhenotypicFeature
,	O
but	O
not	O
lung	O
mechanics	O
,	O
in	O
female	O
mice	B-OrganismTaxon
.	O

BACKGROUND	O
:	O
(	O
Over	O
-	O
)	O
expression	O
of	O
arginase	B-GeneOrGeneProduct
may	O
limit	O
local	O
availability	O
of	O
arginine	O
for	O
nitric	B-ChemicalEntity
oxide	I-ChemicalEntity
synthesis	O
.	O

We	O
investigated	O
the	O
significance	O
of	O
arginase1	B-GeneOrGeneProduct
(	O
ARG1	B-GeneOrGeneProduct
)	O
for	O
the	O
development	O
of	O
airway	O
hyperresponsiveness	O
(	O
AHR	O
)	O
and	O
lung	B-DiseaseOrPhenotypicFeature
inflammation	I-DiseaseOrPhenotypicFeature
in	O
female	O
mice	B-OrganismTaxon
with	O
ovalbumin	B-GeneOrGeneProduct
(	O
OVA	B-GeneOrGeneProduct
)	O
-	O
induced	O
allergic	O
asthma	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
Arg1	B-GeneOrGeneProduct
was	O
ablated	O
in	O
the	O
lung	O
by	O
crossing	O
Arg1	B-GeneOrGeneProduct
fl	O
/	O
fl	O
and	O
Tie2Cre	O
tg	O
/	O
-	O
mice	B-OrganismTaxon
.	O

OVA	B-GeneOrGeneProduct
sensitization	O
and	O
challenge	O
were	O
conducted	O
,	O
and	O
AHR	O
to	O
methacholine	B-ChemicalEntity
was	O
determined	O
using	O
the	O
Flexivent	O
system	O
.	O

Changes	O
in	O
gene	O
expression	O
,	O
chemokine	O
and	O
cytokine	O
secretion	O
,	O
plasma	O
IgE	B-GeneOrGeneProduct
,	O
and	O
lung	O
histology	O
were	O
quantified	O
using	O
RT	O
-	O
qPCR	O
,	O
ELISA	O
,	O
and	O
immunohistochemistry	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Arg1	B-GeneOrGeneProduct
ablation	O
had	O
no	O
influence	O
on	O
the	O
development	O
of	O
OVA	B-GeneOrGeneProduct
-	O
induced	O
AHR	O
,	O
but	O
attenuated	O
OVA	B-GeneOrGeneProduct
-	O
induced	O
increases	O
in	O
expression	O
of	O
Arg2	B-GeneOrGeneProduct
and	O
Nos2	B-GeneOrGeneProduct
,	O
Slc7a1	B-GeneOrGeneProduct
,	O
Slc7a2	B-GeneOrGeneProduct
,	O
and	O
Slc7a7	B-GeneOrGeneProduct
(	O
arginine	B-GeneOrGeneProduct
transporters	I-GeneOrGeneProduct
)	O
,	O
Il4	B-GeneOrGeneProduct
,	O
Il5	B-GeneOrGeneProduct
and	O
Il13	B-GeneOrGeneProduct
(	O
TH2	B-GeneOrGeneProduct
-	O
type	I-GeneOrGeneProduct
cytokines	I-GeneOrGeneProduct
)	O
,	O
Ccl2	B-GeneOrGeneProduct
and	O
Ccl11	B-GeneOrGeneProduct
(	O
chemokines	B-GeneOrGeneProduct
)	O
,	O
Ifng	B-GeneOrGeneProduct
(	O
TH1	B-GeneOrGeneProduct
-	O
type	I-GeneOrGeneProduct
cytokine	I-GeneOrGeneProduct
)	O
,	O
Clca3	B-GeneOrGeneProduct
and	O
Muc5ac	B-GeneOrGeneProduct
(	O
goblet	O
cell	O
markers	O
)	O
,	O
and	O
OVA	B-GeneOrGeneProduct
-	O
specific	O
IgE	B-GeneOrGeneProduct
.	O

Pulmonary	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
protein	O
content	O
increased	O
,	O
but	O
IL	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
5	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
13	I-GeneOrGeneProduct
,	O
TNFalpha	B-GeneOrGeneProduct
and	O
IFNgamma	B-GeneOrGeneProduct
content	O
,	O
and	O
lung	O
histopathology	O
,	O
were	O
not	O
affected	O
.	O

Arg1	B-GeneOrGeneProduct
elimination	O
also	O
decreased	O
number	O
and	O
tightness	O
of	O
correlations	O
between	O
adaptive	O
changes	O
in	O
lung	O
function	O
and	O
inflammatory	B-DiseaseOrPhenotypicFeature
parameters	O
in	O
OVA	B-GeneOrGeneProduct
/	O
OVA	B-GeneOrGeneProduct
-	O
treated	O
female	O
mice	B-OrganismTaxon
.	O

OVA	B-GeneOrGeneProduct
/	O
OVA	B-GeneOrGeneProduct
-	O
treated	O
female	O
mice	B-OrganismTaxon
mounted	O
a	O
higher	O
OVA	B-GeneOrGeneProduct
-	O
IgE	B-GeneOrGeneProduct
response	O
than	O
males	O
,	O
but	O
the	O
correlation	O
between	O
lung	O
function	O
and	O
inflammation	B-DiseaseOrPhenotypicFeature
was	O
lower	O
.	O

Arg1	B-GeneOrGeneProduct
-	O
deficient	O
OVA	B-GeneOrGeneProduct
/	O
OVA	B-GeneOrGeneProduct
-	O
treated	O
females	O
differed	O
from	O
males	O
in	O
a	O
more	O
pronounced	O
decline	O
of	O
arginine	O
-	O
metabolizing	O
and	O
-	O
transporting	O
genes	O
,	O
higher	O
plasma	O
arginine	O
levels	O
,	O
a	O
smaller	O
OVA	B-GeneOrGeneProduct
-	O
specific	O
IgE	B-GeneOrGeneProduct
response	O
,	O
and	O
no	O
improvement	O
of	O
peripheral	O
lung	O
function	O
.	O

CONCLUSION	O
:	O
Complete	O
ablation	O
of	O
Arg1	B-GeneOrGeneProduct
in	O
the	O
lung	O
affects	O
mRNA	O
abundance	O
of	O
arginine	O
-	O
transporting	O
and	O
-	O
metabolizing	O
genes	O
,	O
and	O
pro	O
-	O
inflammatory	B-DiseaseOrPhenotypicFeature
genes	O
,	O
but	O
not	O
methacholine	B-ChemicalEntity
responsiveness	O
or	O
accumulation	O
of	O
inflammatory	B-DiseaseOrPhenotypicFeature
cells	O
.	O
Valproic	B-ChemicalEntity
acid	I-ChemicalEntity
I	O
:	O
time	O
course	O
of	O
lipid	B-ChemicalEntity
peroxidation	O
biomarkers	O
,	O
liver	B-DiseaseOrPhenotypicFeature
toxicity	I-DiseaseOrPhenotypicFeature
,	O
and	O
valproic	B-ChemicalEntity
acid	I-ChemicalEntity
metabolite	O
levels	O
in	O
rats	B-OrganismTaxon
.	O

A	O
single	O
dose	O
of	O
valproic	B-ChemicalEntity
acid	I-ChemicalEntity
(	O
VPA	B-ChemicalEntity
)	O
,	O
which	O
is	O
a	O
widely	O
used	O
antiepileptic	B-ChemicalEntity
drug	I-ChemicalEntity
,	O
is	O
associated	O
with	O
oxidative	O
stress	O
in	O
rats	B-OrganismTaxon
,	O
as	O
recently	O
demonstrated	O
by	O
elevated	O
levels	O
of	O
15	B-ChemicalEntity
-	O
F	I-ChemicalEntity
(	O
2t	I-ChemicalEntity
)	O
-	O
isoprostane	I-ChemicalEntity
(	O
15	B-ChemicalEntity
-	O
F	I-ChemicalEntity
(	O
2t	I-ChemicalEntity
)	O
-	O
IsoP	I-ChemicalEntity
)	O
.	O

To	O
determine	O
whether	O
there	O
was	O
a	O
temporal	O
relationship	O
between	O
VPA	B-ChemicalEntity
-	O
associated	O
oxidative	O
stress	O
and	O
hepatotoxicity	B-DiseaseOrPhenotypicFeature
,	O
adult	O
male	O
Sprague	O
-	O
Dawley	O
rats	B-OrganismTaxon
were	O
treated	O
ip	O
with	O
VPA	B-ChemicalEntity
(	O
500	O
mg	O
/	O
kg	O
)	O
or	O
0	O
.	O
9%	O
saline	O
(	O
vehicle	O
)	O
once	O
daily	O
for	O
2	O
,	O
4	O
,	O
7	O
,	O
10	O
,	O
or	O
14	O
days	O
.	O

Oxidative	O
stress	O
was	O
assessed	O
by	O
determining	O
plasma	O
and	O
liver	O
levels	O
of	O
15	B-ChemicalEntity
-	O
F	I-ChemicalEntity
(	O
2t	I-ChemicalEntity
)	O
-	O
IsoP	I-ChemicalEntity
,	O
lipid	B-ChemicalEntity
hydroperoxides	I-ChemicalEntity
(	O
LPO	B-ChemicalEntity
)	O
,	O
and	O
thiobarbituric	B-ChemicalEntity
acid	I-ChemicalEntity
reactive	I-ChemicalEntity
substances	I-ChemicalEntity
(	O
TBARs	B-ChemicalEntity
)	O
.	O

Plasma	O
and	O
liver	O
15	B-ChemicalEntity
-	O
F	I-ChemicalEntity
(	O
2t	I-ChemicalEntity
)	O
-	O
IsoP	I-ChemicalEntity
were	O
elevated	O
and	O
reached	O
a	O
plateau	O
after	O
day	O
2	O
of	O
VPA	B-ChemicalEntity
treatment	O
compared	O
to	O
control	O
.	O

Liver	O
LPO	B-ChemicalEntity
levels	O
were	O
not	O
elevated	O
until	O
day	O
7	O
of	O
treatment	O
(	O
1	O
.	O
8	O
-	O
fold	O
versus	O
control	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Liver	O
and	O
plasma	O
TBARs	B-ChemicalEntity
were	O
not	O
increased	O
until	O
14	O
days	O
(	O
2	O
-	O
fold	O
vs	O
.	O

control	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Liver	B-DiseaseOrPhenotypicFeature
toxicity	I-DiseaseOrPhenotypicFeature
was	O
evaluated	O
based	O
on	O
serum	O
levels	O
of	O
alpha	B-GeneOrGeneProduct
-	O
glutathione	I-GeneOrGeneProduct
S	I-GeneOrGeneProduct
-	O
transferase	I-GeneOrGeneProduct
(	O
alpha	B-GeneOrGeneProduct
-	O
GST	I-GeneOrGeneProduct
)	O
and	O
by	O
histology	O
.	O

Serum	O
alpha	B-GeneOrGeneProduct
-	O
GST	I-GeneOrGeneProduct
levels	O
were	O
significantly	O
elevated	O
by	O
day	O
4	O
,	O
which	O
corresponded	O
to	O
hepatotoxicity	B-DiseaseOrPhenotypicFeature
as	O
shown	O
by	O
the	O
increasing	O
incidence	O
of	O
inflammation	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
capsule	I-DiseaseOrPhenotypicFeature
,	O
necrosis	B-DiseaseOrPhenotypicFeature
,	O
and	O
steatosis	B-DiseaseOrPhenotypicFeature
throughout	O
the	O
study	O
.	O

The	O
liver	O
levels	O
of	O
beta	O
-	O
oxidation	O
metabolites	O
of	O
VPA	B-ChemicalEntity
were	O
decreased	O
by	O
day	O
14	O
,	O
while	O
the	O
levels	O
of	O
4	B-ChemicalEntity
-	O
ene	I-ChemicalEntity
-	O
VPA	I-ChemicalEntity
and	O
(	O
E	O
)	O
-	O
2	B-ChemicalEntity
,	O
4	I-ChemicalEntity
-	O
diene	I-ChemicalEntity
-	O
VPA	I-ChemicalEntity
were	O
not	O
elevated	O
throughout	O
the	O
study	O
.	O

Overall	O
,	O
these	O
findings	O
indicate	O
that	O
VPA	B-ChemicalEntity
treatment	O
results	O
in	O
oxidative	O
stress	O
,	O
as	O
measured	O
by	O
levels	O
of	O
15	B-ChemicalEntity
-	O
F	I-ChemicalEntity
(	O
2t	I-ChemicalEntity
)	O
-	O
IsoP	I-ChemicalEntity
,	O
which	O
precedes	O
the	O
onset	O
of	O
necrosis	B-DiseaseOrPhenotypicFeature
,	O
steatosis	B-DiseaseOrPhenotypicFeature
,	O
and	O
elevated	O
levels	O
of	O
serum	O
alpha	B-GeneOrGeneProduct
-	O
GST	I-GeneOrGeneProduct
.	O
Delineation	O
of	O
the	O
clinical	O
phenotype	O
associated	O
with	O
OPHN1	B-GeneOrGeneProduct
mutations	O
based	O
on	O
the	O
clinical	O
and	O
neuropsychological	O
evaluation	O
of	O
three	O
families	O
.	O

Recent	O
reports	O
have	O
demonstrated	O
that	O
mutations	O
in	O
the	O
OPHN1	B-GeneOrGeneProduct
gene	O
were	O
responsible	O
for	O
a	O
syndromic	O
rather	O
than	O
non	O
-	O
specific	O
mental	B-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
.	O

Abnormalities	O
of	O
the	O
posterior	O
fossa	O
with	O
cerebellar	B-DiseaseOrPhenotypicFeature
hypoplasia	I-DiseaseOrPhenotypicFeature
have	O
been	O
demonstrated	O
in	O
all	O
male	O
patients	B-OrganismTaxon
reported	O
to	O
date	O
.	O

We	O
report	O
here	O
a	O
new	O
family	O
with	O
X	B-DiseaseOrPhenotypicFeature
-	O
linked	I-DiseaseOrPhenotypicFeature
mental	I-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
due	O
to	O
mutation	O
in	O
OPHN1	B-GeneOrGeneProduct
and	O
present	O
unpublished	O
data	O
about	O
two	O
families	O
previously	O
reported	O
,	O
concerning	O
the	O
facial	O
and	O
psychological	O
phenotype	O
of	O
affected	O
males	O
and	O
carrier	O
females	O
.	O

Our	O
study	O
confirms	O
that	O
cerebellar	B-DiseaseOrPhenotypicFeature
hypoplasia	I-DiseaseOrPhenotypicFeature
is	O
a	O
hallmark	O
of	O
this	O
syndrome	O
.	O

In	O
addition	O
,	O
affected	O
males	O
display	O
facial	O
similarities	O
that	O
can	O
help	O
the	O
diagnosis	O
.	O

Most	O
carrier	O
females	O
have	O
mild	O
mental	B-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
and	O
subtle	O
facial	O
changes	O
.	O
Serum	O
levels	O
of	O
chemokines	B-GeneOrGeneProduct
CCL4	B-GeneOrGeneProduct
and	O
CCL5	B-GeneOrGeneProduct
in	O
cirrhotic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
indicate	O
the	O
presence	O
of	O
hepatocellular	B-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Most	O
hepatocellular	B-DiseaseOrPhenotypicFeature
carcinomas	I-DiseaseOrPhenotypicFeature
(	O
HCCs	B-DiseaseOrPhenotypicFeature
)	O
are	O
diagnosed	O
at	O
an	O
advanced	O
stage	O
.	O

The	O
prognostic	O
value	O
of	O
serum	O
tumour	B-DiseaseOrPhenotypicFeature
markers	O
alpha	B-GeneOrGeneProduct
-	O
fetoprotein	I-GeneOrGeneProduct
(	O
AFP	B-GeneOrGeneProduct
)	O
and	O
des	B-GeneOrGeneProduct
-	O
gamma	I-GeneOrGeneProduct
-	O
carboxy	I-GeneOrGeneProduct
prothrombin	I-GeneOrGeneProduct
(	O
DCP	B-GeneOrGeneProduct
)	O
is	O
limited	O
.	O

The	O
aim	O
of	O
our	O
study	O
is	O
to	O
evaluate	O
the	O
diagnostic	O
value	O
of	O
serum	O
growth	O
factors	O
,	O
apoptotic	O
and	O
inflammatory	B-DiseaseOrPhenotypicFeature
mediators	O
of	O
cirrhotic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
and	O
without	O
HCC	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
Serum	O
samples	O
were	O
collected	O
from	O
cirrhotic	B-DiseaseOrPhenotypicFeature
potential	O
liver	O
transplant	O
patients	B-OrganismTaxon
(	O
LTx	O
)	O
with	O
(	O
n	O
=	O
61	O
)	O
and	O
without	O
HCC	B-DiseaseOrPhenotypicFeature
(	O
n	O
=	O
78	O
)	O
as	O
well	O
as	O
from	O
healthy	O
controls	O
(	O
HCs	O
;	O
n	O
=	O
39	O
)	O
.	O

Serum	O
concentrations	O
of	O
CRP	B-GeneOrGeneProduct
,	O
neopterin	B-ChemicalEntity
and	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
as	O
markers	O
of	O
inflammation	B-DiseaseOrPhenotypicFeature
and	O
thrombopoietin	B-GeneOrGeneProduct
(	O
TPO	B-GeneOrGeneProduct
)	O
,	O
GCSF	B-GeneOrGeneProduct
,	O
FGF	B-GeneOrGeneProduct
basic	I-GeneOrGeneProduct
and	O
VEGF	B-GeneOrGeneProduct
,	O
HMGB1	B-GeneOrGeneProduct
,	O
CK	B-GeneOrGeneProduct
-	O
18	I-GeneOrGeneProduct
(	O
M65	O
)	O
and	O
CK18	B-GeneOrGeneProduct
fragment	O
(	O
M30	O
)	O
and	O
a	O
panel	O
of	O
proinflammatory	B-GeneOrGeneProduct
chemokines	I-GeneOrGeneProduct
(	O
CCL2	B-GeneOrGeneProduct
,	O
CCL3	B-GeneOrGeneProduct
,	O
CCL4	B-GeneOrGeneProduct
,	O
CCL5	B-GeneOrGeneProduct
,	O
CXCL5	B-GeneOrGeneProduct
and	O
IL	B-GeneOrGeneProduct
-	O
8	I-GeneOrGeneProduct
)	O
were	O
measured	O
.	O

Chi	O
square	O
,	O
Fisher	O
exact	O
,	O
Mann	O
-	O
Whitney	O
U	O
-	O
tests	O
,	O
ROC	O
curve	O
analysis	O
and	O
forward	O
stepwise	O
logistic	O
regression	O
analyses	O
were	O
applied	O
.	O

RESULTS	O
:	O
Patients	B-OrganismTaxon
with	O
HCC	B-DiseaseOrPhenotypicFeature
had	O
higher	O
serum	O
TPO	B-GeneOrGeneProduct
and	O
chemokines	B-GeneOrGeneProduct
(	O
P	O
<	O
0	O
.	O
001	O
for	O
TPO	B-GeneOrGeneProduct
,	O
CCL4	B-GeneOrGeneProduct
,	O
CCL5	B-GeneOrGeneProduct
and	O
CXCL5	B-GeneOrGeneProduct
)	O
and	O
lower	O
CCL2	B-GeneOrGeneProduct
(	O
P	O
=	O
0	O
.	O
008	O
)	O
levels	O
than	O
cirrhotic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
without	O
HCC	B-DiseaseOrPhenotypicFeature
.	O

Multivariate	O
forward	O
stepwise	O
regression	O
analysis	O
for	O
significant	O
parameters	O
showed	O
that	O
among	O
the	O
studied	O
parameters	O
CCL4	B-GeneOrGeneProduct
and	O
CCL5	B-GeneOrGeneProduct
(	O
P	O
=	O
0	O
.	O
001	O
)	O
are	O
diagnostic	O
markers	O
of	O
HCC	B-DiseaseOrPhenotypicFeature
.	O

Serum	O
levels	O
of	O
TPO	B-GeneOrGeneProduct
and	O
chemokines	B-GeneOrGeneProduct
were	O
lower	O
,	O
whereas	O
M30	O
was	O
significantly	O
higher	O
in	O
cirrhotic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
than	O
in	O
HCs	O
.	O

CONCLUSIONS	O
:	O
High	O
serum	O
levels	O
of	O
inflammatory	B-DiseaseOrPhenotypicFeature
chemokines	B-GeneOrGeneProduct
such	O
as	O
CCL4	B-GeneOrGeneProduct
and	O
CCL5	B-GeneOrGeneProduct
in	O
the	O
serum	O
of	O
cirrhotic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
indicate	O
the	O
presence	O
of	O
HCC	B-DiseaseOrPhenotypicFeature
.	O
Over	O
-	O
expression	O
of	O
BMP4	B-GeneOrGeneProduct
and	O
BMP5	B-GeneOrGeneProduct
in	O
a	O
child	O
with	O
axial	B-DiseaseOrPhenotypicFeature
skeletal	I-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
and	O
heterotopic	B-DiseaseOrPhenotypicFeature
ossification	I-DiseaseOrPhenotypicFeature
:	O
a	O
new	O
syndrome	O
.	O

Bone	B-GeneOrGeneProduct
morphogenetic	I-GeneOrGeneProduct
proteins	I-GeneOrGeneProduct
(	O
BMPs	B-GeneOrGeneProduct
)	O
are	O
a	O
highly	O
conserved	O
class	O
of	O
signaling	O
molecules	O
that	O
induce	O
ectopic	B-DiseaseOrPhenotypicFeature
cartilage	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
bone	I-DiseaseOrPhenotypicFeature
formation	I-DiseaseOrPhenotypicFeature
in	O
vivo	O
.	O

Dysregulated	O
expression	O
of	O
bone	B-GeneOrGeneProduct
morphogenetic	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
(	O
BMP4	B-GeneOrGeneProduct
)	O
is	O
found	O
in	O
the	O
cells	O
of	O
patients	B-OrganismTaxon
who	O
have	O
fibrodysplasia	B-DiseaseOrPhenotypicFeature
ossificans	I-DiseaseOrPhenotypicFeature
progressiva	I-DiseaseOrPhenotypicFeature
(	O
FOP	B-DiseaseOrPhenotypicFeature
)	O
,	O
a	O
genetic	O
disorder	O
of	O
axial	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
appendicular	I-DiseaseOrPhenotypicFeature
skeletal	I-DiseaseOrPhenotypicFeature
malformation	I-DiseaseOrPhenotypicFeature
and	O
progressive	O
heterotopic	B-DiseaseOrPhenotypicFeature
ossification	I-DiseaseOrPhenotypicFeature
.	O

Loss	O
of	O
function	O
mutations	O
in	O
the	O
bone	B-GeneOrGeneProduct
morphogenetic	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
5	I-GeneOrGeneProduct
(	O
bmp5	B-GeneOrGeneProduct
)	O
gene	O
leading	O
to	O
under	O
-	O
expression	O
of	O
BMP5	B-GeneOrGeneProduct
cause	O
the	O
murine	B-OrganismTaxon
short	B-DiseaseOrPhenotypicFeature
ear	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
,	O
characterized	O
by	O
small	O
malformed	O
ears	O
and	O
a	O
broad	O
range	O
of	O
axial	B-DiseaseOrPhenotypicFeature
skeletal	I-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
.	O

We	O
found	O
features	O
reminiscent	O
of	O
both	O
the	O
short	O
ear	O
mouse	B-OrganismTaxon
and	O
FOP	B-DiseaseOrPhenotypicFeature
in	O
a	O
child	O
with	O
malformed	B-DiseaseOrPhenotypicFeature
external	I-DiseaseOrPhenotypicFeature
ears	I-DiseaseOrPhenotypicFeature
,	O
multiple	B-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
axial	I-DiseaseOrPhenotypicFeature
skeleton	I-DiseaseOrPhenotypicFeature
,	O
and	O
progressive	O
heterotopic	B-DiseaseOrPhenotypicFeature
ossification	I-DiseaseOrPhenotypicFeature
in	O
the	O
neck	O
and	O
back	O
.	O

We	O
examined	O
BMP	B-GeneOrGeneProduct
mRNA	O
expression	O
in	O
transformed	O
lymphocytes	O
by	O
semi	O
-	O
quantitative	O
RT	O
-	O
PCR	O
and	O
protein	O
expression	O
by	O
ELISA	O
assays	O
and	O
immunohistochemistry	O
.	O

Elevated	O
levels	O
of	O
BMP4	B-GeneOrGeneProduct
and	O
BMP5	B-GeneOrGeneProduct
mRNA	O
and	O
protein	O
were	O
detected	O
in	O
the	O
patient	B-OrganismTaxon
'	O
s	O
cells	O
while	O
levels	O
of	O
BMP2	B-GeneOrGeneProduct
mRNA	O
were	O
unchanged	O
.	O

Our	O
data	O
suggest	O
that	O
dysregulated	O
expression	O
of	O
BMP4	B-GeneOrGeneProduct
and	O
BMP5	B-GeneOrGeneProduct
genes	O
is	O
associated	O
with	O
an	O
array	O
of	O
human	B-OrganismTaxon
axial	B-DiseaseOrPhenotypicFeature
skeletal	I-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
similar	O
to	O
the	O
short	O
ear	O
mouse	B-OrganismTaxon
and	O
FOP	B-DiseaseOrPhenotypicFeature
.	O
The	O
activation	O
of	O
spinal	O
N	B-GeneOrGeneProduct
-	O
methyl	I-GeneOrGeneProduct
-	O
D	I-GeneOrGeneProduct
-	O
aspartate	I-GeneOrGeneProduct
receptors	I-GeneOrGeneProduct
may	O
contribute	O
to	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
induced	O
by	O
neuraxial	O
morphine	B-ChemicalEntity
after	O
a	O
noninjurious	O
interval	O
of	O
spinal	B-DiseaseOrPhenotypicFeature
cord	I-DiseaseOrPhenotypicFeature
ischemia	I-DiseaseOrPhenotypicFeature
.	O

We	O
investigated	O
the	O
relationship	O
between	O
the	O
degeneration	O
of	O
spinal	O
motor	O
neurons	O
and	O
activation	O
of	O
N	B-GeneOrGeneProduct
-	O
methyl	I-GeneOrGeneProduct
-	O
d	I-GeneOrGeneProduct
-	O
aspartate	I-GeneOrGeneProduct
(	O
NMDA	I-GeneOrGeneProduct
)	O
receptors	I-GeneOrGeneProduct
after	O
neuraxial	O
morphine	B-ChemicalEntity
following	O
a	O
noninjurious	O
interval	O
of	O
aortic	B-DiseaseOrPhenotypicFeature
occlusion	I-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
.	O

Spinal	B-DiseaseOrPhenotypicFeature
cord	I-DiseaseOrPhenotypicFeature
ischemia	I-DiseaseOrPhenotypicFeature
was	O
induced	O
by	O
aortic	B-DiseaseOrPhenotypicFeature
occlusion	I-DiseaseOrPhenotypicFeature
for	O
6	O
min	O
with	O
a	O
balloon	O
catheter	O
.	O

In	O
a	O
microdialysis	O
study	O
,	O
10	O
muL	O
of	O
saline	O
(	O
group	O
C	O
;	O
n	O
=	O
8	O
)	O
or	O
30	O
mug	O
of	O
morphine	B-ChemicalEntity
(	O
group	O
M	O
;	O
n	O
=	O
8	O
)	O
was	O
injected	O
intrathecally	O
(	O
IT	O
)	O
0	O
.	O
5	O
h	O
after	O
reflow	O
,	O
and	O
30	O
mug	O
of	O
morphine	B-ChemicalEntity
(	O
group	O
SM	O
;	O
n	O
=	O
8	O
)	O
or	O
10	O
muL	O
of	O
saline	O
(	O
group	O
SC	O
;	O
n	O
=	O
8	O
)	O
was	O
injected	O
IT	O
0	O
.	O
5	O
h	O
after	O
sham	O
operation	O
.	O

Microdialysis	O
samples	O
were	O
collected	O
preischemia	O
,	O
before	O
IT	O
injection	O
,	O
and	O
at	O
2	O
,	O
4	O
,	O
8	O
,	O
24	O
,	O
and	O
48	O
h	O
of	O
reperfusion	O
(	O
after	O
IT	O
injection	O
)	O
.	O

Second	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
IT	O
MK	B-ChemicalEntity
-	O
801	I-ChemicalEntity
(	O
30	O
mug	O
)	O
on	O
the	O
histopathologic	O
changes	O
in	O
the	O
spinal	O
cord	O
after	O
morphine	B-ChemicalEntity
-	O
induced	O
spastic	B-DiseaseOrPhenotypicFeature
paraparesis	I-DiseaseOrPhenotypicFeature
.	O

After	O
IT	O
morphine	B-ChemicalEntity
,	O
the	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
glutamate	B-ChemicalEntity
concentration	O
was	O
increased	O
in	O
group	O
M	O
relative	O
to	O
both	O
baseline	O
and	O
group	O
C	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

This	O
increase	O
persisted	O
for	O
8	O
hrs	O
.	O

IT	O
MK	B-ChemicalEntity
-	O
801	I-ChemicalEntity
significantly	O
reduced	O
the	O
number	O
of	O
dark	O
-	O
stained	O
alpha	O
-	O
motoneurons	O
after	O
morphine	B-ChemicalEntity
-	O
induced	O
spastic	B-DiseaseOrPhenotypicFeature
paraparesis	I-DiseaseOrPhenotypicFeature
compared	O
with	O
the	O
saline	O
group	O
.	O

These	O
data	O
indicate	O
that	O
IT	O
morphine	B-ChemicalEntity
induces	O
spastic	B-DiseaseOrPhenotypicFeature
paraparesis	I-DiseaseOrPhenotypicFeature
with	O
a	O
concomitant	O
increase	O
in	O
CSF	O
glutamate	B-ChemicalEntity
,	O
which	O
is	O
involved	O
in	O
NMDA	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
activation	O
.	O

We	O
suggest	O
that	O
opioids	B-ChemicalEntity
may	O
be	O
neurotoxic	B-DiseaseOrPhenotypicFeature
in	O
the	O
setting	O
of	O
spinal	B-DiseaseOrPhenotypicFeature
cord	I-DiseaseOrPhenotypicFeature
ischemia	I-DiseaseOrPhenotypicFeature
via	O
NMDA	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
activation	O
.	O
Association	O
of	O
DRD2	B-GeneOrGeneProduct
polymorphisms	O
and	O
chlorpromazine	B-ChemicalEntity
-	O
induced	O
extrapyramidal	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
in	O
Chinese	O
schizophrenic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

AIM	O
:	O
Extrapyramidal	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
EPS	B-DiseaseOrPhenotypicFeature
)	O
is	O
most	O
commonly	O
affected	O
by	O
typical	O
antipsychotic	B-ChemicalEntity
drugs	I-ChemicalEntity
that	O
have	O
a	O
high	O
affinity	O
with	O
the	O
D2	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
.	O

Recently	O
,	O
many	O
research	O
groups	O
have	O
reported	O
on	O
the	O
positive	O
relationship	O
between	O
the	O
genetic	O
variations	O
in	O
the	O
DRD2	B-GeneOrGeneProduct
gene	O
and	O
the	O
therapeutic	O
response	O
in	O
schizophrenia	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
as	O
a	O
result	O
of	O
the	O
role	O
of	O
variations	O
in	O
the	O
receptor	O
in	O
modulating	O
receptor	O
expression	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluate	O
the	O
role	O
DRD2	B-GeneOrGeneProduct
plays	O
in	O
chlorpromazine	B-ChemicalEntity
-	O
induced	O
EPS	B-DiseaseOrPhenotypicFeature
in	O
schizophrenic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

METHODS	O
:	O
We	O
identified	O
seven	O
SNP	O
(	O
single	O
nucleotide	O
polymorphism	O
)	O
(	O
-	O
141Cins	I-SequenceVariant
>	O
del	I-SequenceVariant
,	O
TaqIB	O
,	O
TaqID	O
,	O
Ser311Cys	B-SequenceVariant
,	O
rs6275	B-SequenceVariant
,	O
rs6277	B-SequenceVariant
and	O
TaqIA	O
)	O
in	O
the	O
DRD2	B-GeneOrGeneProduct
gene	O
in	O
146	O
schizophrenic	B-DiseaseOrPhenotypicFeature
inpatients	B-OrganismTaxon
(	O
59	O
with	O
EPS	B-DiseaseOrPhenotypicFeature
and	O
87	O
without	O
EPS	B-DiseaseOrPhenotypicFeature
according	O
to	O
the	O
Simpson	O
-	O
Angus	O
Scale	O
)	O
treated	O
with	O
chlorpromazine	B-ChemicalEntity
after	O
8	O
weeks	O
.	O

The	O
alleles	O
of	O
all	O
loci	O
were	O
determined	O
by	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
.	O

RESULTS	O
:	O
Polymorphisms	O
TaqID	O
,	O
Ser311Cys	B-SequenceVariant
and	O
rs6277	B-SequenceVariant
were	O
not	O
polymorphic	O
in	O
the	O
population	O
recruited	O
in	O
the	O
present	O
study	O
.	O

No	O
statistical	O
significance	O
was	O
found	O
in	O
the	O
allele	O
distribution	O
of	O
-	O
141Cins	I-SequenceVariant
>	O
del	I-SequenceVariant
,	O
TaqIB	O
,	O
rs6275	B-SequenceVariant
and	O
TaqIA	O
or	O
in	O
the	O
estimated	O
haplotypes	O
(	O
constituted	O
by	O
TaqIB	O
,	O
rs6275	B-SequenceVariant
and	O
TaqIA	O
)	O
in	O
linkage	O
disequilibrium	O
between	O
the	O
two	O
groups	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
did	O
not	O
lend	O
strong	O
support	O
to	O
the	O
view	O
that	O
the	O
genetic	O
variation	O
of	O
the	O
DRD2	B-GeneOrGeneProduct
gene	O
plays	O
a	O
major	O
role	O
in	O
the	O
individually	O
variable	O
adverse	O
effect	O
induced	O
by	O
chlorpromazine	B-ChemicalEntity
,	O
at	O
least	O
in	O
Chinese	O
patients	B-OrganismTaxon
with	O
schizophrenia	B-DiseaseOrPhenotypicFeature
.	O

Our	O
results	O
confirmed	O
a	O
previous	O
study	O
on	O
the	O
relationship	O
between	O
DRD2	B-GeneOrGeneProduct
and	O
EPS	B-DiseaseOrPhenotypicFeature
in	O
Caucasians	O
.	O
Does	O
domperidone	B-ChemicalEntity
potentiate	O
mirtazapine	B-ChemicalEntity
-	O
associated	O
restless	B-DiseaseOrPhenotypicFeature
legs	I-DiseaseOrPhenotypicFeature
syndrome?	I-DiseaseOrPhenotypicFeature
There	O
is	O
now	O
evidence	O
to	O
suggest	O
a	O
central	O
role	O
for	O
the	O
dopaminergic	O
system	O
in	O
restless	B-DiseaseOrPhenotypicFeature
legs	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
RLS	B-DiseaseOrPhenotypicFeature
)	O
.	O

For	O
example	O
,	O
the	O
symptoms	O
of	O
RLS	B-DiseaseOrPhenotypicFeature
can	O
be	O
dramatically	O
improved	O
by	O
levodopa	B-ChemicalEntity
and	O
dopamine	B-ChemicalEntity
agonists	O
,	O
whereas	O
central	O
dopamine	B-ChemicalEntity
D2	I-ChemicalEntity
receptor	I-ChemicalEntity
antagonists	I-ChemicalEntity
can	O
induce	O
or	O
aggravate	O
RLS	B-DiseaseOrPhenotypicFeature
symptoms	O
.	O

To	O
our	O
knowledge	O
,	O
there	O
is	O
no	O
previous	O
report	O
regarding	O
whether	O
domperidone	B-ChemicalEntity
,	O
a	O
peripheral	O
dopamine	B-GeneOrGeneProduct
D2	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
antagonist	O
,	O
can	O
also	O
induce	O
or	O
aggravate	O
symptoms	O
of	O
RLS	B-DiseaseOrPhenotypicFeature
.	O

Mirtazapine	B-ChemicalEntity
,	O
the	O
first	O
noradrenergic	B-ChemicalEntity
and	I-ChemicalEntity
specific	I-ChemicalEntity
serotonergic	I-ChemicalEntity
antidepressant	I-ChemicalEntity
(	O
NaSSA	B-ChemicalEntity
)	O
,	O
has	O
been	O
associated	O
with	O
RLS	B-DiseaseOrPhenotypicFeature
in	O
several	O
recent	O
publications	O
.	O

The	O
authors	O
report	O
here	O
a	O
depressed	B-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
comorbid	O
with	O
postprandial	B-DiseaseOrPhenotypicFeature
dyspepsia	I-DiseaseOrPhenotypicFeature
who	O
developed	O
RLS	B-DiseaseOrPhenotypicFeature
after	O
mirtazapine	B-ChemicalEntity
had	O
been	O
added	O
to	O
his	O
domperidone	B-ChemicalEntity
therapy	O
.	O

Our	O
patient	B-OrganismTaxon
started	O
to	O
have	O
symptoms	O
of	O
RLS	B-DiseaseOrPhenotypicFeature
only	O
after	O
he	O
had	O
been	O
treated	O
with	O
mirtazapine	B-ChemicalEntity
,	O
and	O
his	O
RLS	B-DiseaseOrPhenotypicFeature
symptoms	O
resolved	O
completely	O
upon	O
discontinuation	O
of	O
his	O
mirtazapine	B-ChemicalEntity
.	O

Such	O
a	O
temporal	O
relationship	O
between	O
the	O
use	O
of	O
mirtazapine	B-ChemicalEntity
and	O
the	O
symptoms	O
of	O
RLS	B-DiseaseOrPhenotypicFeature
in	O
our	O
patient	B-OrganismTaxon
did	O
not	O
support	O
a	O
potentiating	O
effect	O
of	O
domperione	B-ChemicalEntity
on	O
mirtazapine	B-ChemicalEntity
-	O
associated	O
RLS	B-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
physicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
mirtazapine	B-ChemicalEntity
can	O
be	O
associated	O
with	O
RLS	B-DiseaseOrPhenotypicFeature
in	O
some	O
individuals	O
,	O
especially	O
those	O
receiving	O
concomitant	O
dopamine	B-ChemicalEntity
D2	I-ChemicalEntity
receptor	I-ChemicalEntity
antagonists	I-ChemicalEntity
.	O
End	B-DiseaseOrPhenotypicFeature
-	O
stage	I-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
ESRD	B-DiseaseOrPhenotypicFeature
)	O
after	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
using	O
calcineurin	B-GeneOrGeneProduct
-	O
based	O
immunotherapy	O
:	O
risk	O
of	O
development	O
and	O
treatment	O
.	O

BACKGROUND	O
:	O
The	O
calcineurin	B-GeneOrGeneProduct
inhibitors	O
cyclosporine	B-ChemicalEntity
and	O
tacrolimus	B-ChemicalEntity
are	O
both	O
known	O
to	O
be	O
nephrotoxic	B-DiseaseOrPhenotypicFeature
.	O

Their	O
use	O
in	O
orthotopic	O
liver	O
transplantation	O
(	O
OLTX	O
)	O
has	O
dramatically	O
improved	O
success	O
rates	O
.	O

Recently	O
,	O
however	O
,	O
we	O
have	O
had	O
an	O
increase	O
of	O
patients	B-OrganismTaxon
who	O
are	O
presenting	O
after	O
OLTX	O
with	O
end	B-DiseaseOrPhenotypicFeature
-	O
stage	I-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
ESRD	B-DiseaseOrPhenotypicFeature
)	O
.	O

This	O
retrospective	O
study	O
examines	O
the	O
incidence	O
and	O
treatment	O
of	O
ESRD	B-DiseaseOrPhenotypicFeature
and	O
chronic	B-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
(	O
CRF	B-DiseaseOrPhenotypicFeature
)	O
in	O
OLTX	O
patients	B-OrganismTaxon
.	O

METHODS	O
:	O
Patients	B-OrganismTaxon
receiving	O
an	O
OLTX	O
only	O
from	O
June	O
1985	O
through	O
December	O
of	O
1994	O
who	O
survived	O
6	O
months	O
postoperatively	O
were	O
studied	O
(	O
n	O
=	O
834	O
)	O
.	O

Our	O
prospectively	O
collected	O
database	O
was	O
the	O
source	O
of	O
information	O
.	O

Patients	B-OrganismTaxon
were	O
divided	O
into	O
three	O
groups	O
:	O
Controls	O
,	O
no	O
CRF	B-DiseaseOrPhenotypicFeature
or	O
ESRD	B-DiseaseOrPhenotypicFeature
,	O
n	O
=	O
748	O
;	O
CRF	B-DiseaseOrPhenotypicFeature
,	O
sustained	O
serum	O
creatinine	B-ChemicalEntity
>	O
2	O
.	O
5	O
mg	O
/	O
dl	O
,	O
n	O
=	O
41	O
;	O
and	O
ESRD	B-DiseaseOrPhenotypicFeature
,	O
n	O
=	O
45	O
.	O

Groups	O
were	O
compared	O
for	O
preoperative	O
laboratory	O
variables	O
,	O
diagnosis	O
,	O
postoperative	O
variables	O
,	O
survival	O
,	O
type	O
of	O
ESRD	B-DiseaseOrPhenotypicFeature
therapy	O
,	O
and	O
survival	O
from	O
onset	O
of	O
ESRD	B-DiseaseOrPhenotypicFeature
.	O

RESULTS	O
:	O
At	O
13	O
years	O
after	O
OLTX	O
,	O
the	O
incidence	O
of	O
severe	O
renal	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
was	O
18	O
.	O
1%	O
(	O
CRF	B-DiseaseOrPhenotypicFeature
8	O
.	O
6%	O
and	O
ESRD	B-DiseaseOrPhenotypicFeature
9	O
.	O
5%	O
)	O
.	O

Compared	O
with	O
control	O
patients	B-OrganismTaxon
,	O
CRF	B-DiseaseOrPhenotypicFeature
and	O
ESRD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
had	O
higher	O
preoperative	O
serum	O
creatinine	B-ChemicalEntity
levels	O
,	O
a	O
greater	O
percentage	O
of	O
patients	B-OrganismTaxon
with	O
hepatorenal	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
,	O
higher	O
percentage	O
requirement	O
for	O
dialysis	O
in	O
the	O
first	O
3	O
months	O
postoperatively	O
,	O
and	O
a	O
higher	O
1	O
-	O
year	O
serum	O
creatinine	B-ChemicalEntity
.	O

Multivariate	O
stepwise	O
logistic	O
regression	O
analysis	O
using	O
preoperative	O
and	O
postoperative	O
variables	O
identified	O
that	O
an	O
increase	O
of	O
serum	O
creatinine	B-ChemicalEntity
compared	O
with	O
average	O
at	O
1	O
year	O
,	O
3	O
months	O
,	O
and	O
4	O
weeks	O
postoperatively	O
were	O
independent	O
risk	O
factors	O
for	O
the	O
development	O
of	O
CRF	B-DiseaseOrPhenotypicFeature
or	O
ESRD	B-DiseaseOrPhenotypicFeature
with	O
odds	O
ratios	O
of	O
2	O
.	O
6	O
,	O
2	O
.	O
2	O
,	O
and	O
1	O
.	O
6	O
,	O
respectively	O
.	O

Overall	O
survival	O
from	O
the	O
time	O
of	O
OLTX	O
was	O
not	O
significantly	O
different	O
among	O
groups	O
,	O
but	O
by	O
year	O
13	O
,	O
the	O
survival	O
of	O
the	O
patients	B-OrganismTaxon
who	O
had	O
ESRD	B-DiseaseOrPhenotypicFeature
was	O
only	O
28	O
.	O
2%	O
compared	O
with	O
54	O
.	O
6%	O
in	O
the	O
control	O
group	O
.	O

Patients	B-OrganismTaxon
developing	O
ESRD	B-DiseaseOrPhenotypicFeature
had	O
a	O
6	O
-	O
year	O
survival	O
after	O
onset	O
of	O
ESRD	B-DiseaseOrPhenotypicFeature
of	O
27%	O
for	O
the	O
patients	B-OrganismTaxon
receiving	O
hemodialysis	O
versus	O
71	O
.	O
4%	O
for	O
the	O
patients	B-OrganismTaxon
developing	O
ESRD	B-DiseaseOrPhenotypicFeature
who	O
subsequently	O
received	O
kidney	O
transplants	O
.	O

CONCLUSIONS	O
:	O
Patients	B-OrganismTaxon
who	O
are	O
more	O
than	O
10	O
years	O
post	O
-	O
OLTX	O
have	O
CRF	B-DiseaseOrPhenotypicFeature
and	O
ESRD	B-DiseaseOrPhenotypicFeature
at	O
a	O
high	O
rate	O
.	O

The	O
development	O
of	O
ESRD	B-DiseaseOrPhenotypicFeature
decreases	O
survival	O
,	O
particularly	O
in	O
those	O
patients	B-OrganismTaxon
treated	O
with	O
dialysis	O
only	O
.	O

Patients	B-OrganismTaxon
who	O
develop	O
ESRD	B-DiseaseOrPhenotypicFeature
have	O
a	O
higher	O
preoperative	O
and	O
1	O
-	O
year	O
serum	O
creatinine	B-ChemicalEntity
and	O
are	O
more	O
likely	O
to	O
have	O
hepatorenal	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
an	O
increase	O
of	O
serum	O
creatinine	B-ChemicalEntity
at	O
various	O
times	O
postoperatively	O
is	O
more	O
predictive	O
of	O
the	O
development	O
of	O
CRF	B-DiseaseOrPhenotypicFeature
or	O
ESRD	B-DiseaseOrPhenotypicFeature
.	O

New	O
strategies	O
for	O
long	O
-	O
term	O
immunosuppression	O
may	O
be	O
needed	O
to	O
decrease	O
this	O
complication	O
.	O
Alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
as	O
a	O
novel	O
phenotype	O
modifier	O
.	O

Approximately	O
30%	O
of	O
alleles	O
causing	O
genetic	O
disorders	O
generate	O
premature	O
termination	O
codons	O
(	O
PTCs	O
)	O
,	O
which	O
are	O
usually	O
associated	O
with	O
severe	O
phenotypes	O
.	O

However	O
,	O
bypassing	O
the	O
deleterious	O
stop	O
codon	O
can	O
lead	O
to	O
a	O
mild	O
disease	O
outcome	O
.	O

Splicing	O
at	O
NAGNAG	O
tandem	O
splice	O
sites	O
has	O
been	O
reported	O
to	O
result	O
in	O
insertion	O
or	O
deletion	O
(	O
indel	O
)	O
of	O
three	O
nucleotides	O
.	O

We	O
identified	O
such	O
a	O
mechanism	O
as	O
the	O
origin	O
of	O
the	O
mild	O
to	O
asymptomatic	O
phenotype	O
observed	O
in	O
cystic	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
homozygous	O
for	O
the	O
E831X	B-SequenceVariant
mutation	O
(	O
2623G	B-SequenceVariant
>	O
T	I-SequenceVariant
)	O
in	O
the	O
CFTR	B-GeneOrGeneProduct
gene	O
.	O

Analyses	O
performed	O
on	O
nasal	O
epithelial	O
cell	O
mRNA	O
detected	O
three	O
distinct	O
isoforms	O
,	O
a	O
considerably	O
more	O
complex	O
situation	O
than	O
expected	O
for	O
a	O
single	O
nucleotide	O
substitution	O
.	O

Structure	O
-	O
function	O
studies	O
and	O
in	O
silico	O
analyses	O
provided	O
the	O
first	O
experimental	O
evidence	O
of	O
an	O
indel	O
of	O
a	O
stop	O
codon	O
by	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
acceptor	O
site	O
.	O

In	O
addition	O
to	O
contributing	O
to	O
proteome	O
plasticity	O
,	O
alternative	O
splicing	O
at	O
a	O
NAGNAG	O
tandem	O
site	O
can	O
thus	O
remove	O
a	O
disease	O
-	O
causing	O
UAG	O
stop	O
codon	O
.	O

This	O
molecular	O
study	O
reveals	O
a	O
naturally	O
occurring	O
mechanism	O
where	O
the	O
effect	O
of	O
either	O
modifier	O
genes	O
or	O
epigenetic	O
factors	O
could	O
be	O
suspected	O
.	O

This	O
finding	O
is	O
of	O
importance	O
for	O
genetic	O
counseling	O
as	O
well	O
as	O
for	O
deciding	O
appropriate	O
therapeutic	O
strategies	O
.	O
Differential	O
impact	O
of	O
immune	O
escape	O
mutations	O
G145R	B-SequenceVariant
and	O
P120T	B-SequenceVariant
on	O
the	O
replication	O
of	O
lamivudine	B-ChemicalEntity
-	O
resistant	O
hepatitis	B-ChemicalEntity
B	I-ChemicalEntity
virus	I-ChemicalEntity
e	I-ChemicalEntity
antigen	I-ChemicalEntity
-	O
positive	O
and	O
-	O
negative	O
strains	O
.	O

Immune	O
escape	O
variants	O
of	O
the	O
hepatitis	B-OrganismTaxon
B	I-OrganismTaxon
virus	I-OrganismTaxon
(	O
HBV	B-OrganismTaxon
)	O
represent	O
an	O
emerging	O
clinical	O
challenge	O
,	O
because	O
they	O
can	O
be	O
associated	O
with	O
vaccine	O
escape	O
,	O
HBV	B-OrganismTaxon
reactivation	O
,	O
and	O
failure	O
of	O
diagnostic	O
tests	O
.	O

Recent	O
data	O
suggest	O
a	O
preferential	O
selection	O
of	O
immune	O
escape	O
mutants	O
in	O
distinct	O
peripheral	O
blood	O
leukocyte	O
compartments	O
of	O
infected	O
individuals	O
.	O

We	O
therefore	O
systematically	O
analyzed	O
the	O
functional	O
impact	O
of	O
the	O
most	O
prevalent	O
immune	O
escape	O
variants	O
,	O
the	O
sG145R	O
and	O
sP120T	O
mutants	O
,	O
on	O
the	O
viral	O
replication	O
efficacy	O
and	O
antiviral	O
drug	O
susceptibility	O
of	O
common	O
treatment	O
-	O
associated	O
mutants	O
with	O
resistance	O
to	O
lamivudine	B-ChemicalEntity
(	O
LAM	B-ChemicalEntity
)	O
and	O
/	O
or	O
HBeAg	B-ChemicalEntity
negativity	O
.	O

Replication	O
-	O
competent	O
HBV	B-OrganismTaxon
strains	O
with	O
sG145R	O
or	O
sP120T	O
and	O
LAM	B-ChemicalEntity
resistance	O
(	O
rtM204I	O
or	O
rtL180M	O
/	O
rtM204V	O
)	O
were	O
generated	O
on	O
an	O
HBeAg	B-ChemicalEntity
-	O
positive	O
and	O
an	O
HBeAg	B-ChemicalEntity
-	O
negative	O
background	O
with	O
precore	B-GeneOrGeneProduct
(	O
PC	B-GeneOrGeneProduct
)	O
and	O
basal	O
core	O
promoter	O
(	O
BCP	O
)	O
mutants	O
.	O

The	O
sG145R	O
mutation	O
strongly	O
reduced	O
HBsAg	B-ChemicalEntity
levels	O
and	O
was	O
able	O
to	O
fully	O
restore	O
the	O
impaired	O
replication	O
of	O
LAM	B-ChemicalEntity
-	O
resistant	O
HBV	B-OrganismTaxon
mutants	O
to	O
the	O
levels	O
of	O
wild	O
-	O
type	O
HBV	B-OrganismTaxon
,	O
and	O
PC	B-GeneOrGeneProduct
or	O
BCP	O
mutations	O
further	O
enhanced	O
viral	O
replication	O
.	O

Although	O
the	O
sP120T	O
substitution	O
also	O
impaired	O
HBsAg	B-ChemicalEntity
secretion	O
,	O
it	O
did	O
not	O
enhance	O
the	O
replication	O
of	O
LAM	B-ChemicalEntity
-	O
resistant	O
clones	O
.	O

However	O
,	O
the	O
concomitant	O
occurrence	O
of	O
HBeAg	B-ChemicalEntity
negativity	O
(	O
PC	B-GeneOrGeneProduct
/	O
BCP	O
)	O
,	O
sP120T	O
,	O
and	O
LAM	B-ChemicalEntity
resistance	O
resulted	O
in	O
the	O
restoration	O
of	O
replication	O
to	O
levels	O
of	O
wild	O
-	O
type	O
HBV	B-OrganismTaxon
.	O

In	O
all	O
clones	O
with	O
combined	O
immune	O
escape	O
and	O
LAM	B-ChemicalEntity
resistance	O
mutations	O
,	O
the	O
nucleotide	O
analogues	O
adefovir	B-ChemicalEntity
and	O
tenofovir	B-ChemicalEntity
remained	O
effective	O
in	O
suppressing	O
viral	O
replication	O
in	O
vitro	O
.	O

These	O
findings	O
reveal	O
the	O
differential	O
impact	O
of	O
immune	O
escape	O
variants	O
on	O
the	O
replication	O
and	O
drug	O
susceptibility	O
of	O
complex	O
HBV	B-OrganismTaxon
mutants	O
,	O
supporting	O
the	O
need	O
of	O
close	O
surveillance	O
and	O
treatment	O
adjustment	O
in	O
response	O
to	O
the	O
selection	O
of	O
distinct	O
mutational	O
patterns	O
.	O
Bilateral	O
haemorrhagic	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
globus	I-DiseaseOrPhenotypicFeature
pallidus	I-DiseaseOrPhenotypicFeature
after	O
cocaine	B-ChemicalEntity
and	O
alcohol	B-ChemicalEntity
intoxication	O
.	O

Cocaine	B-ChemicalEntity
is	O
a	O
risk	O
factor	O
for	O
both	O
ischemic	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
haemorrhagic	I-DiseaseOrPhenotypicFeature
stroke	I-DiseaseOrPhenotypicFeature
.	O

We	O
present	O
the	O
case	O
of	O
a	O
31	O
-	O
year	O
-	O
old	O
man	B-OrganismTaxon
with	O
bilateral	O
ischemia	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
globus	I-DiseaseOrPhenotypicFeature
pallidus	I-DiseaseOrPhenotypicFeature
after	O
excessive	O
alcohol	B-ChemicalEntity
and	O
intranasal	O
cocaine	B-ChemicalEntity
use	O
.	O

Drug	O
-	O
related	O
globus	B-DiseaseOrPhenotypicFeature
pallidus	I-DiseaseOrPhenotypicFeature
infarctions	I-DiseaseOrPhenotypicFeature
are	O
most	O
often	O
associated	O
with	O
heroin	B-ChemicalEntity
.	O

Bilateral	O
basal	B-DiseaseOrPhenotypicFeature
ganglia	I-DiseaseOrPhenotypicFeature
infarcts	I-DiseaseOrPhenotypicFeature
after	O
the	O
use	O
of	O
cocaine	B-ChemicalEntity
,	O
without	O
concurrent	O
heroin	B-ChemicalEntity
use	O
,	O
have	O
never	O
been	O
reported	O
.	O

In	O
our	O
patient	B-OrganismTaxon
,	O
transient	O
cardiac	B-DiseaseOrPhenotypicFeature
arrhythmia	I-DiseaseOrPhenotypicFeature
or	O
respiratory	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
related	O
to	O
cocaine	B-ChemicalEntity
and	O
/	O
or	O
ethanol	B-ChemicalEntity
use	O
were	O
the	O
most	O
likely	O
causes	O
of	O
cerebral	B-DiseaseOrPhenotypicFeature
hypoperfusion	I-DiseaseOrPhenotypicFeature
.	O
Detailed	O
spectral	O
profile	O
analysis	O
of	O
penicillin	B-ChemicalEntity
-	O
induced	O
epileptiform	B-DiseaseOrPhenotypicFeature
activity	I-DiseaseOrPhenotypicFeature
in	O
anesthetized	O
rats	B-OrganismTaxon
.	O

Penicillin	B-ChemicalEntity
model	O
is	O
a	O
widely	O
used	O
experimental	O
model	O
for	O
epilepsy	B-DiseaseOrPhenotypicFeature
research	O
.	O

In	O
the	O
present	O
study	O
we	O
aimed	O
to	O
portray	O
a	O
detailed	O
spectral	O
analysis	O
of	O
penicillin	B-ChemicalEntity
-	O
induced	O
epileptiform	B-DiseaseOrPhenotypicFeature
activity	I-DiseaseOrPhenotypicFeature
in	O
comparison	O
with	O
basal	O
brain	O
activity	O
in	O
anesthetized	O
Wistar	O
rats	B-OrganismTaxon
.	O

Male	O
Wistar	O
rats	B-OrganismTaxon
were	O
anesthetized	O
with	O
i	O
.	O
p	O
.	O

urethane	B-ChemicalEntity
and	O
connected	O
to	O
an	O
electrocorticogram	O
setup	O
.	O

After	O
a	O
short	O
period	O
of	O
basal	O
activity	O
recording	O
,	O
epileptic	B-DiseaseOrPhenotypicFeature
focus	O
was	O
induced	O
by	O
injecting	O
400IU	O
/	O
2	O
microl	O
penicillin	B-ChemicalEntity
-	O
G	I-ChemicalEntity
potassium	I-ChemicalEntity
into	O
the	O
left	O
lateral	O
ventricle	O
while	O
the	O
cortical	O
activity	O
was	O
continuously	O
recorded	O
.	O

Basal	O
activity	O
,	O
latent	O
period	O
and	O
the	O
penicillin	B-ChemicalEntity
-	O
induced	O
epileptiform	B-DiseaseOrPhenotypicFeature
activity	I-DiseaseOrPhenotypicFeature
periods	O
were	O
then	O
analyzed	O
using	O
both	O
conventional	O
methods	O
and	O
spectral	O
analysis	O
.	O

Spectral	O
analyses	O
were	O
conducted	O
by	O
dividing	O
the	O
whole	O
spectrum	O
into	O
different	O
frequency	O
bands	O
including	O
delta	O
,	O
theta	O
(	O
slow	O
and	O
fast	O
)	O
,	O
alpha	O
-	O
sigma	O
,	O
beta	O
(	O
1	O
and	O
2	O
)	O
and	O
gamma	O
(	O
1	O
and	O
2	O
)	O
bands	O
.	O

Our	O
results	O
show	O
that	O
the	O
most	O
affected	O
frequency	O
bands	O
were	O
delta	O
,	O
theta	O
,	O
beta	O
-	O
2	O
and	O
gamma	O
-	O
2	O
bands	O
during	O
the	O
epileptiform	B-DiseaseOrPhenotypicFeature
activity	I-DiseaseOrPhenotypicFeature
and	O
there	O
were	O
marked	O
differences	O
in	O
terms	O
of	O
spectral	O
densities	O
between	O
three	O
investigated	O
episodes	O
(	O
basal	O
activity	O
,	O
latent	O
period	O
and	O
epileptiform	B-DiseaseOrPhenotypicFeature
activity	I-DiseaseOrPhenotypicFeature
)	O
.	O

Our	O
results	O
may	O
help	O
to	O
analyze	O
novel	O
data	O
obtained	O
using	O
similar	O
experimental	O
models	O
and	O
the	O
simple	O
analysis	O
method	O
described	O
here	O
can	O
be	O
used	O
in	O
similar	O
studies	O
to	O
investigate	O
the	O
basic	O
neuronal	O
mechanism	O
of	O
this	O
or	O
other	O
types	O
of	O
experimental	O
epilepsies	B-DiseaseOrPhenotypicFeature
.	O
Exaggerated	O
expression	O
of	O
inflammatory	B-DiseaseOrPhenotypicFeature
mediators	O
in	O
vasoactive	B-GeneOrGeneProduct
intestinal	I-GeneOrGeneProduct
polypeptide	I-GeneOrGeneProduct
knockout	O
(	O
VIP	B-GeneOrGeneProduct
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
with	O
cyclophosphamide	B-ChemicalEntity
(	O
CYP	B-ChemicalEntity
)	O
-	O
induced	O
cystitis	B-DiseaseOrPhenotypicFeature
.	O

Vasoactive	B-GeneOrGeneProduct
intestinal	I-GeneOrGeneProduct
polypeptide	I-GeneOrGeneProduct
(	O
VIP	B-GeneOrGeneProduct
)	O
is	O
an	O
immunomodulatory	O
neuropeptide	O
distributed	O
in	O
micturition	O
pathways	O
.	O

VIP	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
exhibit	O
altered	O
bladder	O
function	O
and	O
neurochemical	O
properties	O
in	O
micturition	O
pathways	O
after	O
cyclophosphamide	B-ChemicalEntity
(	O
CYP	B-ChemicalEntity
)	O
-	O
induced	O
cystitis	B-DiseaseOrPhenotypicFeature
.	O

Given	O
VIP	B-GeneOrGeneProduct
'	O
s	O
role	O
as	O
an	O
anti	O
-	O
inflammatory	B-DiseaseOrPhenotypicFeature
mediator	O
,	O
we	O
hypothesized	O
that	O
VIP	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
would	O
exhibit	O
enhanced	O
inflammatory	B-DiseaseOrPhenotypicFeature
mediator	O
expression	O
after	O
cystitis	B-DiseaseOrPhenotypicFeature
.	O

A	O
mouse	B-OrganismTaxon
inflammatory	B-DiseaseOrPhenotypicFeature
cytokine	O
and	O
receptor	O
RT2	O
profiler	O
array	O
was	O
used	O
to	O
determine	O
regulated	O
transcripts	O
in	O
the	O
urinary	O
bladder	O
of	O
wild	O
type	O
(	O
WT	O
)	O
and	O
VIP	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
with	O
or	O
without	O
CYP	B-ChemicalEntity
-	O
induced	O
cystitis	B-DiseaseOrPhenotypicFeature
(	O
150	O
mg	O
/	O
kg	O
;	O
i	O
.	O
p	O
.	O
;	O
48	O
h	O
)	O
.	O

Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	O
versus	O
CYP	B-ChemicalEntity
treatment	O
(	O
48	O
h	O
)	O
,	O
VIP	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
control	O
versus	O
CYP	B-ChemicalEntity
treatment	O
(	O
48	O
h	O
)	O
,	O
WT	O
control	O
versus	O
VIP	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
control	O
,	O
and	O
WT	O
with	O
CYP	B-ChemicalEntity
treatment	O
(	O
48	O
h	O
)	O
versus	O
VIP	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
with	O
CYP	B-ChemicalEntity
treatment	O
(	O
48	O
h	O
)	O
.	O

The	O
genes	O
presented	O
represent	O
(	O
1	O
)	O
greater	O
than	O
1	O
.	O
5	O
-	O
fold	O
change	O
in	O
either	O
direction	O
and	O
(	O
2	O
)	O
the	O
p	O
value	O
is	O
less	O
than	O
0	O
.	O
05	O
for	O
the	O
comparison	O
being	O
made	O
.	O

Several	O
regulated	O
genes	O
were	O
validated	O
using	O
enzyme	O
-	O
linked	O
immunoassays	O
including	O
IL	B-GeneOrGeneProduct
-	O
1beta	I-GeneOrGeneProduct
and	O
CXCL1	B-GeneOrGeneProduct
.	O

CYP	B-ChemicalEntity
treatment	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
increased	O
expression	O
of	O
CXCL1	B-GeneOrGeneProduct
and	O
IL	B-GeneOrGeneProduct
-	O
1beta	I-GeneOrGeneProduct
in	O
the	O
urinary	O
bladder	O
of	O
WT	O
and	O
VIP	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
,	O
but	O
expression	O
in	O
VIP	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
with	O
CYP	B-ChemicalEntity
treatment	O
was	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
greater	O
(	O
4	O
.	O
2	O
-	O
to	O
13	O
-	O
fold	O
increase	O
)	O
than	O
that	O
observed	O
in	O
WT	O
urinary	O
bladder	O
(	O
3	O
.	O
6	O
-	O
to	O
5	O
-	O
fold	O
increase	O
)	O
.	O

The	O
data	O
suggest	O
that	O
in	O
VIP	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
with	O
bladder	B-DiseaseOrPhenotypicFeature
inflammation	I-DiseaseOrPhenotypicFeature
,	O
inflammatory	B-DiseaseOrPhenotypicFeature
mediators	O
are	O
increased	O
above	O
that	O
observed	O
in	O
WT	O
with	O
CYP	B-ChemicalEntity
.	O

This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	O
bladder	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
in	O
VIP	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
with	O
bladder	B-DiseaseOrPhenotypicFeature
inflammation	I-DiseaseOrPhenotypicFeature
and	O
altered	O
neurochemical	O
expression	O
in	O
micturition	O
pathways	O
.	O
Seizures	B-DiseaseOrPhenotypicFeature
associated	O
with	O
levofloxacin	B-ChemicalEntity
:	O
case	O
presentation	O
and	O
literature	O
review	O
.	O

PURPOSE	O
:	O
We	O
present	O
a	O
case	O
of	O
a	O
patient	B-OrganismTaxon
who	O
developed	O
seizures	B-DiseaseOrPhenotypicFeature
shortly	O
after	O
initiating	O
treatment	O
with	O
levofloxacin	B-ChemicalEntity
and	O
to	O
discuss	O
the	O
potential	O
drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
cytochrome	B-GeneOrGeneProduct
P450	I-GeneOrGeneProduct
(	O
CYP	I-GeneOrGeneProduct
)	O
1A2	I-GeneOrGeneProduct
in	O
this	O
case	O
,	O
as	O
well	O
as	O
in	O
other	O
cases	O
,	O
of	O
levofloxacin	B-ChemicalEntity
-	O
induced	O
seizures	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
Several	O
biomedical	O
databases	O
were	O
searched	O
including	O
MEDLINE	O
,	O
Cochrane	O
and	O
Ovid	O
.	O

The	O
main	O
search	O
terms	O
utilized	O
were	O
case	O
report	O
and	O
levofloxacin	B-ChemicalEntity
.	O

The	O
search	O
was	O
limited	O
to	O
studies	O
published	O
in	O
English	O
.	O

RESULTS	O
:	O
Six	O
cases	O
of	O
levofloxacin	B-ChemicalEntity
-	O
induced	O
seizures	B-DiseaseOrPhenotypicFeature
have	O
been	O
reported	O
in	O
the	O
literature	O
.	O

Drug	O
-	O
drug	O
interactions	O
related	O
to	O
the	O
inhibition	O
of	O
CYP1A2	B-GeneOrGeneProduct
by	O
levofloxacin	B-ChemicalEntity
are	O
likely	O
involved	O
in	O
the	O
clinical	O
outcome	O
of	O
these	O
cases	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
are	O
exhorted	O
to	O
pay	O
close	O
attention	O
when	O
initiating	O
levofloxacin	B-ChemicalEntity
therapy	O
in	O
patients	B-OrganismTaxon
taking	O
medications	O
with	O
epileptogenic	O
properties	O
that	O
are	O
CYP1A2	B-GeneOrGeneProduct
substrates	O
.	O
Takotsubo	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
or	O
apical	B-DiseaseOrPhenotypicFeature
ballooning	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
)	O
secondary	O
to	O
Zolmitriptan	B-ChemicalEntity
.	O

Takotsubo	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
TS	B-DiseaseOrPhenotypicFeature
)	O
,	O
also	O
known	O
as	O
broken	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
,	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	B-DiseaseOrPhenotypicFeature
coronary	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
ie	O
,	O
ST	O
-	O
segment	O
elevation	O
,	O
T	O
wave	O
inversions	O
,	O
and	O
pathologic	O
Q	O
waves	O
)	O
.	O

We	O
report	O
a	O
case	O
of	O
54	O
-	O
year	O
-	O
old	O
woman	B-OrganismTaxon
with	O
medical	O
history	O
of	O
mitral	B-DiseaseOrPhenotypicFeature
valve	I-DiseaseOrPhenotypicFeature
prolapse	I-DiseaseOrPhenotypicFeature
and	O
migraines	B-DiseaseOrPhenotypicFeature
,	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	B-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
and	O
electrocardiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
segment	O
elevation	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
positive	O
troponin	O
I	O
.	O

Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	B-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
consistent	O
with	O
TS	B-DiseaseOrPhenotypicFeature
.	O

Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	B-OrganismTaxon
took	O
zolmitriptan	B-ChemicalEntity
sparingly	O
only	O
when	O
she	O
had	O
migraines	B-DiseaseOrPhenotypicFeature
.	O

But	O
before	O
this	O
event	O
,	O
she	O
was	O
taking	O
zolmitriptan	B-ChemicalEntity
2	O
-	O
3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	B-DiseaseOrPhenotypicFeature
headache	I-DiseaseOrPhenotypicFeature
.	O

She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
active	O
,	O
rides	O
horses	B-OrganismTaxon
,	O
and	O
does	O
show	O
jumping	O
without	O
any	O
limitations	O
in	O
her	O
physical	O
activity	O
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
recent	O
stress	O
or	O
status	B-DiseaseOrPhenotypicFeature
migrainosus	I-DiseaseOrPhenotypicFeature
.	O

Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	B-DiseaseOrPhenotypicFeature
artery	I-DiseaseOrPhenotypicFeature
vasospasm	I-DiseaseOrPhenotypicFeature
secondary	O
to	O
zolmitriptan	B-ChemicalEntity
,	O
but	O
none	O
of	O
the	O
cases	O
were	O
associated	O
with	O
TS	B-DiseaseOrPhenotypicFeature
.	O
Characterization	O
of	O
Bietti	B-DiseaseOrPhenotypicFeature
crystalline	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
CYP4V2	B-GeneOrGeneProduct
mutations	O
.	O

PURPOSE	O
:	O
Mutations	O
of	O
the	O
CYP4V2	B-GeneOrGeneProduct
gene	O
,	O
a	O
novel	O
family	O
member	O
of	O
the	O
cytochrome	B-GeneOrGeneProduct
P450	I-GeneOrGeneProduct
genes	O
on	O
chromosome	O
4q35	O
,	O
have	O
recently	O
been	O
identified	O
in	O
patients	B-OrganismTaxon
with	O
Bietti	B-DiseaseOrPhenotypicFeature
crystalline	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
(	O
BCD	B-DiseaseOrPhenotypicFeature
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene	O
in	O
BCD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
from	O
Singapore	O
,	O
and	O
to	O
characterize	O
their	O
phenotype	O
.	O

METHODS	O
:	O
Nine	O
patients	B-OrganismTaxon
with	O
BCD	B-DiseaseOrPhenotypicFeature
from	O
six	O
families	O
were	O
recruited	O
into	O
the	O
study	O
.	O

The	O
11	O
exons	O
of	O
the	O
CYP4V2	B-GeneOrGeneProduct
gene	O
were	O
amplified	O
from	O
genomic	O
DNA	O
of	O
patients	B-OrganismTaxon
by	O
polymerase	O
chain	O
reaction	O
and	O
then	O
sequenced	O
.	O

Detailed	O
characterization	O
of	O
the	O
patients	B-OrganismTaxon
'	O
phenotype	O
was	O
performed	O
with	O
fundal	O
photography	O
,	O
visual	O
field	O
testing	O
,	O
fundal	O
fluorescein	O
angiography	O
,	O
and	O
electroretinography	O
(	O
ERG	O
)	O
.	O

RESULTS	O
:	O
Three	O
pathogenic	O
mutations	O
were	O
identified	O
;	O
two	O
mutations	O
,	O
S482X	B-SequenceVariant
and	O
K386T	B-SequenceVariant
,	O
were	O
novel	O
and	O
found	O
in	O
three	O
patients	B-OrganismTaxon
.	O

The	O
third	O
mutation	O
,	O
a	O
previously	O
identified	O
15	B-SequenceVariant
-	O
bp	I-SequenceVariant
deletion	I-SequenceVariant
that	O
included	O
the	O
3	O
'	O
splice	O
site	O
for	O
exon	O
7	O
,	O
was	O
found	O
in	O
all	O
nine	O
patients	B-OrganismTaxon
,	O
with	O
six	O
patients	B-OrganismTaxon
carrying	O
the	O
deletion	O
in	O
the	O
homozygous	O
state	O
.	O

Haplotype	O
analysis	O
in	O
patients	B-OrganismTaxon
and	O
controls	O
indicated	O
a	O
founder	O
effect	O
for	O
this	O
deletion	O
mutation	O
in	O
exon	O
7	O
.	O

Clinical	O
heterogeneity	O
was	O
present	O
in	O
the	O
patients	B-OrganismTaxon
.	O

Compound	O
heterozygotes	O
for	O
the	O
deletion	O
in	O
exon	O
7	O
seemed	O
to	O
have	O
more	O
severe	O
disease	O
compared	O
to	O
patients	B-OrganismTaxon
homozygous	O
for	O
the	O
deletion	O
.	O

There	O
was	O
good	O
correlation	O
between	O
clinical	O
stage	O
of	O
disease	O
and	O
ERG	O
changes	O
,	O
but	O
age	O
did	O
not	O
correlate	O
with	O
disease	O
severity	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
identified	O
novel	O
mutations	O
in	O
the	O
CYP4V2	B-GeneOrGeneProduct
gene	O
as	O
a	O
cause	O
of	O
BCD	B-DiseaseOrPhenotypicFeature
.	O

A	O
high	O
carrier	O
frequency	O
for	O
the	O
15	B-SequenceVariant
-	O
bp	I-SequenceVariant
deletion	I-SequenceVariant
in	O
exon	O
7	O
may	O
exist	O
in	O
the	O
Singapore	O
population	O
.	O

Phenotype	O
characterization	O
showed	O
clinical	O
heterogeneity	O
,	O
and	O
age	O
did	O
not	O
correlate	O
with	O
disease	O
severity	O
.	O
Genetic	O
polymorphism	O
of	O
the	O
binding	O
domain	O
of	O
surfactant	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
-	O
A2	I-GeneOrGeneProduct
increases	O
susceptibility	O
to	O
meningococcal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Meningococcal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
occurs	O
after	O
colonization	O
of	O
the	O
nasopharynx	O
with	O
Neisseria	B-DiseaseOrPhenotypicFeature
meningitidis	I-DiseaseOrPhenotypicFeature
.	O

Surfactant	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
SP	I-GeneOrGeneProduct
)	O
-	O
A	I-GeneOrGeneProduct
and	O
SP	B-GeneOrGeneProduct
-	O
D	I-GeneOrGeneProduct
are	O
pattern	O
-	O
recognition	O
molecules	O
of	O
the	O
respiratory	O
tract	O
that	O
activate	O
inflammatory	B-DiseaseOrPhenotypicFeature
and	O
phagocytic	O
defences	O
after	O
binding	O
to	O
microbial	O
sugars	B-ChemicalEntity
.	O

Variation	O
in	O
the	O
genes	O
of	O
the	O
surfactant	O
proteins	O
affects	O
the	O
expression	O
and	O
function	O
of	O
these	O
molecules	O
.	O

METHODS	O
:	O
Allele	O
frequencies	O
of	O
SP	B-GeneOrGeneProduct
-	O
A1	I-GeneOrGeneProduct
,	O
SP	B-GeneOrGeneProduct
-	O
A2	I-GeneOrGeneProduct
,	O
and	O
SP	B-GeneOrGeneProduct
-	O
D	I-GeneOrGeneProduct
were	O
determined	O
by	O
polymerase	O
chain	O
reaction	O
in	O
303	O
patients	B-OrganismTaxon
with	O
microbiologically	O
proven	O
meningococcal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
,	O
including	O
18	O
patients	B-OrganismTaxon
who	O
died	B-DiseaseOrPhenotypicFeature
,	O
and	O
222	O
healthy	O
control	O
subjects	O
.	O

RESULTS	O
:	O
Homozygosity	O
of	O
allele	O
1A1	O
of	O
SP	B-GeneOrGeneProduct
-	O
A2	I-GeneOrGeneProduct
increased	O
the	O
risk	O
of	O
meningococcal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
7	O
.	O
4	O
;	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
3	O
-	O
42	O
.	O
4	O
)	O
;	O
carriage	O
of	O
1A5	O
reduced	O
the	O
risk	O
(	O
OR	O
,	O
0	O
.	O
3	O
;	O
95%	O
CI	O
,	O
0	O
.	O
1	O
-	O
0	O
.	O
97	O
)	O
.	O

An	O
analysis	O
of	O
the	O
multiple	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
SP	B-GeneOrGeneProduct
-	O
A	I-GeneOrGeneProduct
demonstrated	O
that	O
homozygosity	O
for	O
alleles	O
encoding	O
lysine	B-SequenceVariant
(	O
in	I-SequenceVariant
1A1	I-SequenceVariant
)	O
rather	I-SequenceVariant
than	I-SequenceVariant
glutamine	I-SequenceVariant
(	O
in	I-SequenceVariant
1A5	I-SequenceVariant
)	O
at	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
223	I-SequenceVariant
in	O
the	O
carbohydrate	B-ChemicalEntity
recognition	O
domain	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
meningococcal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
OR	O
,	O
6	O
.	O
7	O
;	O
95%	O
CI	O
,	O
1	O
.	O
4	O
-	O
31	O
.	O
5	O
)	O
.	O

Carriage	O
of	O
alleles	O
encoding	O
lysine	B-SequenceVariant
at	I-SequenceVariant
residue	I-SequenceVariant
223	I-SequenceVariant
was	O
found	O
in	O
61%	O
of	O
patients	B-OrganismTaxon
who	O
died	B-DiseaseOrPhenotypicFeature
,	O
compared	O
with	O
35%	O
of	O
those	O
who	O
survived	O
(	O
OR	O
adjusted	O
for	O
age	O
,	O
2	O
.	O
9	O
;	O
95%	O
CI	O
,	O
1	O
.	O
1	O
-	O
7	O
.	O
7	O
)	O
.	O

Genetic	O
variation	O
of	O
SP	B-GeneOrGeneProduct
-	O
A1	I-GeneOrGeneProduct
and	O
SP	B-GeneOrGeneProduct
-	O
D	I-GeneOrGeneProduct
was	O
not	O
associated	O
with	O
meningococcal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

CONCLUSIONS	O
:	O
Gene	O
polymorphism	O
resulting	O
in	O
the	O
substitution	O
of	O
glutamine	B-SequenceVariant
with	I-SequenceVariant
lysine	I-SequenceVariant
at	I-SequenceVariant
residue	I-SequenceVariant
223	I-SequenceVariant
in	O
the	O
carbohydrate	B-ChemicalEntity
recognition	O
domain	O
of	O
SP	B-GeneOrGeneProduct
-	O
A2	I-GeneOrGeneProduct
increases	O
susceptibility	O
to	O
meningococcal	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
,	O
as	O
well	O
as	O
the	O
risk	O
of	O
death	B-DiseaseOrPhenotypicFeature
.	O
Risk	O
factors	O
and	O
predictors	O
of	O
levodopa	B-ChemicalEntity
-	O
induced	O
dyskinesia	B-DiseaseOrPhenotypicFeature
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

Chronic	O
pulsatile	O
levodopa	B-ChemicalEntity
therapy	O
for	O
Parkinson	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
PD	B-DiseaseOrPhenotypicFeature
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	B-DiseaseOrPhenotypicFeature
.	O

We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa	B-ChemicalEntity
-	O
induced	O
dyskinesia	B-DiseaseOrPhenotypicFeature
among	O
multiethnic	O
Malaysian	O
patients	B-OrganismTaxon
with	O
PD	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
involving	O
95	O
patients	B-OrganismTaxon
with	O
PD	B-DiseaseOrPhenotypicFeature
on	O
uninterrupted	O
levodopa	B-ChemicalEntity
therapy	O
for	O
at	O
least	O
6	O
months	O
.	O

The	O
instrument	O
used	O
was	O
the	O
UPDRS	O
questionnaires	O
.	O

The	O
predictors	O
of	O
dyskinesia	B-DiseaseOrPhenotypicFeature
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

RESULTS	O
:	O
The	O
mean	O
age	O
was	O
65	O
.	O
6	O
+	O
8	O
.	O
5	O
years	O
.	O

The	O
mean	O
onset	O
age	O
was	O
58	O
.	O
5	O
+	O
9	O
.	O
8	O
years	O
.	O

The	O
median	O
disease	O
duration	O
was	O
6	O
(	O
7	O
)	O
years	O
.	O

Dyskinesia	B-DiseaseOrPhenotypicFeature
was	O
present	O
in	O
44%	O
(	O
n	O
=	O
42	O
)	O
with	O
median	O
levodopa	B-ChemicalEntity
therapy	O
of	O
3	O
years	O
.	O

There	O
were	O
64	O
.	O
3%	O
Chinese	O
,	O
31%	O
Malays	O
,	O
and	O
3	O
.	O
7%	O
Indians	O
and	O
other	O
ethnic	O
groups	O
.	O

Eighty	O
-	O
one	O
percent	O
of	O
patients	B-OrganismTaxon
with	O
dyskinesia	B-DiseaseOrPhenotypicFeature
had	O
clinical	O
fluctuations	O
.	O

Patients	B-OrganismTaxon
with	O
dyskinesia	B-DiseaseOrPhenotypicFeature
had	O
lower	O
onset	O
age	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
duration	O
of	O
levodopa	B-ChemicalEntity
therapy	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
longer	O
disease	O
duration	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
higher	O
total	O
daily	O
levodopa	B-ChemicalEntity
dose	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
than	O
patients	B-OrganismTaxon
without	O
dyskinesia	B-DiseaseOrPhenotypicFeature
.	O

The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	B-DiseaseOrPhenotypicFeature
were	O
duration	O
of	O
levodopa	B-ChemicalEntity
therapy	O
,	O
onset	O
age	O
,	O
and	O
total	O
daily	O
levodopa	B-ChemicalEntity
dose	O
.	O

CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
levodopa	B-ChemicalEntity
-	O
induced	O
dyskinesia	B-DiseaseOrPhenotypicFeature
in	O
our	O
patients	B-OrganismTaxon
was	O
44%	O
.	O

The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	B-ChemicalEntity
therapy	O
,	O
total	O
daily	O
levodopa	B-ChemicalEntity
dose	O
,	O
and	O
onset	O
age	O
.	O
Novel	O
CACNA1S	B-GeneOrGeneProduct
mutation	O
causes	O
autosomal	O
dominant	O
hypokalemic	B-DiseaseOrPhenotypicFeature
periodic	I-DiseaseOrPhenotypicFeature
paralysis	I-DiseaseOrPhenotypicFeature
in	O
a	O
South	O
American	O
family	O
.	O

Hypokalaemic	B-DiseaseOrPhenotypicFeature
periodic	I-DiseaseOrPhenotypicFeature
paralysis	I-DiseaseOrPhenotypicFeature
(	O
HypoPP	B-DiseaseOrPhenotypicFeature
)	O
is	O
an	O
autosomal	B-DiseaseOrPhenotypicFeature
dominant	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
,	O
which	O
is	O
characterized	O
by	O
periodic	O
attacks	O
of	O
muscle	B-DiseaseOrPhenotypicFeature
weakness	I-DiseaseOrPhenotypicFeature
associated	O
with	O
a	O
decrease	O
in	O
the	O
serum	O
potassium	B-ChemicalEntity
level	O
.	O

A	O
major	O
disease	O
-	O
causing	O
gene	O
for	O
HypoPP	B-DiseaseOrPhenotypicFeature
has	O
been	O
identified	O
as	O
CACNA1S	B-GeneOrGeneProduct
,	O
which	O
encodes	O
the	O
skeletal	B-GeneOrGeneProduct
muscle	I-GeneOrGeneProduct
calcium	I-GeneOrGeneProduct
channel	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
-	O
subunit	I-GeneOrGeneProduct
with	O
four	O
transmembrane	O
domains	O
(	O
I	O
-	O
IV	O
)	O
,	O
each	O
with	O
six	O
transmembrane	O
segments	O
(	O
S1	O
-	O
S6	O
)	O
.	O

To	O
date	O
,	O
all	O
CACNA1S	B-GeneOrGeneProduct
mutations	O
identified	O
in	O
HypoPP	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
are	O
located	O
within	O
the	O
voltage	O
-	O
sensor	O
S4	O
segment	O
.	O

In	O
this	O
study	O
we	O
report	O
a	O
novel	O
CACNA1S	B-GeneOrGeneProduct
mutation	O
in	O
a	O
new	O
region	O
of	O
the	O
protein	O
,	O
the	O
S3	O
segment	O
of	O
domain	O
III	O
.	O

We	O
characterized	O
a	O
four	O
-	O
generation	O
South	O
American	O
family	O
with	O
HypoPP	B-DiseaseOrPhenotypicFeature
.	O

Genetic	O
analysis	O
identified	O
a	O
novel	O
V876E	B-SequenceVariant
mutation	O
in	O
all	O
HypoPP	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
in	O
the	O
family	O
,	O
but	O
not	O
in	O
normal	O
family	O
members	O
or	O
160	O
control	O
people	O
.	O

Clinical	O
analysis	O
indicates	O
that	O
mutation	O
V876E	B-SequenceVariant
is	O
associated	O
with	O
a	O
severe	O
outcome	O
as	O
characterized	O
by	O
a	O
very	O
early	O
age	O
of	O
onset	O
,	O
complete	O
penetrance	O
and	O
a	O
severe	O
prognosis	O
including	O
death	B-DiseaseOrPhenotypicFeature
.	O

These	O
results	O
identify	O
a	O
new	O
mutation	O
in	O
CACNA1S	B-GeneOrGeneProduct
and	O
expand	O
the	O
spectrum	O
of	O
CACNA1S	B-GeneOrGeneProduct
mutations	O
associated	O
with	O
HypoPP	B-DiseaseOrPhenotypicFeature
.	O
Elevation	O
of	O
ADAM10	B-GeneOrGeneProduct
,	O
ADAM17	B-GeneOrGeneProduct
,	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
and	O
MMP	B-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
expression	O
with	O
media	O
degeneration	O
features	O
CaCl2	B-ChemicalEntity
-	O
induced	O
thoracic	B-DiseaseOrPhenotypicFeature
aortic	I-DiseaseOrPhenotypicFeature
aneurysm	I-DiseaseOrPhenotypicFeature
in	O
a	O
rat	B-OrganismTaxon
model	O
.	O

PURPOSE	O
:	O
This	O
study	O
was	O
designed	O
to	O
establish	O
a	O
rat	B-OrganismTaxon
model	O
of	O
thoracic	B-DiseaseOrPhenotypicFeature
aortic	I-DiseaseOrPhenotypicFeature
aneurysm	I-DiseaseOrPhenotypicFeature
(	O
TAA	B-DiseaseOrPhenotypicFeature
)	O
by	O
calcium	B-ChemicalEntity
chloride	I-ChemicalEntity
(	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
)	O
-	O
induced	O
arterial	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	O
to	O
explore	O
the	O
potential	O
role	O
of	O
a	B-GeneOrGeneProduct
disintegrin	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
metalloproteinase	I-GeneOrGeneProduct
(	O
ADAM	B-GeneOrGeneProduct
)	O
,	O
matrix	B-GeneOrGeneProduct
metalloproteinases	I-GeneOrGeneProduct
(	O
MMPs	B-GeneOrGeneProduct
)	O
and	O
their	O
endogenous	O
inhibitors	O
(	O
TIMPs	O
)	O
in	O
TAA	B-DiseaseOrPhenotypicFeature
formation	O
.	O

METHODS	O
:	O
Thoracic	O
aorta	O
of	O
male	O
Sprague	O
-	O
Dawley	O
rats	B-OrganismTaxon
was	O
exposed	O
to	O
0	O
.	O
5M	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
or	O
normal	O
saline	O
(	O
NaCl	B-ChemicalEntity
)	O
.	O

After	O
12weeks	O
,	O
animals	O
were	O
euthanized	O
,	O
and	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
-	O
treated	O
,	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
-	O
untreated	O
(	O
n	O
=	O
12	O
)	O
and	O
NaCl	B-ChemicalEntity
-	O
treated	O
aortic	O
segments	O
(	O
n	O
=	O
12	O
)	O
were	O
collected	O
for	O
histological	O
and	O
molecular	O
assessments	O
.	O

MMP	B-GeneOrGeneProduct
-	O
TIMP	B-GeneOrGeneProduct
and	O
ADAM	B-GeneOrGeneProduct
mRNAs	O
were	O
semi	O
-	O
quantitatively	O
analyzed	O
and	O
protein	O
expressions	O
were	O
determined	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Despite	O
similar	O
external	O
diameters	O
among	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
-	O
treated	O
,	O
non	O
-	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
-	O
treated	O
and	O
NaCl	B-ChemicalEntity
-	O
treated	O
segments	O
,	O
aneurymal	O
alteration	O
(	O
n	O
=	O
6	O
,	O
50%	O
)	O
,	O
media	O
degeneration	O
with	O
regional	O
disruption	O
,	O
fragmentation	O
of	O
elastic	O
fiber	O
,	O
and	O
increased	O
collagen	O
deposition	O
(	O
n	O
=	O
12	O
,	O
100%	O
)	O
were	O
demonstrated	O
in	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
-	O
treated	O
segments	O
.	O

MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
,	O
MMP	B-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
,	O
ADAM	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
and	O
ADAM	B-GeneOrGeneProduct
-	O
17	I-GeneOrGeneProduct
mRNA	O
levels	O
were	O
increased	O
in	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
-	O
treated	O
segments	O
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
with	O
trends	O
of	O
elevation	O
in	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
-	O
untreated	O
segments	O
,	O
as	O
compared	O
with	O
NaCl	B-ChemicalEntity
-	O
treated	O
segments	O
.	O

Immunohistochemistry	O
displayed	O
significantly	O
increased	O
expressions	O
of	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
,	O
MMP	B-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
,	O
ADAM	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
and	O
ADAM	B-GeneOrGeneProduct
-	O
17	I-GeneOrGeneProduct
(	O
all	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
intima	O
and	O
media	O
for	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
-	O
treated	O
segments	O
.	O

TIMP	B-GeneOrGeneProduct
mRNA	O
and	O
tissue	O
levels	O
did	O
not	O
differ	O
obviously	O
among	O
the	O
three	O
aortic	O
segments	O
.	O

CONCLUSION	O
:	O
This	O
study	O
establishes	O
a	O
TAA	B-DiseaseOrPhenotypicFeature
model	O
by	O
periarterial	O
CaCl	B-ChemicalEntity
(	O
2	I-ChemicalEntity
)	O
exposure	O
in	O
rats	B-OrganismTaxon
,	O
and	O
demonstrates	O
a	O
significant	O
elevation	O
of	O
expression	O
of	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
,	O
MMP	B-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
,	O
ADAM10	B-GeneOrGeneProduct
and	O
ADAM17	B-GeneOrGeneProduct
in	O
the	O
pathogenesis	O
of	O
vascular	O
remodeling	O
.	O
Expanding	O
clinical	O
spectrum	O
of	O
non	B-DiseaseOrPhenotypicFeature
-	O
autoimmune	I-DiseaseOrPhenotypicFeature
hyperthyroidism	I-DiseaseOrPhenotypicFeature
due	O
to	O
an	O
activating	O
germline	O
mutation	O
,	O
p	B-SequenceVariant
.	O
M453T	I-SequenceVariant
,	O
in	O
the	O
thyrotropin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
gene	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
clinical	O
and	O
genetic	O
features	O
of	O
a	O
Thai	O
family	O
with	O
non	B-DiseaseOrPhenotypicFeature
-	O
autoimmune	I-DiseaseOrPhenotypicFeature
hyperthyroidism	I-DiseaseOrPhenotypicFeature
(	O
NAH	B-DiseaseOrPhenotypicFeature
)	O
caused	O
by	O
an	O
activating	O
germline	O
mutation	O
in	O
the	O
thyrotropin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
TSHR	B-GeneOrGeneProduct
)	O
gene	O
.	O

PATIENTS	B-OrganismTaxon
:	O
Three	O
affected	O
individuals	O
from	O
the	O
same	O
family	O
(	O
a	O
father	O
and	O
his	O
two	O
children	O
)	O
were	O
studied	O
.	O

Clinical	O
and	O
imaging	O
findings	O
were	O
reviewed	O
and	O
compared	O
.	O

GENETIC	O
ANALYSIS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
and	O
mutation	O
analysis	O
of	O
the	O
entire	O
coding	O
sequence	O
of	O
the	O
TSHR	B-GeneOrGeneProduct
gene	O
was	O
performed	O
in	O
both	O
children	O
and	O
their	O
parents	O
by	O
direct	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
germline	O
T	B-SequenceVariant
to	I-SequenceVariant
C	I-SequenceVariant
transition	O
in	O
exon	O
10	O
of	O
the	O
TSHR	B-GeneOrGeneProduct
gene	O
(	O
c	B-SequenceVariant
.	O
1358T	I-SequenceVariant
-	O
-	O
>	O
C	I-SequenceVariant
)	O
resulting	O
in	O
the	O
substitution	O
of	O
methionine	B-SequenceVariant
(	O
ATG	I-SequenceVariant
)	O
by	I-SequenceVariant
threonine	I-SequenceVariant
(	O
ACG	I-SequenceVariant
)	O
at	I-SequenceVariant
codon	I-SequenceVariant
453	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
M453T	I-SequenceVariant
)	O
was	O
identified	O
in	O
the	O
father	O
and	O
his	O
two	O
children	O
.	O

They	O
presented	O
with	O
different	O
clinical	O
severity	O
and	O
variable	O
age	O
of	O
onset	O
.	O

In	O
addition	O
to	O
hyperthyroidism	B-DiseaseOrPhenotypicFeature
,	O
ventriculomegaly	B-DiseaseOrPhenotypicFeature
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
were	O
consistently	O
found	O
in	O
all	O
affected	O
individuals	O
.	O

CONCLUSIONS	O
:	O
Ventriculomegaly	B-DiseaseOrPhenotypicFeature
and	O
bilateral	O
shortening	O
of	O
the	O
fifth	O
metacarpal	O
bones	O
and	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
might	O
be	O
characteristic	O
features	O
of	O
NAH	B-DiseaseOrPhenotypicFeature
because	O
of	O
an	O
activating	O
TSHR	B-GeneOrGeneProduct
germline	O
mutation	O
.	O

In	O
addition	O
,	O
the	O
shortening	O
of	O
the	O
middle	O
phalanges	O
of	O
the	O
fifth	O
fingers	O
has	O
never	O
been	O
previously	O
described	O
,	O
expanding	O
the	O
phenotypic	O
spectrum	O
of	O
the	O
disease	O
.	O
Identification	O
of	O
a	O
novel	O
FBN1	B-GeneOrGeneProduct
gene	O
mutation	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

PURPOSE	O
:	O
To	O
identify	O
the	O
mutation	O
in	O
the	O
fibrillin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
gene	O
(	O
FBN1	B-GeneOrGeneProduct
)	O
in	O
a	O
Chinese	O
family	O
with	O
Marfan	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
MFS	B-DiseaseOrPhenotypicFeature
)	O
.	O

METHODS	O
:	O
Patients	B-OrganismTaxon
and	O
family	O
members	O
were	O
given	O
complete	O
physical	O
,	O
ophthalmic	O
,	O
and	O
cardiovascular	O
examinations	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
leukocytes	O
of	O
venous	O
blood	O
of	O
six	O
individuals	O
in	O
the	O
family	O
and	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

All	O
of	O
the	O
65	O
coding	O
exons	O
and	O
their	O
flanking	O
intronic	O
boundaries	O
of	O
FBN1	B-GeneOrGeneProduct
were	O
amplified	O
in	O
the	O
proband	O
by	O
polymerase	O
chain	O
reaction	O
and	O
followed	O
by	O
direct	O
sequencing	O
.	O

The	O
mutation	O
identified	O
in	O
the	O
proband	O
was	O
screened	O
in	O
the	O
other	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
by	O
direct	O
sequencing	O
.	O

Protein	O
conservation	O
analysis	O
was	O
performed	O
in	O
six	O
species	O
using	O
an	O
online	O
ClustalW	O
tool	O
.	O

Protein	O
structure	O
was	O
modeled	O
based	O
on	O
the	O
Protein	O
data	O
bank	O
and	O
mutated	O
in	O
DeepView	O
v4	O
.	O
0	O
.	O
1	O
to	O
predict	O
the	O
functional	O
consequences	O
of	O
the	O
mutation	O
.	O

RESULTS	O
:	O
A	O
novel	O
heterozygous	O
c	B-SequenceVariant
.	O
3703T	I-SequenceVariant
>	O
C	I-SequenceVariant
change	O
in	O
exon	O
29	O
of	O
FBN1	B-GeneOrGeneProduct
was	O
detected	O
in	O
the	O
proband	O
,	O
which	O
resulted	O
in	O
the	O
substitution	O
of	O
serine	B-SequenceVariant
by	I-SequenceVariant
proline	I-SequenceVariant
at	I-SequenceVariant
codon	I-SequenceVariant
1235	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
S1235P	I-SequenceVariant
)	O
.	O

This	O
mutation	O
was	O
also	O
present	O
in	O
two	O
family	O
members	O
but	O
absent	O
in	O
the	O
other	O
,	O
unaffected	O
family	O
members	O
and	O
the	O
170	O
healthy	O
Chinese	O
individuals	O
.	O

The	O
mutant	O
residue	O
located	O
in	O
the	O
calcium	B-ChemicalEntity
binding	O
epidermal	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
like	O
#	O
15	O
domain	O
is	O
highly	O
conserved	O
among	O
mammalian	O
species	O
and	O
could	O
probably	O
induce	O
conformation	O
change	O
of	O
the	O
domain	O
.	O

CONCLUSIONS	O
:	O
We	O
indentified	O
a	O
novel	O
p	B-SequenceVariant
.	O
S1235P	I-SequenceVariant
mutation	O
in	O
FBN1	B-GeneOrGeneProduct
,	O
which	O
is	O
the	O
causative	O
mutation	O
for	O
MFS	B-DiseaseOrPhenotypicFeature
in	O
this	O
family	O
.	O

Our	O
result	O
expands	O
the	O
mutation	O
spectrum	O
of	O
FBN1	B-GeneOrGeneProduct
and	O
contributes	O
to	O
the	O
study	O
of	O
the	O
molecular	O
pathogenesis	O
of	O
Marfan	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O
CD72	B-GeneOrGeneProduct
polymorphisms	O
associated	O
with	O
alternative	O
splicing	O
modify	O
susceptibility	O
to	O
human	B-OrganismTaxon
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
through	O
epistatic	O
interaction	O
with	O
FCGR2B	B-GeneOrGeneProduct
.	O

We	O
previously	O
reported	O
association	O
of	O
FCGR2B	B-GeneOrGeneProduct
-	O
Ile232Thr	B-SequenceVariant
with	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
(	O
SLE	B-DiseaseOrPhenotypicFeature
)	O
in	O
three	O
Asian	O
populations	O
.	O

Because	O
polymorphism	O
of	O
CD72	B-GeneOrGeneProduct
,	O
another	O
inhibitory	O
receptor	O
of	O
B	O
cells	O
,	O
was	O
associated	O
with	O
murine	B-OrganismTaxon
SLE	B-DiseaseOrPhenotypicFeature
,	O
we	O
identified	O
human	B-OrganismTaxon
CD72	B-GeneOrGeneProduct
polymorphisms	O
,	O
tested	O
their	O
association	O
with	O
SLE	B-DiseaseOrPhenotypicFeature
and	O
examined	O
genetic	O
interaction	O
with	O
FCGR2B	B-GeneOrGeneProduct
in	O
the	O
Japanese	O
(	O
160	O
SLE	B-DiseaseOrPhenotypicFeature
,	O
277	O
controls	O
)	O
,	O
Thais	O
(	O
87	O
SLE	B-DiseaseOrPhenotypicFeature
,	O
187	O
controls	O
)	O
and	O
Caucasians	O
(	O
94	O
families	O
containing	O
SLE	B-DiseaseOrPhenotypicFeature
members	O
)	O
.	O

Four	O
polymorphisms	O
and	O
six	O
rare	O
variations	O
were	O
detected	O
.	O

The	O
former	O
constituted	O
two	O
major	O
haplotypes	O
that	O
contained	O
one	O
or	O
two	O
repeats	O
of	O
13	O
nucleotides	O
in	O
intron	O
8	O
(	O
designated	O
as	O
*	O
1	O
and	O
*	O
2	O
,	O
respectively	O
)	O
.	O

Although	O
association	O
with	O
susceptibility	O
to	O
SLE	B-DiseaseOrPhenotypicFeature
was	O
not	O
detected	O
,	O
the	O
*	O
1	O
allele	O
was	O
significantly	O
associated	O
with	O
nephritis	B-DiseaseOrPhenotypicFeature
among	O
the	O
Japanese	O
patients	B-OrganismTaxon
(	O
P	O
=	O
0	O
.	O
024	O
)	O
.	O

RT	O
-	O
PCR	O
identified	O
a	O
novel	O
alternatively	O
spliced	O
(	O
AS	O
)	O
transcript	O
that	O
was	O
expressed	O
at	O
the	O
protein	O
level	O
in	O
COS	B-CellLine
-	O
7	I-CellLine
transfectants	O
.	O

The	O
ratio	O
of	O
AS	O
/	O
common	O
isoforms	O
was	O
strikingly	O
increased	O
in	O
individuals	O
with	O
*	O
2	O
/	O
*	O
2	O
genotype	O
when	O
compared	O
with	O
*	O
1	O
/	O
*	O
1	O
(	O
P	O
=	O
0	O
.	O
000038	O
)	O
or	O
*	O
1	O
/	O
*	O
2	O
(	O
P	O
=	O
0	O
.	O
0085	O
)	O
genotypes	O
.	O

Using	O
the	O
two	O
Asian	O
cohorts	O
,	O
significant	O
association	O
of	O
FCGR2B	B-GeneOrGeneProduct
-	O
232Thr	B-SequenceVariant
/	O
Thr	O
with	O
SLE	B-DiseaseOrPhenotypicFeature
was	O
observed	O
only	O
in	O
the	O
presence	O
of	O
CD72	B-GeneOrGeneProduct
-	O
*	O
1	O
/	O
*	O
1	O
genotype	O
(	O
OR	O
4	O
.	O
63	O
,	O
95%	O
CI	O
1	O
.	O
47	O
-	O
14	O
.	O
6	O
,	O
P	O
=	O
0	O
.	O
009	O
versus	O
FCGR2B	B-GeneOrGeneProduct
-	O
232Ile	B-SequenceVariant
/	O
Ile	O
plus	O
CD72	B-GeneOrGeneProduct
-	O
*	O
2	O
/	O
*	O
2	O
)	O
.	O

Minigene	O
assays	O
demonstrated	O
that	O
the	O
13	O
-	O
nucleotide	O
repeat	O
and	O
4	O
bp	O
deletion	O
within	O
the	O
same	O
haplotype	O
of	O
intron	O
8	O
could	O
regulate	O
alternative	O
splicing	O
.	O

The	O
AS	O
isoform	O
lacks	O
exon	O
8	O
,	O
and	O
is	O
deduced	O
to	O
contain	O
49	O
amino	O
acid	O
changes	O
in	O
the	O
membrane	O
-	O
distal	O
portion	O
of	O
the	O
extracellular	O
domain	O
,	O
where	O
considerable	O
amino	O
acid	O
changes	O
are	O
known	O
in	O
CD72	B-GeneOrGeneProduct
(	O
c	O
)	O
allele	O
associated	O
with	O
murine	B-OrganismTaxon
SLE	B-DiseaseOrPhenotypicFeature
.	O

These	O
results	O
indicated	O
that	O
the	O
presence	O
of	O
CD72	B-GeneOrGeneProduct
-	O
*	O
2	O
allele	O
decreases	O
risk	O
for	O
human	B-OrganismTaxon
SLE	B-DiseaseOrPhenotypicFeature
conferred	O
by	O
FCGR2B	B-GeneOrGeneProduct
-	O
232Thr	B-SequenceVariant
,	O
possibly	O
by	O
increasing	O
the	O
AS	O
isoform	O
of	O
CD72	B-GeneOrGeneProduct
.	O
Vaccine	O
candidates	O
derived	O
from	O
a	O
novel	O
infectious	O
cDNA	O
clone	O
of	O
an	O
American	O
genotype	O
dengue	B-OrganismTaxon
virus	I-OrganismTaxon
type	I-OrganismTaxon
2	I-OrganismTaxon
.	O

BACKGROUND	O
:	O
A	O
dengue	B-OrganismTaxon
virus	I-OrganismTaxon
type	I-OrganismTaxon
2	I-OrganismTaxon
(	O
DEN	B-OrganismTaxon
-	O
2	I-OrganismTaxon
Tonga	O
/	O
74	O
)	O
isolated	O
from	O
a	O
1974	O
epidemic	O
was	O
characterized	O
by	O
mild	O
illness	O
and	O
belongs	O
to	O
the	O
American	O
genotype	O
of	O
DEN	B-OrganismTaxon
-	O
2	I-OrganismTaxon
viruses	O
.	O

To	O
prepare	O
a	O
vaccine	O
candidate	O
,	O
a	O
previously	O
described	O
30	B-SequenceVariant
nucleotide	I-SequenceVariant
deletion	I-SequenceVariant
(	O
Delta30	B-SequenceVariant
)	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
of	O
DEN	B-OrganismTaxon
-	O
4	I-OrganismTaxon
has	O
been	O
engineered	O
into	O
the	O
DEN	B-OrganismTaxon
-	O
2	I-OrganismTaxon
isolate	O
.	O

METHODS	O
:	O
A	O
full	O
-	O
length	O
cDNA	O
clone	O
was	O
generated	O
from	O
the	O
DEN	B-OrganismTaxon
-	O
2	I-OrganismTaxon
virus	O
and	O
used	O
to	O
produce	O
recombinant	O
DEN	B-OrganismTaxon
-	O
2	I-OrganismTaxon
(	O
rDEN	B-OrganismTaxon
-	O
2	I-OrganismTaxon
)	O
and	O
rDEN2Delta30	B-OrganismTaxon
.	O

Viruses	O
were	O
evaluated	O
for	O
replication	O
in	O
SCID	O
mice	B-OrganismTaxon
transplanted	O
with	O
human	B-OrganismTaxon
hepatoma	B-DiseaseOrPhenotypicFeature
cells	O
(	O
SCID	B-CellLine
-	O
HuH	I-CellLine
-	O
7	I-CellLine
mice	B-OrganismTaxon
)	O
,	O
in	O
mosquitoes	O
,	O
and	O
in	O
rhesus	B-OrganismTaxon
monkeys	I-OrganismTaxon
.	O

Neutralizing	O
antibody	O
induction	O
and	O
protective	O
efficacy	O
were	O
also	O
assessed	O
in	O
rhesus	B-OrganismTaxon
monkeys	I-OrganismTaxon
.	O

RESULTS	O
:	O
The	O
rDEN2Delta30	B-OrganismTaxon
virus	O
was	O
ten	O
-	O
fold	O
reduced	O
in	O
replication	O
in	O
SCID	B-CellLine
-	O
HuH	I-CellLine
-	O
7	I-CellLine
mice	B-OrganismTaxon
when	O
compared	O
to	O
the	O
parent	O
virus	O
.	O

The	O
rDEN	B-OrganismTaxon
-	O
2	I-OrganismTaxon
viruses	O
were	O
not	O
infectious	O
for	O
Aedes	B-OrganismTaxon
mosquitoes	I-OrganismTaxon
,	O
but	O
both	O
readily	O
infected	O
Toxorynchites	B-OrganismTaxon
mosquitoes	I-OrganismTaxon
.	O

In	O
rhesus	B-OrganismTaxon
monkeys	I-OrganismTaxon
,	O
rDEN2Delta30	B-OrganismTaxon
appeared	O
to	O
be	O
slightly	O
attenuated	O
when	O
compared	O
to	O
the	O
parent	O
virus	O
as	O
measured	O
by	O
duration	O
and	O
peak	O
of	O
viremia	B-DiseaseOrPhenotypicFeature
and	O
neutralizing	O
antibody	O
induction	O
.	O

A	O
derivative	O
of	O
rDEN2Delta30	B-OrganismTaxon
,	O
designated	O
rDEN2Delta30	B-OrganismTaxon
-	O
4995	I-SequenceVariant
,	O
was	O
generated	O
by	O
incorporation	O
of	O
a	O
point	O
mutation	O
previously	O
identified	O
in	O
the	O
NS3	B-GeneOrGeneProduct
gene	O
of	O
DEN	B-OrganismTaxon
-	O
4	I-OrganismTaxon
and	O
was	O
found	O
to	O
be	O
more	O
attenuated	O
than	O
rDEN2Delta30	B-OrganismTaxon
in	O
SCID	B-CellLine
-	O
HuH	I-CellLine
-	O
7	I-CellLine
mice	B-OrganismTaxon
.	O

CONCLUSIONS	O
:	O
The	O
rDEN2Delta30	B-OrganismTaxon
and	O
rDEN2Delta30	B-OrganismTaxon
-	O
4995	I-SequenceVariant
viruses	O
can	O
be	O
considered	O
for	O
evaluation	O
in	O
humans	B-OrganismTaxon
and	O
for	O
inclusion	O
in	O
a	O
tetravalent	O
dengue	B-DiseaseOrPhenotypicFeature
vaccine	O
.	O
The	O
effects	O
of	O
short	O
-	O
term	O
raloxifene	B-ChemicalEntity
therapy	O
on	O
fibrinolysis	O
markers	O
:	O
TAFI	B-GeneOrGeneProduct
,	O
tPA	B-GeneOrGeneProduct
,	O
and	O
PAI	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
.	O

BACKGROUND	O
:	O
Markers	O
of	O
fibrinolysis	O
,	O
thrombin	B-GeneOrGeneProduct
-	O
activatable	I-GeneOrGeneProduct
fibrinolysis	I-GeneOrGeneProduct
inhibitor	I-GeneOrGeneProduct
(	O
TAFI	B-GeneOrGeneProduct
)	O
,	O
tissue	B-GeneOrGeneProduct
-	O
type	I-GeneOrGeneProduct
plasminogen	I-GeneOrGeneProduct
activator	I-GeneOrGeneProduct
(	O
tPA	B-GeneOrGeneProduct
)	O
,	O
and	O
plasminogen	B-GeneOrGeneProduct
activator	I-GeneOrGeneProduct
inhibitor	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
PAI	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
levels	O
were	O
studied	O
for	O
the	O
evaluation	O
of	O
short	O
-	O
term	O
effects	O
of	O
raloxifene	B-ChemicalEntity
administration	O
in	O
postmenopausal	O
women	B-OrganismTaxon
.	O

METHODS	O
:	O
Thirty	O
-	O
nine	O
postmenopausal	O
women	B-OrganismTaxon
with	O
osteopenia	B-DiseaseOrPhenotypicFeature
or	O
osteoporosis	B-DiseaseOrPhenotypicFeature
were	O
included	O
in	O
this	O
prospective	O
,	O
controlled	O
clinical	O
study	O
.	O

Twenty	O
-	O
five	O
women	B-OrganismTaxon
were	O
given	O
raloxifene	B-ChemicalEntity
hydrochloride	I-ChemicalEntity
(	O
60	O
mg	O
/	O
day	O
)	O
plus	O
calcium	B-ChemicalEntity
(	O
500	O
mg	O
/	O
day	O
)	O
.	O

Age	O
-	O
matched	O
controls	O
(	O
n	O
=	O
14	O
)	O
were	O
given	O
only	O
calcium	B-ChemicalEntity
.	O

Plasma	O
TAFI	B-GeneOrGeneProduct
,	O
tPA	B-GeneOrGeneProduct
,	O
and	O
PAI	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
antigen	O
levels	O
were	O
measured	O
at	O
baseline	O
and	O
after	O
3	O
months	O
of	O
treatment	O
by	O
commercially	O
available	O
ELISA	O
kits	O
.	O

Variations	O
of	O
individuals	O
were	O
assessed	O
by	O
Wilcoxon	O
'	O
s	O
test	O
.	O

Relationship	O
between	O
those	O
markers	O
and	O
demographic	O
characteristics	O
were	O
investigated	O
.	O

RESULTS	O
:	O
Three	O
months	O
of	O
raloxifene	B-ChemicalEntity
treatment	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
TAFI	B-GeneOrGeneProduct
antigen	O
concentrations	O
(	O
16%	O
change	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
a	O
significant	O
increase	O
in	O
tPA	B-GeneOrGeneProduct
antigen	O
concentrations	O
(	O
25%	O
change	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

A	O
significant	O
correlation	O
was	O
found	O
between	O
baseline	O
TAFI	B-GeneOrGeneProduct
antigen	O
concentrations	O
and	O
the	O
duration	O
of	O
amenorrhea	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
33	O
)	O
.	O

CONCLUSION	O
:	O
We	O
suggest	O
that	O
the	O
increased	O
risk	O
of	O
venous	B-DiseaseOrPhenotypicFeature
thromboembolism	I-DiseaseOrPhenotypicFeature
due	O
to	O
raloxifene	B-ChemicalEntity
treatment	O
may	O
be	O
related	O
to	O
increased	O
tPA	B-GeneOrGeneProduct
levels	O
,	O
but	O
not	O
TAFI	B-GeneOrGeneProduct
levels	O
.	O
NEK2	B-GeneOrGeneProduct
serves	O
as	O
a	O
prognostic	O
biomarker	O
for	O
hepatocellular	B-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
.	O

Never	B-GeneOrGeneProduct
in	I-GeneOrGeneProduct
mitosis	I-GeneOrGeneProduct
gene	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
(	O
NIMA	I-GeneOrGeneProduct
)	O
-	O
related	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
(	O
NEK2	B-GeneOrGeneProduct
)	O
is	O
a	O
microtubule	B-GeneOrGeneProduct
-	O
associated	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
that	O
regulates	O
spindle	O
assembly	O
in	O
human	B-OrganismTaxon
cells	O
and	O
is	O
overexpressed	O
in	O
various	O
malignancies	B-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
the	O
role	O
of	O
NEK2	B-GeneOrGeneProduct
in	O
hepatocellular	B-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
(	O
HCC	B-DiseaseOrPhenotypicFeature
)	O
remains	O
undetermined	O
.	O

We	O
performed	O
RNA	O
-	O
seq	O
of	O
the	O
HCC	B-DiseaseOrPhenotypicFeature
cell	O
line	O
SMMC	B-CellLine
-	O
7721	I-CellLine
and	O
the	O
normal	O
liver	O
cell	O
line	O
HL	B-CellLine
-	O
7702	I-CellLine
using	O
the	O
Ion	O
Proton	O
System	O
.	O

NEK2	B-GeneOrGeneProduct
expression	O
was	O
detected	O
using	O
quantitative	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
in	O
two	O
cell	O
lines	O
and	O
5	O
matched	O
HCC	B-DiseaseOrPhenotypicFeature
and	O
adjacent	O
non	O
-	O
tumorous	O
liver	O
tissues	O
.	O

The	O
correlation	O
between	O
survival	O
and	O
NEK2	B-GeneOrGeneProduct
expression	O
was	O
analyzed	O
in	O
359	O
patients	B-OrganismTaxon
with	O
HCC	B-DiseaseOrPhenotypicFeature
using	O
RNASeqV2	O
data	O
available	O
from	O
The	O
Cancer	B-DiseaseOrPhenotypicFeature
Genome	O
Atlas	O
(	O
TCGA	O
)	O
website	O
(	O
https	O
:	O
/	O
/	O
tcga	O
-	O
data	O
.	O
nci	O
.	O
nih	O
.	O
gov	O
/	O
tcga	O
/	O
)	O
.	O

The	O
expression	O
of	O
NEK2	B-GeneOrGeneProduct
,	O
phospho	O
-	O
AKT	B-GeneOrGeneProduct
and	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
was	O
evaluated	O
by	O
immunohistochemistry	O
in	O
63	O
cases	O
of	O
HCC	B-DiseaseOrPhenotypicFeature
and	O
matched	O
adjacent	O
non	O
-	O
tumorous	O
liver	O
tissues	O
.	O

Relationships	O
between	O
protein	O
expression	O
and	O
clinicopathological	O
parameters	O
were	O
assessed	O
,	O
and	O
the	O
correlations	O
between	O
NEK2	B-GeneOrGeneProduct
with	O
phospho	O
-	O
AKT	B-GeneOrGeneProduct
and	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
expressions	O
were	O
evaluated	O
.	O

A	O
total	O
of	O
610	O
differentially	O
expressed	O
genes	O
(	O
DEGs	O
)	O
were	O
revealed	O
in	O
the	O
transcriptome	O
comparison	O
,	O
297	O
of	O
which	O
were	O
upregulated	O
and	O
313	O
were	O
downregulated	O
in	O
HCC	B-DiseaseOrPhenotypicFeature
.	O

NEK2	B-GeneOrGeneProduct
,	O
as	O
the	O
most	O
obviously	O
different	O
DEG	O
in	O
cells	O
and	O
tissues	O
from	O
the	O
RNA	O
-	O
seq	O
data	O
,	O
was	O
listed	O
as	O
an	O
HCC	B-DiseaseOrPhenotypicFeature
candidate	O
biomarker	O
for	O
further	O
verification	O
.	O

NEK2	B-GeneOrGeneProduct
was	O
overexpressed	O
in	O
HCC	B-DiseaseOrPhenotypicFeature
cells	O
and	O
tissues	O
(	O
P	O
=	O
0	O
.	O
002	O
,	O
P	O
=	O
0	O
.	O
013	O
)	O
and	O
HCC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
a	O
high	O
expression	O
of	O
NEK2	B-GeneOrGeneProduct
had	O
a	O
poor	O
prognosis	O
(	O
P	O
=	O
0	O
.	O
0145	O
)	O
.	O

Clinical	O
analysis	O
indicated	O
that	O
the	O
overexpression	O
of	O
NEK2	B-GeneOrGeneProduct
in	O
HCC	B-DiseaseOrPhenotypicFeature
was	O
significantly	O
correlated	O
with	O
diolame	O
complete	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
tumor	B-DiseaseOrPhenotypicFeature
nodule	O
number	O
(	O
P	O
=	O
0	O
.	O
012	O
)	O
and	O
recurrence	O
(	O
P	O
=	O
0	O
.	O
004	O
)	O
.	O

NEK2	B-GeneOrGeneProduct
expression	O
was	O
positively	O
correlated	O
with	O
the	O
expression	O
of	O
phospho	O
-	O
AKT	B-GeneOrGeneProduct
(	O
r	O
=	O
0	O
.	O
883	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
(	O
r	O
=	O
0	O
.	O
781	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Overexpression	O
of	O
NEK2	B-GeneOrGeneProduct
was	O
associated	O
with	O
clinicopathological	O
characteristics	O
and	O
poor	O
patient	B-OrganismTaxon
outcomes	O
,	O
suggesting	O
that	O
NEK2	B-GeneOrGeneProduct
serves	O
as	O
a	O
prognostic	O
biomarker	O
for	O
HCC	B-DiseaseOrPhenotypicFeature
.	O

Alteration	O
of	O
NEK2	B-GeneOrGeneProduct
protein	O
levels	O
may	O
contribute	O
to	O
invasion	O
and	O
metastasis	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
HCC	I-DiseaseOrPhenotypicFeature
,	O
which	O
may	O
occur	O
through	O
activation	O
of	O
AKT	B-GeneOrGeneProduct
signaling	O
and	O
promotion	O
of	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
expression	O
.	O
The	O
number	O
of	O
lymph	B-DiseaseOrPhenotypicFeature
node	I-DiseaseOrPhenotypicFeature
metastases	I-DiseaseOrPhenotypicFeature
in	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
correlates	O
with	O
the	O
angiotensin	B-GeneOrGeneProduct
I	I-GeneOrGeneProduct
-	O
converting	I-GeneOrGeneProduct
enzyme	I-GeneOrGeneProduct
gene	O
insertion	O
/	O
deletion	O
polymorphism	O
.	O

PURPOSE	O
:	O
In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
substantiate	O
the	O
putative	O
significance	O
of	O
angiotensin	B-GeneOrGeneProduct
I	I-GeneOrGeneProduct
-	O
converting	I-GeneOrGeneProduct
enzyme	I-GeneOrGeneProduct
(	O
ACE	B-GeneOrGeneProduct
)	O
on	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
biology	O
by	O
investigating	O
the	O
influence	O
of	O
its	O
gene	O
polymorphism	O
on	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
progression	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Genomic	O
DNA	O
was	O
purified	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
or	O
tissue	O
specimens	O
.	O

Amplified	O
ACE	B-GeneOrGeneProduct
gene	O
fragments	O
were	O
separated	O
on	O
agarose	B-ChemicalEntity
gels	O
.	O

D	O
or	O
I	O
alleles	O
were	O
identified	O
by	O
the	O
presence	O
of	O
190	O
-	O
or	O
490	O
-	O
bp	O
fragments	O
,	O
respectively	O
.	O

Local	O
expression	O
of	O
ACE	B-GeneOrGeneProduct
was	O
investigated	O
by	O
immunohistochemistry	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
four	O
of	O
113	O
(	O
21%	O
)	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
had	O
the	O
II	O
,	O
57	O
(	O
51%	O
)	O
the	O
ID	O
,	O
and	O
32	O
(	O
28%	O
)	O
the	O
DD	O
genotype	O
.	O

The	O
distribution	O
of	O
the	O
ACE	B-GeneOrGeneProduct
genotypes	O
did	O
not	O
differ	O
significantly	O
from	O
the	O
control	O
group	O
of	O
189	O
patients	B-OrganismTaxon
without	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
the	O
ACE	B-GeneOrGeneProduct
genotypes	O
correlated	O
with	O
the	O
number	O
of	O
lymph	B-DiseaseOrPhenotypicFeature
node	I-DiseaseOrPhenotypicFeature
metastases	I-DiseaseOrPhenotypicFeature
and	O
the	O
Unio	O
Internationale	O
Contra	O
Cancrum	O
(	O
UICC	O
)	O
tumor	B-DiseaseOrPhenotypicFeature
stage	O
.	O

Patients	B-OrganismTaxon
with	O
the	O
II	O
genotype	O
had	O
a	O
highly	O
significantly	O
smaller	O
number	O
of	O
lymph	B-DiseaseOrPhenotypicFeature
node	I-DiseaseOrPhenotypicFeature
metastases	I-DiseaseOrPhenotypicFeature
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
a	O
significantly	O
lower	O
UICC	O
tumor	B-DiseaseOrPhenotypicFeature
stage	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
than	O
patients	B-OrganismTaxon
with	O
the	O
DD	O
genotype	O
.	O

No	O
correlation	O
was	O
found	O
between	O
tumor	B-DiseaseOrPhenotypicFeature
type	O
,	O
tumor	B-DiseaseOrPhenotypicFeature
location	O
,	O
local	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
,	O
distant	O
metastases	B-DiseaseOrPhenotypicFeature
,	O
and	O
the	O
ACE	B-GeneOrGeneProduct
genotype	O
.	O

The	O
expression	O
of	O
ACE	B-GeneOrGeneProduct
in	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
was	O
investigated	O
by	O
immunohistochemistry	O
in	O
100	O
of	O
113	O
patients	B-OrganismTaxon
.	O

ACE	B-GeneOrGeneProduct
was	O
expressed	O
by	O
endothelial	O
cells	O
in	O
all	O
(	O
100%	O
)	O
specimens	O
and	O
by	O
tumor	B-DiseaseOrPhenotypicFeature
cells	O
in	O
56	O
(	O
56%	O
)	O
specimens	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
shows	O
that	O
ACE	B-GeneOrGeneProduct
is	O
expressed	O
locally	O
in	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
and	O
that	O
the	O
gene	O
polymorphism	O
influences	O
metastatic	O
behavior	O
.	O
POLG	B-GeneOrGeneProduct
mutations	O
associated	O
with	O
Alpers	B-DiseaseOrPhenotypicFeature
'	O
syndrome	I-DiseaseOrPhenotypicFeature
and	O
mitochondrial	B-DiseaseOrPhenotypicFeature
DNA	I-DiseaseOrPhenotypicFeature
depletion	I-DiseaseOrPhenotypicFeature
.	O

Alpers	B-DiseaseOrPhenotypicFeature
'	O
syndrome	I-DiseaseOrPhenotypicFeature
is	O
a	O
fatal	O
neurogenetic	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
first	O
described	O
more	O
than	O
70	O
years	O
ago	O
.	O

It	O
is	O
an	O
autosomal	O
recessive	O
,	O
developmental	O
mitochondrial	B-DiseaseOrPhenotypicFeature
DNA	I-DiseaseOrPhenotypicFeature
depletion	I-DiseaseOrPhenotypicFeature
disorder	O
characterized	O
by	O
deficiency	O
in	O
mitochondrial	O
DNA	B-GeneOrGeneProduct
polymerase	I-GeneOrGeneProduct
gamma	I-GeneOrGeneProduct
(	O
POLG	B-GeneOrGeneProduct
)	O
catalytic	O
activity	O
,	O
refractory	O
seizures	B-DiseaseOrPhenotypicFeature
,	O
neurodegeneration	B-DiseaseOrPhenotypicFeature
,	O
and	O
liver	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

In	O
two	O
unrelated	O
pedigrees	O
of	O
Alpers	B-DiseaseOrPhenotypicFeature
'	O
syndrome	I-DiseaseOrPhenotypicFeature
,	O
each	O
affected	O
child	O
was	O
found	O
to	O
carry	O
a	O
homozygous	O
mutation	O
in	O
exon	O
17	O
of	O
the	O
POLG	B-GeneOrGeneProduct
locus	O
that	O
led	O
to	O
a	O
Glu873Stop	B-SequenceVariant
mutation	O
just	O
upstream	O
of	O
the	O
polymerase	O
domain	O
of	O
the	O
protein	O
.	O

In	O
addition	O
,	O
each	O
affected	O
child	O
was	O
heterozygous	O
for	O
the	O
G1681A	B-SequenceVariant
mutation	O
in	O
exon	O
7	O
that	O
led	O
to	O
an	O
Ala467Thr	B-SequenceVariant
substitution	O
in	O
POLG	B-GeneOrGeneProduct
,	O
within	O
the	O
linker	O
region	O
of	O
the	O
protein	O
.	O
Zebrafish	B-OrganismTaxon
chordin	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
and	O
chordin	B-GeneOrGeneProduct
are	O
functionally	O
redundant	O
in	O
regulating	O
patterning	O
of	O
the	O
dorsoventral	O
axis	O
.	O

Chordin	B-GeneOrGeneProduct
is	O
the	O
prototype	O
of	O
a	O
group	O
of	O
cysteine	B-GeneOrGeneProduct
-	O
rich	I-GeneOrGeneProduct
domain	I-GeneOrGeneProduct
-	O
containing	I-GeneOrGeneProduct
proteins	I-GeneOrGeneProduct
that	O
bind	O
and	O
modulate	O
signaling	O
of	O
various	O
TGFbeta	B-GeneOrGeneProduct
-	O
like	O
ligands	O
.	O

Chordin	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
(	O
CHL1	B-GeneOrGeneProduct
and	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
)	O
are	O
two	O
members	O
of	O
this	O
group	O
that	O
have	O
been	O
described	O
in	O
human	B-OrganismTaxon
,	O
mouse	B-OrganismTaxon
,	O
and	O
chick	B-OrganismTaxon
.	O

However	O
,	O
in	O
vivo	O
roles	O
for	O
CHL1	B-GeneOrGeneProduct
and	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
in	O
early	O
development	O
are	O
unknown	O
due	O
to	O
lack	O
of	O
loss	O
-	O
of	O
-	O
function	O
analysis	O
.	O

Here	O
we	O
identify	O
and	O
characterize	O
zebrafish	B-OrganismTaxon
,	O
Danio	B-OrganismTaxon
rerio	I-OrganismTaxon
,	O
CHL	B-GeneOrGeneProduct
(	O
Chl	B-GeneOrGeneProduct
)	O
.	O

The	O
chl	B-GeneOrGeneProduct
gene	O
is	O
on	O
a	O
region	O
of	O
chromosome	O
21	O
syntenic	O
with	O
the	O
area	O
of	O
murine	B-OrganismTaxon
chromosome	O
7	O
bearing	O
the	O
CHL2	B-GeneOrGeneProduct
gene	O
.	O

Inability	O
to	O
identify	O
a	O
separate	O
zebrafish	B-OrganismTaxon
gene	O
corresponding	O
to	O
the	O
mammalian	O
CHL1	B-GeneOrGeneProduct
gene	O
suggests	O
that	O
Chl	B-GeneOrGeneProduct
may	O
serve	O
roles	O
in	O
zebrafish	B-OrganismTaxon
distributed	O
between	O
CHL1	B-GeneOrGeneProduct
and	O
CHL2	B-GeneOrGeneProduct
in	O
other	O
species	O
.	O

Chl	B-GeneOrGeneProduct
is	O
a	O
maternal	O
factor	O
that	O
is	O
also	O
zygotically	O
expressed	O
later	O
in	O
development	O
and	O
has	O
spatiotemporal	O
expression	O
patterns	O
that	O
differ	O
from	O
but	O
overlap	O
those	O
of	O
zebrafish	B-OrganismTaxon
chordin	B-GeneOrGeneProduct
(	O
Chd	B-GeneOrGeneProduct
)	O
,	O
suggesting	O
differences	O
but	O
also	O
possible	O
overlap	O
in	O
developmental	O
roles	O
of	O
the	O
two	O
proteins	O
.	O

Chl	B-GeneOrGeneProduct
,	O
like	O
Chd	B-GeneOrGeneProduct
,	O
dorsalizes	O
embryos	O
upon	O
overexpression	O
and	O
is	O
cleaved	O
by	O
BMP1	B-GeneOrGeneProduct
,	O
which	O
antagonizes	O
this	O
activity	O
.	O

Loss	O
-	O
of	O
-	O
function	O
experiments	O
demonstrate	O
that	O
Chl	B-GeneOrGeneProduct
serves	O
as	O
a	O
BMP	B-GeneOrGeneProduct
antagonist	O
with	O
functions	O
that	O
overlap	O
and	O
are	O
redundant	O
with	O
those	O
of	O
Chd	B-GeneOrGeneProduct
in	O
forming	O
the	O
dorsoventral	O
axis	O
.	O
Polymorphic	O
forms	O
of	O
prostate	B-GeneOrGeneProduct
specific	I-GeneOrGeneProduct
antigen	I-GeneOrGeneProduct
and	O
their	O
interaction	O
with	O
androgen	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
trinucleotide	O
repeats	O
in	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Recent	O
data	O
has	O
suggested	O
that	O
polymorphisms	O
in	O
the	O
prostate	B-GeneOrGeneProduct
specific	I-GeneOrGeneProduct
antigen	I-GeneOrGeneProduct
(	O
PSA	B-GeneOrGeneProduct
)	O
may	O
increase	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
PC	B-DiseaseOrPhenotypicFeature
)	O
risk	O
.	O

The	O
PSA	B-GeneOrGeneProduct
gene	O
contains	O
a	O
G	B-SequenceVariant
/	O
A	I-SequenceVariant
substitution	O
in	O
the	O
androgen	B-ChemicalEntity
response	O
element	O
(	O
ARE	O
)	O
1	O
region	O
.	O

The	O
androgen	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
AR	B-GeneOrGeneProduct
)	O
gene	O
has	O
polymorphic	O
regions	O
containing	O
variable	O
length	O
glutamine	O
and	O
glycine	O
repeats	O
and	O
these	O
are	O
believed	O
to	O
be	O
associated	O
with	O
PC	B-DiseaseOrPhenotypicFeature
risk	O
.	O

The	O
effect	O
on	O
PC	B-DiseaseOrPhenotypicFeature
risks	O
from	O
PSA	B-GeneOrGeneProduct
polymorphisms	O
alone	O
and	O
synergistically	O
with	O
the	O
AR	B-GeneOrGeneProduct
gene	O
was	O
examined	O
in	O
this	O
report	O
.	O

METHODS	O
:	O
One	O
hundred	O
PC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
an	O
age	O
matched	O
cohort	O
of	O
79	O
benign	B-DiseaseOrPhenotypicFeature
prostate	I-DiseaseOrPhenotypicFeature
hyperplasia	I-DiseaseOrPhenotypicFeature
and	O
67	O
population	O
controls	O
were	O
entered	O
in	O
this	O
study	O
.	O

DNA	O
was	O
extracted	O
from	O
blood	O
and	O
PSA	B-GeneOrGeneProduct
/	O
ARE	O
promoter	O
region	O
amplified	O
by	O
PCR	O
.	O

PCR	O
products	O
were	O
cut	O
with	O
Nhe	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
restriction	O
enzyme	O
to	O
distinguish	O
G	B-SequenceVariant
/	O
A	I-SequenceVariant
alleles	O
.	O

AR	B-GeneOrGeneProduct
/	O
CAG	B-SequenceVariant
and	I-SequenceVariant
GGC	I-SequenceVariant
repeat	I-SequenceVariant
length	O
was	O
detected	O
by	O
automated	O
fluorescence	O
from	O
PCR	O
products	O
.	O

RESULTS	O
:	O
We	O
found	O
a	O
significantly	O
higher	O
PSA	B-GeneOrGeneProduct
/	O
GG	O
distribution	O
in	O
PC	B-DiseaseOrPhenotypicFeature
(	O
30%	O
)	O
than	O
either	O
benign	B-DiseaseOrPhenotypicFeature
prostatic	I-DiseaseOrPhenotypicFeature
hyperplasia	I-DiseaseOrPhenotypicFeature
(	O
BPH	B-DiseaseOrPhenotypicFeature
)	O
(	O
18%	O
)	O
or	O
population	O
controls	O
(	O
16%	O
)	O
(	O
P	O
=	O
0	O
.	O
025	O
)	O
.	O

Furthermore	O
the	O
GG	O
distribution	O
within	O
cases	O
was	O
even	O
greater	O
in	O
younger	O
men	B-OrganismTaxon
(	O
<	O
65	O
years	O
;	O
42%	O
;	O
P	O
=	O
0	O
.	O
012	O
)	O
.	O

Additionally	O
,	O
when	O
PSA	B-GeneOrGeneProduct
genotype	O
was	O
cross	O
classified	O
with	O
CAG	B-SequenceVariant
repeat	I-SequenceVariant
,	O
significantly	O
more	O
cases	O
than	O
both	O
BPH	B-DiseaseOrPhenotypicFeature
and	O
population	O
controls	O
were	O
observed	O
to	O
have	O
a	O
short	O
(	O
<	O
22	O
)	O
CAG	O
/	O
GG	O
genotype	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
indicate	O
that	O
the	O
PSA	B-GeneOrGeneProduct
/	O
ARE	O
GG	O
genotype	O
confers	O
an	O
increased	O
risk	O
of	O
PC	B-DiseaseOrPhenotypicFeature
especially	O
among	O
younger	O
men	B-OrganismTaxon
.	O

Moreover	O
,	O
we	O
confirm	O
previous	O
results	O
that	O
a	O
short	O
glutamine	B-SequenceVariant
repeat	I-SequenceVariant
in	O
conjunction	O
with	O
GG	O
genotype	O
significantly	O
increases	O
the	O
risk	O
of	O
malignant	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O
A	O
homozygous	O
mutation	O
in	O
LYRM7	B-GeneOrGeneProduct
/	O
MZM1L	B-GeneOrGeneProduct
associated	O
with	O
early	O
onset	O
encephalopathy	B-DiseaseOrPhenotypicFeature
,	O
lactic	B-DiseaseOrPhenotypicFeature
acidosis	I-DiseaseOrPhenotypicFeature
,	O
and	O
severe	O
reduction	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
mitochondrial	I-DiseaseOrPhenotypicFeature
complex	I-DiseaseOrPhenotypicFeature
III	I-DiseaseOrPhenotypicFeature
activity	O
.	O

Mutations	O
in	O
nuclear	O
genes	O
associated	O
with	O
defective	B-DiseaseOrPhenotypicFeature
complex	I-DiseaseOrPhenotypicFeature
III	I-DiseaseOrPhenotypicFeature
(	O
cIII	I-DiseaseOrPhenotypicFeature
)	O
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
mitochondrial	I-DiseaseOrPhenotypicFeature
respiratory	O
chain	O
are	O
rare	O
,	O
having	O
been	O
found	O
in	O
only	O
two	O
cIII	B-GeneOrGeneProduct
assembly	O
factors	O
and	O
,	O
as	O
private	O
changes	O
in	O
single	O
families	O
,	O
three	O
cIII	B-GeneOrGeneProduct
structural	O
subunits	O
.	O

Recently	O
,	O
human	B-OrganismTaxon
LYRM7	B-GeneOrGeneProduct
/	O
MZM1L	B-GeneOrGeneProduct
,	O
the	O
ortholog	O
of	O
yeast	B-OrganismTaxon
MZM1	B-GeneOrGeneProduct
,	O
has	O
been	O
identified	O
as	O
a	O
new	O
assembly	O
factor	O
for	O
cIII	B-GeneOrGeneProduct
.	O

In	O
a	O
baby	O
patient	B-OrganismTaxon
with	O
early	O
onset	O
,	O
severe	O
encephalopathy	B-DiseaseOrPhenotypicFeature
,	O
lactic	B-DiseaseOrPhenotypicFeature
acidosis	I-DiseaseOrPhenotypicFeature
and	O
profound	O
,	O
isolated	O
cIII	B-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
in	O
skeletal	O
muscle	O
,	O
we	O
identified	O
a	O
disease	O
-	O
segregating	O
homozygous	O
mutation	O
(	O
c	B-SequenceVariant
.	O
73G	I-SequenceVariant
>	O
A	I-SequenceVariant
)	O
in	O
LYRM7	B-GeneOrGeneProduct
/	O
MZM1L	B-GeneOrGeneProduct
,	O
predicting	O
a	O
drastic	O
change	O
in	O
a	O
highly	O
conserved	O
amino	O
-	O
acid	O
residue	O
(	O
p	B-SequenceVariant
.	O
Asp25Asn	I-SequenceVariant
)	O
.	O

In	O
a	O
mzm1D	B-GeneOrGeneProduct
yeast	B-OrganismTaxon
strain	O
,	O
the	O
expression	O
of	O
a	O
mzm1	B-GeneOrGeneProduct
(	O
D25N	B-SequenceVariant
)	O
mutant	O
allele	O
caused	O
temperature	O
-	O
sensitive	O
respiratory	B-DiseaseOrPhenotypicFeature
growth	I-DiseaseOrPhenotypicFeature
defect	I-DiseaseOrPhenotypicFeature
,	O
decreased	O
oxygen	B-ChemicalEntity
consumption	O
,	O
impaired	O
maturation	O
/	O
stabilization	O
of	O
the	O
Rieske	B-GeneOrGeneProduct
Fe	I-GeneOrGeneProduct
-	O
S	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
,	O
and	O
reduced	O
complex	B-GeneOrGeneProduct
III	I-GeneOrGeneProduct
activity	O
and	O
amount	O
.	O

LYRM7	B-GeneOrGeneProduct
/	O
MZM1L	B-GeneOrGeneProduct
is	O
a	O
novel	O
disease	O
gene	O
,	O
causing	O
cIII	B-DiseaseOrPhenotypicFeature
-	O
defective	I-DiseaseOrPhenotypicFeature
,	O
early	O
onset	O
,	O
severe	O
mitochondrial	B-DiseaseOrPhenotypicFeature
encephalopathy	I-DiseaseOrPhenotypicFeature
.	O
cDNA	O
sequence	O
and	O
chromosomal	O
localization	O
of	O
the	O
remaining	O
three	O
human	B-OrganismTaxon
nuclear	B-GeneOrGeneProduct
encoded	I-GeneOrGeneProduct
iron	I-GeneOrGeneProduct
sulphur	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
IP	I-GeneOrGeneProduct
)	O
subunits	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
I	I-GeneOrGeneProduct
:	O
the	O
human	B-OrganismTaxon
IP	B-GeneOrGeneProduct
fraction	O
is	O
completed	O
.	O

NADH	B-GeneOrGeneProduct
:	O
ubiquinone	I-GeneOrGeneProduct
oxidoreductase	I-GeneOrGeneProduct
(	O
complex	I-GeneOrGeneProduct
I	I-GeneOrGeneProduct
)	O
of	O
the	O
mitochondrial	O
respiratory	O
chain	O
can	O
be	O
fragmented	O
in	O
a	O
flavoprotein	B-GeneOrGeneProduct
(	O
FP	B-GeneOrGeneProduct
)	O
,	O
iron	B-GeneOrGeneProduct
-	O
sulfur	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
IP	B-GeneOrGeneProduct
)	O
,	O
and	O
hydrophobic	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
HP	B-GeneOrGeneProduct
)	O
subfraction	O
.	O

The	O
IP	B-GeneOrGeneProduct
subfraction	O
is	O
hypothesized	O
to	O
be	O
significant	O
,	O
since	O
it	O
contains	O
important	O
prosthetic	O
groups	O
highly	O
conserved	O
among	O
species	O
.	O

We	O
cloned	O
the	O
cDNA	O
of	O
three	O
remaining	O
human	B-OrganismTaxon
NADH	B-GeneOrGeneProduct
:	O
ubiquinone	I-GeneOrGeneProduct
oxidoreductase	I-GeneOrGeneProduct
subunits	I-GeneOrGeneProduct
of	O
this	O
IP	B-GeneOrGeneProduct
fraction	O
:	O
the	O
NDUFS2	B-GeneOrGeneProduct
(	O
49	O
kDa	O
)	O
,	O
NDUFS3	B-GeneOrGeneProduct
(	O
30	O
kDa	O
)	O
,	O
and	O
NDUFS6	B-GeneOrGeneProduct
(	O
13	O
kDa	O
)	O
subunits	O
.	O

All	O
presented	O
cDNAs	O
include	O
the	O
complete	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
,	O
which	O
consist	O
of	O
1392	O
,	O
795	O
,	O
and	O
375	O
base	O
pairs	O
,	O
coding	O
for	O
463	O
,	O
264	O
,	O
and	O
124	O
amino	O
acids	O
,	O
respectively	O
.	O

The	O
latter	O
show	O
96	O
,	O
90	O
,	O
and	O
83%	O
homology	O
with	O
the	O
corresponding	O
bovine	B-OrganismTaxon
translation	O
products	O
.	O

The	O
3	O
'	O
untranslated	O
regions	O
(	O
UTR	O
)	O
are	O
complete	O
in	O
all	O
three	O
cDNAs	O
.	O

Polymerase	O
chain	O
reaction	O
performed	O
with	O
DNA	O
isolated	O
from	O
somatic	O
human	B-OrganismTaxon
-	O
rodent	O
cell	O
hybrids	O
containing	O
defined	O
human	B-OrganismTaxon
chromosomes	O
as	O
template	O
gave	O
a	O
human	B-OrganismTaxon
-	O
specific	O
signal	O
which	O
mapped	O
the	O
NDUFS2	B-GeneOrGeneProduct
and	O
NDUFS3	B-GeneOrGeneProduct
subunits	O
to	O
chromosomes	O
1	O
and	O
11	O
,	O
respectively	O
.	O

In	O
the	O
case	O
of	O
the	O
NDUFS6	B-GeneOrGeneProduct
subunit	O
a	O
pseudogene	O
may	O
be	O
present	O
since	O
signals	O
were	O
seen	O
in	O
the	O
lanes	O
containing	O
chromosomes	O
5	O
and	O
6	O
.	O

The	O
NDUFS2	B-GeneOrGeneProduct
contains	O
a	O
highly	O
conserved	O
protein	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
C	I-GeneOrGeneProduct
phosphorylation	O
site	O
and	O
the	O
NDUFS3	B-GeneOrGeneProduct
subunit	O
contains	O
a	O
highly	O
conserved	O
casein	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
phosphorylation	O
site	O
which	O
make	O
them	O
strong	O
candidates	O
for	O
future	O
mutation	O
detection	O
studies	O
in	O
enzymatic	B-DiseaseOrPhenotypicFeature
complex	I-DiseaseOrPhenotypicFeature
I	I-DiseaseOrPhenotypicFeature
-	O
deficient	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O
The	O
FH	B-GeneOrGeneProduct
mutation	O
database	O
:	O
an	O
online	O
database	O
of	O
fumarate	B-GeneOrGeneProduct
hydratase	I-GeneOrGeneProduct
mutations	O
involved	O
in	O
the	O
MCUL	B-DiseaseOrPhenotypicFeature
(	O
HLRCC	B-DiseaseOrPhenotypicFeature
)	O
tumor	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
and	O
congenital	O
fumarase	B-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Fumarate	B-GeneOrGeneProduct
hydratase	I-GeneOrGeneProduct
(	O
HGNC	O
approved	O
gene	O
symbol	O
-	O
FH	B-GeneOrGeneProduct
)	O
,	O
also	O
known	O
as	O
fumarase	B-GeneOrGeneProduct
,	O
is	O
an	O
enzyme	O
of	O
the	O
tricarboxylic	B-ChemicalEntity
acid	I-ChemicalEntity
(	O
TCA	B-ChemicalEntity
)	O
cycle	O
,	O
involved	O
in	O
fundamental	O
cellular	O
energy	O
production	O
.	O

First	O
described	O
by	O
Zinn	O
et	O
al	O
in	O
1986	O
,	O
deficiency	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
FH	I-DiseaseOrPhenotypicFeature
results	O
in	O
early	O
onset	O
,	O
severe	O
encephalopathy	B-DiseaseOrPhenotypicFeature
.	O

In	O
2002	O
,	O
the	O
Multiple	O
Leiomyoma	B-DiseaseOrPhenotypicFeature
Consortium	O
identified	O
heterozygous	O
germline	O
mutations	O
of	O
FH	B-GeneOrGeneProduct
in	O
patients	B-OrganismTaxon
with	O
multiple	B-DiseaseOrPhenotypicFeature
cutaneous	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
uterine	I-DiseaseOrPhenotypicFeature
leiomyomas	I-DiseaseOrPhenotypicFeature
,	O
(	O
MCUL	B-DiseaseOrPhenotypicFeature
:	O
OMIM	B-DiseaseOrPhenotypicFeature
150800	I-DiseaseOrPhenotypicFeature
)	O
.	O

In	O
some	O
families	O
renal	B-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
also	O
forms	O
a	O
component	O
of	O
the	O
complex	O
and	O
as	O
such	O
has	O
been	O
described	O
as	O
hereditary	B-DiseaseOrPhenotypicFeature
leiomyomatosis	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
HLRCC	B-DiseaseOrPhenotypicFeature
:	O
OMIM	B-DiseaseOrPhenotypicFeature
605839	I-DiseaseOrPhenotypicFeature
)	O
.	O

The	O
identification	O
of	O
FH	B-GeneOrGeneProduct
as	O
a	O
tumor	B-DiseaseOrPhenotypicFeature
suppressor	O
was	O
an	O
unexpected	O
finding	O
and	O
following	O
the	O
identification	O
of	O
subunits	O
of	O
succinate	O
dehydrogenase	O
in	O
2000	O
and	O
2001	O
,	O
was	O
only	O
the	O
second	O
description	O
of	O
the	O
involvement	O
of	O
an	O
enzyme	O
of	O
intermediary	O
metabolism	O
in	O
tumorigenesis	B-DiseaseOrPhenotypicFeature
.	O

DESCRIPTION	O
:	O
The	O
FH	B-GeneOrGeneProduct
mutation	O
database	O
is	O
a	O
part	O
of	O
the	O
TCA	B-ChemicalEntity
cycle	O
gene	O
mutation	O
database	O
(	O
formerly	O
the	O
succinate	O
dehydrogenase	O
gene	O
mutation	O
database	O
)	O
and	O
is	O
based	O
on	O
the	O
Leiden	O
Open	O
(	O
source	O
)	O
Variation	O
Database	O
(	O
LOVD	O
)	O
system	O
.	O

The	O
variants	O
included	O
in	O
the	O
database	O
were	O
derived	O
from	O
the	O
published	O
literature	O
and	O
annotated	O
to	O
conform	O
to	O
current	O
mutation	O
nomenclature	O
.	O

The	O
FH	B-GeneOrGeneProduct
database	O
applies	O
HGVS	O
nomenclature	O
guidelines	O
,	O
and	O
will	O
assist	O
researchers	O
in	O
applying	O
these	O
guidelines	O
when	O
directly	O
submitting	O
new	O
sequence	O
variants	O
online	O
.	O

Since	O
the	O
first	O
molecular	O
characterization	O
of	O
an	O
FH	B-GeneOrGeneProduct
mutation	O
by	O
Bourgeron	O
et	O
al	O
in	O
1994	O
,	O
a	O
series	O
of	O
reports	O
of	O
both	O
FH	B-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
patients	B-OrganismTaxon
with	O
MCUL	B-DiseaseOrPhenotypicFeature
/	O
HLRRC	B-DiseaseOrPhenotypicFeature
have	O
described	O
107	O
variants	O
,	O
of	O
which	O
93	O
are	O
thought	O
to	O
be	O
pathogenic	O
.	O

The	O
most	O
common	O
type	O
of	O
mutation	O
is	O
missense	O
(	O
57%	O
)	O
,	O
followed	O
by	O
frameshifts	O
&	O
nonsense	O
(	O
27%	O
)	O
,	O
and	O
diverse	O
deletions	O
,	O
insertions	O
and	O
duplications	O
.	O

Here	O
we	O
introduce	O
an	O
online	O
database	O
detailing	O
all	O
reported	O
FH	B-GeneOrGeneProduct
sequence	O
variants	O
.	O

CONCLUSION	O
:	O
The	O
FH	B-GeneOrGeneProduct
mutation	O
database	O
strives	O
to	O
systematically	O
unify	O
all	O
current	O
genetic	O
knowledge	O
of	O
FH	B-GeneOrGeneProduct
variants	O
.	O

We	O
believe	O
that	O
this	O
knowledge	O
will	O
assist	O
clinical	O
geneticists	O
and	O
treating	O
physicians	O
when	O
advising	O
patients	B-OrganismTaxon
and	O
their	O
families	O
,	O
will	O
provide	O
a	O
rapid	O
and	O
convenient	O
resource	O
for	O
research	O
scientists	O
,	O
and	O
may	O
eventually	O
assist	O
in	O
gaining	O
novel	O
insights	O
into	O
FH	B-GeneOrGeneProduct
and	O
its	O
related	O
clinical	O
syndromes	O
.	O
Mechanisms	O
Underlying	O
Latent	O
Disease	O
Risk	O
Associated	O
with	O
Early	O
-	O
Life	O
Arsenic	B-ChemicalEntity
Exposure	O
:	O
Current	O
Research	O
Trends	O
and	O
Scientific	O
Gaps	O
.	O

BACKGROUND	O
:	O
Millions	O
of	O
individuals	O
worldwide	O
,	O
particularly	O
those	O
living	O
in	O
rural	O
and	O
developing	O
areas	O
,	O
are	O
exposed	O
to	O
harmful	O
levels	O
of	O
inorganic	B-ChemicalEntity
arsenic	I-ChemicalEntity
(	O
iAs	B-ChemicalEntity
)	O
in	O
their	O
drinking	O
water	O
.	O

Inorganic	B-ChemicalEntity
As	I-ChemicalEntity
exposure	O
during	O
key	O
developmental	O
periods	O
is	O
associated	O
with	O
a	O
variety	O
of	O
adverse	O
health	O
effects	O
including	O
those	O
that	O
are	O
evident	O
in	O
adulthood	O
.	O

There	O
is	O
considerable	O
interest	O
in	O
identifying	O
the	O
molecular	O
mechanisms	O
that	O
relate	O
early	O
-	O
life	O
iAs	B-ChemicalEntity
exposure	O
to	O
the	O
development	O
of	O
these	O
latent	O
diseases	O
,	O
particularly	O
in	O
relationship	O
to	O
cancer	B-DiseaseOrPhenotypicFeature
.	O

OBJECTIVES	O
:	O
This	O
work	O
summarizes	O
research	O
on	O
the	O
molecular	O
mechanisms	O
that	O
underlie	O
the	O
increased	O
risk	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
development	O
in	O
adulthood	O
that	O
is	O
associated	O
with	O
early	O
-	O
life	O
iAs	B-ChemicalEntity
exposure	O
.	O

DISCUSSION	O
:	O
Epigenetic	O
reprogramming	O
that	O
imparts	O
functional	O
changes	O
in	O
gene	O
expression	O
,	O
the	O
development	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
stem	O
cells	O
,	O
and	O
immunomodulation	O
are	O
plausible	O
underlying	O
mechanisms	O
by	O
which	O
early	O
-	O
life	O
iAs	B-ChemicalEntity
exposure	O
elicits	O
latent	O
carcinogenic	B-DiseaseOrPhenotypicFeature
effects	O
.	O

CONCLUSIONS	O
:	O
Evidence	O
is	O
mounting	O
that	O
relates	O
early	O
-	O
life	O
iAs	B-ChemicalEntity
exposure	O
and	O
cancer	B-DiseaseOrPhenotypicFeature
development	O
later	O
in	O
life	O
.	O

Future	O
research	O
should	O
include	O
animal	O
studies	O
that	O
address	O
mechanistic	O
hypotheses	O
and	O
studies	O
of	O
human	B-OrganismTaxon
populations	O
that	O
integrate	O
early	O
-	O
life	O
exposure	O
,	O
molecular	O
alterations	O
,	O
and	O
latent	O
disease	O
outcomes	O
.	O
Two	O
novel	O
mutations	O
in	O
SRY	B-GeneOrGeneProduct
gene	O
form	O
Chinese	O
sex	B-DiseaseOrPhenotypicFeature
reversal	I-DiseaseOrPhenotypicFeature
XY	I-DiseaseOrPhenotypicFeature
females	O
.	O

The	O
SRY	B-GeneOrGeneProduct
gene	O
(	O
sex	O
determining	O
region	O
on	O
Y	O
chromosome	O
)	O
acts	O
as	O
TDF	O
and	O
is	O
required	O
for	O
regulating	O
male	O
sex	O
determination	O
.	O

SRY	B-GeneOrGeneProduct
represents	O
a	O
transcription	O
factor	O
belonging	O
to	O
the	O
superfamily	O
of	O
genes	O
sharing	O
the	O
HMG	O
-	O
box	O
motif	O
(	O
high	O
-	O
mobility	O
group	O
-	O
box	O
)	O
,	O
which	O
acts	O
as	O
DNA	O
binding	O
region	O
.	O

Deletion	O
and	O
inactivating	O
mutations	O
of	O
SRY	B-GeneOrGeneProduct
are	O
among	O
the	O
known	O
causes	O
of	O
XY	B-DiseaseOrPhenotypicFeature
sex	I-DiseaseOrPhenotypicFeature
reversal	I-DiseaseOrPhenotypicFeature
.	O

Here	O
,	O
we	O
described	O
the	O
screening	O
of	O
10	O
patients	B-OrganismTaxon
who	O
presented	O
with	O
46	B-DiseaseOrPhenotypicFeature
,	O
XY	I-DiseaseOrPhenotypicFeature
sex	I-DiseaseOrPhenotypicFeature
reversal	I-DiseaseOrPhenotypicFeature
for	O
mutations	O
in	O
open	O
reading	O
frame	O
(	O
ORF	O
)	O
of	O
SRY	B-GeneOrGeneProduct
gene	O
.	O

DNA	O
was	O
isolated	O
from	O
blood	O
samples	O
using	O
standard	O
techniques	O
.	O

A	O
609	O
bp	O
fragment	O
from	O
the	O
central	O
portion	O
of	O
the	O
SRY	B-GeneOrGeneProduct
gene	O
was	O
amplified	O
,	O
using	O
primers	O
XES	O
-	O
2	O
and	O
XES	O
-	O
7	O
.	O

The	O
amplified	O
PCR	O
fragments	O
were	O
cloned	O
into	O
the	O
pUCm	O
-	O
T	O
vectors	O
,	O
and	O
direct	O
sequencing	O
were	O
carried	O
out	O
on	O
an	O
ABI	O
377	O
-	O
3	O
automated	O
DNA	O
sequencer	O
to	O
detect	O
the	O
mutation	O
.	O

PCR	O
-	O
restriction	O
enzyme	O
digestion	O
was	O
applied	O
to	O
detect	O
the	O
results	O
of	O
DNA	O
sequencing	O
.	O

In	O
two	O
patients	B-OrganismTaxon
,	O
de	O
novo	O
mutations	O
led	O
to	O
an	O
amino	O
acid	O
substitution	O
.	O

An	O
A	B-SequenceVariant
was	I-SequenceVariant
replaced	I-SequenceVariant
by	I-SequenceVariant
a	I-SequenceVariant
G	I-SequenceVariant
in	I-SequenceVariant
codon	I-SequenceVariant
38	I-SequenceVariant
upstream	O
of	O
the	O
5	O
'	O
border	O
outside	O
the	O
HMG	O
box	O
of	O
the	O
SRY	B-GeneOrGeneProduct
gene	O
,	O
resulting	O
in	O
the	O
replacement	O
of	O
the	O
amino	O
acid	O
glutamate	B-SequenceVariant
by	I-SequenceVariant
glycine	I-SequenceVariant
.	O

Another	O
heterozygous	O
T	B-SequenceVariant
to	I-SequenceVariant
A	I-SequenceVariant
transition	I-SequenceVariant
at	I-SequenceVariant
the	I-SequenceVariant
nucleotide	I-SequenceVariant
position	I-SequenceVariant
+	O
387	I-SequenceVariant
which	O
encodes	O
for	O
a	O
Tyrosine	B-SequenceVariant
(	O
Tyr	I-SequenceVariant
)	O
instead	I-SequenceVariant
of	I-SequenceVariant
a	I-SequenceVariant
Term	I-SequenceVariant
,	O
whereas	O
her	O
father	O
was	O
proven	O
to	O
have	O
the	O
wild	O
-	O
type	O
sequence	O
.	O

These	O
point	O
mutations	O
have	O
been	O
confirmed	O
with	O
PCR	O
-	O
restrict	O
enzyme	O
method	O
.	O

As	O
demonstrated	O
by	O
the	O
Human	B-OrganismTaxon
Gene	O
Mutation	O
Database	O
analysis	O
,	O
homology	O
search	O
,	O
and	O
review	O
of	O
the	O
literature	O
,	O
these	O
two	O
mutations	O
were	O
not	O
described	O
previously	O
and	O
brought	O
the	O
total	O
number	O
of	O
SRY	B-GeneOrGeneProduct
gene	O
nucleotide	O
substitutions	O
(	O
missense	O
/	O
nonsense	O
)	O
to	O
45	O
.	O

These	O
findings	O
indicated	O
that	O
these	O
amino	O
acid	O
substitutions	O
may	O
be	O
responsible	O
for	O
the	O
sex	B-DiseaseOrPhenotypicFeature
reversal	I-DiseaseOrPhenotypicFeature
,	O
not	O
only	O
inside	O
the	O
HMG	O
-	O
box	O
but	O
also	O
outside	O
the	O
HMG	O
-	O
box	O
.	O

The	O
two	O
novel	O
mutations	O
in	O
SRY	B-GeneOrGeneProduct
gene	O
provided	O
valuable	O
information	O
for	O
understanding	O
the	O
molecular	O
mechanism	O
of	O
the	O
patient	B-OrganismTaxon
with	O
46	B-DiseaseOrPhenotypicFeature
,	O
XY	I-DiseaseOrPhenotypicFeature
female	I-DiseaseOrPhenotypicFeature
sex	I-DiseaseOrPhenotypicFeature
reversal	I-DiseaseOrPhenotypicFeature
.	O
Superoxide	B-GeneOrGeneProduct
dismutase	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
overexpression	O
in	O
mice	B-OrganismTaxon
abolishes	O
maternal	B-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
-	O
induced	O
endoplasmic	O
reticulum	O
stress	O
in	O
diabetic	B-DiseaseOrPhenotypicFeature
embryopathy	B-DiseaseOrPhenotypicFeature
.	O

OBJECTIVE	O
:	O
Both	O
oxidative	O
stress	O
and	O
endoplasmic	O
reticulum	O
stress	O
(	O
ER	O
stress	O
)	O
are	O
causal	O
events	O
in	O
diabetic	B-DiseaseOrPhenotypicFeature
embryopathy	B-DiseaseOrPhenotypicFeature
.	O

We	O
tested	O
whether	O
oxidative	O
stress	O
causes	O
ER	O
stress	O
.	O

STUDY	O
DESIGN	O
:	O
Wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
superoxide	B-GeneOrGeneProduct
dismutase	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
SOD1	B-GeneOrGeneProduct
)	O
-	O
overexpressing	O
day	O
8	O
.	O
75	O
embryos	O
from	O
nondiabetic	O
WT	O
control	O
with	O
SOD1	B-GeneOrGeneProduct
transgenic	O
male	O
and	O
diabetic	B-DiseaseOrPhenotypicFeature
WT	O
female	O
with	O
SOD1	B-GeneOrGeneProduct
transgenic	O
male	O
were	O
analyzed	O
for	O
ER	O
stress	O
markers	O
:	O
C	B-GeneOrGeneProduct
/	O
EBP	I-GeneOrGeneProduct
-	O
homologous	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
CHOP	B-GeneOrGeneProduct
)	O
,	O
calnexin	B-GeneOrGeneProduct
,	O
eukaryotic	B-GeneOrGeneProduct
initiation	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
2a	I-GeneOrGeneProduct
(	O
eIF2a	B-GeneOrGeneProduct
)	O
,	O
protein	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
ribonucleic	I-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
(	O
RNA	I-GeneOrGeneProduct
)	O
-	O
like	I-GeneOrGeneProduct
ER	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
(	O
PERK	B-GeneOrGeneProduct
)	O
,	O
binding	B-GeneOrGeneProduct
immunoglobulin	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
,	O
protein	B-GeneOrGeneProduct
disulfide	I-GeneOrGeneProduct
isomerase	I-GeneOrGeneProduct
family	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
member	I-GeneOrGeneProduct
3	I-GeneOrGeneProduct
,	O
kinases	B-GeneOrGeneProduct
inositol	I-GeneOrGeneProduct
-	O
requiring	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
-	O
1a	I-GeneOrGeneProduct
(	O
IRE1a	B-GeneOrGeneProduct
)	O
,	O
and	O
the	O
X	B-GeneOrGeneProduct
-	O
box	I-GeneOrGeneProduct
binding	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
XBP1	B-GeneOrGeneProduct
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
splicing	O
.	O

RESULTS	O
:	O
Maternal	B-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
significantly	O
increased	O
the	O
levels	O
of	O
CHOP	B-GeneOrGeneProduct
,	O
calnexin	B-GeneOrGeneProduct
,	O
phosphorylated	O
(	O
p	O
)	O
-	O
eIF2a	B-GeneOrGeneProduct
,	O
p	O
-	O
PERK	B-GeneOrGeneProduct
,	O
and	O
p	O
-	O
IRE1a	B-GeneOrGeneProduct
;	O
triggered	O
XBP1	B-GeneOrGeneProduct
mRNA	O
splicing	O
;	O
and	O
enhanced	O
ER	O
chaperone	O
gene	O
expression	O
in	O
WT	O
embryos	O
.	O

SOD1	B-GeneOrGeneProduct
overexpression	O
blocked	O
these	O
diabetes	B-DiseaseOrPhenotypicFeature
-	O
induced	O
ER	O
stress	O
markers	O
.	O

CONCLUSION	O
:	O
Mitigating	O
oxidative	O
stress	O
via	O
SOD1	B-GeneOrGeneProduct
overexpression	O
blocks	O
maternal	B-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
-	O
induced	O
ER	O
stress	O
in	O
vivo	O
.	O
The	O
human	B-OrganismTaxon
AHR	B-GeneOrGeneProduct
:	O
identification	O
of	O
single	O
nucleotide	O
polymorphisms	O
from	O
six	O
ethnic	O
populations	O
.	O

BACKGROUND	O
:	O
The	O
effects	O
of	O
2	B-ChemicalEntity
,	O
3	I-ChemicalEntity
,	O
7	I-ChemicalEntity
,	O
8	I-ChemicalEntity
-	O
tetrachlorodibenzo	I-ChemicalEntity
-	O
p	I-ChemicalEntity
-	O
dioxin	I-ChemicalEntity
and	O
related	O
dioxin	B-ChemicalEntity
-	O
like	O
chemicals	O
are	O
mediated	O
through	O
binding	O
-	O
dependent	O
activation	O
of	O
the	O
cytosolic	O
aryl	B-GeneOrGeneProduct
hydrocarbon	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
AHR	B-GeneOrGeneProduct
)	O
.	O

The	O
human	B-OrganismTaxon
AHR	B-GeneOrGeneProduct
is	O
a	O
low	O
-	O
affinity	O
receptor	O
relative	O
to	O
most	O
rodents	O
,	O
but	O
some	O
reports	O
suggest	O
that	O
there	O
may	O
be	O
individuals	O
with	O
polymorphic	O
high	O
-	O
affinity	O
receptors	O
,	O
thereby	O
possibly	O
increasing	O
the	O
sensitivity	O
to	O
dioxins	B-ChemicalEntity
in	O
such	O
people	O
.	O

METHODS	O
:	O
Although	O
no	O
polymorphisms	O
have	O
been	O
reported	O
in	O
the	O
ligand	O
binding	O
region	O
of	O
the	O
AHR	B-GeneOrGeneProduct
in	O
the	O
over	O
100	O
reported	O
sequences	O
,	O
we	O
sequenced	O
108	O
additional	O
human	B-OrganismTaxon
AHR	B-GeneOrGeneProduct
genes	O
in	O
an	O
effort	O
to	O
further	O
identify	O
single	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
within	O
the	O
open	O
reading	O
frames	O
of	O
the	O
AHR	B-GeneOrGeneProduct
locus	O
.	O

The	O
DNA	O
was	O
sequenced	O
from	O
six	O
ethnic	O
populations	O
that	O
included	O
Japanese	O
,	O
Chinese	O
,	O
European	O
/	O
Caucasian	O
,	O
African	O
-	O
American	O
,	O
South	O
East	O
Asian	O
,	O
and	O
Hispanic	O
.	O

RESULTS	O
:	O
Six	O
exonic	O
SNPs	O
were	O
identified	O
;	O
four	O
had	O
been	O
described	O
as	O
previously	O
reported	O
and	O
two	O
seem	O
to	O
be	O
novel	O
.	O

Four	O
of	O
the	O
SNPs	O
identified	O
lead	O
to	O
amino	O
acid	O
changes	O
in	O
the	O
AHR	B-GeneOrGeneProduct
protein	O
and	O
two	O
of	O
the	O
SNPs	O
lead	O
to	O
synonymous	O
substitutions	O
.	O

An	O
additional	O
four	O
SNPs	O
have	O
been	O
reported	O
elsewhere	O
that	O
were	O
not	O
identified	O
in	O
the	O
current	O
analysis	O
.	O

With	O
these	O
new	O
sequences	O
,	O
more	O
than	O
200	O
human	B-OrganismTaxon
AHR	B-GeneOrGeneProduct
gene	O
sequences	O
have	O
been	O
analyzed	O
for	O
SNPs	O
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
very	O
limited	O
presence	O
of	O
polymorphisms	O
in	O
the	O
core	O
ligand	O
binding	O
region	O
of	O
the	O
human	B-OrganismTaxon
AHR	B-GeneOrGeneProduct
.	O

Other	O
regions	O
,	O
such	O
as	O
the	O
transactivation	O
domain	O
,	O
seem	O
to	O
be	O
slightly	O
more	O
polymorphic	O
in	O
the	O
human	B-OrganismTaxon
population	O
and	O
the	O
impact	O
on	O
functionality	O
should	O
be	O
further	O
examined	O
.	O
A	O
Cys	B-SequenceVariant
23	I-SequenceVariant
-	O
Ser	I-SequenceVariant
23	I-SequenceVariant
substitution	O
in	O
the	O
5	B-GeneOrGeneProduct
-	O
HT	I-GeneOrGeneProduct
(	O
2C	I-GeneOrGeneProduct
)	O
receptor	I-GeneOrGeneProduct
gene	O
influences	O
body	O
weight	O
regulation	O
in	O
females	O
with	O
seasonal	B-DiseaseOrPhenotypicFeature
affective	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
:	O
an	O
Austrian	O
-	O
Canadian	O
collaborative	O
study	O
.	O

Most	O
females	O
with	O
seasonal	B-DiseaseOrPhenotypicFeature
affective	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
(	O
SAD	B-DiseaseOrPhenotypicFeature
)	O
exhibit	O
atypical	O
vegetative	O
symptoms	O
such	O
as	O
overeating	O
,	O
and	O
weight	B-DiseaseOrPhenotypicFeature
gain	I-DiseaseOrPhenotypicFeature
when	I-DiseaseOrPhenotypicFeature
depressed	I-DiseaseOrPhenotypicFeature
.	O

The	O
serotonin	B-GeneOrGeneProduct
2C	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
5	B-GeneOrGeneProduct
-	O
HT	I-GeneOrGeneProduct
(	O
2C	I-GeneOrGeneProduct
)	O
)	O
plays	O
a	O
key	O
role	O
in	O
control	O
of	O
appetite	O
and	O
satiety	O
.	O

A	O
5	B-GeneOrGeneProduct
-	O
HT	I-GeneOrGeneProduct
(	O
2C	I-GeneOrGeneProduct
)	O
Cys	B-SequenceVariant
23	I-SequenceVariant
Ser	I-SequenceVariant
substitution	O
,	O
coded	O
for	O
by	O
a	O
single	O
nucleotide	O
polymorphism	O
(	O
Cys	B-SequenceVariant
23	I-SequenceVariant
Ser	I-SequenceVariant
)	O
within	O
the	O
5	B-GeneOrGeneProduct
-	O
HT	I-GeneOrGeneProduct
(	O
2C	I-GeneOrGeneProduct
)	O
gene	O
,	O
has	O
been	O
shown	O
to	O
influence	O
5	B-GeneOrGeneProduct
-	O
HT	I-GeneOrGeneProduct
(	O
2C	I-GeneOrGeneProduct
)	O
function	O
.	O

We	O
hypothesized	O
that	O
Cys	B-SequenceVariant
23	I-SequenceVariant
Ser	I-SequenceVariant
influences	O
weight	O
regulation	O
in	O
females	O
with	O
SAD	B-DiseaseOrPhenotypicFeature
.	O

Two	O
independent	O
samples	O
from	O
Austria	O
(	O
162	O
females	O
with	O
SAD	B-DiseaseOrPhenotypicFeature
,	O
119	O
controls	O
)	O
,	O
and	O
Canada	O
(	O
90	O
females	O
with	O
SAD	B-DiseaseOrPhenotypicFeature
,	O
42	O
controls	O
)	O
were	O
genotyped	O
for	O
Cys	B-SequenceVariant
23	I-SequenceVariant
Ser	I-SequenceVariant
.	O

Influence	O
on	O
weight	O
regulation	O
was	O
analyzed	O
within	O
patients	B-OrganismTaxon
with	O
atypical	O
features	O
.	O

In	O
Austrians	O
,	O
genotype	O
distribution	O
differed	O
between	O
patients	B-OrganismTaxon
and	O
controls	O
(	O
p	O
=	O
0	O
.	O
044	O
)	O
and	O
Cys	B-SequenceVariant
23	I-SequenceVariant
Ser	I-SequenceVariant
was	O
associated	O
with	O
weight	O
(	O
p	O
=	O
0	O
.	O
039	O
)	O
,	O
body	O
mass	O
index	O
(	O
BMI	O
;	O
p	O
=	O
0	O
.	O
038	O
)	O
,	O
and	O
seasonal	O
appetite	O
change	O
(	O
p	O
=	O
0	O
.	O
031	O
)	O
.	O

All	O
values	O
were	O
highest	O
in	O
Cys	O
/	O
Cys	O
,	O
intermediate	O
in	O
Cys	O
/	O
Ser	O
,	O
and	O
lowest	O
in	O
Ser	O
/	O
Ser	O
carriers	O
.	O

In	O
Canadian	O
patients	B-OrganismTaxon
,	O
Cys	B-SequenceVariant
23	I-SequenceVariant
Ser	I-SequenceVariant
was	O
associated	O
with	O
minimum	O
lifetime	O
BMI	O
(	O
p	O
=	O
0	O
.	O
046	O
)	O
,	O
with	O
lowest	O
values	O
in	O
Ser	O
/	O
Ser	O
carriers	O
.	O

Our	O
data	O
provide	O
evidence	O
that	O
Cys	B-SequenceVariant
23	I-SequenceVariant
Ser	I-SequenceVariant
mediates	O
severity	O
of	O
weight	O
regulation	O
disturbances	O
in	O
females	O
with	O
SAD	B-DiseaseOrPhenotypicFeature
,	O
and	O
the	O
gene	O
-	O
dose	O
effect	O
-	O
like	O
differences	O
suggest	O
a	O
direct	O
functional	O
role	O
of	O
Cys	B-SequenceVariant
23	I-SequenceVariant
Ser	I-SequenceVariant
in	O
the	O
behavioral	O
regulation	O
of	O
body	O
weight	O
.	O
Rab6c	B-GeneOrGeneProduct
,	O
a	O
new	O
member	O
of	O
the	O
rab	B-GeneOrGeneProduct
gene	O
family	O
,	O
is	O
involved	O
in	O
drug	O
resistance	O
in	O
MCF7	B-CellLine
/	O
AdrR	I-CellLine
cells	O
.	O

A	O
new	O
Rab6	B-GeneOrGeneProduct
homolog	O
cDNA	O
,	O
Rab6c	B-GeneOrGeneProduct
,	O
was	O
discovered	O
by	O
a	O
hypermethylated	O
DNA	O
fragment	O
probe	O
that	O
was	O
isolated	O
from	O
a	O
human	B-OrganismTaxon
multidrug	O
resistant	O
(	O
MDR	O
)	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
line	O
,	O
MCF7	B-CellLine
/	O
AdrR	I-CellLine
,	O
by	O
the	O
methylation	O
sensitive	O
-	O
representational	O
difference	O
analysis	O
(	O
MS	O
-	O
RDA	O
)	O
technique	O
.	O

Rab6c	B-GeneOrGeneProduct
was	O
found	O
to	O
be	O
under	O
-	O
expressed	O
in	O
MCF7	B-CellLine
/	O
AdrR	I-CellLine
and	O
MES	B-CellLine
-	O
SA	I-CellLine
/	O
Dx5	I-CellLine
(	O
a	O
human	B-OrganismTaxon
MDR	O
uterine	B-DiseaseOrPhenotypicFeature
sarcoma	I-DiseaseOrPhenotypicFeature
cell	O
line	O
)	O
compared	O
with	O
their	O
non	O
-	O
MDR	O
parental	O
cell	O
lines	O
.	O

MCF7	B-CellLine
/	O
AdrR	I-CellLine
cells	O
expressing	O
the	O
exogenous	O
Rab6c	B-GeneOrGeneProduct
exhibited	O
less	O
resistance	O
to	O
several	O
anti	O
-	O
cancer	O
drugs	O
,	O
such	O
as	O
doxorubicin	B-ChemicalEntity
(	O
DOX	B-ChemicalEntity
)	O
,	O
taxol	B-ChemicalEntity
,	O
vinblastine	B-ChemicalEntity
,	O
and	O
vincristine	B-ChemicalEntity
,	O
than	O
the	O
control	O
cells	O
containing	O
the	O
empty	O
vector	O
.	O

Flow	O
cytometry	O
experiments	O
confirmed	O
that	O
the	O
transfectants	O
'	O
diminished	O
resistance	O
to	O
DOX	B-ChemicalEntity
was	O
caused	O
by	O
increased	O
drug	O
accumulation	O
induced	O
by	O
the	O
exogenous	O
Rab6c	B-GeneOrGeneProduct
.	O

These	O
results	O
indicate	O
that	O
Rab6c	B-GeneOrGeneProduct
is	O
involved	O
in	O
drug	O
resistance	O
in	O
MCF7	B-CellLine
/	O
AdrR	I-CellLine
cells	O
.	O
Genome	O
-	O
wide	O
loss	O
-	O
of	O
-	O
function	O
genetic	O
screening	O
identifies	O
opioid	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
u1	I-GeneOrGeneProduct
as	O
a	O
key	O
regulator	O
of	O
L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
resistance	O
in	O
pediatric	O
acute	B-DiseaseOrPhenotypicFeature
lymphoblastic	I-DiseaseOrPhenotypicFeature
leukemia	I-DiseaseOrPhenotypicFeature
.	O

L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
is	O
a	O
critical	O
chemotherapeutic	O
agent	O
for	O
acute	B-DiseaseOrPhenotypicFeature
lymphoblastic	I-DiseaseOrPhenotypicFeature
leukemia	I-DiseaseOrPhenotypicFeature
(	O
ALL	B-DiseaseOrPhenotypicFeature
)	O
.	O

It	O
hydrolyzes	O
plasma	O
asparagine	B-ChemicalEntity
into	O
aspartate	B-ChemicalEntity
and	O
NH3	B-ChemicalEntity
,	O
causing	O
asparagine	B-DiseaseOrPhenotypicFeature
deficit	I-DiseaseOrPhenotypicFeature
and	O
inhibition	O
of	O
protein	O
synthesis	O
and	O
eventually	O
,	O
leukemic	B-DiseaseOrPhenotypicFeature
cell	O
death	O
.	O

However	O
,	O
patient	B-OrganismTaxon
relapse	O
often	O
occurs	O
due	O
to	O
development	O
of	O
resistance	O
.	O

The	O
molecular	O
mechanism	O
by	O
which	O
ALL	B-DiseaseOrPhenotypicFeature
cells	O
acquire	O
resistance	O
to	O
L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
is	O
unknown	O
.	O

Therefore	O
,	O
we	O
sought	O
to	O
identify	O
genes	O
that	O
are	O
involved	O
in	O
L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
resistance	O
in	O
primary	O
leukemic	B-DiseaseOrPhenotypicFeature
cells	O
.	O

By	O
unbiased	O
genome	O
-	O
wide	O
RNAi	O
screening	O
,	O
we	O
found	O
that	O
among	O
10	O
resistant	O
ALL	B-DiseaseOrPhenotypicFeature
clones	O
,	O
six	O
hits	O
were	O
for	O
opioid	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
mu	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
oprm1	B-GeneOrGeneProduct
)	O
,	O
two	O
hits	O
were	O
for	O
carbonic	B-GeneOrGeneProduct
anhydrase	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
ca1	B-GeneOrGeneProduct
)	O
and	O
another	O
two	O
hits	O
were	O
for	O
ubiquitin	B-GeneOrGeneProduct
-	O
conjugating	I-GeneOrGeneProduct
enzyme	I-GeneOrGeneProduct
E2C	I-GeneOrGeneProduct
(	O
ube2c	B-GeneOrGeneProduct
)	O
.	O

We	O
also	O
found	O
that	O
OPRM1	B-GeneOrGeneProduct
is	O
expressed	O
in	O
all	O
leukemic	B-DiseaseOrPhenotypicFeature
cells	O
tested	O
.	O

Specific	O
knockdown	O
of	O
OPRM1	B-GeneOrGeneProduct
confers	O
L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
resistance	O
,	O
validating	O
our	O
genome	O
-	O
wide	O
retroviral	O
shRNA	O
library	O
screening	O
data	O
.	O

Methadone	B-ChemicalEntity
,	O
an	O
agonist	O
of	O
OPRM1	B-GeneOrGeneProduct
,	O
enhances	O
the	O
sensitivity	O
of	O
parental	O
leukemic	B-DiseaseOrPhenotypicFeature
cells	O
,	O
but	O
not	O
OPRM1	B-GeneOrGeneProduct
-	O
depleted	O
cells	O
,	O
to	O
L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
treatment	O
,	O
indicating	O
that	O
OPRM1	B-GeneOrGeneProduct
is	O
required	O
for	O
the	O
synergistic	O
action	O
of	O
L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
and	O
methadone	B-ChemicalEntity
,	O
and	O
that	O
OPRM1	B-GeneOrGeneProduct
loss	O
promotes	O
leukemic	B-DiseaseOrPhenotypicFeature
cell	O
survival	O
likely	O
through	O
downregulation	O
of	O
the	O
OPRM1	B-GeneOrGeneProduct
-	O
mediated	O
apoptotic	O
pathway	O
.	O

Consistent	O
with	O
this	O
premise	O
,	O
patient	B-OrganismTaxon
leukemic	B-DiseaseOrPhenotypicFeature
cells	O
with	O
relatively	O
high	O
levels	O
of	O
OPRM1	B-GeneOrGeneProduct
are	O
more	O
sensitive	O
to	O
L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
treatment	O
compared	O
to	O
OPRM1	B-GeneOrGeneProduct
-	O
depleted	O
leukemic	B-DiseaseOrPhenotypicFeature
cells	O
,	O
further	O
indicating	O
that	O
OPRM1	B-GeneOrGeneProduct
loss	O
has	O
a	O
crucial	O
role	O
in	O
L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
resistance	O
in	O
leukemic	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

Thus	O
,	O
our	O
study	O
demonstrates	O
for	O
the	O
first	O
time	O
,	O
a	O
novel	O
OPRM1	B-GeneOrGeneProduct
-	O
mediated	O
mechanism	O
for	O
L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
resistance	O
in	O
ALL	B-DiseaseOrPhenotypicFeature
,	O
and	O
identifies	O
OPRM1	B-GeneOrGeneProduct
as	O
a	O
functional	O
biomarker	O
for	O
defining	O
high	O
-	O
risk	O
subpopulations	O
and	O
for	O
the	O
detection	O
of	O
evolving	O
resistant	O
clones	O
.	O

Oprm1	B-GeneOrGeneProduct
may	O
also	O
be	O
utilized	O
for	O
effective	O
treatment	O
of	O
L	B-ChemicalEntity
-	O
asparaginase	I-ChemicalEntity
-	O
resistant	O
ALL	B-DiseaseOrPhenotypicFeature
.	O
Oncogene	O
advance	O
online	O
publication	O
,	O
26	O
June	O
2017	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
onc	O
.	O
2017	O
.	O
211	O
.	O
rTMS	O
of	O
supplementary	O
motor	O
area	O
modulates	O
therapy	O
-	O
induced	O
dyskinesias	B-DiseaseOrPhenotypicFeature
in	O
Parkinson	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

The	O
neural	O
mechanisms	O
and	O
circuitry	O
involved	O
in	O
levodopa	B-ChemicalEntity
-	O
induced	O
dyskinesia	B-DiseaseOrPhenotypicFeature
are	O
unclear	O
.	O

Using	O
repetitive	O
transcranial	O
magnetic	O
stimulation	O
(	O
rTMS	O
)	O
over	O
the	O
supplementary	O
motor	O
area	O
(	O
SMA	O
)	O
in	O
a	O
group	O
of	O
patients	B-OrganismTaxon
with	O
advanced	O
Parkinson	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
,	O
the	O
authors	O
investigated	O
whether	O
modulation	O
of	O
SMA	O
excitability	O
may	O
result	O
in	O
a	O
modification	O
of	O
a	O
dyskinetic	B-DiseaseOrPhenotypicFeature
state	O
induced	O
by	O
continuous	O
apomorphine	B-ChemicalEntity
infusion	O
.	O

rTMS	O
at	O
1	O
Hz	O
was	O
observed	O
to	O
markedly	O
reduce	O
drug	B-DiseaseOrPhenotypicFeature
-	O
induced	I-DiseaseOrPhenotypicFeature
dyskinesias	I-DiseaseOrPhenotypicFeature
,	O
whereas	O
5	O
-	O
Hz	O
rTMS	O
induced	O
a	O
slight	O
but	O
not	O
significant	O
increase	O
.	O
Two	O
novel	O
mutations	O
in	O
the	O
MEN1	B-GeneOrGeneProduct
gene	O
in	O
subjects	O
with	O
multiple	B-DiseaseOrPhenotypicFeature
endocrine	I-DiseaseOrPhenotypicFeature
neoplasia	I-DiseaseOrPhenotypicFeature
-	O
1	I-DiseaseOrPhenotypicFeature
.	O

Multiple	B-DiseaseOrPhenotypicFeature
endocrine	I-DiseaseOrPhenotypicFeature
neoplasia	I-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
(	O
MEN1	B-DiseaseOrPhenotypicFeature
)	O
is	O
characterized	O
by	O
parathyroid	O
,	O
enteropancreatic	B-DiseaseOrPhenotypicFeature
endocrine	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
pituitary	I-DiseaseOrPhenotypicFeature
adenomas	I-DiseaseOrPhenotypicFeature
as	O
well	O
as	O
germline	O
mutation	O
of	O
the	O
MEN1	B-GeneOrGeneProduct
gene	O
.	O

We	O
describe	O
2	O
families	O
with	O
MEN1	B-GeneOrGeneProduct
with	O
novel	O
mutations	O
in	O
the	O
MEN1	B-GeneOrGeneProduct
gene	O
.	O

One	O
family	O
was	O
of	O
Turkish	O
origin	O
,	O
and	O
the	O
index	O
patient	B-OrganismTaxon
had	O
primary	B-DiseaseOrPhenotypicFeature
hyperparathyroidism	I-DiseaseOrPhenotypicFeature
(	O
PHPT	B-DiseaseOrPhenotypicFeature
)	O
plus	O
a	O
prolactinoma	B-DiseaseOrPhenotypicFeature
;	O
three	O
relatives	O
had	O
PHPT	B-DiseaseOrPhenotypicFeature
only	O
.	O

The	O
index	O
patient	B-OrganismTaxon
in	O
the	O
second	O
family	O
was	O
a	O
46	O
-	O
yr	O
-	O
old	O
woman	B-OrganismTaxon
of	O
Chinese	O
origin	O
living	O
in	O
Taiwan	O
.	O

This	O
patient	B-OrganismTaxon
presented	O
with	O
a	O
complaint	O
of	O
epigastric	O
pain	B-DiseaseOrPhenotypicFeature
and	O
watery	O
diarrhea	B-DiseaseOrPhenotypicFeature
over	O
the	O
past	O
3	O
months	O
,	O
and	O
had	O
undergone	O
subtotal	O
parathyroidectomy	O
and	O
enucleation	O
of	O
pancreatic	B-DiseaseOrPhenotypicFeature
islet	I-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
tumor	I-DiseaseOrPhenotypicFeature
about	O
10	O
yr	O
before	O
.	O

There	O
was	O
also	O
a	O
prolactinoma	B-DiseaseOrPhenotypicFeature
.	O

Sequence	O
analysis	O
of	O
the	O
MEN1	B-GeneOrGeneProduct
gene	O
from	O
leukocyte	O
genomic	O
DNA	O
revealed	O
heterozygous	O
mutations	O
in	O
both	O
probands	O
.	O

The	O
Turkish	O
patient	B-OrganismTaxon
and	O
her	O
affected	O
relatives	O
all	O
had	O
a	O
heterozygous	O
A	B-SequenceVariant
to	I-SequenceVariant
G	I-SequenceVariant
transition	I-SequenceVariant
at	I-SequenceVariant
codon	I-SequenceVariant
557	I-SequenceVariant
(	O
AAG	I-SequenceVariant
-	O
-	O
>	O
GAG	I-SequenceVariant
)	O
of	O
exon	O
10	O
of	O
MEN1	B-GeneOrGeneProduct
that	O
results	O
in	O
a	O
replacement	O
of	O
lysine	B-SequenceVariant
by	I-SequenceVariant
glutamic	I-SequenceVariant
acid	I-SequenceVariant
.	O

The	O
Chinese	O
index	O
patient	B-OrganismTaxon
and	O
one	O
of	O
her	O
siblings	O
had	O
a	O
heterozygous	O
mutation	B-SequenceVariant
at	I-SequenceVariant
codon	I-SequenceVariant
418	I-SequenceVariant
of	I-SequenceVariant
exon	I-SequenceVariant
9	I-SequenceVariant
(	O
GAC	I-SequenceVariant
-	O
-	O
>	O
TAT	I-SequenceVariant
)	O
that	O
results	O
in	O
a	O
substitution	O
of	O
aspartic	B-SequenceVariant
acid	I-SequenceVariant
by	I-SequenceVariant
tyrosine	I-SequenceVariant
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
2	O
novel	O
missense	O
mutations	O
in	O
the	O
MEN1	B-GeneOrGeneProduct
gene	O
.	O
Sex	O
-	O
differential	O
genetic	O
effect	O
of	O
phosphodiesterase	B-GeneOrGeneProduct
4D	I-GeneOrGeneProduct
(	O
PDE4D	B-GeneOrGeneProduct
)	O
on	O
carotid	B-DiseaseOrPhenotypicFeature
atherosclerosis	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
The	O
phosphodiesterase	B-GeneOrGeneProduct
4D	I-GeneOrGeneProduct
(	O
PDE4D	B-GeneOrGeneProduct
)	O
gene	O
was	O
reported	O
as	O
a	O
susceptibility	O
gene	O
to	O
stroke	B-DiseaseOrPhenotypicFeature
.	O

The	O
genetic	O
effect	O
might	O
be	O
attributed	O
to	O
its	O
role	O
in	O
modulating	O
the	O
atherogenic	B-DiseaseOrPhenotypicFeature
process	O
in	O
the	O
carotid	O
arteries	O
.	O

Using	O
carotid	O
intima	O
-	O
media	O
thickness	O
(	O
IMT	O
)	O
and	O
plaque	O
index	O
as	O
phenotypes	O
,	O
the	O
present	O
study	O
sought	O
to	O
determine	O
the	O
influence	O
of	O
this	O
gene	O
on	O
subclinical	O
atherosclerosis	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
Carotid	O
ultrasonography	O
was	O
performed	O
on	O
1013	O
stroke	B-DiseaseOrPhenotypicFeature
-	O
free	O
subjects	O
who	O
participated	O
in	O
the	O
health	O
screening	O
programs	O
(	O
age	O
52	O
.	O
6	O
+	O
/	O
-	O
12	O
.	O
2	O
;	O
47	O
.	O
6%	O
men	B-OrganismTaxon
)	O
.	O

Genotype	O
distribution	O
was	O
compared	O
among	O
the	O
high	O
-	O
risk	O
(	O
plaque	O
index	O
>	O
or	O
=	O
4	O
)	O
,	O
low	O
-	O
risk	O
(	O
index	O
=	O
1	O
-	O
3	O
)	O
,	O
and	O
reference	O
(	O
index	O
=	O
0	O
)	O
groups	O
.	O

We	O
analyzed	O
continuous	O
IMT	O
data	O
and	O
further	O
dichotomized	O
IMT	O
data	O
using	O
mean	O
plus	O
one	O
standard	O
deviation	O
as	O
the	O
cutoff	O
level	O
.	O

Because	O
the	O
plaque	O
prevalence	O
and	O
IMT	O
values	O
displayed	O
a	O
notable	O
difference	O
between	O
men	B-OrganismTaxon
and	O
women	B-OrganismTaxon
,	O
we	O
carried	O
out	O
sex	O
-	O
specific	O
analyses	O
in	O
addition	O
to	O
analyzing	O
the	O
overall	O
data	O
.	O

Rs702553	B-SequenceVariant
at	O
the	O
PDE4D	B-GeneOrGeneProduct
gene	O
was	O
selected	O
because	O
it	O
conferred	O
a	O
risk	O
for	O
young	O
stroke	B-DiseaseOrPhenotypicFeature
in	O
our	O
previous	O
report	O
.	O

Previous	O
young	O
stroke	B-DiseaseOrPhenotypicFeature
data	O
(	O
190	O
cases	O
and	O
211	O
controls	O
)	O
with	O
an	O
additional	O
532	O
control	O
subjects	O
without	O
ultrasonic	O
data	O
were	O
shown	O
as	O
a	O
cross	O
-	O
validation	O
for	O
the	O
genetic	O
effect	O
.	O

RESULTS	O
:	O
In	O
the	O
overall	O
analyses	O
,	O
the	O
rare	O
homozygote	O
of	O
rs702553	B-SequenceVariant
led	O
to	O
an	O
OR	O
of	O
3	O
.	O
1	O
(	O
p	O
=	O
0	O
.	O
034	O
)	O
for	O
a	O
plaque	O
index	O
>	O
or	O
=	O
4	O
.	O

When	O
subjects	O
were	O
stratified	O
by	O
sex	O
,	O
the	O
genetic	O
effect	O
was	O
only	O
evident	O
in	O
men	B-OrganismTaxon
but	O
not	O
in	O
women	B-OrganismTaxon
.	O

Comparing	O
male	O
subjects	O
with	O
plaque	O
index	O
>	O
or	O
=	O
4	O
and	O
those	O
with	O
plaque	O
index	O
=	O
0	O
,	O
the	O
TT	O
genotype	O
was	O
over	O
-	O
represented	O
(	O
27	O
.	O
6%	O
vs	O
.	O

13	O
.	O
4%	O
,	O
p	O
=	O
0	O
.	O
008	O
)	O
.	O

For	O
dichotomized	O
IMT	O
data	O
in	O
men	B-OrganismTaxon
,	O
the	O
TT	O
genotype	O
had	O
an	O
OR	O
of	O
2	O
.	O
1	O
(	O
p	O
=	O
0	O
.	O
032	O
)	O
for	O
a	O
thicker	O
IMT	O
at	O
the	O
common	O
carotid	O
artery	O
compared	O
with	O
the	O
(	O
AA	O
+	O
AT	O
)	O
genotypes	O
.	O

In	O
women	B-OrganismTaxon
,	O
neither	O
IMT	O
nor	O
plaque	O
index	O
was	O
associated	O
with	O
rs702553	B-SequenceVariant
.	O

Similarly	O
,	O
SNP	O
rs702553	B-SequenceVariant
was	O
only	O
significant	O
in	O
young	O
stroke	B-DiseaseOrPhenotypicFeature
men	B-OrganismTaxon
(	O
OR	O
=	O
1	O
.	O
8	O
,	O
p	O
=	O
0	O
.	O
025	O
)	O
but	O
not	O
in	O
women	B-OrganismTaxon
(	O
p	O
=	O
0	O
.	O
27	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
present	O
study	O
demonstrates	O
a	O
sex	O
-	O
differential	O
effect	O
of	O
PDE4D	B-GeneOrGeneProduct
on	O
IMT	O
,	O
plaque	O
index	O
and	O
stroke	B-DiseaseOrPhenotypicFeature
,	O
which	O
highlights	O
its	O
influence	O
on	O
various	O
aspects	O
of	O
atherogenesis	B-DiseaseOrPhenotypicFeature
.	O
Reduced	O
adiponectin	B-GeneOrGeneProduct
expression	O
after	O
high	O
-	O
fat	O
diet	O
is	O
associated	O
with	O
selective	O
up	O
-	O
regulation	O
of	O
ALDH1A1	B-GeneOrGeneProduct
and	O
further	O
retinoic	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
signaling	O
in	O
adipose	O
tissue	O
.	O

Adiponectin	B-GeneOrGeneProduct
is	O
an	O
adipocyte	O
-	O
derived	O
adipokine	B-GeneOrGeneProduct
with	O
potent	O
antidiabetic	O
,	O
anti	O
-	O
inflammatory	B-DiseaseOrPhenotypicFeature
,	O
and	O
antiatherogenic	O
activity	O
.	O

Long	O
-	O
term	O
,	O
high	O
-	O
fat	O
diet	O
results	O
in	O
gain	O
of	O
body	O
weight	O
,	O
adiposity	B-DiseaseOrPhenotypicFeature
,	O
further	O
inflammatory	B-DiseaseOrPhenotypicFeature
-	O
based	O
cardiovascular	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
,	O
and	O
reduced	O
adiponectin	B-GeneOrGeneProduct
secretion	O
.	O

Vitamin	B-ChemicalEntity
A	I-ChemicalEntity
derivatives	O
/	O
retinoids	B-ChemicalEntity
are	O
involved	O
in	O
several	O
of	O
these	O
processes	O
,	O
which	O
mainly	O
take	O
place	O
in	O
white	O
adipose	O
tissue	O
(	O
WAT	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
adiponectin	B-GeneOrGeneProduct
expression	O
as	O
a	O
function	O
of	O
dietary	O
high	O
-	O
fat	O
and	O
high	O
-	O
vitamin	B-ChemicalEntity
A	I-ChemicalEntity
conditions	O
in	O
mice	B-OrganismTaxon
.	O

A	O
decrease	O
of	O
adiponectin	B-GeneOrGeneProduct
expression	O
in	O
addition	O
to	O
an	O
up	O
-	O
regulation	O
of	O
aldehyde	B-GeneOrGeneProduct
dehydrogenase	I-GeneOrGeneProduct
A1	I-GeneOrGeneProduct
(	O
ALDH1A1	B-GeneOrGeneProduct
)	O
,	O
retinoid	O
signaling	O
,	O
and	O
retinoic	B-ChemicalEntity
acid	I-ChemicalEntity
response	O
element	O
signaling	O
was	O
selectively	O
observed	O
in	O
WAT	O
of	O
mice	B-OrganismTaxon
fed	O
a	O
normal	O
-	O
vitamin	B-ChemicalEntity
A	I-ChemicalEntity
,	O
high	O
-	O
fat	O
diet	O
.	O

Reduced	O
adiponectin	B-GeneOrGeneProduct
expression	O
in	O
WAT	O
was	O
also	O
observed	O
in	O
mice	B-OrganismTaxon
fed	O
a	O
high	O
-	O
vitamin	B-ChemicalEntity
A	I-ChemicalEntity
diet	O
.	O

Adipocyte	O
cell	O
culture	O
revealed	O
that	O
endogenous	O
and	O
synthetic	O
retinoic	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
RAR	I-GeneOrGeneProduct
)	O
a	I-GeneOrGeneProduct
-	O
and	O
RARg	B-GeneOrGeneProduct
-	O
selective	O
agonists	O
,	O
as	O
well	O
as	O
a	O
synthetic	O
retinoid	B-GeneOrGeneProduct
X	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
agonist	O
,	O
efficiently	O
reduced	O
adiponectin	B-GeneOrGeneProduct
expression	O
,	O
whereas	O
ALDH1A1	B-GeneOrGeneProduct
expression	O
only	O
increased	O
with	O
RAR	B-GeneOrGeneProduct
agonists	O
.	O

We	O
conclude	O
that	O
reduced	O
adiponectin	B-GeneOrGeneProduct
expression	O
under	O
high	O
-	O
fat	O
dietary	O
conditions	O
is	O
dependent	O
on	O
1	O
)	O
increased	O
ALDH1A1	B-GeneOrGeneProduct
expression	O
in	O
adipocytes	O
,	O
which	O
does	O
not	O
increase	O
all	O
-	O
trans	O
-	O
retinoic	B-ChemicalEntity
acid	I-ChemicalEntity
levels	O
;	O
2	O
)	O
further	O
RAR	B-GeneOrGeneProduct
ligand	O
-	O
induced	O
,	O
WAT	O
-	O
selective	O
,	O
increased	O
retinoic	B-ChemicalEntity
acid	I-ChemicalEntity
response	O
element	O
-	O
mediated	O
signaling	O
;	O
and	O
3	O
)	O
RAR	B-GeneOrGeneProduct
ligand	O
-	O
dependent	O
reduction	O
of	O
adiponectin	B-GeneOrGeneProduct
expression	O
.	O
-	O
Landrier	O
,	O
J	O
.	O
-	O
F	O
.	O
,	O
Kasiri	O
,	O
E	O
.	O
,	O
Karkeni	O
,	O
E	O
.	O
,	O
Mihaly	O
,	O
J	O
.	O
,	O
Beke	O
,	O
G	O
.	O
,	O
Weiss	O
,	O
K	O
.	O
,	O
Lucas	O
,	O
R	O
.	O
,	O
Aydemir	O
,	O
G	O
.	O
,	O
Salles	O
,	O
J	O
.	O
,	O
Walrand	O
,	O
S	O
.	O
,	O
de	O
Lera	O
,	O
A	O
.	O

R	O
.	O
,	O
Ruhl	O
,	O
R	O
.	O

Reduced	O
adiponectin	B-GeneOrGeneProduct
expression	O
after	O
high	O
-	O
fat	O
diet	O
is	O
associated	O
with	O
selective	O
up	O
-	O
regulation	O
of	O
ALDH1A1	B-GeneOrGeneProduct
and	O
further	O
retinoic	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
signaling	O
in	O
adipose	O
tissue	O
.	O
Effect	O
of	O
the	O
abrogation	O
of	O
TGF	B-GeneOrGeneProduct
-	O
beta1	I-GeneOrGeneProduct
by	O
antisense	O
oligonucleotides	B-ChemicalEntity
on	O
the	O
expression	O
of	O
TGF	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
-	O
isoforms	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
their	I-GeneOrGeneProduct
receptors	I-GeneOrGeneProduct
I	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
in	O
isolated	O
fibroblasts	O
from	O
keloid	B-DiseaseOrPhenotypicFeature
scars	I-DiseaseOrPhenotypicFeature
.	O

Disequilibrium	O
of	O
dermal	O
wound	O
repair	O
can	O
result	O
in	O
continued	O
accumulation	O
of	O
ECM	O
and	O
excessive	O
scar	O
formation	O
.	O

In	O
susceptible	O
genetically	O
predisposed	O
individuals	O
,	O
keloid	B-DiseaseOrPhenotypicFeature
formation	O
can	O
be	O
observed	O
.	O

Keloid	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
represents	O
a	O
benign	O
dermal	O
fibroproliferative	O
tumor	B-DiseaseOrPhenotypicFeature
that	O
is	O
unique	O
to	O
humans	B-OrganismTaxon
.	O

TGF	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
is	O
known	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
disease	O
which	O
is	O
still	O
not	O
fully	O
understood	O
.	O

The	O
isoforms	O
TGF	B-GeneOrGeneProduct
-	O
beta1	I-GeneOrGeneProduct
and	O
TGF	B-GeneOrGeneProduct
-	O
beta2	I-GeneOrGeneProduct
have	O
profibrotic	O
properties	O
,	O
whereas	O
TGF	B-GeneOrGeneProduct
-	O
beta3	I-GeneOrGeneProduct
may	O
have	O
antifibrotic	O
functions	O
.	O

TGF	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
exerts	O
its	O
influence	O
by	O
binding	O
to	O
type	B-GeneOrGeneProduct
I	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
type	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
TGF	I-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
receptors	I-GeneOrGeneProduct
,	O
thereby	O
forming	O
a	O
complex	O
and	O
activating	O
specific	O
downstream	O
effector	O
molecules	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
TGF	B-GeneOrGeneProduct
-	O
beta1	I-GeneOrGeneProduct
targeting	O
by	O
antisense	O
oligonucleotides	B-ChemicalEntity
on	O
the	O
RNA	O
synthesis	O
and	O
protein	O
expression	O
of	O
TGF	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
isoforms	O
and	O
their	O
receptors	O
in	O
keloid	B-DiseaseOrPhenotypicFeature
-	O
derived	O
fibroblasts	O
.	O

In	O
tissue	O
samples	O
with	O
normal	O
fibroblasts	O
(	O
NFs	O
)	O
serving	O
as	O
control	O
samples	O
,	O
expression	O
of	O
TGF	B-GeneOrGeneProduct
-	O
beta1	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
-	O
beta2	I-GeneOrGeneProduct
was	O
decreased	O
when	O
compared	O
to	O
keloid	B-DiseaseOrPhenotypicFeature
fibroblasts	O
(	O
KFs	O
)	O
,	O
while	O
expression	O
of	O
TGF	B-GeneOrGeneProduct
-	O
beta3	I-GeneOrGeneProduct
and	O
of	O
TGF	B-GeneOrGeneProduct
-	O
betaRII	I-GeneOrGeneProduct
was	O
significantly	O
higher	O
in	O
NFs	O
.	O

In	O
the	O
ELISA	O
assay	O
,	O
abrogation	O
of	O
TGF	B-GeneOrGeneProduct
-	O
beta1	I-GeneOrGeneProduct
led	O
to	O
a	O
significant	O
decrease	O
in	O
TGF	B-GeneOrGeneProduct
-	O
beta1	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
-	O
beta2	I-GeneOrGeneProduct
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Expression	O
of	O
TGF	B-GeneOrGeneProduct
-	O
beta2	I-GeneOrGeneProduct
mRNA	O
was	O
reduced	O
.	O

Expression	O
of	O
TGF	B-GeneOrGeneProduct
-	O
beta3	I-GeneOrGeneProduct
mRNA	O
revealed	O
contrary	O
patterns	O
in	O
KFs	O
from	O
different	O
patients	B-OrganismTaxon
while	O
expression	O
of	O
TGF	B-GeneOrGeneProduct
-	O
betaRI	I-GeneOrGeneProduct
was	O
found	O
to	O
be	O
equal	O
during	O
the	O
measurement	O
period	O
.	O

TGF	B-GeneOrGeneProduct
-	O
betaRII	I-GeneOrGeneProduct
mRNA	O
expression	O
was	O
increased	O
after	O
48	O
and	O
72	O
h	O
respectively	O
.	O

There	O
is	O
growing	O
evidence	O
for	O
a	O
regulatory	O
mechanism	O
between	O
TGF	B-GeneOrGeneProduct
-	O
beta1	I-GeneOrGeneProduct
and	O
its	O
receptors	O
.	O

Our	O
findings	O
support	O
this	O
theory	O
by	O
suggesting	O
interrelations	O
between	O
the	O
different	O
TGF	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
isoforms	O
and	O
their	O
receptors	O
.	O

Abnormal	O
response	O
of	O
KFs	O
to	O
TGF	O
-	O
betamight	O
reflect	O
a	O
modification	O
in	O
the	O
regulatory	O
pathway	O
that	O
occurs	O
at	O
the	O
receptor	O
level	O
or	O
during	O
intracellular	O
trans	O
-	O
duction	O
.	O

Improving	O
the	O
understanding	O
of	O
TGF	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
in	O
keloid	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
could	O
lead	O
to	O
the	O
development	O
of	O
clinically	O
useful	O
therapeutic	O
modalities	O
for	O
treatment	O
of	O
keloid	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
or	O
even	O
allow	O
identification	O
of	O
preventive	O
strategies	O
.	O
TAK1	B-GeneOrGeneProduct
is	O
an	O
essential	O
regulator	O
of	O
BMP	B-GeneOrGeneProduct
signalling	O
in	O
cartilage	O
.	O

TGFbeta	B-GeneOrGeneProduct
activated	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
TAK1	B-GeneOrGeneProduct
)	O
,	O
a	O
member	O
of	O
the	O
MAPKKK	B-GeneOrGeneProduct
family	O
,	O
controls	O
diverse	O
functions	O
ranging	O
from	O
innate	O
and	O
adaptive	O
immune	O
system	O
activation	O
to	O
vascular	O
development	O
and	O
apoptosis	O
.	O

To	O
analyse	O
the	O
in	O
vivo	O
function	O
of	O
TAK1	B-GeneOrGeneProduct
in	O
cartilage	O
,	O
we	O
generated	O
mice	B-OrganismTaxon
with	O
a	O
conditional	O
deletion	O
of	O
Tak1	B-GeneOrGeneProduct
driven	O
by	O
the	O
collagen	B-GeneOrGeneProduct
2	I-GeneOrGeneProduct
promoter	O
.	O

Tak1	B-GeneOrGeneProduct
(	O
col2	B-GeneOrGeneProduct
)	O
mice	B-OrganismTaxon
displayed	O
severe	O
chondrodysplasia	B-DiseaseOrPhenotypicFeature
with	O
runting	O
,	O
impaired	O
formation	O
of	O
secondary	O
centres	O
of	O
ossification	O
,	O
and	O
joint	B-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
including	O
elbow	B-DiseaseOrPhenotypicFeature
dislocation	I-DiseaseOrPhenotypicFeature
and	O
tarsal	B-DiseaseOrPhenotypicFeature
fusion	I-DiseaseOrPhenotypicFeature
.	O

This	O
phenotype	O
resembled	O
that	O
of	O
bone	B-GeneOrGeneProduct
morphogenetic	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
BMPR	I-GeneOrGeneProduct
)	O
1	I-GeneOrGeneProduct
and	O
Gdf5	B-GeneOrGeneProduct
-	O
deficient	O
mice	B-OrganismTaxon
.	O

BMPR	B-GeneOrGeneProduct
signalling	O
was	O
markedly	O
impaired	O
in	O
TAK1	B-GeneOrGeneProduct
-	O
deficient	O
chondrocytes	O
as	O
evidenced	O
by	O
reduced	O
expression	O
of	O
known	O
BMP	B-GeneOrGeneProduct
target	O
genes	O
as	O
well	O
as	O
reduced	O
phosphorylation	O
of	O
Smad1	B-GeneOrGeneProduct
/	O
5	I-GeneOrGeneProduct
/	O
8	I-GeneOrGeneProduct
and	O
p38	B-GeneOrGeneProduct
/	O
Jnk	B-GeneOrGeneProduct
/	O
Erk	B-GeneOrGeneProduct
MAP	B-GeneOrGeneProduct
kinases	I-GeneOrGeneProduct
.	O

TAK1	B-GeneOrGeneProduct
mediates	O
Smad1	B-GeneOrGeneProduct
phosphorylation	O
at	O
C	O
-	O
terminal	O
serine	O
residues	O
.	O

These	O
findings	O
provide	O
the	O
first	O
in	O
vivo	O
evidence	O
in	O
a	O
mammalian	O
system	O
that	O
TAK1	B-GeneOrGeneProduct
is	O
required	O
for	O
BMP	B-GeneOrGeneProduct
signalling	O
and	O
functions	O
as	O
an	O
upstream	O
activating	O
kinase	O
for	O
Smad1	B-GeneOrGeneProduct
/	O
5	I-GeneOrGeneProduct
/	O
8	I-GeneOrGeneProduct
in	O
addition	O
to	O
its	O
known	O
role	O
in	O
regulating	O
MAP	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
pathways	O
.	O

Our	O
experiments	O
reveal	O
an	O
essential	O
role	O
for	O
TAK1	B-GeneOrGeneProduct
in	O
the	O
morphogenesis	O
,	O
growth	O
,	O
and	O
maintenance	O
of	O
cartilage	O
.	O
Promoter	O
insertion	O
/	O
deletion	O
in	O
the	O
IRF5	B-GeneOrGeneProduct
gene	O
is	O
highly	O
associated	O
with	O
susceptibility	O
to	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
in	O
distinct	O
populations	O
,	O
but	O
exerts	O
a	O
modest	O
effect	O
on	O
gene	O
expression	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
.	O

OBJECTIVE	O
:	O
We	O
examined	O
the	O
genetic	O
association	O
of	O
the	O
promoter	O
insertion	O
/	O
deletion	O
(	O
indel	O
)	O
in	O
IRF5	B-GeneOrGeneProduct
gene	O
with	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
(	O
SLE	B-DiseaseOrPhenotypicFeature
)	O
in	O
distinct	O
populations	O
and	O
assessed	O
its	O
role	O
in	O
gene	O
expression	O
.	O

METHODS	O
:	O
Four	O
IRF5	B-GeneOrGeneProduct
polymorphisms	O
were	O
genotyped	O
in	O
1488	O
SLE	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
1466	O
controls	O
.	O

Gene	O
expression	O
was	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
using	O
RNA	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
.	O

RESULTS	O
:	O
The	O
promoter	O
indel	O
and	O
rs2070197	B-SequenceVariant
had	O
independent	O
genetic	O
effects	O
,	O
which	O
accounted	O
for	O
the	O
association	O
of	O
rs2004640	B-SequenceVariant
and	O
rs10954213	B-SequenceVariant
.	O

Gene	O
expression	O
analysis	O
revealed	O
that	O
rs10954213	B-SequenceVariant
exerted	O
the	O
greatest	O
influence	O
on	O
IRF5	B-GeneOrGeneProduct
transcript	O
levels	O
.	O

CONCLUSION	O
:	O
We	O
corroborated	O
the	O
association	O
of	O
the	O
promoter	O
indel	O
with	O
SLE	B-DiseaseOrPhenotypicFeature
in	O
5	O
different	O
populations	O
and	O
revealed	O
that	O
rs10954213	B-SequenceVariant
is	O
the	O
main	O
single	O
-	O
nucleotide	O
polymorphism	O
responsible	O
for	O
altered	O
IRF5	B-GeneOrGeneProduct
expression	O
in	O
PBMC	O
.	O
Tissue	O
-	O
Specific	O
Ablation	O
of	O
the	O
LIF	B-GeneOrGeneProduct
Receptor	I-GeneOrGeneProduct
in	O
the	O
Murine	B-OrganismTaxon
Uterine	O
Epithelium	O
Results	O
in	O
Implantation	O
Failure	O
.	O

The	O
cytokine	O
leukemia	B-GeneOrGeneProduct
inhibitory	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
LIF	B-GeneOrGeneProduct
)	O
is	O
essential	O
for	O
rendering	O
the	O
uterus	O
receptive	O
for	O
blastocyst	O
implantation	O
.	O

In	O
mice	B-OrganismTaxon
,	O
LIF	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
expression	O
(	O
LIFR	B-GeneOrGeneProduct
)	O
is	O
largely	O
restricted	O
to	O
the	O
uterine	O
luminal	O
epithelium	O
(	O
LE	O
)	O
.	O

LIF	B-GeneOrGeneProduct
,	O
secreted	O
from	O
the	O
endometrial	O
glands	O
(	O
GEs	O
)	O
,	O
binds	O
to	O
the	O
LIFR	B-GeneOrGeneProduct
,	O
activating	O
the	O
Janus	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
-	O
signal	B-GeneOrGeneProduct
transducer	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
activation	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
transcription	I-GeneOrGeneProduct
(	O
STAT	I-GeneOrGeneProduct
)	O
3	I-GeneOrGeneProduct
(	O
Jak	B-GeneOrGeneProduct
-	O
Stat3	B-GeneOrGeneProduct
)	O
signaling	O
pathway	O
in	O
the	O
LE	O
.	O

JAK	B-GeneOrGeneProduct
-	O
STAT	B-GeneOrGeneProduct
activation	O
converts	O
the	O
LE	O
to	O
a	O
receptive	O
state	O
so	O
that	O
juxtaposed	O
blastocysts	O
begin	O
to	O
implant	O
.	O

To	O
specifically	O
delete	O
the	O
LIFR	B-GeneOrGeneProduct
in	O
the	O
LE	O
,	O
we	O
derived	O
a	O
line	O
of	O
mice	B-OrganismTaxon
in	O
which	O
Cre	O
recombinase	O
was	O
inserted	O
into	O
the	O
endogenous	O
lactoferrin	B-GeneOrGeneProduct
gene	O
(	O
Ltf	B-GeneOrGeneProduct
-	O
Cre	O
)	O
.	O

Lactoferrin	B-GeneOrGeneProduct
expression	O
in	O
the	O
LE	O
is	O
induced	O
by	O
E2	O
,	O
and	O
we	O
demonstrate	O
that	O
Cre	O
recombinase	O
activity	O
is	O
restricted	O
to	O
the	O
LE	O
and	O
GE	O
.	O

To	O
determine	O
the	O
requirement	O
of	O
the	O
LIFR	B-GeneOrGeneProduct
in	O
implantation	O
,	O
we	O
derived	O
an	O
additional	O
mouse	B-OrganismTaxon
line	O
carrying	O
a	O
conditional	O
(	O
floxed	O
)	O
Lifr	B-GeneOrGeneProduct
flx	O
/	O
flx	O
gene	O
.	O

Crossing	O
Ltf	B-GeneOrGeneProduct
-	O
Cre	O
mice	B-OrganismTaxon
with	O
Lifr	B-GeneOrGeneProduct
flx	O
/	O
flx	O
mice	B-OrganismTaxon
generated	O
Lifr	B-GeneOrGeneProduct
flx	O
/	O
D	O
:	O
Ltf	B-GeneOrGeneProduct
Cre	O
/	O
+	O
females	O
that	O
were	O
overtly	O
normal	O
but	O
infertile	O
.	O

Many	O
of	O
these	O
females	O
,	O
despite	O
repeated	O
matings	O
,	O
did	O
not	O
become	O
pregnant	O
.	O

Unimplanted	O
blastocysts	O
were	O
recovered	O
from	O
the	O
Lifr	B-GeneOrGeneProduct
flx	O
/	O
D	O
:	O
Ltf	B-GeneOrGeneProduct
Cre	O
/	O
+	O
uteri	O
and	O
,	O
when	O
transferred	O
to	O
wild	O
-	O
type	O
recipients	O
,	O
implanted	O
normally	O
,	O
indicating	O
that	O
uterine	O
receptivity	O
rather	O
than	O
the	O
embryo	O
'	O
s	O
competency	O
is	O
compromised	O
.	O

The	O
loss	O
of	O
Lifr	B-GeneOrGeneProduct
results	O
in	O
both	O
the	O
failure	O
for	O
STAT3	B-GeneOrGeneProduct
to	O
translocate	O
to	O
the	O
LE	O
nuclei	O
and	O
a	O
reduction	O
in	O
the	O
expression	O
of	O
the	O
LIF	B-GeneOrGeneProduct
regulated	O
gene	O
Msx1	B-GeneOrGeneProduct
that	O
regulates	O
uterine	O
receptivity	O
.	O

These	O
results	O
reveal	O
that	O
uterine	O
expression	O
of	O
the	O
LIFR	B-GeneOrGeneProduct
is	O
essential	O
for	O
embryo	O
implantation	O
and	O
further	O
define	O
the	O
components	O
of	O
the	O
LIF	B-GeneOrGeneProduct
signaling	O
pathway	O
necessary	O
for	O
effective	O
implantation	O
.	O
Psoriasin	B-GeneOrGeneProduct
promotes	O
invasion	O
,	O
aggregation	O
and	O
survival	O
of	O
pancreatic	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
;	O
association	O
with	O
disease	O
progression	O
.	O

Psoriasin	B-GeneOrGeneProduct
(	O
S100A7	B-GeneOrGeneProduct
)	O
is	O
an	O
11	O
-	O
kDa	O
small	O
calcium	B-GeneOrGeneProduct
binding	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
initially	O
isolated	O
from	O
psoriatic	B-DiseaseOrPhenotypicFeature
skin	I-DiseaseOrPhenotypicFeature
lesions	I-DiseaseOrPhenotypicFeature
.	O

It	O
belongs	O
to	O
the	O
S100	B-GeneOrGeneProduct
family	O
of	O
proteins	O
which	O
play	O
an	O
important	O
role	O
in	O
a	O
range	O
of	O
cell	O
functions	O
including	O
proliferation	O
,	O
differentiation	O
,	O
migration	O
and	O
apoptosis	O
.	O

Aberrant	O
Psoriasin	B-GeneOrGeneProduct
expression	O
has	O
been	O
implicated	O
in	O
a	O
range	O
of	O
cancers	B-DiseaseOrPhenotypicFeature
and	O
is	O
often	O
associated	O
with	O
poor	O
prognosis	O
.	O

This	O
study	O
examined	O
the	O
role	O
of	O
Psoriasin	B-GeneOrGeneProduct
on	O
pancreatic	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
functions	O
and	O
the	O
implication	O
in	O
progression	O
of	O
the	O
disease	O
.	O

Expression	O
of	O
Psoriasin	B-GeneOrGeneProduct
was	O
determined	O
in	O
a	O
cohort	O
of	O
pancreatic	O
tissues	O
comprised	O
of	O
126	O
pancreatic	B-DiseaseOrPhenotypicFeature
tumours	I-DiseaseOrPhenotypicFeature
and	O
114	O
adjacent	O
non	O
-	O
tumour	O
pancreatic	O
tissues	O
.	O

Knockdown	O
and	O
overexpression	O
of	O
Psoriasin	B-GeneOrGeneProduct
in	O
pancreatic	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
was	O
performed	O
using	O
specifically	O
constructed	O
plasmids	O
,	O
which	O
either	O
had	O
anti	O
-	O
Psoriasin	B-GeneOrGeneProduct
ribozyme	O
transgene	O
or	O
the	O
full	O
length	O
human	B-OrganismTaxon
Psoriasin	B-GeneOrGeneProduct
coding	O
sequence	O
.	O

Psoriasin	B-GeneOrGeneProduct
knockdown	O
and	O
overexpression	O
was	O
verified	O
using	O
conventional	O
RT	O
-	O
PCR	O
and	O
qPCR	O
.	O

The	O
effect	O
of	O
manipulating	O
Psoriasin	B-GeneOrGeneProduct
expression	O
on	O
pancreatic	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
functions	O
was	O
assessed	O
using	O
several	O
in	O
vitro	O
cell	O
function	O
assays	O
.	O

Local	O
invasive	O
pancreatic	B-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
extended	O
beyond	O
the	O
pancreas	O
expressed	O
higher	O
levels	O
of	O
Psoriasin	B-GeneOrGeneProduct
transcripts	O
compared	O
with	O
the	O
cancers	B-DiseaseOrPhenotypicFeature
confined	O
to	O
the	O
pancreas	O
.	O

Primary	B-DiseaseOrPhenotypicFeature
tumours	I-DiseaseOrPhenotypicFeature
with	O
distant	O
metastases	B-DiseaseOrPhenotypicFeature
exhibited	O
a	O
reduced	O
expression	O
of	O
Psoriasin	B-GeneOrGeneProduct
.	O

Psoriasin	B-GeneOrGeneProduct
overexpression	O
cell	O
lines	O
exhibited	O
significantly	O
increased	O
growth	O
and	O
migration	O
compared	O
to	O
control	O
cells	O
.	O

In	O
addition	O
,	O
Psoriasin	B-GeneOrGeneProduct
overexpression	O
resulted	O
in	O
increased	O
pancreatic	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
invasion	O
which	O
was	O
associated	O
with	O
upregulation	O
of	O
matrix	B-GeneOrGeneProduct
metalloproteinase	I-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
(	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
)	O
and	O
MMP	B-GeneOrGeneProduct
-	O
9	I-GeneOrGeneProduct
.	O

Overexpression	O
of	O
Psoriasin	B-GeneOrGeneProduct
also	O
promoted	O
aggregation	O
and	O
survival	O
of	O
pancreatic	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
when	O
they	O
lost	O
anchorage	O
.	O

Taken	O
together	O
,	O
higher	O
expression	O
of	O
Psoriasin	B-GeneOrGeneProduct
was	O
associated	O
with	O
local	O
invasion	O
in	O
pancreatic	B-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
.	O

Psoriasin	B-GeneOrGeneProduct
expression	O
is	O
associated	O
with	O
pancreatic	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
growth	O
,	O
migration	O
,	O
cell	O
-	O
matrix	O
adhesion	O
,	O
and	O
invasion	O
via	O
regulation	O
of	O
MMPs	B-GeneOrGeneProduct
.	O

As	O
such	O
,	O
the	O
proposed	O
implications	O
of	O
Psoriasin	B-GeneOrGeneProduct
in	O
invasion	O
,	O
disease	O
progression	O
and	O
as	O
a	O
potential	O
therapeutic	O
target	O
warrant	O
further	O
investigation	O
.	O
Influence	O
of	O
interleukin	B-GeneOrGeneProduct
12B	I-GeneOrGeneProduct
(	O
IL12B	B-GeneOrGeneProduct
)	O
polymorphisms	O
on	O
spontaneous	O
and	O
treatment	O
-	O
induced	O
recovery	O
from	O
hepatitis	B-DiseaseOrPhenotypicFeature
C	I-DiseaseOrPhenotypicFeature
virus	I-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Interleukin	B-GeneOrGeneProduct
-	O
12	I-GeneOrGeneProduct
(	O
IL	B-GeneOrGeneProduct
-	O
12	I-GeneOrGeneProduct
)	O
governs	O
the	O
Th1	O
-	O
type	O
immune	O
response	O
,	O
affecting	O
the	O
spontaneous	O
and	O
treatment	O
-	O
induced	O
recovery	O
from	O
HCV	B-DiseaseOrPhenotypicFeature
-	O
infection	I-DiseaseOrPhenotypicFeature
.	O

We	O
investigated	O
whether	O
the	O
IL12B	B-GeneOrGeneProduct
polymorphisms	O
within	O
the	O
promoter	O
region	O
(	O
4	B-SequenceVariant
bp	I-SequenceVariant
insertion	I-SequenceVariant
/	O
deletion	I-SequenceVariant
)	O
and	O
the	O
3	O
'	O
-	O
UTR	O
(	O
1188	B-SequenceVariant
-	O
A	I-SequenceVariant
/	O
C	I-SequenceVariant
)	O
,	O
which	O
have	O
been	O
reported	O
to	O
influence	O
IL	B-GeneOrGeneProduct
-	O
12	I-GeneOrGeneProduct
synthesis	O
,	O
are	O
associated	O
with	O
the	O
outcome	O
of	O
HCV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
We	O
analyzed	O
186	O
individuals	O
with	O
spontaneous	O
HCV	B-OrganismTaxon
clearance	O
,	O
501	O
chronically	O
HCV	B-DiseaseOrPhenotypicFeature
infected	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
and	O
217	O
healthy	O
controls	O
.	O

IL12B	B-GeneOrGeneProduct
3	O
'	O
-	O
UTR	O
and	O
promoter	O
genotyping	O
was	O
performed	O
by	O
Taqman	O
-	O
based	O
assays	O
with	O
allele	O
-	O
specific	O
oligonucleotide	B-ChemicalEntity
probes	O
and	O
PCR	O
-	O
based	O
allele	O
-	O
specific	O
DNA	O
-	O
amplification	O
,	O
respectively	O
.	O

RESULTS	O
:	O
The	O
proportion	O
of	O
IL12B	B-GeneOrGeneProduct
promoter	O
and	O
3	O
'	O
-	O
UTR	O
genotypes	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
different	O
cohorts	O
.	O

However	O
,	O
HCV	B-DiseaseOrPhenotypicFeature
genotype	I-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
-	O
infected	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
high	O
baseline	O
viremia	B-DiseaseOrPhenotypicFeature
carrying	O
the	O
IL12B	B-GeneOrGeneProduct
3	O
'	O
-	O
UTR	O
1188	B-SequenceVariant
-	O
C	I-SequenceVariant
-	O
allele	O
showed	O
significantly	O
higher	O
sustained	O
virologic	O
response	O
(	O
SVR	O
)	O
rates	O
(	O
25	O
.	O
3%	O
vs	O
.	O

46%	O
vs	O
.	O

54	O
.	O
5%	O
for	O
A	O
/	O
A	O
,	O
A	O
/	O
C	O
and	O
C	O
/	O
C	O
)	O
due	O
to	O
reduced	O
relapse	O
rates	O
(	O
24	O
.	O
2%	O
vs	O
.	O

12%	O
vs	O
.	O

zero	O
%	O
for	O
A	O
/	O
A	O
,	O
A	O
/	O
C	O
and	O
C	O
/	O
C	O
)	O
.	O

CONCLUSIONS	O
:	O
IL12B	B-GeneOrGeneProduct
3	O
'	O
-	O
UTR	O
1188	B-SequenceVariant
-	O
C	I-SequenceVariant
-	O
allele	O
carriers	O
appear	O
to	O
be	O
capable	O
of	O
responding	O
more	O
efficiently	O
to	O
antiviral	O
combination	O
therapy	O
as	O
a	O
consequence	O
of	O
a	O
reduced	O
relapse	O
rate	O
.	O

No	O
association	O
of	O
IL12B	B-GeneOrGeneProduct
polymorphisms	O
and	O
self	O
-	O
limited	O
HCV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
could	O
be	O
demonstrated	O
.	O
Neurofibromin	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
NF1	B-GeneOrGeneProduct
)	O
defects	O
are	O
common	O
in	O
human	B-OrganismTaxon
ovarian	B-DiseaseOrPhenotypicFeature
serous	I-DiseaseOrPhenotypicFeature
carcinomas	I-DiseaseOrPhenotypicFeature
and	O
co	O
-	O
occur	O
with	O
TP53	B-GeneOrGeneProduct
mutations	O
.	O

Ovarian	B-DiseaseOrPhenotypicFeature
serous	I-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
(	O
OSC	B-DiseaseOrPhenotypicFeature
)	O
is	O
the	O
most	O
common	O
and	O
lethal	O
histologic	O
type	O
of	O
ovarian	B-DiseaseOrPhenotypicFeature
epithelial	I-DiseaseOrPhenotypicFeature
malignancy	I-DiseaseOrPhenotypicFeature
.	O

Mutations	O
of	O
TP53	B-GeneOrGeneProduct
and	O
dysfunction	O
of	O
the	O
Brca1	B-GeneOrGeneProduct
and	O
/	O
or	O
Brca2	B-GeneOrGeneProduct
tumor	B-DiseaseOrPhenotypicFeature
-	O
suppressor	O
proteins	O
have	O
been	O
implicated	O
in	O
the	O
molecular	O
pathogenesis	O
of	O
a	O
large	O
fraction	O
of	O
OSCs	B-DiseaseOrPhenotypicFeature
,	O
but	O
frequent	O
somatic	O
mutations	O
in	O
other	O
well	O
-	O
established	O
tumor	B-DiseaseOrPhenotypicFeature
-	O
suppressor	O
genes	O
have	O
not	O
been	O
identified	O
.	O

Using	O
a	O
genome	O
-	O
wide	O
screen	O
of	O
DNA	O
copy	O
number	O
alterations	O
in	O
36	O
primary	O
OSCs	B-DiseaseOrPhenotypicFeature
,	O
we	O
identified	O
two	O
tumors	B-DiseaseOrPhenotypicFeature
with	O
apparent	O
homozygous	O
deletions	O
of	O
the	O
NF1	B-GeneOrGeneProduct
gene	O
.	O

Subsequently	O
,	O
18	O
ovarian	B-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
-	O
derived	O
cell	O
lines	O
and	O
41	O
primary	O
OSCs	B-DiseaseOrPhenotypicFeature
were	O
evaluated	O
for	O
NF1	B-GeneOrGeneProduct
alterations	O
.	O

Markedly	O
reduced	O
or	O
absent	O
expression	O
of	O
Nf1	B-GeneOrGeneProduct
protein	O
was	O
observed	O
in	O
6	O
of	O
the	O
18	O
cell	O
lines	O
,	O
and	O
using	O
the	O
protein	O
truncation	O
test	O
and	O
sequencing	O
of	O
cDNA	O
and	O
genomic	O
DNA	O
,	O
NF1	B-GeneOrGeneProduct
mutations	O
resulting	O
in	O
deletion	O
of	O
exons	O
and	O
/	O
or	O
aberrant	O
splicing	O
of	O
NF1	B-GeneOrGeneProduct
transcripts	O
were	O
detected	O
in	O
5	O
of	O
the	O
6	O
cell	O
lines	O
with	O
loss	O
of	O
NF1	B-GeneOrGeneProduct
expression	O
.	O

Similarly	O
,	O
NF1	B-GeneOrGeneProduct
alterations	O
including	O
homozygous	O
deletions	O
and	O
splicing	O
mutations	O
were	O
identified	O
in	O
9	O
(	O
22%	O
)	O
of	O
41	O
primary	O
OSCs	B-DiseaseOrPhenotypicFeature
.	O

As	O
expected	O
,	O
tumors	B-DiseaseOrPhenotypicFeature
and	O
cell	O
lines	O
with	O
NF1	B-GeneOrGeneProduct
defects	O
lacked	O
mutations	O
in	O
KRAS	B-GeneOrGeneProduct
or	O
BRAF	B-GeneOrGeneProduct
but	O
showed	O
Ras	B-GeneOrGeneProduct
pathway	O
activation	O
based	O
on	O
immunohistochemical	O
detection	O
of	O
phosphorylated	O
MAPK	B-GeneOrGeneProduct
(	O
primary	O
tumors	B-DiseaseOrPhenotypicFeature
)	O
or	O
increased	O
levels	O
of	O
GTP	B-ChemicalEntity
-	O
bound	O
Ras	B-GeneOrGeneProduct
(	O
cell	O
lines	O
)	O
.	O

The	O
TP53	B-GeneOrGeneProduct
tumor	B-DiseaseOrPhenotypicFeature
-	O
suppressor	O
gene	O
was	O
mutated	O
in	O
all	O
OSCs	B-DiseaseOrPhenotypicFeature
with	O
documented	O
NF1	B-GeneOrGeneProduct
mutation	O
,	O
suggesting	O
that	O
the	O
pathways	O
regulated	O
by	O
these	O
two	O
tumor	B-DiseaseOrPhenotypicFeature
-	O
suppressor	O
proteins	O
often	O
cooperate	O
in	O
the	O
development	O
of	O
ovarian	B-DiseaseOrPhenotypicFeature
carcinomas	I-DiseaseOrPhenotypicFeature
with	O
serous	O
differentiation	O
.	O
Drug	O
-	O
induced	O
long	B-DiseaseOrPhenotypicFeature
QT	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
in	O
injection	O
drug	O
users	O
receiving	O
methadone	B-ChemicalEntity
:	O
high	O
frequency	O
in	O
hospitalized	O
patients	B-OrganismTaxon
and	O
risk	O
factors	O
.	O

BACKGROUND	O
:	O
Drug	O
-	O
induced	O
long	B-DiseaseOrPhenotypicFeature
QT	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
is	O
a	O
serious	O
adverse	O
drug	O
reaction	O
.	O

Methadone	B-ChemicalEntity
prolongs	O
the	O
QT	O
interval	O
in	O
vitro	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
the	O
inpatient	B-OrganismTaxon
setting	O
,	O
the	O
frequency	O
of	O
QT	B-DiseaseOrPhenotypicFeature
interval	I-DiseaseOrPhenotypicFeature
prolongation	I-DiseaseOrPhenotypicFeature
with	O
methadone	B-ChemicalEntity
treatment	O
,	O
its	O
dose	O
dependence	O
,	O
and	O
the	O
importance	O
of	O
cofactors	O
such	O
as	O
drug	O
-	O
drug	O
interactions	O
remain	O
unknown	O
.	O

METHODS	O
:	O
We	O
performed	O
a	O
systematic	O
,	O
retrospective	O
study	O
comparing	O
active	O
or	O
former	O
intravenous	O
drug	O
users	O
receiving	O
methadone	B-ChemicalEntity
and	O
those	O
not	O
receiving	O
methadone	B-ChemicalEntity
among	O
all	O
patients	B-OrganismTaxon
hospitalized	O
over	O
a	O
5	O
-	O
year	O
period	O
in	O
a	O
tertiary	O
care	O
hospital	O
.	O

A	O
total	O
of	O
167	O
patients	B-OrganismTaxon
receiving	O
methadone	B-ChemicalEntity
fulfilled	O
the	O
inclusion	O
criteria	O
and	O
were	O
compared	O
with	O
a	O
control	O
group	O
of	O
80	O
injection	O
drug	O
users	O
not	O
receiving	O
methadone	B-ChemicalEntity
.	O

In	O
addition	O
to	O
methadone	B-ChemicalEntity
dose	O
,	O
15	O
demographic	O
,	O
biological	O
,	O
and	O
pharmacological	O
variables	O
were	O
considered	O
as	O
potential	O
risk	O
factors	O
for	O
QT	B-DiseaseOrPhenotypicFeature
prolongation	I-DiseaseOrPhenotypicFeature
.	O

RESULTS	O
:	O
Among	O
167	O
methadone	B-ChemicalEntity
maintenance	O
patients	B-OrganismTaxon
,	O
the	O
prevalence	O
of	O
QTc	B-DiseaseOrPhenotypicFeature
prolongation	I-DiseaseOrPhenotypicFeature
to	O
0	O
.	O
50	O
second	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
or	O
longer	O
was	O
16	O
.	O
2%	O
compared	O
with	O
0%	O
in	O
80	O
control	O
subjects	O
.	O

Six	O
patients	B-OrganismTaxon
(	O
3	O
.	O
6%	O
)	O
in	O
the	O
methadone	B-ChemicalEntity
group	O
presented	O
torsades	B-DiseaseOrPhenotypicFeature
de	I-DiseaseOrPhenotypicFeature
pointes	I-DiseaseOrPhenotypicFeature
.	O

QTc	O
length	O
was	O
weakly	O
but	O
significantly	O
associated	O
with	O
methadone	B-ChemicalEntity
daily	O
dose	O
(	O
Spearman	O
rank	O
correlation	O
coefficient	O
,	O
0	O
.	O
20	O
;	O
P	O
<	O
.	O
01	O
)	O
.	O

Multivariate	O
regression	O
analysis	O
allowed	O
attribution	O
of	O
31	O
.	O
8%	O
of	O
QTc	O
variability	O
to	O
methadone	B-ChemicalEntity
dose	O
,	O
cytochrome	B-GeneOrGeneProduct
P	I-GeneOrGeneProduct
-	O
450	I-GeneOrGeneProduct
3A4	I-GeneOrGeneProduct
drug	O
-	O
drug	O
interactions	O
,	O
hypokalemia	B-DiseaseOrPhenotypicFeature
,	O
and	O
altered	O
liver	O
function	O
.	O

CONCLUSIONS	O
:	O
QT	B-DiseaseOrPhenotypicFeature
interval	I-DiseaseOrPhenotypicFeature
prolongation	I-DiseaseOrPhenotypicFeature
in	O
methadone	B-ChemicalEntity
maintenance	O
patients	B-OrganismTaxon
hospitalized	O
in	O
a	O
tertiary	O
care	O
center	O
is	O
a	O
frequent	O
finding	O
.	O

Methadone	B-ChemicalEntity
dose	O
,	O
presence	O
of	O
cytochrome	B-ChemicalEntity
P	I-ChemicalEntity
-	O
450	I-ChemicalEntity
3A4	I-ChemicalEntity
inhibitors	I-ChemicalEntity
,	O
potassium	B-ChemicalEntity
level	O
,	O
and	O
liver	O
function	O
contribute	O
to	O
QT	B-DiseaseOrPhenotypicFeature
prolongation	I-DiseaseOrPhenotypicFeature
.	O

Long	B-DiseaseOrPhenotypicFeature
QT	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
can	O
occur	O
with	O
low	O
doses	O
of	O
methadone	B-ChemicalEntity
.	O
Upregulation	O
of	O
centrosomal	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
55	I-GeneOrGeneProduct
is	O
associated	O
with	O
unfavorable	O
prognosis	O
and	O
tumor	B-DiseaseOrPhenotypicFeature
invasion	O
in	O
epithelial	B-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
.	O

Centrosomal	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
55	I-GeneOrGeneProduct
(	O
CEP55	B-GeneOrGeneProduct
)	O
is	O
a	O
cell	O
cycle	O
regulator	O
implicated	O
in	O
development	O
of	O
certain	O
cancers	B-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
characteristics	O
of	O
CEP55	B-GeneOrGeneProduct
expression	O
and	O
its	O
clinical	O
/	O
prognostic	O
significance	O
are	O
unclear	O
in	O
human	B-OrganismTaxon
epithelial	B-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
(	O
EOC	B-DiseaseOrPhenotypicFeature
)	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
expression	O
and	O
clinicopathological	O
significance	O
of	O
CEP55	B-GeneOrGeneProduct
in	O
patients	B-OrganismTaxon
with	O
EOC	B-DiseaseOrPhenotypicFeature
and	O
its	O
role	O
in	O
regulating	O
invasion	O
and	O
metastasis	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
cell	O
lines	O
.	O

CEP55	B-GeneOrGeneProduct
mRNA	O
and	O
protein	O
expression	O
levels	O
were	O
detected	O
by	O
quantitative	O
real	O
-	O
time	O
PCR	O
(	O
qRT	O
-	O
PCR	O
)	O
,	O
Western	O
blotting	O
,	O
and	O
immunohistochemistry	O
(	O
IHC	O
)	O
.	O

Potential	O
associations	O
of	O
CEP55	B-GeneOrGeneProduct
expression	O
scores	O
with	O
clinical	O
parameters	O
and	O
patient	B-OrganismTaxon
survival	O
were	O
evaluated	O
.	O

CEP55	B-GeneOrGeneProduct
function	O
was	O
investigated	O
further	O
using	O
RNA	O
interference	O
,	O
wound	O
healing	O
assay	O
,	O
transwell	O
assay	O
,	O
immunofluorescence	O
analysis	O
,	O
qRT	O
-	O
PCR	O
,	O
and	O
Western	O
blotting	O
.	O

CEP55	B-GeneOrGeneProduct
was	O
significantly	O
upregulated	O
in	O
ovarian	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
lines	O
and	O
lesions	O
compared	O
with	O
normal	O
cells	O
and	O
adjacent	O
noncancerous	O
ovarian	O
tissues	O
.	O

In	O
the	O
213	O
EOC	B-DiseaseOrPhenotypicFeature
samples	O
,	O
CEP55	B-GeneOrGeneProduct
protein	O
levels	O
were	O
positively	O
correlated	O
with	O
clinical	O
stage	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
lymph	B-DiseaseOrPhenotypicFeature
node	I-DiseaseOrPhenotypicFeature
metastasis	I-DiseaseOrPhenotypicFeature
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
intraperitoneal	B-DiseaseOrPhenotypicFeature
metastasis	I-DiseaseOrPhenotypicFeature
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
tumor	B-DiseaseOrPhenotypicFeature
recurrence	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
differentiation	O
grade	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
residual	O
tumor	B-DiseaseOrPhenotypicFeature
size	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
ascites	B-DiseaseOrPhenotypicFeature
see	O
tumor	B-DiseaseOrPhenotypicFeature
cells	O
(	O
P	O
=	O
0	O
.	O
020	O
)	O
,	O
and	O
serum	O
CA153	B-GeneOrGeneProduct
level	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Moreover	O
,	O
patients	B-OrganismTaxon
with	O
aberrant	O
CEP55	B-GeneOrGeneProduct
protein	O
expression	O
showed	O
tendencies	O
to	O
receive	O
neoadjuvant	O
chemotherapy	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
cytoreductive	O
surgery	O
(	O
P	O
=	O
0	O
.	O
020	O
)	O
.	O

By	O
contrast	O
,	O
no	O
significant	O
correlation	O
was	O
detected	O
between	O
the	O
protein	O
levels	O
and	O
patient	B-OrganismTaxon
age	O
,	O
histological	O
type	O
,	O
or	O
serum	O
CA125	B-GeneOrGeneProduct
,	O
CA199	B-GeneOrGeneProduct
,	O
CA724	B-GeneOrGeneProduct
,	O
NSE	B-GeneOrGeneProduct
,	O
CEA	B-GeneOrGeneProduct
,	O
and	O
b	B-GeneOrGeneProduct
-	O
HCG	I-GeneOrGeneProduct
levels	O
.	O

Patients	B-OrganismTaxon
with	O
high	O
CEP55	B-GeneOrGeneProduct
protein	O
expression	O
had	O
shorter	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
compared	O
with	O
those	O
with	O
low	O
CEP55	B-GeneOrGeneProduct
expression	O
.	O

Multivariate	O
analysis	O
implicated	O
CEP55	B-GeneOrGeneProduct
as	O
an	O
independent	O
prognostic	O
indicator	O
for	O
EOC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

Additionally	O
,	O
downregulation	O
of	O
CEP55	B-GeneOrGeneProduct
in	O
ovarian	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
remarkably	O
inhibited	O
cellular	O
motility	O
and	O
invasion	O
.	O

Aberrant	O
CEP55	B-GeneOrGeneProduct
expression	O
may	O
predict	O
unfavorable	O
clinical	O
outcomes	O
in	O
EOC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
play	O
an	O
important	O
role	O
in	O
regulating	O
invasion	O
in	O
ovarian	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
.	O

Thus	O
,	O
CEP55	B-GeneOrGeneProduct
may	O
serve	O
as	O
a	O
prognostic	O
marker	O
and	O
therapeutic	O
target	O
for	O
EOC	B-DiseaseOrPhenotypicFeature
.	O
Identification	O
of	O
novel	O
susceptibility	O
genes	O
in	O
childhood	O
-	O
onset	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
using	O
a	O
uniquely	O
designed	O
candidate	O
gene	O
pathway	O
platform	O
.	O

OBJECTIVE	O
:	O
Childhood	O
-	O
onset	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
(	O
SLE	B-DiseaseOrPhenotypicFeature
)	O
presents	O
a	O
unique	O
subgroup	O
of	O
patients	B-OrganismTaxon
for	O
genetic	O
study	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
identify	O
susceptibility	O
genes	O
contributing	O
to	O
SLE	B-DiseaseOrPhenotypicFeature
,	O
using	O
a	O
novel	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
to	O
investigate	O
gene	O
expression	O
in	O
patients	B-OrganismTaxon
with	O
childhood	O
-	O
onset	O
SLE	B-DiseaseOrPhenotypicFeature
and	O
both	O
of	O
their	O
parents	O
.	O

METHODS	O
:	O
Utilizing	O
bioinformatic	O
tools	O
,	O
a	O
platform	O
of	O
9	O
,	O
412	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
from	O
1	O
,	O
204	O
genes	O
was	O
designed	O
and	O
validated	O
.	O

Molecular	O
inversion	O
probes	O
and	O
high	O
-	O
throughput	O
SNP	O
technologies	O
were	O
used	O
for	O
assay	O
development	O
.	O

Seven	O
hundred	O
fifty	O
three	O
subjects	O
,	O
corresponding	O
to	O
251	O
full	O
trios	O
of	O
childhood	O
-	O
onset	O
SLE	B-DiseaseOrPhenotypicFeature
families	O
,	O
were	O
genotyped	O
and	O
analyzed	O
using	O
transmission	O
disequilibrium	O
testing	O
(	O
TDT	O
)	O
and	O
multitest	O
corrections	O
.	O

RESULTS	O
:	O
Family	O
-	O
based	O
TDT	O
showed	O
a	O
significant	O
association	O
of	O
SLE	B-DiseaseOrPhenotypicFeature
with	O
a	O
N673S	B-SequenceVariant
polymorphism	O
in	O
the	O
P	B-GeneOrGeneProduct
-	O
selectin	I-GeneOrGeneProduct
gene	O
(	O
SELP	B-GeneOrGeneProduct
)	O
(	O
P	O
=	O
5	O
.	O
74	O
x	O
10	O
(	O
-	O
6	O
)	O
)	O
and	O
a	O
C203S	B-SequenceVariant
polymorphism	O
in	O
the	O
interleukin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
associated	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
gene	O
(	O
IRAK1	B-GeneOrGeneProduct
)	O
(	O
P	O
=	O
9	O
.	O
58	O
x	O
10	O
(	O
-	O
6	O
)	O
)	O
.	O

These	O
2	O
SNPs	O
had	O
a	O
false	O
discovery	O
rate	O
for	O
multitest	O
correction	O
of	O
<	O
0	O
.	O
05	O
,	O
and	O
therefore	O
a	O
>	O
95%	O
probability	O
of	O
being	O
considered	O
as	O
proven	O
.	O

Furthermore	O
,	O
7	O
additional	O
SNPs	O
showed	O
q	O
values	O
of	O
<	O
0	O
.	O
5	O
,	O
suggesting	O
association	O
with	O
SLE	B-DiseaseOrPhenotypicFeature
and	O
providing	O
a	O
direction	O
for	O
followup	O
studies	O
.	O

These	O
additional	O
genes	O
notably	O
included	O
TNFRSF6	B-GeneOrGeneProduct
(	O
Fas	B-GeneOrGeneProduct
)	O
and	O
IRF5	B-GeneOrGeneProduct
,	O
supporting	O
previous	O
findings	O
of	O
their	O
association	O
with	O
SLE	B-DiseaseOrPhenotypicFeature
pathogenesis	O
.	O

CONCLUSION	O
:	O
SELP	B-GeneOrGeneProduct
and	O
IRAK1	B-GeneOrGeneProduct
were	O
identified	O
as	O
novel	O
SLE	B-DiseaseOrPhenotypicFeature
-	O
associated	O
genes	O
with	O
a	O
high	O
degree	O
of	O
significance	O
,	O
suggesting	O
new	O
directions	O
in	O
understanding	O
the	O
pathogenesis	O
of	O
SLE	B-DiseaseOrPhenotypicFeature
.	O

The	O
overall	O
design	O
and	O
results	O
of	O
this	O
study	O
demonstrate	O
that	O
the	O
candidate	O
gene	O
pathway	O
microarray	O
platform	O
used	O
provides	O
a	O
novel	O
and	O
powerful	O
approach	O
that	O
is	O
generally	O
applicable	O
in	O
identifying	O
genetic	O
foundations	O
of	O
complex	O
diseases	O
.	O
A	O
novel	O
compound	O
,	O
maltolyl	B-ChemicalEntity
p	I-ChemicalEntity
-	O
coumarate	I-ChemicalEntity
,	O
attenuates	O
cognitive	B-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
and	O
shows	O
neuroprotective	O
effects	O
in	O
vitro	O
and	O
in	O
vivo	O
dementia	B-DiseaseOrPhenotypicFeature
models	O
.	O

To	O
develop	O
a	O
novel	O
and	O
effective	O
drug	O
that	O
could	O
enhance	O
cognitive	O
function	O
and	O
neuroprotection	O
,	O
we	O
newly	O
synthesized	O
maltolyl	B-ChemicalEntity
p	I-ChemicalEntity
-	O
coumarate	I-ChemicalEntity
by	O
the	O
esterification	O
of	O
maltol	B-ChemicalEntity
and	O
p	B-ChemicalEntity
-	O
coumaric	I-ChemicalEntity
acid	I-ChemicalEntity
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
maltolyl	B-ChemicalEntity
p	I-ChemicalEntity
-	O
coumarate	I-ChemicalEntity
could	O
improve	O
cognitive	B-DiseaseOrPhenotypicFeature
decline	I-DiseaseOrPhenotypicFeature
in	O
scopolamine	B-ChemicalEntity
-	O
injected	O
rats	B-OrganismTaxon
and	O
in	O
amyloid	B-ChemicalEntity
beta	I-ChemicalEntity
peptide	I-ChemicalEntity
(	O
1	I-ChemicalEntity
-	O
42	I-ChemicalEntity
)	O
-	O
infused	O
rats	B-OrganismTaxon
.	O

Maltolyl	B-ChemicalEntity
p	I-ChemicalEntity
-	O
coumarate	I-ChemicalEntity
was	O
found	O
to	O
attenuate	O
cognitive	B-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
in	O
both	O
rat	B-OrganismTaxon
models	O
using	O
passive	O
avoidance	O
test	O
and	O
to	O
reduce	O
apoptotic	O
cell	O
death	O
observed	O
in	O
the	O
hippocampus	O
of	O
the	O
amyloid	B-ChemicalEntity
beta	I-ChemicalEntity
peptide	I-ChemicalEntity
(	O
1	I-ChemicalEntity
-	O
42	I-ChemicalEntity
)	O
-	O
infused	O
rats	B-OrganismTaxon
.	O

We	O
also	O
examined	O
the	O
neuroprotective	O
effects	O
of	O
maltolyl	B-ChemicalEntity
p	I-ChemicalEntity
-	O
coumarate	I-ChemicalEntity
in	O
vitro	O
using	O
SH	B-CellLine
-	O
SY5Y	I-CellLine
cells	O
.	O

Cells	O
were	O
pretreated	O
with	O
maltolyl	B-ChemicalEntity
p	I-ChemicalEntity
-	O
coumarate	I-ChemicalEntity
,	O
before	O
exposed	O
to	O
amyloid	B-ChemicalEntity
beta	I-ChemicalEntity
peptide	I-ChemicalEntity
(	O
1	I-ChemicalEntity
-	O
42	I-ChemicalEntity
)	O
,	O
glutamate	B-ChemicalEntity
or	O
H2O2	B-ChemicalEntity
.	O

We	O
found	O
that	O
maltolyl	B-ChemicalEntity
p	I-ChemicalEntity
-	O
coumarate	I-ChemicalEntity
significantly	O
decreased	O
apoptotic	O
cell	O
death	O
and	O
reduced	O
reactive	B-ChemicalEntity
oxygen	I-ChemicalEntity
species	I-ChemicalEntity
,	O
cytochrome	B-ChemicalEntity
c	I-ChemicalEntity
release	O
,	O
and	O
caspase	B-GeneOrGeneProduct
3	I-GeneOrGeneProduct
activation	O
.	O

Taking	O
these	O
in	O
vitro	O
and	O
in	O
vivo	O
results	O
together	O
,	O
our	O
study	O
suggests	O
that	O
maltolyl	B-ChemicalEntity
p	I-ChemicalEntity
-	O
coumarate	I-ChemicalEntity
is	O
a	O
potentially	O
effective	O
candidate	O
against	O
Alzheimer	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
that	O
is	O
characterized	O
by	O
wide	O
spread	O
neuronal	B-DiseaseOrPhenotypicFeature
death	I-DiseaseOrPhenotypicFeature
and	O
progressive	O
decline	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
cognitive	I-DiseaseOrPhenotypicFeature
function	I-DiseaseOrPhenotypicFeature
.	O
Anticipation	O
in	O
familial	O
lattice	B-DiseaseOrPhenotypicFeature
corneal	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
I	I-DiseaseOrPhenotypicFeature
with	O
R124C	B-SequenceVariant
mutation	O
in	O
the	O
TGFBI	B-GeneOrGeneProduct
(	O
BIGH3	B-GeneOrGeneProduct
)	O
gene	O
.	O

PURPOSE	O
:	O
To	O
report	O
the	O
clinical	O
,	O
ophthalmic	O
,	O
and	O
genetic	O
characteristics	O
for	O
lattice	B-DiseaseOrPhenotypicFeature
corneal	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
I	I-DiseaseOrPhenotypicFeature
(	O
LCDI	B-DiseaseOrPhenotypicFeature
)	O
in	O
a	O
Chilean	O
family	O
.	O

METHODS	O
:	O
Six	O
affected	O
family	O
members	O
were	O
examined	O
clinically	O
including	O
visual	O
acuity	O
,	O
color	O
cornea	O
photography	O
,	O
applanation	O
tonography	O
,	O
and	O
fundoscopy	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
leukocytes	O
from	O
six	O
affected	O
and	O
three	O
unaffected	O
members	O
of	O
a	O
family	O
with	O
lattice	B-DiseaseOrPhenotypicFeature
corneal	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
I	I-DiseaseOrPhenotypicFeature
.	O

Exon	O
4	O
of	O
the	O
transforming	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
induced	I-GeneOrGeneProduct
gene	I-GeneOrGeneProduct
(	O
TGFBI	B-GeneOrGeneProduct
)	O
was	O
screened	O
for	O
the	O
most	O
frequent	O
mutation	O
,	O
R124C	B-SequenceVariant
,	O
in	O
the	O
proband	O
by	O
sequencing	O
.	O

We	O
also	O
designed	O
a	O
rapid	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
method	O
to	O
analyze	O
the	O
same	O
mutation	O
,	O
amplifying	O
exon	O
4	O
and	O
digesting	O
with	O
PstI	B-GeneOrGeneProduct
restriction	O
enzyme	O
.	O

Using	O
this	O
strategy	O
,	O
we	O
analyzed	O
the	O
mutation	O
in	O
six	O
affected	O
and	O
three	O
healthy	O
family	O
members	O
.	O

RESULTS	O
:	O
Three	O
generations	O
of	O
family	O
members	O
were	O
positively	O
diagnosed	O
with	O
lattice	B-DiseaseOrPhenotypicFeature
corneal	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
.	O

Six	O
participants	O
demonstrated	O
LCD1	B-DiseaseOrPhenotypicFeature
in	O
both	O
eyes	O
,	O
most	O
of	O
whom	O
were	O
symmetric	O
.	O

Age	O
at	O
onset	O
of	O
symptoms	O
was	O
variable	O
(	O
3	O
-	O
42	O
years	O
old	O
)	O
.	O

Moreover	O
,	O
in	O
this	O
family	O
,	O
the	O
age	O
of	O
onset	O
of	O
the	O
disease	O
decreased	O
in	O
succeeding	O
generations	O
,	O
which	O
could	O
be	O
interpreted	O
as	O
anticipation	O
.	O

Visual	O
acuity	O
varied	O
from	O
1	O
.	O
0	O
to	O
0	O
.	O
13	O
.	O

Two	O
patients	B-OrganismTaxon
,	O
ages	O
69	O
and	O
44	O
years	O
old	O
,	O
demonstrated	O
a	O
degree	O
of	O
severity	O
""""	O
Bad	O
""""	O
according	O
to	O
best	O
-	O
corrected	O
vision	O
and	O
corneal	O
commitment	O
.	O

The	O
exon	O
4	O
sequence	O
of	O
TGFBI	B-GeneOrGeneProduct
of	O
the	O
proband	O
exhibits	O
the	O
heterozygous	O
single	O
-	O
nucleotide	O
mutation	O
,	O
C417T	B-SequenceVariant
,	O
leading	O
to	O
amino	O
acid	O
substitution	O
(	O
R124C	B-SequenceVariant
)	O
in	O
the	O
encoded	O
TGF	B-GeneOrGeneProduct
-	O
induced	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
.	O

Using	O
PCR	O
-	O
RFLP	O
,	O
we	O
confirmed	O
the	O
heterozygous	O
mutation	O
in	O
six	O
affected	O
family	O
members	O
and	O
excluded	O
it	O
in	O
three	O
healthy	O
members	O
.	O

CONCLUSIONS	O
:	O
The	O
R124C	B-SequenceVariant
mutation	O
in	O
TGFBI	B-GeneOrGeneProduct
cosegregated	O
with	O
LCD	B-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
I	I-DiseaseOrPhenotypicFeature
in	O
the	O
investigated	O
family	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
molecular	O
analysis	O
of	O
LCD	B-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
I	I-DiseaseOrPhenotypicFeature
in	O
Chilean	O
patients	B-OrganismTaxon
.	O

The	O
early	O
onset	O
affected	O
persons	O
in	O
the	O
fourth	O
generation	O
raises	O
the	O
possibility	O
of	O
anticipation	O
.	O
A	O
cross	O
-	O
sectional	O
evaluation	O
of	O
the	O
effect	O
of	O
risperidone	B-ChemicalEntity
and	O
selective	B-ChemicalEntity
serotonin	I-ChemicalEntity
reuptake	I-ChemicalEntity
inhibitors	I-ChemicalEntity
on	O
bone	O
mineral	O
density	O
in	O
boys	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
risperidone	B-ChemicalEntity
-	O
induced	O
hyperprolactinemia	B-DiseaseOrPhenotypicFeature
on	O
trabecular	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
in	O
children	O
and	O
adolescents	O
.	O

METHOD	O
:	O
Medically	O
healthy	O
7	O
-	O
to	O
17	O
-	O
year	O
-	O
old	O
males	O
chronically	O
treated	O
,	O
in	O
a	O
naturalistic	O
setting	O
,	O
with	O
risperidone	B-ChemicalEntity
were	O
recruited	O
for	O
this	O
cross	O
-	O
sectional	O
study	O
through	O
child	O
psychiatry	O
outpatient	B-OrganismTaxon
clinics	O
between	O
November	O
2005	O
and	O
June	O
2007	O
.	O

Anthropometric	O
measurements	O
and	O
laboratory	O
testing	O
were	O
conducted	O
.	O

The	O
clinical	O
diagnoses	O
were	O
based	O
on	O
chart	O
review	O
,	O
and	O
developmental	O
and	O
treatment	O
history	O
was	O
obtained	O
from	O
the	O
medical	O
record	O
.	O

Volumetric	O
BMD	O
of	O
the	O
ultradistal	O
radius	O
was	O
measured	O
using	O
peripheral	O
quantitative	O
computed	O
tomography	O
,	O
and	O
areal	O
BMD	O
of	O
the	O
lumbar	O
spine	O
was	O
estimated	O
using	O
dual	O
-	O
energy	O
x	O
-	O
ray	O
absorptiometry	O
.	O

RESULTS	O
:	O
Hyperprolactinemia	B-DiseaseOrPhenotypicFeature
was	O
present	O
in	O
49%	O
of	O
83	O
boys	O
(	O
n	O
=	O
41	O
)	O
treated	O
with	O
risperidone	B-ChemicalEntity
for	O
a	O
mean	O
of	O
2	O
.	O
9	O
years	O
.	O

Serum	O
testosterone	B-ChemicalEntity
concentration	O
increased	O
with	O
pubertal	O
status	O
but	O
was	O
not	O
affected	O
by	O
hyperprolactinemia	B-DiseaseOrPhenotypicFeature
.	O

As	O
expected	O
,	O
bone	O
mineral	O
content	O
and	O
BMD	O
increased	O
with	O
sexual	O
maturity	O
.	O

After	O
adjusting	O
for	O
the	O
stage	O
of	O
sexual	O
development	O
and	O
height	O
and	O
BMI	O
z	O
scores	O
,	O
serum	O
prolactin	B-GeneOrGeneProduct
was	O
negatively	O
associated	O
with	O
trabecular	O
volumetric	O
BMD	O
at	O
the	O
ultradistal	O
radius	O
(	O
P	O
<	O
.	O
03	O
)	O
.	O

Controlling	O
for	O
relevant	O
covariates	O
,	O
we	O
also	O
found	O
treatment	O
with	O
selective	B-ChemicalEntity
serotonin	I-ChemicalEntity
reuptake	I-ChemicalEntity
inhibitors	I-ChemicalEntity
(	O
SSRIs	B-ChemicalEntity
)	O
to	O
be	O
associated	O
with	O
lower	O
trabecular	O
BMD	O
at	O
the	O
radius	O
(	O
P	O
=	O
.	O
03	O
)	O
and	O
BMD	O
z	O
score	O
at	O
the	O
lumbar	O
spine	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

These	O
findings	O
became	O
more	O
marked	O
when	O
the	O
analysis	O
was	O
restricted	O
to	O
non	O
-	O
Hispanic	O
white	O
patients	B-OrganismTaxon
.	O

Of	O
13	O
documented	O
fractures	B-DiseaseOrPhenotypicFeature
,	O
3	O
occurred	O
after	O
risperidone	B-ChemicalEntity
and	O
SSRIs	B-ChemicalEntity
were	O
started	O
,	O
and	O
none	O
occurred	O
in	O
patients	B-OrganismTaxon
with	O
hyperprolactinemia	B-DiseaseOrPhenotypicFeature
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
study	O
to	O
link	O
risperidone	B-ChemicalEntity
-	O
induced	O
hyperprolactinemia	B-DiseaseOrPhenotypicFeature
and	O
SSRI	B-ChemicalEntity
treatment	O
to	O
lower	O
BMD	O
in	O
children	O
and	O
adolescents	O
.	O

Future	O
research	O
should	O
evaluate	O
the	O
longitudinal	O
course	O
of	O
this	O
adverse	O
event	O
to	O
determine	O
its	O
temporal	O
stability	O
and	O
whether	O
a	O
higher	O
fracture	B-DiseaseOrPhenotypicFeature
rate	O
ensues	O
.	O
Behavioral	O
and	O
neurochemical	O
studies	O
in	O
mice	B-OrganismTaxon
pretreated	O
with	O
garcinielliptone	B-ChemicalEntity
FC	I-ChemicalEntity
in	O
pilocarpine	B-ChemicalEntity
-	O
induced	O
seizures	B-DiseaseOrPhenotypicFeature
.	O

Garcinielliptone	B-ChemicalEntity
FC	I-ChemicalEntity
(	O
GFC	B-ChemicalEntity
)	O
isolated	O
from	O
hexanic	O
fraction	O
seed	O
extract	O
of	O
species	O
Platonia	B-OrganismTaxon
insignis	I-OrganismTaxon
Mart	I-OrganismTaxon
.	O

It	O
is	O
widely	O
used	O
in	O
folk	O
medicine	O
to	O
treat	O
skin	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
in	O
both	O
humans	B-OrganismTaxon
and	O
animals	O
as	O
well	O
as	O
the	O
seed	O
decoction	O
has	O
been	O
used	O
to	O
treat	O
diarrheas	B-DiseaseOrPhenotypicFeature
and	O
inflammatory	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
there	O
is	O
no	O
research	O
on	O
GFC	B-ChemicalEntity
effects	O
in	O
the	O
central	O
nervous	O
system	O
of	O
rodents	O
.	O

The	O
present	O
study	O
aimed	O
to	O
evaluate	O
the	O
GFC	B-ChemicalEntity
effects	O
at	O
doses	O
of	O
25	O
,	O
50	O
or	O
75	O
mg	O
/	O
kg	O
on	O
seizure	B-DiseaseOrPhenotypicFeature
parameters	O
to	O
determine	O
their	O
anticonvulsant	O
activity	O
and	O
its	O
effects	O
on	O
amino	O
acid	O
(	O
r	B-ChemicalEntity
-	O
aminobutyric	I-ChemicalEntity
acid	I-ChemicalEntity
(	O
GABA	B-ChemicalEntity
)	O
,	O
glutamine	B-ChemicalEntity
,	O
aspartate	B-ChemicalEntity
and	O
glutathione	B-ChemicalEntity
)	O
levels	O
as	O
well	O
as	O
on	O
acetylcholinesterase	B-GeneOrGeneProduct
(	O
AChE	B-GeneOrGeneProduct
)	O
activity	O
in	O
mice	B-OrganismTaxon
hippocampus	O
after	O
seizures	B-DiseaseOrPhenotypicFeature
.	O

GFC	B-ChemicalEntity
produced	O
an	O
increased	O
latency	O
to	O
first	O
seizure	B-DiseaseOrPhenotypicFeature
,	O
at	O
doses	O
25mg	O
/	O
kg	O
(	O
20	O
.	O
12	O
+	O
2	O
.	O
20	O
min	O
)	O
,	O
50mg	O
/	O
kg	O
(	O
20	O
.	O
95	O
+	O
2	O
.	O
21	O
min	O
)	O
or	O
75	O
mg	O
/	O
kg	O
(	O
23	O
.	O
43	O
+	O
1	O
.	O
99	O
min	O
)	O
when	O
compared	O
with	O
seized	O
mice	B-OrganismTaxon
.	O

In	O
addition	O
,	O
GABA	B-ChemicalEntity
content	O
of	O
mice	B-OrganismTaxon
hippocampus	O
treated	O
with	O
GFC75	B-ChemicalEntity
plus	O
P400	B-ChemicalEntity
showed	O
an	O
increase	O
of	O
46	O
.	O
90%	O
when	O
compared	O
with	O
seized	O
mice	B-OrganismTaxon
.	O

In	O
aspartate	B-ChemicalEntity
,	O
glutamine	B-ChemicalEntity
and	O
glutamate	B-ChemicalEntity
levels	O
detected	O
a	O
decrease	O
of	O
5	O
.	O
21%	O
,	O
13	O
.	O
55%	O
and	O
21	O
.	O
80%	O
,	O
respectively	O
in	O
mice	B-OrganismTaxon
hippocampus	O
treated	O
with	O
GFC75	B-ChemicalEntity
plus	O
P400	B-ChemicalEntity
when	O
compared	O
with	O
seized	O
mice	B-OrganismTaxon
.	O

Hippocampus	O
mice	B-OrganismTaxon
treated	O
with	O
GFC75	B-ChemicalEntity
plus	O
P400	B-ChemicalEntity
showed	O
an	O
increase	O
in	O
AChE	B-GeneOrGeneProduct
activity	O
(	O
63	O
.	O
30%	O
)	O
when	O
compared	O
with	O
seized	O
mice	B-OrganismTaxon
.	O

The	O
results	O
indicate	O
that	O
GFC	B-ChemicalEntity
can	O
exert	O
anticonvulsant	O
activity	O
and	O
reduce	O
the	O
frequency	O
of	O
installation	O
of	O
pilocarpine	B-ChemicalEntity
-	O
induced	O
status	B-DiseaseOrPhenotypicFeature
epilepticus	I-DiseaseOrPhenotypicFeature
,	O
as	O
demonstrated	O
by	O
increase	O
in	O
latency	O
to	O
first	O
seizure	B-DiseaseOrPhenotypicFeature
and	O
decrease	O
in	O
mortality	O
rate	O
of	O
animals	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
GFC	B-ChemicalEntity
may	O
influence	O
in	O
epileptogenesis	O
and	O
promote	O
anticonvulsant	O
actions	O
in	O
pilocarpine	B-ChemicalEntity
model	O
by	O
modulating	O
the	O
GABA	B-ChemicalEntity
and	O
glutamate	B-ChemicalEntity
contents	O
and	O
of	O
AChE	B-GeneOrGeneProduct
activity	O
in	O
seized	O
mice	B-OrganismTaxon
hippocampus	O
.	O

This	O
compound	O
may	O
be	O
useful	O
to	O
produce	O
neuronal	O
protection	O
and	O
it	O
can	O
be	O
considered	O
as	O
an	O
anticonvulsant	O
agent	O
.	O
Gastrointestinal	B-ChemicalEntity
hormones	I-ChemicalEntity
/	O
neurotransmitters	B-ChemicalEntity
and	O
growth	O
factors	O
can	O
activate	O
P21	B-GeneOrGeneProduct
activated	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
in	O
pancreatic	O
acinar	O
cells	O
by	O
novel	O
mechanisms	O
.	O

P	B-GeneOrGeneProduct
-	O
21	I-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
kinases	I-GeneOrGeneProduct
(	O
PAKs	B-GeneOrGeneProduct
)	O
are	O
serine	B-GeneOrGeneProduct
/	O
threonine	I-GeneOrGeneProduct
kinases	I-GeneOrGeneProduct
comprising	O
six	O
isoforms	O
divided	O
in	O
two	O
groups	O
,	O
group	O
-	O
I	O
(	O
PAK1	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
)	O
/	O
group	O
-	O
II	O
(	O
PAK4	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
)	O
which	O
play	O
important	O
roles	O
in	O
cell	O
cytoskeletal	O
dynamics	O
,	O
survival	O
,	O
secretion	O
and	O
proliferation	O
and	O
are	O
activated	O
by	O
diverse	O
stimuli	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
PAKs	B-GeneOrGeneProduct
ability	O
to	O
be	O
activated	O
by	O
gastrointestinal	B-ChemicalEntity
(	O
GI	I-ChemicalEntity
)	O
hormones	I-ChemicalEntity
/	O
neurotransmitters	B-ChemicalEntity
/	O
growth	O
-	O
factors	O
.	O

We	O
used	O
rat	B-OrganismTaxon
pancreatic	O
acini	O
to	O
explore	O
the	O
ability	O
of	O
GI	B-ChemicalEntity
-	O
hormones	I-ChemicalEntity
/	O
neurotransmitters	B-ChemicalEntity
/	O
growth	O
-	O
factors	O
to	O
activate	O
Group	B-GeneOrGeneProduct
-	O
I	I-GeneOrGeneProduct
-	O
PAKs	I-GeneOrGeneProduct
and	O
the	O
signaling	O
cascades	O
involved	O
.	O

Only	O
PAK2	B-GeneOrGeneProduct
was	O
present	O
in	O
acini	O
.	O

PAK2	B-GeneOrGeneProduct
was	O
activated	O
by	O
some	O
pancreatic	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
-	O
factors	I-GeneOrGeneProduct
[	O
EGF	B-GeneOrGeneProduct
,	O
PDGF	B-GeneOrGeneProduct
,	O
bFGF	B-GeneOrGeneProduct
]	O
,	O
by	O
secretagogues	O
activating	O
phospholipase	B-GeneOrGeneProduct
-	O
C	I-GeneOrGeneProduct
(	O
PLC	B-GeneOrGeneProduct
)	O
[	O
CCK	B-GeneOrGeneProduct
,	O
carbachol	B-ChemicalEntity
,	O
bombesin	B-ChemicalEntity
]	O
and	O
by	O
post	O
-	O
receptor	O
stimulants	O
activating	O
PKC	B-GeneOrGeneProduct
[	O
TPA	B-ChemicalEntity
]	O
,	O
but	O
not	O
agents	O
only	O
mobilizing	O
cellular	O
calcium	B-ChemicalEntity
or	O
increasing	O
cyclic	B-ChemicalEntity
AMP	I-ChemicalEntity
.	O

CCK	B-GeneOrGeneProduct
-	O
activation	O
of	O
PAK2	B-GeneOrGeneProduct
required	O
both	O
high	O
-	O
and	O
low	O
-	O
affinity	O
-	O
CCK1	B-GeneOrGeneProduct
-	O
receptor	I-GeneOrGeneProduct
-	O
state	O
activation	O
.	O

It	O
was	O
partially	O
reduced	O
by	O
PKC	B-GeneOrGeneProduct
-	O
or	O
Src	B-GeneOrGeneProduct
-	O
inhibition	O
,	O
but	O
not	O
with	O
PI3K	B-GeneOrGeneProduct
-	O
inhibitors	O
(	O
wortmannin	B-ChemicalEntity
,	O
LY294002	B-ChemicalEntity
)	O
or	O
thapsigargin	B-ChemicalEntity
.	O

IPA	B-ChemicalEntity
-	O
3	I-ChemicalEntity
,	O
which	O
prevents	O
PAK2	B-GeneOrGeneProduct
binding	O
to	O
small	B-GeneOrGeneProduct
-	O
GTPases	I-GeneOrGeneProduct
partially	O
inhibited	O
PAK2	B-GeneOrGeneProduct
-	O
activation	O
,	O
as	O
well	O
as	O
reduced	O
CCK	B-GeneOrGeneProduct
-	O
induced	O
ERK1	B-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
activation	O
and	O
amylase	B-GeneOrGeneProduct
release	O
induced	O
by	O
CCK	B-GeneOrGeneProduct
or	O
bombesin	B-ChemicalEntity
.	O

This	O
study	O
demonstrates	O
pancreatic	O
acini	O
,	O
possess	O
only	O
one	O
Group	B-GeneOrGeneProduct
-	O
I	I-GeneOrGeneProduct
-	O
PAK	I-GeneOrGeneProduct
,	O
PAK2	B-GeneOrGeneProduct
.	O

CCK	B-GeneOrGeneProduct
and	O
other	O
GI	B-ChemicalEntity
-	O
hormones	I-ChemicalEntity
/	O
neurotransmitters	B-ChemicalEntity
/	O
growth	O
-	O
factors	O
activate	O
PAK2	B-GeneOrGeneProduct
via	O
small	B-GeneOrGeneProduct
GTPases	I-GeneOrGeneProduct
(	O
CDC42	B-GeneOrGeneProduct
/	O
Rac1	B-GeneOrGeneProduct
)	O
,	O
PKC	B-GeneOrGeneProduct
and	O
SFK	B-GeneOrGeneProduct
but	O
not	O
cytosolic	O
calcium	B-ChemicalEntity
or	O
PI3K	B-GeneOrGeneProduct
.	O

CCK	B-GeneOrGeneProduct
-	O
activation	O
of	O
PAK2	B-GeneOrGeneProduct
showed	O
several	O
novel	O
features	O
being	O
dependent	O
on	O
both	O
receptor	O
-	O
activation	O
states	O
,	O
having	O
PLC	B-GeneOrGeneProduct
-	O
and	O
PKC	B-GeneOrGeneProduct
-	O
dependent	O
/	O
independent	O
components	O
and	O
small	B-GeneOrGeneProduct
-	O
GTPase	I-GeneOrGeneProduct
-	O
dependent	O
/	O
independent	O
components	O
.	O

These	O
results	O
show	O
that	O
PAK2	B-GeneOrGeneProduct
is	O
important	O
in	O
signaling	O
cascades	O
activated	O
by	O
numerous	O
pancreatic	O
stimuli	O
which	O
mediate	O
their	O
various	O
physiological	O
/	O
pathophysiological	O
responses	O
and	O
thus	O
could	O
be	O
a	O
promising	O
target	O
for	O
the	O
development	O
of	O
therapies	O
in	O
some	O
pancreatic	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
such	O
as	O
pancreatitis	B-DiseaseOrPhenotypicFeature
.	O

Evaluation	O
of	O
RGS4	B-GeneOrGeneProduct
as	O
a	O
candidate	O
gene	O
for	O
schizophrenia	B-DiseaseOrPhenotypicFeature
.	O

Several	O
studies	O
have	O
suggested	O
that	O
the	O
regulator	B-GeneOrGeneProduct
of	I-GeneOrGeneProduct
G	I-GeneOrGeneProduct
-	O
protein	I-GeneOrGeneProduct
signaling	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
(	O
RGS4	B-GeneOrGeneProduct
)	O
may	O
be	O
a	O
positional	O
and	O
functional	O
candidate	O
gene	O
for	O
schizophrenia	B-DiseaseOrPhenotypicFeature
.	O

Three	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
located	O
at	O
the	O
promoter	O
region	O
(	O
SNP4	O
and	O
SNP7	O
)	O
and	O
the	O
intron	O
1	O
(	O
SNP18	O
)	O
of	O
RGS4	B-GeneOrGeneProduct
have	O
been	O
verified	O
in	O
different	O
ethnic	O
groups	O
.	O

Positive	O
results	O
have	O
been	O
reported	O
in	O
these	O
SNPs	O
with	O
different	O
numbers	O
of	O
SNP	O
combinatory	O
haplotypes	O
.	O

In	O
this	O
study	O
,	O
these	O
three	O
SNP	O
markers	O
were	O
genotyped	O
in	O
218	O
schizophrenia	B-DiseaseOrPhenotypicFeature
pedigrees	O
of	O
Taiwan	O
(	O
864	O
individuals	O
)	O
for	O
association	O
analysis	O
.	O

Among	O
these	O
three	O
SNPs	O
,	O
neither	O
SNP4	O
,	O
SNP7	O
,	O
SNP18	O
has	O
shown	O
significant	O
association	O
with	O
schizophrenia	B-DiseaseOrPhenotypicFeature
in	O
single	O
locus	O
association	O
analysis	O
,	O
nor	O
any	O
compositions	O
of	O
the	O
three	O
SNP	O
haplotypes	O
has	O
shown	O
significantly	O
associations	O
with	O
the	O
DSM	O
-	O
IV	O
diagnosed	O
schizophrenia	B-DiseaseOrPhenotypicFeature
.	O

Our	O
results	O
fail	O
to	O
support	O
the	O
RGS4	B-GeneOrGeneProduct
as	O
a	O
candidate	O
gene	O
for	O
schizophrenia	B-DiseaseOrPhenotypicFeature
when	O
evaluated	O
from	O
these	O
three	O
SNP	O
markers	O
.	O
Gastrointestinal	O
tolerability	O
of	O
etoricoxib	B-ChemicalEntity
in	O
rheumatoid	B-DiseaseOrPhenotypicFeature
arthritis	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
:	O
results	O
of	O
the	O
etoricoxib	B-ChemicalEntity
vs	O
diclofenac	B-ChemicalEntity
sodium	I-ChemicalEntity
gastrointestinal	O
tolerability	O
and	O
effectiveness	O
trial	O
(	O
EDGE	O
-	O
II	O
)	O
.	O

OBJECTIVE	O
:	O
A	O
randomised	O
,	O
double	O
-	O
blind	O
study	O
to	O
compare	O
the	O
gastrointestinal	O
(	O
GI	O
)	O
tolerability	O
,	O
safety	O
and	O
efficacy	O
of	O
etoricoxib	B-ChemicalEntity
and	O
diclofenac	B-ChemicalEntity
in	O
patients	B-OrganismTaxon
with	O
rheumatoid	B-DiseaseOrPhenotypicFeature
arthritis	I-DiseaseOrPhenotypicFeature
(	O
RA	B-DiseaseOrPhenotypicFeature
)	O
.	O

PATIENTS	B-OrganismTaxon
AND	O
METHODS	O
:	O
A	O
total	O
of	O
4086	O
patients	B-OrganismTaxon
(	O
mean	O
age	O
60	O
.	O
8	O
years	O
)	O
diagnosed	O
with	O
RA	B-DiseaseOrPhenotypicFeature
were	O
enrolled	O
and	O
received	O
etoricoxib	B-ChemicalEntity
90	O
mg	O
daily	O
(	O
n	O
=	O
2032	O
)	O
or	O
diclofenac	B-ChemicalEntity
75	O
mg	O
twice	O
daily	O
(	O
n	O
=	O
2054	O
)	O
.	O

Use	O
of	O
gastroprotective	O
agents	O
and	O
low	O
-	O
dose	O
aspirin	B-ChemicalEntity
was	O
allowed	O
.	O

The	O
prespecified	O
primary	O
end	O
point	O
consisted	O
of	O
the	O
cumulative	O
rate	O
of	O
patient	B-OrganismTaxon
discontinuations	O
due	O
to	O
clinical	O
and	O
laboratory	O
GI	B-DiseaseOrPhenotypicFeature
adverse	I-DiseaseOrPhenotypicFeature
experiences	I-DiseaseOrPhenotypicFeature
(	O
AEs	O
)	O
.	O

General	O
safety	O
was	O
also	O
assessed	O
,	O
including	O
adjudicated	O
thrombotic	B-DiseaseOrPhenotypicFeature
cardiovascular	I-DiseaseOrPhenotypicFeature
event	O
data	O
.	O

Efficacy	O
was	O
evaluated	O
using	O
the	O
Patient	B-OrganismTaxon
Global	O
Assessment	O
of	O
Disease	O
Status	O
(	O
PGADS	O
;	O
0	O
-	O
4	O
point	O
scale	O
)	O
.	O

RESULTS	O
:	O
Mean	O
(	O
SD	O
;	O
maximum	O
)	O
duration	O
of	O
treatment	O
was	O
19	O
.	O
3	O
(	O
10	O
.	O
3	O
;	O
32	O
.	O
9	O
)	O
and	O
19	O
.	O
1	O
(	O
10	O
.	O
4	O
;	O
33	O
.	O
1	O
)	O
months	O
in	O
the	O
etoricoxib	B-ChemicalEntity
and	O
diclofenac	B-ChemicalEntity
groups	O
,	O
respectively	O
.	O

The	O
cumulative	O
discontinuation	O
rate	O
due	O
to	O
GI	B-DiseaseOrPhenotypicFeature
AEs	I-DiseaseOrPhenotypicFeature
was	O
significantly	O
lower	O
with	O
etoricoxib	B-ChemicalEntity
than	O
diclofenac	B-ChemicalEntity
(	O
5	O
.	O
2	O
vs	O
8	O
.	O
5	O
events	O
per	O
100	O
patient	B-OrganismTaxon
-	O
years	O
,	O
respectively	O
;	O
hazard	O
ratio	O
0	O
.	O
62	O
(	O
95%	O
CI	O
:	O
0	O
.	O
47	O
,	O
0	O
.	O
81	O
;	O
p	O
<	O
or	O
=	O
0	O
.	O
001	O
)	O
)	O
.	O

The	O
incidence	O
of	O
discontinuations	O
for	O
hypertension	B-DiseaseOrPhenotypicFeature
-	O
related	O
and	O
oedema	B-DiseaseOrPhenotypicFeature
-	O
related	O
AEs	O
were	O
significantly	O
higher	O
with	O
etoricoxib	B-ChemicalEntity
(	O
2	O
.	O
5%	O
and	O
1	O
.	O
1%	O
respectively	O
)	O
compared	O
with	O
diclofenac	B-ChemicalEntity
(	O
1	O
.	O
5%	O
and	O
0	O
.	O
4%	O
respectively	O
;	O
p	O
<	O
0	O
.	O
001	O
for	O
hypertension	B-DiseaseOrPhenotypicFeature
and	O
p	O
<	O
0	O
.	O
01	O
for	O
oedema	B-DiseaseOrPhenotypicFeature
)	O
.	O

Etoricoxib	B-ChemicalEntity
and	O
diclofenac	B-ChemicalEntity
treatment	O
resulted	O
in	O
similar	O
efficacy	O
(	O
PGADS	O
mean	O
changes	O
from	O
baseline	O
-	O
0	O
.	O
62	O
vs	O
-	O
0	O
.	O
58	O
,	O
respectively	O
)	O
.	O

CONCLUSIONS	O
:	O
Etoricoxib	B-ChemicalEntity
90	O
mg	O
demonstrated	O
a	O
significantly	O
lower	O
risk	O
for	O
discontinuing	O
treatment	O
due	O
to	O
GI	B-DiseaseOrPhenotypicFeature
AEs	I-DiseaseOrPhenotypicFeature
compared	O
with	O
diclofenac	B-ChemicalEntity
150	O
mg	O
.	O

Discontinuations	O
from	O
renovascular	O
AEs	O
,	O
although	O
less	O
common	O
than	O
discontinuations	O
from	O
GI	B-DiseaseOrPhenotypicFeature
AEs	I-DiseaseOrPhenotypicFeature
,	O
were	O
significantly	O
higher	O
with	O
etoricoxib	B-ChemicalEntity
.	O
Putative	O
Prostate	B-DiseaseOrPhenotypicFeature
Cancer	I-DiseaseOrPhenotypicFeature
Risk	O
SNP	O
in	O
an	O
Androgen	B-GeneOrGeneProduct
Receptor	I-GeneOrGeneProduct
-	O
Binding	O
Site	O
of	O
the	O
Melanophilin	B-GeneOrGeneProduct
Gene	O
Illustrates	O
Enrichment	O
of	O
Risk	O
SNPs	O
in	O
Androgen	B-GeneOrGeneProduct
Receptor	I-GeneOrGeneProduct
Target	O
Sites	O
.	O

Genome	O
-	O
wide	O
association	O
studies	O
have	O
identified	O
genomic	O
loci	O
,	O
whose	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
predispose	O
to	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
PCa	B-DiseaseOrPhenotypicFeature
)	O
.	O

However	O
,	O
the	O
mechanisms	O
of	O
most	O
of	O
these	O
variants	O
are	O
largely	O
unknown	O
.	O

We	O
integrated	O
chromatin	O
-	O
immunoprecipitation	O
-	O
coupled	O
sequencing	O
and	O
microarray	O
expression	O
profiling	O
in	O
TMPRSS2	B-GeneOrGeneProduct
-	O
ERG	B-GeneOrGeneProduct
gene	O
rearrangement	O
positive	O
DUCaP	B-CellLine
cells	O
with	O
the	O
GWAS	O
PCa	B-DiseaseOrPhenotypicFeature
risk	O
SNPs	O
catalog	O
to	O
identify	O
disease	O
susceptibility	O
SNPs	O
localized	O
within	O
functional	O
androgen	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
binding	O
sites	O
(	O
ARBSs	B-GeneOrGeneProduct
)	O
.	O

Among	O
the	O
48	O
GWAS	O
index	O
risk	O
SNPs	O
and	O
3	O
,	O
917	O
linked	O
SNPs	O
,	O
80	O
were	O
found	O
located	O
in	O
ARBSs	B-GeneOrGeneProduct
.	O

Of	O
these	O
,	O
rs11891426	B-SequenceVariant
:	O
T	B-SequenceVariant
>	O
G	I-SequenceVariant
in	O
an	O
intron	O
of	O
the	O
melanophilin	B-GeneOrGeneProduct
gene	O
(	O
MLPH	B-GeneOrGeneProduct
)	O
was	O
within	O
a	O
novel	O
putative	O
auxiliary	O
AR	B-GeneOrGeneProduct
-	O
binding	O
motif	O
,	O
which	O
is	O
enriched	O
in	O
the	O
neighborhood	O
of	O
canonical	O
androgen	B-ChemicalEntity
-	O
responsive	O
elements	O
.	O

T	B-SequenceVariant
>	O
G	I-SequenceVariant
exchange	O
attenuated	O
the	O
transcriptional	O
activity	O
of	O
the	O
ARBS	B-GeneOrGeneProduct
in	O
an	O
AR	B-GeneOrGeneProduct
reporter	O
gene	O
assay	O
.	O

The	O
expression	O
of	O
MLPH	B-GeneOrGeneProduct
in	O
primary	O
prostate	B-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
was	O
significantly	O
lower	O
in	O
those	O
with	O
the	O
G	O
compared	O
with	O
the	O
T	O
allele	O
and	O
correlated	O
significantly	O
with	O
AR	B-GeneOrGeneProduct
protein	O
.	O

Higher	O
melanophilin	B-GeneOrGeneProduct
level	O
in	O
prostate	O
tissue	O
of	O
patients	B-OrganismTaxon
with	O
a	O
favorable	O
PCa	B-DiseaseOrPhenotypicFeature
risk	O
profile	O
points	O
out	O
a	O
tumor	B-DiseaseOrPhenotypicFeature
-	O
suppressive	O
effect	O
.	O

These	O
results	O
unravel	O
a	O
hidden	O
link	O
between	O
AR	B-GeneOrGeneProduct
and	O
a	O
functional	O
putative	O
PCa	B-DiseaseOrPhenotypicFeature
risk	O
SNP	O
,	O
whose	O
allele	O
alteration	O
affects	O
androgen	B-ChemicalEntity
regulation	O
of	O
its	O
host	O
gene	O
MLPH	B-GeneOrGeneProduct
.	O
Cultured	B-ChemicalEntity
mycelium	I-ChemicalEntity
Cordyceps	I-ChemicalEntity
sinensis	I-ChemicalEntity
protects	O
liver	O
sinusoidal	O
endothelial	O
cells	O
in	O
acute	O
liver	B-DiseaseOrPhenotypicFeature
injured	I-DiseaseOrPhenotypicFeature
mice	B-OrganismTaxon
.	O

Cultured	B-ChemicalEntity
mycelium	I-ChemicalEntity
Cordyceps	I-ChemicalEntity
sinensis	I-ChemicalEntity
(	O
CMCS	B-ChemicalEntity
)	O
was	O
widely	O
used	O
for	O
a	O
variety	O
of	O
diseases	O
including	O
liver	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
,	O
the	O
current	O
study	O
aims	O
to	O
investigate	O
the	O
protective	O
effects	O
of	O
CMCS	B-ChemicalEntity
on	O
liver	O
sinusoidal	O
endothelial	O
cells	O
(	O
LSECs	O
)	O
in	O
acute	O
injury	B-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
and	O
related	O
action	O
mechanisms	O
.	O

The	O
mice	B-OrganismTaxon
were	O
injected	O
intraperitoneally	O
with	O
lipopolysaccharide	B-ChemicalEntity
(	O
LPS	B-ChemicalEntity
)	O
and	O
D	B-ChemicalEntity
-	O
galactosamine	I-ChemicalEntity
(	O
D	B-ChemicalEntity
-	O
GalN	I-ChemicalEntity
)	O
.	O

39	O
male	O
BABL	B-CellLine
/	O
c	I-CellLine
mice	B-OrganismTaxon
were	O
randomly	O
divided	O
into	O
four	O
groups	O
:	O
normal	O
control	O
,	O
model	O
control	O
,	O
CMCS	B-ChemicalEntity
treatment	O
and	O
1	B-ChemicalEntity
,	O
10	I-ChemicalEntity
-	O
phenanthroline	I-ChemicalEntity
treatment	O
groups	O
.	O

The	O
Serum	O
liver	O
function	O
parameters	O
including	O
alanine	B-GeneOrGeneProduct
aminotransferase	I-GeneOrGeneProduct
(	O
ALT	B-GeneOrGeneProduct
)	O
and	O
aspartate	B-GeneOrGeneProduct
aminotransferase	I-GeneOrGeneProduct
(	O
AST	B-GeneOrGeneProduct
)	O
levels	O
were	O
assayed	O
with	O
the	O
commercial	O
kit	O
.	O

The	O
inflammation	B-DiseaseOrPhenotypicFeature
and	O
scaffold	O
structure	O
in	O
liver	O
were	O
stained	O
with	O
hematoxylin	O
and	O
eosin	O
and	O
silver	O
staining	O
respectively	O
.	O

The	O
LSECs	O
and	O
sub	O
-	O
endothelial	O
basement	O
membrane	O
were	O
observed	O
with	O
the	O
scanning	O
and	O
transmission	O
electronic	O
microscope	O
.	O

The	O
protein	O
expressions	O
of	O
intercellular	B-GeneOrGeneProduct
adhesion	I-GeneOrGeneProduct
molecule	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
ICAM	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
and	O
vascular	B-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
adhesion	I-GeneOrGeneProduct
molecule	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
VCAM	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
in	O
liver	O
were	O
analyzed	O
with	O
Western	O
blotting	O
.	O

Expression	O
of	O
von	B-GeneOrGeneProduct
Willebrand	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
vWF	B-GeneOrGeneProduct
)	O
was	O
investigated	O
with	O
immunofluorescence	O
staining	O
.	O

The	O
lipid	B-ChemicalEntity
peroxidation	O
indicators	O
including	O
antisuperoxideanion	O
(	O
ASAFR	O
)	O
,	O
hydroxyl	B-ChemicalEntity
free	I-ChemicalEntity
radical	I-ChemicalEntity
(	O
.	O
OH	I-ChemicalEntity
)	O
,	O
superoxide	B-GeneOrGeneProduct
dismutase	I-GeneOrGeneProduct
(	O
SOD	B-GeneOrGeneProduct
)	O
,	O
malondialdehyde	B-ChemicalEntity
and	O
glutathione	B-GeneOrGeneProduct
S	I-GeneOrGeneProduct
-	O
transferase	I-GeneOrGeneProduct
(	O
GST	B-GeneOrGeneProduct
)	O
were	O
determined	O
with	O
kits	O
,	O
and	O
matrix	B-GeneOrGeneProduct
metalloproteinase	I-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
9	I-GeneOrGeneProduct
(	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
/	O
9	I-GeneOrGeneProduct
)	O
activities	O
in	O
liver	O
were	O
analyzed	O
with	O
gelatin	O
zymography	O
and	O
in	O
situ	O
fluorescent	O
zymography	O
respectively	O
.	O

The	O
model	O
mice	B-OrganismTaxon
had	O
much	O
higher	O
serum	O
levels	O
of	O
ALT	B-GeneOrGeneProduct
and	O
AST	B-GeneOrGeneProduct
than	O
the	O
normal	O
mice	B-OrganismTaxon
.	O

Compared	O
to	O
that	O
in	O
the	O
normal	O
control	O
,	O
more	O
severe	O
liver	B-DiseaseOrPhenotypicFeature
inflammation	I-DiseaseOrPhenotypicFeature
and	O
hepatocyte	O
apoptosis	O
,	O
worse	O
hepatic	O
lipid	B-ChemicalEntity
peroxidation	O
demonstrated	O
by	O
the	O
increased	O
ASAFR	O
,	O
.	O
OH	I-ChemicalEntity
and	O
MDA	B-ChemicalEntity
,	O
but	O
decreased	O
SOD	B-GeneOrGeneProduct
and	O
GST	B-GeneOrGeneProduct
,	O
increased	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
/	O
9	I-GeneOrGeneProduct
activities	O
and	O
VCAM	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
,	O
ICAM	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
and	O
vWF	B-GeneOrGeneProduct
expressions	O
,	O
which	O
revealed	O
obvious	O
LSEC	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	O
scaffold	O
structure	O
broken	O
,	O
were	O
shown	O
in	O
the	O
model	O
control	O
.	O

Compared	O
with	O
the	O
model	O
group	O
,	O
CMCS	B-ChemicalEntity
and	O
1	B-ChemicalEntity
,	O
10	I-ChemicalEntity
-	O
phenanthroline	I-ChemicalEntity
significantly	O
improved	O
serum	O
ALT	B-GeneOrGeneProduct
/	O
AST	B-GeneOrGeneProduct
,	O
attenuated	O
hepatic	B-DiseaseOrPhenotypicFeature
inflammation	I-DiseaseOrPhenotypicFeature
and	O
improved	O
peroxidative	O
injury	B-DiseaseOrPhenotypicFeature
in	I-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
,	O
decreased	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
/	O
9	I-GeneOrGeneProduct
activities	O
in	O
liver	O
tissue	O
,	O
improved	O
integration	O
of	O
scaffold	O
structure	O
,	O
and	O
decreased	O
protein	O
expression	O
of	O
VCAM	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
and	O
ICAM	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
.	O

CMCS	B-ChemicalEntity
could	O
protect	O
LSECs	B-DiseaseOrPhenotypicFeature
from	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	O
maintain	O
the	O
microvasculature	O
integration	O
in	O
acute	O
injured	B-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
of	O
mice	B-OrganismTaxon
induced	O
by	O
LPS	B-ChemicalEntity
/	O
D	B-ChemicalEntity
-	O
GalN	I-ChemicalEntity
.	O

Its	O
action	O
mechanism	O
was	O
associated	O
with	O
the	O
down	O
-	O
regulation	O
of	O
MMP	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
/	O
9	I-GeneOrGeneProduct
activities	O
and	O
inhibition	O
of	O
peroxidation	O
in	O
injured	B-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
.	O
Defining	O
an	O
EPOR	B-GeneOrGeneProduct
-	O
regulated	O
transcriptome	O
for	O
primary	O
progenitors	O
,	O
including	O
Tnfr	B-GeneOrGeneProduct
-	O
sf13c	I-GeneOrGeneProduct
as	O
a	O
novel	O
mediator	O
of	O
EPO	B-GeneOrGeneProduct
-	O
dependent	O
erythroblast	O
formation	O
.	O

Certain	O
concepts	O
concerning	O
EPO	B-GeneOrGeneProduct
/	O
EPOR	B-GeneOrGeneProduct
action	O
modes	O
have	O
been	O
challenged	O
by	O
in	O
vivo	O
studies	O
:	O
Bcl	B-GeneOrGeneProduct
-	O
x	I-GeneOrGeneProduct
levels	O
are	O
elevated	O
in	O
maturing	O
erythroblasts	O
,	O
but	O
not	O
in	O
their	O
progenitors	O
;	O
truncated	O
EPOR	B-GeneOrGeneProduct
alleles	O
that	O
lack	O
a	O
major	O
p85	B-GeneOrGeneProduct
/	O
PI3K	I-GeneOrGeneProduct
recruitment	O
site	O
nonetheless	O
promote	O
polycythemia	B-DiseaseOrPhenotypicFeature
;	O
and	O
Erk1	B-GeneOrGeneProduct
disruption	O
unexpectedly	O
bolsters	O
erythropoiesis	O
.	O

To	O
discover	O
novel	O
EPO	B-GeneOrGeneProduct
/	O
EPOR	B-GeneOrGeneProduct
action	O
routes	O
,	O
global	O
transcriptome	O
analyses	O
presently	O
are	O
applied	O
to	O
interrogate	O
EPO	B-GeneOrGeneProduct
/	O
EPOR	B-GeneOrGeneProduct
effects	O
on	O
primary	O
bone	O
marrow	O
-	O
derived	O
CFUe	O
-	O
like	O
progenitors	O
.	O

Overall	O
,	O
160	O
EPO	B-GeneOrGeneProduct
/	O
EPOR	B-GeneOrGeneProduct
target	O
transcripts	O
were	O
significantly	O
modulated	O
2	O
-	O
to	O
21	O
.	O
8	O
-	O
fold	O
.	O

A	O
unique	O
set	O
of	O
EPO	B-GeneOrGeneProduct
-	O
regulated	O
survival	O
factors	O
included	O
Lyl1	B-GeneOrGeneProduct
,	O
Gas5	B-GeneOrGeneProduct
,	O
Pim3	B-GeneOrGeneProduct
,	O
Pim1	B-GeneOrGeneProduct
,	O
Bim	B-GeneOrGeneProduct
,	O
Trib3	B-GeneOrGeneProduct
and	O
Serpina	B-GeneOrGeneProduct
3g	I-GeneOrGeneProduct
.	O

EPO	B-GeneOrGeneProduct
/	O
EPOR	B-GeneOrGeneProduct
-	O
modulated	O
cell	O
cycle	O
mediators	O
included	O
Cdc25a	B-GeneOrGeneProduct
,	O
Btg3	B-GeneOrGeneProduct
,	O
Cyclin	B-GeneOrGeneProduct
-	O
d2	I-GeneOrGeneProduct
,	O
p27	B-GeneOrGeneProduct
-	O
kip1	I-GeneOrGeneProduct
,	O
Cyclin	B-GeneOrGeneProduct
-	O
g2	I-GeneOrGeneProduct
and	O
CyclinB1	B-GeneOrGeneProduct
-	O
IP	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
.	O

EPO	B-GeneOrGeneProduct
regulation	O
of	O
signal	O
transduction	O
factors	O
was	O
also	O
interestingly	O
complex	O
.	O

For	O
example	O
,	O
not	O
only	O
Socs3	B-GeneOrGeneProduct
plus	O
Socs2	B-GeneOrGeneProduct
but	O
also	O
Spred2	B-GeneOrGeneProduct
,	O
Spred1	B-GeneOrGeneProduct
and	O
Eaf1	B-GeneOrGeneProduct
were	O
EPO	B-GeneOrGeneProduct
-	O
induced	O
as	O
negative	O
-	O
feedback	O
components	O
.	O

Socs2	B-GeneOrGeneProduct
,	O
plus	O
five	O
additional	O
targets	O
,	O
further	O
proved	O
to	O
comprise	O
new	O
EPOR	B-GeneOrGeneProduct
/	O
Jak2	B-GeneOrGeneProduct
/	O
Stat5	B-GeneOrGeneProduct
response	O
genes	O
(	O
which	O
are	O
important	O
for	O
erythropoiesis	O
during	O
anemia	B-DiseaseOrPhenotypicFeature
)	O
.	O

Among	O
receptors	O
,	O
an	O
atypical	O
TNF	B-GeneOrGeneProduct
-	O
receptor	I-GeneOrGeneProduct
Tnfr	B-GeneOrGeneProduct
-	O
sf13c	I-GeneOrGeneProduct
was	O
up	O
-	O
modulated	O
>	O
5	O
-	O
fold	O
by	O
EPO	B-GeneOrGeneProduct
.	O

Functionally	O
,	O
Tnfr	B-GeneOrGeneProduct
-	O
sf13c	I-GeneOrGeneProduct
ligation	O
proved	O
to	O
both	O
promote	O
proerythroblast	O
survival	O
,	O
and	O
substantially	O
enhance	O
erythroblast	O
formation	O
.	O

The	O
EPOR	B-GeneOrGeneProduct
therefore	O
engages	O
a	O
sophisticated	O
set	O
of	O
transcriptome	O
response	O
circuits	O
,	O
with	O
Tnfr	B-GeneOrGeneProduct
-	O
sf13c	I-GeneOrGeneProduct
deployed	O
as	O
one	O
novel	O
positive	O
regulator	O
of	O
proerythroblast	O
formation	O
.	O
Novel	O
CRELD1	B-GeneOrGeneProduct
gene	O
mutations	O
in	O
patients	B-OrganismTaxon
with	O
atrioventricular	B-DiseaseOrPhenotypicFeature
septal	I-DiseaseOrPhenotypicFeature
defect	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Atrioventricular	B-DiseaseOrPhenotypicFeature
septal	I-DiseaseOrPhenotypicFeature
defects	I-DiseaseOrPhenotypicFeature
(	O
AVSDs	B-DiseaseOrPhenotypicFeature
)	O
occur	O
as	O
clinical	O
defects	O
of	O
several	O
different	O
syndromes	O
,	O
as	O
autosomal	B-DiseaseOrPhenotypicFeature
dominant	I-DiseaseOrPhenotypicFeature
defects	I-DiseaseOrPhenotypicFeature
,	O
and	O
as	O
sporadically	O
occurring	O
malformations	B-DiseaseOrPhenotypicFeature
.	O

Consequently	O
,	O
there	O
is	O
genetic	O
heterogeneity	O
,	O
but	O
until	O
recently	O
,	O
little	O
is	O
known	O
about	O
the	O
genes	O
involving	O
in	O
the	O
pathogenesis	O
of	O
AVSD	B-DiseaseOrPhenotypicFeature
.	O

CRELD1	B-GeneOrGeneProduct
gene	O
,	O
a	O
novel	O
cell	O
adhesion	O
molecule	O
,	O
is	O
a	O
candidate	O
gene	O
for	O
AVSD	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
This	O
study	O
included	O
133	O
patients	B-OrganismTaxon
with	O
AVSD	B-DiseaseOrPhenotypicFeature
and	O
200	O
healthy	O
controls	O
.	O

Peripheral	O
blood	O
samples	O
were	O
collected	O
and	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
leukocytes	O
.	O

CRELD1	B-GeneOrGeneProduct
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
with	O
specific	O
primers	O
.	O

The	O
sequences	O
of	O
PCR	O
products	O
were	O
compared	O
between	O
the	O
patients	B-OrganismTaxon
and	O
controls	O
.	O

RESULTS	O
:	O
In	O
a	O
patient	B-OrganismTaxon
,	O
a	O
C	B-SequenceVariant
-	O
to	I-SequenceVariant
-	O
G	I-SequenceVariant
transition	I-SequenceVariant
was	I-SequenceVariant
identified	I-SequenceVariant
at	I-SequenceVariant
nucleotide	I-SequenceVariant
857	I-SequenceVariant
in	O
exon	O
8	O
that	O
resulted	O
in	O
a	O
substitution	O
of	O
alanine	B-SequenceVariant
for	I-SequenceVariant
proline	I-SequenceVariant
at	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
286	I-SequenceVariant
in	O
the	O
first	O
calcium	B-ChemicalEntity
-	O
binding	O
EGF	B-GeneOrGeneProduct
domain	O
.	O

This	O
patient	B-OrganismTaxon
had	O
an	O
isolated	O
partial	O
AVSD	B-DiseaseOrPhenotypicFeature
and	O
the	O
mutation	O
was	O
inherited	O
from	O
her	O
mother	O
.	O

Another	O
mutation	O
was	O
detected	O
in	O
a	O
patient	B-OrganismTaxon
with	O
a	O
partial	O
AVSD	B-DiseaseOrPhenotypicFeature
and	O
evidence	O
of	O
Down	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

The	O
heterozygous	O
c	B-SequenceVariant
.	O
973G	I-SequenceVariant
>	O
A	I-SequenceVariant
transition	O
in	O
exon	O
9	O
resulted	O
in	O
a	O
substitution	O
of	O
lysine	B-SequenceVariant
for	I-SequenceVariant
glutamic	I-SequenceVariant
acid	I-SequenceVariant
at	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
325	I-SequenceVariant
(	O
E325K	B-SequenceVariant
)	O
in	O
the	O
second	O
calcium	B-ChemicalEntity
-	O
binding	O
EGF	B-GeneOrGeneProduct
domain	O
.	O

CONCLUSIONS	O
:	O
Two	O
novel	O
CRELD1	B-GeneOrGeneProduct
mutations	O
were	O
identified	O
in	O
the	O
calcium	B-ChemicalEntity
-	O
binding	O
EGF	B-GeneOrGeneProduct
domain	O
in	O
patients	B-OrganismTaxon
with	O
AVSD	B-DiseaseOrPhenotypicFeature
.	O

CRELD1	B-GeneOrGeneProduct
is	O
likely	O
to	O
be	O
an	O
AVSD	B-DiseaseOrPhenotypicFeature
-	O
susceptibility	O
gene	O
and	O
CRELD1	B-GeneOrGeneProduct
mutations	O
may	O
increase	O
the	O
risk	O
of	O
developing	O
a	O
heart	B-DiseaseOrPhenotypicFeature
defect	I-DiseaseOrPhenotypicFeature
rather	O
than	O
being	O
a	O
direct	O
causative	O
mutation	O
.	O
The	O
differential	O
effects	O
of	O
bupivacaine	B-ChemicalEntity
and	O
lidocaine	B-ChemicalEntity
on	O
prostaglandin	B-GeneOrGeneProduct
E2	I-GeneOrGeneProduct
release	O
,	O
cyclooxygenase	B-GeneOrGeneProduct
gene	O
expression	O
and	O
pain	B-DiseaseOrPhenotypicFeature
in	O
a	O
clinical	O
pain	B-DiseaseOrPhenotypicFeature
model	O
.	O

BACKGROUND	O
:	O
In	O
addition	O
to	O
blocking	O
nociceptive	O
input	O
from	O
surgical	O
sites	O
,	O
long	O
-	O
acting	O
local	O
anesthetics	O
might	O
directly	O
modulate	O
inflammation	B-DiseaseOrPhenotypicFeature
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
the	O
proinflammatory	O
effects	O
of	O
bupivacaine	B-ChemicalEntity
on	O
local	O
prostaglandin	B-GeneOrGeneProduct
E2	I-GeneOrGeneProduct
(	O
PGE2	B-GeneOrGeneProduct
)	O
production	O
and	O
cyclooxygenase	B-GeneOrGeneProduct
(	O
COX	B-GeneOrGeneProduct
)	O
gene	O
expression	O
that	O
increases	O
postoperative	B-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
in	O
human	B-OrganismTaxon
subjects	O
.	O

METHODS	O
:	O
Subjects	O
(	O
n	O
=	O
114	O
)	O
undergoing	O
extraction	O
of	O
impacted	O
third	O
molars	O
received	O
either	O
2%	O
lidocaine	B-ChemicalEntity
or	O
0	O
.	O
5%	O
bupivacaine	B-ChemicalEntity
before	O
surgery	O
and	O
either	O
rofecoxib	B-ChemicalEntity
50	O
mg	O
or	O
placebo	O
orally	O
90	O
min	O
before	O
surgery	O
and	O
for	O
the	O
following	O
48	O
h	O
.	O

Oral	O
mucosal	O
biopsies	O
were	O
taken	O
before	O
surgery	O
and	O
48	O
h	O
after	O
surgery	O
.	O

After	O
extraction	O
,	O
a	O
microdialysis	O
probe	O
was	O
placed	O
at	O
the	O
surgical	O
site	O
for	O
PGE2	B-GeneOrGeneProduct
and	O
thromboxane	B-ChemicalEntity
B2	I-ChemicalEntity
(	O
TXB2	B-ChemicalEntity
)	O
measurements	O
.	O

RESULTS	O
:	O
The	O
bupivacaine	B-ChemicalEntity
/	O
rofecoxib	B-ChemicalEntity
group	O
reported	O
significantly	O
less	O
pain	B-DiseaseOrPhenotypicFeature
,	O
as	O
assessed	O
by	O
a	O
visual	O
analog	O
scale	O
,	O
compared	O
with	O
the	O
other	O
three	O
treatment	O
groups	O
over	O
the	O
first	O
4	O
h	O
.	O

However	O
,	O
the	O
bupivacaine	B-ChemicalEntity
/	O
placebo	O
group	O
reported	O
significantly	O
more	O
pain	B-DiseaseOrPhenotypicFeature
at	O
24	O
h	O
and	O
PGE2	B-GeneOrGeneProduct
levels	O
during	O
the	O
first	O
4	O
h	O
were	O
significantly	O
higher	O
than	O
the	O
other	O
three	O
treatment	O
groups	O
.	O

Moreover	O
,	O
bupivacaine	B-ChemicalEntity
significantly	O
increased	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
gene	O
expression	O
at	O
48	O
h	O
as	O
compared	O
with	O
the	O
lidocaine	B-ChemicalEntity
/	O
placebo	O
group	O
.	O

Thromboxane	B-ChemicalEntity
levels	O
were	O
not	O
significantly	O
affected	O
by	O
any	O
of	O
the	O
treatments	O
,	O
indicating	O
that	O
the	O
effects	O
seen	O
were	O
attributable	O
to	O
inhibition	O
of	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
,	O
but	O
not	O
COX	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
bupivacaine	B-ChemicalEntity
stimulates	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
gene	O
expression	O
after	O
tissue	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
,	O
which	O
is	O
associated	O
with	O
higher	O
PGE2	B-GeneOrGeneProduct
production	O
and	O
pain	B-DiseaseOrPhenotypicFeature
after	O
the	O
local	O
anesthetic	O
effect	O
dissipates	O
.	O
Syncope	B-DiseaseOrPhenotypicFeature
and	O
QT	B-DiseaseOrPhenotypicFeature
prolongation	I-DiseaseOrPhenotypicFeature
among	O
patients	B-OrganismTaxon
treated	O
with	O
methadone	B-ChemicalEntity
for	O
heroin	B-DiseaseOrPhenotypicFeature
dependence	I-DiseaseOrPhenotypicFeature
in	O
the	O
city	O
of	O
Copenhagen	O
.	O

BACKGROUND	O
:	O
Methadone	B-ChemicalEntity
is	O
prescribed	O
to	O
heroin	B-DiseaseOrPhenotypicFeature
addicts	I-DiseaseOrPhenotypicFeature
to	O
decrease	O
illicit	O
opioid	B-ChemicalEntity
use	O
.	O

Prolongation	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
QT	I-DiseaseOrPhenotypicFeature
interval	I-DiseaseOrPhenotypicFeature
in	O
the	O
ECG	O
of	O
patients	B-OrganismTaxon
with	O
torsade	B-DiseaseOrPhenotypicFeature
de	I-DiseaseOrPhenotypicFeature
pointes	I-DiseaseOrPhenotypicFeature
(	O
TdP	B-DiseaseOrPhenotypicFeature
)	O
has	O
been	O
reported	O
in	O
methadone	B-ChemicalEntity
users	O
.	O

As	O
heroin	B-DiseaseOrPhenotypicFeature
addicts	I-DiseaseOrPhenotypicFeature
sometimes	O
faint	O
while	O
using	O
illicit	O
drugs	O
,	O
doctors	O
might	O
attribute	O
too	O
many	O
episodes	O
of	O
syncope	B-DiseaseOrPhenotypicFeature
to	O
illicit	O
drug	O
use	O
and	O
thereby	O
underestimate	O
the	O
incidence	O
of	O
TdP	B-DiseaseOrPhenotypicFeature
in	O
this	O
special	O
population	O
,	O
and	O
the	O
high	O
mortality	O
in	O
this	O
population	O
may	O
,	O
in	O
part	O
,	O
be	O
caused	O
by	O
the	O
proarrhythmic	O
effect	O
of	O
methadone	B-ChemicalEntity
.	O

METHODS	O
:	O
In	O
this	O
cross	O
-	O
sectional	O
study	O
interview	O
,	O
ECGs	O
and	O
blood	O
samples	O
were	O
collected	O
in	O
a	O
population	O
of	O
adult	O
heroin	B-DiseaseOrPhenotypicFeature
addicts	I-DiseaseOrPhenotypicFeature
treated	O
with	O
methadone	B-ChemicalEntity
or	O
buprenorphine	B-ChemicalEntity
on	O
a	O
daily	O
basis	O
.	O

Of	O
the	O
patients	B-OrganismTaxon
at	O
the	O
Drug	O
Addiction	O
Service	O
in	O
the	O
municipal	O
of	O
Copenhagen	O
,	O
450	O
(	O
approximately	O
52%	O
)	O
were	O
included	O
.	O

The	O
QT	O
interval	O
was	O
estimated	O
from	O
12	O
lead	O
ECGs	O
.	O

All	O
participants	O
were	O
interviewed	O
about	O
any	O
experience	O
of	O
syncope	B-DiseaseOrPhenotypicFeature
.	O

The	O
association	O
between	O
opioid	B-ChemicalEntity
dose	O
and	O
QT	O
,	O
and	O
methadone	B-ChemicalEntity
dose	O
and	O
reporting	O
of	O
syncope	B-DiseaseOrPhenotypicFeature
was	O
assessed	O
using	O
multivariate	O
linear	O
regression	O
and	O
logistic	O
regression	O
,	O
respectively	O
.	O

RESULTS	O
:	O
Methadone	B-ChemicalEntity
dose	O
was	O
associated	O
with	O
longer	B-DiseaseOrPhenotypicFeature
QT	I-DiseaseOrPhenotypicFeature
interval	I-DiseaseOrPhenotypicFeature
of	O
0	O
.	O
140	O
ms	O
/	O
mg	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

No	O
association	O
between	O
buprenorphine	B-ChemicalEntity
and	O
QTc	O
was	O
found	O
.	O

Among	O
the	O
subjects	O
treated	O
with	O
methadone	B-ChemicalEntity
,	O
28%	O
men	B-OrganismTaxon
and	O
32%	O
women	B-OrganismTaxon
had	O
prolonged	B-DiseaseOrPhenotypicFeature
QTc	I-DiseaseOrPhenotypicFeature
interval	I-DiseaseOrPhenotypicFeature
.	O

None	O
of	O
the	O
subjects	O
treated	O
with	O
buprenorphine	B-ChemicalEntity
had	O
QTc	O
interval	O
>	O
0	O
.	O
440	O
s	O
(	O
(	O
1	O
/	O
2	O
)	O
)	O
.	O

A	O
50	O
mg	O
higher	O
methadone	B-ChemicalEntity
dose	O
was	O
associated	O
with	O
a	O
1	O
.	O
2	O
(	O
95%	O
CI	O
1	O
.	O
1	O
to	O
1	O
.	O
4	O
)	O
times	O
higher	O
odds	O
for	O
syncope	B-DiseaseOrPhenotypicFeature
.	O

CONCLUSIONS	O
:	O
Methadone	B-ChemicalEntity
is	O
associated	O
with	O
QT	B-DiseaseOrPhenotypicFeature
prolongation	I-DiseaseOrPhenotypicFeature
and	O
higher	O
reporting	O
of	O
syncope	B-DiseaseOrPhenotypicFeature
in	O
a	O
population	O
of	O
heroin	B-DiseaseOrPhenotypicFeature
addicts	I-DiseaseOrPhenotypicFeature
.	O
Clusters	O
of	O
multidrug	O
-	O
resistant	O
Mycobacterium	B-OrganismTaxon
tuberculosis	I-OrganismTaxon
cases	O
,	O
Europe	O
.	O

Molecular	O
surveillance	O
of	O
multidrug	B-DiseaseOrPhenotypicFeature
-	O
resistant	I-DiseaseOrPhenotypicFeature
tuberculosis	I-DiseaseOrPhenotypicFeature
(	O
MDR	B-DiseaseOrPhenotypicFeature
TB	I-DiseaseOrPhenotypicFeature
)	O
was	O
implemented	O
in	O
Europe	O
as	O
case	O
reporting	O
in	O
2005	O
.	O

For	O
all	O
new	O
MDR	B-DiseaseOrPhenotypicFeature
TB	I-DiseaseOrPhenotypicFeature
cases	O
detected	O
from	O
January	O
2003	O
through	O
June	O
2007	O
,	O
countries	O
reported	O
case	O
-	O
based	O
epidemiologic	O
data	O
and	O
DNA	O
fingerprint	O
patterns	O
of	O
MDR	B-DiseaseOrPhenotypicFeature
TB	I-DiseaseOrPhenotypicFeature
strains	O
when	O
available	O
.	O

International	O
clusters	O
were	O
detected	O
and	O
analyzed	O
.	O

From	O
2003	O
through	O
mid	O
-	O
2007	O
in	O
Europe	O
,	O
2	O
,	O
494	O
cases	O
of	O
MDR	B-DiseaseOrPhenotypicFeature
TB	I-DiseaseOrPhenotypicFeature
were	O
reported	O
from	O
24	O
European	O
countries	O
.	O

Epidemiologic	O
and	O
molecular	O
data	O
were	O
linked	O
for	O
593	O
(	O
39%	O
)	O
cases	O
,	O
and	O
672	O
insertion	O
sequence	O
6110	O
DNA	O
fingerprint	O
patterns	O
were	O
reported	O
from	O
19	O
countries	O
.	O

Of	O
these	O
patterns	O
,	O
288	O
(	O
43%	O
)	O
belonged	O
to	O
18	O
European	O
clusters	O
;	O
7	O
clusters	O
(	O
242	O
/	O
288	O
cases	O
,	O
84%	O
)	O
were	O
characterized	O
by	O
strains	O
of	O
the	O
Beijing	O
genotype	O
family	O
,	O
including	O
the	O
largest	O
cluster	O
(	O
175	O
/	O
288	O
cases	O
,	O
61%	O
)	O
.	O

Both	O
clustering	O
and	O
the	O
Beijing	O
genotype	O
were	O
associated	O
with	O
strains	O
originating	O
in	O
eastern	O
European	O
countries	O
.	O

Molecular	O
cluster	O
detection	O
contributes	O
to	O
identification	O
of	O
transmission	O
profile	O
,	O
risk	O
factors	O
,	O
and	O
control	O
measures	O
.	O
Association	O
study	O
of	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4	B-GeneOrGeneProduct
with	O
schizophrenia	B-DiseaseOrPhenotypicFeature
,	O
depression	B-DiseaseOrPhenotypicFeature
,	O
and	O
heroin	B-DiseaseOrPhenotypicFeature
addiction	I-DiseaseOrPhenotypicFeature
.	O

This	O
study	O
investigated	O
the	O
possible	O
association	O
between	O
three	O
functional	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
the	O
dopamine	B-GeneOrGeneProduct
D4	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
DRD4	B-GeneOrGeneProduct
)	O
gene	O
and	O
schizophrenia	B-DiseaseOrPhenotypicFeature
,	O
depression	B-DiseaseOrPhenotypicFeature
,	O
and	O
heroin	B-DiseaseOrPhenotypicFeature
addiction	I-DiseaseOrPhenotypicFeature
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
venous	O
blood	O
leukocytes	O
of	O
322	O
unrelated	O
patients	B-OrganismTaxon
with	O
schizophrenia	B-DiseaseOrPhenotypicFeature
,	O
156	O
patients	B-OrganismTaxon
with	O
depression	B-DiseaseOrPhenotypicFeature
,	O
300	O
patients	B-OrganismTaxon
with	O
heroin	B-DiseaseOrPhenotypicFeature
addiction	I-DiseaseOrPhenotypicFeature
,	O
and	O
300	O
healthy	O
unrelated	O
individuals	O
.	O

Polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
DRD4	B-GeneOrGeneProduct
(	O
-	O
120	I-SequenceVariant
bp	I-SequenceVariant
duplication	I-SequenceVariant
,	O
-	O
616C	I-SequenceVariant
/	O
G	I-SequenceVariant
,	O
and	O
-	O
521C	I-SequenceVariant
/	O
T	I-SequenceVariant
)	O
were	O
genotyped	O
using	O
allele	O
-	O
specific	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

Genotype	O
and	O
allele	O
were	O
analyzed	O
using	O
SPSS	O
11	O
.	O
5	O
software	O
.	O

Results	O
of	O
this	O
analysis	O
indicated	O
that	O
there	O
is	O
a	O
strong	O
finding	O
of	O
-	O
120	I-SequenceVariant
bp	I-SequenceVariant
duplication	I-SequenceVariant
allele	O
frequencies	O
with	O
schizophrenia	B-DiseaseOrPhenotypicFeature
(	O
p	O
=	O
0	O
.	O
008	O
)	O
and	O
weak	O
finding	O
with	O
-	O
1240	I-SequenceVariant
L	I-SequenceVariant
/	O
S	I-SequenceVariant
and	O
for	O
paranoid	B-DiseaseOrPhenotypicFeature
schizophrenia	I-DiseaseOrPhenotypicFeature
(	O
p	O
=	O
0	O
.	O
022	O
)	O
.	O

Interestingly	O
,	O
there	O
is	O
a	O
stronger	O
finding	O
with	O
-	O
521	I-SequenceVariant
C	I-SequenceVariant
/	O
T	I-SequenceVariant
allele	O
frequencies	O
with	O
heroin	B-DiseaseOrPhenotypicFeature
dependence	I-DiseaseOrPhenotypicFeature
(	O
p	O
=	O
0	O
.	O
0002	O
)	O
.	O

These	O
observations	O
strongly	O
suggest	O
that	O
the	O
-	O
120	I-SequenceVariant
-	O
bp	I-SequenceVariant
duplication	I-SequenceVariant
polymorphism	O
of	O
DRD4	B-GeneOrGeneProduct
is	O
associated	O
with	O
schizophrenia	B-DiseaseOrPhenotypicFeature
and	O
that	O
the	O
-	O
521	I-SequenceVariant
C	I-SequenceVariant
/	O
T	I-SequenceVariant
polymorphism	O
is	O
associated	O
with	O
heroin	B-DiseaseOrPhenotypicFeature
addiction	I-DiseaseOrPhenotypicFeature
.	O
Lack	O
of	O
major	O
involvement	O
of	O
human	B-OrganismTaxon
uroplakin	B-GeneOrGeneProduct
genes	O
in	O
vesicoureteral	B-DiseaseOrPhenotypicFeature
reflux	I-DiseaseOrPhenotypicFeature
:	O
implications	O
for	O
disease	O
heterogeneity	O
.	O

BACKGROUND	O
:	O
Primary	O
vesicoureteral	B-DiseaseOrPhenotypicFeature
reflux	I-DiseaseOrPhenotypicFeature
(	O
VUR	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
hereditary	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
characterized	O
by	O
the	O
retrograde	O
flow	O
of	O
urine	O
into	O
the	O
ureters	O
and	O
kidneys	O
.	O

It	O
affects	O
about	O
1%	O
of	O
the	O
young	O
children	O
and	O
is	O
thus	O
one	O
of	O
the	O
most	O
common	O
hereditary	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
.	O

Its	O
associated	O
nephropathy	B-DiseaseOrPhenotypicFeature
is	O
an	O
important	O
cause	O
of	O
end	B-DiseaseOrPhenotypicFeature
-	O
stage	I-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
in	O
children	O
and	O
adults	O
.	O

Recent	O
studies	O
indicate	O
that	O
genetic	O
ablation	O
of	O
mouse	B-OrganismTaxon
uroplakin	B-GeneOrGeneProduct
(	O
UP	I-GeneOrGeneProduct
)	O
III	I-GeneOrGeneProduct
gene	O
,	O
which	O
encodes	O
a	O
47	O
kD	O
urothelial	O
-	O
specific	O
integral	O
membrane	O
protein	O
forming	O
urothelial	O
plaques	O
,	O
causes	O
VUR	B-DiseaseOrPhenotypicFeature
and	O
hydronephrosis	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
To	O
begin	O
to	O
determine	O
whether	O
mutations	O
in	O
UP	B-GeneOrGeneProduct
genes	O
might	O
play	O
a	O
role	O
in	O
human	B-OrganismTaxon
VUR	B-DiseaseOrPhenotypicFeature
,	O
we	O
genotyped	O
all	O
four	O
UP	B-GeneOrGeneProduct
genes	O
in	O
76	O
patients	B-OrganismTaxon
with	O
radiologically	O
proven	O
primary	O
VUR	B-DiseaseOrPhenotypicFeature
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
and	O
sequencing	O
of	O
all	O
their	O
exons	O
plus	O
50	O
to	O
150	O
bp	O
of	O
flanking	O
intronic	O
sequences	O
.	O

RESULTS	O
:	O
Eighteen	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
were	O
identified	O
,	O
seven	O
of	O
which	O
were	O
missense	O
,	O
with	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
.	O

Since	O
healthy	O
relatives	O
of	O
the	O
VUR	B-DiseaseOrPhenotypicFeature
probands	O
are	O
not	O
reliable	O
negative	O
controls	O
for	O
VUR	B-DiseaseOrPhenotypicFeature
,	O
we	O
used	O
a	O
population	O
of	O
90	O
race	O
-	O
matched	O
,	O
healthy	O
individuals	O
,	O
unrelated	O
to	O
the	O
VUR	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
as	O
controls	O
to	O
perform	O
an	O
association	O
study	O
.	O

Most	O
of	O
the	O
SNPs	O
were	O
not	O
found	O
to	O
be	O
significantly	O
associated	O
with	O
VUR	B-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
SNP1	O
of	O
UP	B-GeneOrGeneProduct
Ia	I-GeneOrGeneProduct
gene	O
affecting	O
a	O
C	B-SequenceVariant
to	I-SequenceVariant
T	I-SequenceVariant
conversion	O
and	O
an	O
Ala7Val	B-SequenceVariant
change	O
,	O
and	O
SNP7	O
of	O
UP	B-GeneOrGeneProduct
III	I-GeneOrGeneProduct
affecting	O
a	O
C	B-SequenceVariant
to	I-SequenceVariant
G	I-SequenceVariant
conversion	O
and	O
a	O
Pro154Ala	B-SequenceVariant
change	O
,	O
were	O
marginally	O
associated	O
with	O
VUR	B-DiseaseOrPhenotypicFeature
(	O
both	O
P	O
=	O
0	O
.	O
08	O
)	O
.	O

Studies	O
of	O
additional	O
cases	O
yielded	O
a	O
second	O
set	O
of	O
data	O
that	O
,	O
in	O
combination	O
with	O
the	O
first	O
set	O
,	O
confirmed	O
a	O
weak	O
association	O
of	O
UP	B-GeneOrGeneProduct
III	I-GeneOrGeneProduct
SNP7	O
in	O
VUR	B-DiseaseOrPhenotypicFeature
(	O
P	O
=	O
0	O
.	O
036	O
adjusted	O
for	O
both	O
subsets	O
of	O
cases	O
vs	O
.	O

controls	O
)	O
.	O

CONCLUSION	O
:	O
Such	O
a	O
weak	O
association	O
and	O
the	O
lack	O
of	O
families	O
with	O
simple	O
dominant	O
Mendelian	O
inheritance	O
suggest	O
that	O
missense	O
changes	O
of	O
uroplakin	B-GeneOrGeneProduct
genes	O
cannot	O
play	O
a	O
dominant	O
role	O
in	O
causing	O
VUR	B-DiseaseOrPhenotypicFeature
in	O
humans	B-OrganismTaxon
,	O
although	O
they	O
may	O
be	O
weak	O
risk	O
factors	O
contributing	O
to	O
a	O
complex	O
polygenic	O
disease	O
.	O

The	O
fact	O
that	O
no	O
truncation	O
or	O
frame	O
shift	O
mutations	O
have	O
been	O
found	O
in	O
any	O
of	O
the	O
VUR	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
coupled	O
with	O
our	O
recent	O
finding	O
that	O
some	O
breeding	O
pairs	O
of	O
UP	B-GeneOrGeneProduct
III	I-GeneOrGeneProduct
knockout	O
mice	B-OrganismTaxon
yield	O
litters	O
that	O
show	O
not	O
only	O
VUR	B-DiseaseOrPhenotypicFeature
,	O
but	O
also	O
severe	O
hydronephrosis	B-DiseaseOrPhenotypicFeature
and	O
neonatal	B-DiseaseOrPhenotypicFeature
death	I-DiseaseOrPhenotypicFeature
,	O
raises	O
the	O
possibility	O
that	O
major	O
uroplakin	B-GeneOrGeneProduct
mutations	O
could	O
be	O
embryonically	O
or	O
postnatally	O
lethal	O
in	O
humans	B-OrganismTaxon
.	O
Midline	O
B3	O
serotonin	B-ChemicalEntity
nerves	O
in	O
rat	B-OrganismTaxon
medulla	O
are	O
involved	O
in	O
hypotensive	B-DiseaseOrPhenotypicFeature
effect	O
of	O
methyldopa	B-ChemicalEntity
.	O

Previous	O
experiments	O
in	O
this	O
laboratory	O
have	O
shown	O
that	O
microinjection	O
of	O
methyldopa	B-ChemicalEntity
onto	O
the	O
ventrolateral	O
cells	O
of	O
the	O
B3	O
serotonin	B-ChemicalEntity
neurons	O
in	O
the	O
medulla	O
elicits	O
a	O
hypotensive	B-DiseaseOrPhenotypicFeature
response	O
mediated	O
by	O
a	O
projection	O
descending	O
into	O
the	O
spinal	O
cord	O
.	O

The	O
present	O
experiments	O
were	O
designed	O
to	O
investigate	O
the	O
role	O
of	O
the	O
midline	O
cells	O
of	O
the	O
B3	O
serotonin	B-ChemicalEntity
neurons	O
in	O
the	O
medulla	O
,	O
coinciding	O
with	O
the	O
raphe	O
magnus	O
.	O

In	O
spontaneously	O
hypertensive	B-DiseaseOrPhenotypicFeature
,	O
stroke	B-DiseaseOrPhenotypicFeature
-	O
prone	O
rats	B-OrganismTaxon
,	O
microinjection	O
of	O
methyldopa	B-ChemicalEntity
into	O
the	O
area	O
of	O
the	O
midline	O
B3	O
serotonin	B-ChemicalEntity
cell	O
group	O
in	O
the	O
ventral	O
medulla	O
caused	O
a	O
potent	O
hypotension	B-DiseaseOrPhenotypicFeature
of	O
30	O
-	O
40	O
mm	O
Hg	O
,	O
which	O
was	O
maximal	O
2	O
-	O
3	O
h	O
after	O
administration	O
and	O
was	O
abolished	O
by	O
the	O
serotonin	B-ChemicalEntity
neurotoxin	O
5	B-ChemicalEntity
,	O
7	I-ChemicalEntity
-	O
dihydroxytryptamine	I-ChemicalEntity
(	O
5	B-ChemicalEntity
,	O
7	I-ChemicalEntity
-	O
DHT	I-ChemicalEntity
)	O
injected	O
intracerebroventricularly	O
.	O

However	O
,	O
intraspinal	O
injection	O
of	O
5	B-ChemicalEntity
,	O
7	I-ChemicalEntity
-	O
DHT	I-ChemicalEntity
to	O
produce	O
a	O
more	O
selective	O
lesion	O
of	O
only	O
descending	O
serotonin	B-ChemicalEntity
projections	O
in	O
the	O
spinal	O
cord	O
did	O
not	O
affect	O
this	O
hypotension	B-DiseaseOrPhenotypicFeature
.	O

Further	O
,	O
5	B-ChemicalEntity
,	O
7	I-ChemicalEntity
-	O
DHT	I-ChemicalEntity
lesion	O
of	O
serotonin	B-ChemicalEntity
nerves	O
travelling	O
in	O
the	O
median	O
forebrain	O
bundle	O
,	O
one	O
of	O
the	O
main	O
ascending	O
pathways	O
from	O
the	O
B3	O
serotonin	B-ChemicalEntity
cells	O
,	O
did	O
not	O
affect	O
the	O
fall	O
in	O
blood	O
pressure	O
associated	O
with	O
a	O
midline	O
B3	O
serotonin	B-ChemicalEntity
methyldopa	B-ChemicalEntity
injection	O
.	O

It	O
is	O
concluded	O
therefore	O
that	O
,	O
unlike	O
the	O
ventrolateral	O
B3	O
cells	O
which	O
mediate	O
a	O
methyldopa	B-ChemicalEntity
-	O
induced	O
hypotension	B-DiseaseOrPhenotypicFeature
via	O
descending	O
projections	O
,	O
the	O
midline	O
serotonin	B-ChemicalEntity
B3	O
cells	O
in	O
the	O
medulla	O
contribute	O
to	O
the	O
hypotensive	B-DiseaseOrPhenotypicFeature
action	O
of	O
methyldopa	B-ChemicalEntity
,	O
either	O
by	O
way	O
of	O
an	O
ascending	O
projection	O
which	O
does	O
not	O
pass	O
through	O
the	O
median	O
forebrain	O
bundle	O
,	O
or	O
through	O
a	O
projection	O
restricted	O
to	O
the	O
caudal	O
brainstem	O
.	O
A	O
novel	O
mutation	O
screening	O
system	O
for	O
Ehlers	B-DiseaseOrPhenotypicFeature
-	O
Danlos	I-DiseaseOrPhenotypicFeature
Syndrome	I-DiseaseOrPhenotypicFeature
,	O
vascular	I-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
by	O
high	O
-	O
resolution	O
melting	O
curve	O
analysis	O
in	O
combination	O
with	O
small	O
amplicon	O
genotyping	O
using	O
genomic	O
DNA	O
.	O

Ehlers	B-DiseaseOrPhenotypicFeature
-	O
Danlos	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
,	O
vascular	I-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
(	O
vEDS	B-DiseaseOrPhenotypicFeature
)	O
(	O
MIM	B-DiseaseOrPhenotypicFeature
#	O
130050	I-DiseaseOrPhenotypicFeature
)	O
is	O
an	O
autosomal	B-DiseaseOrPhenotypicFeature
dominant	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
caused	O
by	O
type	B-GeneOrGeneProduct
III	I-GeneOrGeneProduct
procollagen	I-GeneOrGeneProduct
gene	O
(	O
COL3A1	B-GeneOrGeneProduct
)	O
mutations	O
.	O

Most	O
COL3A1	B-GeneOrGeneProduct
mutations	O
are	O
detected	O
by	O
using	O
total	O
RNA	O
from	O
patient	B-OrganismTaxon
-	O
derived	O
fibroblasts	O
,	O
which	O
requires	O
an	O
invasive	O
skin	O
biopsy	O
.	O

High	O
-	O
resolution	O
melting	O
curve	O
analysis	O
(	O
hrMCA	O
)	O
has	O
recently	O
been	O
developed	O
as	O
a	O
post	O
-	O
PCR	O
mutation	O
scanning	O
method	O
which	O
enables	O
simple	O
,	O
rapid	O
,	O
cost	O
-	O
effective	O
,	O
and	O
highly	O
sensitive	O
mutation	O
screening	O
of	O
large	O
genes	O
.	O

We	O
established	O
a	O
hrMCA	O
method	O
to	O
screen	O
for	O
COL3A1	B-GeneOrGeneProduct
mutations	O
using	O
genomic	O
DNA	O
.	O

PCR	O
primers	O
pairs	O
for	O
COL3A1	B-GeneOrGeneProduct
(	O
52	O
amplicons	O
)	O
were	O
designed	O
to	O
cover	O
all	O
coding	O
regions	O
of	O
the	O
52	O
exons	O
,	O
including	O
the	O
splicing	O
sites	O
.	O

We	O
used	O
15	O
DNA	O
samples	O
(	O
8	O
validation	O
samples	O
and	O
7	O
samples	O
of	O
clinically	O
suspected	O
vEDS	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
)	O
in	O
this	O
study	O
.	O

The	O
eight	O
known	O
COL3A1	B-GeneOrGeneProduct
mutations	O
in	O
validation	O
samples	O
were	O
all	O
successfully	O
detected	O
by	O
the	O
hrMCA	O
.	O

In	O
addition	O
,	O
we	O
identified	O
five	O
novel	O
COL3A1	B-GeneOrGeneProduct
mutations	O
,	O
including	O
one	O
deletion	O
(	O
c	B-SequenceVariant
.	O
2187delA	I-SequenceVariant
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
c	B-SequenceVariant
.	O
2992C	I-SequenceVariant
>	O
T	I-SequenceVariant
)	O
that	O
could	O
not	O
be	O
determined	O
by	O
the	O
conventional	O
total	O
RNA	O
method	O
.	O

Furthermore	O
,	O
we	O
established	O
a	O
small	O
amplicon	O
genotyping	O
(	O
SAG	O
)	O
method	O
for	O
detecting	O
three	O
high	O
frequency	O
coding	O
-	O
region	O
SNPs	O
(	O
rs1800255	B-SequenceVariant
:	O
G	B-SequenceVariant
>	O
A	I-SequenceVariant
,	O
rs1801184	B-SequenceVariant
:	O
T	B-SequenceVariant
>	O
C	I-SequenceVariant
,	O
and	O
rs2271683	B-SequenceVariant
:	O
A	B-SequenceVariant
>	O
G	I-SequenceVariant
)	O
in	O
COL3A1	B-GeneOrGeneProduct
to	O
differentiate	O
mutations	O
before	O
sequencing	O
.	O

The	O
use	O
of	O
hrMCA	O
in	O
combination	O
with	O
SAG	O
from	O
genomic	O
DNA	O
enables	O
rapid	O
detection	O
of	O
COL3A1	B-GeneOrGeneProduct
mutations	O
with	O
high	O
efficiency	O
and	O
specificity	O
.	O

A	O
better	O
understanding	O
of	O
the	O
genotype	O
-	O
phenotype	O
correlation	O
in	O
COL3A1	B-GeneOrGeneProduct
using	O
this	O
method	O
will	O
lead	O
to	O
improve	O
in	O
diagnosis	O
and	O
treatment	O
.	O
Quinine	B-ChemicalEntity
-	O
induced	O
arrhythmia	B-DiseaseOrPhenotypicFeature
in	O
a	O
patient	O
with	O
severe	B-DiseaseOrPhenotypicFeature
malaria	I-DiseaseOrPhenotypicFeature
.	O

It	O
was	O
reported	O
that	O
there	O
was	O
a	O
case	O
of	O
severe	B-DiseaseOrPhenotypicFeature
malaria	I-DiseaseOrPhenotypicFeature
patient	O
with	O
jaundice	B-DiseaseOrPhenotypicFeature
who	O
presented	O
with	O
arrhythmia	B-DiseaseOrPhenotypicFeature
(	O
premature	B-DiseaseOrPhenotypicFeature
ventricular	I-DiseaseOrPhenotypicFeature
contraction	I-DiseaseOrPhenotypicFeature
)	O
while	O
getting	O
quinine	B-ChemicalEntity
infusion	O
was	O
reported	O
.	O

A	O
man	O
,	O
25	O
years	O
old	O
,	O
was	O
admitted	O
to	O
hospital	O
with	O
high	O
fever	B-DiseaseOrPhenotypicFeature
,	O
chill	B-DiseaseOrPhenotypicFeature
,	O
vomiting	B-DiseaseOrPhenotypicFeature
,	O
jaundice	B-DiseaseOrPhenotypicFeature
.	O

The	O
patient	O
was	O
fully	O
conscious	O
,	O
blood	O
pressure	O
120	O
/	O
80	O
mmHg	O
,	O
pulse	O
rate	O
100	O
x	O
/	O
minute	O
,	O
regular	O
.	O

On	O
admission	O
,	O
laboratory	O
examination	O
showed	O
Plasmodium	B-OrganismTaxon
falciparum	I-OrganismTaxon
(	O
+	O
+	O
+	O
+	O
)	O
,	O
total	O
bilirubin	B-ChemicalEntity
8	O
.	O
25	O
mg	O
/	O
dL	O
,	O
conjugated	O
bilirubin	B-ChemicalEntity
4	O
.	O
36	O
mg	O
/	O
dL	O
,	O
unconjugated	O
bilirubin	B-ChemicalEntity
3	O
.	O
89	O
mg	O
/	O
dL	O
,	O
potassium	B-ChemicalEntity
3	O
.	O
52	O
meq	O
/	O
L	O
Patient	O
was	O
diagnosed	O
as	O
severe	B-DiseaseOrPhenotypicFeature
malaria	I-DiseaseOrPhenotypicFeature
with	O
jaundice	B-DiseaseOrPhenotypicFeature
and	O
got	O
quinine	B-ChemicalEntity
infusion	O
in	O
dextrose	B-ChemicalEntity
5%	O
500	O
mg	O
/	O
8	O
hour	O
.	O

On	O
the	O
second	O
day	O
the	O
patient	O
had	O
vomitus	B-DiseaseOrPhenotypicFeature
,	O
diarrhea	B-DiseaseOrPhenotypicFeature
,	O
tinnitus	B-DiseaseOrPhenotypicFeature
,	O
loss	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
hearing	I-DiseaseOrPhenotypicFeature
.	O

After	O
30	O
hours	O
of	O
quinine	B-ChemicalEntity
infusion	O
the	O
patient	O
felt	O
palpitation	B-DiseaseOrPhenotypicFeature
and	O
electrocardiography	O
(	O
ECG	O
)	O
recording	O
showed	O
premature	B-DiseaseOrPhenotypicFeature
ventricular	I-DiseaseOrPhenotypicFeature
contraction	I-DiseaseOrPhenotypicFeature
(	O
PVC	B-DiseaseOrPhenotypicFeature
)	O
>	O
5	O
x	O
/	O
minute	O
,	O
trigemini	O
,	O
constant	O
type	O
-	O
-	O
sinoatrial	B-DiseaseOrPhenotypicFeature
block	I-DiseaseOrPhenotypicFeature
,	O
positive	O
U	O
wave	O
.	O

He	O
was	O
treated	O
with	O
lidocaine	B-ChemicalEntity
50	O
mg	O
intravenously	O
followed	O
by	O
infusion	O
1500	O
mg	O
in	O
dextrose	B-ChemicalEntity
5%	O
/	O
24	O
hour	O
and	O
potassium	B-ChemicalEntity
aspartate	I-ChemicalEntity
tablet	O
.	O

Quinine	B-ChemicalEntity
infusion	O
was	O
discontinued	O
and	O
changed	O
with	O
sulfate	O
quinine	B-ChemicalEntity
tablets	O
.	O

Three	O
hours	O
later	O
the	O
patient	O
felt	O
better	O
,	O
the	O
frequency	O
of	O
PVC	B-DiseaseOrPhenotypicFeature
reduced	O
to	O
4	O
-	O
5	O
x	O
/	O
minute	O
and	O
on	O
the	O
third	O
day	O
ECG	O
was	O
normal	O
,	O
potassium	B-ChemicalEntity
level	O
was	O
3	O
.	O
34	O
meq	O
/	O
L	O
.	O

He	O
was	O
discharged	O
on	O
7th	O
day	O
in	O
good	O
condition	O
.	O

Quinine	B-ChemicalEntity
,	O
like	O
quinidine	B-ChemicalEntity
,	O
is	O
a	O
chincona	B-ChemicalEntity
alkaloid	I-ChemicalEntity
that	O
has	O
anti	O
-	O
arrhythmic	B-DiseaseOrPhenotypicFeature
property	O
,	O
although	O
it	O
also	O
pro	O
-	O
arrhythmic	B-DiseaseOrPhenotypicFeature
that	O
can	O
cause	O
various	O
arrhythmias	B-DiseaseOrPhenotypicFeature
,	O
including	O
severe	O
arrhythmia	B-DiseaseOrPhenotypicFeature
such	O
as	O
multiple	O
PVC	B-DiseaseOrPhenotypicFeature
.	O

Administration	O
of	O
parenteral	O
quinine	B-ChemicalEntity
must	O
be	O
done	O
carefully	O
and	O
with	O
good	O
observation	O
because	O
of	O
its	O
pro	O
-	O
arrhythmic	B-DiseaseOrPhenotypicFeature
effect	O
,	O
especially	O
in	O
older	O
patients	O
who	O
have	O
heart	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
or	O
patients	O
with	O
electrolyte	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
(	O
hypokalemia	B-DiseaseOrPhenotypicFeature
)	O
which	O
frequently	O
occurs	O
due	O
to	O
vomiting	B-DiseaseOrPhenotypicFeature
and	O
or	O
diarrhea	B-DiseaseOrPhenotypicFeature
in	O
malaria	B-DiseaseOrPhenotypicFeature
cases	O
.	O
Low	O
frequency	O
of	O
deafness	B-DiseaseOrPhenotypicFeature
-	O
associated	O
GJB2	B-GeneOrGeneProduct
variants	O
in	O
Kenya	O
and	O
Sudan	O
and	O
novel	O
GJB2	B-GeneOrGeneProduct
variants	O
.	O

A	O
large	O
proportion	O
of	O
non	B-DiseaseOrPhenotypicFeature
-	O
syndromic	I-DiseaseOrPhenotypicFeature
autosomal	I-DiseaseOrPhenotypicFeature
recessive	I-DiseaseOrPhenotypicFeature
deafness	I-DiseaseOrPhenotypicFeature
(	O
NSARD	B-DiseaseOrPhenotypicFeature
)	O
in	O
many	O
populations	O
is	O
caused	O
by	O
variants	O
of	O
the	O
GJB2	B-GeneOrGeneProduct
gene	O
.	O

Here	O
,	O
the	O
frequency	O
of	O
GJB2	B-GeneOrGeneProduct
variants	O
was	O
studied	O
in	O
406	O
and	O
183	O
apparently	O
unrelated	O
children	O
from	O
Kenya	O
and	O
Sudan	O
,	O
respectively	O
,	O
with	O
mostly	O
severe	O
to	O
profound	O
non	B-DiseaseOrPhenotypicFeature
-	O
syndromic	I-DiseaseOrPhenotypicFeature
deafness	I-DiseaseOrPhenotypicFeature
.	O

Nine	O
(	O
2	O
.	O
2	O
%	O
)	O
Kenyan	O
and	O
12	O
(	O
6	O
.	O
6	O
%	O
)	O
of	O
the	O
Sudanese	O
children	O
only	O
were	O
carriers	O
of	O
variants	O
within	O
the	O
coding	O
sequence	O
of	O
the	O
GJB2	B-GeneOrGeneProduct
gene	O
.	O

Variants	O
in	O
the	O
5	O
'	O
-	O
adjacent	O
region	O
were	O
detected	O
in	O
further	O
115	O
individuals	O
.	O

A	O
total	O
of	O
10	O
novel	O
variants	O
was	O
recognized	O
,	O
among	O
them	O
four	O
variants	O
in	O
the	O
adjacent	O
5	O
'	O
-	O
region	O
of	O
the	O
GJB2	B-GeneOrGeneProduct
coding	O
exon	O
2	O
(	O
g	B-SequenceVariant
.	O
3318	I-SequenceVariant
-	O
6T	I-SequenceVariant
>	O
A	I-SequenceVariant
,	O
g	B-SequenceVariant
.	O
3318	I-SequenceVariant
-	O
15C	I-SequenceVariant
>	O
T	I-SequenceVariant
,	O
g	B-SequenceVariant
.	O
3318	I-SequenceVariant
-	O
34C	I-SequenceVariant
>	O
T	I-SequenceVariant
,	O
g	B-SequenceVariant
.	O
3318	I-SequenceVariant
-	O
35T	I-SequenceVariant
>	O
G	I-SequenceVariant
)	O
,	O
a	O
6	O
base	O
-	O
pair	O
deletion	O
(	O
g	B-SequenceVariant
.	O
3455_3460del	I-SequenceVariant
[	O
p	B-SequenceVariant
.	O
Asp46_Gln48delinsGlu	I-SequenceVariant
]	O
)	O
,	O
a	O
variant	O
leading	O
to	O
a	O
stop	O
codon	O
(	O
g	B-SequenceVariant
.	O
3512C	I-SequenceVariant
>	O
A	I-SequenceVariant
[	O
p	B-SequenceVariant
.	O
Tyr65X	I-SequenceVariant
]	O
)	O
,	O
synonymous	O
variants	O
(	O
g	B-SequenceVariant
.	O
3395C	I-SequenceVariant
>	O
T	I-SequenceVariant
[	O
p	B-SequenceVariant
.	O
Thr26	I-SequenceVariant
]	O
,	O
g	B-SequenceVariant
.	O
3503C	I-SequenceVariant
>	O
T	I-SequenceVariant
[	O
p	B-SequenceVariant
.	O
Asn62	I-SequenceVariant
]	O
,	O
g	B-SequenceVariant
.	O
3627A	I-SequenceVariant
>	O
C	I-SequenceVariant
[	O
p	B-SequenceVariant
.	O
Arg104	I-SequenceVariant
]	O
)	O
,	O
and	O
one	O
non	O
-	O
synonymous	O
variant	O
(	O
g	B-SequenceVariant
.	O
3816C	I-SequenceVariant
>	O
A	I-SequenceVariant
[	O
p	B-SequenceVariant
.	O
Val167Met	I-SequenceVariant
]	O
)	O
.	O

In	O
addition	O
,	O
the	O
previously	O
described	O
variants	O
g	B-SequenceVariant
.	O
3352delG	I-SequenceVariant
(	O
commonly	O
designated	O
30delG	B-SequenceVariant
or	O
35	B-SequenceVariant
delG	I-SequenceVariant
)	O
,	O
g	B-SequenceVariant
.	O
3426G	I-SequenceVariant
>	O
A	I-SequenceVariant
[	O
p	B-SequenceVariant
.	O
Val37Ile	I-SequenceVariant
]	O
,	O
g	B-SequenceVariant
.	O
3697G	I-SequenceVariant
>	O
A	I-SequenceVariant
[	O
p	B-SequenceVariant
.	O
Arg127His	I-SequenceVariant
]	O
,	O
g	B-SequenceVariant
.	O
3774G	I-SequenceVariant
>	O
A	I-SequenceVariant
[	O
p	B-SequenceVariant
.	O
Val153Ile	I-SequenceVariant
]	O
,	O
and	O
g	B-SequenceVariant
.	O
3795G	I-SequenceVariant
>	O
A	I-SequenceVariant
[	O
p	B-SequenceVariant
.	O
Gly160Ser	I-SequenceVariant
]	O
were	O
identified	O
.	O

With	O
the	O
exception	O
of	O
g	B-SequenceVariant
.	O
3318	I-SequenceVariant
-	O
34C	I-SequenceVariant
>	O
T	I-SequenceVariant
and	O
g	B-SequenceVariant
.	O
3352delG	I-SequenceVariant
,	O
all	O
variants	O
occurred	O
heterozygously	O
.	O

For	O
most	O
of	O
the	O
variants	O
identified	O
in	O
the	O
Kenyan	O
and	O
Sudanese	O
study	O
population	O
,	O
a	O
causative	O
association	O
with	O
NSARD	B-DiseaseOrPhenotypicFeature
appears	O
to	O
be	O
unlikely	O
.	O

Compared	O
to	O
many	O
other	O
ethnic	O
groups	O
,	O
deafness	B-DiseaseOrPhenotypicFeature
-	O
associated	O
variants	O
of	O
the	O
coding	O
region	O
of	O
GJB2	B-GeneOrGeneProduct
are	O
rare	O
in	O
Sudan	O
and	O
Kenya	O
,	O
suggesting	O
a	O
role	O
of	O
other	O
genetic	O
,	O
or	O
epigenetic	O
factors	O
as	O
a	O
cause	O
for	O
deafness	B-DiseaseOrPhenotypicFeature
in	O
these	O
countries	O
.	O
A	O
novel	O
point	O
mutation	O
in	O
helix	O
10	O
of	O
the	O
human	B-OrganismTaxon
glucocorticoid	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
causes	O
generalized	O
glucocorticoid	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
by	O
disrupting	O
the	O
structure	O
of	O
the	O
ligand	O
-	O
binding	O
domain	O
.	O

CONTEXT	O
:	O
Generalized	O
glucocorticoid	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
syndrome	O
is	O
a	O
rare	O
familial	O
or	O
sporadic	O
condition	O
characterized	O
by	O
partial	O
insensitivity	O
to	O
glucocorticoids	B-ChemicalEntity
,	O
caused	O
by	O
mutations	O
in	O
the	O
glucocorticoid	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
GR	B-GeneOrGeneProduct
)	O
gene	O
.	O

Most	O
of	O
the	O
reported	O
cases	O
are	O
adults	O
,	O
demonstrating	O
symptoms	O
associated	O
with	O
mineralocorticoid	B-ChemicalEntity
and	O
/	O
or	O
adrenal	O
androgen	B-ChemicalEntity
excess	O
caused	O
by	O
compensatively	O
increased	O
secretion	O
of	O
the	O
adrenocorticotropic	O
hormone	O
.	O

PATIENT	B-OrganismTaxon
:	O
We	O
identified	O
a	O
new	O
2	O
-	O
yr	O
-	O
old	O
female	O
case	O
of	O
generalized	O
glucocorticoid	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
syndrome	O
.	O

The	O
patient	B-OrganismTaxon
(	O
TJ	O
)	O
presented	O
with	O
a	O
generalized	O
seizure	B-DiseaseOrPhenotypicFeature
associated	O
with	O
hypoglycemia	B-DiseaseOrPhenotypicFeature
and	O
hypokalemia	B-DiseaseOrPhenotypicFeature
.	O

She	O
also	O
had	O
hypertension	B-DiseaseOrPhenotypicFeature
and	O
premature	B-DiseaseOrPhenotypicFeature
pubarche	I-DiseaseOrPhenotypicFeature
,	O
whereas	O
dexamethasone	B-ChemicalEntity
effectively	O
suppressed	O
these	O
clinical	O
manifestations	O
.	O

RESULTS	O
:	O
The	O
patient	B-OrganismTaxon
'	O
s	O
GR	B-GeneOrGeneProduct
gene	O
had	O
a	O
heterozygotic	O
mutation	O
(	O
G	I-SequenceVariant
-	O
-	O
>	O
A	I-SequenceVariant
)	O
at	I-SequenceVariant
nucleotide	I-SequenceVariant
position	I-SequenceVariant
2141	I-SequenceVariant
(	O
exon	O
8	O
)	O
,	O
which	O
resulted	O
in	O
substitution	O
of	O
arginine	B-SequenceVariant
by	I-SequenceVariant
glutamine	I-SequenceVariant
at	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
position	I-SequenceVariant
714	I-SequenceVariant
in	O
the	O
ligand	O
-	O
binding	O
domain	O
(	O
LBD	O
)	O
of	O
the	O
GR	B-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
.	O

Molecular	O
analysis	O
revealed	O
that	O
the	O
mutant	O
receptor	O
had	O
significantly	O
impaired	O
transactivation	O
activity	O
with	O
a	O
2	O
-	O
fold	O
reduction	O
in	O
affinity	O
to	O
ligand	O
.	O

It	O
showed	O
attenuated	O
transactivation	O
of	O
the	O
activation	O
function	O
(	O
AF	O
)	O
-	O
2	O
and	O
reduced	O
binding	O
to	O
a	O
p160	B-GeneOrGeneProduct
nuclear	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
coactivator	I-GeneOrGeneProduct
.	O

Computer	O
-	O
based	O
structural	O
analysis	O
revealed	O
that	O
replacement	O
of	O
arginine	B-SequenceVariant
by	I-SequenceVariant
glutamine	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
714	I-SequenceVariant
transmitted	O
a	O
conformational	O
change	O
to	O
the	O
LBD	O
and	O
the	O
AF	O
-	O
2	O
transactivation	O
surface	O
,	O
resulting	O
in	O
a	O
decreased	O
binding	O
affinity	O
to	O
ligand	O
and	O
to	O
the	O
LXXLL	O
coactivator	O
motif	O
.	O

CONCLUSIONS	O
:	O
Dexamethasone	B-ChemicalEntity
treatment	O
is	O
effective	O
in	O
controlling	O
the	O
premature	B-DiseaseOrPhenotypicFeature
pubarche	I-DiseaseOrPhenotypicFeature
,	O
hypoglycemia	B-DiseaseOrPhenotypicFeature
,	O
hypertension	B-DiseaseOrPhenotypicFeature
,	O
and	O
hypokalemia	B-DiseaseOrPhenotypicFeature
in	O
this	O
child	O
case	O
,	O
wherein	O
arginine	B-SequenceVariant
714	I-SequenceVariant
plays	O
a	O
key	O
role	O
in	O
the	O
proper	O
formation	O
of	O
the	O
ligand	O
-	O
binding	O
pocket	O
and	O
the	O
AF	O
-	O
2	O
surface	O
of	O
the	O
GR	B-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
LBD	O
.	O
Inactivation	O
of	O
Sag	B-GeneOrGeneProduct
/	O
Rbx2	B-GeneOrGeneProduct
/	O
Roc2	B-GeneOrGeneProduct
e3	B-GeneOrGeneProduct
ubiquitin	I-GeneOrGeneProduct
ligase	I-GeneOrGeneProduct
triggers	O
senescence	O
and	O
inhibits	O
kras	B-GeneOrGeneProduct
-	O
induced	O
immortalization	O
.	O

Our	O
recent	O
study	O
showed	O
that	O
SAG	B-GeneOrGeneProduct
/	O
RBX2	B-GeneOrGeneProduct
E3	B-GeneOrGeneProduct
ubiquitin	I-GeneOrGeneProduct
ligase	I-GeneOrGeneProduct
regulates	O
apoptosis	O
and	O
vasculogenesis	O
by	O
promoting	O
degradation	O
of	O
NOXA	B-GeneOrGeneProduct
and	O
NF1	B-GeneOrGeneProduct
,	O
and	O
co	O
-	O
operates	O
with	O
Kras	B-GeneOrGeneProduct
to	O
promote	O
lung	B-DiseaseOrPhenotypicFeature
tumorigenesis	I-DiseaseOrPhenotypicFeature
by	O
activating	O
NFkappaB	B-GeneOrGeneProduct
and	O
mTOR	B-GeneOrGeneProduct
pathways	O
via	O
targeted	O
degradation	O
of	O
tumor	B-DiseaseOrPhenotypicFeature
suppressive	O
substrates	O
including	O
IkappaB	B-GeneOrGeneProduct
,	O
DEPTOR	B-GeneOrGeneProduct
,	O
p21	B-GeneOrGeneProduct
and	O
p27	B-GeneOrGeneProduct
.	O

Here	O
we	O
investigated	O
the	O
role	O
of	O
Sag	B-GeneOrGeneProduct
/	O
Rbx2	B-GeneOrGeneProduct
E3	B-GeneOrGeneProduct
ligase	I-GeneOrGeneProduct
in	O
cellular	O
senescence	O
and	O
immortalization	O
of	O
mouse	B-OrganismTaxon
embryonic	O
fibroblasts	O
(	O
MEFs	O
)	O
and	O
report	O
that	O
Sag	B-GeneOrGeneProduct
is	O
required	O
for	O
proper	O
cell	O
proliferation	O
and	O
Kras	B-GeneOrGeneProduct
(	O
G12D	B-SequenceVariant
)	O
-	O
induced	O
immortalization	O
.	O

Sag	B-GeneOrGeneProduct
inactivation	O
by	O
genetic	O
deletion	O
remarkably	O
suppresses	O
cell	O
proliferation	O
by	O
inducing	O
senescence	O
,	O
which	O
is	O
associated	O
with	O
accumulation	O
of	O
p16	B-GeneOrGeneProduct
,	O
but	O
not	O
p53	B-GeneOrGeneProduct
.	O

Mechanistically	O
,	O
Sag	B-GeneOrGeneProduct
deletion	O
caused	O
accumulation	O
of	O
Jun	B-GeneOrGeneProduct
-	O
B	I-GeneOrGeneProduct
,	O
a	O
substrate	O
of	O
Sag	B-GeneOrGeneProduct
-	O
Fbxw7	B-GeneOrGeneProduct
E3	B-GeneOrGeneProduct
ligase	I-GeneOrGeneProduct
and	O
a	O
transcription	O
factor	O
that	O
drives	O
p16	B-GeneOrGeneProduct
transcription	O
.	O

Importantly	O
,	O
senescence	O
triggered	O
by	O
Sag	B-GeneOrGeneProduct
deletion	O
can	O
be	O
largely	O
rescued	O
by	O
simultaneous	O
deletion	O
of	O
Cdkn2a	B-GeneOrGeneProduct
,	O
the	O
p16	B-GeneOrGeneProduct
encoding	O
gene	O
,	O
indicating	O
its	O
causal	O
role	O
.	O

Furthermore	O
,	O
Kras	B-GeneOrGeneProduct
(	O
G12D	B-SequenceVariant
)	O
-	O
induced	O
immortalization	O
can	O
also	O
be	O
abrogated	O
by	O
Sag	B-GeneOrGeneProduct
deletion	O
via	O
senescence	O
induction	O
,	O
which	O
is	O
again	O
rescued	O
by	O
simultaneous	O
deletion	O
of	O
Cdkn2a	B-GeneOrGeneProduct
.	O

Finally	O
,	O
we	O
found	O
that	O
Sag	B-GeneOrGeneProduct
deletion	O
inactivates	O
Kras	B-GeneOrGeneProduct
(	O
G12D	B-SequenceVariant
)	O
activity	O
and	O
block	O
the	O
MAPK	B-GeneOrGeneProduct
signaling	O
pathway	O
,	O
together	O
with	O
accumulated	O
p16	B-GeneOrGeneProduct
,	O
to	O
induce	O
senescence	O
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
Sag	B-GeneOrGeneProduct
is	O
a	O
Kras	B-GeneOrGeneProduct
(	O
G12D	B-SequenceVariant
)	O
-	O
cooperating	O
oncogene	O
required	O
for	O
Kras	B-GeneOrGeneProduct
(	O
G12D	B-SequenceVariant
)	O
-	O
induced	O
immortalization	O
and	O
transformation	O
,	O
and	O
targeting	O
SAG	B-GeneOrGeneProduct
-	O
SCF	B-GeneOrGeneProduct
E3	B-GeneOrGeneProduct
ligase	I-GeneOrGeneProduct
may	O
,	O
therefore	O
,	O
have	O
therapeutic	O
value	O
for	O
senescence	O
-	O
based	O
cancer	B-DiseaseOrPhenotypicFeature
treatment	O
.	O
In	O
vivo	O
evidences	O
suggesting	O
the	O
role	O
of	O
oxidative	O
stress	O
in	O
pathogenesis	O
of	O
vancomycin	B-ChemicalEntity
-	O
induced	O
nephrotoxicity	B-DiseaseOrPhenotypicFeature
:	O
protection	O
by	O
erdosteine	B-ChemicalEntity
.	O

The	O
aims	O
of	O
this	O
study	O
were	O
to	O
examine	O
vancomycin	B-ChemicalEntity
(	O
VCM	B-ChemicalEntity
)	O
-	O
induced	O
oxidative	O
stress	O
that	O
promotes	O
production	O
of	O
reactive	B-ChemicalEntity
oxygen	I-ChemicalEntity
species	I-ChemicalEntity
(	O
ROS	B-ChemicalEntity
)	O
and	O
to	O
investigate	O
the	O
role	O
of	O
erdosteine	B-ChemicalEntity
,	O
an	O
expectorant	O
agent	O
,	O
which	O
has	O
also	O
antioxidant	B-ChemicalEntity
properties	O
,	O
on	O
kidney	O
tissue	O
against	O
the	O
possible	O
VCM	B-ChemicalEntity
-	O
induced	O
renal	B-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
.	O

Rats	B-OrganismTaxon
were	O
divided	O
into	O
three	O
groups	O
:	O
sham	O
,	O
VCM	B-ChemicalEntity
and	O
VCM	B-ChemicalEntity
plus	O
erdosteine	B-ChemicalEntity
.	O

VCM	B-ChemicalEntity
was	O
administrated	O
intraperitoneally	O
(	O
i	O
.	O
p	O
.	O
)	O
with	O
200mgkg	O
(	O
-	O
1	O
)	O
twice	O
daily	O
for	O
7	O
days	O
.	O

Erdosteine	B-ChemicalEntity
was	O
administered	O
orally	O
.	O

VCM	B-ChemicalEntity
administration	O
to	O
control	O
rats	B-OrganismTaxon
significantly	O
increased	O
renal	O
malondialdehyde	B-ChemicalEntity
(	O
MDA	B-ChemicalEntity
)	O
and	O
urinary	O
N	B-GeneOrGeneProduct
-	O
acetyl	I-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
-	O
d	I-GeneOrGeneProduct
-	O
glucosaminidase	I-GeneOrGeneProduct
(	O
NAG	B-GeneOrGeneProduct
,	O
a	O
marker	O
of	O
renal	B-DiseaseOrPhenotypicFeature
tubular	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
)	O
excretion	O
but	O
decreased	O
superoxide	B-ChemicalEntity
dismutase	I-ChemicalEntity
(	O
SOD	B-ChemicalEntity
)	O
and	O
catalase	B-GeneOrGeneProduct
(	O
CAT	B-GeneOrGeneProduct
)	O
activities	O
.	O

Erdosteine	B-ChemicalEntity
administration	O
with	O
VCM	B-ChemicalEntity
injections	O
caused	O
significantly	O
decreased	O
renal	O
MDA	B-ChemicalEntity
and	O
urinary	O
NAG	B-GeneOrGeneProduct
excretion	O
,	O
and	O
increased	O
SOD	B-ChemicalEntity
activity	O
,	O
but	O
not	O
CAT	B-GeneOrGeneProduct
activity	O
in	O
renal	O
tissue	O
when	O
compared	O
with	O
VCM	B-ChemicalEntity
alone	O
.	O

Erdosteine	B-ChemicalEntity
showed	O
histopathological	O
protection	O
against	O
VCM	B-ChemicalEntity
-	O
induced	O
nephrotoxicity	B-DiseaseOrPhenotypicFeature
.	O

There	O
were	O
a	O
significant	O
dilatation	O
of	O
tubular	O
lumens	O
,	O
extensive	O
epithelial	O
cell	O
vacuolization	O
,	O
atrophy	B-DiseaseOrPhenotypicFeature
,	O
desquamation	B-DiseaseOrPhenotypicFeature
,	O
and	O
necrosis	B-DiseaseOrPhenotypicFeature
in	O
VCM	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
more	O
than	O
those	O
of	O
the	O
control	O
and	O
the	O
erdosteine	B-ChemicalEntity
groups	O
.	O

Erdosteine	B-ChemicalEntity
caused	O
a	O
marked	O
reduction	O
in	O
the	O
extent	O
of	O
tubular	O
damage	O
.	O

It	O
is	O
concluded	O
that	O
oxidative	O
tubular	O
damage	O
plays	O
an	O
important	O
role	O
in	O
the	O
VCM	B-ChemicalEntity
-	O
induced	O
nephrotoxicity	B-DiseaseOrPhenotypicFeature
and	O
the	O
modulation	O
of	O
oxidative	O
stress	O
with	O
erdosteine	B-ChemicalEntity
reduces	O
the	O
VCM	B-ChemicalEntity
-	O
induced	O
kidney	B-DiseaseOrPhenotypicFeature
damage	I-DiseaseOrPhenotypicFeature
both	O
at	O
the	O
biochemical	O
and	O
histological	O
levels	O
.	O
Bone	B-GeneOrGeneProduct
morphogenetic	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
interacts	O
with	O
activin	B-GeneOrGeneProduct
and	O
GnRH	B-GeneOrGeneProduct
to	O
modulate	O
gonadotrophin	B-GeneOrGeneProduct
secretion	O
in	O
LbetaT2	B-CellLine
gonadotrophs	O
.	O

We	O
have	O
shown	O
previously	O
that	O
,	O
in	O
sheep	B-OrganismTaxon
primary	O
pituitary	O
cells	O
,	O
bone	B-GeneOrGeneProduct
morphogenetic	I-GeneOrGeneProduct
proteins	I-GeneOrGeneProduct
(	O
BMP	I-GeneOrGeneProduct
)	O
-	O
4	I-GeneOrGeneProduct
inhibits	O
FSHbeta	B-GeneOrGeneProduct
mRNA	O
expression	O
and	O
FSH	B-GeneOrGeneProduct
release	O
.	O

In	O
contrast	O
,	O
in	O
mouse	B-OrganismTaxon
LbetaT2	B-CellLine
gonadotrophs	O
,	O
others	O
have	O
shown	O
a	O
stimulatory	O
effect	O
of	O
BMPs	B-GeneOrGeneProduct
on	O
basal	O
or	O
activin	B-GeneOrGeneProduct
-	O
stimulated	O
FSHbeta	B-GeneOrGeneProduct
promoter	O
-	O
driven	O
transcription	O
.	O

As	O
a	O
species	O
comparison	O
with	O
our	O
previous	O
results	O
,	O
we	O
used	O
LbetaT2	B-CellLine
cells	O
to	O
investigate	O
the	O
effects	O
of	O
BMP	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
on	O
gonadotrophin	B-GeneOrGeneProduct
mRNA	O
and	O
secretion	O
modulated	O
by	O
activin	B-GeneOrGeneProduct
and	O
GnRH	B-GeneOrGeneProduct
.	O

BMP	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
alone	O
had	O
no	O
effect	O
on	O
FSH	B-GeneOrGeneProduct
production	O
,	O
but	O
enhanced	O
the	O
activin	B-GeneOrGeneProduct
+	O
GnRH	B-GeneOrGeneProduct
-	O
induced	O
stimulation	O
of	O
FSHbeta	B-GeneOrGeneProduct
mRNA	O
and	O
FSH	B-GeneOrGeneProduct
secretion	O
,	O
without	O
any	O
effect	O
on	O
follistatin	B-GeneOrGeneProduct
mRNA	O
.	O

BMP	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
reduced	O
LHbeta	B-GeneOrGeneProduct
mRNA	O
up	O
-	O
regulation	O
in	O
response	O
to	O
GnRH	B-GeneOrGeneProduct
(	O
+	O
/	O
-	O
activin	B-GeneOrGeneProduct
)	O
and	O
decreased	O
GnRH	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
expression	O
,	O
which	O
would	O
favour	O
FSH	B-GeneOrGeneProduct
,	O
rather	O
than	O
LH	B-GeneOrGeneProduct
,	O
synthesis	O
and	O
secretion	O
.	O

In	O
contrast	O
to	O
sheep	B-OrganismTaxon
pituitary	O
gonadotrophs	O
,	O
which	O
express	O
only	O
BMP	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
types	I-GeneOrGeneProduct
IA	I-GeneOrGeneProduct
(	O
BMPRIA	I-GeneOrGeneProduct
)	O
and	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
(	O
BMPRII	I-GeneOrGeneProduct
)	O
,	O
LbetaT2	B-CellLine
cells	O
also	O
express	O
BMPRIB	B-GeneOrGeneProduct
.	O

Smad1	B-GeneOrGeneProduct
/	O
5	I-GeneOrGeneProduct
phosphorylation	O
induced	O
by	O
BMP	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
,	O
indicating	O
activation	O
of	O
BMP	B-GeneOrGeneProduct
signalling	O
,	O
was	O
the	O
same	O
whether	O
BMP	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
was	O
used	O
alone	O
or	O
combined	O
with	O
activin	B-GeneOrGeneProduct
+	O
/	O
-	O
GnRH	B-GeneOrGeneProduct
.	O

We	O
hypothesized	O
that	O
activin	B-GeneOrGeneProduct
and	O
/	O
or	O
GnRH	B-GeneOrGeneProduct
pathways	O
may	O
be	O
modulated	O
by	O
BMP	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
,	O
but	O
neither	O
the	O
activin	B-GeneOrGeneProduct
-	O
stimulated	O
phosphorylation	O
of	O
Smad2	B-GeneOrGeneProduct
/	O
3	I-GeneOrGeneProduct
nor	O
the	O
GnRH	B-GeneOrGeneProduct
-	O
induced	O
ERK1	B-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
or	O
cAMP	B-GeneOrGeneProduct
response	I-GeneOrGeneProduct
element	I-GeneOrGeneProduct
-	O
binding	I-GeneOrGeneProduct
phosphorylation	O
were	O
modified	O
.	O

However	O
,	O
the	O
GnRH	B-GeneOrGeneProduct
-	O
induced	O
activation	O
of	O
p38	B-GeneOrGeneProduct
MAPK	I-GeneOrGeneProduct
was	O
decreased	O
by	O
BMP	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
.	O

This	O
was	O
associated	O
with	O
increased	O
FSHbeta	B-GeneOrGeneProduct
mRNA	O
levels	O
and	O
FSH	B-GeneOrGeneProduct
secretion	O
,	O
but	O
decreased	O
LHbeta	B-GeneOrGeneProduct
mRNA	O
levels	O
.	O

These	O
results	O
confirm	O
1	O
.	O

BMPs	B-GeneOrGeneProduct
as	O
important	O
modulators	O
of	O
activin	B-GeneOrGeneProduct
and	O
/	O
or	O
GnRH	B-GeneOrGeneProduct
-	O
stimulated	O
gonadotrophin	B-GeneOrGeneProduct
synthesis	O
and	O
release	O
and	O
2	O
.	O

important	O
species	O
differences	O
in	O
these	O
effects	O
,	O
which	O
could	O
relate	O
to	O
differences	O
in	O
BMP	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
expression	O
in	O
gonadotrophs	O
.	O
Single	O
nucleotide	O
polymorphisms	O
of	O
the	O
HNF4alpha	B-GeneOrGeneProduct
gene	O
are	O
associated	O
with	O
the	O
conversion	O
to	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
:	O
the	O
STOP	O
-	O
NIDDM	O
trial	O
.	O

Hepatocyte	B-GeneOrGeneProduct
nuclear	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
4alpha	I-GeneOrGeneProduct
(	O
HNF4alpha	B-GeneOrGeneProduct
)	O
is	O
a	O
transcription	O
factor	O
,	O
which	O
is	O
necessary	O
for	O
normal	O
function	O
of	O
human	B-OrganismTaxon
liver	O
and	O
pancreatic	O
islets	O
.	O

We	O
investigated	O
whether	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
of	O
HNF4A	B-GeneOrGeneProduct
,	O
encoding	O
HNF4alpha	B-GeneOrGeneProduct
,	O
influenced	O
the	O
conversion	O
from	O
impaired	B-DiseaseOrPhenotypicFeature
glucose	I-DiseaseOrPhenotypicFeature
tolerance	I-DiseaseOrPhenotypicFeature
(	O
IGT	B-DiseaseOrPhenotypicFeature
)	O
to	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
in	O
subjects	O
of	O
the	O
STOP	O
-	O
NIDDM	O
trial	O
.	O

This	O
trial	O
aimed	O
at	O
evaluating	O
the	O
effect	O
of	O
acarbose	B-ChemicalEntity
compared	O
to	O
placebo	O
in	O
the	O
prevention	O
of	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
.	O

Eight	O
SNPs	O
covering	O
the	O
intragenic	O
and	O
alternate	O
P2	O
promoter	O
regions	O
of	O
HNF4A	B-GeneOrGeneProduct
were	O
genotyped	O
in	O
study	O
samples	O
using	O
the	O
TaqMan	O
Allelic	O
Discrimination	O
Assays	O
.	O

Three	O
SNPs	O
in	O
the	O
P2	O
promoter	O
region	O
(	O
rs4810424	B-SequenceVariant
,	O
rs1884614	B-SequenceVariant
,	O
and	O
rs2144908	B-SequenceVariant
)	O
were	O
in	O
almost	O
complete	O
association	O
(	O
D	O
'	O
>	O
0	O
.	O
97	O
,	O
r	O
(	O
2	O
)	O
>	O
0	O
.	O
95	O
)	O
and	O
,	O
therefore	O
,	O
only	O
rs4810424	B-SequenceVariant
was	O
included	O
in	O
further	O
analyses	O
.	O

Female	O
carriers	O
of	O
the	O
less	O
frequent	O
C	O
allele	O
of	O
rs4810424	B-SequenceVariant
had	O
a	O
1	O
.	O
7	O
-	O
fold	O
elevated	O
risk	O
[	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
1	O
.	O
09	O
-	O
2	O
.	O
66	O
;	O
P	O
=	O
0	O
.	O
020	O
]	O
for	O
the	O
conversion	O
to	O
diabetes	B-DiseaseOrPhenotypicFeature
compared	O
to	O
women	B-OrganismTaxon
with	O
the	O
common	O
genotype	O
after	O
the	O
adjustment	O
for	O
age	O
,	O
treatment	O
group	O
(	O
placebo	O
or	O
acarbose	B-ChemicalEntity
)	O
,	O
smoking	O
,	O
weight	O
at	O
baseline	O
,	O
and	O
weight	O
change	O
.	O

No	O
association	O
was	O
found	O
in	O
men	B-OrganismTaxon
.	O

Haplotype	O
analysis	O
based	O
on	O
three	O
SNPs	O
(	O
rs4810424	B-SequenceVariant
,	O
rs2071197	B-SequenceVariant
,	O
and	O
rs3818247	B-SequenceVariant
)	O
representing	O
the	O
linkage	O
disequilibrium	O
blocks	O
in	O
our	O
study	O
population	O
indicated	O
that	O
the	O
conversion	O
to	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
was	O
dependent	O
on	O
the	O
number	O
of	O
risk	O
alleles	O
in	O
different	O
haplotypes	O
in	O
women	B-OrganismTaxon
.	O

Our	O
results	O
suggest	O
that	O
SNPs	O
of	O
HNF4A	B-GeneOrGeneProduct
and	O
their	O
haplotypes	O
predispose	O
to	O
type	B-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
in	O
female	O
subjects	O
of	O
the	O
STOP	O
-	O
NIDDM	O
study	O
population	O
.	O
Identification	O
of	O
three	O
F5	B-GeneOrGeneProduct
gene	O
mutations	O
associated	O
with	O
inherited	B-DiseaseOrPhenotypicFeature
coagulation	I-DiseaseOrPhenotypicFeature
factor	I-DiseaseOrPhenotypicFeature
V	I-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
in	O
two	O
Chinese	O
pedigrees	O
.	O

To	O
investigate	O
the	O
molecular	O
defects	O
in	O
two	O
Chinese	O
pedigrees	O
with	O
inherited	B-DiseaseOrPhenotypicFeature
factor	I-DiseaseOrPhenotypicFeature
V	I-DiseaseOrPhenotypicFeature
(	O
FV	I-DiseaseOrPhenotypicFeature
)	O
deficiency	I-DiseaseOrPhenotypicFeature
.	O

A	O
37	O
-	O
year	O
-	O
old	O
male	O
(	O
proband	O
1	O
)	O
and	O
an	O
18	O
-	O
month	O
-	O
old	O
boy	O
(	O
proband	O
2	O
)	O
were	O
diagnosed	O
as	O
inherited	B-DiseaseOrPhenotypicFeature
coagulation	I-DiseaseOrPhenotypicFeature
FV	I-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
by	O
severely	O
reduced	O
plasma	O
levels	O
of	O
FV	B-GeneOrGeneProduct
activity	O
and	O
antigen	O
.	O

All	O
25	O
exons	O
and	O
their	O
flanking	O
sequence	O
of	O
F5	B-GeneOrGeneProduct
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
for	O
both	O
probands	O
and	O
the	O
PCR	O
products	O
were	O
directly	O
sequenced	O
.	O

Total	O
RNA	O
was	O
extracted	O
from	O
the	O
peripheral	O
lymphocytes	O
of	O
proband	O
1	O
for	O
detecting	O
the	O
changes	O
at	O
mRNA	O
level	O
.	O

The	O
homozygous	O
deletion	O
IVS8	B-SequenceVariant
-	O
2A	I-SequenceVariant
>	O
G	I-SequenceVariant
was	O
identified	O
in	O
the	O
F5	B-GeneOrGeneProduct
gene	O
of	O
proband	O
1	O
and	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
analysis	O
revealed	O
the	O
abolishment	O
of	O
the	O
canonical	O
splicing	O
site	O
by	O
the	O
mutation	O
and	O
the	O
activation	O
of	O
the	O
cryptic	O
acceptor	O
site	O
24	O
bp	O
upstream	O
instead	O
.	O

The	O
insertion	B-SequenceVariant
introduced	I-SequenceVariant
eight	I-SequenceVariant
additional	I-SequenceVariant
amino	I-SequenceVariant
acids	I-SequenceVariant
(	O
AA	O
)	O
into	O
the	O
FV	B-GeneOrGeneProduct
protein	O
.	O

Two	O
heterozygous	O
mutations	O
of	O
F5	B-GeneOrGeneProduct
gene	O
were	O
discovered	O
in	O
proband	O
2	O
.	O

The	O
2238	B-SequenceVariant
-	O
9del	I-SequenceVariant
AG	I-SequenceVariant
in	O
exon	O
13	O
introduced	O
a	O
premature	O
termination	O
code	O
at	O
689	B-SequenceVariant
AA	I-SequenceVariant
and	O
the	O
substitution	O
of	O
G6410	B-SequenceVariant
by	I-SequenceVariant
T	I-SequenceVariant
in	O
exon	O
23	O
lead	O
to	O
the	O
missense	O
mutation	O
Gly2079Val	B-SequenceVariant
.	O

Three	O
F5	B-GeneOrGeneProduct
gene	O
mutations	O
,	O
IVS8	B-SequenceVariant
-	O
2A	I-SequenceVariant
>	O
G	I-SequenceVariant
,	O
2238	B-SequenceVariant
-	O
9del	I-SequenceVariant
AG	I-SequenceVariant
and	O
G6410T	B-SequenceVariant
,	O
have	O
been	O
identified	O
in	O
two	O
Chinese	O
pedigree	O
with	O
congenital	B-DiseaseOrPhenotypicFeature
FV	I-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
,	O
respectively	O
.	O
Gene	O
therapy	O
for	O
cystic	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
airway	O
disease	O
-	O
is	O
clinical	O
success	O
imminent?	O
Cystic	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
(	O
CF	B-DiseaseOrPhenotypicFeature
)	O
was	O
one	O
of	O
the	O
first	O
inherited	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
for	O
which	O
gene	O
therapy	O
was	O
seriously	O
considered	O
as	O
a	O
realistic	O
option	O
for	O
treatment	O
,	O
and	O
as	O
such	O
,	O
it	O
has	O
long	O
provided	O
a	O
paradigm	O
for	O
gene	O
therapy	O
of	O
inherited	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
despite	O
the	O
cloning	O
of	O
the	O
cystic	B-GeneOrGeneProduct
fibrosis	I-GeneOrGeneProduct
transmembrane	I-GeneOrGeneProduct
conductance	I-GeneOrGeneProduct
regulator	I-GeneOrGeneProduct
gene	O
in	O
1989	O
,	O
over	O
15	O
years	O
later	O
a	O
practical	O
gene	O
therapy	O
for	O
CF	B-DiseaseOrPhenotypicFeature
has	O
not	O
eventuated	O
.	O

There	O
are	O
a	O
number	O
of	O
reasons	O
for	O
this	O
,	O
and	O
analysis	O
of	O
the	O
specific	O
issues	O
that	O
have	O
delayed	O
the	O
successful	O
development	O
of	O
gene	O
therapy	O
for	O
CF	B-DiseaseOrPhenotypicFeature
also	O
provides	O
general	O
insights	O
into	O
the	O
practical	O
complexities	O
involved	O
in	O
the	O
development	O
of	O
gene	O
therapy	O
for	O
inherited	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
.	O

The	O
issues	O
which	O
have	O
prevented	O
the	O
application	O
of	O
gene	O
therapy	O
for	O
CF	B-DiseaseOrPhenotypicFeature
to	O
date	O
include	O
the	O
lack	O
of	O
suitable	O
gene	O
delivery	O
technologies	O
,	O
the	O
complexities	O
of	O
the	O
interactions	O
between	O
the	O
host	O
and	O
vector	O
,	O
the	O
biology	O
of	O
the	O
lung	O
airways	O
,	O
and	O
the	O
nature	O
of	O
the	O
pathology	O
found	O
in	O
individuals	O
with	O
CF	B-DiseaseOrPhenotypicFeature
.	O

We	O
will	O
discuss	O
the	O
history	O
of	O
CF	B-DiseaseOrPhenotypicFeature
gene	O
therapy	O
with	O
specific	O
reference	O
to	O
these	O
and	O
other	O
issues	O
that	O
pre	O
-	O
occupy	O
the	O
field	O
at	O
present	O
:	O
namely	O
,	O
the	O
question	O
of	O
what	O
vectors	O
appear	O
to	O
be	O
suitable	O
for	O
airway	O
gene	O
delivery	O
in	O
CF	B-DiseaseOrPhenotypicFeature
,	O
what	O
cells	O
must	O
be	O
targeted	O
,	O
how	O
airway	O
epithelium	O
defences	O
can	O
be	O
overcome	O
or	O
eluded	O
to	O
allow	O
efficient	O
gene	O
delivery	O
,	O
how	O
to	O
ensure	O
safe	O
and	O
long	O
-	O
term	O
transgene	O
expression	O
and	O
the	O
need	O
to	O
identify	O
relevant	O
surrogate	O
success	O
measures	O
that	O
can	O
be	O
used	O
to	O
assess	O
the	O
outcome	O
of	O
gene	O
therapy	O
in	O
CF	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O
Amisulpride	B-ChemicalEntity
related	O
tic	B-DiseaseOrPhenotypicFeature
-	O
like	I-DiseaseOrPhenotypicFeature
symptoms	I-DiseaseOrPhenotypicFeature
in	O
an	O
adolescent	O
schizophrenic	B-DiseaseOrPhenotypicFeature
.	O

Tic	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	B-ChemicalEntity
such	O
as	O
risperidone	B-ChemicalEntity
,	O
olanzapine	B-ChemicalEntity
and	O
ziprasidone	B-ChemicalEntity
.	O

However	O
,	O
there	O
are	O
two	O
case	O
reports	O
that	O
show	O
tic	B-DiseaseOrPhenotypicFeature
-	O
like	I-DiseaseOrPhenotypicFeature
symptoms	I-DiseaseOrPhenotypicFeature
,	O
including	O
motor	O
and	O
phonic	O
variants	O
,	O
occurring	O
during	O
treatment	O
with	O
quetiapine	B-ChemicalEntity
or	O
clozapine	B-ChemicalEntity
.	O

We	O
present	O
a	O
15	O
-	O
year	O
-	O
old	O
girl	O
schizophrenic	B-DiseaseOrPhenotypicFeature
who	O
developed	O
frequent	O
involuntary	B-DiseaseOrPhenotypicFeature
eye	I-DiseaseOrPhenotypicFeature
-	O
blinking	I-DiseaseOrPhenotypicFeature
movements	I-DiseaseOrPhenotypicFeature
after	O
5	O
months	O
of	O
amisulpride	B-ChemicalEntity
treatment	O
(	O
1000	O
mg	O
per	O
day	O
)	O
.	O

The	O
tic	B-DiseaseOrPhenotypicFeature
-	O
like	I-DiseaseOrPhenotypicFeature
symptoms	I-DiseaseOrPhenotypicFeature
resolved	O
completely	O
after	O
we	O
reduced	O
the	O
dose	O
of	O
amisulpride	B-ChemicalEntity
down	O
to	O
800	O
mg	O
per	O
day	O
.	O

However	O
,	O
her	O
psychosis	B-DiseaseOrPhenotypicFeature
recurred	O
after	O
the	O
dose	O
reduction	O
.	O

We	O
then	O
placed	O
her	O
on	O
an	O
additional	O
100	O
mg	O
per	O
day	O
of	O
quetiapine	B-ChemicalEntity
.	O

She	O
has	O
been	O
in	O
complete	O
remission	O
under	O
the	O
combined	O
medications	O
for	O
more	O
than	O
one	O
year	O
and	O
maintains	O
a	O
fair	O
role	O
function	O
.	O

No	O
more	O
tic	B-DiseaseOrPhenotypicFeature
-	O
like	I-DiseaseOrPhenotypicFeature
symptoms	I-DiseaseOrPhenotypicFeature
or	O
other	O
side	O
effects	O
have	O
been	O
reported	O
.	O

Together	O
with	O
previously	O
reported	O
cases	O
,	O
our	O
patient	B-OrganismTaxon
suggests	O
that	O
tic	B-DiseaseOrPhenotypicFeature
-	O
like	I-DiseaseOrPhenotypicFeature
symptoms	I-DiseaseOrPhenotypicFeature
might	O
occur	O
in	O
certain	O
vulnerable	O
individuals	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	B-ChemicalEntity
such	O
as	O
quetiapine	B-ChemicalEntity
,	O
clozapine	B-ChemicalEntity
,	O
or	O
amisulpride	B-ChemicalEntity
.	O
Context	O
-	O
and	O
cell	O
-	O
dependent	O
effects	O
of	O
Delta	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
targeting	O
in	O
the	O
bone	O
marrow	O
microenvironment	O
.	O

Delta	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
(	O
Dll4	B-GeneOrGeneProduct
)	O
is	O
a	O
ligand	O
of	O
the	O
Notch	B-GeneOrGeneProduct
pathway	O
family	O
which	O
has	O
been	O
widely	O
studied	O
in	O
the	O
context	O
of	O
tumor	B-DiseaseOrPhenotypicFeature
angiogenesis	O
,	O
its	O
blockade	O
shown	O
to	O
result	O
in	O
non	O
-	O
productive	O
angiogenesis	O
and	O
halted	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
.	O

As	O
Dll4	B-GeneOrGeneProduct
inhibitors	O
enter	O
the	O
clinic	O
,	O
there	O
is	O
an	O
emerging	O
need	O
to	O
understand	O
their	O
side	O
effects	O
,	O
namely	O
the	O
systemic	O
consequences	O
of	O
Dll4	B-GeneOrGeneProduct
:	O
Notch	B-GeneOrGeneProduct
blockade	O
in	O
tissues	O
other	O
than	O
tumors	B-DiseaseOrPhenotypicFeature
.	O

The	O
present	O
study	O
focused	O
on	O
the	O
effects	O
of	O
systemic	O
anti	O
-	O
Dll4	B-GeneOrGeneProduct
targeting	O
in	O
the	O
bone	O
marrow	O
(	O
BM	O
)	O
microenvironment	O
.	O

Here	O
we	O
show	O
that	O
Dll4	B-GeneOrGeneProduct
blockade	O
with	O
monoclonal	O
antibodies	O
perturbs	O
the	O
BM	O
vascular	O
niche	O
of	O
sub	O
-	O
lethally	O
irradiated	O
mice	B-OrganismTaxon
,	O
resulting	O
in	O
increased	O
CD31	B-GeneOrGeneProduct
(	O
+	O
)	O
,	O
VE	B-GeneOrGeneProduct
-	O
Cadherin	I-GeneOrGeneProduct
(	O
+	O
)	O
and	O
c	B-GeneOrGeneProduct
-	O
kit	I-GeneOrGeneProduct
(	O
+	O
)	O
vessel	O
density	O
,	O
and	O
also	O
increased	O
megakaryocytes	O
,	O
whereas	O
CD105	B-GeneOrGeneProduct
(	O
+	O
)	O
,	O
VEGFR3	B-GeneOrGeneProduct
(	O
+	O
)	O
,	O
SMA	B-GeneOrGeneProduct
(	O
+	O
)	O
and	O
lectin	B-GeneOrGeneProduct
(	O
+	O
)	O
vessel	O
density	O
remained	O
unaltered	O
.	O

We	O
investigated	O
also	O
the	O
expression	O
of	O
angiocrine	O
genes	O
upon	O
Dll4	B-GeneOrGeneProduct
treatment	O
in	O
vivo	O
,	O
and	O
demonstrate	O
that	O
IGFbp2	B-GeneOrGeneProduct
,	O
IGFbp3	B-GeneOrGeneProduct
,	O
Angpt2	B-GeneOrGeneProduct
,	O
Dll4	B-GeneOrGeneProduct
,	O
DHH	B-GeneOrGeneProduct
and	O
VEGF	B-GeneOrGeneProduct
-	O
A	I-GeneOrGeneProduct
are	O
upregulated	O
,	O
while	O
FGF1	B-GeneOrGeneProduct
and	O
CSF2	B-GeneOrGeneProduct
are	O
reduced	O
.	O

In	O
vitro	O
treatment	O
of	O
endothelial	O
cells	O
with	O
anti	O
-	O
Dll4	B-GeneOrGeneProduct
reduced	O
Akt	B-GeneOrGeneProduct
phosphorylation	O
while	O
maintaining	O
similar	O
levels	O
of	O
Erk	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
phosphorylation	O
.	O

Besides	O
its	O
effects	O
in	O
the	O
BM	O
vascular	O
niche	O
,	O
anti	O
-	O
Dll4	B-GeneOrGeneProduct
treatment	O
perturbed	O
hematopoiesis	O
,	O
as	O
evidenced	O
by	O
increased	O
myeloid	O
(	O
CD11b	B-GeneOrGeneProduct
(	O
+	O
)	O
)	O
,	O
decreased	O
B	O
(	O
B220	B-GeneOrGeneProduct
(	O
+	O
)	O
)	O
and	O
T	O
(	O
CD3	B-GeneOrGeneProduct
(	O
+	O
)	O
)	O
lymphoid	O
BM	O
content	O
of	O
treated	O
mice	B-OrganismTaxon
,	O
with	O
a	O
corresponding	O
increase	O
in	O
myeloid	O
circulating	O
cells	O
.	O

Moreover	O
,	O
anti	O
-	O
Dll4	B-GeneOrGeneProduct
treatment	O
also	O
increased	O
the	O
number	O
of	O
CFU	O
-	O
M	O
and	O
-	O
G	O
colonies	O
in	O
methylcellulose	O
assays	O
,	O
independently	O
of	O
Notch1	B-GeneOrGeneProduct
.	O

Finally	O
,	O
anti	O
-	O
Dll4	B-GeneOrGeneProduct
treatment	O
of	O
donor	O
BM	O
improved	O
the	O
hematopoietic	O
recovery	O
of	O
lethally	O
irradiated	O
recipients	O
in	O
a	O
transplant	O
setting	O
.	O

Together	O
,	O
our	O
data	O
reveals	O
the	O
hematopoietic	O
(	O
BM	O
)	O
effects	O
of	O
systemic	O
anti	O
-	O
Dll4	B-GeneOrGeneProduct
treatment	O
result	O
from	O
qualitative	O
vascular	O
changes	O
and	O
also	O
direct	O
hematopoietic	O
cell	O
modulation	O
,	O
which	O
may	O
be	O
favorable	O
in	O
a	O
transplant	O
setting	O
.	O
Impact	O
of	O
CCR5delta32	B-GeneOrGeneProduct
host	O
genetic	O
background	O
and	O
disease	O
progression	O
on	O
HIV	B-OrganismTaxon
-	O
1	I-OrganismTaxon
intrahost	O
evolutionary	O
processes	O
:	O
efficient	O
hypothesis	O
testing	O
through	O
hierarchical	O
phylogenetic	O
models	O
.	O

The	O
interplay	O
between	O
C	B-GeneOrGeneProduct
-	O
C	I-GeneOrGeneProduct
chemokine	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
type	I-GeneOrGeneProduct
5	I-GeneOrGeneProduct
(	O
CCR5	B-GeneOrGeneProduct
)	O
host	O
genetic	O
background	O
,	O
disease	O
progression	O
,	O
and	O
intrahost	O
HIV	B-OrganismTaxon
-	O
1	I-OrganismTaxon
evolutionary	O
dynamics	O
remains	O
unclear	O
because	O
differences	O
in	O
viral	O
evolution	O
between	O
hosts	O
limit	O
the	O
ability	O
to	O
draw	O
conclusions	O
across	O
hosts	O
stratified	O
into	O
clinically	O
relevant	O
populations	O
.	O

Similar	O
inference	O
problems	O
are	O
proliferating	O
across	O
many	O
measurably	O
evolving	O
pathogens	O
for	O
which	O
intrahost	O
sequence	O
samples	O
are	O
readily	O
available	O
.	O

To	O
this	O
end	O
,	O
we	O
propose	O
novel	O
hierarchical	O
phylogenetic	O
models	O
(	O
HPMs	O
)	O
that	O
incorporate	O
fixed	O
effects	O
to	O
test	O
for	O
differences	O
in	O
dynamics	O
across	O
host	O
populations	O
in	O
a	O
formal	O
statistical	O
framework	O
employing	O
stochastic	O
search	O
variable	O
selection	O
and	O
model	O
averaging	O
.	O

To	O
clarify	O
the	O
role	O
of	O
CCR5	B-GeneOrGeneProduct
host	O
genetic	O
background	O
and	O
disease	O
progression	O
on	O
viral	O
evolutionary	O
patterns	O
,	O
we	O
obtain	O
gp120	B-GeneOrGeneProduct
envelope	O
sequences	O
from	O
clonal	O
HIV	B-OrganismTaxon
-	O
1	I-OrganismTaxon
variants	O
isolated	O
at	O
multiple	O
time	O
points	O
in	O
the	O
course	O
of	O
infection	B-DiseaseOrPhenotypicFeature
from	O
populations	O
of	O
HIV	B-DiseaseOrPhenotypicFeature
-	O
1	I-DiseaseOrPhenotypicFeature
-	O
infected	I-DiseaseOrPhenotypicFeature
individuals	O
who	O
only	O
harbored	O
CCR5	B-GeneOrGeneProduct
-	O
using	O
HIV	B-OrganismTaxon
-	O
1	I-OrganismTaxon
variants	O
at	O
all	O
time	O
points	O
.	O

Presence	O
or	O
absence	O
of	O
a	O
CCR5	B-GeneOrGeneProduct
wt	O
/	O
DD32	B-SequenceVariant
genotype	O
and	O
progressive	O
or	O
long	O
-	O
term	O
nonprogressive	O
course	O
of	O
infection	B-DiseaseOrPhenotypicFeature
stratify	O
the	O
clinical	O
populations	O
in	O
a	O
two	O
-	O
way	O
design	O
.	O

As	O
compared	O
with	O
the	O
standard	O
approach	O
of	O
analyzing	O
sequences	O
from	O
each	O
patient	B-OrganismTaxon
independently	O
,	O
the	O
HPM	O
provides	O
more	O
efficient	O
estimation	O
of	O
evolutionary	O
parameters	O
such	O
as	O
nucleotide	O
substitution	O
rates	O
and	O
d	O
(	O
N	O
)	O
/	O
d	O
(	O
S	O
)	O
rate	O
ratios	O
,	O
as	O
shown	O
by	O
significant	O
shrinkage	O
of	O
the	O
estimator	O
variance	O
.	O

The	O
fixed	O
effects	O
also	O
correct	O
for	O
nonindependence	O
of	O
data	O
between	O
populations	O
and	O
results	O
in	O
even	O
further	O
shrinkage	O
of	O
individual	O
patient	B-OrganismTaxon
estimates	O
.	O

Model	O
selection	O
suggests	O
an	O
association	O
between	O
nucleotide	O
substitution	O
rate	O
and	O
disease	O
progression	O
,	O
but	O
a	O
role	O
for	O
CCR5	B-GeneOrGeneProduct
genotype	O
remains	O
elusive	O
.	O

Given	O
the	O
absence	O
of	O
clear	O
d	O
(	O
N	O
)	O
/	O
d	O
(	O
S	O
)	O
differences	O
between	O
patient	B-OrganismTaxon
groups	O
,	O
delayed	O
onset	O
of	O
AIDS	B-DiseaseOrPhenotypicFeature
symptoms	O
appears	O
to	O
be	O
solely	O
associated	O
with	O
lower	O
viral	O
replication	O
rates	O
rather	O
than	O
with	O
differences	O
in	O
selection	O
on	O
amino	O
acid	O
fixation	O
.	O
Phenylephrine	B-ChemicalEntity
but	O
not	O
ephedrine	B-ChemicalEntity
reduces	O
frontal	O
lobe	O
oxygenation	O
following	O
anesthesia	O
-	O
induced	O
hypotension	B-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Vasopressor	O
agents	O
are	O
used	O
to	O
correct	O
anesthesia	O
-	O
induced	O
hypotension	B-DiseaseOrPhenotypicFeature
.	O

We	O
describe	O
the	O
effect	O
of	O
phenylephrine	B-ChemicalEntity
and	O
ephedrine	B-ChemicalEntity
on	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
following	O
anesthesia	O
-	O
induced	O
hypotension	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
Following	O
induction	O
of	O
anesthesia	O
by	O
fentanyl	B-ChemicalEntity
(	O
0	O
.	O
15	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
and	O
propofol	B-ChemicalEntity
(	O
2	O
.	O
0	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
,	O
13	O
patients	B-OrganismTaxon
received	O
phenylephrine	B-ChemicalEntity
(	O
0	O
.	O
1	O
mg	O
iv	O
)	O
and	O
12	O
patients	B-OrganismTaxon
received	O
ephedrine	B-ChemicalEntity
(	O
10	O
mg	O
iv	O
)	O
to	O
restore	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
.	O

Heart	O
rate	O
(	O
HR	O
)	O
,	O
MAP	O
,	O
stroke	B-DiseaseOrPhenotypicFeature
volume	O
(	O
SV	O
)	O
,	O
cardiac	O
output	O
(	O
CO	O
)	O
,	O
and	O
frontal	O
lobe	O
oxygenation	O
(	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
)	O
were	O
registered	O
.	O

RESULTS	O
:	O
Induction	O
of	O
anesthesia	O
was	O
followed	O
by	O
a	O
decrease	O
in	O
MAP	O
,	O
HR	O
,	O
SV	O
,	O
and	O
CO	O
concomitant	O
with	O
an	O
elevation	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

After	O
administration	O
of	O
phenylephrine	B-ChemicalEntity
,	O
MAP	O
increased	O
(	O
51	O
+	O
/	O
-	O
12	O
to	O
81	O
+	O
/	O
-	O
13	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
;	O
mean	O
+	O
/	O
-	O
SD	O
)	O
.	O

However	O
,	O
a	O
14%	O
(	O
from	O
70	O
+	O
/	O
-	O
8%	O
to	O
60	O
+	O
/	O
-	O
7%	O
)	O
reduction	O
in	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
followed	O
with	O
no	O
change	O
in	O
CO	O
(	O
3	O
.	O
7	O
+	O
/	O
-	O
1	O
.	O
1	O
to	O
3	O
.	O
4	O
+	O
/	O
-	O
0	O
.	O
9	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
.	O

The	O
administration	O
of	O
ephedrine	B-ChemicalEntity
led	O
to	O
a	O
similar	O
increase	O
in	O
MAP	O
(	O
53	O
+	O
/	O
-	O
9	O
to	O
79	O
+	O
/	O
-	O
8	O
mmHg	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
restored	O
CO	O
(	O
3	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
2	O
to	O
5	O
.	O
0	O
+	O
/	O
-	O
1	O
.	O
3	O
l	O
min	O
(	O
-	O
1	O
)	O
)	O
,	O
and	O
preserved	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
utilization	O
of	O
phenylephrine	B-ChemicalEntity
to	O
correct	O
hypotension	B-DiseaseOrPhenotypicFeature
induced	O
by	O
anesthesia	O
has	O
a	O
negative	O
impact	O
on	O
S	O
(	O
c	O
)	O
O	O
(	O
2	O
)	O
while	O
ephedrine	B-ChemicalEntity
maintains	O
frontal	O
lobe	O
oxygenation	O
potentially	O
related	O
to	O
an	O
increase	O
in	O
CO	O
.	O
Interleukin	B-GeneOrGeneProduct
6	I-GeneOrGeneProduct
(	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
)	O
and	O
Tumor	B-GeneOrGeneProduct
Necrosis	I-GeneOrGeneProduct
Factor	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
(	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
)	O
Single	O
Nucleotide	O
Polymorphisms	O
(	O
SNPs	O
)	O
,	O
Inflammation	B-DiseaseOrPhenotypicFeature
and	O
Metabolism	O
in	O
Gestational	B-DiseaseOrPhenotypicFeature
Diabetes	I-DiseaseOrPhenotypicFeature
Mellitus	I-DiseaseOrPhenotypicFeature
in	O
Inner	O
Mongolia	O
.	O

BACKGROUND	O
Gestational	B-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
(	O
GDM	B-DiseaseOrPhenotypicFeature
)	O
is	O
common	O
all	O
over	O
the	O
world	O
.	O

GDM	B-DiseaseOrPhenotypicFeature
women	B-OrganismTaxon
are	O
with	O
inflammatory	B-DiseaseOrPhenotypicFeature
and	O
metabolisms	B-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
few	O
studies	O
have	O
focused	O
on	O
the	O
association	O
of	O
IL	B-GeneOrGeneProduct
-	O
65	I-GeneOrGeneProduct
-	O
72C	I-SequenceVariant
/	O
G	I-SequenceVariant
and	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
-	O
857C	I-SequenceVariant
/	O
T	I-SequenceVariant
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
inflammatory	B-DiseaseOrPhenotypicFeature
biomarkers	O
,	O
and	O
metabolic	O
indexes	O
in	O
women	B-OrganismTaxon
with	O
GDM	B-DiseaseOrPhenotypicFeature
,	O
especially	O
in	O
the	O
Inner	O
Mongolia	O
population	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
associations	O
of	O
IL	B-GeneOrGeneProduct
-	O
65	I-GeneOrGeneProduct
-	O
72C	I-SequenceVariant
/	O
G	I-SequenceVariant
and	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
-	O
857C	I-SequenceVariant
/	O
T	I-SequenceVariant
SNPs	O
,	O
and	O
inflammation	B-DiseaseOrPhenotypicFeature
and	O
metabolic	O
biomarkers	O
in	O
women	B-OrganismTaxon
with	O
GDM	B-DiseaseOrPhenotypicFeature
pregnancies	O
.	O

MATERIAL	O
AND	O
METHODS	O
Blood	O
samples	O
and	O
placentas	O
from	O
140	O
women	B-OrganismTaxon
with	O
GDM	B-DiseaseOrPhenotypicFeature
and	O
140	O
women	B-OrganismTaxon
with	O
healthy	O
pregnancies	O
were	O
collected	O
.	O

Matrix	O
-	O
assisted	O
laser	O
desorption	O
ionization	O
time	O
of	O
flight	O
mass	O
spectrometry	O
(	O
MALDI	O
-	O
TOF	O
-	O
MS	O
)	O
and	O
MassARRAY	O
-	O
IPLEX	O
were	O
performed	O
to	O
analyze	O
IL	B-GeneOrGeneProduct
-	O
65	I-GeneOrGeneProduct
-	O
72C	I-SequenceVariant
/	O
G	I-SequenceVariant
and	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
-	O
857C	I-SequenceVariant
/	O
T	I-SequenceVariant
SNPs	O
.	O

Enzyme	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
was	O
performed	O
to	O
analyze	O
inflammatory	B-DiseaseOrPhenotypicFeature
biomarkers	O
and	O
adipokines	B-GeneOrGeneProduct
.	O

RESULTS	O
Distribution	O
frequency	O
of	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
-	O
857CT	I-SequenceVariant
(	O
OR	O
=	O
3	O
.	O
316	O
,	O
95%	O
CI	O
=	O
1	O
.	O
092	O
-	O
8	O
.	O
304	O
,	O
p	O
=	O
0	O
.	O
025	O
)	O
in	O
women	B-OrganismTaxon
with	O
GDM	B-DiseaseOrPhenotypicFeature
pregnancies	O
were	O
obviously	O
higher	O
than	O
that	O
in	O
women	B-OrganismTaxon
with	O
healthy	O
pregnancies	O
.	O

Women	B-OrganismTaxon
with	O
GDM	B-DiseaseOrPhenotypicFeature
were	O
of	O
older	O
maternal	O
age	O
,	O
had	O
higher	O
BMI	O
,	O
were	O
more	O
nulliparous	O
,	O
and	O
had	O
T2DM	B-DiseaseOrPhenotypicFeature
and	O
GDM	B-DiseaseOrPhenotypicFeature
history	O
,	O
compared	O
to	O
women	B-OrganismTaxon
with	O
healthy	O
pregnancies	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Inflammatory	B-DiseaseOrPhenotypicFeature
biomarkers	O
in	O
serum	O
(	O
hs	O
-	O
CRP	B-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
8	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
/	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
ratio	O
)	O
and	O
placental	O
(	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
8	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
/	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
ratio	O
,	O
IL	B-GeneOrGeneProduct
-	O
1b	I-GeneOrGeneProduct
,	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
)	O
were	O
significantly	O
different	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
between	O
women	B-OrganismTaxon
with	O
GDM	B-DiseaseOrPhenotypicFeature
and	O
women	B-OrganismTaxon
with	O
healthy	O
pregnancies	O
.	O

Differences	O
were	O
found	O
for	O
serum	O
FBG	O
,	O
FINS	O
,	O
HOMA	O
-	O
IR	O
,	O
and	O
HOMA	O
-	O
beta	O
,	O
and	O
placental	O
IRS	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
,	O
IRS	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
,	O
leptin	B-GeneOrGeneProduct
,	O
adiponectin	B-GeneOrGeneProduct
,	O
visfatin	B-GeneOrGeneProduct
,	O
RBP	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
,	O
chemerin	B-GeneOrGeneProduct
,	O
nesfatin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
,	O
FATP	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
,	O
EL	B-GeneOrGeneProduct
,	O
LPL	B-GeneOrGeneProduct
,	O
FABP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
,	O
FABP	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
,	O
FABP	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
,	O
and	O
FABP	B-GeneOrGeneProduct
-	O
5	I-GeneOrGeneProduct
.	O

CONCLUSIONS	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
-	O
857C	I-SequenceVariant
/	O
T	I-SequenceVariant
SNP	O
,	O
hs	O
-	O
CRP	B-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
8	I-GeneOrGeneProduct
,	O
and	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
/	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
were	O
associated	O
with	O
GDM	B-DiseaseOrPhenotypicFeature
in	O
women	B-OrganismTaxon
from	O
Inner	O
Mongolia	O
,	O
as	O
was	O
serious	O
inflammation	B-DiseaseOrPhenotypicFeature
and	O
disordered	B-DiseaseOrPhenotypicFeature
lipid	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
glucose	I-DiseaseOrPhenotypicFeature
metabolisms	I-DiseaseOrPhenotypicFeature
.	O
Estrogen	B-ChemicalEntity
prevents	O
cholesteryl	B-ChemicalEntity
ester	I-ChemicalEntity
accumulation	O
in	O
macrophages	O
induced	O
by	O
the	O
HIV	B-GeneOrGeneProduct
protease	I-GeneOrGeneProduct
inhibitor	O
ritonavir	B-ChemicalEntity
.	O

Individuals	O
with	O
HIV	B-OrganismTaxon
can	O
now	O
live	O
long	O
lives	O
with	O
drug	O
therapy	O
that	O
often	O
includes	O
protease	O
inhibitors	O
such	O
as	O
ritonavir	B-ChemicalEntity
.	O

Many	O
patients	O
,	O
however	O
,	O
develop	O
negative	O
long	O
-	O
term	O
side	O
effects	O
such	O
as	O
premature	B-DiseaseOrPhenotypicFeature
atherosclerosis	I-DiseaseOrPhenotypicFeature
.	O

We	O
have	O
previously	O
demonstrated	O
that	O
ritonavir	B-ChemicalEntity
treatment	O
increases	O
atherosclerotic	B-DiseaseOrPhenotypicFeature
lesion	I-DiseaseOrPhenotypicFeature
formation	O
in	O
male	O
mice	B-OrganismTaxon
to	O
a	O
greater	O
extent	O
than	O
in	O
female	O
mice	B-OrganismTaxon
.	O

Furthermore	O
,	O
peripheral	O
blood	O
monocytes	O
isolated	O
from	O
ritonavir	B-ChemicalEntity
-	O
treated	O
females	O
had	O
less	O
cholesteryl	B-ChemicalEntity
ester	I-ChemicalEntity
accumulation	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
investigated	O
the	O
molecular	O
mechanisms	O
by	O
which	O
female	O
hormones	O
influence	O
cholesterol	B-ChemicalEntity
metabolism	O
in	O
macrophages	O
in	O
response	O
to	O
the	O
HIV	B-GeneOrGeneProduct
protease	I-GeneOrGeneProduct
inhibitor	O
ritonavir	B-ChemicalEntity
.	O

We	O
have	O
utilized	O
the	O
human	B-OrganismTaxon
monocyte	O
cell	O
line	O
,	O
THP	B-CellLine
-	O
1	I-CellLine
as	O
a	O
model	O
to	O
address	O
this	O
question	O
.	O

Briefly	O
,	O
cells	O
were	O
differentiated	O
for	O
72	O
h	O
with	O
100	O
nM	O
PMA	O
to	O
obtain	O
a	O
macrophage	O
-	O
like	O
phenotype	O
in	O
the	O
presence	O
or	O
absence	O
of	O
1	O
nM	O
17beta	B-ChemicalEntity
-	O
estradiol	I-ChemicalEntity
(	O
E2	B-ChemicalEntity
)	O
,	O
100	O
nM	O
progesterone	B-ChemicalEntity
or	O
vehicle	O
(	O
0	O
.	O
01%	O
ethanol	B-ChemicalEntity
)	O
.	O

Cells	O
were	O
then	O
treated	O
with	O
30	O
ng	O
/	O
ml	O
ritonavir	B-ChemicalEntity
or	O
vehicle	O
in	O
the	O
presence	O
of	O
aggregated	O
LDL	O
for	O
24	O
h	O
.	O

Cell	O
extracts	O
were	O
harvested	O
,	O
and	O
lipid	B-ChemicalEntity
or	O
total	O
RNA	O
was	O
isolated	O
.	O

E2	B-ChemicalEntity
decreased	O
the	O
accumulation	O
of	O
cholesteryl	B-ChemicalEntity
esters	I-ChemicalEntity
in	O
macrophages	O
following	O
ritonavir	B-ChemicalEntity
treatment	O
.	O

Ritonavir	B-ChemicalEntity
increased	O
the	O
expression	O
of	O
the	O
scavenger	O
receptor	O
,	O
CD36	B-GeneOrGeneProduct
mRNA	O
,	O
responsible	O
for	O
the	O
uptake	O
of	O
LDL	O
.	O

Additionally	O
,	O
ritonavir	B-ChemicalEntity
treatment	O
selectively	O
increased	O
the	O
relative	O
levels	O
of	O
PPARgamma	B-GeneOrGeneProduct
mRNA	O
,	O
a	O
transcription	O
factor	O
responsible	O
for	O
the	O
regulation	O
of	O
CD36	B-GeneOrGeneProduct
mRNA	O
expression	O
.	O

Treatment	O
with	O
E2	B-ChemicalEntity
,	O
however	O
,	O
failed	O
to	O
prevent	O
these	O
increases	O
at	O
the	O
mRNA	O
level	O
.	O

E2	B-ChemicalEntity
did	O
,	O
however	O
,	O
significantly	O
suppress	O
CD36	B-GeneOrGeneProduct
protein	O
levels	O
as	O
measured	O
by	O
fluorescent	O
immunocytochemistry	O
.	O

This	O
data	O
suggests	O
that	O
E2	B-ChemicalEntity
modifies	O
the	O
expression	O
of	O
CD36	B-GeneOrGeneProduct
at	O
the	O
level	O
of	O
protein	O
expression	O
in	O
monocyte	O
-	O
derived	O
macrophages	O
resulting	O
in	O
reduced	O
cholesteryl	B-ChemicalEntity
ester	I-ChemicalEntity
accumulation	O
following	O
ritonavir	B-ChemicalEntity
treatment	O
.	O
Single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
of	O
the	O
FMR1	B-GeneOrGeneProduct
gene	O
in	O
autistic	B-DiseaseOrPhenotypicFeature
and	O
mentally	B-DiseaseOrPhenotypicFeature
retarded	I-DiseaseOrPhenotypicFeature
children	O
in	O
Japan	O
.	O

Fragile	B-DiseaseOrPhenotypicFeature
X	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
mental	B-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
in	O
males	O
,	O
and	O
patients	B-OrganismTaxon
with	O
fragile	B-DiseaseOrPhenotypicFeature
X	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
occasionally	O
develop	O
autism	B-DiseaseOrPhenotypicFeature
.	O

It	O
is	O
usually	O
caused	O
by	O
an	O
expansion	O
of	O
the	O
trinucleotide	O
repeat	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
FMR1	B-GeneOrGeneProduct
gene	O
,	O
but	O
in	O
a	O
small	O
number	O
of	O
patients	B-OrganismTaxon
deletions	O
and	O
point	O
mutations	O
have	O
been	O
identified	O
.	O

We	O
screened	O
all	O
17	O
exons	O
of	O
the	O
FMR1	B-GeneOrGeneProduct
gene	O
for	O
mutations	O
in	O
90	O
autistic	B-DiseaseOrPhenotypicFeature
or	O
mentally	B-DiseaseOrPhenotypicFeature
retarded	I-DiseaseOrPhenotypicFeature
children	O
using	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
.	O

No	O
mutations	O
were	O
found	O
in	O
76	O
male	O
patients	B-OrganismTaxon
.	O

However	O
,	O
one	O
female	O
patient	B-OrganismTaxon
was	O
heterozygous	O
for	O
a	O
normal	O
allele	O
and	O
a	O
mutant	O
allele	O
with	O
an	O
A	B-SequenceVariant
to	I-SequenceVariant
C	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
nucleotide	I-SequenceVariant
879	I-SequenceVariant
in	O
exon	O
9	O
.	O

This	O
mutation	O
was	O
not	O
found	O
in	O
50	O
controls	O
.	O

Reverse	O
transcription	O
-	O
PCR	O
revealed	O
that	O
a	O
large	O
proportion	O
of	O
the	O
mutant	O
transcripts	O
were	O
spliced	O
aberrantly	O
,	O
causing	O
premature	O
termination	O
of	O
the	O
protein	O
synthesis	O
.	O

Although	O
uncommon	O
,	O
point	O
mutations	O
in	O
the	O
FMR1	B-GeneOrGeneProduct
gene	O
may	O
be	O
a	O
cause	O
of	O
autism	B-DiseaseOrPhenotypicFeature
and	O
mental	B-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
in	O
Japanese	O
patients	B-OrganismTaxon
.	O
Homozygously	O
deleted	O
gene	O
DACH1	B-GeneOrGeneProduct
regulates	O
tumor	B-DiseaseOrPhenotypicFeature
-	O
initiating	O
activity	O
of	O
glioma	B-DiseaseOrPhenotypicFeature
cells	O
.	O

Loss	O
or	O
reduction	O
in	O
function	O
of	O
tumor	B-DiseaseOrPhenotypicFeature
suppressor	O
genes	O
contributes	O
to	O
tumorigenesis	B-DiseaseOrPhenotypicFeature
.	O

Here	O
,	O
by	O
allelic	O
DNA	O
copy	O
number	O
analysis	O
using	O
single	O
-	O
nucleotide	O
polymorphism	O
genotyping	O
array	O
and	O
mass	O
spectrometry	O
,	O
we	O
report	O
homozygous	O
deletion	O
in	O
glioblastoma	B-DiseaseOrPhenotypicFeature
multiformes	O
at	O
chromosome	O
13q21	O
,	O
where	O
DACH1	B-GeneOrGeneProduct
gene	O
is	O
located	O
.	O

We	O
found	O
decreased	O
cell	O
proliferation	O
of	O
a	O
series	O
of	O
glioma	B-DiseaseOrPhenotypicFeature
cell	O
lines	O
by	O
forced	O
expression	O
of	O
DACH1	B-GeneOrGeneProduct
.	O

We	O
then	O
generated	O
U87TR	B-CellLine
-	O
Da	I-CellLine
glioma	B-DiseaseOrPhenotypicFeature
cells	O
,	O
where	O
DACH1	B-GeneOrGeneProduct
expression	O
could	O
be	O
activated	O
by	O
exposure	O
of	O
the	O
cells	O
to	O
doxycycline	B-ChemicalEntity
.	O

Both	O
ex	O
vivo	O
cellular	O
proliferation	O
and	O
in	O
vivo	O
growth	O
of	O
s	O
.	O
c	O
.	O

transplanted	O
tumors	B-DiseaseOrPhenotypicFeature
in	O
mice	B-OrganismTaxon
are	O
reduced	O
in	O
U87TR	B-CellLine
-	O
Da	I-CellLine
cells	O
with	O
DACH1	B-GeneOrGeneProduct
expression	O
(	O
U87	B-CellLine
-	O
DACH1	B-GeneOrGeneProduct
-	O
high	O
)	O
,	O
compared	O
with	O
DACH1	B-GeneOrGeneProduct
-	O
nonexpressing	O
U87TR	B-CellLine
-	O
Da	I-CellLine
cells	O
(	O
U87	B-CellLine
-	O
DACH1	B-GeneOrGeneProduct
-	O
low	O
)	O
.	O

U87	B-CellLine
-	O
DACH1	B-GeneOrGeneProduct
-	O
low	O
cells	O
form	O
spheroids	O
with	O
CD133	B-GeneOrGeneProduct
and	O
Nestin	B-GeneOrGeneProduct
expression	O
in	O
serum	O
-	O
free	O
medium	O
but	O
U87	B-CellLine
-	O
DACH1	B-GeneOrGeneProduct
-	O
high	O
cells	O
do	O
not	O
.	O

Compared	O
with	O
spheroid	O
-	O
forming	O
U87	B-CellLine
-	O
DACH1	B-GeneOrGeneProduct
-	O
low	O
cells	O
,	O
adherent	O
U87	B-CellLine
-	O
DACH1	B-GeneOrGeneProduct
-	O
high	O
cells	O
display	O
lower	O
tumorigenicity	O
,	O
indicating	O
DACH1	B-GeneOrGeneProduct
decreases	O
the	O
number	O
of	O
tumor	B-DiseaseOrPhenotypicFeature
-	O
initiating	O
cells	O
.	O

Gene	O
expression	O
analysis	O
and	O
chromatin	O
immunoprecipitation	O
assay	O
reveal	O
that	O
fibroblast	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
(	O
FGF2	B-GeneOrGeneProduct
/	O
bFGF	B-GeneOrGeneProduct
)	O
is	O
transcriptionally	O
repressed	O
by	O
DACH1	B-GeneOrGeneProduct
,	O
especially	O
in	O
cells	O
cultured	O
in	O
serum	O
-	O
free	O
medium	O
.	O

Exogenous	O
bFGF	B-GeneOrGeneProduct
rescues	O
spheroid	O
-	O
forming	O
activity	O
and	O
tumorigenicity	O
of	O
the	O
U87	B-CellLine
-	O
DACH1	B-GeneOrGeneProduct
-	O
high	O
cells	O
,	O
suggesting	O
that	O
loss	O
of	O
DACH1	B-GeneOrGeneProduct
increases	O
the	O
number	O
of	O
tumor	B-DiseaseOrPhenotypicFeature
-	O
initiating	O
cells	O
through	O
transcriptional	O
activation	O
of	O
bFGF	B-GeneOrGeneProduct
.	O

These	O
results	O
illustrate	O
that	O
DACH1	B-GeneOrGeneProduct
is	O
a	O
distinctive	O
tumor	B-DiseaseOrPhenotypicFeature
suppressor	O
,	O
which	O
does	O
not	O
only	O
suppress	O
growth	O
of	O
tumor	B-DiseaseOrPhenotypicFeature
cells	O
but	O
also	O
regulates	O
bFGF	B-GeneOrGeneProduct
-	O
mediated	O
tumor	B-DiseaseOrPhenotypicFeature
-	O
initiating	O
activity	O
of	O
glioma	B-DiseaseOrPhenotypicFeature
cells	O
.	O
Focal	B-DiseaseOrPhenotypicFeature
dermal	I-DiseaseOrPhenotypicFeature
hypoplasia	I-DiseaseOrPhenotypicFeature
resulting	O
from	O
a	O
new	O
nonsense	O
mutation	O
,	O
p	B-SequenceVariant
.	O
E300X	I-SequenceVariant
,	O
in	O
the	O
PORCN	B-GeneOrGeneProduct
gene	O
.	O

BACKGROUND	O
:	O
Focal	B-DiseaseOrPhenotypicFeature
dermal	I-DiseaseOrPhenotypicFeature
hypoplasia	I-DiseaseOrPhenotypicFeature
(	O
FDH	B-DiseaseOrPhenotypicFeature
)	O
(	O
OMIM	B-DiseaseOrPhenotypicFeature
305600	I-DiseaseOrPhenotypicFeature
)	O
is	O
an	O
X	B-DiseaseOrPhenotypicFeature
-	O
linked	I-DiseaseOrPhenotypicFeature
dominant	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
of	O
ecto	O
-	O
mesodermal	O
development	O
.	O

Also	O
known	O
as	O
Goltz	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
,	O
FDH	B-DiseaseOrPhenotypicFeature
presents	O
with	O
characteristic	O
linear	O
streaks	O
of	O
hypoplastic	B-DiseaseOrPhenotypicFeature
dermis	I-DiseaseOrPhenotypicFeature
and	O
variable	O
abnormalities	O
of	O
bone	O
,	O
nails	O
,	O
hair	O
,	O
limbs	O
,	O
teeth	O
and	O
eyes	O
.	O

The	O
molecular	O
basis	O
of	O
FDH	B-DiseaseOrPhenotypicFeature
involves	O
mutations	O
in	O
the	O
PORCN	B-GeneOrGeneProduct
gene	O
,	O
which	O
encodes	O
an	O
enzyme	O
that	O
allows	O
membrane	O
targeting	O
and	O
secretion	O
of	O
several	O
Wnt	O
proteins	O
critical	O
for	O
normal	O
tissue	O
development	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
molecular	O
basis	O
of	O
FDH	B-DiseaseOrPhenotypicFeature
in	O
a	O
2	O
-	O
year	O
-	O
old	O
Thai	O
girl	O
who	O
presented	O
at	O
birth	O
with	O
depressed	B-DiseaseOrPhenotypicFeature
,	O
pale	O
linear	O
scars	O
on	O
the	O
trunk	O
and	O
limbs	O
,	O
sparse	O
brittle	O
hair	O
,	O
syndactyly	O
of	O
the	O
right	O
middle	O
and	O
ring	O
fingers	O
,	O
dental	B-DiseaseOrPhenotypicFeature
caries	I-DiseaseOrPhenotypicFeature
and	O
radiological	O
features	O
of	O
osteopathia	O
striata	O
.	O

METHODS	O
:	O
Sequencing	O
of	O
genomic	O
DNA	O
from	O
the	O
affected	O
individual	O
and	O
both	O
parents	O
to	O
search	O
for	O
pathogenic	O
mutations	O
in	O
PORCN	B-GeneOrGeneProduct
gene	O
.	O

RESULTS	O
:	O
DNA	O
sequencing	O
disclosed	O
a	O
heterozygous	O
G	B-SequenceVariant
>	O
T	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
nucleotide	I-SequenceVariant
c	I-SequenceVariant
.	O
898	I-SequenceVariant
within	O
exon	O
10	O
(	O
NM_203475	O
.	O
1	O
)	O
,	O
converting	O
a	O
glutamic	B-SequenceVariant
acid	I-SequenceVariant
residue	I-SequenceVariant
(	O
GAA	I-SequenceVariant
)	O
to	I-SequenceVariant
a	I-SequenceVariant
premature	I-SequenceVariant
termination	I-SequenceVariant
codon	I-SequenceVariant
(	O
TAA	I-SequenceVariant
)	O
.	O

This	O
mutation	O
,	O
designated	O
p	B-SequenceVariant
.	O
E300X	I-SequenceVariant
,	O
was	O
not	O
detected	O
in	O
DNA	O
from	O
either	O
parent	O
or	O
in	O
100	O
control	O
chromosomes	O
.	O

CONCLUSION	O
:	O
Identification	O
of	O
this	O
new	O
de	O
novo	O
nonsense	O
mutation	O
confirms	O
the	O
diagnosis	O
of	O
FDH	B-DiseaseOrPhenotypicFeature
in	O
this	O
child	O
and	O
highlights	O
the	O
clinical	O
importance	O
of	O
PORCN	B-GeneOrGeneProduct
and	O
Wnt	O
signalling	O
pathways	O
in	O
embryogenesis	O
.	O
Human	B-OrganismTaxon
mu	B-GeneOrGeneProduct
opiate	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
.	O

cDNA	O
and	O
genomic	O
clones	O
,	O
pharmacologic	O
characterization	O
and	O
chromosomal	O
assignment	O
.	O

A	O
human	B-OrganismTaxon
mu	B-GeneOrGeneProduct
opiate	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
cDNA	O
has	O
been	O
identified	O
from	O
a	O
cerebral	O
cortical	O
cDNA	O
library	O
using	O
sequences	O
from	O
the	O
rat	B-OrganismTaxon
mu	B-GeneOrGeneProduct
opiate	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
cDNA	O
.	O

The	O
human	B-OrganismTaxon
mu	B-GeneOrGeneProduct
opiate	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
h	B-GeneOrGeneProduct
mu	I-GeneOrGeneProduct
OR1	I-GeneOrGeneProduct
)	O
shares	O
95%	O
amino	O
acid	O
identity	O
with	O
the	O
rat	B-OrganismTaxon
sequence	O
.	O

The	O
expressed	O
mu	B-GeneOrGeneProduct
OR1	I-GeneOrGeneProduct
recognized	O
tested	O
opiate	B-ChemicalEntity
drugs	O
and	O
opioid	B-ChemicalEntity
peptides	I-ChemicalEntity
in	O
a	O
sodium	B-ChemicalEntity
-	O
and	O
GTP	B-ChemicalEntity
-	O
sensitive	O
fashion	O
with	O
affinities	O
virtually	O
identical	O
to	O
those	O
displayed	O
by	O
the	O
rat	B-OrganismTaxon
mu	B-GeneOrGeneProduct
opiate	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
.	O

Effects	O
on	O
cyclic	B-ChemicalEntity
AMP	I-ChemicalEntity
are	O
similar	O
to	O
those	O
noted	O
for	O
the	O
rat	B-OrganismTaxon
mu	B-GeneOrGeneProduct
opiate	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
.	O

An	O
18	O
kb	O
genomic	O
clone	O
hybridizing	O
with	O
the	O
h	B-GeneOrGeneProduct
mu	I-GeneOrGeneProduct
OR1	I-GeneOrGeneProduct
cDNA	O
contains	O
63	O
and	O
489	O
bp	O
exonic	O
sequences	O
flanked	O
by	O
splice	O
donor	O
/	O
acceptor	O
sequences	O
.	O

Analysis	O
of	O
hybridization	O
to	O
DNA	O
prepared	O
from	O
human	B-OrganismTaxon
rodent	O
hybrid	O
cell	O
lines	O
and	O
chromosomal	O
in	O
situ	O
hybridization	O
studies	O
indicate	O
localization	O
to	O
6q24	O
-	O
25	O
.	O

An	O
MspI	O
polymorphism	O
,	O
producing	O
a	O
3	O
.	O
7	O
kb	O
band	O
,	O
may	O
prove	O
useful	O
in	O
assessing	O
this	O
gene	O
'	O
s	O
involvement	O
in	O
neuropsychiatric	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
involving	O
opiatergic	O
systems	O
.	O
An	O
Ag	B-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
G	B-SequenceVariant
-	O
>	O
A	I-SequenceVariant
gene	O
polymorphism	O
associated	O
with	O
b	B-GeneOrGeneProduct
(	O
0	I-GeneOrGeneProduct
)	O
39	I-GeneOrGeneProduct
thalassemia	I-GeneOrGeneProduct
globin	I-GeneOrGeneProduct
gene	O
and	O
high	O
fetal	B-GeneOrGeneProduct
hemoglobin	I-GeneOrGeneProduct
production	O
.	O

BACKGROUND	O
:	O
Increase	O
of	O
the	O
expression	O
of	O
g	B-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
gene	O
and	O
high	O
production	O
of	O
fetal	B-GeneOrGeneProduct
hemoglobin	I-GeneOrGeneProduct
(	O
HbF	B-GeneOrGeneProduct
)	O
in	O
b	B-DiseaseOrPhenotypicFeature
-	O
thalassemia	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
is	O
widely	O
accepted	O
as	O
associated	O
with	O
a	O
milder	O
or	O
even	O
asymptomatic	O
disease	O
.	O

The	O
search	O
for	O
HbF	B-GeneOrGeneProduct
-	O
associated	O
polymorphisms	O
(	O
such	O
as	O
the	O
XmnI	O
,	O
BCL11A	B-GeneOrGeneProduct
and	O
MYB	B-GeneOrGeneProduct
polymorphisms	O
)	O
has	O
recently	O
gained	O
great	O
attention	O
,	O
in	O
order	O
to	O
stratify	O
b	B-DiseaseOrPhenotypicFeature
-	O
thalassemia	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
respect	O
to	O
expectancy	O
of	O
the	O
first	O
transfusion	O
,	O
need	O
for	O
annual	O
intake	O
of	O
blood	O
,	O
response	O
to	O
HbF	B-GeneOrGeneProduct
inducers	O
(	O
the	O
most	O
studied	O
of	O
which	O
is	O
hydroxyurea	O
)	O
.	O

METHODS	O
:	O
Ag	B-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
gene	O
sequencing	O
was	O
performed	O
on	O
genomic	O
DNA	O
isolated	O
from	O
a	O
total	O
of	O
75	O
b	B-DiseaseOrPhenotypicFeature
-	O
thalassemia	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
including	O
31	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(	O
0	O
)	O
39	O
,	O
33	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
,	O
9	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
,	O
one	O
b	O
(	O
0	O
)	O
IVSI	O
-	O
1	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
6	O
and	O
one	O
b	O
(	O
0	O
)	O
39	O
/	O
b	O
(	O
+	O
)	O
IVSI	O
-	O
6	O
.	O

RESULTS	O
:	O
The	O
results	O
show	O
that	O
the	O
rs368698783	B-SequenceVariant
polymorphism	O
is	O
present	O
in	O
b	B-DiseaseOrPhenotypicFeature
-	O
thalassemia	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
in	O
the	O
5	O
'	O
UTR	O
sequence	O
(	O
+	O
25	O
)	O
of	O
the	O
Ag	B-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
gene	O
,	O
known	O
to	O
affect	O
the	O
LYAR	B-GeneOrGeneProduct
(	O
human	B-OrganismTaxon
homologue	O
of	O
mouse	B-OrganismTaxon
Ly	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
antibody	I-GeneOrGeneProduct
reactive	I-GeneOrGeneProduct
clone	I-GeneOrGeneProduct
)	O
binding	O
site	O
5	O
'	O
-	O
GGTTAT	O
-	O
3	O
'	O
.	O

This	O
Ag	B-GeneOrGeneProduct
(	O
+	O
25	I-SequenceVariant
G	I-SequenceVariant
-	O
>	O
A	I-SequenceVariant
)	O
polymorphism	O
is	O
associated	O
with	O
the	O
Gg	B-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
-	O
XmnI	O
polymorphism	O
and	O
both	O
are	O
linked	O
with	O
the	O
b	B-GeneOrGeneProduct
(	O
0	I-GeneOrGeneProduct
)	O
39	I-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
gene	O
,	O
but	O
not	O
with	O
the	O
b	B-GeneOrGeneProduct
(	O
+	O
)	O
IVSI	I-GeneOrGeneProduct
-	O
110	I-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
gene	O
.	O

In	O
agreement	O
with	O
the	O
expectation	O
that	O
this	O
mutation	O
alters	O
the	O
LYAR	B-GeneOrGeneProduct
binding	O
activity	O
,	O
we	O
found	O
that	O
the	O
Ag	B-GeneOrGeneProduct
(	O
+	O
25	I-SequenceVariant
G	I-SequenceVariant
-	O
>	O
A	I-SequenceVariant
)	O
and	O
Gg	B-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
-	O
XmnI	O
polymorphisms	O
are	O
associated	O
with	O
high	O
HbF	B-GeneOrGeneProduct
in	O
erythroid	O
precursor	O
cells	O
isolated	O
from	O
b	B-DiseaseOrPhenotypicFeature
(	O
0	I-DiseaseOrPhenotypicFeature
)	O
39	I-DiseaseOrPhenotypicFeature
/	O
b	I-DiseaseOrPhenotypicFeature
(	O
0	I-DiseaseOrPhenotypicFeature
)	O
39	I-DiseaseOrPhenotypicFeature
thalassemia	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

CONCLUSIONS	O
:	O
As	O
a	O
potential	O
explanation	O
of	O
our	O
findings	O
,	O
we	O
hypothesize	O
that	O
in	O
b	B-DiseaseOrPhenotypicFeature
-	O
thalassemia	I-DiseaseOrPhenotypicFeature
the	O
Gg	B-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
-	O
XmnI	O
/	O
Ag	B-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
-	O
(	O
G	B-SequenceVariant
-	O
>	O
A	I-SequenceVariant
)	O
genotype	O
is	O
frequently	O
under	O
genetic	O
linkage	O
with	O
b	B-DiseaseOrPhenotypicFeature
(	O
0	I-DiseaseOrPhenotypicFeature
)	O
-	O
thalassemia	I-DiseaseOrPhenotypicFeature
mutations	O
,	O
but	O
not	O
with	O
the	O
b	B-DiseaseOrPhenotypicFeature
(	O
+	O
)	O
-	O
thalassemia	I-DiseaseOrPhenotypicFeature
mutation	O
here	O
studied	O
(	O
i	O
.	O
e	O
.	O

b	O
(	O
+	O
)	O
IVSI	O
-	O
110	O
)	O
and	O
that	O
this	O
genetic	O
combination	O
has	O
been	O
selected	O
within	O
the	O
population	O
of	O
b	B-DiseaseOrPhenotypicFeature
(	O
0	I-DiseaseOrPhenotypicFeature
)	O
-	O
thalassemia	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
due	O
to	O
functional	O
association	O
with	O
high	O
HbF	B-GeneOrGeneProduct
.	O

Here	O
we	O
describe	O
the	O
characterization	O
of	O
the	O
rs368698783	B-SequenceVariant
(	O
+	O
25	I-SequenceVariant
G	I-SequenceVariant
-	O
>	O
A	I-SequenceVariant
)	O
polymorphism	O
of	O
the	O
Ag	B-GeneOrGeneProduct
-	O
globin	I-GeneOrGeneProduct
gene	O
associated	O
in	O
b	B-DiseaseOrPhenotypicFeature
(	O
0	I-DiseaseOrPhenotypicFeature
)	O
39	I-DiseaseOrPhenotypicFeature
thalassemia	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
high	O
HbF	B-GeneOrGeneProduct
in	O
erythroid	O
precursor	O
cells	O
.	O
Alcohol	B-ChemicalEntity
consumption	O
and	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
incidence	O
and	O
progression	O
:	O
A	O
Mendelian	O
randomisation	O
study	O
.	O

Prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
is	O
the	O
most	O
common	O
cancer	B-DiseaseOrPhenotypicFeature
in	O
men	B-OrganismTaxon
in	O
developed	O
countries	O
,	O
and	O
is	O
a	O
target	O
for	O
risk	O
reduction	O
strategies	O
.	O

The	O
effects	O
of	O
alcohol	B-ChemicalEntity
consumption	O
on	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
incidence	O
and	O
survival	O
remain	O
unclear	O
,	O
potentially	O
due	O
to	O
methodological	O
limitations	O
of	O
observational	O
studies	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
associations	O
of	O
genetic	O
variants	O
in	O
alcohol	B-ChemicalEntity
-	O
metabolising	O
genes	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
incidence	O
and	O
survival	O
.	O

We	O
analysed	O
data	O
from	O
23	O
,	O
868	O
men	B-OrganismTaxon
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
and	O
23	O
,	O
051	O
controls	O
from	O
25	O
studies	O
within	O
the	O
international	O
PRACTICAL	O
Consortium	O
.	O

Study	O
-	O
specific	O
associations	O
of	O
68	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
8	O
alcohol	B-ChemicalEntity
-	O
metabolising	O
genes	O
(	O
Alcohol	B-GeneOrGeneProduct
Dehydrogenases	I-GeneOrGeneProduct
(	O
ADHs	B-GeneOrGeneProduct
)	O
and	O
Aldehyde	B-GeneOrGeneProduct
Dehydrogenases	I-GeneOrGeneProduct
(	O
ALDHs	B-GeneOrGeneProduct
)	O
)	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
diagnosis	O
and	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
-	O
specific	O
mortality	O
,	O
by	O
grade	O
,	O
were	O
assessed	O
using	O
logistic	O
and	O
Cox	O
regression	O
models	O
,	O
respectively	O
.	O

The	O
data	O
across	O
the	O
25	O
studies	O
were	O
meta	O
-	O
analysed	O
using	O
fixed	O
-	O
effect	O
and	O
random	O
-	O
effects	O
models	O
.	O

We	O
found	O
little	O
evidence	O
that	O
variants	O
in	O
alcohol	B-ChemicalEntity
metabolising	O
genes	O
were	O
associated	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
diagnosis	O
.	O

Four	O
variants	O
in	O
two	O
genes	O
exceeded	O
the	O
multiple	O
testing	O
threshold	O
for	O
associations	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
mortality	O
in	O
fixed	O
-	O
effect	O
meta	O
-	O
analyses	O
.	O

SNPs	O
within	O
ALDH1A2	B-GeneOrGeneProduct
associated	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
mortality	O
were	O
rs1441817	B-SequenceVariant
(	O
fixed	O
effects	O
hazard	O
ratio	O
,	O
HRfixed	O
=	O
0	O
.	O
78	O
;	O
95%	O
confidence	O
interval	O
(	O
95%CI	O
)	O
:	O
0	O
.	O
66	O
,	O
0	O
.	O
91	O
;	O
p	O
values	O
=	O
0	O
.	O
002	O
)	O
;	O
rs12910509	B-SequenceVariant
,	O
HRfixed	O
=	O
0	O
.	O
76	O
;	O
95%CI	O
:	O
0	O
.	O
64	O
,	O
0	O
.	O
91	O
;	O
p	O
values	O
=	O
0	O
.	O
003	O
)	O
;	O
and	O
rs8041922	B-SequenceVariant
(	O
HRfixed	O
=	O
0	O
.	O
76	O
;	O
95%CI	O
:	O
0	O
.	O
64	O
,	O
0	O
.	O
91	O
;	O
p	O
values	O
=	O
0	O
.	O
002	O
)	O
.	O

These	O
SNPs	O
were	O
in	O
linkage	O
disequilibrium	O
with	O
each	O
other	O
.	O

In	O
ALDH1B1	B-GeneOrGeneProduct
,	O
rs10973794	B-SequenceVariant
(	O
HRfixed	O
=	O
1	O
.	O
43	O
;	O
95%CI	O
:	O
1	O
.	O
14	O
,	O
1	O
.	O
79	O
;	O
p	O
values	O
=	O
0	O
.	O
002	O
)	O
was	O
associated	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
mortality	O
in	O
men	B-OrganismTaxon
with	O
low	O
-	O
grade	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

These	O
results	O
suggest	O
that	O
alcohol	B-ChemicalEntity
consumption	O
is	O
unlikely	O
to	O
affect	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
incidence	O
,	O
but	O
it	O
may	O
influence	O
disease	O
progression	O
.	O
Novel	O
somatic	O
MEN1	B-GeneOrGeneProduct
gene	O
alterations	O
in	O
sporadic	O
primary	B-DiseaseOrPhenotypicFeature
hyperparathyroidism	I-DiseaseOrPhenotypicFeature
and	O
correlation	O
with	O
clinical	O
characteristics	O
.	O

Primary	B-DiseaseOrPhenotypicFeature
hyperparathyroidism	I-DiseaseOrPhenotypicFeature
(	O
pHPT	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
common	O
endocrine	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
that	O
in	O
more	O
than	O
95%	O
of	O
cases	O
is	O
sporadic	O
and	O
only	O
in	O
some	O
cases	O
is	O
caused	O
by	O
inherited	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
,	O
isolated	O
or	O
as	O
part	O
of	O
multiple	B-DiseaseOrPhenotypicFeature
endocrine	I-DiseaseOrPhenotypicFeature
neoplasia	I-DiseaseOrPhenotypicFeature
(	O
MEN1	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
)	O
.	O

Somatic	O
mutations	O
of	O
MEN1	B-GeneOrGeneProduct
gene	O
have	O
also	O
been	O
described	O
in	O
sporadic	O
parathyroid	B-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
.	O

In	O
our	O
study	O
,	O
we	O
examined	O
the	O
presence	O
of	O
alterations	O
in	O
MEN1	B-GeneOrGeneProduct
gene	O
in	O
a	O
series	O
of	O
39	O
patients	B-OrganismTaxon
who	O
had	O
undergone	O
surgery	O
for	O
sporadic	O
pHPT	B-DiseaseOrPhenotypicFeature
(	O
35	O
with	O
parathyroid	B-DiseaseOrPhenotypicFeature
adenoma	I-DiseaseOrPhenotypicFeature
or	I-DiseaseOrPhenotypicFeature
hyperplasia	I-DiseaseOrPhenotypicFeature
,	O
4	O
with	O
a	O
carcinoma	B-DiseaseOrPhenotypicFeature
)	O
.	O

A	O
genotype	O
-	O
phenotype	O
correlation	O
was	O
also	O
analysed	O
.	O

After	O
DNA	O
extraction	O
from	O
paraffin	B-ChemicalEntity
-	O
embedded	O
tissues	O
,	O
we	O
amplified	O
by	O
PCR	O
and	O
sequenced	O
the	O
exons	O
2	O
-	O
10	O
of	O
the	O
MEN1	B-GeneOrGeneProduct
gene	O
.	O

Somatic	O
MEN1	B-GeneOrGeneProduct
mutations	O
were	O
detected	O
in	O
6	O
of	O
the	O
35	O
patients	B-OrganismTaxon
with	O
a	O
benign	B-DiseaseOrPhenotypicFeature
parathyroid	I-DiseaseOrPhenotypicFeature
lesion	I-DiseaseOrPhenotypicFeature
examined	O
(	O
17	O
.	O
1%	O
)	O
,	O
whereas	O
no	O
alterations	O
were	O
found	O
in	O
the	O
carcinomas	B-DiseaseOrPhenotypicFeature
.	O

Four	O
novel	O
MEN1	B-GeneOrGeneProduct
gene	O
mutations	O
were	O
identified	O
as	O
follows	O
:	O
one	O
frameshift	O
mutation	O
(	O
222insT	B-SequenceVariant
,	O
exon	O
2	O
)	O
,	O
one	O
frameshift	O
deletion	O
(	O
912delTA	B-SequenceVariant
,	O
exon	O
5	O
)	O
,	O
one	O
in	O
-	O
frame	O
deletion	O
(	O
835del18	B-SequenceVariant
,	O
exon	O
4	O
)	O
and	O
one	O
missense	O
mutation	O
(	O
P291A	B-SequenceVariant
,	O
exon	O
6	O
)	O
.	O

In	O
addition	O
,	O
one	O
missense	O
mutation	O
(	O
L89R	B-SequenceVariant
,	O
exon	O
2	O
)	O
and	O
one	O
nonsense	O
mutation	O
(	O
Q536X	B-SequenceVariant
,	O
exon	O
10	O
)	O
were	O
previously	O
reported	O
.	O

Moreover	O
,	O
two	O
polymorphisms	O
were	O
also	O
found	O
:	O
one	O
allele	O
carried	O
a	O
R171Q	B-SequenceVariant
polymorphism	O
(	O
1	O
/	O
39	O
tumors	B-DiseaseOrPhenotypicFeature
)	O
,	O
while	O
a	O
D418D	B-SequenceVariant
polymorphism	O
(	O
GAC	B-SequenceVariant
/	O
GAT	I-SequenceVariant
)	O
was	O
found	O
in	O
15	O
and	O
8	O
tumors	B-DiseaseOrPhenotypicFeature
in	O
hetero	O
(	O
CT	O
)	O
and	O
homozygosity	O
(	O
TT	O
)	O
,	O
respectively	O
.	O

In	O
no	O
case	O
(	O
mutations	O
and	O
/	O
or	O
polymorphisms	O
)	O
did	O
we	O
find	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
demonstrate	O
the	O
presence	O
of	O
somatic	O
alterations	O
of	O
the	O
MEN1	B-GeneOrGeneProduct
tumor	B-DiseaseOrPhenotypicFeature
suppressor	O
gene	O
in	O
about	O
one	O
fifth	O
of	O
benign	O
sporadic	O
parathyroid	B-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
.	O

The	O
absence	O
of	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
,	O
however	O
,	O
suggests	O
the	O
involvement	O
of	O
other	O
genetic	O
/	O
epigenetic	O
factors	O
for	O
the	O
full	O
expression	O
of	O
the	O
disease	O
.	O
Lack	O
of	O
association	O
between	O
ADRA2B	B-GeneOrGeneProduct
-	O
4825	I-SequenceVariant
gene	I-SequenceVariant
insertion	I-SequenceVariant
/	O
deletion	I-SequenceVariant
polymorphism	O
and	O
migraine	B-DiseaseOrPhenotypicFeature
in	O
Chinese	O
Han	O
population	O
.	O

OBJECTIVE	O
:	O
The	O
present	O
study	O
aimed	O
to	O
estimate	O
the	O
association	O
between	O
susceptibility	O
to	O
migraine	B-DiseaseOrPhenotypicFeature
and	O
the	O
12	B-SequenceVariant
-	O
nucleotide	I-SequenceVariant
insertion	I-SequenceVariant
/	O
deletion	I-SequenceVariant
(	O
indel	I-SequenceVariant
)	O
polymorphism	O
in	O
promoter	O
region	O
of	O
alpha	B-GeneOrGeneProduct
(	O
2B	I-GeneOrGeneProduct
)	O
-	O
adrenergic	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
gene	O
(	O
ADRA2B	B-GeneOrGeneProduct
)	O
.	O

METHODS	O
:	O
A	O
case	O
-	O
control	O
study	O
was	O
carried	O
out	O
in	O
Chinese	O
Han	O
population	O
,	O
including	O
368	O
cases	O
of	O
migraine	B-DiseaseOrPhenotypicFeature
and	O
517	O
controls	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
samples	O
,	O
and	O
DNA	O
fragments	O
containing	O
the	O
site	O
of	O
polymorphism	O
were	O
amplified	O
by	O
PCR	O
.	O

Data	O
were	O
adjusted	O
for	O
sex	O
,	O
age	O
,	O
migraine	B-DiseaseOrPhenotypicFeature
history	O
and	O
family	O
history	O
,	O
and	O
analyzed	O
using	O
a	O
logistic	O
regression	O
model	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
association	O
between	O
indel	O
polymorphism	O
and	O
migraine	B-DiseaseOrPhenotypicFeature
,	O
at	O
either	O
the	O
allele	O
or	O
the	O
genotype	O
level	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
do	O
not	O
support	O
a	O
functional	O
significance	O
of	O
ADRA2B	B-GeneOrGeneProduct
indel	B-SequenceVariant
polymorphism	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
-	O
4825	I-SequenceVariant
relative	O
to	O
the	O
start	O
codon	O
in	O
the	O
far	O
upstream	O
region	O
of	O
the	O
promoter	O
in	O
the	O
present	O
migraine	B-DiseaseOrPhenotypicFeature
subjects	O
.	O
Aryl	B-GeneOrGeneProduct
hydrocarbon	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
interacting	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
AIP	B-GeneOrGeneProduct
)	O
gene	O
mutation	O
analysis	O
in	O
children	O
and	O
adolescents	O
with	O
sporadic	O
pituitary	B-DiseaseOrPhenotypicFeature
adenomas	I-DiseaseOrPhenotypicFeature
.	O

OBJECTIVE	O
:	O
Pituitary	B-DiseaseOrPhenotypicFeature
adenomas	I-DiseaseOrPhenotypicFeature
occur	O
rarely	O
in	O
childhood	O
and	O
adolescence	O
.	O

Pituitary	B-DiseaseOrPhenotypicFeature
adenoma	I-DiseaseOrPhenotypicFeature
predisposition	O
(	O
PAP	O
)	O
has	O
been	O
recently	O
associated	O
with	O
germline	O
mutations	O
in	O
the	O
aryl	B-GeneOrGeneProduct
hydrocarbon	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
interacting	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
AIP	B-GeneOrGeneProduct
)	O
gene	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
examine	O
the	O
proportion	O
of	O
germline	O
AIP	B-GeneOrGeneProduct
mutations	O
in	O
apparently	O
sporadic	O
paediatric	O
pituitary	B-DiseaseOrPhenotypicFeature
adenomas	I-DiseaseOrPhenotypicFeature
.	O

DESIGN	O
:	O
Genomic	O
DNA	O
was	O
analysed	O
for	O
mutations	O
in	O
the	O
AIP	B-GeneOrGeneProduct
gene	O
,	O
by	O
PCR	O
amplification	O
and	O
direct	O
sequencing	O
.	O

PATIENTS	B-OrganismTaxon
:	O
A	O
population	O
-	O
based	O
cohort	O
consisting	O
of	O
36	O
apparently	O
sporadic	O
paediatric	O
pituitary	B-DiseaseOrPhenotypicFeature
adenoma	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
referred	O
to	O
two	O
medical	O
centres	O
in	O
Italy	O
,	O
was	O
included	O
in	O
the	O
study	O
.	O

Patients	B-OrganismTaxon
were	O
either	O
less	O
than	O
18	O
years	O
at	O
diagnosis	O
,	O
or	O
showed	O
clinical	O
evidence	O
of	O
adenoma	B-DiseaseOrPhenotypicFeature
development	O
before	O
the	O
age	O
of	O
18	O
years	O
.	O

RESULTS	O
:	O
A	O
heterozygous	O
in	O
-	O
frame	O
deletion	O
Y248del	B-SequenceVariant
(	O
c	B-SequenceVariant
.	O
742_744delTAC	I-SequenceVariant
)	O
was	O
identified	O
in	O
one	O
GH	B-DiseaseOrPhenotypicFeature
-	O
secreting	I-DiseaseOrPhenotypicFeature
adenoma	I-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
.	O

Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
analysis	O
of	O
tumour	B-DiseaseOrPhenotypicFeature
DNA	O
revealed	O
the	O
loss	O
of	O
the	O
wild	O
-	O
type	O
allele	O
.	O

First	O
degree	O
relatives	O
carrying	O
the	O
mutation	O
were	O
clinically	O
unaffected	O
.	O

CONCLUSIONS	O
:	O
While	O
mutations	O
were	O
absent	O
in	O
non	O
-	O
GH	B-DiseaseOrPhenotypicFeature
-	O
secreting	I-DiseaseOrPhenotypicFeature
adenoma	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
germline	O
AIP	B-GeneOrGeneProduct
mutations	O
can	O
be	O
found	O
in	O
children	O
and	O
adolescents	O
with	O
GH	B-DiseaseOrPhenotypicFeature
-	O
secreting	I-DiseaseOrPhenotypicFeature
tumours	I-DiseaseOrPhenotypicFeature
,	O
even	O
in	O
the	O
absence	O
of	O
family	O
history	O
.	O

The	O
present	O
study	O
reports	O
the	O
AIP	B-GeneOrGeneProduct
mutation	O
analysis	O
results	O
on	O
patients	B-OrganismTaxon
of	O
a	O
single	O
ethnic	O
origin	O
.	O

Clearly	O
,	O
further	O
studies	O
are	O
needed	O
to	O
improve	O
our	O
knowledge	O
on	O
the	O
role	O
of	O
AIP	B-GeneOrGeneProduct
in	O
paediatric	O
pituitary	B-DiseaseOrPhenotypicFeature
adenomas	I-DiseaseOrPhenotypicFeature
.	O
A	O
novel	O
missense	O
mutation	O
in	O
the	O
paired	O
domain	O
of	O
human	B-OrganismTaxon
PAX9	B-GeneOrGeneProduct
causes	O
oligodontia	B-DiseaseOrPhenotypicFeature
.	O

PAX9	B-GeneOrGeneProduct
and	O
MSX1	B-GeneOrGeneProduct
are	O
transcription	O
factors	O
that	O
play	O
essential	O
roles	O
in	O
craniofacial	O
and	O
limb	O
development	O
.	O

In	O
humans	B-OrganismTaxon
,	O
mutations	O
in	O
both	O
genes	O
are	O
associated	O
with	O
nonsyndromic	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
syndromic	I-DiseaseOrPhenotypicFeature
oligodontia	I-DiseaseOrPhenotypicFeature
,	O
respectively	O
.	O

We	O
screened	O
one	O
family	O
with	O
nonsyndromic	B-DiseaseOrPhenotypicFeature
oligodontia	I-DiseaseOrPhenotypicFeature
for	O
mutations	O
in	O
PAX9	B-GeneOrGeneProduct
and	O
MSX1	B-GeneOrGeneProduct
.	O

Single	O
stranded	O
conformational	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
and	O
sequencing	O
revealed	O
a	O
novel	O
heterozygous	O
C139T	B-SequenceVariant
transition	O
in	O
PAX9	B-GeneOrGeneProduct
in	O
the	O
affected	O
members	O
of	O
the	O
family	O
.	O

There	O
were	O
no	O
mutations	O
detected	O
in	O
the	O
entire	O
coding	O
sequence	O
of	O
MSX1	B-GeneOrGeneProduct
.	O

The	O
C139T	B-SequenceVariant
mutation	O
,	O
predicted	O
to	O
result	O
in	O
the	O
substitution	O
of	O
an	O
arginine	B-SequenceVariant
by	I-SequenceVariant
a	I-SequenceVariant
tryptophan	I-SequenceVariant
(	O
R47W	B-SequenceVariant
)	O
in	O
the	O
N	O
-	O
terminal	O
subdomain	O
,	O
affected	O
conserved	O
residues	O
in	O
the	O
PAX9	B-GeneOrGeneProduct
paired	O
domain	O
.	O

To	O
elucidate	O
the	O
pathogenic	O
mechanism	O
producing	O
oligodontia	B-DiseaseOrPhenotypicFeature
phenotype	I-DiseaseOrPhenotypicFeature
caused	O
by	O
this	O
mutation	O
,	O
we	O
analyzed	O
the	O
binding	O
of	O
wild	O
-	O
type	O
and	O
mutant	O
PAX9	B-GeneOrGeneProduct
paired	O
domain	O
protein	O
to	O
double	O
-	O
stranded	O
DNA	O
targets	O
.	O

The	O
R47W	B-SequenceVariant
mutation	O
dramatically	O
reduced	O
DNA	O
binding	O
suggesting	O
that	O
the	O
mutant	O
protein	O
with	O
consequent	O
haploinsufficiency	O
results	O
in	O
a	O
clinical	O
phenotype	O
.	O
Availability	O
of	O
human	B-OrganismTaxon
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
in	O
assessment	O
of	O
drug	O
potential	O
for	O
QT	B-DiseaseOrPhenotypicFeature
prolongation	I-DiseaseOrPhenotypicFeature
.	O

Field	O
potential	O
duration	O
(	O
FPD	O
)	O
in	O
human	B-OrganismTaxon
-	O
induced	O
pluripotent	O
stem	O
cell	O
-	O
derived	O
cardiomyocytes	O
(	O
hiPS	O
-	O
CMs	O
)	O
,	O
which	O
can	O
express	O
QT	O
interval	O
in	O
an	O
electrocardiogram	O
,	O
is	O
reported	O
to	O
be	O
a	O
useful	O
tool	O
to	O
predict	O
K	B-ChemicalEntity
(	O
+	O
)	O
channel	I-ChemicalEntity
and	I-ChemicalEntity
Ca	I-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
channel	I-ChemicalEntity
blocker	I-ChemicalEntity
effects	O
on	O
QT	O
interval	O
.	O

However	O
,	O
there	O
is	O
no	O
report	O
showing	O
that	O
this	O
technique	O
can	O
be	O
used	O
to	O
predict	O
multichannel	O
blocker	O
potential	O
for	O
QT	B-DiseaseOrPhenotypicFeature
prolongation	I-DiseaseOrPhenotypicFeature
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
show	O
that	O
FPD	O
from	O
MEA	O
(	O
Multielectrode	O
array	O
)	O
of	O
hiPS	O
-	O
CMs	O
can	O
detect	O
QT	B-DiseaseOrPhenotypicFeature
prolongation	I-DiseaseOrPhenotypicFeature
induced	O
by	O
multichannel	O
blockers	O
.	O

hiPS	O
-	O
CMs	O
were	O
seeded	O
onto	O
MEA	O
and	O
FPD	O
was	O
measured	O
for	O
2min	O
every	O
10min	O
for	O
30min	O
after	O
drug	O
exposure	O
for	O
the	O
vehicle	O
and	O
each	O
drug	O
concentration	O
.	O

IKr	O
and	O
IKs	O
blockers	O
concentration	O
-	O
dependently	O
prolonged	O
corrected	O
FPD	O
(	O
FPDc	O
)	O
,	O
whereas	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
channel	I-ChemicalEntity
blockers	I-ChemicalEntity
concentration	O
-	O
dependently	O
shortened	O
FPDc	O
.	O

Also	O
,	O
the	O
multichannel	O
blockers	O
Amiodarone	B-ChemicalEntity
,	O
Paroxetine	B-ChemicalEntity
,	O
Terfenadine	B-ChemicalEntity
and	O
Citalopram	B-ChemicalEntity
prolonged	O
FPDc	O
in	O
a	O
concentration	O
dependent	O
manner	O
.	O

Finally	O
,	O
the	O
IKr	O
blockers	O
,	O
Terfenadine	B-ChemicalEntity
and	O
Citalopram	B-ChemicalEntity
,	O
which	O
are	O
reported	O
to	O
cause	O
Torsade	B-DiseaseOrPhenotypicFeature
de	I-DiseaseOrPhenotypicFeature
Pointes	I-DiseaseOrPhenotypicFeature
(	O
TdP	B-DiseaseOrPhenotypicFeature
)	O
in	O
clinical	O
practice	O
,	O
produced	O
early	O
afterdepolarization	O
(	O
EAD	O
)	O
.	O

hiPS	O
-	O
CMs	O
using	O
MEA	O
system	O
and	O
FPDc	O
can	O
predict	O
the	O
effects	O
of	O
drug	O
candidates	O
on	O
QT	O
interval	O
.	O

This	O
study	O
also	O
shows	O
that	O
this	O
assay	O
can	O
help	O
detect	O
EAD	O
for	O
drugs	O
with	O
TdP	B-DiseaseOrPhenotypicFeature
potential	O
.	O
A	O
novel	O
splicing	O
mutation	O
in	O
SLC12A3	B-GeneOrGeneProduct
associated	O
with	O
Gitelman	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
and	O
idiopathic	B-DiseaseOrPhenotypicFeature
intracranial	I-DiseaseOrPhenotypicFeature
hypertension	I-DiseaseOrPhenotypicFeature
.	O

We	O
report	O
a	O
case	O
of	O
Gitelman	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
GS	B-DiseaseOrPhenotypicFeature
)	O
in	O
a	O
dizygotic	O
twin	O
who	O
presented	O
at	O
12	O
years	O
of	O
age	O
with	O
growth	B-DiseaseOrPhenotypicFeature
delay	I-DiseaseOrPhenotypicFeature
,	O
metabolic	B-DiseaseOrPhenotypicFeature
alkalosis	I-DiseaseOrPhenotypicFeature
,	O
hypomagnesemia	B-DiseaseOrPhenotypicFeature
and	O
hypokalemia	B-DiseaseOrPhenotypicFeature
with	O
inappropriate	O
kaliuresis	O
,	O
and	O
idiopathic	B-DiseaseOrPhenotypicFeature
intracranial	I-DiseaseOrPhenotypicFeature
hypertension	I-DiseaseOrPhenotypicFeature
with	O
bilateral	B-DiseaseOrPhenotypicFeature
papilledema	I-DiseaseOrPhenotypicFeature
(	O
pseudotumor	B-DiseaseOrPhenotypicFeature
cerebri	I-DiseaseOrPhenotypicFeature
)	O
.	O

The	O
patient	B-OrganismTaxon
,	O
her	O
twin	O
sister	O
,	O
and	O
her	O
mother	O
also	O
presented	O
with	O
cerebral	B-DiseaseOrPhenotypicFeature
cavernous	I-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
.	O

Based	O
on	O
the	O
early	O
onset	O
and	O
normocalciuria	O
,	O
Bartter	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
was	O
diagnosed	O
first	O
.	O

However	O
,	O
mutation	O
analysis	O
showed	O
that	O
the	O
proband	O
is	O
a	O
compound	O
heterozygote	O
for	O
2	O
mutations	O
in	O
SLC12A3	B-GeneOrGeneProduct
:	O
a	O
substitution	O
of	O
serine	B-SequenceVariant
by	I-SequenceVariant
leucine	I-SequenceVariant
at	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
position	I-SequenceVariant
555	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Ser555Leu	I-SequenceVariant
)	O
and	O
a	O
novel	O
guanine	B-SequenceVariant
to	I-SequenceVariant
cytosine	I-SequenceVariant
transition	O
at	O
the	O
5	O
'	O
splice	O
site	O
of	O
intron	O
22	O
(	O
c	B-SequenceVariant
.	O
2633	I-SequenceVariant
+	O
1G	I-SequenceVariant
>	O
C	I-SequenceVariant
)	O
,	O
providing	O
the	O
molecular	O
diagnosis	O
of	O
GS	B-DiseaseOrPhenotypicFeature
.	O

These	O
mutations	O
were	O
not	O
detected	O
in	O
200	O
normal	O
chromosomes	O
and	O
cosegregated	O
within	O
the	O
family	O
.	O

Analysis	O
of	O
complementary	O
DNA	O
showed	O
that	O
the	O
heterozygous	O
nucleotide	O
change	O
c	B-SequenceVariant
.	O
2633	I-SequenceVariant
+	O
1G	I-SequenceVariant
>	O
C	I-SequenceVariant
caused	O
the	O
appearance	O
of	O
2	O
RNA	O
molecules	O
,	O
1	O
normal	O
transcript	O
and	O
1	O
skipping	O
the	O
entire	O
exon	O
22	O
(	O
r	B-SequenceVariant
.	O
2521_2634del	I-SequenceVariant
)	O
.	O

Supplementation	O
with	O
potassium	B-ChemicalEntity
and	O
magnesium	B-ChemicalEntity
improved	O
clinical	O
symptoms	O
and	O
resulted	O
in	O
catch	O
-	O
up	O
growth	O
,	O
but	O
vision	O
remained	O
impaired	O
.	O

Three	O
similar	O
associations	O
of	O
Bartter	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
/	O
GS	B-DiseaseOrPhenotypicFeature
with	O
pseudotumor	B-DiseaseOrPhenotypicFeature
cerebri	I-DiseaseOrPhenotypicFeature
were	O
found	O
in	O
the	O
literature	O
,	O
suggesting	O
that	O
electrolyte	B-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
and	O
secondary	B-DiseaseOrPhenotypicFeature
aldosteronism	I-DiseaseOrPhenotypicFeature
may	O
have	O
a	O
role	O
in	O
idiopathic	B-DiseaseOrPhenotypicFeature
intracranial	I-DiseaseOrPhenotypicFeature
hypertension	I-DiseaseOrPhenotypicFeature
.	O

This	O
study	O
provides	O
further	O
evidence	O
for	O
the	O
phenotypical	O
heterogeneity	O
of	O
GS	B-DiseaseOrPhenotypicFeature
and	O
its	O
association	O
with	O
severe	O
manifestations	O
in	O
children	O
.	O

It	O
also	O
shows	O
the	O
independent	O
segregation	O
of	O
familial	B-DiseaseOrPhenotypicFeature
cavernomatosis	I-DiseaseOrPhenotypicFeature
and	O
GS	B-DiseaseOrPhenotypicFeature
.	O
Regulation	O
of	O
lung	O
endothelial	O
permeability	O
and	O
inflammatory	B-DiseaseOrPhenotypicFeature
responses	O
by	O
prostaglandin	B-ChemicalEntity
A2	I-ChemicalEntity
:	O
role	O
of	O
EP4	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
.	O

The	O
role	O
of	O
prostaglandin	B-ChemicalEntity
A2	I-ChemicalEntity
(	O
PGA2	B-ChemicalEntity
)	O
in	O
modulation	O
of	O
vascular	O
endothelial	O
function	O
is	O
unknown	O
.	O

We	O
investigated	O
effects	O
of	O
PGA2	B-ChemicalEntity
on	O
pulmonary	O
endothelial	O
cell	O
(	O
EC	O
)	O
permeability	O
and	O
inflammatory	B-DiseaseOrPhenotypicFeature
activation	O
and	O
identified	O
a	O
receptor	O
mediating	O
these	O
effects	O
.	O

PGA2	B-ChemicalEntity
enhanced	O
the	O
EC	O
barrier	O
and	O
protected	O
against	O
barrier	O
dysfunction	O
caused	O
by	O
vasoactive	O
peptide	O
thrombin	B-GeneOrGeneProduct
and	O
proinflammatory	B-DiseaseOrPhenotypicFeature
bacterial	O
wall	O
lipopolysaccharide	B-ChemicalEntity
(	O
LPS	B-ChemicalEntity
)	O
.	O

Receptor	O
screening	O
using	O
pharmacological	O
and	O
molecular	O
inhibitory	O
approaches	O
identified	O
EP4	B-GeneOrGeneProduct
as	O
a	O
novel	O
PGA2	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
.	O

EP4	B-GeneOrGeneProduct
mediated	O
barrier	O
-	O
protective	O
effects	O
of	O
PGA2	B-ChemicalEntity
by	O
activating	O
Rap1	B-GeneOrGeneProduct
/	O
Rac1	I-GeneOrGeneProduct
GTPase	I-GeneOrGeneProduct
and	O
protein	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
targets	O
at	O
cell	O
adhesions	O
and	O
cytoskeleton	O
:	O
VE	B-GeneOrGeneProduct
-	O
cadherin	I-GeneOrGeneProduct
,	O
p120	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
,	O
ZO	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
,	O
cortactin	B-GeneOrGeneProduct
,	O
and	O
VASP	B-GeneOrGeneProduct
.	O

PGA2	B-ChemicalEntity
also	O
suppressed	O
LPS	B-ChemicalEntity
-	O
induced	O
inflammatory	B-DiseaseOrPhenotypicFeature
signaling	O
by	O
inhibiting	O
the	O
NFkB	B-GeneOrGeneProduct
pathway	O
and	O
expression	O
of	O
EC	B-GeneOrGeneProduct
adhesion	I-GeneOrGeneProduct
molecules	I-GeneOrGeneProduct
ICAM1	B-GeneOrGeneProduct
and	O
VCAM1	B-GeneOrGeneProduct
.	O

These	O
effects	O
were	O
abolished	O
by	O
pharmacological	O
or	O
molecular	O
inhibition	O
of	O
EP4	B-GeneOrGeneProduct
.	O

In	O
vivo	O
,	O
PGA2	B-ChemicalEntity
was	O
protective	O
in	O
two	O
distinct	O
models	O
of	O
acute	B-DiseaseOrPhenotypicFeature
lung	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
(	O
ALI	B-DiseaseOrPhenotypicFeature
)	O
:	O
LPS	B-ChemicalEntity
-	O
induced	O
inflammatory	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	O
two	O
-	O
hit	O
ALI	B-DiseaseOrPhenotypicFeature
caused	O
by	O
suboptimal	O
mechanical	O
ventilation	O
and	O
injection	O
of	O
thrombin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
activating	O
peptide	O
.	O

These	O
protective	O
effects	O
were	O
abolished	O
in	O
mice	B-OrganismTaxon
with	O
endothelial	O
-	O
specific	O
EP4	B-GeneOrGeneProduct
knockout	O
.	O

The	O
results	O
suggest	O
a	O
novel	O
role	O
for	O
the	O
PGA2	B-ChemicalEntity
-	O
EP4	B-GeneOrGeneProduct
axis	O
in	O
vascular	O
EC	O
protection	O
that	O
is	O
critical	O
for	O
improvement	O
of	O
pathological	O
states	O
associated	O
with	O
increased	O
vascular	O
leakage	O
and	O
inflammation	B-DiseaseOrPhenotypicFeature
.	O
Genetic	O
polymorphisms	O
in	O
the	O
carbonyl	B-GeneOrGeneProduct
reductase	I-GeneOrGeneProduct
3	I-GeneOrGeneProduct
gene	O
CBR3	B-GeneOrGeneProduct
and	O
the	O
NAD	B-GeneOrGeneProduct
(	O
P	I-GeneOrGeneProduct
)	O
H	I-GeneOrGeneProduct
:	O
quinone	I-GeneOrGeneProduct
oxidoreductase	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
gene	O
NQO1	B-GeneOrGeneProduct
in	O
patients	B-OrganismTaxon
who	O
developed	O
anthracycline	B-ChemicalEntity
-	O
related	O
congestive	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
after	O
childhood	O
cancer	B-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Exposure	O
to	O
anthracyclines	B-ChemicalEntity
as	O
part	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
therapy	O
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
congestive	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
(	O
CHF	B-DiseaseOrPhenotypicFeature
)	O
.	O

The	O
potential	O
role	O
of	O
genetic	O
risk	O
factors	O
in	O
anthracycline	B-ChemicalEntity
-	O
related	O
CHF	B-DiseaseOrPhenotypicFeature
remains	O
to	O
be	O
defined	O
.	O

Thus	O
,	O
in	O
this	O
study	O
,	O
the	O
authors	O
examined	O
whether	O
common	O
polymorphisms	O
in	O
candidate	O
genes	O
involved	O
in	O
the	O
pharmacodynamics	O
of	O
anthracyclines	B-ChemicalEntity
(	O
in	O
particular	O
,	O
the	O
nicotinamide	B-GeneOrGeneProduct
adenine	I-GeneOrGeneProduct
dinucleotide	I-GeneOrGeneProduct
phosphate	I-GeneOrGeneProduct
:	O
quinone	I-GeneOrGeneProduct
oxidoreductase	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
gene	O
NQO1	B-GeneOrGeneProduct
and	O
the	O
carbonyl	B-GeneOrGeneProduct
reductase	I-GeneOrGeneProduct
3	I-GeneOrGeneProduct
gene	O
CBR3	B-GeneOrGeneProduct
)	O
had	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline	B-ChemicalEntity
-	O
related	O
CHF	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
A	O
nested	O
case	O
-	O
control	O
study	O
was	O
conducted	O
within	O
a	O
cohort	O
of	O
1979	O
patients	B-OrganismTaxon
enrolled	O
in	O
the	O
Childhood	O
Cancer	O
Survivor	O
Study	O
who	O
received	O
treatment	O
with	O
anthracyclines	B-ChemicalEntity
and	O
had	O
available	O
DNA	O
.	O

Thirty	O
patients	B-OrganismTaxon
with	O
CHF	B-DiseaseOrPhenotypicFeature
(	O
cases	O
)	O
and	O
115	O
matched	O
controls	O
were	O
genotyped	O
for	O
polymorphisms	O
in	O
NQO1	B-GeneOrGeneProduct
(	O
NQO1	B-GeneOrGeneProduct
*	O
2	O
)	O
and	O
CBR3	B-GeneOrGeneProduct
(	O
the	O
CBR3	B-GeneOrGeneProduct
valine	B-SequenceVariant
[	O
V	I-SequenceVariant
]	O
to	I-SequenceVariant
methionine	I-SequenceVariant
[	O
M	I-SequenceVariant
]	O
substitution	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
244	I-SequenceVariant
[	O
V244M	B-SequenceVariant
]	O
)	O
.	O

Enzyme	O
activity	O
assays	O
with	O
recombinant	O
CBR3	B-GeneOrGeneProduct
isoforms	O
(	O
CBR3	B-GeneOrGeneProduct
V244	B-SequenceVariant
and	O
CBR3	B-GeneOrGeneProduct
M244	B-SequenceVariant
)	O
and	O
the	O
anthracycline	B-ChemicalEntity
substrate	O
doxorubicin	B-ChemicalEntity
were	O
used	O
to	O
investigate	O
the	O
functional	O
impact	O
of	O
the	O
CBR3	B-GeneOrGeneProduct
V244M	B-SequenceVariant
polymorphism	O
.	O

RESULTS	O
:	O
Multivariate	O
analyses	O
adjusted	O
for	O
sex	O
and	O
primary	O
disease	O
recurrence	O
were	O
used	O
to	O
test	O
for	O
associations	O
between	O
the	O
candidate	O
genetic	O
polymorphisms	O
(	O
NQO1	B-GeneOrGeneProduct
*	O
2	O
and	O
CBR3	B-GeneOrGeneProduct
V244M	B-SequenceVariant
)	O
and	O
the	O
risk	O
of	O
CHF	B-DiseaseOrPhenotypicFeature
.	O

Analyses	O
indicated	O
no	O
association	O
between	O
the	O
NQO1	B-GeneOrGeneProduct
*	O
2	O
polymorphism	O
and	O
the	O
risk	O
of	O
anthracycline	B-ChemicalEntity
-	O
related	O
CHF	B-DiseaseOrPhenotypicFeature
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
1	O
.	O
04	O
;	O
P	O
=	O
.	O
97	O
)	O
.	O

There	O
was	O
a	O
trend	O
toward	O
an	O
association	O
between	O
the	O
CBR3	B-GeneOrGeneProduct
V244M	B-SequenceVariant
polymorphism	O
and	O
the	O
risk	O
of	O
CHF	B-DiseaseOrPhenotypicFeature
(	O
OR	O
,	O
8	O
.	O
16	O
;	O
P	O
=	O
.	O
056	O
for	O
G	O
/	O
G	O
vs	O
A	O
/	O
A	O
;	O
OR	O
,	O
5	O
.	O
44	O
;	O
P	O
=	O
.	O
092	O
for	O
G	O
/	O
A	O
vs	O
A	O
/	O
A	O
)	O
.	O

In	O
line	O
,	O
recombinant	O
CBR3	B-GeneOrGeneProduct
V244	B-SequenceVariant
(	O
G	O
allele	O
)	O
synthesized	O
2	O
.	O
6	O
-	O
fold	O
more	O
cardiotoxic	B-DiseaseOrPhenotypicFeature
doxorubicinol	B-ChemicalEntity
per	O
unit	O
of	O
time	O
than	O
CBR3	B-GeneOrGeneProduct
M244	B-SequenceVariant
(	O
A	O
allele	O
;	O
CBR3	B-GeneOrGeneProduct
V244	B-SequenceVariant
[	O
8	O
.	O
26	O
+	O
/	O
-	O
3	O
.	O
57	O
nmol	O
/	O
hour	O
.	O
mg	O
]	O
vs	O
CBR3	B-GeneOrGeneProduct
M244	B-SequenceVariant
[	O
3	O
.	O
22	O
+	O
/	O
-	O
0	O
.	O
67	O
nmol	O
/	O
hour	O
.	O
mg	O
]	O
;	O
P	O
=	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
functional	O
CBR3	B-GeneOrGeneProduct
V244M	B-SequenceVariant
polymorphism	O
may	O
have	O
an	O
impact	O
on	O
the	O
risk	O
of	O
anthracycline	B-ChemicalEntity
-	O
related	O
CHF	B-DiseaseOrPhenotypicFeature
among	O
childhood	O
cancer	B-DiseaseOrPhenotypicFeature
survivors	O
by	O
modulating	O
the	O
intracardiac	O
formation	O
of	O
cardiotoxic	B-DiseaseOrPhenotypicFeature
anthracycline	B-ChemicalEntity
alcohol	I-ChemicalEntity
metabolites	O
.	O

Larger	O
confirmatory	O
case	O
-	O
control	O
studies	O
are	O
warranted	O
.	O
A	O
polymorphism	O
of	O
C	B-SequenceVariant
-	O
to	I-SequenceVariant
-	O
T	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
-	O
31	I-SequenceVariant
IL1B	B-GeneOrGeneProduct
is	O
associated	O
with	O
the	O
risk	O
of	O
advanced	O
gastric	B-DiseaseOrPhenotypicFeature
adenocarcinoma	I-DiseaseOrPhenotypicFeature
in	O
a	O
Japanese	O
population	O
.	O

Proinflammatory	B-GeneOrGeneProduct
cytokine	I-GeneOrGeneProduct
gene	O
polymorphisms	O
have	O
been	O
demonstrated	O
to	O
associate	O
with	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
,	O
of	O
which	O
IL1B	B-GeneOrGeneProduct
-	O
31T	I-SequenceVariant
/	O
C	I-SequenceVariant
and	O
-	O
511C	I-SequenceVariant
/	O
T	I-SequenceVariant
changes	O
have	O
been	O
well	O
investigated	O
due	O
to	O
the	O
possibility	O
that	O
they	O
may	O
alter	O
the	O
IL1B	B-GeneOrGeneProduct
transcription	O
.	O

The	O
signal	O
transduction	O
target	O
upon	O
interleukin	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
(	O
IL1beta	B-GeneOrGeneProduct
)	O
stimulation	O
,	O
the	O
nuclear	B-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
kappa	I-GeneOrGeneProduct
B	I-GeneOrGeneProduct
(	O
NFkappaB	B-GeneOrGeneProduct
)	O
activation	O
,	O
supports	O
cancer	B-DiseaseOrPhenotypicFeature
development	O
,	O
signal	O
transduction	O
in	O
which	O
is	O
mediated	O
by	O
FS	B-GeneOrGeneProduct
-	O
7	I-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
-	O
associated	I-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
surface	I-GeneOrGeneProduct
antigen	I-GeneOrGeneProduct
(	O
FAS	B-GeneOrGeneProduct
)	O
signaling	O
.	O

Based	O
on	O
recent	O
papers	O
describing	O
the	O
prognostic	O
roles	O
of	O
the	O
polymorphisms	O
and	O
the	O
NFkappaB	B-GeneOrGeneProduct
functions	O
on	O
cancer	B-DiseaseOrPhenotypicFeature
development	O
,	O
we	O
sought	O
to	O
determine	O
if	O
Japanese	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
were	O
affected	O
by	O
the	O
IL1B	B-GeneOrGeneProduct
-	O
31	O
/	O
-	O
511	O
and	O
FAS	B-GeneOrGeneProduct
-	O
670	O
polymorphisms	O
.	O

A	O
case	O
-	O
control	O
study	O
was	O
conducted	O
on	O
incident	O
gastric	B-DiseaseOrPhenotypicFeature
adenocarcinoma	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
(	O
n	O
=	O
271	O
)	O
and	O
age	O
-	O
gender	O
frequency	O
-	O
matched	O
control	O
subjects	O
(	O
n	O
=	O
271	O
)	O
.	O

We	O
observed	O
strong	O
linkage	O
disequilibrium	O
between	O
the	O
T	B-SequenceVariant
allele	I-SequenceVariant
at	I-SequenceVariant
-	O
511	I-SequenceVariant
and	O
the	O
C	B-SequenceVariant
allele	I-SequenceVariant
at	I-SequenceVariant
-	O
31	I-SequenceVariant
and	O
between	O
the	O
C	B-SequenceVariant
allele	I-SequenceVariant
at	I-SequenceVariant
-	O
511	I-SequenceVariant
and	O
the	O
T	B-SequenceVariant
allele	I-SequenceVariant
at	I-SequenceVariant
-	O
31	I-SequenceVariant
in	O
IL1B	B-GeneOrGeneProduct
in	O
both	O
the	O
cases	O
and	O
controls	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
94	O
)	O
.	O

Neither	O
IL1B	B-GeneOrGeneProduct
-	O
31	O
,	O
-	O
511	O
nor	O
FAS	B-GeneOrGeneProduct
-	O
670	O
polymorphisms	O
showed	O
significantly	O
different	O
risks	O
of	O
gastric	B-DiseaseOrPhenotypicFeature
adenocarcinoma	I-DiseaseOrPhenotypicFeature
.	O

Though	O
FAS	B-GeneOrGeneProduct
-	O
670	O
polymorphisms	O
did	O
not	O
show	O
any	O
significant	O
difference	O
,	O
the	O
proportion	O
of	O
subjects	O
with	O
IL1B	B-GeneOrGeneProduct
-	O
31TT	I-SequenceVariant
(	O
or	O
IL1B	B-GeneOrGeneProduct
-	O
511CC	I-SequenceVariant
)	O
increased	O
according	O
to	O
stage	O
(	O
trend	O
P	O
=	O
0	O
.	O
019	O
)	O
.	O

In	O
particular	O
,	O
subjects	O
with	O
stage	O
IV	O
had	O
a	O
two	O
times	O
higher	O
probability	O
of	O
having	O
either	O
IL1B	B-GeneOrGeneProduct
-	O
31TT	I-SequenceVariant
(	O
or	O
IL1B	B-GeneOrGeneProduct
-	O
511CC	I-SequenceVariant
)	O
genotype	O
compared	O
with	O
stage	O
I	O
subjects	O
.	O

These	O
observations	O
suggest	O
that	O
IL1B	B-GeneOrGeneProduct
-	O
31TT	I-SequenceVariant
and	O
IL1B	B-GeneOrGeneProduct
-	O
511CC	I-SequenceVariant
are	O
associated	O
with	O
disease	O
progression	O
.	O
On	O
the	O
pivotal	O
role	O
of	O
PPARa	B-GeneOrGeneProduct
in	O
adaptation	O
of	O
the	O
heart	O
to	O
hypoxia	B-DiseaseOrPhenotypicFeature
and	O
why	O
fat	O
in	O
the	O
diet	O
increases	O
hypoxic	B-DiseaseOrPhenotypicFeature
injury	O
.	O

The	O
role	O
of	O
peroxisome	B-GeneOrGeneProduct
proliferator	I-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
a	I-GeneOrGeneProduct
(	O
PPARa	B-GeneOrGeneProduct
)	O
-	O
mediated	O
metabolic	O
remodeling	O
in	O
cardiac	O
adaptation	O
to	O
hypoxia	B-DiseaseOrPhenotypicFeature
has	O
yet	O
to	O
be	O
defined	O
.	O

Here	O
,	O
mice	B-OrganismTaxon
were	O
housed	O
in	O
hypoxia	B-DiseaseOrPhenotypicFeature
for	O
3	O
wk	O
before	O
in	O
vivo	O
contractile	O
function	O
was	O
measured	O
using	O
cine	O
MRI	O
.	O

In	O
isolated	O
,	O
perfused	O
hearts	O
,	O
energetics	O
were	O
measured	O
using	O
(	O
31	O
)	O
P	O
magnetic	O
resonance	O
spectroscopy	O
(	O
MRS	O
)	O
,	O
and	O
glycolysis	O
and	O
fatty	B-ChemicalEntity
acid	I-ChemicalEntity
oxidation	O
were	O
measured	O
using	O
[	O
(	O
3	I-ChemicalEntity
)	O
H	I-ChemicalEntity
]	O
labeling	O
.	O

Compared	O
with	O
a	O
normoxic	O
,	O
chow	O
-	O
fed	O
control	O
mouse	B-OrganismTaxon
heart	O
,	O
hypoxia	B-DiseaseOrPhenotypicFeature
decreased	O
PPARa	B-GeneOrGeneProduct
expression	O
,	O
fatty	B-ChemicalEntity
acid	I-ChemicalEntity
oxidation	O
,	O
and	O
mitochondrial	B-GeneOrGeneProduct
uncoupling	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
3	I-GeneOrGeneProduct
(	O
UCP3	B-GeneOrGeneProduct
)	O
levels	O
,	O
while	O
increasing	O
glycolysis	O
,	O
all	O
of	O
which	O
served	O
to	O
maintain	O
normal	O
ATP	B-ChemicalEntity
concentrations	O
(	O
[	O
ATP	B-ChemicalEntity
]	O
)	O
and	O
thereby	O
,	O
ejection	O
fractions	O
.	O

A	O
high	O
-	O
fat	O
diet	O
increased	O
cardiac	O
PPARa	B-GeneOrGeneProduct
expression	O
,	O
fatty	B-ChemicalEntity
acid	I-ChemicalEntity
oxidation	O
,	O
and	O
UCP3	B-GeneOrGeneProduct
levels	O
with	O
decreased	O
glycolysis	O
.	O

Hypoxia	B-DiseaseOrPhenotypicFeature
was	O
unable	O
to	O
alter	O
the	O
high	O
PPARa	B-GeneOrGeneProduct
expression	O
or	O
reverse	O
the	O
metabolic	O
changes	O
caused	O
by	O
the	O
high	O
-	O
fat	O
diet	O
,	O
with	O
the	O
result	O
that	O
[	O
ATP	B-ChemicalEntity
]	O
and	O
contractile	O
function	O
decreased	O
significantly	O
.	O

The	O
adaptive	O
metabolic	O
changes	O
caused	O
by	O
hypoxia	B-DiseaseOrPhenotypicFeature
in	O
control	O
mouse	B-OrganismTaxon
hearts	O
were	O
found	O
to	O
have	O
occurred	O
already	O
in	O
PPARa	B-GeneOrGeneProduct
-	O
deficient	O
(	O
PPARa	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
)	O
mouse	B-OrganismTaxon
hearts	O
and	O
sustained	O
function	O
in	O
hypoxia	B-DiseaseOrPhenotypicFeature
despite	O
an	O
inability	O
for	O
further	O
metabolic	O
remodeling	O
.	O

We	O
conclude	O
that	O
decreased	O
cardiac	O
PPARa	B-GeneOrGeneProduct
expression	O
is	O
essential	O
for	O
adaptive	O
metabolic	O
remodeling	O
in	O
hypoxia	B-DiseaseOrPhenotypicFeature
,	O
but	O
is	O
prevented	O
by	O
dietary	O
fat	O
.	O
-	O
Cole	O
,	O
M	O
.	O

A	O
.	O
,	O
Abd	O
Jamil	O
,	O
A	O
.	O

H	O
.	O
,	O
Heather	O
,	O
L	O
.	O

C	O
.	O
,	O
Murray	O
,	O
A	O
.	O

J	O
.	O
,	O
Sutton	O
,	O
E	O
.	O

R	O
.	O
,	O
Slingo	O
,	O
M	O
.	O
,	O
Sebag	O
-	O
Montefiore	O
,	O
L	O
.	O
,	O
Tan	O
,	O
S	O
.	O

C	O
.	O
,	O
Aksentijevic	O
,	O
D	O
.	O
,	O
Gildea	O
,	O
O	O
.	O

S	O
.	O
,	O
Stuckey	O
,	O
D	O
.	O

J	O
.	O
,	O
Yeoh	O
,	O
K	O
.	O

K	O
.	O
,	O
Carr	O
,	O
C	O
.	O

A	O
.	O
,	O
Evans	O
,	O
R	O
.	O

D	O
.	O
,	O
Aasum	O
,	O
E	O
.	O
,	O
Schofield	O
,	O
C	O
.	O

J	O
.	O
,	O
Ratcliffe	O
,	O
P	O
.	O

J	O
.	O
,	O
Neubauer	O
,	O
S	O
.	O
,	O
Robbins	O
,	O
P	O
.	O

A	O
.	O
,	O
Clarke	O
,	O
K	O
.	O

On	O
the	O
pivotal	O
role	O
of	O
PPARa	B-GeneOrGeneProduct
in	O
adaptation	O
of	O
the	O
heart	O
to	O
hypoxia	B-DiseaseOrPhenotypicFeature
and	O
why	O
fat	O
in	O
the	O
diet	O
increases	O
hypoxic	B-DiseaseOrPhenotypicFeature
injury	O
.	O
High	O
-	O
dose	O
tranexamic	B-ChemicalEntity
Acid	I-ChemicalEntity
is	O
associated	O
with	O
nonischemic	O
clinical	O
seizures	B-DiseaseOrPhenotypicFeature
in	O
cardiac	O
surgical	O
patients	B-OrganismTaxon
.	O

BACKGROUND	O
:	O
In	O
2	O
separate	O
centers	O
,	O
we	O
observed	O
a	O
notable	O
increase	O
in	O
the	O
incidence	O
of	O
postoperative	O
convulsive	B-DiseaseOrPhenotypicFeature
seizures	I-DiseaseOrPhenotypicFeature
from	O
1	O
.	O
3%	O
to	O
3	O
.	O
8%	O
in	O
patients	B-OrganismTaxon
having	O
undergone	O
major	O
cardiac	O
surgical	O
procedures	O
.	O

These	O
events	O
were	O
temporally	O
coincident	O
with	O
the	O
initial	O
use	O
of	O
high	O
-	O
dose	O
tranexamic	B-ChemicalEntity
acid	I-ChemicalEntity
(	O
TXA	B-ChemicalEntity
)	O
therapy	O
after	O
withdrawal	O
of	O
aprotinin	O
from	O
general	O
clinical	O
usage	O
.	O

The	O
purpose	O
of	O
this	O
review	O
was	O
to	O
perform	O
a	O
retrospective	O
analysis	O
to	O
examine	O
whether	O
there	O
was	O
a	O
relation	O
between	O
TXA	B-ChemicalEntity
usage	O
and	O
seizures	B-DiseaseOrPhenotypicFeature
after	O
cardiac	O
surgery	O
.	O

METHODS	O
:	O
An	O
in	O
-	O
depth	O
chart	O
review	O
was	O
undertaken	O
in	O
all	O
24	O
patients	B-OrganismTaxon
who	O
developed	O
perioperative	O
seizures	B-DiseaseOrPhenotypicFeature
.	O

Electroencephalographic	O
activity	O
was	O
recorded	O
in	O
11	O
of	O
these	O
patients	B-OrganismTaxon
,	O
and	O
all	O
patients	B-OrganismTaxon
had	O
a	O
formal	O
neurological	O
evaluation	O
and	O
brain	O
imaging	O
studies	O
.	O

RESULTS	O
:	O
Twenty	O
-	O
one	O
of	O
the	O
24	O
patients	B-OrganismTaxon
did	O
not	O
have	O
evidence	O
of	O
new	O
cerebral	B-DiseaseOrPhenotypicFeature
ischemic	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
,	O
but	O
seizures	B-DiseaseOrPhenotypicFeature
were	O
likely	O
due	O
to	O
ischemic	B-DiseaseOrPhenotypicFeature
brain	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
in	O
3	O
patients	B-OrganismTaxon
.	O

All	O
patients	B-OrganismTaxon
with	O
seizures	B-DiseaseOrPhenotypicFeature
did	O
not	O
have	O
permanent	O
neurological	B-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
.	O

All	O
24	O
patients	B-OrganismTaxon
with	O
seizures	B-DiseaseOrPhenotypicFeature
received	O
high	O
doses	O
of	O
TXA	B-ChemicalEntity
intraoperatively	O
ranging	O
from	O
61	O
to	O
259	O
mg	O
/	O
kg	O
,	O
had	O
a	O
mean	O
age	O
of	O
69	O
.	O
9	O
years	O
,	O
and	O
21	O
of	O
24	O
had	O
undergone	O
open	O
chamber	O
rather	O
than	O
coronary	O
bypass	O
procedures	O
.	O

All	O
but	O
one	O
patient	B-OrganismTaxon
were	O
managed	O
using	O
cardiopulmonary	O
bypass	O
.	O

No	O
evidence	O
of	O
brain	B-DiseaseOrPhenotypicFeature
ischemic	I-DiseaseOrPhenotypicFeature
,	O
metabolic	O
,	O
or	O
hyperthermia	B-DiseaseOrPhenotypicFeature
-	O
induced	O
causes	O
for	O
their	O
seizures	B-DiseaseOrPhenotypicFeature
was	O
apparent	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
use	O
of	O
high	O
-	O
dose	O
TXA	B-ChemicalEntity
in	O
older	O
patients	B-OrganismTaxon
in	O
conjunction	O
with	O
cardiopulmonary	O
bypass	O
and	O
open	O
-	O
chamber	O
cardiac	O
surgery	O
is	O
associated	O
with	O
clinical	O
seizures	B-DiseaseOrPhenotypicFeature
in	O
susceptible	O
patients	B-OrganismTaxon
.	O
Cardioprotective	O
effect	O
of	O
tincture	B-ChemicalEntity
of	I-ChemicalEntity
Crataegus	I-ChemicalEntity
on	O
isoproterenol	B-ChemicalEntity
-	O
induced	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
.	O

Tincture	B-ChemicalEntity
of	I-ChemicalEntity
Crataegus	I-ChemicalEntity
(	O
TCR	B-ChemicalEntity
)	O
,	O
an	O
alcoholic	B-ChemicalEntity
extract	I-ChemicalEntity
of	I-ChemicalEntity
the	I-ChemicalEntity
berries	I-ChemicalEntity
of	I-ChemicalEntity
hawthorn	I-ChemicalEntity
(	O
Crataegus	B-ChemicalEntity
oxycantha	I-ChemicalEntity
)	O
,	O
is	O
used	O
in	O
herbal	O
and	O
homeopathic	O
medicine	O
.	O

The	O
present	O
study	O
was	O
done	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
TCR	B-ChemicalEntity
on	O
experimentally	O
induced	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
.	O

Pretreatment	O
of	O
TCR	B-ChemicalEntity
,	O
at	O
a	O
dose	O
of	O
0	O
.	O
5	O
mL	O
/	O
100	O
g	O
bodyweight	O
per	O
day	O
,	O
orally	O
for	O
30	O
days	O
,	O
prevented	O
the	O
increase	O
in	O
lipid	B-ChemicalEntity
peroxidation	O
and	O
activity	O
of	O
marker	O
enzymes	O
observed	O
in	O
isoproterenol	B-ChemicalEntity
-	O
induced	O
rats	B-OrganismTaxon
(	O
85	O
mg	O
kg	O
(	O
-	O
1	O
)	O
s	O
.	O

c	O
.	O

for	O
2	O
days	O
at	O
an	O
interval	O
of	O
24	O
h	O
)	O
.	O

TCR	B-ChemicalEntity
prevented	O
the	O
isoproterenol	B-ChemicalEntity
-	O
induced	O
decrease	O
in	O
antioxidant	O
enzymes	O
in	O
the	O
heart	O
and	O
increased	O
the	O
rate	O
of	O
ADP	B-ChemicalEntity
-	O
stimulated	O
oxygen	B-ChemicalEntity
uptake	O
and	O
respiratory	O
coupling	O
ratio	O
.	O

TCR	B-ChemicalEntity
protected	O
against	O
pathological	O
changes	O
induced	O
by	O
isoproterenol	B-ChemicalEntity
in	O
rat	B-OrganismTaxon
heart	O
.	O

The	O
results	O
show	O
that	O
pretreatment	O
with	O
TCR	B-ChemicalEntity
may	O
be	O
useful	O
in	O
preventing	O
the	O
damage	O
induced	O
by	O
isoproterenol	B-ChemicalEntity
in	O
rat	B-OrganismTaxon
heart	O
.	O
Transgelin	B-GeneOrGeneProduct
increases	O
metastatic	O
potential	O
of	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
in	O
vivo	O
and	O
alters	O
expression	O
of	O
genes	O
involved	O
in	O
cell	O
motility	O
.	O

BACKGROUND	O
:	O
Transgelin	B-GeneOrGeneProduct
is	O
an	O
actin	B-GeneOrGeneProduct
-	O
binding	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
that	O
promotes	O
motility	O
in	O
normal	O
cells	O
.	O

Although	O
the	O
role	O
of	O
transgelin	B-GeneOrGeneProduct
in	O
cancer	B-DiseaseOrPhenotypicFeature
is	O
controversial	O
,	O
a	O
number	O
of	O
studies	O
have	O
shown	O
that	O
elevated	O
levels	O
correlate	O
with	O
aggressive	O
tumor	B-DiseaseOrPhenotypicFeature
behavior	O
,	O
advanced	O
stage	O
,	O
and	O
poor	O
prognosis	O
.	O

Here	O
we	O
sought	O
to	O
determine	O
the	O
role	O
of	O
transgelin	B-GeneOrGeneProduct
more	O
directly	O
by	O
determining	O
whether	O
experimental	O
manipulation	O
of	O
transgelin	B-GeneOrGeneProduct
levels	O
in	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
CRC	B-DiseaseOrPhenotypicFeature
)	O
cells	O
led	O
to	O
changes	O
in	O
metastatic	O
potential	O
in	O
vivo	O
.	O

METHODS	O
:	O
Isogenic	O
CRC	B-DiseaseOrPhenotypicFeature
cell	O
lines	O
that	O
differ	O
in	O
transgelin	B-GeneOrGeneProduct
expression	O
were	O
characterized	O
using	O
in	O
vitro	O
assays	O
of	O
growth	O
and	O
invasiveness	O
and	O
a	O
mouse	B-OrganismTaxon
tail	O
vein	O
assay	O
of	O
experimental	O
metastasis	O
.	O

Downstream	O
effects	O
of	O
transgelin	B-GeneOrGeneProduct
overexpression	O
were	O
investigated	O
by	O
gene	O
expression	O
profiling	O
and	O
quantitative	O
PCR	O
.	O

RESULTS	O
:	O
Stable	O
overexpression	O
of	O
transgelin	B-GeneOrGeneProduct
in	O
RKO	B-CellLine
cells	O
,	O
which	O
have	O
low	O
endogenous	O
levels	O
,	O
led	O
to	O
increased	O
invasiveness	O
,	O
growth	O
at	O
low	O
density	O
,	O
and	O
growth	O
in	O
soft	O
agar	O
.	O

Overexpression	O
also	O
led	O
to	O
an	O
increase	O
in	O
the	O
number	O
and	O
size	O
of	O
lung	B-DiseaseOrPhenotypicFeature
metastases	I-DiseaseOrPhenotypicFeature
in	O
the	O
mouse	B-OrganismTaxon
tail	O
vein	O
injection	O
model	O
.	O

Similarly	O
,	O
attenuation	O
of	O
transgelin	B-GeneOrGeneProduct
expression	O
in	O
HCT116	B-CellLine
cells	O
,	O
which	O
have	O
high	O
endogenous	O
levels	O
,	O
decreased	O
metastases	B-DiseaseOrPhenotypicFeature
in	O
the	O
same	O
model	O
.	O

Investigation	O
of	O
mRNA	O
expression	O
patterns	O
showed	O
that	O
transgelin	B-GeneOrGeneProduct
overexpression	O
altered	O
the	O
levels	O
of	O
approximately	O
250	O
other	O
transcripts	O
,	O
with	O
over	O
-	O
representation	O
of	O
genes	O
that	O
affect	O
function	O
of	O
actin	B-GeneOrGeneProduct
or	O
other	O
cytoskeletal	B-GeneOrGeneProduct
proteins	I-GeneOrGeneProduct
.	O

Changes	O
included	O
increases	O
in	O
HOOK1	B-GeneOrGeneProduct
,	O
SDCCAG8	B-GeneOrGeneProduct
,	O
ENAH	B-GeneOrGeneProduct
/	O
Mena	B-GeneOrGeneProduct
,	O
and	O
TNS1	B-GeneOrGeneProduct
and	O
decreases	O
in	O
EMB	B-GeneOrGeneProduct
,	O
BCL11B	B-GeneOrGeneProduct
,	O
and	O
PTPRD	B-GeneOrGeneProduct
.	O

CONCLUSIONS	O
:	O
Increases	O
or	O
decreases	O
in	O
transgelin	B-GeneOrGeneProduct
levels	O
have	O
reciprocal	O
effects	O
on	O
tumor	B-DiseaseOrPhenotypicFeature
cell	O
behavior	O
,	O
with	O
higher	O
expression	O
promoting	O
metastasis	O
.	O

Chronic	O
overexpression	O
influences	O
steady	O
-	O
state	O
levels	O
of	O
mRNAs	O
for	O
metastasis	O
-	O
related	O
genes	O
.	O
Vitamin	B-ChemicalEntity
E	I-ChemicalEntity
reduces	O
cardiovascular	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
in	O
individuals	O
with	O
diabetes	B-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
and	O
the	O
haptoglobin	B-GeneOrGeneProduct
2	O
-	O
2	O
genotype	O
.	O

AIMS	O
:	O
Individuals	O
with	O
both	O
diabetes	B-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
(	O
DM	B-DiseaseOrPhenotypicFeature
)	O
and	O
the	O
Haptoglobin	B-GeneOrGeneProduct
(	O
Hp	B-GeneOrGeneProduct
)	O
2	O
-	O
2	O
genotype	O
are	O
at	O
increased	O
risk	O
of	O
cardiovascular	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

As	O
the	O
antioxidant	O
function	O
of	O
the	O
Hp	B-GeneOrGeneProduct
2	O
-	O
2	O
protein	O
is	O
impaired	O
,	O
we	O
sought	O
to	O
test	O
the	O
pharmacogenomic	O
hypothesis	O
that	O
antioxidant	B-ChemicalEntity
vitamin	B-ChemicalEntity
E	I-ChemicalEntity
supplementation	O
would	O
provide	O
cardiovascular	O
protection	O
to	O
Hp	B-GeneOrGeneProduct
2	O
-	O
2	O
DM	B-DiseaseOrPhenotypicFeature
individuals	O
.	O

MATERIALS	O
&	O
METHODS	O
:	O
We	O
determined	O
the	O
Hp	B-GeneOrGeneProduct
genotype	O
on	O
DM	B-DiseaseOrPhenotypicFeature
participants	O
from	O
two	O
trials	O
(	O
HOPE	O
and	O
ICARE	O
)	O
and	O
assessed	O
the	O
effect	O
of	O
vitamin	B-ChemicalEntity
E	I-ChemicalEntity
by	O
Hp	B-GeneOrGeneProduct
genotype	O
on	O
their	O
common	O
prespecified	O
outcome	O
,	O
the	O
composite	O
of	O
stroke	B-DiseaseOrPhenotypicFeature
,	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
and	O
cardiovascular	B-DiseaseOrPhenotypicFeature
death	I-DiseaseOrPhenotypicFeature
.	O

Data	O
was	O
analyzed	O
with	O
a	O
fixed	O
-	O
effect	O
model	O
.	O

These	O
results	O
were	O
input	O
into	O
a	O
simulation	O
model	O
,	O
the	O
Evidence	O
Based	O
Medicine	O
Integrator	O
,	O
in	O
order	O
to	O
estimate	O
their	O
long	O
-	O
term	O
implications	O
in	O
a	O
real	O
-	O
world	O
population	O
from	O
Kaiser	O
Permanente	O
(	O
CA	O
,	O
USA	O
)	O
.	O

RESULTS	O
:	O
Meta	O
-	O
analysis	O
of	O
the	O
two	O
trials	O
demonstrated	O
a	O
significant	O
overall	O
reduction	O
in	O
the	O
composite	O
end	O
point	O
in	O
Hp	B-GeneOrGeneProduct
2	O
-	O
2	O
DM	B-DiseaseOrPhenotypicFeature
individuals	O
with	O
vitamin	B-ChemicalEntity
E	I-ChemicalEntity
(	O
odds	O
ratio	O
:	O
0	O
.	O
58	O
;	O
95%	O
CI	O
:	O
0	O
.	O
40	O
-	O
0	O
.	O
86	O
;	O
p	O
=	O
0	O
.	O
006	O
)	O
.	O

There	O
was	O
a	O
statistically	O
significant	O
interaction	O
between	O
the	O
Hp	B-GeneOrGeneProduct
genotype	O
and	O
vitamin	B-ChemicalEntity
E	I-ChemicalEntity
on	O
the	O
composite	O
end	O
point	O
.	O

In	O
these	O
trials	O
,	O
Hp	B-GeneOrGeneProduct
typing	O
of	O
69	O
DM	B-DiseaseOrPhenotypicFeature
individuals	O
and	O
treating	O
those	O
with	O
the	O
Hp	B-GeneOrGeneProduct
2	O
-	O
2	O
with	O
vitamin	B-ChemicalEntity
E	I-ChemicalEntity
prevented	O
one	O
myocardial	B-DiseaseOrPhenotypicFeature
infarct	I-DiseaseOrPhenotypicFeature
,	O
stroke	B-DiseaseOrPhenotypicFeature
or	O
cardiovascular	B-DiseaseOrPhenotypicFeature
death	I-DiseaseOrPhenotypicFeature
.	O

Lifelong	O
administration	O
of	O
vitamin	B-ChemicalEntity
E	I-ChemicalEntity
to	O
Hp	B-GeneOrGeneProduct
2	O
-	O
2	O
DM	B-DiseaseOrPhenotypicFeature
individuals	O
in	O
the	O
Kaiser	O
population	O
would	O
increase	O
their	O
life	O
expectancy	O
by	O
3	O
years	O
.	O

CONCLUSION	O
:	O
A	O
pharmacogenomic	O
strategy	O
of	O
screening	O
DM	B-DiseaseOrPhenotypicFeature
individuals	O
for	O
the	O
Hp	B-GeneOrGeneProduct
genotype	O
and	O
treating	O
those	O
with	O
Hp	B-GeneOrGeneProduct
2	O
-	O
2	O
with	O
vitamin	B-ChemicalEntity
E	I-ChemicalEntity
appears	O
to	O
be	O
highly	O
clinically	O
effective	O
.	O
Clopidogrel	B-ChemicalEntity
pharmacogenomics	O
and	O
risk	O
of	O
inadequate	O
platelet	O
inhibition	O
:	O
US	O
FDA	O
recommendations	O
.	O

Antiplatelet	O
therapy	O
with	O
clopidogrel	B-ChemicalEntity
is	O
the	O
current	O
standard	O
of	O
care	O
for	O
coronary	B-DiseaseOrPhenotypicFeature
artery	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
undergoing	O
a	O
percutaneous	O
coronary	O
intervention	O
.	O

However	O
,	O
approximately	O
25%	O
of	O
patients	B-OrganismTaxon
experience	O
a	O
subtherapeutic	O
antiplatelet	O
response	O
.	O

Clopidogrel	B-ChemicalEntity
is	O
a	O
prodrug	O
that	O
undergoes	O
hepatic	O
biotransformation	O
by	O
CYP2C19	B-GeneOrGeneProduct
into	O
its	O
active	O
metabolite	O
.	O

Several	O
studies	O
have	O
reported	O
that	O
,	O
compared	O
with	O
wild	O
-	O
type	O
individuals	O
,	O
CYP2C19	B-GeneOrGeneProduct
variant	O
allele	O
carriers	O
exhibit	O
a	O
significantly	O
lower	O
capacity	O
to	O
metabolize	O
clopidogrel	B-ChemicalEntity
into	O
its	O
active	O
metabolite	O
and	O
inhibit	O
platelet	O
activation	O
,	O
and	O
are	O
therefore	O
at	O
significantly	O
higher	O
risk	O
of	O
adverse	O
cardiovascular	O
events	O
.	O

Consequently	O
,	O
the	O
US	O
FDA	O
has	O
recently	O
changed	O
clopidogrel	B-ChemicalEntity
'	O
s	O
prescribing	O
information	O
to	O
highlight	O
the	O
impact	O
of	O
CYP2C19	B-GeneOrGeneProduct
genotype	O
on	O
clopidogrel	B-ChemicalEntity
pharmacokinetics	O
,	O
pharmacodynamics	O
and	O
clinical	O
response	O
.	O

Future	O
studies	O
remain	O
necessary	O
to	O
develop	O
effective	O
personalized	O
therapeutic	O
strategies	O
for	O
CYP2C19	B-GeneOrGeneProduct
variant	O
allele	O
carriers	O
and	O
other	O
individuals	O
at	O
risk	O
for	O
clopidogrel	B-ChemicalEntity
nonresponsiveness	O
.	O
Myc	B-GeneOrGeneProduct
enhances	O
B	B-GeneOrGeneProduct
-	O
cell	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
signaling	O
in	O
precancerous	B-DiseaseOrPhenotypicFeature
B	O
cells	O
and	O
confers	O
resistance	O
to	O
Btk	B-GeneOrGeneProduct
inhibition	O
.	O

Dysregulation	O
of	O
the	O
oncogenic	O
transcription	O
factor	O
MYC	B-GeneOrGeneProduct
induces	O
B	O
-	O
cell	O
transformation	O
and	O
is	O
a	O
driver	O
for	O
B	B-DiseaseOrPhenotypicFeature
-	O
cell	I-DiseaseOrPhenotypicFeature
non	I-DiseaseOrPhenotypicFeature
-	O
Hodgkin	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
(	O
B	B-DiseaseOrPhenotypicFeature
-	O
NHL	I-DiseaseOrPhenotypicFeature
)	O
.	O

MYC	B-GeneOrGeneProduct
overexpression	O
in	O
B	B-DiseaseOrPhenotypicFeature
-	O
NHL	I-DiseaseOrPhenotypicFeature
is	O
associated	O
with	O
more	O
aggressive	O
phenotypes	O
and	O
poor	O
prognosis	O
.	O

Although	O
genomic	O
studies	O
suggest	O
a	O
link	O
between	O
MYC	B-GeneOrGeneProduct
overexpression	O
and	O
B	B-GeneOrGeneProduct
-	O
cell	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
BCR	B-GeneOrGeneProduct
)	O
signaling	O
molecules	O
in	O
B	B-DiseaseOrPhenotypicFeature
-	O
NHL	I-DiseaseOrPhenotypicFeature
,	O
signaling	O
pathways	O
essential	O
to	O
Myc	B-GeneOrGeneProduct
-	O
mediated	O
B	O
-	O
cell	O
transformation	O
have	O
not	O
been	O
fully	O
elucidated	O
.	O

We	O
utilized	O
intracellular	O
phospho	O
-	O
flow	O
cytometry	O
to	O
investigate	O
the	O
relationship	O
between	O
Myc	B-GeneOrGeneProduct
and	O
BCR	B-GeneOrGeneProduct
signaling	O
in	O
pre	O
-	O
malignant	O
B	O
cells	O
.	O

Utilizing	O
the	O
Eu	O
-	O
myc	B-GeneOrGeneProduct
mouse	B-OrganismTaxon
model	O
,	O
where	O
Myc	B-GeneOrGeneProduct
is	O
overexpressed	O
specifically	O
in	O
B	O
cells	O
,	O
both	O
basal	O
and	O
stimulated	O
BCR	B-GeneOrGeneProduct
signaling	O
were	O
increased	O
in	O
precancerous	B-DiseaseOrPhenotypicFeature
B	O
lymphocytes	O
from	O
Eu	O
-	O
myc	B-GeneOrGeneProduct
mice	B-OrganismTaxon
compared	O
with	O
wild	O
-	O
type	O
littermates	O
.	O

B	O
cells	O
overexpressing	O
Myc	B-GeneOrGeneProduct
displayed	O
constitutively	O
higher	O
levels	O
of	O
activated	O
CD79a	B-GeneOrGeneProduct
,	O
Btk	B-GeneOrGeneProduct
,	O
Plcg2	B-GeneOrGeneProduct
and	O
Erk1	B-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
.	O

Notably	O
,	O
Myc	B-GeneOrGeneProduct
-	O
overexpressing	O
B	O
cells	O
maintained	O
elevated	O
BCR	B-GeneOrGeneProduct
signaling	O
despite	O
treatment	O
with	O
ibrutinib	B-ChemicalEntity
,	O
a	O
Bruton	B-GeneOrGeneProduct
'	O
s	I-GeneOrGeneProduct
tyrosine	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
inhibitor	O
.	O

Furthermore	O
,	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
pathway	O
signaling	O
was	O
also	O
increased	O
in	O
Eu	O
-	O
myc	B-GeneOrGeneProduct
B	O
cells	O
,	O
and	O
this	O
increase	O
was	O
partially	O
suppressed	O
with	O
ibrutinib	B-ChemicalEntity
.	O

In	O
addition	O
,	O
experiments	O
with	O
Btk	B-GeneOrGeneProduct
-	O
null	O
B	O
cells	O
revealed	O
off	O
-	O
target	O
effects	O
of	O
ibrutinib	B-ChemicalEntity
on	O
BCR	B-GeneOrGeneProduct
signaling	O
.	O

Our	O
data	O
show	O
that	O
in	O
pre	O
-	O
malignant	O
B	O
cells	O
,	O
Myc	B-GeneOrGeneProduct
overexpression	O
is	O
sufficient	O
to	O
activate	O
BCR	B-GeneOrGeneProduct
and	O
PI3K	B-GeneOrGeneProduct
/	O
Akt	B-GeneOrGeneProduct
signaling	O
pathways	O
and	O
further	O
enhances	O
signaling	O
following	O
BCR	B-GeneOrGeneProduct
ligation	O
.	O

Therefore	O
,	O
our	O
results	O
indicate	O
that	O
precancerous	B-DiseaseOrPhenotypicFeature
B	O
cells	O
have	O
already	O
acquired	O
enhanced	O
survival	O
and	O
growth	O
capabilities	O
before	O
transformation	O
,	O
and	O
that	O
elevated	O
MYC	B-GeneOrGeneProduct
levels	O
confer	O
resistance	O
to	O
pharmacologic	O
inhibitors	O
of	O
BCR	B-GeneOrGeneProduct
signaling	O
,	O
which	O
has	O
significant	O
implications	O
for	O
B	B-DiseaseOrPhenotypicFeature
-	O
NHL	I-DiseaseOrPhenotypicFeature
treatment	O
.	O
Genetic	O
investigation	O
of	O
four	O
meiotic	O
genes	O
in	O
women	B-OrganismTaxon
with	O
premature	B-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
.	O

OBJECTIVE	O
:	O
The	O
goal	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
mutations	O
of	O
meiotic	O
genes	O
,	O
such	O
as	O
disrupted	O
meiotic	O
cDNA	O
(	O
DMC1	B-GeneOrGeneProduct
)	O
,	O
MutS	B-GeneOrGeneProduct
homolog	O
(	O
MSH4	B-GeneOrGeneProduct
)	O
,	O
MSH5	B-GeneOrGeneProduct
,	O
and	O
S	B-OrganismTaxon
.	O

cerevisiae	I-OrganismTaxon
homolog	O
(	O
SPO11	B-GeneOrGeneProduct
)	O
,	O
were	O
associated	O
with	O
premature	B-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
(	O
POF	B-DiseaseOrPhenotypicFeature
)	O
.	O

DESIGN	O
:	O
Case	O
-	O
control	O
study	O
.	O

METHODS	O
:	O
Blood	O
sampling	O
,	O
karyotype	O
,	O
hormonal	O
dosage	O
,	O
ultrasound	O
,	O
and	O
ovarian	O
biopsy	O
were	O
carried	O
out	O
on	O
most	O
patients	B-OrganismTaxon
.	O

However	O
,	O
the	O
main	O
outcome	O
measure	O
was	O
the	O
sequencing	O
of	O
genomic	O
DNA	O
from	O
peripheral	O
blood	O
samples	O
of	O
41	O
women	B-OrganismTaxon
with	O
POF	B-DiseaseOrPhenotypicFeature
and	O
36	O
fertile	O
women	B-OrganismTaxon
(	O
controls	O
)	O
.	O

RESULTS	O
:	O
A	O
single	O
heterozygous	O
missense	O
mutation	O
,	O
substitution	O
of	O
a	O
cytosine	B-SequenceVariant
residue	I-SequenceVariant
with	I-SequenceVariant
thymidine	I-SequenceVariant
in	O
exon	O
2	O
of	O
MSH5	B-GeneOrGeneProduct
,	O
was	O
found	O
in	O
two	O
Caucasian	O
women	B-OrganismTaxon
in	O
whom	O
POF	B-DiseaseOrPhenotypicFeature
developed	O
at	O
18	O
and	O
36	O
years	O
of	O
age	O
.	O

This	O
mutation	O
resulted	O
in	O
replacement	O
of	O
a	O
non	O
-	O
polar	O
amino	O
acid	O
(	O
proline	I-SequenceVariant
)	O
with	I-SequenceVariant
a	I-SequenceVariant
polar	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
(	O
serine	I-SequenceVariant
)	O
at	I-SequenceVariant
position	I-SequenceVariant
29	I-SequenceVariant
(	O
P29S	B-SequenceVariant
)	O
.	O

Neither	O
36	O
control	O
women	B-OrganismTaxon
nor	O
39	O
other	O
patients	B-OrganismTaxon
with	O
POF	B-DiseaseOrPhenotypicFeature
possessed	O
this	O
genetic	O
perturbation	O
.	O

Another	O
POF	B-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
of	O
African	O
origin	O
showed	O
a	O
homozygous	O
nucleotide	O
change	O
in	O
the	O
tenth	O
of	O
DMC1	B-GeneOrGeneProduct
gene	O
that	O
led	O
to	O
an	O
alteration	O
of	O
the	O
amino	O
acid	O
composition	O
of	O
the	O
protein	O
(	O
M200V	B-SequenceVariant
)	O
.	O

CONCLUSIONS	O
:	O
The	O
symptoms	O
of	O
infertility	B-DiseaseOrPhenotypicFeature
observed	O
in	O
the	O
DMC1	B-GeneOrGeneProduct
homozygote	O
mutation	O
carrier	O
and	O
in	O
both	O
patients	B-OrganismTaxon
with	O
a	O
heterozygous	O
substitution	O
in	O
exon	O
2	O
of	O
the	O
MSH5	B-GeneOrGeneProduct
gene	O
provide	O
indirect	O
evidence	O
of	O
the	O
role	O
of	O
genes	O
involved	O
in	O
meiotic	O
recombination	O
in	O
the	O
regulation	O
of	O
ovarian	O
function	O
.	O

MSH5	B-GeneOrGeneProduct
and	O
DMC1	B-GeneOrGeneProduct
mutations	O
may	O
be	O
one	O
explanation	O
for	O
POF	B-DiseaseOrPhenotypicFeature
,	O
albeit	O
uncommon	O
.	O
Nicotine	B-ChemicalEntity
antagonizes	O
caffeine	B-ChemicalEntity
-	O
but	O
not	O
pentylenetetrazole	B-ChemicalEntity
-	O
induced	O
anxiogenic	B-DiseaseOrPhenotypicFeature
effect	I-DiseaseOrPhenotypicFeature
in	O
mice	B-OrganismTaxon
.	O

RATIONALE	O
:	O
Nicotine	B-ChemicalEntity
and	O
caffeine	B-ChemicalEntity
are	O
widely	O
consumed	O
licit	O
psychoactive	B-ChemicalEntity
drugs	I-ChemicalEntity
worldwide	O
.	O

Epidemiological	O
studies	O
showed	O
that	O
they	O
were	O
generally	O
used	O
concurrently	O
.	O

Although	O
some	O
studies	O
in	O
experimental	O
animals	O
indicate	O
clear	O
pharmacological	O
interactions	O
between	O
them	O
,	O
no	O
studies	O
have	O
shown	O
a	O
specific	O
interaction	O
on	O
anxiety	B-DiseaseOrPhenotypicFeature
responses	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
investigates	O
the	O
effects	O
of	O
nicotine	B-ChemicalEntity
on	O
anxiety	B-DiseaseOrPhenotypicFeature
induced	O
by	O
caffeine	B-ChemicalEntity
and	O
another	O
anxiogenic	B-ChemicalEntity
drug	I-ChemicalEntity
,	O
pentylenetetrazole	B-ChemicalEntity
,	O
in	O
mice	B-OrganismTaxon
.	O

The	O
elevated	O
plus	O
-	O
maze	O
(	O
EPM	O
)	O
test	O
was	O
used	O
to	O
evaluate	O
the	O
effects	O
of	O
drugs	O
on	O
anxiety	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
Adult	O
male	O
Swiss	O
Webster	O
mice	B-OrganismTaxon
(	O
25	O
-	O
32	O
g	O
)	O
were	O
given	O
nicotine	B-ChemicalEntity
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
s	O
.	O
c	O
.	O
)	O
or	O
saline	O
10	O
min	O
before	O
caffeine	B-ChemicalEntity
(	O
70	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
or	O
pentylenetetrazole	B-ChemicalEntity
(	O
15	O
and	O
30	O
mg	O
/	O
kg	O
i	O
.	O
p	O
.	O
)	O
injections	O
.	O

After	O
15	O
min	O
,	O
mice	B-OrganismTaxon
were	O
evaluated	O
for	O
their	O
open	O
-	O
and	O
closed	O
-	O
arm	O
time	O
and	O
entries	O
on	O
the	O
EPM	O
for	O
a	O
10	O
-	O
min	O
session	O
.	O

Locomotor	O
activity	O
was	O
recorded	O
for	O
individual	O
groups	O
by	O
using	O
the	O
same	O
treatment	O
protocol	O
with	O
the	O
EPM	O
test	O
.	O

RESULTS	O
:	O
Nicotine	B-ChemicalEntity
(	O
0	O
.	O
05	O
-	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
itself	O
did	O
not	O
produce	O
any	O
significant	O
effect	O
in	O
the	O
EPM	O
test	O
,	O
whereas	O
caffeine	B-ChemicalEntity
(	O
70	O
mg	O
/	O
kg	O
)	O
and	O
pentylenetetrazole	B-ChemicalEntity
(	O
30	O
mg	O
/	O
kg	O
)	O
produced	O
an	O
anxiogenic	B-DiseaseOrPhenotypicFeature
effect	I-DiseaseOrPhenotypicFeature
,	O
apparent	O
with	O
decreases	O
in	O
open	O
-	O
arm	O
time	O
and	O
entry	O
.	O

Nicotine	B-ChemicalEntity
(	O
0	O
.	O
25	O
mg	O
/	O
kg	O
)	O
pretreatment	O
blocked	O
the	O
caffeine	B-ChemicalEntity
-	O
but	O
not	O
pentylenetetrazole	B-ChemicalEntity
-	O
induced	O
anxiety	B-DiseaseOrPhenotypicFeature
.	O

Administration	O
of	O
each	O
drug	O
and	O
their	O
combinations	O
did	O
not	O
produce	O
any	O
effect	O
on	O
locomotor	O
activity	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
antagonistic	O
effect	O
of	O
nicotine	B-ChemicalEntity
on	O
caffeine	B-ChemicalEntity
-	O
induced	O
anxiety	B-DiseaseOrPhenotypicFeature
is	O
specific	O
to	O
caffeine	B-ChemicalEntity
,	O
instead	O
of	O
a	O
non	O
-	O
specific	O
anxiolytic	O
effect	O
.	O

Thus	O
,	O
it	O
may	O
extend	O
the	O
current	O
findings	O
on	O
the	O
interaction	O
between	O
nicotine	B-ChemicalEntity
and	O
caffeine	B-ChemicalEntity
.	O
Behavioral	O
effects	O
of	O
pubertal	O
anabolic	B-ChemicalEntity
androgenic	I-ChemicalEntity
steroid	I-ChemicalEntity
exposure	O
in	O
male	O
rats	B-OrganismTaxon
with	O
low	O
serotonin	B-ChemicalEntity
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
interactive	O
effects	O
of	O
chronic	O
anabolic	B-ChemicalEntity
androgenic	I-ChemicalEntity
steroid	I-ChemicalEntity
(	O
AAS	B-ChemicalEntity
)	O
exposure	O
and	O
brain	O
serotonin	B-ChemicalEntity
(	O
5	B-ChemicalEntity
-	O
hydroxytryptamine	I-ChemicalEntity
,	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
)	O
depletion	O
on	O
behavior	O
of	O
pubertal	O
male	O
rats	B-OrganismTaxon
.	O

Serotonin	B-ChemicalEntity
was	O
depleted	O
beginning	O
on	O
postnatal	O
day	O
26	O
with	O
parachlorophenylalanine	B-ChemicalEntity
(	O
PCPA	B-ChemicalEntity
100	O
mg	O
/	O
kg	O
,	O
every	O
other	O
day	O
)	O
;	O
controls	O
received	O
saline	O
.	O

At	O
puberty	O
(	O
P40	O
)	O
,	O
half	O
the	O
PCPA	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
and	O
half	O
the	O
saline	O
-	O
treated	O
rats	B-OrganismTaxon
began	O
treatment	O
with	O
testosterone	B-ChemicalEntity
(	O
T	B-ChemicalEntity
,	O
5	O
mg	O
/	O
kg	O
,	O
5	O
days	O
/	O
week	O
)	O
.	O

Behavioral	O
measures	O
included	O
locomotion	O
,	O
irritability	B-DiseaseOrPhenotypicFeature
,	O
copulation	O
,	O
partner	O
preference	O
,	O
and	O
aggression	B-DiseaseOrPhenotypicFeature
.	O

Animals	O
were	O
tested	O
for	O
aggression	B-DiseaseOrPhenotypicFeature
in	O
their	O
home	O
cage	O
,	O
both	O
with	O
and	O
without	O
physical	O
provocation	O
(	O
mild	O
tail	O
pinch	O
)	O
.	O

Brain	O
levels	O
of	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
and	O
its	O
metabolite	O
,	O
5	B-ChemicalEntity
-	O
hydroxyindoleacetic	I-ChemicalEntity
acid	I-ChemicalEntity
(	O
5	B-ChemicalEntity
-	O
HIAA	I-ChemicalEntity
)	O
,	O
were	O
determined	O
using	O
HPLC	O
.	O

PCPA	B-ChemicalEntity
significantly	O
and	O
substantially	O
depleted	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
and	O
5	B-ChemicalEntity
-	O
HIAA	I-ChemicalEntity
in	O
all	O
brain	O
regions	O
examined	O
.	O

Chronic	O
T	B-ChemicalEntity
treatment	O
significantly	O
decreased	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
and	O
5	B-ChemicalEntity
-	O
HIAA	I-ChemicalEntity
in	O
certain	O
brain	O
areas	O
,	O
but	O
to	O
a	O
much	O
lesser	O
extent	O
than	O
PCPA	B-ChemicalEntity
.	O

Chronic	O
exposure	O
to	O
PCPA	B-ChemicalEntity
alone	O
significantly	O
decreased	O
locomotor	O
activity	O
and	O
increased	O
irritability	B-DiseaseOrPhenotypicFeature
but	O
had	O
no	O
effect	O
on	O
sexual	O
behavior	O
,	O
partner	O
preference	O
,	O
or	O
aggression	B-DiseaseOrPhenotypicFeature
.	O

T	B-ChemicalEntity
alone	O
had	O
no	O
effect	O
on	O
locomotion	O
,	O
irritability	B-DiseaseOrPhenotypicFeature
,	O
or	O
sexual	O
behavior	O
but	O
increased	O
partner	O
preference	O
and	O
aggression	B-DiseaseOrPhenotypicFeature
.	O

The	O
most	O
striking	O
effect	O
of	O
combining	O
T	B-ChemicalEntity
+	O
PCPA	B-ChemicalEntity
was	O
a	O
significant	O
increase	O
in	O
attack	O
frequency	O
as	O
well	O
as	O
a	O
significant	O
decrease	O
in	O
the	O
latency	O
to	O
attack	O
,	O
particularly	O
following	O
physical	O
provocation	O
.	O

Based	O
on	O
these	O
data	O
,	O
it	O
can	O
be	O
speculated	O
that	O
pubertal	O
AAS	B-ChemicalEntity
users	O
with	O
low	O
central	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
may	O
be	O
especially	O
prone	O
to	O
exhibit	O
aggressive	B-DiseaseOrPhenotypicFeature
behavior	I-DiseaseOrPhenotypicFeature
.	O
DNA	O
damage	O
and	O
repair	O
in	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
-	O
-	O
a	O
correlation	O
with	O
the	O
hOGG1	B-GeneOrGeneProduct
and	O
RAD51	B-GeneOrGeneProduct
genes	O
polymorphisms	O
.	O

The	O
cell	O
'	O
s	O
susceptibility	O
to	O
mutagens	O
and	O
its	O
ability	O
to	O
repair	O
DNA	O
lesions	O
are	O
important	O
for	O
cancer	B-DiseaseOrPhenotypicFeature
induction	O
,	O
promotion	O
and	O
progression	O
.	O

Both	O
the	O
mutagens	O
'	O
sensitivity	O
and	O
the	O
efficacy	O
of	O
DNA	O
repair	O
may	O
be	O
affected	O
by	O
variation	O
in	O
several	O
genes	O
,	O
including	O
DNA	O
repair	O
genes	O
.	O

The	O
hOGG1	B-GeneOrGeneProduct
gene	O
encodes	O
glycosylase	O
of	O
base	O
excision	O
repair	O
and	O
RAD51	B-GeneOrGeneProduct
specifies	O
a	O
key	O
protein	O
in	O
homologues	O
recombination	O
repair	O
.	O

Both	O
can	O
be	O
involved	O
in	O
the	O
repair	O
of	O
oxidative	O
DNA	O
lesions	O
,	O
which	O
can	O
contribute	O
to	O
stomach	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

In	O
the	O
present	O
work	O
we	O
determined	O
the	O
level	O
of	O
basal	O
and	O
oxidative	O
DNA	O
damage	O
and	O
the	O
kinetics	O
of	O
removal	O
of	O
DNA	O
damage	O
induced	O
by	O
hydrogen	B-ChemicalEntity
peroxide	I-ChemicalEntity
in	O
peripheral	O
blood	O
lymphocytes	O
of	O
30	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
30	O
healthy	O
individuals	O
.	O

The	O
metrics	O
from	O
DNA	O
damage	O
and	O
repair	O
study	O
were	O
correlated	O
with	O
the	O
genotypes	O
of	O
common	O
polymorphisms	O
of	O
the	O
hOGG1	B-GeneOrGeneProduct
and	O
RAD51	B-GeneOrGeneProduct
genes	O
:	O
a	O
G	B-SequenceVariant
-	O
-	O
>	O
C	I-SequenceVariant
transversion	I-SequenceVariant
at	I-SequenceVariant
1245	I-SequenceVariant
position	I-SequenceVariant
of	O
the	O
hOGG1	B-GeneOrGeneProduct
gene	O
producing	O
a	O
Ser	B-SequenceVariant
-	O
-	O
>	O
Cys	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
the	I-SequenceVariant
codon	I-SequenceVariant
326	I-SequenceVariant
(	O
the	O
Ser326Cys	B-SequenceVariant
polymorphism	O
)	O
and	O
a	O
G	B-SequenceVariant
-	O
-	O
>	O
C	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
135	I-SequenceVariant
(	O
5	O
'	O
-	O
untranslated	O
region	O
)	O
of	O
the	O
RAD51	B-GeneOrGeneProduct
gene	O
(	O
the	O
G135C	B-SequenceVariant
polymorphism	O
)	O
.	O

DNA	O
damage	O
and	O
repair	O
were	O
evaluated	O
by	O
alkaline	O
single	O
cell	O
gel	O
electrophoresis	O
(	O
comet	O
assay	O
)	O
assisted	O
by	O
DNA	O
repair	O
enzymes	O
:	O
endonuclease	B-GeneOrGeneProduct
III	I-GeneOrGeneProduct
(	O
Nth	B-GeneOrGeneProduct
)	O
and	O
formamidopyrimidine	B-GeneOrGeneProduct
-	O
DNA	I-GeneOrGeneProduct
glycosylase	I-GeneOrGeneProduct
(	O
Fpg	B-GeneOrGeneProduct
)	O
,	O
preferentially	O
recognizing	O
oxidized	O
DNA	O
bases	O
.	O

The	O
genotypes	O
of	O
the	O
polymorphism	O
were	O
determined	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
PCR	O
.	O

We	O
observed	O
a	O
strong	O
association	O
between	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
occurrence	O
,	O
impaired	O
DNA	O
repair	O
in	O
human	B-OrganismTaxon
lymphocytes	O
and	O
the	O
G	B-SequenceVariant
/	O
C	I-SequenceVariant
genotype	O
of	O
the	O
G135C	B-SequenceVariant
polymorphism	O
of	O
the	O
RAD51	B-GeneOrGeneProduct
gene	O
.	O

Moreover	O
,	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
that	O
genotype	O
and	O
stomach	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
occurrence	O
in	O
subjects	O
with	O
high	O
level	O
of	O
oxidatively	O
damaged	O
DNA	O
.	O

We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
the	O
Ser1245Cys	B-SequenceVariant
polymorphism	O
of	O
the	O
hOGG1	B-GeneOrGeneProduct
gene	O
and	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
,	O
including	O
subjects	O
with	O
impaired	O
DNA	O
repair	O
and	O
/	O
or	O
high	O
levels	O
of	O
endogenous	O
oxidative	O
DNA	O
lesions	O
.	O

Therefore	O
,	O
our	O
result	O
suggest	O
that	O
the	O
G135C	B-SequenceVariant
polymorphism	O
of	O
the	O
RAD51	B-GeneOrGeneProduct
gene	O
may	O
be	O
linked	O
with	O
gastric	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
by	O
the	O
modulation	O
of	O
the	O
cellular	O
response	O
to	O
oxidative	O
stress	O
and	O
this	O
polymorphism	O
may	O
be	O
a	O
useful	O
additional	O
marker	O
in	O
this	O
disease	O
along	O
with	O
the	O
genetic	O
or	O
/	O
and	O
environmental	O
indicators	O
of	O
oxidative	O
stress	O
.	O
Ca2	B-ChemicalEntity
+	O
dependence	O
of	O
the	O
Ca2	B-ChemicalEntity
+	O
-	O
selective	O
TRPV6	B-GeneOrGeneProduct
channel	O
.	O

Microfluorimetry	O
and	O
patch	O
-	O
clamp	O
experiments	O
were	O
performed	O
on	O
TRPV6	B-GeneOrGeneProduct
-	O
expressing	O
HEK	B-CellLine
cells	O
to	O
determine	O
whether	O
this	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
-	O
sensing	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
channel	O
is	O
constitutively	O
active	O
.	O

Intact	O
cells	O
loaded	O
with	O
fura	B-ChemicalEntity
-	O
2	I-ChemicalEntity
had	O
an	O
elevated	O
intracellular	O
free	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
concentration	O
(	O
(	O
i	O
)	O
)	O
,	O
which	O
decreased	O
to	O
the	O
same	O
level	O
such	O
as	O
in	O
non	O
-	O
transfected	O
cells	O
if	O
external	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
was	O
chelated	O
by	O
EGTA	B-ChemicalEntity
.	O

Whole	O
cell	O
recordings	O
from	O
non	O
-	O
transfected	O
HEK	B-CellLine
cells	O
and	O
cells	O
expressing	O
human	B-OrganismTaxon
TRPV6	B-GeneOrGeneProduct
revealed	O
the	O
presence	O
of	O
a	O
basal	O
inward	O
current	O
in	O
both	O
types	O
of	O
cells	O
when	O
the	O
internal	O
solution	O
contained	O
0	O
.	O
1	O
mm	O
EGTA	B-ChemicalEntity
and	O
100	O
nm	O
(	O
i	O
)	O
or	O
if	O
the	O
cytosolic	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
buffering	O
remained	O
undisturbed	O
in	O
perforated	O
patch	O
-	O
clamp	O
experiments	O
.	O

If	O
recombinantly	O
expressed	O
TRPV6	B-GeneOrGeneProduct
forms	O
open	O
channels	O
,	O
one	O
would	O
expect	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
-	O
induced	O
current	O
inhibition	O
,	O
because	O
TRPV6	B-GeneOrGeneProduct
is	O
negatively	O
regulated	O
by	O
internal	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
.	O

However	O
,	O
dialyzing	O
solutions	O
with	O
high	O
such	O
as	O
1	O
microm	O
into	O
TRPV6	B-GeneOrGeneProduct
-	O
expressing	O
cells	O
did	O
not	O
block	O
the	O
basal	O
inward	O
current	O
,	O
which	O
was	O
not	O
different	O
from	O
the	O
recordings	O
from	O
non	O
-	O
transfected	O
cells	O
.	O

In	O
contrast	O
,	O
dialyzing	O
0	O
.	O
5	O
mm	O
EGTA	B-ChemicalEntity
into	O
TRPV6	B-GeneOrGeneProduct
-	O
expressing	O
cells	O
readily	O
activated	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
inward	O
currents	O
,	O
which	O
were	O
undetectable	O
in	O
non	O
-	O
transfected	O
cells	O
.	O

Interestingly	O
,	O
monovalent	O
cations	O
permeated	O
the	O
TRPV6	B-GeneOrGeneProduct
channels	O
under	O
conditions	O
where	O
no	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
permeation	O
was	O
detectable	O
,	O
indicating	O
that	O
divalent	O
cations	O
block	O
TRPV6	B-GeneOrGeneProduct
channels	O
from	O
the	O
extracellular	O
side	O
.	O

Like	O
human	B-OrganismTaxon
TRPV6	B-GeneOrGeneProduct
,	O
the	O
truncated	O
human	B-OrganismTaxon
TRPV6	B-GeneOrGeneProduct
(	O
Delta695	B-SequenceVariant
-	O
725	I-SequenceVariant
)	O
,	O
which	O
lacks	O
the	O
C	O
-	O
terminal	O
domain	O
required	O
for	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
-	O
calmodulin	O
binding	O
,	O
does	O
not	O
form	O
constitutive	O
active	O
channels	O
,	O
whereas	O
the	O
human	B-OrganismTaxon
TRPV6	B-GeneOrGeneProduct
(	O
D542A	B-SequenceVariant
)	O
,	O
carrying	O
a	O
point	O
mutation	O
in	O
the	O
presumed	O
pore	O
region	O
,	O
does	O
not	O
function	O
as	O
a	O
channel	O
.	O

In	O
summary	O
,	O
no	O
constitutive	O
open	O
TRPV6	B-GeneOrGeneProduct
channels	O
were	O
detected	O
in	O
patch	O
-	O
clamp	O
experiments	O
from	O
transfected	O
HEK	B-CellLine
cells	O
.	O

However	O
,	O
channel	O
activity	O
is	O
highly	O
regulated	O
by	O
intracellular	O
and	O
extracellular	O
divalent	O
cations	O
.	O
Memory	O
function	O
and	O
serotonin	B-GeneOrGeneProduct
transporter	I-GeneOrGeneProduct
promoter	O
gene	O
polymorphism	O
in	O
ecstasy	B-ChemicalEntity
(	O
MDMA	B-ChemicalEntity
)	O
users	O
.	O

Although	O
3	B-ChemicalEntity
,	O
4	I-ChemicalEntity
-	O
methylenedioxymethamphetamine	I-ChemicalEntity
(	O
MDMA	B-ChemicalEntity
or	O
ecstasy	B-ChemicalEntity
)	O
has	O
been	O
shown	O
to	O
damage	O
brain	O
serotonin	B-ChemicalEntity
(	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
)	O
neurons	O
in	O
animals	O
and	O
possibly	O
humans	B-OrganismTaxon
,	O
little	O
is	O
known	O
about	O
the	O
long	O
-	O
term	O
consequences	O
of	O
MDMA	B-ChemicalEntity
-	O
induced	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
neurotoxic	B-DiseaseOrPhenotypicFeature
lesions	I-DiseaseOrPhenotypicFeature
on	O
functions	O
in	O
which	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
is	O
involved	O
,	O
such	O
as	O
cognitive	O
function	O
.	O

Because	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
transporters	O
play	O
a	O
key	O
element	O
in	O
the	O
regulation	O
of	O
synaptic	O
5	B-ChemicalEntity
-	O
HT	I-ChemicalEntity
transmission	O
it	O
may	O
be	O
important	O
to	O
control	O
for	O
the	O
potential	O
covariance	O
effect	O
of	O
a	O
polymorphism	O
in	O
the	O
5	B-GeneOrGeneProduct
-	O
HT	I-GeneOrGeneProduct
transporter	I-GeneOrGeneProduct
promoter	I-GeneOrGeneProduct
gene	I-GeneOrGeneProduct
region	I-GeneOrGeneProduct
(	O
5	B-GeneOrGeneProduct
-	O
HTTLPR	I-GeneOrGeneProduct
)	O
when	O
studying	O
the	O
effects	O
of	O
MDMA	B-ChemicalEntity
as	O
well	O
as	O
cognitive	O
functioning	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
effects	O
of	O
moderate	O
and	O
heavy	O
MDMA	B-ChemicalEntity
use	O
on	O
cognitive	O
function	O
,	O
as	O
well	O
as	O
the	O
effects	O
of	O
long	O
-	O
term	O
abstention	O
from	O
MDMA	B-ChemicalEntity
,	O
in	O
subjects	O
genotyped	O
for	O
5	B-GeneOrGeneProduct
-	O
HTTLPR	I-GeneOrGeneProduct
.	O

A	O
second	O
aim	O
of	O
the	O
study	O
was	O
to	O
determine	O
whether	O
these	O
effects	O
differ	O
for	O
females	O
and	O
males	O
.	O

Fifteen	O
moderate	O
MDMA	B-ChemicalEntity
users	O
(	O
<	O
55	O
lifetime	O
tablets	O
)	O
,	O
22	O
heavy	O
MDMA	B-ChemicalEntity
+	O
users	O
(	O
>	O
55	O
lifetime	O
tablets	O
)	O
,	O
16	O
ex	O
-	O
MDMA	B-ChemicalEntity
+	O
users	O
(	O
last	O
tablet	O
>	O
1	O
year	O
ago	O
)	O
and	O
13	O
controls	O
were	O
compared	O
on	O
a	O
battery	O
of	O
neuropsychological	O
tests	O
.	O

DNA	O
from	O
peripheral	O
nuclear	O
blood	O
cells	O
was	O
genotyped	O
for	O
5	B-GeneOrGeneProduct
-	O
HTTLPR	I-GeneOrGeneProduct
using	O
standard	O
polymerase	O
chain	O
reaction	O
methods	O
.	O
A	O
significant	O
group	O
effect	O
was	O
observed	O
only	O
on	O
memory	O
function	O
tasks	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
but	O
not	O
on	O
reaction	O
times	O
(	O
p	O
=	O
0	O
.	O
61	O
)	O
or	O
attention	O
/	O
executive	O
functioning	O
(	O
p	O
=	O
0	O
.	O
59	O
)	O
.	O

Heavy	O
and	O
ex	O
-	O
MDMA	B-ChemicalEntity
+	O
users	O
performed	O
significantly	O
poorer	O
on	O
memory	O
tasks	O
than	O
controls	O
.	O

In	O
contrast	O
,	O
no	O
evidence	O
of	O
memory	B-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
was	O
observed	O
in	O
moderate	O
MDMA	B-ChemicalEntity
users	O
.	O

No	O
significant	O
effect	O
of	O
5	B-GeneOrGeneProduct
-	O
HTTLPR	I-GeneOrGeneProduct
or	O
gender	O
was	O
observed	O
.	O

While	O
the	O
use	O
of	O
MDMA	B-ChemicalEntity
in	O
quantities	O
that	O
may	O
be	O
considered	O
""""	O
moderate	O
""""	O
is	O
not	O
associated	O
with	O
impaired	B-DiseaseOrPhenotypicFeature
memory	I-DiseaseOrPhenotypicFeature
functioning	I-DiseaseOrPhenotypicFeature
,	O
heavy	O
use	O
of	O
MDMA	B-ChemicalEntity
use	O
may	O
lead	O
to	O
long	O
lasting	O
memory	B-DiseaseOrPhenotypicFeature
impairments	I-DiseaseOrPhenotypicFeature
.	O

No	O
effect	O
of	O
5	B-GeneOrGeneProduct
-	O
HTTLPR	I-GeneOrGeneProduct
or	O
gender	O
on	O
memory	O
function	O
or	O
MDMA	B-ChemicalEntity
use	O
was	O
observed	O
.	O
Effects	O
of	O
common	O
germline	O
genetic	O
variation	O
in	O
cell	O
cycle	O
control	O
genes	O
on	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
survival	O
:	O
results	O
from	O
a	O
population	O
-	O
based	O
cohort	O
.	O

INTRODUCTION	O
:	O
Somatic	O
alterations	O
have	O
been	O
shown	O
to	O
correlate	O
with	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
prognosis	O
and	O
survival	O
,	O
but	O
less	O
is	O
known	O
about	O
the	O
effects	O
of	O
common	O
inherited	O
genetic	O
variation	O
.	O

Of	O
particular	O
interest	O
are	O
genes	O
involved	O
in	O
cell	O
cycle	O
pathways	O
,	O
which	O
regulate	O
cell	O
division	O
.	O

METHODS	O
:	O
We	O
examined	O
associations	O
between	O
common	O
germline	O
genetic	O
variation	O
in	O
13	O
genes	O
involved	O
in	O
cell	O
cycle	O
control	O
(	O
CCND1	B-GeneOrGeneProduct
,	O
CCND2	B-GeneOrGeneProduct
,	O
CCND3	B-GeneOrGeneProduct
,	O
CCNE1	B-GeneOrGeneProduct
,	O
CDK2	B-GeneOrGeneProduct
[	O
p33	I-GeneOrGeneProduct
]	O
,	O
CDK4	B-GeneOrGeneProduct
,	O
CDK6	B-GeneOrGeneProduct
,	O
CDKN1A	B-GeneOrGeneProduct
[	O
p21	B-GeneOrGeneProduct
,	O
Cip1	B-GeneOrGeneProduct
]	O
,	O
CDKN1B	B-GeneOrGeneProduct
[	O
p27	B-GeneOrGeneProduct
,	O
Kip1	I-GeneOrGeneProduct
]	O
,	O
CDKN2A	B-GeneOrGeneProduct
[	O
p16	B-GeneOrGeneProduct
]	O
,	O
CDKN2B	B-GeneOrGeneProduct
[	O
p15	B-GeneOrGeneProduct
]	O
,	O
CDKN2C	B-GeneOrGeneProduct
[	O
p18	B-GeneOrGeneProduct
]	O
,	O
and	O
CDKN2D	B-GeneOrGeneProduct
[	O
p19	B-GeneOrGeneProduct
]	O
)	O
and	O
survival	O
among	O
women	B-OrganismTaxon
diagnosed	O
with	O
invasive	B-DiseaseOrPhenotypicFeature
breast	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
participating	O
in	O
the	O
SEARCH	O
(	O
Studies	O
of	O
Epidemiology	O
and	O
Risk	O
factors	O
in	O
Cancer	O
Heredity	O
)	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
study	O
.	O

DNA	O
from	O
up	O
to	O
4	O
,	O
470	O
women	B-OrganismTaxon
was	O
genotyped	O
for	O
85	O
polymorphisms	O
that	O
tag	O
the	O
known	O
common	O
polymorphisms	O
(	O
minor	O
allele	O
frequency	O
>	O
0	O
.	O
05	O
)	O
in	O
the	O
genes	O
.	O

The	O
genotypes	O
of	O
each	O
polymorphism	O
were	O
tested	O
for	O
association	O
with	O
survival	O
using	O
Cox	O
regression	O
analysis	O
.	O

RESULTS	O
:	O
The	O
rare	O
allele	O
of	O
the	O
tagging	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
rs2479717	B-SequenceVariant
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	B-DiseaseOrPhenotypicFeature
(	O
hazard	O
ratio	O
=	O
1	O
.	O
26	O
per	O
rare	O
allele	O
carried	O
,	O
95%	O
confidence	O
interval	O
:	O
1	O
.	O
12	O
to	O
1	O
.	O
42	O
;	O
P	O
=	O
0	O
.	O
0001	O
)	O
,	O
which	O
was	O
not	O
attenuated	O
after	O
adjusting	O
for	O
tumour	B-DiseaseOrPhenotypicFeature
stage	O
,	O
grade	O
,	O
and	O
treatment	O
.	O

This	O
SNP	O
is	O
part	O
of	O
a	O
large	O
linkage	O
disequilibrium	O
block	O
,	O
which	O
contains	O
CCND3	B-GeneOrGeneProduct
,	O
BYSL	B-GeneOrGeneProduct
,	O
TRFP	B-GeneOrGeneProduct
,	O
USP49	B-GeneOrGeneProduct
,	O
C6ofr49	B-GeneOrGeneProduct
,	O
FRS3	B-GeneOrGeneProduct
,	O
and	O
PGC	B-GeneOrGeneProduct
.	O

We	O
evaluated	O
the	O
association	O
of	O
survival	O
and	O
somatic	O
expression	O
of	O
these	O
genes	O
in	O
breast	B-DiseaseOrPhenotypicFeature
tumours	I-DiseaseOrPhenotypicFeature
using	O
expression	O
microarray	O
data	O
from	O
seven	O
published	O
datasets	O
.	O

Elevated	O
expression	O
of	O
the	O
C6orf49	B-GeneOrGeneProduct
transcript	O
was	O
associated	O
with	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
survival	O
,	O
adding	O
biological	O
interest	O
to	O
the	O
finding	O
.	O

CONCLUSION	O
:	O
It	O
is	O
possible	O
that	O
CCND3	B-GeneOrGeneProduct
rs2479717	B-SequenceVariant
,	O
or	O
another	O
variant	O
it	O
tags	O
,	O
is	O
associated	O
with	O
prognosis	O
after	O
a	O
diagnosis	O
of	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

Further	O
study	O
is	O
required	O
to	O
validate	O
this	O
finding	O
.	O
Disruption	O
of	O
a	O
synaptotagmin	B-GeneOrGeneProduct
(	O
SYT14	B-GeneOrGeneProduct
)	O
associated	O
with	O
neurodevelopmental	B-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
.	O

We	O
report	O
cytogenetic	O
and	O
molecular	O
studies	O
of	O
a	O
de	O
novo	O
,	O
apparently	O
balanced	O
t	O
(	O
1	O
;	O
3	O
)	O
(	O
q32	O
.	O
1	O
;	O
q25	O
.	O
1	O
)	O
identified	O
in	O
a	O
12	O
-	O
year	O
-	O
old	O
female	O
(	O
designated	O
DGAP128	O
)	O
with	O
cerebral	B-DiseaseOrPhenotypicFeature
atrophy	I-DiseaseOrPhenotypicFeature
,	O
macrocephaly	B-DiseaseOrPhenotypicFeature
seizures	B-DiseaseOrPhenotypicFeature
,	O
and	O
developmental	B-DiseaseOrPhenotypicFeature
delay	I-DiseaseOrPhenotypicFeature
.	O

A	O
combination	O
of	O
fluorescence	O
in	O
situ	O
hybridization	O
(	O
FISH	O
)	O
and	O
Southern	O
blot	O
analysis	O
demonstrated	O
disruption	O
of	O
a	O
synaptotagmin	B-GeneOrGeneProduct
gene	O
(	O
SYT14	B-GeneOrGeneProduct
)	O
at	O
the	O
1q32	O
breakpoint	O
.	O

Expression	O
of	O
SYT14	B-GeneOrGeneProduct
in	O
human	B-OrganismTaxon
brain	O
was	O
confirmed	O
using	O
Northern	O
analysis	O
.	O

Because	O
members	O
of	O
the	O
synaptotagmin	B-GeneOrGeneProduct
family	O
of	O
proteins	O
function	O
as	O
sensors	O
that	O
link	O
changes	O
in	O
calcium	B-ChemicalEntity
levels	O
with	O
a	O
variety	O
of	O
biological	O
processes	O
,	O
including	O
neurotransmission	O
and	O
hormone	O
-	O
responsiveness	O
,	O
SYT14	B-GeneOrGeneProduct
is	O
an	O
intriguing	O
candidate	O
gene	O
for	O
the	O
abnormal	O
development	O
in	O
this	O
child	O
.	O

This	O
is	O
the	O
first	O
known	O
constitutional	O
rearrangement	O
of	O
SYT14	B-GeneOrGeneProduct
,	O
and	O
further	O
systematic	O
genetic	O
analysis	O
and	O
clinical	O
studies	O
of	O
DGAP128	O
may	O
offer	O
unique	O
insights	O
into	O
the	O
role	O
of	O
SYT14	B-GeneOrGeneProduct
in	O
neurodevelopment	O
.	O
Atorvastatin	B-ChemicalEntity
prevented	O
and	O
reversed	O
dexamethasone	B-ChemicalEntity
-	O
induced	O
hypertension	B-DiseaseOrPhenotypicFeature
in	O
the	O
rat	B-OrganismTaxon
.	O

To	O
assess	O
the	O
antioxidant	B-ChemicalEntity
effects	O
of	O
atorvastatin	B-ChemicalEntity
(	O
atorva	B-ChemicalEntity
)	O
on	O
dexamethasone	B-ChemicalEntity
(	O
dex	B-ChemicalEntity
)	O
-	O
induced	O
hypertension	B-DiseaseOrPhenotypicFeature
,	O
60	O
male	O
Sprague	O
-	O
Dawley	O
rats	B-OrganismTaxon
were	O
treated	O
with	O
atorva	B-ChemicalEntity
30	O
mg	O
/	O
kg	O
/	O
day	O
or	O
tap	O
water	O
for	O
15	O
days	O
.	O

Dex	B-ChemicalEntity
increased	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
from	O
109	O
+	O
/	O
-	O
1	O
.	O
8	O
to	O
135	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
and	O
plasma	O
superoxide	B-ChemicalEntity
(	O
5711	O
+	O
/	O
-	O
284	O
.	O
9	O
saline	O
,	O
7931	O
+	O
/	O
-	O
392	O
.	O
8	O
U	O
/	O
ml	O
dex	B-ChemicalEntity
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

In	O
this	O
prevention	O
study	O
,	O
SBP	O
in	O
the	O
atorva	B-ChemicalEntity
+	O
dex	B-ChemicalEntity
group	O
was	O
increased	O
from	O
115	O
+	O
/	O
-	O
0	O
.	O
4	O
to	O
124	O
+	O
/	O
-	O
1	O
.	O
5	O
mmHg	O
,	O
but	O
this	O
was	O
significantly	O
lower	O
than	O
in	O
the	O
dex	B-ChemicalEntity
-	O
only	O
group	O
(	O
P	O
'	O
<	O
0	O
.	O
05	O
)	O
.	O

Atorva	B-ChemicalEntity
reversed	O
dex	B-ChemicalEntity
-	O
induced	O
hypertension	B-DiseaseOrPhenotypicFeature
(	O
129	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
,	O
vs	O
.	O

135	O
+	O
/	O
-	O
0	O
.	O
6	O
mmHg	O
P	O
'	O
<	O
0	O
.	O
05	O
)	O
and	O
decreased	O
plasma	O
superoxide	B-ChemicalEntity
(	O
7931	O
+	O
/	O
-	O
392	O
.	O
8	O
dex	B-ChemicalEntity
,	O
1187	O
+	O
/	O
-	O
441	O
.	O
2	O
atorva	B-ChemicalEntity
+	O
dex	B-ChemicalEntity
,	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Plasma	O
nitrate	B-ChemicalEntity
/	O
nitrite	B-ChemicalEntity
(	O
NOx	B-ChemicalEntity
)	O
was	O
decreased	O
in	O
dex	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
compared	O
to	O
saline	O
-	O
treated	O
rats	B-OrganismTaxon
(	O
11	O
.	O
2	O
+	O
/	O
-	O
1	O
.	O
08	O
microm	O
,	O
15	O
.	O
3	O
+	O
/	O
-	O
1	O
.	O
17	O
microm	O
,	O
respectively	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Atorva	B-ChemicalEntity
affected	O
neither	O
plasma	O
NOx	B-ChemicalEntity
nor	O
thymus	O
weight	O
.	O

Thus	O
,	O
atorvastatin	B-ChemicalEntity
prevented	O
and	O
reversed	O
dexamethasone	B-ChemicalEntity
-	O
induced	O
hypertension	B-DiseaseOrPhenotypicFeature
in	O
the	O
rat	B-OrganismTaxon
.	O
Comparison	O
of	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
findings	O
in	O
advanced	O
idiopathic	B-DiseaseOrPhenotypicFeature
Parkinson	I-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

A	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
pilot	O
study	O
to	O
compare	O
the	O
results	O
of	O
stereotactic	O
unilateral	O
pallidotomy	O
and	O
subthalamotomy	O
in	O
advanced	O
idiopathic	B-DiseaseOrPhenotypicFeature
Parkinson	I-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
PD	B-DiseaseOrPhenotypicFeature
)	O
refractory	O
to	O
medical	O
treatment	O
was	O
designed	O
.	O

Ten	O
consecutive	O
patients	B-OrganismTaxon
(	O
mean	O
age	O
,	O
58	O
.	O
4	O
+	O
/	O
-	O
6	O
.	O
8	O
years	O
;	O
7	O
men	B-OrganismTaxon
,	O
3	O
women	B-OrganismTaxon
)	O
with	O
similar	O
characteristics	O
at	O
the	O
duration	O
of	O
disease	O
(	O
mean	O
disease	O
time	O
,	O
8	O
.	O
4	O
+	O
/	O
-	O
3	O
.	O
5	O
years	O
)	O
,	O
disabling	O
motor	O
fluctuations	O
(	O
Hoehn	O
_	O
Yahr	O
stage	O
3	O
-	O
5	O
in	O
off	O
-	O
drug	O
phases	O
)	O
and	O
levodopa	B-ChemicalEntity
-	O
induced	O
dyskinesias	B-DiseaseOrPhenotypicFeature
were	O
selected	O
.	O

All	O
patients	B-OrganismTaxon
had	O
bilateral	O
symptoms	O
and	O
their	O
levodopa	B-ChemicalEntity
equivalent	O
dosing	O
were	O
analysed	O
.	O

Six	O
patients	B-OrganismTaxon
were	O
operated	O
on	O
in	O
the	O
globus	O
pallidus	O
interna	O
(	O
GPi	O
)	O
and	O
four	O
in	O
the	O
subthalamic	O
nucleus	O
(	O
STN	O
)	O
.	O

Clinical	O
evaluation	O
included	O
the	O
use	O
of	O
the	O
Unified	O
Parkinson	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
Disease	I-DiseaseOrPhenotypicFeature
Rating	O
Scale	O
(	O
UPDRS	O
)	O
,	O
Hoehn_Yahr	O
score	O
and	O
Schwab	O
England	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
score	O
in	O
'	O
on	O
'	O
-	O
and	O
'	O
off	O
'	O
-	O
drug	O
conditions	O
before	O
surgery	O
and	O
6	O
months	O
after	O
surgery	O
.	O

There	O
was	O
statistically	O
significant	O
improvement	O
in	O
all	O
contralateral	O
major	O
parkinsonian	B-DiseaseOrPhenotypicFeature
motor	O
signs	O
in	O
all	O
patients	B-OrganismTaxon
followed	O
for	O
6	O
months	O
.	O

Levodopa	B-ChemicalEntity
equivalent	O
daily	O
intake	O
was	O
significantly	O
reduced	O
in	O
the	O
STN	O
group	O
.	O

Changes	O
in	O
UPDRS	O
,	O
Hoehn	O
_	O
Yahr	O
and	O
Schwab	O
England	O
ADL	O
scores	O
were	O
similar	O
in	O
both	O
groups	O
.	O

Cognitive	O
functions	O
were	O
unchanged	O
in	O
both	O
groups	O
.	O

Complications	O
were	O
observed	O
in	O
two	O
patients	B-OrganismTaxon
:	O
one	O
had	O
a	O
left	O
homonymous	B-DiseaseOrPhenotypicFeature
hemianopsia	I-DiseaseOrPhenotypicFeature
after	O
pallidotomy	O
and	O
another	O
one	O
developed	O
left	O
hemiballistic	O
movements	O
3	O
days	O
after	O
subthalamotomy	O
which	O
partly	O
improved	O
within	O
1	O
month	O
with	O
Valproate	B-ChemicalEntity
1000	O
mg	O
/	O
day	O
.	O

The	O
findings	O
of	O
this	O
study	O
suggest	O
that	O
lesions	O
of	O
the	O
unilateral	O
STN	O
and	O
GPi	O
are	O
equally	O
effective	O
treatment	O
for	O
patients	B-OrganismTaxon
with	O
advanced	O
PD	B-DiseaseOrPhenotypicFeature
refractory	O
to	O
medical	O
treatment	O
.	O
Cholecystokinin	B-ChemicalEntity
-	O
octapeptide	I-ChemicalEntity
restored	O
morphine	B-ChemicalEntity
-	O
induced	O
hippocampal	O
long	O
-	O
term	O
potentiation	O
impairment	O
in	O
rats	B-OrganismTaxon
.	O

Cholecystokinin	B-ChemicalEntity
-	O
octapeptide	I-ChemicalEntity
(	O
CCK	B-ChemicalEntity
-	O
8	I-ChemicalEntity
)	O
,	O
which	O
is	O
a	O
typical	O
brain	O
-	O
gut	O
peptide	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
on	O
the	O
central	O
nervous	O
system	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK	B-ChemicalEntity
-	O
8	I-ChemicalEntity
significantly	O
alleviated	O
morphine	B-ChemicalEntity
-	O
induced	O
amnesia	B-DiseaseOrPhenotypicFeature
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	B-ChemicalEntity
-	O
treated	O
animals	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK	B-ChemicalEntity
-	O
8	I-ChemicalEntity
on	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(	O
LPP	O
)	O
-	O
granule	O
cell	O
synapse	O
of	O
rat	B-OrganismTaxon
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine	B-ChemicalEntity
-	O
treated	O
rats	B-OrganismTaxon
.	O

Population	O
spikes	O
(	O
PS	O
)	O
,	O
which	O
were	O
evoked	O
by	O
stimulation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
region	O
.	O

Acute	O
morphine	B-ChemicalEntity
(	O
30mg	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
treatment	O
significantly	O
attenuated	O
hippocampal	O
LTP	O
and	O
CCK	B-ChemicalEntity
-	O
8	I-ChemicalEntity
(	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	B-ChemicalEntity
injection	O
.	O

Furthermore	O
,	O
microinjection	O
of	O
CCK	B-ChemicalEntity
-	O
8	I-ChemicalEntity
(	O
0	O
.	O
1	O
and	O
1ug	O
,	O
i	O
.	O
c	O
.	O
v	O
.	O
)	O
also	O
significantly	O
augmented	O
hippocampal	O
LTP	O
in	O
saline	O
-	O
treated	O
(	O
1ml	O
/	O
kg	O
,	O
s	O
.	O
c	O
.	O
)	O
rats	B-OrganismTaxon
.	O

Pre	O
-	O
treatment	O
of	O
the	O
CCK2	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
antagonist	O
L	B-ChemicalEntity
-	O
365	I-ChemicalEntity
,	O
260	I-ChemicalEntity
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
reversed	O
the	O
effects	O
of	O
CCK	B-ChemicalEntity
-	O
8	I-ChemicalEntity
,	O
but	O
the	O
CCK1	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
antagonist	O
L	B-ChemicalEntity
-	O
364	I-ChemicalEntity
,	O
718	I-ChemicalEntity
(	O
10ug	O
,	O
i	O
.	O
c	O
.	O
v	O
)	O
did	O
not	O
.	O

The	O
present	O
results	O
demonstrate	O
that	O
CCK	B-ChemicalEntity
-	O
8	I-ChemicalEntity
attenuates	O
the	O
effect	O
of	O
morphine	B-ChemicalEntity
on	O
hippocampal	O
LTP	O
through	O
CCK2	B-GeneOrGeneProduct
receptors	I-GeneOrGeneProduct
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK	B-ChemicalEntity
-	O
8	I-ChemicalEntity
on	O
morphine	B-ChemicalEntity
-	O
induced	O
memory	B-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
.	O
Distinct	O
patterns	O
of	O
germ	O
-	O
line	O
deletions	O
in	O
MLH1	B-GeneOrGeneProduct
and	O
MSH2	B-GeneOrGeneProduct
:	O
the	O
implication	O
of	O
Alu	O
repetitive	O
element	O
in	O
the	O
genetic	O
etiology	O
of	O
Lynch	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
HNPCC	B-DiseaseOrPhenotypicFeature
)	O
.	O

A	O
relatively	O
high	O
frequency	O
of	O
germ	O
-	O
line	O
genomic	O
rearrangements	O
in	O
MLH1	B-GeneOrGeneProduct
and	O
MSH2	B-GeneOrGeneProduct
has	O
been	O
reported	O
among	O
Lynch	B-DiseaseOrPhenotypicFeature
Syndrome	I-DiseaseOrPhenotypicFeature
(	O
HNPCC	B-DiseaseOrPhenotypicFeature
)	O
patients	B-OrganismTaxon
from	O
different	O
ethnic	O
populations	O
.	O

To	O
investigate	O
the	O
underlying	O
molecular	O
mechanisms	O
,	O
we	O
characterized	O
the	O
DNA	O
breakpoints	O
of	O
11	O
germ	O
-	O
line	O
deletions	O
,	O
six	O
for	O
MLH1	B-GeneOrGeneProduct
and	O
five	O
for	O
MSH2	B-GeneOrGeneProduct
.	O

Distinct	O
deletion	O
patterns	O
were	O
found	O
for	O
the	O
two	O
genes	O
.	O

The	O
five	O
cases	O
of	O
MSH2	B-GeneOrGeneProduct
deletions	O
result	O
exclusively	O
from	O
intragenic	O
unequal	O
recombination	O
mediated	O
by	O
repetitive	O
Alu	O
sequences	O
.	O

In	O
contrast	O
,	O
five	O
out	O
of	O
the	O
six	O
MLH1	B-GeneOrGeneProduct
deletions	O
are	O
due	O
to	O
recombinations	O
involving	O
sequences	O
of	O
no	O
significant	O
homology	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

A	O
detailed	O
analysis	O
of	O
the	O
DNA	O
breakpoints	O
in	O
the	O
two	O
genes	O
,	O
previously	O
characterized	O
by	O
other	O
groups	O
,	O
validated	O
the	O
observation	O
that	O
Alu	O
-	O
mediated	O
unequal	O
recombination	O
is	O
the	O
main	O
type	O
of	O
deletion	O
in	O
MSH2	B-GeneOrGeneProduct
(	O
n	O
=	O
34	O
)	O
,	O
but	O
not	O
in	O
MLH1	B-GeneOrGeneProduct
(	O
n	O
=	O
21	O
)	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
.	O

Plotting	O
the	O
distribution	O
of	O
known	O
DNA	O
breakpoints	O
among	O
the	O
introns	O
of	O
the	O
two	O
genes	O
showed	O
that	O
,	O
the	O
highest	O
breakpoint	O
density	O
is	O
co	O
-	O
localized	O
with	O
the	O
highest	O
Alu	O
density	O
.	O

Our	O
study	O
suggests	O
that	O
Alu	O
is	O
a	O
promoting	O
factor	O
for	O
the	O
genomic	O
recombinations	O
in	O
both	O
MLH1	B-GeneOrGeneProduct
and	O
MSH2	B-GeneOrGeneProduct
,	O
and	O
the	O
local	O
Alu	O
density	O
may	O
be	O
involved	O
in	O
shaping	O
the	O
deletion	O
pattern	O
.	O
Vitamin	B-GeneOrGeneProduct
D	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
expression	O
is	O
associated	O
with	O
PIK3CA	B-GeneOrGeneProduct
and	O
KRAS	B-GeneOrGeneProduct
mutations	O
in	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

Vitamin	B-ChemicalEntity
D	I-ChemicalEntity
is	O
associated	O
with	O
decreased	O
risks	O
of	O
various	O
cancers	B-DiseaseOrPhenotypicFeature
,	O
including	O
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

The	O
vitamin	B-GeneOrGeneProduct
D	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
VDR	B-GeneOrGeneProduct
)	O
is	O
a	O
transcription	O
factor	O
,	O
which	O
plays	O
an	O
important	O
role	O
in	O
cellular	O
differentiation	O
and	O
inhibition	O
of	O
proliferation	O
.	O

A	O
link	O
between	O
VDR	B-GeneOrGeneProduct
and	O
the	O
RAS	B-GeneOrGeneProduct
-	O
mitogen	B-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
(	O
MAPK	B-GeneOrGeneProduct
)	O
or	O
phosphatidylinositol	B-GeneOrGeneProduct
3	I-GeneOrGeneProduct
-	O
kinase	I-GeneOrGeneProduct
(	O
PI3K	B-GeneOrGeneProduct
)	O
-	O
AKT	B-GeneOrGeneProduct
pathway	O
has	O
been	O
suggested	O
.	O

However	O
,	O
the	O
prognostic	O
role	O
of	O
VDR	B-GeneOrGeneProduct
expression	O
or	O
its	O
relationship	O
with	O
PIK3CA	B-GeneOrGeneProduct
or	O
KRAS	B-GeneOrGeneProduct
mutation	O
remains	O
uncertain	O
.	O

Among	O
619	O
colorectal	B-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
in	O
two	O
prospective	O
cohort	O
studies	O
,	O
233	O
(	O
38%	O
)	O
tumors	B-DiseaseOrPhenotypicFeature
showed	O
VDR	B-GeneOrGeneProduct
overexpression	O
by	O
immunohistochemistry	O
.	O

We	O
analyzed	O
for	O
PIK3CA	B-GeneOrGeneProduct
and	O
KRAS	B-GeneOrGeneProduct
mutations	O
and	O
LINE	O
-	O
1	O
methylation	O
by	O
Pyrosequencing	O
,	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
,	O
and	O
DNA	O
methylation	O
(	O
epigenetic	O
changes	O
)	O
in	O
eight	O
CpG	O
island	O
methylator	O
phenotype	O
(	O
CIMP	O
)	O
-	O
specific	O
promoters	O
[	O
CACNA1G	B-GeneOrGeneProduct
,	O
CDKN2A	B-GeneOrGeneProduct
(	O
p16	B-GeneOrGeneProduct
)	O
,	O
CRABP1	B-GeneOrGeneProduct
,	O
IGF2	B-GeneOrGeneProduct
,	O
MLH1	B-GeneOrGeneProduct
,	O
NEUROG1	B-GeneOrGeneProduct
,	O
RUNX3	B-GeneOrGeneProduct
,	O
and	O
SOCS1	B-GeneOrGeneProduct
]	O
by	O
MethyLight	O
(	O
real	O
-	O
time	O
PCR	O
)	O
.	O

VDR	B-GeneOrGeneProduct
overexpression	O
was	O
significantly	O
associated	O
with	O
KRAS	B-GeneOrGeneProduct
mutation	O
(	O
odds	O
ratio	O
,	O
1	O
.	O
55	O
;	O
95%	O
confidence	O
interval	O
,	O
1	O
.	O
11	O
-	O
2	O
.	O
16	O
)	O
and	O
PIK3CA	B-GeneOrGeneProduct
mutation	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
17	O
;	O
95%	O
confidence	O
interval	O
,	O
1	O
.	O
36	O
-	O
3	O
.	O
47	O
)	O
,	O
both	O
of	O
which	O
persisted	O
in	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

VDR	B-GeneOrGeneProduct
was	O
not	O
independently	O
associated	O
with	O
body	O
mass	O
index	O
,	O
family	O
history	O
of	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
,	O
tumor	B-DiseaseOrPhenotypicFeature
location	O
(	O
colon	O
versus	O
rectum	O
)	O
,	O
stage	O
,	O
tumor	B-DiseaseOrPhenotypicFeature
grade	O
,	O
signet	O
ring	O
cells	O
,	O
CIMP	O
,	O
MSI	O
,	O
LINE	O
-	O
1	O
hypomethylation	O
,	O
BRAF	B-GeneOrGeneProduct
,	O
p53	B-GeneOrGeneProduct
,	O
p21	B-GeneOrGeneProduct
,	O
beta	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
,	O
or	O
cyclooxygenase	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
.	O

VDR	B-GeneOrGeneProduct
expression	O
was	O
not	O
significantly	O
related	O
with	O
patient	B-OrganismTaxon
survival	O
,	O
prognosis	O
,	O
or	O
clinical	O
outcome	O
.	O

In	O
conclusion	O
,	O
VDR	B-GeneOrGeneProduct
overexpression	O
in	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
is	O
independently	O
associated	O
with	O
PIK3CA	B-GeneOrGeneProduct
and	O
KRAS	B-GeneOrGeneProduct
mutations	O
.	O

Our	O
data	O
support	O
potential	O
interactions	O
between	O
the	O
VDR	B-GeneOrGeneProduct
,	O
RAS	B-GeneOrGeneProduct
-	O
MAPK	B-GeneOrGeneProduct
and	O
PI3K	B-GeneOrGeneProduct
-	O
AKT	B-GeneOrGeneProduct
pathways	O
,	O
and	O
possible	O
influence	O
by	O
KRAS	B-GeneOrGeneProduct
or	O
PIK3CA	B-GeneOrGeneProduct
mutation	O
on	O
therapy	O
or	O
chemoprevention	O
targeting	O
VDR	B-GeneOrGeneProduct
.	O
Identification	O
of	O
novel	O
type	O
VII	B-GeneOrGeneProduct
collagen	I-GeneOrGeneProduct
gene	O
mutations	O
resulting	O
in	O
severe	O
recessive	B-DiseaseOrPhenotypicFeature
dystrophic	I-DiseaseOrPhenotypicFeature
epidermolysis	I-DiseaseOrPhenotypicFeature
bullosa	I-DiseaseOrPhenotypicFeature
.	O

In	O
this	O
work	O
,	O
we	O
studied	O
the	O
proband	O
in	O
a	O
small	O
nuclear	O
family	O
of	O
Chinese	O
and	O
Dutch	O
/	O
German	O
descent	O
and	O
identified	O
two	O
novel	O
mutations	O
in	O
the	O
type	O
VII	B-GeneOrGeneProduct
collagen	I-GeneOrGeneProduct
gene	O
leading	O
to	O
recessive	B-DiseaseOrPhenotypicFeature
dystrophic	I-DiseaseOrPhenotypicFeature
epidermolysis	I-DiseaseOrPhenotypicFeature
bullosa	I-DiseaseOrPhenotypicFeature
,	O
Hallopeau	B-DiseaseOrPhenotypicFeature
-	O
Siemens	I-DiseaseOrPhenotypicFeature
variant	O
(	O
HS	B-DiseaseOrPhenotypicFeature
-	O
RDEB	I-DiseaseOrPhenotypicFeature
)	O
.	O

The	O
maternal	O
mutation	O
is	O
a	O
single	B-SequenceVariant
base	I-SequenceVariant
pair	I-SequenceVariant
deletion	I-SequenceVariant
of	I-SequenceVariant
a	I-SequenceVariant
cytosine	I-SequenceVariant
nucleotide	I-SequenceVariant
in	O
exon	O
26	O
,	O
designated	O
3472delC	B-SequenceVariant
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
a	O
premature	O
termination	O
codon	O
(	O
PTC	O
)	O
within	O
the	O
same	O
exon	O
,	O
7	O
bp	O
downstream	O
of	O
the	O
site	O
of	O
the	O
mutation	O
.	O

The	O
paternal	O
mutation	O
is	O
a	O
G	B-SequenceVariant
-	O
-	O
>	O
A	I-SequenceVariant
transition	O
located	O
at	O
the	O
5	O
'	O
donor	O
splice	O
site	O
within	O
intron	O
51	O
,	O
designated	O
IVS51	B-SequenceVariant
+	O
1G	I-SequenceVariant
-	O
-	O
>	O
A	I-SequenceVariant
.	O

This	O
mutation	O
leads	O
to	O
the	O
activation	O
of	O
a	O
cryptic	O
splice	O
site	O
,	O
32	O
bp	O
downstream	O
of	O
the	O
mutation	O
site	O
and	O
to	O
subsequent	O
aberrant	O
out	O
-	O
of	O
-	O
frame	O
splicing	O
,	O
resulting	O
in	O
two	O
alternative	O
mRNA	O
transcripts	O
and	O
a	O
downstream	O
PTC	O
.	O

To	O
our	O
knowledge	O
,	O
these	O
two	O
mutations	O
have	O
not	O
been	O
previously	O
reported	O
.	O

These	O
findings	O
extend	O
the	O
body	O
of	O
evidence	O
for	O
compound	O
heterozygous	O
mutations	O
leading	O
to	O
HS	B-DiseaseOrPhenotypicFeature
-	O
RDEB	I-DiseaseOrPhenotypicFeature
and	O
provide	O
the	O
basis	O
for	O
prenatal	O
diagnosis	O
in	O
this	O
family	O
.	O
Detection	O
of	O
EGFR	B-GeneOrGeneProduct
mutations	O
in	O
plasma	O
DNA	O
from	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
by	O
mass	O
spectrometry	O
genotyping	O
is	O
predictive	O
of	O
tumor	B-DiseaseOrPhenotypicFeature
EGFR	B-GeneOrGeneProduct
status	O
and	O
response	O
to	O
EGFR	B-GeneOrGeneProduct
inhibitors	O
.	O

AIMS	O
:	O
EGFR	B-GeneOrGeneProduct
mutations	O
now	O
guide	O
the	O
clinical	O
use	O
of	O
EGFR	B-GeneOrGeneProduct
-	O
targeted	O
therapy	O
in	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
standard	O
EGFR	B-GeneOrGeneProduct
mutation	O
analysis	O
requires	O
a	O
minimum	O
amount	O
of	O
tumor	B-DiseaseOrPhenotypicFeature
tissue	O
,	O
which	O
may	O
not	O
be	O
available	O
in	O
certain	O
situations	O
.	O

In	O
this	O
study	O
,	O
we	O
combined	O
a	O
mass	O
spectrometry	O
genotyping	O
assay	O
(	O
Sequenom	O
)	O
with	O
a	O
mutant	O
-	O
enriched	O
PCR	O
(	O
ME	O
-	O
PCR	O
)	O
to	O
detect	O
EGFR	B-GeneOrGeneProduct
mutations	O
in	O
free	O
plasma	O
DNA	O
from	O
patients	B-OrganismTaxon
with	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

METHOD	O
:	O
DNAs	O
were	O
extracted	O
from	O
31	O
plasma	O
samples	O
from	O
31	O
patients	B-OrganismTaxon
and	O
analyzed	O
by	O
both	O
methods	O
for	O
EGFR	B-GeneOrGeneProduct
Exon	O
19	O
deletion	O
and	O
EGFR	B-GeneOrGeneProduct
L858R	B-SequenceVariant
mutation	O
.	O

Results	O
in	O
plasma	O
DNA	O
samples	O
were	O
compared	O
with	O
EGFR	B-GeneOrGeneProduct
mutation	O
status	O
obtained	O
in	O
tumor	B-DiseaseOrPhenotypicFeature
DNA	O
(	O
18	O
/	O
31	O
EGFR	B-GeneOrGeneProduct
mutant	O
)	O
.	O

The	O
relationship	O
of	O
EGFR	B-GeneOrGeneProduct
mutation	O
status	O
in	O
tumor	B-DiseaseOrPhenotypicFeature
and	O
/	O
or	O
plasma	O
samples	O
to	O
overall	O
survival	O
was	O
assessed	O
.	O

RESULTS	O
:	O
The	O
EGFR	B-GeneOrGeneProduct
mutation	O
status	O
in	O
plasma	O
DNA	O
was	O
identical	O
to	O
the	O
primary	O
tumor	B-DiseaseOrPhenotypicFeature
in	O
61%	O
of	O
patients	B-OrganismTaxon
(	O
19	O
/	O
31	O
)	O
.	O

By	O
mass	O
spectrometry	O
genotyping	O
,	O
the	O
plasma	O
samples	O
contained	O
mutant	O
DNA	O
corresponding	O
to	O
5	O
/	O
14	O
EGFR	B-GeneOrGeneProduct
Exon	O
19	O
deletions	O
and	O
3	O
/	O
4	O
EGFR	B-GeneOrGeneProduct
L858R	B-SequenceVariant
mutations	O
previously	O
diagnosed	O
in	O
the	O
matched	O
tumors	B-DiseaseOrPhenotypicFeature
.	O

Two	O
samples	O
were	O
positive	O
in	O
plasma	O
DNA	O
but	O
negative	O
in	O
primary	O
tumor	B-DiseaseOrPhenotypicFeature
tissue	O
.	O

Results	O
were	O
similar	O
for	O
samples	O
studied	O
by	O
ME	O
-	O
PCR	O
.	O

For	O
patients	B-OrganismTaxon
treated	O
with	O
erlotinib	B-ChemicalEntity
,	O
overall	O
survival	O
was	O
correlated	O
with	O
the	O
presence	O
of	O
EGFR	B-GeneOrGeneProduct
mutation	O
in	O
plasma	O
and	O
/	O
or	O
tumor	B-DiseaseOrPhenotypicFeature
tissue	O
(	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
with	O
the	O
two	O
patients	B-OrganismTaxon
positive	O
only	O
in	O
plasma	O
DNA	O
showing	O
responses	O
and	O
favorable	O
outcomes	O
.	O

CONCLUSION	O
:	O
The	O
detection	O
of	O
EGFR	B-GeneOrGeneProduct
mutations	O
in	O
plasma	O
DNA	O
samples	O
by	O
mass	O
spectrometry	O
genotyping	O
and	O
ME	O
-	O
PCR	O
is	O
feasible	O
.	O

A	O
positive	O
EGFR	B-GeneOrGeneProduct
result	O
in	O
plasma	O
DNA	O
has	O
a	O
high	O
predictive	O
value	O
for	O
tumor	B-DiseaseOrPhenotypicFeature
EGFR	B-GeneOrGeneProduct
status	O
and	O
for	O
favorable	O
clinical	O
course	O
on	O
EGFR	B-GeneOrGeneProduct
-	O
targeted	O
therapy	O
and	O
could	O
therefore	O
be	O
useful	O
in	O
guiding	O
clinical	O
decisions	O
in	O
patients	B-OrganismTaxon
with	O
insufficient	O
or	O
unavailable	O
tumor	B-DiseaseOrPhenotypicFeature
specimens	O
.	O
Dynamic	O
subunit	O
turnover	O
in	O
ESCRT	B-GeneOrGeneProduct
-	O
III	I-GeneOrGeneProduct
assemblies	O
is	O
regulated	O
by	O
Vps4	B-GeneOrGeneProduct
to	O
mediate	O
membrane	O
remodelling	O
during	O
cytokinesis	O
.	O

The	O
endosomal	B-GeneOrGeneProduct
sorting	I-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
required	I-GeneOrGeneProduct
for	I-GeneOrGeneProduct
transport	I-GeneOrGeneProduct
(	O
ESCRT	I-GeneOrGeneProduct
)	O
-	O
III	I-GeneOrGeneProduct
mediates	O
membrane	O
fission	O
in	O
fundamental	O
cellular	O
processes	O
,	O
including	O
cytokinesis	O
.	O

ESCRT	B-GeneOrGeneProduct
-	O
III	I-GeneOrGeneProduct
is	O
thought	O
to	O
form	O
persistent	O
filaments	O
that	O
over	O
time	O
increase	O
their	O
curvature	O
to	O
constrict	O
membranes	O
.	O

Unexpectedly	O
,	O
we	O
found	O
that	O
ESCRT	B-GeneOrGeneProduct
-	O
III	I-GeneOrGeneProduct
at	O
the	O
midbody	O
of	O
human	B-OrganismTaxon
cells	O
rapidly	O
turns	O
over	O
subunits	O
with	O
cytoplasmic	O
pools	O
while	O
gradually	O
forming	O
larger	O
assemblies	O
.	O

ESCRT	B-GeneOrGeneProduct
-	O
III	I-GeneOrGeneProduct
turnover	O
depended	O
on	O
the	O
ATPase	B-GeneOrGeneProduct
VPS4	B-GeneOrGeneProduct
,	O
which	O
accumulated	O
at	O
the	O
midbody	O
simultaneously	O
with	O
ESCRT	B-GeneOrGeneProduct
-	O
III	I-GeneOrGeneProduct
subunits	O
,	O
and	O
was	O
required	O
for	O
assembly	O
of	O
functional	O
ESCRT	B-GeneOrGeneProduct
-	O
III	I-GeneOrGeneProduct
structures	O
.	O

In	O
vitro	O
,	O
the	O
Vps2	B-GeneOrGeneProduct
/	O
Vps24	B-GeneOrGeneProduct
subunits	O
of	O
ESCRT	B-GeneOrGeneProduct
-	O
III	I-GeneOrGeneProduct
formed	O
side	O
-	O
by	O
-	O
side	O
filaments	O
with	O
Snf7	B-GeneOrGeneProduct
and	O
inhibited	O
further	O
polymerization	O
,	O
but	O
the	O
growth	O
inhibition	O
was	O
alleviated	O
by	O
the	O
addition	O
of	O
Vps4	B-GeneOrGeneProduct
and	O
ATP	B-ChemicalEntity
.	O

High	O
-	O
speed	O
atomic	O
force	O
microscopy	O
further	O
revealed	O
highly	O
dynamic	O
arrays	O
of	O
growing	O
and	O
shrinking	O
ESCRT	B-GeneOrGeneProduct
-	O
III	I-GeneOrGeneProduct
spirals	O
in	O
the	O
presence	O
of	O
Vps4	B-GeneOrGeneProduct
.	O

Continuous	O
ESCRT	B-GeneOrGeneProduct
-	O
III	I-GeneOrGeneProduct
remodelling	O
by	O
subunit	O
turnover	O
might	O
facilitate	O
shape	O
adaptions	O
to	O
variable	O
membrane	O
geometries	O
,	O
with	O
broad	O
implications	O
for	O
diverse	O
cellular	O
processes	O
.	O
Acute	O
effects	O
of	O
N	B-ChemicalEntity
-	O
(	O
2	I-ChemicalEntity
-	O
propylpentanoyl	I-ChemicalEntity
)	O
urea	I-ChemicalEntity
on	O
hippocampal	O
amino	O
acid	O
neurotransmitters	O
in	O
pilocarpine	B-ChemicalEntity
-	O
induced	O
seizure	B-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
anticonvulsant	O
activity	O
as	O
well	O
as	O
the	O
effects	O
on	O
the	O
level	O
of	O
hippocampal	O
amino	O
acid	O
neurotransmitters	O
(	O
glutamate	B-ChemicalEntity
,	O
aspartate	B-ChemicalEntity
,	O
glycine	B-ChemicalEntity
and	O
GABA	B-ChemicalEntity
)	O
of	O
N	B-ChemicalEntity
-	O
(	O
2	I-ChemicalEntity
-	O
propylpentanoyl	I-ChemicalEntity
)	O
urea	I-ChemicalEntity
(	O
VPU	B-ChemicalEntity
)	O
in	O
comparison	O
to	O
its	O
parent	O
compound	O
,	O
valproic	B-ChemicalEntity
acid	I-ChemicalEntity
(	O
VPA	B-ChemicalEntity
)	O
.	O

VPU	B-ChemicalEntity
was	O
more	O
potent	O
than	O
VPA	B-ChemicalEntity
,	O
exhibiting	O
the	O
median	O
effective	O
dose	O
(	O
ED	O
(	O
50	O
)	O
)	O
of	O
49	O
mg	O
/	O
kg	O
in	O
protecting	O
rats	B-OrganismTaxon
against	O
pilocarpine	B-ChemicalEntity
-	O
induced	O
seizure	B-DiseaseOrPhenotypicFeature
whereas	O
the	O
corresponding	O
value	O
for	O
VPA	B-ChemicalEntity
was	O
322	O
mg	O
/	O
kg	O
.	O

In	O
vivo	O
microdialysis	O
demonstrated	O
that	O
an	O
intraperitoneal	O
administration	O
of	O
pilocarpine	B-ChemicalEntity
induced	O
a	O
pronounced	O
increment	O
of	O
hippocampal	O
glutamate	B-ChemicalEntity
and	O
aspartate	B-ChemicalEntity
whereas	O
no	O
significant	O
change	O
was	O
observed	O
on	O
the	O
level	O
of	O
glycine	B-ChemicalEntity
and	O
GABA	B-ChemicalEntity
.	O

Pretreatment	O
with	O
either	O
VPU	B-ChemicalEntity
(	O
50	O
and	O
100	O
mg	O
/	O
kg	O
)	O
or	O
VPA	B-ChemicalEntity
(	O
300	O
and	O
600	O
mg	O
/	O
kg	O
)	O
completely	O
abolished	O
pilocarpine	B-ChemicalEntity
-	O
evoked	O
increases	O
in	O
extracellular	O
glutamate	B-ChemicalEntity
and	O
aspartate	B-ChemicalEntity
.	O

In	O
addition	O
,	O
a	O
statistically	O
significant	O
reduction	O
was	O
also	O
observed	O
on	O
the	O
level	O
of	O
GABA	B-ChemicalEntity
and	O
glycine	B-ChemicalEntity
but	O
less	O
than	O
a	O
drastic	O
reduction	O
of	O
glutamate	B-ChemicalEntity
and	O
aspartate	B-ChemicalEntity
level	O
.	O

Based	O
on	O
the	O
finding	O
that	O
VPU	B-ChemicalEntity
and	O
VPA	B-ChemicalEntity
could	O
protect	O
the	O
animals	O
against	O
pilocarpine	B-ChemicalEntity
-	O
induced	O
seizure	B-DiseaseOrPhenotypicFeature
it	O
is	O
suggested	O
that	O
the	O
reduction	O
of	O
inhibitory	O
amino	O
acid	O
neurotransmitters	O
was	O
comparatively	O
minor	O
and	O
offset	O
by	O
a	O
pronounced	O
reduction	O
of	O
glutamate	B-ChemicalEntity
and	O
aspartate	B-ChemicalEntity
.	O

Therefore	O
,	O
like	O
VPA	B-ChemicalEntity
,	O
the	O
finding	O
that	O
VPU	B-ChemicalEntity
could	O
drastically	O
reduce	O
pilocarpine	B-ChemicalEntity
-	O
induced	O
increases	O
in	O
glutamate	B-ChemicalEntity
and	O
aspartate	B-ChemicalEntity
should	O
account	O
,	O
at	O
least	O
partly	O
,	O
for	O
its	O
anticonvulsant	O
activity	O
observed	O
in	O
pilocarpine	B-ChemicalEntity
-	O
induced	O
seizure	B-DiseaseOrPhenotypicFeature
in	O
experimental	O
animals	O
.	O

Some	O
other	O
mechanism	O
than	O
those	O
being	O
reported	O
herein	O
should	O
be	O
further	O
investigated	O
.	O
Carrier	O
frequency	O
of	O
mutation	O
657del5	B-SequenceVariant
in	O
the	O
NBS1	B-GeneOrGeneProduct
gene	O
in	O
a	O
population	O
of	O
Polish	O
pediatric	O
patients	B-OrganismTaxon
with	O
sporadic	B-DiseaseOrPhenotypicFeature
lymphoid	I-DiseaseOrPhenotypicFeature
malignancies	I-DiseaseOrPhenotypicFeature
.	O

Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
NBS	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
human	B-OrganismTaxon
autosomal	B-DiseaseOrPhenotypicFeature
recessive	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
characterized	O
by	O
genomic	O
instability	O
and	O
enhanced	O
cancer	B-DiseaseOrPhenotypicFeature
predisposition	O
,	O
in	O
particular	O
to	O
lymphoma	B-DiseaseOrPhenotypicFeature
and	O
leukemia	B-DiseaseOrPhenotypicFeature
.	O

Recently	O
,	O
significantly	O
higher	O
frequencies	O
of	O
heterozygous	O
carriers	O
of	O
the	O
Slavic	O
founder	O
NBS1	B-GeneOrGeneProduct
mutation	O
,	O
657del5	B-SequenceVariant
,	O
were	O
found	O
in	O
Russian	O
children	O
with	O
sporadic	B-DiseaseOrPhenotypicFeature
lymphoid	I-DiseaseOrPhenotypicFeature
malignancies	I-DiseaseOrPhenotypicFeature
,	O
and	O
in	O
Polish	O
adults	O
with	O
non	B-DiseaseOrPhenotypicFeature
-	O
Hodgkin	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
(	O
NHL	B-DiseaseOrPhenotypicFeature
)	O
.	O

In	O
addition	O
,	O
the	O
substitution	O
643C	B-SequenceVariant
>	O
T	I-SequenceVariant
(	O
R215W	B-SequenceVariant
)	O
has	O
also	O
been	O
found	O
in	O
excess	O
among	O
children	O
with	O
acute	B-DiseaseOrPhenotypicFeature
lymphoblastic	I-DiseaseOrPhenotypicFeature
leukemia	I-DiseaseOrPhenotypicFeature
(	O
ALL	B-DiseaseOrPhenotypicFeature
)	O
.	O

In	O
an	O
attempt	O
to	O
asses	O
the	O
contribution	O
of	O
both	O
mutations	O
to	O
the	O
development	O
of	O
sporadic	B-DiseaseOrPhenotypicFeature
lymphoid	I-DiseaseOrPhenotypicFeature
malignancies	I-DiseaseOrPhenotypicFeature
,	O
we	O
analyzed	O
DNA	O
samples	O
from	O
a	O
large	O
group	O
of	O
Polish	O
pediatric	O
patients	B-OrganismTaxon
.	O

The	O
NBS1	B-GeneOrGeneProduct
mutation	O
657del5	B-SequenceVariant
on	O
one	O
allele	O
was	O
found	O
in	O
3	O
of	O
270	O
patients	B-OrganismTaxon
with	O
ALL	B-DiseaseOrPhenotypicFeature
and	O
2	O
of	O
212	O
children	O
and	O
adolescents	O
with	O
NHL	B-DiseaseOrPhenotypicFeature
;	O
no	O
carrier	O
was	O
found	O
among	O
63	O
patients	B-OrganismTaxon
with	O
Hodgkin	B-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
(	O
HL	B-DiseaseOrPhenotypicFeature
)	O
.	O

No	O
carriers	O
of	O
the	O
variant	O
R215W	B-SequenceVariant
were	O
detected	O
in	O
any	O
studied	O
group	O
.	O

The	O
relative	O
frequency	O
of	O
the	O
657del5	B-SequenceVariant
mutation	O
was	O
calculated	O
from	O
a	O
total	O
of	O
6	O
,	O
984	O
controls	O
matched	O
by	O
place	O
of	O
patient	B-OrganismTaxon
residence	O
,	O
of	O
whom	O
42	O
were	O
found	O
to	O
be	O
carriers	O
(	O
frequency	O
=	O
0	O
.	O
006	O
)	O
.	O

In	O
the	O
analyzed	O
population	O
with	O
malignancies	B-DiseaseOrPhenotypicFeature
,	O
an	O
increased	O
odds	O
ratio	O
for	O
the	O
occurrence	O
of	O
mutation	O
657del5	B-SequenceVariant
was	O
found	O
in	O
comparison	O
with	O
the	O
control	O
Polish	O
population	O
(	O
OR	O
range	O
1	O
.	O
48	O
-	O
1	O
.	O
85	O
,	O
95%	O
confidence	O
interval	O
1	O
.	O
18	O
-	O
2	O
.	O
65	O
)	O
.	O

This	O
finding	O
indicates	O
that	O
the	O
frequency	O
of	O
the	O
mutation	O
carriers	O
was	O
indeed	O
increased	O
in	O
patients	B-OrganismTaxon
with	O
ALL	B-DiseaseOrPhenotypicFeature
and	O
NHL	B-DiseaseOrPhenotypicFeature
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Nonetheless	O
,	O
NBS1	B-GeneOrGeneProduct
gene	O
heterozygosity	O
is	O
not	O
a	O
major	O
risk	O
factor	O
for	O
lymphoid	B-DiseaseOrPhenotypicFeature
malignancies	I-DiseaseOrPhenotypicFeature
in	O
childhood	O
and	O
adolescence	O
.	O
TNFR	B-GeneOrGeneProduct
-	O
associated	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
deficiency	O
in	O
B	O
lymphocytes	O
predisposes	O
to	O
chronic	B-DiseaseOrPhenotypicFeature
lymphocytic	I-DiseaseOrPhenotypicFeature
leukemia	I-DiseaseOrPhenotypicFeature
/	O
small	B-DiseaseOrPhenotypicFeature
lymphocytic	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
in	O
mice	B-OrganismTaxon
.	O

We	O
have	O
previously	O
shown	O
that	O
transgenic	O
(	O
tg	O
)	O
mice	B-OrganismTaxon
expressing	O
in	O
B	O
lymphocytes	O
both	O
BCL	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
and	O
a	O
TNFR	B-GeneOrGeneProduct
-	O
associated	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
(	O
TRAF2	B-GeneOrGeneProduct
)	O
mutant	O
lacking	O
the	O
really	O
interesting	O
new	O
gene	O
and	O
zinc	O
finger	O
domains	O
(	O
TRAF2DN	O
)	O
develop	O
small	B-DiseaseOrPhenotypicFeature
lymphocytic	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
and	O
chronic	B-DiseaseOrPhenotypicFeature
lymphocytic	I-DiseaseOrPhenotypicFeature
leukemia	I-DiseaseOrPhenotypicFeature
with	O
high	O
incidence	O
(	O
Zapata	O
et	O
al	O
.	O

2004	O
.	O

Proc	O
.	O

Nat	O
.	O

Acad	O
.	O

Sci	O
.	O

USA	O
101	O
:	O
16600	O
-	O
16605	O
)	O
.	O

Further	O
analysis	O
of	O
the	O
expression	O
of	O
TRAF2	B-GeneOrGeneProduct
and	O
TRAF2DN	O
in	O
purified	O
B	O
cells	O
demonstrated	O
that	O
expression	O
of	O
both	O
endogenous	O
TRAF2	B-GeneOrGeneProduct
and	O
tg	O
TRAF2DN	O
was	O
negligible	O
in	O
Traf2DN	B-CellLine
-	O
tg	I-CellLine
B	I-CellLine
cells	O
compared	O
with	O
wild	O
-	O
type	O
mice	B-OrganismTaxon
.	O

This	O
was	O
the	O
result	O
of	O
proteasome	B-GeneOrGeneProduct
-	O
dependent	O
degradation	O
,	O
and	O
rendered	O
TRAF2DN	O
B	O
cells	O
as	O
bona	O
fide	O
TRAF2	B-GeneOrGeneProduct
-	O
deficient	O
B	O
cells	O
.	O

Similar	O
to	O
B	O
cells	O
with	O
targeted	O
Traf2	B-GeneOrGeneProduct
deletion	O
,	O
Traf2DN	B-CellLine
-	O
tg	I-CellLine
mice	B-OrganismTaxon
show	O
expanded	O
marginal	O
zone	O
B	O
cell	O
population	O
and	O
have	O
constitutive	O
p100	B-GeneOrGeneProduct
NF	I-GeneOrGeneProduct
-	O
kappaB2	I-GeneOrGeneProduct
processing	O
.	O

Also	O
,	O
TRAF3	B-GeneOrGeneProduct
,	O
X	B-GeneOrGeneProduct
-	O
linked	I-GeneOrGeneProduct
inhibitor	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
apoptosis	I-GeneOrGeneProduct
,	O
and	O
Bcl	B-GeneOrGeneProduct
-	O
X	I-GeneOrGeneProduct
(	O
L	I-GeneOrGeneProduct
)	O
expression	O
levels	O
were	O
increased	O
,	O
whereas	O
cellular	B-GeneOrGeneProduct
inhibitors	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
apoptosis	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
levels	O
were	O
drastically	O
reduced	O
compared	O
with	O
those	O
found	O
in	O
wild	O
-	O
type	O
B	O
cells	O
.	O

Moreover	O
,	O
consistent	O
with	O
previous	O
results	O
,	O
we	O
also	O
show	O
that	O
TRAF2	B-GeneOrGeneProduct
was	O
required	O
for	O
efficient	O
JNK	B-GeneOrGeneProduct
and	O
ERK	B-GeneOrGeneProduct
activation	O
in	O
response	O
to	O
CD40	B-GeneOrGeneProduct
engagement	O
.	O

However	O
,	O
TRAF2	B-GeneOrGeneProduct
was	O
deleterious	O
for	O
BCR	B-GeneOrGeneProduct
-	O
mediated	O
activation	O
of	O
these	O
kinases	O
.	O

In	O
contrast	O
,	O
TRAF2	B-GeneOrGeneProduct
deficiency	O
had	O
no	O
effect	O
on	O
CD40	B-GeneOrGeneProduct
-	O
mediated	O
p38	B-GeneOrGeneProduct
MAPK	I-GeneOrGeneProduct
activation	O
but	O
significantly	O
reduced	O
BCR	B-GeneOrGeneProduct
-	O
mediated	O
p38	B-GeneOrGeneProduct
activation	O
.	O

Finally	O
,	O
we	O
further	O
confirm	O
that	O
TRAF2	B-GeneOrGeneProduct
was	O
required	O
for	O
CD40	B-GeneOrGeneProduct
-	O
mediated	O
proliferation	O
,	O
but	O
its	O
absence	O
relieved	O
B	O
cells	O
of	O
the	O
need	O
for	O
B	B-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
activating	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
for	O
survival	O
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
TRAF2	B-GeneOrGeneProduct
deficiency	O
cooperates	O
with	O
BCL	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
in	O
promoting	O
chronic	B-DiseaseOrPhenotypicFeature
lymphocytic	I-DiseaseOrPhenotypicFeature
leukemia	I-DiseaseOrPhenotypicFeature
/	O
small	B-DiseaseOrPhenotypicFeature
lymphocytic	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
in	O
mice	B-OrganismTaxon
,	O
possibly	O
by	O
specifically	O
enforcing	O
marginal	O
zone	O
B	O
cell	O
accumulation	O
,	O
increasing	O
X	B-GeneOrGeneProduct
-	O
linked	I-GeneOrGeneProduct
inhibitor	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
apoptosis	I-GeneOrGeneProduct
expression	O
,	O
and	O
rendering	O
B	O
cells	O
independent	O
of	O
B	B-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
activating	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
for	O
survival	O
.	O
Association	O
of	O
adipocyte	O
genes	O
with	O
ASP	B-GeneOrGeneProduct
expression	O
:	O
a	O
microarray	O
analysis	O
of	O
subcutaneous	O
and	O
omental	O
adipose	O
tissue	O
in	O
morbidly	O
obese	B-DiseaseOrPhenotypicFeature
subjects	O
.	O

BACKGROUND	O
:	O
Prevalence	O
of	O
obesity	B-DiseaseOrPhenotypicFeature
is	O
increasing	O
to	O
pandemic	O
proportions	O
.	O

However	O
,	O
obese	B-DiseaseOrPhenotypicFeature
subjects	O
differ	O
in	O
insulin	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
,	O
adipokine	B-GeneOrGeneProduct
production	O
and	O
co	O
-	O
morbidities	O
.	O

Based	O
on	O
fasting	O
plasma	O
analysis	O
,	O
obese	B-DiseaseOrPhenotypicFeature
subjects	O
were	O
grouped	O
as	O
Low	O
Acylation	B-GeneOrGeneProduct
Stimulating	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
ASP	B-GeneOrGeneProduct
)	O
and	O
Triglyceride	B-ChemicalEntity
(	O
TG	B-ChemicalEntity
)	O
(	O
LAT	O
)	O
vs	O
High	O
ASP	B-GeneOrGeneProduct
and	O
TG	B-ChemicalEntity
(	O
HAT	O
)	O
.	O

Subcutaneous	O
(	O
SC	O
)	O
and	O
omental	O
(	O
OM	O
)	O
adipose	O
tissues	O
(	O
n	O
=	O
21	O
)	O
were	O
analysed	O
by	O
microarray	O
,	O
and	O
biologic	O
pathways	O
in	O
lipid	B-ChemicalEntity
metabolism	O
and	O
inflammation	B-DiseaseOrPhenotypicFeature
were	O
specifically	O
examined	O
.	O

METHODS	O
:	O
LAT	O
and	O
HAT	O
groups	O
were	O
matched	O
in	O
age	O
,	O
obesity	B-DiseaseOrPhenotypicFeature
,	O
insulin	B-GeneOrGeneProduct
,	O
and	O
glucose	B-ChemicalEntity
,	O
and	O
had	O
similar	O
expression	O
of	O
insulin	B-GeneOrGeneProduct
-	O
related	O
genes	O
(	O
InsR	B-GeneOrGeneProduct
,	O
IRS	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
.	O

ASP	B-GeneOrGeneProduct
related	O
genes	O
tended	O
to	O
be	O
increased	O
in	O
the	O
HAT	O
group	O
and	O
were	O
correlated	O
(	O
factor	B-GeneOrGeneProduct
B	I-GeneOrGeneProduct
,	O
adipsin	B-GeneOrGeneProduct
,	O
complement	B-GeneOrGeneProduct
C3	I-GeneOrGeneProduct
,	O
p	O
<	O
0	O
.	O
01	O
each	O
)	O
.	O

Differences	O
between	O
LAT	O
and	O
HAT	O
group	O
were	O
almost	O
exclusively	O
in	O
SC	O
tissue	O
,	O
with	O
little	O
difference	O
in	O
OM	O
tissue	O
.	O

Increased	O
C5L2	B-GeneOrGeneProduct
(	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
an	O
ASP	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
,	O
in	O
HAT	O
suggests	O
a	O
compensatory	O
ASP	B-GeneOrGeneProduct
pathway	O
,	O
associated	O
with	O
increased	O
TG	B-ChemicalEntity
storage	O
.	O

RESULTS	O
:	O
HAT	O
adipose	O
tissue	O
demonstrated	O
increased	O
lipid	B-ChemicalEntity
related	O
genes	O
for	O
storage	O
(	O
CD36	B-GeneOrGeneProduct
,	O
DGAT1	B-GeneOrGeneProduct
,	O
DGAT2	B-GeneOrGeneProduct
,	O
SCD1	B-GeneOrGeneProduct
,	O
FASN	B-GeneOrGeneProduct
,	O
and	O
LPL	B-GeneOrGeneProduct
)	O
,	O
lipolysis	O
(	O
HSL	B-GeneOrGeneProduct
,	O
CES1	B-GeneOrGeneProduct
,	O
perilipin	B-GeneOrGeneProduct
)	O
,	O
fatty	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
binding	I-GeneOrGeneProduct
proteins	I-GeneOrGeneProduct
(	O
FABP1	B-GeneOrGeneProduct
,	O
FABP3	B-GeneOrGeneProduct
)	O
and	O
adipocyte	O
differentiation	O
markers	O
(	O
CEBPalpha	B-GeneOrGeneProduct
,	O
CEBPbeta	B-GeneOrGeneProduct
,	O
PPARgamma	B-GeneOrGeneProduct
)	O
.	O

By	O
contrast	O
,	O
oxidation	O
related	O
genes	O
were	O
decreased	O
(	O
AMPK	B-GeneOrGeneProduct
,	O
UCP1	B-GeneOrGeneProduct
,	O
CPT1	B-GeneOrGeneProduct
,	O
FABP7	B-GeneOrGeneProduct
)	O
.	O

HAT	O
subjects	O
had	O
increased	O
anti	O
-	O
inflammatory	B-DiseaseOrPhenotypicFeature
genes	O
TGFB1	B-GeneOrGeneProduct
,	O
TIMP1	B-GeneOrGeneProduct
,	O
TIMP3	B-GeneOrGeneProduct
,	O
and	O
TIMP4	B-GeneOrGeneProduct
while	O
proinflammatory	B-DiseaseOrPhenotypicFeature
PIG7	B-GeneOrGeneProduct
and	O
MMP2	B-GeneOrGeneProduct
were	O
also	O
significantly	O
increased	O
;	O
all	O
genes	O
,	O
p	O
<	O
0	O
.	O
025	O
.	O

CONCLUSION	O
:	O
Taken	O
together	O
,	O
the	O
profile	O
of	O
C5L2	B-GeneOrGeneProduct
receptor	O
,	O
ASP	B-GeneOrGeneProduct
gene	O
expression	O
and	O
metabolic	O
factors	O
in	O
adipose	O
tissue	O
from	O
morbidly	O
obese	B-DiseaseOrPhenotypicFeature
HAT	O
subjects	O
suggests	O
a	O
compensatory	O
response	O
associated	O
with	O
the	O
increased	O
plasma	O
ASP	B-GeneOrGeneProduct
and	O
TG	B-ChemicalEntity
.	O
MHC	B-GeneOrGeneProduct
region	O
and	O
risk	O
of	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
in	O
African	O
American	O
women	B-OrganismTaxon
.	O

The	O
major	B-GeneOrGeneProduct
histocompatibility	I-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
(	O
MHC	B-GeneOrGeneProduct
)	O
on	O
chromosome	O
6p21	O
is	O
a	O
key	O
contributor	O
to	O
the	O
genetic	O
basis	O
of	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
(	O
SLE	B-DiseaseOrPhenotypicFeature
)	O
.	O

Although	O
SLE	B-DiseaseOrPhenotypicFeature
affects	O
African	O
Americans	O
disproportionately	O
compared	O
to	O
European	O
Americans	O
,	O
there	O
has	O
been	O
no	O
comprehensive	O
analysis	O
of	O
the	O
MHC	B-GeneOrGeneProduct
region	O
in	O
relationship	O
to	O
SLE	B-DiseaseOrPhenotypicFeature
in	O
African	O
Americans	O
.	O

We	O
conducted	O
a	O
screening	O
of	O
the	O
MHC	B-GeneOrGeneProduct
region	O
for	O
1	O
,	O
536	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
and	O
the	O
deletion	O
of	O
the	O
C4A	B-GeneOrGeneProduct
gene	O
in	O
a	O
SLE	B-DiseaseOrPhenotypicFeature
case	O
-	O
control	O
study	O
(	O
380	O
cases	O
,	O
765	O
age	O
-	O
matched	O
controls	O
)	O
nested	O
within	O
the	O
prospective	O
Black	O
Women	B-OrganismTaxon
'	O
s	O
Health	O
Study	O
.	O

We	O
also	O
genotyped	O
1	O
,	O
509	O
ancestral	O
informative	O
markers	O
throughout	O
the	O
genome	O
to	O
estimate	O
European	O
ancestry	O
to	O
control	O
for	O
population	O
stratification	O
due	O
to	O
population	O
admixture	O
.	O

The	O
most	O
strongly	O
associated	O
SNP	O
with	O
SLE	B-DiseaseOrPhenotypicFeature
was	O
the	O
rs9271366	B-SequenceVariant
(	O
odds	O
ratio	O
,	O
OR	O
=	O
1	O
.	O
70	O
,	O
p	O
=	O
5	O
.	O
6	O
10	O
(	O
-	O
5	O
)	O
)	O
near	O
the	O
HLA	B-GeneOrGeneProduct
-	O
DRB1	I-GeneOrGeneProduct
gene	O
.	O

Conditional	O
haplotype	O
analysis	O
revealed	O
three	O
other	O
SNPs	O
,	O
rs204890	B-SequenceVariant
(	O
OR	O
=	O
1	O
.	O
86	O
,	O
p	O
=	O
1	O
.	O
2	O
10	O
(	O
-	O
4	O
)	O
)	O
,	O
rs2071349	B-SequenceVariant
(	O
OR	O
=	O
1	O
.	O
53	O
,	O
p	O
=	O
1	O
.	O
0	O
10	O
(	O
-	O
3	O
)	O
)	O
,	O
and	O
rs2844580	B-SequenceVariant
(	O
OR	O
=	O
1	O
.	O
43	O
,	O
p	O
=	O
1	O
.	O
3	O
10	O
(	O
-	O
3	O
)	O
)	O
,	O
to	O
be	O
associated	O
with	O
SLE	B-DiseaseOrPhenotypicFeature
independent	O
of	O
the	O
rs9271366	B-SequenceVariant
SNP	O
.	O

In	O
univariate	O
analysis	O
,	O
the	O
OR	O
for	O
the	O
C4A	B-GeneOrGeneProduct
deletion	O
was	O
1	O
.	O
38	O
,	O
p	O
=	O
0	O
.	O
075	O
,	O
but	O
after	O
simultaneous	O
adjustment	O
for	O
the	O
other	O
four	O
SNPs	O
the	O
odds	O
ratio	O
was	O
1	O
.	O
01	O
,	O
p	O
=	O
0	O
.	O
98	O
.	O

A	O
genotype	O
score	O
combining	O
the	O
four	O
newly	O
identified	O
SNPs	O
showed	O
an	O
additive	O
risk	O
according	O
to	O
the	O
number	O
of	O
high	O
-	O
risk	O
alleles	O
(	O
OR	O
=	O
1	O
.	O
67	O
per	O
high	O
-	O
risk	O
allele	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Our	O
strongest	O
signal	O
,	O
the	O
rs9271366	B-SequenceVariant
SNP	O
,	O
was	O
also	O
associated	O
with	O
higher	O
risk	O
of	O
SLE	B-DiseaseOrPhenotypicFeature
in	O
a	O
previous	O
Chinese	O
genome	O
-	O
wide	O
association	O
study	O
(	O
GWAS	O
)	O
.	O

In	O
addition	O
,	O
two	O
SNPs	O
found	O
in	O
a	O
GWAS	O
of	O
European	O
ancestry	O
women	B-OrganismTaxon
were	O
confirmed	O
in	O
our	O
study	O
,	O
indicating	O
that	O
African	O
Americans	O
share	O
some	O
genetic	O
risk	O
factors	O
for	O
SLE	B-DiseaseOrPhenotypicFeature
with	O
European	O
and	O
Chinese	O
subjects	O
.	O

In	O
summary	O
,	O
we	O
found	O
four	O
independent	O
signals	O
in	O
the	O
MHC	B-GeneOrGeneProduct
region	O
associated	O
with	O
risk	O
of	O
SLE	B-DiseaseOrPhenotypicFeature
in	O
African	O
American	O
women	B-OrganismTaxon
.	O
Polymorphic	O
MLH1	B-GeneOrGeneProduct
and	O
risk	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	B-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Methylating	O
agents	O
are	O
effective	O
chemotherapy	O
agents	O
for	O
Hodgkin	B-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
,	O
but	O
are	O
associated	O
with	O
the	O
development	O
of	O
second	O
primary	O
cancers	B-DiseaseOrPhenotypicFeature
.	O

Cytotoxicity	B-DiseaseOrPhenotypicFeature
of	O
methylating	O
agents	O
is	O
mediated	O
primarily	O
by	O
the	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
system	O
.	O

Loss	O
of	O
MLH1	B-GeneOrGeneProduct
,	O
a	O
major	O
component	O
of	O
DNA	O
MMR	O
,	O
results	O
in	O
tolerance	O
to	O
the	O
cytotoxic	B-DiseaseOrPhenotypicFeature
effects	O
of	O
methylating	O
agents	O
and	O
persistence	O
of	O
mutagenised	O
cells	O
at	O
high	O
risk	O
of	O
malignant	O
transformation	O
.	O

We	O
hypothesised	O
that	O
a	O
common	O
substitution	O
in	O
the	O
basal	O
promoter	O
of	O
MLH1	B-GeneOrGeneProduct
(	O
position	O
-	O
93	O
,	O
rs1800734	B-SequenceVariant
)	O
modifies	O
the	O
risk	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
after	O
methylating	O
chemotherapy	O
.	O

METHODS	O
:	O
133	O
patients	B-OrganismTaxon
who	O
developed	O
cancer	B-DiseaseOrPhenotypicFeature
following	O
chemotherapy	O
and	O
/	O
or	O
radiotherapy	O
(	O
n	O
=	O
133	O
)	O
,	O
420	O
patients	B-OrganismTaxon
diagnosed	O
with	O
de	O
novo	O
myeloid	B-DiseaseOrPhenotypicFeature
leukaemia	I-DiseaseOrPhenotypicFeature
,	O
242	O
patients	B-OrganismTaxon
diagnosed	O
with	O
primary	B-DiseaseOrPhenotypicFeature
Hodgkin	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
,	O
and	O
1177	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
MLH1	B-GeneOrGeneProduct
-	O
93	O
polymorphism	O
by	O
allelic	O
discrimination	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
and	O
restriction	O
fragment	O
length	O
polymorphism	O
assay	O
.	O

Odds	O
ratios	O
and	O
95%	O
confidence	O
intervals	O
for	O
cancer	B-DiseaseOrPhenotypicFeature
risk	O
by	O
MLH1	B-GeneOrGeneProduct
-	O
93	O
polymorphism	O
status	O
,	O
and	O
stratified	O
by	O
previous	O
exposure	O
to	O
methylating	O
chemotherapy	O
,	O
were	O
calculated	O
using	O
unconditional	O
logistic	O
regression	O
.	O

RESULTS	O
:	O
Carrier	O
frequency	O
of	O
the	O
MLH1	B-GeneOrGeneProduct
-	O
93	O
variant	O
was	O
higher	O
in	O
patients	B-OrganismTaxon
who	O
developed	O
therapy	O
related	O
acute	B-DiseaseOrPhenotypicFeature
myeloid	I-DiseaseOrPhenotypicFeature
leukaemia	I-DiseaseOrPhenotypicFeature
(	O
t	O
-	O
AML	B-DiseaseOrPhenotypicFeature
)	O
(	O
75	O
.	O
0%	O
,	O
n	O
=	O
12	O
)	O
or	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
53	O
.	O
3%	O
.	O

n	O
=	O
15	O
)	O
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	B-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
compared	O
to	O
patients	B-OrganismTaxon
without	O
previous	O
methylating	O
exposure	O
(	O
t	O
-	O
AML	B-DiseaseOrPhenotypicFeature
,	O
30	O
.	O
4%	O
,	O
n	O
=	O
69	O
;	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
27	O
.	O
2%	O
,	O
n	O
=	O
22	O
)	O
.	O

The	O
MLH1	B-GeneOrGeneProduct
-	O
93	O
variant	O
allele	O
was	O
also	O
over	O
-	O
represented	O
in	O
t	O
-	O
AML	B-DiseaseOrPhenotypicFeature
cases	O
when	O
compared	O
to	O
de	O
novo	O
AML	B-DiseaseOrPhenotypicFeature
cases	O
(	O
36	O
.	O
9%	O
,	O
n	O
=	O
420	O
)	O
and	O
healthy	O
controls	O
(	O
36	O
.	O
3%	O
,	O
n	O
=	O
952	O
)	O
,	O
and	O
was	O
associated	O
with	O
a	O
significantly	O
increased	O
risk	O
of	O
developing	O
t	O
-	O
AML	B-DiseaseOrPhenotypicFeature
(	O
odds	O
ratio	O
5	O
.	O
31	O
,	O
95%	O
confidence	O
interval	O
1	O
.	O
40	O
to	O
20	O
.	O
15	O
)	O
,	O
but	O
only	O
in	O
patients	B-OrganismTaxon
previously	O
treated	O
with	O
a	O
methylating	O
agent	O
.	O

CONCLUSIONS	O
:	O
These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
common	O
polymorphism	O
at	O
position	O
-	O
93	O
in	O
the	O
core	O
promoter	O
of	O
MLH1	B-GeneOrGeneProduct
defines	O
a	O
risk	O
allele	O
for	O
the	O
development	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
after	O
methylating	O
chemotherapy	O
for	O
Hodgkin	B-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
replication	O
of	O
this	O
finding	O
in	O
larger	O
studies	O
is	O
suggested	O
.	O
Genetic	O
variation	O
in	O
the	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
gene	O
and	O
the	O
association	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
.	O

COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
is	O
a	O
key	O
enzyme	O
in	O
the	O
conversion	O
of	O
arachidonic	B-ChemicalEntity
acid	I-ChemicalEntity
to	O
prostaglandins	B-ChemicalEntity
.	O

The	O
prostaglandins	B-ChemicalEntity
produced	O
by	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
are	O
involved	O
in	O
inflammation	B-DiseaseOrPhenotypicFeature
and	O
pain	B-DiseaseOrPhenotypicFeature
response	O
in	O
different	O
tissues	O
in	O
the	O
body	O
.	O

Accumulating	O
evidence	O
from	O
epidemiologic	O
studies	O
,	O
chemical	O
carcinogen	O
-	O
induced	O
rodent	O
models	O
and	O
clinical	O
trials	O
indicate	O
that	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
plays	O
a	O
role	O
in	O
human	B-OrganismTaxon
carcinogenesis	B-DiseaseOrPhenotypicFeature
and	O
is	O
overexpressed	O
in	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
tissue	O
.	O

We	O
examined	O
whether	O
sequence	O
variants	O
in	O
the	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
gene	O
are	O
associated	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
.	O

We	O
analyzed	O
a	O
large	O
population	O
-	O
based	O
case	O
-	O
control	O
study	O
,	O
cancer	B-DiseaseOrPhenotypicFeature
prostate	I-DiseaseOrPhenotypicFeature
in	O
Sweden	O
(	O
CAPS	O
)	O
consisting	O
of	O
1	O
,	O
378	O
cases	O
and	O
782	O
controls	O
.	O

We	O
evaluated	O
16	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
spanning	O
the	O
entire	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
gene	O
in	O
94	O
subjects	O
of	O
the	O
control	O
group	O
.	O

Five	O
SNPs	O
had	O
a	O
minor	O
allele	O
frequency	O
of	O
more	O
than	O
5%	O
in	O
our	O
study	O
population	O
and	O
these	O
were	O
genotyped	O
in	O
all	O
case	O
patients	B-OrganismTaxon
and	O
control	O
subjects	O
and	O
gene	O
-	O
specific	O
haplotypes	O
were	O
constructed	O
.	O

A	O
statistically	O
significant	O
difference	O
in	O
allele	O
frequency	O
between	O
cases	O
and	O
controls	O
was	O
observed	O
for	O
2	O
of	O
the	O
SNPs	O
(	O
+	O
3100	I-SequenceVariant
T	I-SequenceVariant
/	O
G	I-SequenceVariant
and	O
+	O
8365	I-SequenceVariant
C	I-SequenceVariant
/	O
T	I-SequenceVariant
)	O
,	O
with	O
an	O
odds	O
ratio	O
of	O
0	O
.	O
78	O
(	O
95%	O
CI	O
=	O
0	O
.	O
64	O
-	O
0	O
.	O
96	O
)	O
and	O
0	O
.	O
65	O
(	O
95%	O
CI	O
=	O
0	O
.	O
45	O
-	O
0	O
.	O
94	O
)	O
respectively	O
.	O

In	O
the	O
haplotype	O
analysis	O
,	O
1	O
haplotype	O
carrying	O
the	O
variant	O
allele	O
from	O
both	O
+	O
3100	I-SequenceVariant
T	I-SequenceVariant
/	O
G	I-SequenceVariant
and	O
+	O
8365	I-SequenceVariant
C	I-SequenceVariant
/	O
T	I-SequenceVariant
,	O
with	O
a	O
population	O
frequency	O
of	O
3%	O
,	O
was	O
also	O
significantly	O
associated	O
with	O
decreased	O
risk	O
of	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
p	O
=	O
0	O
.	O
036	O
,	O
global	O
simulated	O
p	O
-	O
value	O
=	O
0	O
.	O
046	O
)	O
.	O

This	O
study	O
supports	O
the	O
hypothesis	O
that	O
inflammation	B-DiseaseOrPhenotypicFeature
is	O
involved	O
in	O
prostate	B-DiseaseOrPhenotypicFeature
carcinogenesis	I-DiseaseOrPhenotypicFeature
and	O
that	O
sequence	O
variation	O
within	O
the	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
gene	O
influence	O
the	O
risk	O
of	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O
Glutamatergic	O
neurotransmission	O
mediated	O
by	O
NMDA	B-GeneOrGeneProduct
receptors	I-GeneOrGeneProduct
in	O
the	O
inferior	O
colliculus	O
can	O
modulate	O
haloperidol	B-ChemicalEntity
-	O
induced	O
catalepsy	B-DiseaseOrPhenotypicFeature
.	O

The	O
inferior	O
colliculus	O
(	O
IC	O
)	O
is	O
primarily	O
involved	O
in	O
the	O
processing	O
of	O
auditory	O
information	O
,	O
but	O
it	O
is	O
distinguished	O
from	O
other	O
auditory	O
nuclei	O
in	O
the	O
brainstem	O
by	O
its	O
connections	O
with	O
structures	O
of	O
the	O
motor	O
system	O
.	O

Functional	O
evidence	O
relating	O
the	O
IC	O
to	O
motor	O
behavior	O
derives	O
from	O
experiments	O
showing	O
that	O
activation	O
of	O
the	O
IC	O
by	O
electrical	O
stimulation	O
or	O
excitatory	O
amino	O
acid	O
microinjection	O
causes	O
freezing	O
,	O
escape	O
-	O
like	O
behavior	O
,	O
and	O
immobility	O
.	O

However	O
,	O
the	O
nature	O
of	O
this	O
immobility	O
is	O
still	O
unclear	O
.	O

The	O
present	O
study	O
examined	O
the	O
influence	O
of	O
excitatory	O
amino	O
acid	O
-	O
mediated	O
mechanisms	O
in	O
the	O
IC	O
on	O
the	O
catalepsy	B-DiseaseOrPhenotypicFeature
induced	O
by	O
the	O
dopamine	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
blocker	O
haloperidol	B-ChemicalEntity
administered	O
systemically	O
(	O
1	O
or	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
in	O
rats	B-OrganismTaxon
.	O

Haloperidol	B-ChemicalEntity
-	O
induced	O
catalepsy	B-DiseaseOrPhenotypicFeature
was	O
challenged	O
with	O
prior	O
intracollicular	O
microinjections	O
of	O
glutamate	B-GeneOrGeneProduct
NMDA	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
antagonists	O
,	O
MK	B-ChemicalEntity
-	O
801	I-ChemicalEntity
(	O
15	O
or	O
30	O
mmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
and	O
AP7	B-ChemicalEntity
(	O
10	O
or	O
20	O
nmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
,	O
or	O
of	O
the	O
NMDA	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
agonist	O
N	B-ChemicalEntity
-	O
methyl	I-ChemicalEntity
-	O
d	I-ChemicalEntity
-	O
aspartate	I-ChemicalEntity
(	O
NMDA	B-ChemicalEntity
,	O
20	O
or	O
30	O
nmol	O
/	O
0	O
.	O
5	O
microl	O
)	O
.	O

The	O
results	O
showed	O
that	O
intracollicular	O
microinjection	O
of	O
MK	B-ChemicalEntity
-	O
801	I-ChemicalEntity
and	O
AP7	B-ChemicalEntity
previous	O
to	O
systemic	O
injections	O
of	O
haloperidol	B-ChemicalEntity
significantly	O
attenuated	O
the	O
catalepsy	B-DiseaseOrPhenotypicFeature
,	O
as	O
indicated	O
by	O
a	O
reduced	O
latency	O
to	O
step	O
down	O
from	O
a	O
horizontal	O
bar	O
.	O

Accordingly	O
,	O
intracollicular	O
microinjection	O
of	O
NMDA	B-ChemicalEntity
increased	O
the	O
latency	O
to	O
step	O
down	O
the	O
bar	O
.	O

These	O
findings	O
suggest	O
that	O
glutamate	B-ChemicalEntity
-	O
mediated	O
mechanisms	O
in	O
the	O
neural	O
circuits	O
at	O
the	O
IC	O
level	O
influence	O
haloperidol	B-ChemicalEntity
-	O
induced	O
catalepsy	B-DiseaseOrPhenotypicFeature
and	O
participate	O
in	O
the	O
regulation	O
of	O
motor	O
activity	O
.	O
Antioxidant	B-ChemicalEntity
effects	O
of	O
bovine	B-OrganismTaxon
lactoferrin	B-GeneOrGeneProduct
on	O
dexamethasone	B-ChemicalEntity
-	O
induced	O
hypertension	B-DiseaseOrPhenotypicFeature
in	O
rat	B-OrganismTaxon
.	O

Dexamethasone	B-ChemicalEntity
-	O
(	O
Dex	B-ChemicalEntity
-	O
)	O
induced	O
hypertension	B-DiseaseOrPhenotypicFeature
is	O
associated	O
with	O
enhanced	O
oxidative	O
stress	O
.	O

Lactoferrin	B-GeneOrGeneProduct
(	O
LF	B-GeneOrGeneProduct
)	O
is	O
an	O
iron	B-ChemicalEntity
-	O
binding	O
glycoprotein	B-GeneOrGeneProduct
with	O
antihypertensive	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	B-GeneOrGeneProduct
on	O
oxidative	O
stress	O
and	O
hypertension	B-DiseaseOrPhenotypicFeature
upon	O
Dex	B-ChemicalEntity
administration	O
.	O

Male	O
Wistar	O
rats	B-OrganismTaxon
were	O
treated	O
by	O
Dex	B-ChemicalEntity
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
day	O
subcutaneously	O
)	O
or	O
saline	O
for	O
14	O
days	O
.	O

Oral	O
bovine	B-OrganismTaxon
LF	B-GeneOrGeneProduct
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reversal	O
study	O
.	O

In	O
a	O
prevention	O
study	O
,	O
rats	B-OrganismTaxon
received	O
4	O
days	O
of	O
LF	B-GeneOrGeneProduct
treatment	O
followed	O
by	O
Dex	B-ChemicalEntity
and	O
continued	O
during	O
the	O
test	O
period	O
.	O

Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
using	O
tail	O
-	O
cuff	O
method	O
.	O

Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	B-ChemicalEntity
activity	O
.	O

Plasma	O
hydrogen	B-ChemicalEntity
peroxide	I-ChemicalEntity
(	O
H2O2	B-ChemicalEntity
)	O
concentration	O
and	O
ferric	B-ChemicalEntity
reducing	O
antioxidant	O
power	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O

Dexamethasone	B-ChemicalEntity
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	B-ChemicalEntity
level	O
and	O
decreased	O
thymus	O
and	O
body	O
weights	O
.	O

LF	B-GeneOrGeneProduct
lowered	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
dose	O
dependently	O
prevented	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
Dex	B-ChemicalEntity
-	O
induced	O
hypertension	B-DiseaseOrPhenotypicFeature
.	O

LF	B-GeneOrGeneProduct
prevented	O
body	O
weight	B-DiseaseOrPhenotypicFeature
loss	I-DiseaseOrPhenotypicFeature
and	O
significantly	O
reduced	O
the	O
elevated	O
plasma	O
H2O2	B-ChemicalEntity
and	O
increased	O
FRAP	O
values	O
.	O

Chronic	O
administration	O
of	O
LF	B-GeneOrGeneProduct
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	B-ChemicalEntity
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex	B-ChemicalEntity
-	O
induced	O
hypertension	B-DiseaseOrPhenotypicFeature
,	O
suggesting	O
the	O
role	O
of	O
inhibition	O
of	O
oxidative	O
stress	O
as	O
another	O
mechanism	O
of	O
antihypertensive	O
action	O
of	O
LF	B-GeneOrGeneProduct
.	O
Role	O
of	O
protein	B-GeneOrGeneProduct
arginine	I-GeneOrGeneProduct
methyltransferase	I-GeneOrGeneProduct
5	I-GeneOrGeneProduct
in	O
inflammation	B-DiseaseOrPhenotypicFeature
and	O
migration	O
of	O
fibroblast	O
-	O
like	O
synoviocytes	O
in	O
rheumatoid	B-DiseaseOrPhenotypicFeature
arthritis	I-DiseaseOrPhenotypicFeature
.	O

To	O
probe	O
the	O
role	O
of	O
protein	B-GeneOrGeneProduct
arginine	I-GeneOrGeneProduct
methyltransferase	I-GeneOrGeneProduct
5	I-GeneOrGeneProduct
(	O
PRMT5	B-GeneOrGeneProduct
)	O
in	O
regulating	O
inflammation	B-DiseaseOrPhenotypicFeature
,	O
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
fibroblast	O
-	O
like	O
synoviocytes	O
(	O
FLSs	O
)	O
from	O
patients	B-OrganismTaxon
with	O
rheumatoid	B-DiseaseOrPhenotypicFeature
arthritis	I-DiseaseOrPhenotypicFeature
(	O
RA	B-DiseaseOrPhenotypicFeature
)	O
.	O

FLSs	O
were	O
separated	O
from	O
synovial	O
tissues	O
(	O
STs	O
)	O
from	O
patients	B-OrganismTaxon
with	O
RA	B-DiseaseOrPhenotypicFeature
and	O
osteoarthritis	B-DiseaseOrPhenotypicFeature
(	O
OA	B-DiseaseOrPhenotypicFeature
)	O
.	O

An	O
inhibitor	O
of	O
PRMT5	B-GeneOrGeneProduct
(	O
EPZ015666	B-ChemicalEntity
)	O
and	O
short	O
interference	O
RNA	O
(	O
siRNA	O
)	O
against	O
PRMT5	B-GeneOrGeneProduct
were	O
used	O
to	O
inhibit	O
PRMT5	B-GeneOrGeneProduct
expression	O
.	O

The	O
standard	O
of	O
protein	O
was	O
measured	O
by	O
Western	O
blot	O
or	O
immunofluorescence	O
.	O

The	O
excretion	O
and	O
genetic	O
expression	O
of	O
inflammatory	B-DiseaseOrPhenotypicFeature
factors	O
were	O
,	O
respectively	O
,	O
estimated	O
by	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
and	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

Migration	O
and	O
invasion	O
in	O
vitro	O
were	O
detected	O
by	O
Boyden	O
chamber	O
assay	O
.	O

FLSs	O
proliferation	O
was	O
detected	O
by	O
BrdU	O
incorporation	O
.	O

Increased	O
PRMT5	B-GeneOrGeneProduct
was	O
discovered	O
in	O
STs	O
and	O
FLSs	O
from	O
patients	B-OrganismTaxon
with	O
RA	B-DiseaseOrPhenotypicFeature
.	O

In	O
RA	B-DiseaseOrPhenotypicFeature
FLSs	O
,	O
the	O
level	O
of	O
PRMT5	B-GeneOrGeneProduct
was	O
up	O
-	O
regulated	O
by	O
stimulation	O
with	O
IL	B-GeneOrGeneProduct
-	O
1b	I-GeneOrGeneProduct
and	O
TNF	B-GeneOrGeneProduct
-	O
a	I-GeneOrGeneProduct
.	O

Inhibition	O
of	O
PRMT5	B-GeneOrGeneProduct
by	O
EPZ015666	B-ChemicalEntity
and	O
siRNA	O
-	O
mediated	O
knockdown	O
reduced	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
and	O
IL	B-GeneOrGeneProduct
-	O
8	I-GeneOrGeneProduct
production	O
,	O
and	O
proliferation	O
of	O
RA	B-DiseaseOrPhenotypicFeature
FLSs	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
PRMT5	B-GeneOrGeneProduct
decreased	O
in	O
vitro	O
migration	O
and	O
invasion	O
of	O
RA	B-DiseaseOrPhenotypicFeature
FLSs	O
.	O

Furthermore	O
,	O
EPZ015666	B-ChemicalEntity
restrained	O
the	O
phosphorylation	O
of	O
IkB	B-GeneOrGeneProduct
kinaseb	I-GeneOrGeneProduct
and	O
IkBa	B-GeneOrGeneProduct
,	O
as	O
well	O
as	O
nucleus	O
transsituation	O
of	O
p65	B-GeneOrGeneProduct
as	O
well	O
as	O
AKT	B-GeneOrGeneProduct
in	O
FLSs	O
.	O

PRMT5	B-GeneOrGeneProduct
regulated	O
the	O
production	O
of	O
inflammatory	B-DiseaseOrPhenotypicFeature
factors	O
,	O
cell	O
proliferation	O
,	O
migration	O
and	O
invasion	O
of	O
RA	B-DiseaseOrPhenotypicFeature
FLS	O
,	O
which	O
was	O
mediated	O
by	O
the	O
NF	B-GeneOrGeneProduct
-	O
kB	I-GeneOrGeneProduct
and	O
AKT	B-GeneOrGeneProduct
pathways	O
.	O

Our	O
data	O
suggested	O
that	O
targeting	O
PRMT5	B-GeneOrGeneProduct
to	O
prevent	O
synovial	B-DiseaseOrPhenotypicFeature
inflammation	I-DiseaseOrPhenotypicFeature
and	O
destruction	O
might	O
be	O
a	O
promising	O
therapy	O
for	O
RA	B-DiseaseOrPhenotypicFeature
.	O
Protein	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
C	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
-	O
dependent	O
signaling	O
mediates	O
endometrial	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
growth	O
and	O
tumorigenesis	B-DiseaseOrPhenotypicFeature
.	O

Endometrial	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
is	O
the	O
most	O
common	O
invasive	O
gynecologic	B-DiseaseOrPhenotypicFeature
malignancy	I-DiseaseOrPhenotypicFeature
,	O
yet	O
molecular	O
mechanisms	O
and	O
signaling	O
pathways	O
underlying	O
its	O
etiology	O
and	O
pathophysiology	O
remain	O
poorly	O
characterized	O
.	O

We	O
sought	O
to	O
define	O
a	O
functional	O
role	O
for	O
the	O
protein	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
C	I-GeneOrGeneProduct
(	O
PKC	B-GeneOrGeneProduct
)	O
isoform	O
,	O
PKCalpha	B-GeneOrGeneProduct
,	O
in	O
an	O
established	O
cell	O
model	O
of	O
endometrial	B-DiseaseOrPhenotypicFeature
adenocarcinoma	I-DiseaseOrPhenotypicFeature
.	O

Ishikawa	B-CellLine
cells	O
depleted	O
of	O
PKCalpha	B-GeneOrGeneProduct
protein	O
grew	O
slower	O
,	O
formed	O
fewer	O
colonies	O
in	O
anchorage	O
-	O
independent	O
growth	O
assays	O
and	O
exhibited	O
impaired	O
xenograft	O
tumor	B-DiseaseOrPhenotypicFeature
formation	O
in	O
nude	O
mice	B-OrganismTaxon
.	O

Consistent	O
with	O
impaired	O
growth	O
,	O
PKCalpha	B-GeneOrGeneProduct
knockdown	O
increased	O
levels	O
of	O
the	O
cyclin	B-GeneOrGeneProduct
-	O
dependent	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
(	O
CDK	B-GeneOrGeneProduct
)	O
inhibitors	O
p21	B-GeneOrGeneProduct
(	O
Cip1	B-GeneOrGeneProduct
/	O
WAF1	B-GeneOrGeneProduct
)	O
(	O
p21	B-GeneOrGeneProduct
)	O
and	O
p27	B-GeneOrGeneProduct
(	O
Kip1	B-GeneOrGeneProduct
)	O
(	O
p27	B-GeneOrGeneProduct
)	O
.	O

Despite	O
the	O
absence	O
of	O
functional	O
phosphatase	B-GeneOrGeneProduct
and	I-GeneOrGeneProduct
tensin	I-GeneOrGeneProduct
homolog	I-GeneOrGeneProduct
(	O
PTEN	B-GeneOrGeneProduct
)	O
protein	O
in	O
Ishikawa	B-CellLine
cells	O
,	O
PKCalpha	B-GeneOrGeneProduct
knockdown	O
reduced	O
Akt	B-GeneOrGeneProduct
phosphorylation	O
at	O
serine	B-SequenceVariant
473	I-SequenceVariant
and	O
concomitantly	O
inhibited	O
phosphorylation	O
of	O
the	O
Akt	B-GeneOrGeneProduct
target	O
,	O
glycogen	B-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
-	O
3beta	I-GeneOrGeneProduct
(	O
GSK	B-GeneOrGeneProduct
-	O
3beta	I-GeneOrGeneProduct
)	O
.	O

PKCalpha	B-GeneOrGeneProduct
knockdown	O
also	O
resulted	O
in	O
decreased	O
basal	O
ERK	B-GeneOrGeneProduct
phosphorylation	O
and	O
attenuated	O
ERK	B-GeneOrGeneProduct
activation	O
following	O
EGF	B-GeneOrGeneProduct
stimulation	O
.	O

p21	B-GeneOrGeneProduct
and	O
p27	B-GeneOrGeneProduct
expression	O
was	O
not	O
increased	O
by	O
treatment	O
of	O
Ishikawa	B-CellLine
cells	O
with	O
ERK	B-GeneOrGeneProduct
and	O
Akt	B-GeneOrGeneProduct
inhibitors	O
,	O
suggesting	O
that	O
PKCalpha	B-GeneOrGeneProduct
regulates	O
CDK	B-GeneOrGeneProduct
expression	O
independently	O
of	O
Akt	B-GeneOrGeneProduct
and	O
ERK	B-GeneOrGeneProduct
.	O

Immunohistochemical	O
analysis	O
of	O
Grade	O
1	O
endometrioid	B-DiseaseOrPhenotypicFeature
adenocarcinoma	I-DiseaseOrPhenotypicFeature
revealed	O
aberrant	O
PKCalpha	B-GeneOrGeneProduct
expression	O
,	O
with	O
foci	O
of	O
elevated	O
PKCalpha	B-GeneOrGeneProduct
staining	O
,	O
not	O
observed	O
in	O
normal	O
endometrium	O
.	O

These	O
studies	O
demonstrate	O
a	O
critical	O
role	O
for	O
PKCalpha	B-GeneOrGeneProduct
signaling	O
in	O
endometrial	O
tumorigenesis	B-DiseaseOrPhenotypicFeature
by	O
regulating	O
expression	O
of	O
CDK	B-GeneOrGeneProduct
inhibitors	O
p21	B-GeneOrGeneProduct
and	O
p27	B-GeneOrGeneProduct
and	O
activation	O
of	O
Akt	B-GeneOrGeneProduct
and	O
ERK	B-GeneOrGeneProduct
-	O
dependent	O
proliferative	O
pathways	O
.	O

Thus	O
,	O
targeting	O
PKCalpha	B-GeneOrGeneProduct
may	O
provide	O
novel	O
therapeutic	O
options	O
in	O
endometrial	B-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
.	O
Common	O
BRCA2	B-GeneOrGeneProduct
variants	O
and	O
modification	O
of	O
breast	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
in	O
BRCA1	B-GeneOrGeneProduct
mutation	O
carriers	O
.	O

The	O
HH	O
genotype	O
of	O
the	O
nonconservative	O
amino	O
acid	O
substitution	O
polymorphism	O
N372H	B-SequenceVariant
in	O
the	O
BRCA2	B-GeneOrGeneProduct
gene	O
was	O
reported	O
to	O
be	O
associated	O
with	O
a	O
1	O
.	O
3	O
-	O
to	O
1	O
.	O
5	O
-	O
fold	O
increase	O
in	O
risk	O
of	O
both	O
breast	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

As	O
these	O
studies	O
concerned	O
sporadic	O
cancer	B-DiseaseOrPhenotypicFeature
cases	O
,	O
we	O
investigated	O
whether	O
N372H	B-SequenceVariant
and	O
another	O
common	O
variant	O
located	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
(	O
203G	B-SequenceVariant
>	O
A	I-SequenceVariant
)	O
of	O
the	O
BRCA2	B-GeneOrGeneProduct
gene	O
modify	O
breast	B-DiseaseOrPhenotypicFeature
or	I-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
in	O
BRCA1	B-GeneOrGeneProduct
mutation	O
carriers	O
.	O

The	O
study	O
includes	O
778	O
women	B-OrganismTaxon
carrying	O
a	O
BRCA1	B-GeneOrGeneProduct
germ	O
-	O
line	O
mutation	O
belonging	O
to	O
403	O
families	O
.	O

The	O
two	O
BRCA2	B-GeneOrGeneProduct
variants	O
were	O
analyzed	O
by	O
the	O
TaqMan	O
allelic	O
discrimination	O
technique	O
.	O

Genotypes	O
were	O
analyzed	O
by	O
disease	O
-	O
free	O
survival	O
analysis	O
using	O
a	O
Cox	O
proportional	O
hazards	O
model	O
.	O

We	O
found	O
no	O
evidence	O
of	O
a	O
significant	O
modification	O
of	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
penetrance	O
in	O
BRCA1	B-GeneOrGeneProduct
mutation	O
carriers	O
by	O
either	O
polymorphism	O
.	O

In	O
respect	O
of	O
ovarian	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
,	O
we	O
also	O
saw	O
no	O
effect	O
with	O
the	O
N372H	B-SequenceVariant
variant	O
but	O
we	O
did	O
observe	O
a	O
borderline	O
association	O
with	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
203A	B-SequenceVariant
allele	O
(	O
hazard	O
ratio	O
,	O
1	O
.	O
43	O
;	O
CI	O
,	O
1	O
.	O
01	O
-	O
2	O
.	O
00	O
)	O
.	O

In	O
contrast	O
to	O
the	O
result	O
of	O
Healey	O
et	O
al	O
.	O

on	O
newborn	O
females	O
and	O
adult	O
female	O
controls	O
,	O
we	O
found	O
no	O
departure	O
from	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
in	O
the	O
distribution	O
of	O
N372H	B-SequenceVariant
alleles	O
for	O
our	O
female	O
BRCA1	B-GeneOrGeneProduct
carriers	O
.	O

We	O
conclude	O
that	O
if	O
these	O
single	O
-	O
nucleotide	O
polymorphisms	O
do	O
modify	O
the	O
risk	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
in	O
BRCA1	B-GeneOrGeneProduct
mutation	O
carriers	O
,	O
their	O
effects	O
are	O
not	O
significantly	O
larger	O
than	O
that	O
of	O
N372H	B-SequenceVariant
previously	O
observed	O
in	O
the	O
general	O
population	O
.	O
New	O
mutations	O
,	O
hotspots	O
,	O
and	O
founder	O
effects	O
in	O
Brazilian	O
patients	B-OrganismTaxon
with	O
steroid	B-DiseaseOrPhenotypicFeature
5alpha	I-DiseaseOrPhenotypicFeature
-	O
reductase	I-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
.	O

Mutations	O
of	O
the	O
steroid	B-GeneOrGeneProduct
5alpha	I-GeneOrGeneProduct
-	O
reductase	I-GeneOrGeneProduct
type	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
(	O
SRD5A2	B-GeneOrGeneProduct
)	O
gene	O
in	O
46	O
,	O
XY	O
subjects	O
cause	O
masculinization	O
defects	O
of	O
varying	O
degrees	O
,	O
due	O
to	O
reduced	O
or	O
impaired	O
enzymatic	O
activity	O
.	O

In	O
this	O
study	O
,	O
sequence	O
abnormalities	O
of	O
the	O
SRD5A2	B-GeneOrGeneProduct
gene	O
were	O
assessed	O
by	O
polymerase	O
chain	O
reaction	O
with	O
specific	O
primers	O
and	O
automated	O
sequencing	O
analysis	O
in	O
DNA	O
samples	O
from	O
20	O
patients	B-OrganismTaxon
with	O
suspected	O
steroid	B-DiseaseOrPhenotypicFeature
5alpha	I-DiseaseOrPhenotypicFeature
-	O
reductase	I-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
2	I-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
from	O
18	O
Brazilian	O
families	O
.	O

Eleven	O
subjects	O
presented	O
SRD5A2	B-GeneOrGeneProduct
homozygous	O
single	O
-	O
base	O
mutations	O
(	O
two	O
first	O
cousins	O
and	O
four	O
unrelated	O
patients	B-OrganismTaxon
with	O
G183S	B-SequenceVariant
,	O
two	O
with	O
R246W	B-SequenceVariant
,	O
one	O
with	O
del642T	B-SequenceVariant
,	O
one	O
with	O
G196S	B-SequenceVariant
,	O
and	O
one	O
with	O
217_218insC	B-SequenceVariant
plus	O
the	O
A49T	B-SequenceVariant
variant	O
in	O
heterozygosis	O
)	O
,	O
whereas	O
four	O
were	O
compound	O
heterozygotes	O
(	O
one	O
with	O
Q126R	B-SequenceVariant
/	O
IVS3	B-SequenceVariant
+	O
1G	I-SequenceVariant
>	O
A	I-SequenceVariant
,	O
one	O
with	O
Q126R	B-SequenceVariant
/	O
del418T	B-SequenceVariant
,	O
and	O
two	O
brothers	O
with	O
Q126R	B-SequenceVariant
/	O
G158R	B-SequenceVariant
)	O
.	O

Three	O
patients	B-OrganismTaxon
were	O
heterozygous	O
for	O
A207D	B-SequenceVariant
,	O
G196S	B-SequenceVariant
,	O
and	O
R266W	B-SequenceVariant
substitutions	O
.	O

The	O
V89L	B-SequenceVariant
polymorphism	O
was	O
found	O
in	O
heterozygosis	O
in	O
one	O
of	O
them	O
(	O
with	O
A207D	B-SequenceVariant
)	O
and	O
in	O
one	O
case	O
with	O
an	O
otherwise	O
normal	O
gene	O
sequence	O
.	O

The	O
A49T	B-SequenceVariant
variant	O
was	O
also	O
detected	O
in	O
heterozygosis	O
in	O
the	O
second	O
case	O
without	O
other	O
sequencing	O
abnormalities	O
.	O

Four	O
patients	B-OrganismTaxon
harbor	O
yet	O
non	O
-	O
described	O
SRD5A2	B-GeneOrGeneProduct
gene	O
mutations	O
:	O
a	O
single	O
nucleotide	O
deletion	O
(	O
del642T	B-SequenceVariant
)	O
,	O
a	O
G158R	B-SequenceVariant
amino	O
acid	O
substitution	O
,	O
a	O
splice	O
junction	O
mutation	O
(	O
IVS3	B-SequenceVariant
+	O
1G	I-SequenceVariant
>	O
A	I-SequenceVariant
)	O
,	O
and	O
the	O
insertion	O
of	O
a	O
cytosine	O
(	O
217_218insC	B-SequenceVariant
)	O
occurring	O
at	O
a	O
CCCC	O
motif	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
single	O
-	O
nucleotide	O
insertion	O
in	O
the	O
coding	O
sequence	O
of	O
the	O
SRD5A2	B-GeneOrGeneProduct
gene	O
.	O

In	O
addition	O
to	O
these	O
new	O
mutations	O
,	O
this	O
investigation	O
reveals	O
the	O
prevalence	O
of	O
G183S	B-SequenceVariant
substitution	O
among	O
a	O
subset	O
of	O
African	O
-	O
Brazilian	O
patients	B-OrganismTaxon
and	O
presents	O
evidences	O
of	O
the	O
recurrence	O
of	O
already	O
known	O
mutations	O
.	O
Effects	O
of	O
ginsenosides	B-ChemicalEntity
on	O
opioid	B-ChemicalEntity
-	O
induced	O
hyperalgesia	B-DiseaseOrPhenotypicFeature
in	O
mice	B-OrganismTaxon
.	O

Opioid	B-ChemicalEntity
-	O
induced	O
hyperalgesia	B-DiseaseOrPhenotypicFeature
(	O
OIH	B-DiseaseOrPhenotypicFeature
)	O
is	O
characterized	O
by	O
nociceptive	O
sensitization	O
caused	O
by	O
the	O
cessation	O
of	O
chronic	O
opioid	B-ChemicalEntity
use	O
.	O

OIH	B-DiseaseOrPhenotypicFeature
can	O
limit	O
the	O
clinical	O
use	O
of	O
opioid	B-ChemicalEntity
analgesics	O
and	O
complicate	O
withdrawal	O
from	O
opioid	B-DiseaseOrPhenotypicFeature
addiction	I-DiseaseOrPhenotypicFeature
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
Re	B-ChemicalEntity
,	O
Rg1	I-ChemicalEntity
,	O
and	I-ChemicalEntity
Rb1	I-ChemicalEntity
ginsenosides	I-ChemicalEntity
,	O
the	O
bioactive	O
components	O
of	O
ginseng	B-OrganismTaxon
,	O
on	O
OIH	B-DiseaseOrPhenotypicFeature
.	O

OIH	B-DiseaseOrPhenotypicFeature
was	O
achieved	O
in	O
mice	B-OrganismTaxon
after	O
subcutaneous	O
administration	O
of	O
morphine	B-ChemicalEntity
for	O
7	O
consecutive	O
days	O
three	O
times	O
per	O
day	O
.	O

During	O
withdrawal	O
(	O
days	O
8	O
and	O
9	O
)	O
,	O
these	O
mice	B-OrganismTaxon
were	O
administered	O
Re	B-ChemicalEntity
,	O
Rg1	B-ChemicalEntity
,	O
or	O
Rb1	B-ChemicalEntity
intragastrically	O
two	O
times	O
per	O
day	O
.	O

On	O
the	O
test	O
day	O
(	O
day	O
10	O
)	O
,	O
mice	B-OrganismTaxon
were	O
subjected	O
to	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-ChemicalEntity
acid	I-ChemicalEntity
-	O
induced	O
writhing	O
test	O
.	O

Re	B-ChemicalEntity
(	O
300	O
mg	O
/	O
kg	O
)	O
inhibited	O
OIH	B-DiseaseOrPhenotypicFeature
in	O
both	O
the	O
thermal	O
sensitivity	O
test	O
and	O
the	O
acetic	B-ChemicalEntity
acid	I-ChemicalEntity
-	O
induced	O
writhing	O
test	O
.	O

However	O
,	O
the	O
Rg1	B-ChemicalEntity
and	I-ChemicalEntity
Rb1	I-ChemicalEntity
ginsenosides	I-ChemicalEntity
failed	O
to	O
prevent	O
OIH	B-DiseaseOrPhenotypicFeature
in	O
either	O
test	O
.	O

Furthermore	O
,	O
Rg1	B-ChemicalEntity
showed	O
a	O
tendency	O
to	O
aggravate	O
OIH	B-DiseaseOrPhenotypicFeature
in	O
the	O
acetic	B-ChemicalEntity
acid	I-ChemicalEntity
-	O
induced	O
writhing	O
test	O
.	O

Our	O
data	O
suggested	O
that	O
the	O
ginsenoside	B-ChemicalEntity
Re	I-ChemicalEntity
,	O
but	O
not	O
Rg1	B-ChemicalEntity
or	O
Rb1	B-ChemicalEntity
,	O
may	O
contribute	O
toward	O
reversal	O
of	O
OIH	B-DiseaseOrPhenotypicFeature
.	O
Association	O
study	O
of	O
complement	B-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
H	I-GeneOrGeneProduct
,	O
C2	B-GeneOrGeneProduct
,	O
CFB	B-GeneOrGeneProduct
,	O
and	O
C3	B-GeneOrGeneProduct
and	O
age	B-DiseaseOrPhenotypicFeature
-	O
related	I-DiseaseOrPhenotypicFeature
macular	I-DiseaseOrPhenotypicFeature
degeneration	I-DiseaseOrPhenotypicFeature
in	O
a	O
Han	O
Chinese	O
population	O
.	O

PURPOSE	O
:	O
Genes	O
in	O
the	O
complement	O
pathway	O
,	O
including	O
complement	B-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
H	I-GeneOrGeneProduct
(	O
CFH	B-GeneOrGeneProduct
)	O
,	O
C2	B-GeneOrGeneProduct
/	O
BF	I-GeneOrGeneProduct
,	O
and	O
C3	B-GeneOrGeneProduct
,	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
age	B-DiseaseOrPhenotypicFeature
-	O
related	I-DiseaseOrPhenotypicFeature
macular	I-DiseaseOrPhenotypicFeature
degeneration	I-DiseaseOrPhenotypicFeature
(	O
AMD	B-DiseaseOrPhenotypicFeature
)	O
.	O

Genetic	O
variants	O
,	O
single	O
-	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
,	O
in	O
these	O
genes	O
were	O
geno	O
-	O
typed	O
for	O
a	O
case	O
-	O
control	O
association	O
study	O
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O

METHODS	O
:	O
One	O
hundred	O
and	O
fifty	O
-	O
eight	O
patients	B-OrganismTaxon
with	O
wet	O
AMD	B-DiseaseOrPhenotypicFeature
,	O
80	O
patients	B-OrganismTaxon
with	O
soft	O
drusen	B-DiseaseOrPhenotypicFeature
,	O
and	O
220	O
matched	O
control	O
subjects	O
were	O
recruited	O
among	O
Han	O
Chinese	O
in	O
mainland	O
China	O
.	O

Seven	O
SNPs	O
in	O
CFH	B-GeneOrGeneProduct
and	O
two	O
SNPs	O
in	O
C2	B-GeneOrGeneProduct
,	O
CFB	B-GeneOrGeneProduct
'	O
,	O
and	O
C3	B-GeneOrGeneProduct
were	O
genotyped	O
using	O
the	O
ABI	O
SNaPshot	O
method	O
.	O

A	O
deletion	O
of	O
84	O
,	O
682	O
base	O
pairs	O
covering	O
the	O
CFHR1	B-GeneOrGeneProduct
and	O
CFHR3	B-GeneOrGeneProduct
genes	O
was	O
detected	O
by	O
direct	O
polymerase	O
chain	O
reaction	O
and	O
gel	O
electrophoresis	O
.	O

RESULTS	O
:	O
Four	O
SNPs	O
,	O
including	O
rs3753394	B-SequenceVariant
(	O
P	O
=	O
0	O
.	O
0276	O
)	O
,	O
rs800292	B-SequenceVariant
(	O
P	O
=	O
0	O
.	O
0266	O
)	O
,	O
rs1061170	B-SequenceVariant
(	O
P	O
=	O
0	O
.	O
00514	O
)	O
,	O
and	O
rs1329428	B-SequenceVariant
(	O
P	O
=	O
0	O
.	O
0089	O
)	O
,	O
in	O
CFH	B-GeneOrGeneProduct
showed	O
a	O
significant	O
association	O
with	O
wet	O
AMD	B-DiseaseOrPhenotypicFeature
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O

A	O
haplotype	O
containing	O
these	O
four	O
SNPs	O
(	O
CATA	O
)	O
significantly	O
increased	O
protection	O
of	O
wet	O
AMD	B-DiseaseOrPhenotypicFeature
with	O
a	O
P	O
value	O
of	O
0	O
.	O
0005	O
and	O
an	O
odds	O
ratio	O
of	O
0	O
.	O
29	O
(	O
95%	O
confidence	O
interval	O
:	O
0	O
.	O
15	O
-	O
0	O
.	O
60	O
)	O
.	O

Unlike	O
in	O
other	O
populations	O
,	O
rs2274700	B-SequenceVariant
and	O
rs1410996	B-SequenceVariant
did	O
not	O
show	O
a	O
significant	O
association	O
with	O
AMD	B-DiseaseOrPhenotypicFeature
in	O
the	O
Chinese	O
population	O
of	O
this	O
study	O
.	O

None	O
of	O
the	O
SNPs	O
in	O
CFH	B-GeneOrGeneProduct
showed	O
a	O
significant	O
association	O
with	O
drusen	B-DiseaseOrPhenotypicFeature
,	O
and	O
none	O
of	O
the	O
SNPs	O
in	O
CFH	B-GeneOrGeneProduct
,	O
C2	B-GeneOrGeneProduct
,	O
CFB	B-GeneOrGeneProduct
,	O
and	O
C3	B-GeneOrGeneProduct
showed	O
a	O
significant	O
association	O
with	O
either	O
wet	O
AMD	B-DiseaseOrPhenotypicFeature
or	O
drusen	B-DiseaseOrPhenotypicFeature
in	O
the	O
cohort	O
of	O
this	O
study	O
.	O

The	O
CFHR1	B-GeneOrGeneProduct
and	O
CFHR3	B-GeneOrGeneProduct
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
Chinese	O
population	O
and	O
was	O
not	O
associated	O
with	O
wet	O
AMD	B-DiseaseOrPhenotypicFeature
or	O
drusen	B-DiseaseOrPhenotypicFeature
.	O

CONCLUSION	O
:	O
This	O
study	O
showed	O
that	O
SNPs	O
rs3753394	B-SequenceVariant
(	O
P	O
=	O
0	O
.	O
0276	O
)	O
,	O
rs800292	B-SequenceVariant
(	O
P	O
=	O
0	O
.	O
0266	O
)	O
,	O
rs1061170	B-SequenceVariant
(	O
P	O
=	O
0	O
.	O
00514	O
)	O
,	O
and	O
rs1329428	B-SequenceVariant
(	O
P	O
=	O
0	O
.	O
0089	O
)	O
,	O
but	O
not	O
rs7535263	B-SequenceVariant
,	O
rs1410996	B-SequenceVariant
,	O
or	O
rs2274700	B-SequenceVariant
,	O
in	O
CFH	B-GeneOrGeneProduct
were	O
significantly	O
associated	O
with	O
wet	O
AMD	B-DiseaseOrPhenotypicFeature
in	O
a	O
mainland	O
Han	O
Chinese	O
population	O
.	O

This	O
study	O
showed	O
that	O
CFH	B-GeneOrGeneProduct
was	O
more	O
likely	O
to	O
be	O
AMD	B-DiseaseOrPhenotypicFeature
susceptibility	O
gene	O
at	O
Chr	O
.	O
1q31	O
based	O
on	O
the	O
finding	O
that	O
the	O
CFHR1	B-GeneOrGeneProduct
and	O
CFHR3	B-GeneOrGeneProduct
deletion	O
was	O
not	O
polymorphic	O
in	O
the	O
cohort	O
of	O
this	O
study	O
,	O
and	O
none	O
of	O
the	O
SNPs	O
that	O
were	O
significantly	O
associated	O
with	O
AMD	B-DiseaseOrPhenotypicFeature
in	O
a	O
white	O
population	O
in	O
C2	B-GeneOrGeneProduct
,	O
CFB	B-GeneOrGeneProduct
,	O
and	O
C3	B-GeneOrGeneProduct
genes	O
showed	O
a	O
significant	O
association	O
with	O
AMD	B-DiseaseOrPhenotypicFeature
.	O
Seven	O
novel	O
and	O
six	O
de	O
novo	O
PHEX	B-GeneOrGeneProduct
gene	O
mutations	O
in	O
patients	B-OrganismTaxon
with	O
hypophosphatemic	B-DiseaseOrPhenotypicFeature
rickets	I-DiseaseOrPhenotypicFeature
.	O

Inactivating	O
mutations	O
in	O
phosphate	B-GeneOrGeneProduct
-	O
regulating	I-GeneOrGeneProduct
gene	I-GeneOrGeneProduct
with	I-GeneOrGeneProduct
homologies	I-GeneOrGeneProduct
to	I-GeneOrGeneProduct
endopeptidase	I-GeneOrGeneProduct
on	I-GeneOrGeneProduct
the	I-GeneOrGeneProduct
X	I-GeneOrGeneProduct
chromosome	I-GeneOrGeneProduct
(	O
PHEX	B-GeneOrGeneProduct
)	O
have	O
been	O
identified	O
as	O
a	O
cause	O
of	O
X	B-DiseaseOrPhenotypicFeature
-	O
linked	I-DiseaseOrPhenotypicFeature
hypophosphatemic	I-DiseaseOrPhenotypicFeature
rickets	I-DiseaseOrPhenotypicFeature
(	O
XLH	B-DiseaseOrPhenotypicFeature
;	O
OMIM	B-DiseaseOrPhenotypicFeature
307800	I-DiseaseOrPhenotypicFeature
)	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
enrolled	O
43	O
patients	B-OrganismTaxon
from	O
18	O
unrelated	O
families	O
clinically	O
diagnosed	O
with	O
hypophosphatemic	B-DiseaseOrPhenotypicFeature
rickets	I-DiseaseOrPhenotypicFeature
and	O
250	O
healthy	O
controls	O
.	O

For	O
each	O
available	O
individual	O
,	O
all	O
22	O
exons	O
with	O
their	O
exon	O
-	O
intron	O
boundaries	O
of	O
the	O
PHEX	B-GeneOrGeneProduct
gene	O
were	O
directly	O
sequenced	O
.	O

The	O
levels	O
of	O
serum	O
fibroblast	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
23	I-GeneOrGeneProduct
(	O
FGF23	B-GeneOrGeneProduct
)	O
were	O
measured	O
as	O
well	O
.	O

Sequencing	O
analysis	O
detected	O
17	O
different	O
PHEX	B-GeneOrGeneProduct
gene	O
mutations	O
,	O
and	O
7	O
of	O
these	O
were	O
identified	O
as	O
novel	O
:	O
3	O
missense	O
mutations	O
,	O
including	O
c	B-SequenceVariant
.	O
304G	I-SequenceVariant
>	O
A	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Gly102Arg	I-SequenceVariant
)	O
in	O
exon	O
3	O
,	O
c	B-SequenceVariant
.	O
229T	I-SequenceVariant
>	O
C	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Cys77Arg	I-SequenceVariant
)	O
in	O
exon	O
3	O
and	O
c	B-SequenceVariant
.	O
824T	I-SequenceVariant
>	O
C	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Leu275Pro	I-SequenceVariant
)	O
in	O
exon	O
7	O
;	O
2	O
deletion	O
mutations	O
,	O
including	O
c	B-SequenceVariant
.	O
528delT	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Glu177LysfsX44	I-SequenceVariant
)	O
in	O
exon	O
5	O
and	O
c	B-SequenceVariant
.	O
1234delA	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Ser412ValfsX12	I-SequenceVariant
)	O
in	O
exon	O
11	O
;	O
and	O
2	O
alternative	O
splicing	O
mutations	O
,	O
including	O
c	B-SequenceVariant
.	O
436_436	I-SequenceVariant
+	O
1delAG	I-SequenceVariant
in	O
intron	O
4	O
at	O
splicing	O
donor	O
sites	O
and	O
c	B-SequenceVariant
.	O
1483	I-SequenceVariant
-	O
1G	I-SequenceVariant
>	O
C	I-SequenceVariant
in	O
intron	O
13	O
at	O
splicing	O
acceptor	O
sites	O
.	O

Moreover	O
,	O
6	O
mutations	O
were	O
proven	O
to	O
be	O
de	O
novo	O
in	O
6	O
sporadic	O
cases	O
and	O
the	O
probands	O
were	O
all	O
females	O
.	O

No	O
mutations	O
were	O
found	O
in	O
the	O
250	O
healthy	O
controls	O
.	O

The	O
serum	O
levels	O
of	O
FGF23	B-GeneOrGeneProduct
varied	O
widely	O
among	O
the	O
patients	B-OrganismTaxon
with	O
XLH	B-DiseaseOrPhenotypicFeature
,	O
and	O
no	O
significant	O
difference	O
was	O
found	O
when	O
compared	O
with	O
those	O
of	O
the	O
healthy	O
controls	O
.	O

On	O
the	O
whole	O
,	O
the	O
findings	O
of	O
this	O
study	O
provide	O
new	O
insight	O
into	O
the	O
spectrum	O
of	O
PHEX	B-GeneOrGeneProduct
mutations	O
and	O
provide	O
potential	O
evidence	O
of	O
a	O
critical	O
domain	O
in	O
PHEX	B-GeneOrGeneProduct
protein	O
.	O

In	O
addition	O
,	O
the	O
finding	O
of	O
an	O
overlap	O
of	O
the	O
serum	O
FGF23	B-GeneOrGeneProduct
levels	O
between	O
the	O
patients	B-OrganismTaxon
with	O
XLH	B-DiseaseOrPhenotypicFeature
and	O
the	O
healthy	O
controls	O
indicates	O
its	O
limited	O
diagnostic	O
value	O
in	O
XLH	B-DiseaseOrPhenotypicFeature
.	O
Hepatocyte	B-GeneOrGeneProduct
nuclear	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
:	O
associations	O
between	O
genetic	O
variability	O
and	O
type	B-DiseaseOrPhenotypicFeature
II	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
and	O
between	O
genetic	O
variability	O
and	O
estimates	O
of	O
insulin	B-GeneOrGeneProduct
secretion	O
.	O

The	O
transcription	O
factor	O
hepatocyte	B-GeneOrGeneProduct
nuclear	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
HNF	I-GeneOrGeneProduct
)	O
-	O
6	I-GeneOrGeneProduct
is	O
an	O
upstream	O
regulator	O
of	O
several	O
genes	O
involved	O
in	O
the	O
pathogenesis	O
of	O
maturity	B-DiseaseOrPhenotypicFeature
-	O
onset	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
of	O
the	O
young	O
.	O

We	O
therefore	O
tested	O
the	O
hypothesis	O
that	O
variability	O
in	O
the	O
HNF	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
gene	O
is	O
associated	O
with	O
subsets	O
of	O
Type	B-DiseaseOrPhenotypicFeature
II	I-DiseaseOrPhenotypicFeature
(	O
non	I-DiseaseOrPhenotypicFeature
-	O
insulin	I-DiseaseOrPhenotypicFeature
-	O
dependent	I-DiseaseOrPhenotypicFeature
)	O
diabetes	I-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
and	O
estimates	O
of	O
insulin	B-GeneOrGeneProduct
secretion	O
in	O
glucose	B-ChemicalEntity
tolerant	O
subjects	O
.	O

We	O
cloned	O
the	O
coding	O
region	O
as	O
well	O
as	O
the	O
intron	O
-	O
exon	O
boundaries	O
of	O
the	O
HNF	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
gene	O
.	O

We	O
then	O
examined	O
them	O
on	O
genomic	O
DNA	O
in	O
six	O
MODY	B-GeneOrGeneProduct
probands	O
without	O
mutations	O
in	O
the	O
MODY1	B-GeneOrGeneProduct
,	O
MODY3	B-GeneOrGeneProduct
and	O
MODY4	B-GeneOrGeneProduct
genes	O
and	O
in	O
54	O
patients	B-OrganismTaxon
with	O
late	O
-	O
onset	O
Type	B-DiseaseOrPhenotypicFeature
II	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
by	O
combined	O
single	O
strand	O
conformational	O
polymorphism	O
-	O
heteroduplex	O
analysis	O
followed	O
by	O
direct	O
sequencing	O
of	O
identified	O
variants	O
.	O

An	O
identified	O
missense	O
variant	O
was	O
examined	O
in	O
association	O
studies	O
and	O
genotype	O
-	O
phenotype	O
studies	O
.	O

We	O
identified	O
two	O
silent	O
and	O
one	O
missense	O
(	O
Pro75	B-SequenceVariant
Ala	I-SequenceVariant
)	O
variant	O
.	O

In	O
an	O
association	O
study	O
the	O
allelic	O
frequency	O
of	O
the	O
Pro75Ala	B-SequenceVariant
polymorphism	O
was	O
3	O
.	O
2%	O
(	O
95%	O
confidence	O
interval	O
,	O
1	O
.	O
9	O
-	O
4	O
.	O
5	O
)	O
in	O
330	O
patients	B-OrganismTaxon
with	O
Type	B-DiseaseOrPhenotypicFeature
II	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
compared	O
with	O
4	O
.	O
2%	O
(	O
2	O
.	O
4	O
-	O
6	O
.	O
0	O
)	O
in	O
238	O
age	O
-	O
matched	O
glucose	B-ChemicalEntity
tolerant	O
control	O
subjects	O
.	O

Moreover	O
,	O
in	O
studies	O
of	O
238	O
middle	O
-	O
aged	O
glucose	B-ChemicalEntity
tolerant	O
subjects	O
,	O
of	O
226	O
glucose	B-ChemicalEntity
tolerant	O
offspring	O
of	O
Type	B-DiseaseOrPhenotypicFeature
II	I-DiseaseOrPhenotypicFeature
diabetic	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
of	O
367	O
young	O
healthy	O
subjects	O
,	O
the	O
carriers	O
of	O
the	O
polymorphism	O
did	O
not	O
differ	O
from	O
non	O
-	O
carriers	O
in	O
glucose	B-ChemicalEntity
induced	O
serum	O
insulin	B-GeneOrGeneProduct
or	O
C	B-GeneOrGeneProduct
-	O
peptide	I-GeneOrGeneProduct
responses	O
.	O

Mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
HNF	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
gene	O
are	O
not	O
associated	O
with	O
Type	B-DiseaseOrPhenotypicFeature
II	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
or	O
with	O
changes	O
in	O
insulin	B-GeneOrGeneProduct
responses	O
to	O
glucose	B-ChemicalEntity
among	O
the	O
Caucasians	O
examined	O
.	O
Pethidine	B-ChemicalEntity
-	O
associated	O
seizure	B-DiseaseOrPhenotypicFeature
in	O
a	O
healthy	O
adolescent	O
receiving	O
pethidine	B-ChemicalEntity
for	O
postoperative	B-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
control	O
.	O

A	O
healthy	O
17	O
-	O
year	O
-	O
old	O
male	O
received	O
standard	O
intermittent	O
doses	O
of	O
pethidine	B-ChemicalEntity
via	O
a	O
patient	B-OrganismTaxon
-	O
controlled	O
analgesia	O
(	O
PCA	O
)	O
pump	O
for	O
management	O
of	O
postoperative	B-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
control	O
.	O

Twenty	O
-	O
three	O
h	O
postoperatively	O
he	O
developed	O
a	O
brief	O
self	O
-	O
limited	O
seizure	B-DiseaseOrPhenotypicFeature
.	O

Both	O
plasma	O
pethidine	B-ChemicalEntity
and	O
norpethidine	B-ChemicalEntity
were	O
elevated	O
in	O
the	O
range	O
associated	O
with	O
clinical	O
manifestations	O
of	O
central	O
nervous	O
system	O
excitation	O
.	O

No	O
other	O
risk	O
factors	O
for	O
CNS	O
toxicity	B-DiseaseOrPhenotypicFeature
were	O
identified	O
.	O

This	O
method	O
allowed	O
frequent	O
self	O
-	O
dosing	O
of	O
pethidine	B-ChemicalEntity
at	O
short	O
time	O
intervals	O
and	O
rapid	O
accumulation	O
of	O
pethidine	B-ChemicalEntity
and	O
norpethidine	B-ChemicalEntity
.	O

The	O
routine	O
use	O
of	O
pethidine	B-ChemicalEntity
via	O
PCA	O
even	O
for	O
a	O
brief	O
postoperative	B-DiseaseOrPhenotypicFeature
analgesia	I-DiseaseOrPhenotypicFeature
should	O
be	O
reconsidered	O
.	O
Smoking	O
of	O
crack	B-ChemicalEntity
cocaine	I-ChemicalEntity
as	O
a	O
risk	O
factor	O
for	O
HIV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
among	O
people	O
who	O
use	O
injection	O
drugs	O
.	O

BACKGROUND	O
:	O
Little	O
is	O
known	O
about	O
the	O
possible	O
role	O
that	O
smoking	O
crack	B-ChemicalEntity
cocaine	I-ChemicalEntity
has	O
on	O
the	O
incidence	O
of	O
HIV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

Given	O
the	O
increasing	O
use	O
of	O
crack	B-ChemicalEntity
cocaine	I-ChemicalEntity
,	O
we	O
sought	O
to	O
examine	O
whether	O
use	O
of	O
this	O
illicit	O
drug	O
has	O
become	O
a	O
risk	O
factor	O
for	O
HIV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
We	O
included	O
data	O
from	O
people	O
participating	O
in	O
the	O
Vancouver	O
Injection	O
Drug	O
Users	O
Study	O
who	O
reported	O
injecting	O
illicit	O
drugs	O
at	O
least	O
once	O
in	O
the	O
month	O
before	O
enrolment	O
,	O
lived	O
in	O
the	O
greater	O
Vancouver	O
area	O
,	O
were	O
HIV	B-DiseaseOrPhenotypicFeature
-	O
negative	O
at	O
enrolment	O
and	O
completed	O
at	O
least	O
1	O
follow	O
-	O
up	O
study	O
visit	O
.	O

To	O
determine	O
whether	O
the	O
risk	O
of	O
HIV	B-DiseaseOrPhenotypicFeature
seroconversion	I-DiseaseOrPhenotypicFeature
among	O
daily	O
smokers	O
of	O
crack	B-ChemicalEntity
cocaine	I-ChemicalEntity
changed	O
over	O
time	O
,	O
we	O
used	O
Cox	O
proportional	O
hazards	O
regression	O
and	O
divided	O
the	O
study	O
into	O
3	O
periods	O
:	O
May	O
1	O
,	O
1996	O
-	O
Nov	O
.	O

30	O
,	O
1999	O
(	O
period	O
1	O
)	O
,	O
Dec	O
.	O

1	O
,	O
1999	O
-	O
Nov	O
.	O

30	O
,	O
2002	O
(	O
period	O
2	O
)	O
,	O
and	O
Dec	O
.	O

1	O
,	O
2002	O
-	O
Dec	O
.	O

30	O
,	O
2005	O
(	O
period	O
3	O
)	O
.	O

RESULTS	O
:	O
Overall	O
,	O
1048	O
eligible	O
injection	O
drug	O
users	O
were	O
included	O
in	O
our	O
study	O
.	O

Of	O
these	O
,	O
137	O
acquired	O
HIV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
during	O
follow	O
-	O
up	O
.	O

The	O
mean	O
proportion	O
of	O
participants	O
who	O
reported	O
daily	O
smoking	O
of	O
crack	B-ChemicalEntity
cocaine	I-ChemicalEntity
increased	O
from	O
11	O
.	O
6%	O
in	O
period	O
1	O
to	O
39	O
.	O
7%	O
in	O
period	O
3	O
.	O

After	O
adjusting	O
for	O
potential	O
confounders	O
,	O
we	O
found	O
that	O
the	O
risk	O
of	O
HIV	B-DiseaseOrPhenotypicFeature
seroconversion	I-DiseaseOrPhenotypicFeature
among	O
participants	O
who	O
were	O
daily	O
smokers	O
of	O
crack	B-ChemicalEntity
cocaine	I-ChemicalEntity
increased	O
over	O
time	O
(	O
period	O
1	O
:	O
hazard	O
ratio	O
[	O
HR	O
]	O
1	O
.	O
03	O
,	O
95%	O
confidence	O
interval	O
[	O
CI	O
]	O
0	O
.	O
57	O
-	O
1	O
.	O
85	O
;	O
period	O
2	O
:	O
HR	O
1	O
.	O
68	O
,	O
95%	O
CI	O
1	O
.	O
01	O
-	O
2	O
.	O
80	O
;	O
and	O
period	O
3	O
:	O
HR	O
2	O
.	O
74	O
,	O
95%	O
CI	O
1	O
.	O
06	O
-	O
7	O
.	O
11	O
)	O
.	O

INTERPRETATION	O
:	O
Smoking	O
of	O
crack	B-ChemicalEntity
cocaine	I-ChemicalEntity
was	O
found	O
to	O
be	O
an	O
independent	O
risk	O
factor	O
for	O
HIV	B-DiseaseOrPhenotypicFeature
seroconversion	I-DiseaseOrPhenotypicFeature
among	O
people	O
who	O
were	O
injection	O
drug	O
users	O
.	O

This	O
finding	O
points	O
to	O
the	O
urgent	O
need	O
for	O
evidence	O
-	O
based	O
public	O
health	O
initiatives	O
targeted	O
at	O
people	O
who	O
smoke	O
crack	B-ChemicalEntity
cocaine	I-ChemicalEntity
.	O
Common	O
dihydrofolate	B-GeneOrGeneProduct
reductase	I-GeneOrGeneProduct
19	B-SequenceVariant
-	O
base	I-SequenceVariant
pair	I-SequenceVariant
deletion	I-SequenceVariant
allele	O
:	O
a	O
novel	O
risk	O
factor	O
for	O
preterm	B-DiseaseOrPhenotypicFeature
delivery	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Folate	B-ChemicalEntity
is	O
critical	O
for	O
cell	O
division	O
,	O
a	O
major	O
feature	O
of	O
in	O
utero	O
development	O
.	O

Dihydrofolate	B-GeneOrGeneProduct
reductase	I-GeneOrGeneProduct
(	O
DHFR	B-GeneOrGeneProduct
)	O
is	O
required	O
to	O
convert	O
the	O
folic	B-ChemicalEntity
acid	I-ChemicalEntity
used	O
in	O
supplements	O
and	O
for	O
food	O
fortification	O
and	O
the	O
dihydrofolate	B-ChemicalEntity
produced	O
by	O
thymidylate	B-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
during	O
DNA	O
synthesis	O
to	O
the	O
reduced	O
folate	B-ChemicalEntity
forms	O
used	O
by	O
the	O
cell	O
.	O

OBJECTIVE	O
:	O
We	O
aimed	O
to	O
determine	O
whether	O
a	O
common	O
,	O
recently	O
discovered	O
deletion	O
polymorphism	O
in	O
the	O
DHFR	B-GeneOrGeneProduct
gene	O
is	O
a	O
risk	O
factor	O
for	O
preterm	B-DiseaseOrPhenotypicFeature
delivery	I-DiseaseOrPhenotypicFeature
or	O
low	O
birth	O
weight	O
.	O

DESIGN	O
:	O
We	O
studied	O
324	O
pregnant	O
women	B-OrganismTaxon
from	O
Camden	O
,	O
NJ	O
.	O

Folate	B-ChemicalEntity
intake	O
was	O
computed	O
from	O
folate	B-ChemicalEntity
supplement	O
intake	O
plus	O
the	O
mean	O
of	O
two	O
24	O
-	O
h	O
recalls	O
completed	O
during	O
the	O
course	O
of	O
pregnancy	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
women	B-OrganismTaxon
'	O
s	O
leukocytes	O
and	O
genotyped	O
.	O

RESULTS	O
:	O
Women	B-OrganismTaxon
with	O
a	O
deletion	O
allele	O
had	O
a	O
significantly	O
greater	O
risk	O
of	O
preterm	B-DiseaseOrPhenotypicFeature
delivery	I-DiseaseOrPhenotypicFeature
[	O
adjusted	O
odds	O
ratio	O
(	O
AOR	O
)	O
:	O
3	O
.	O
0	O
;	O
95%	O
CI	O
:	O
1	O
.	O
0	O
,	O
8	O
.	O
8	O
;	O
P	O
<	O
0	O
.	O
05	O
]	O
than	O
did	O
those	O
without	O
a	O
deletion	O
allele	O
.	O

Women	B-OrganismTaxon
with	O
both	O
a	O
DHFR	B-GeneOrGeneProduct
deletion	O
allele	O
and	O
low	O
folate	B-ChemicalEntity
intake	O
(	O
<	O
400	O
microg	O
/	O
d	O
from	O
diet	O
plus	O
supplements	O
)	O
had	O
a	O
significantly	O
greater	O
risk	O
of	O
preterm	B-DiseaseOrPhenotypicFeature
delivery	I-DiseaseOrPhenotypicFeature
(	O
AOR	O
:	O
5	O
.	O
5	O
;	O
95%	O
CI	O
:	O
1	O
.	O
5	O
,	O
20	O
.	O
4	O
;	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
a	O
significantly	O
greater	O
risk	O
of	O
having	O
an	O
infant	O
with	O
a	O
low	O
birth	O
weight	O
(	O
AOR	O
:	O
8	O
.	O
3	O
;	O
95%	O
CI	O
:	O
1	O
.	O
8	O
,	O
38	O
.	O
6	O
;	O
P	O
=	O
0	O
.	O
01	O
)	O
than	O
did	O
women	B-OrganismTaxon
without	O
a	O
deletion	O
allele	O
and	O
with	O
a	O
folate	B-ChemicalEntity
intake	O
>	O
/	O
=	O
400	O
microg	O
/	O
d	O
.	O

CONCLUSIONS	O
:	O
The	O
DHFR	B-GeneOrGeneProduct
19	B-SequenceVariant
-	O
base	I-SequenceVariant
pair	I-SequenceVariant
deletion	I-SequenceVariant
allele	O
may	O
be	O
a	O
risk	O
factor	O
for	O
preterm	B-DiseaseOrPhenotypicFeature
delivery	I-DiseaseOrPhenotypicFeature
.	O

In	O
the	O
presence	O
of	O
low	O
dietary	O
folate	B-ChemicalEntity
,	O
the	O
allele	O
may	O
also	O
be	O
a	O
risk	O
factor	O
for	O
low	O
birth	O
weight	O
.	O

This	O
may	O
be	O
a	O
gene	O
-	O
environment	O
interaction	O
.	O
Nefiracetam	B-ChemicalEntity
(	O
DM	B-ChemicalEntity
-	O
9384	I-ChemicalEntity
)	O
reverses	O
apomorphine	B-ChemicalEntity
-	O
induced	O
amnesia	B-DiseaseOrPhenotypicFeature
of	O
a	O
passive	O
avoidance	O
response	O
:	O
delayed	O
emergence	O
of	O
the	O
memory	O
retention	O
effects	O
.	O

Nefiracetam	B-ChemicalEntity
is	O
a	O
novel	O
pyrrolidone	B-ChemicalEntity
derivative	O
which	O
attenuates	O
scopolamine	B-ChemicalEntity
-	O
induced	O
learning	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
post	I-DiseaseOrPhenotypicFeature
-	O
training	I-DiseaseOrPhenotypicFeature
consolidation	I-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
.	O

Given	O
that	O
apomorphine	B-ChemicalEntity
inhibits	O
passive	O
avoidance	O
retention	O
when	O
given	O
during	O
training	O
or	O
in	O
a	O
defined	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
,	O
we	O
evaluated	O
the	O
ability	O
of	O
nefiracetam	B-ChemicalEntity
to	O
attenuate	O
amnesia	B-DiseaseOrPhenotypicFeature
induced	O
by	O
dopaminergic	B-ChemicalEntity
agonism	I-ChemicalEntity
.	O

A	O
step	O
-	O
down	O
passive	O
avoidance	O
paradigm	O
was	O
employed	O
and	O
nefiracetam	B-ChemicalEntity
(	O
3	O
mg	O
/	O
kg	O
)	O
and	O
apomorphine	B-ChemicalEntity
(	O
0	O
.	O
5	O
mg	O
/	O
kg	O
)	O
were	O
given	O
alone	O
or	O
in	O
combination	O
during	O
training	O
and	O
at	O
the	O
10	O
-	O
12h	O
post	O
-	O
training	O
period	O
of	O
consolidation	O
.	O

Co	O
-	O
administration	O
of	O
nefiracetam	B-ChemicalEntity
and	O
apomorphine	B-ChemicalEntity
during	O
training	O
or	O
10h	O
thereafter	O
produced	O
no	O
significant	O
anti	O
-	O
amnesic	B-DiseaseOrPhenotypicFeature
effect	O
.	O

However	O
,	O
administration	O
of	O
nefiracetam	B-ChemicalEntity
during	O
training	O
completely	O
reversed	O
the	O
amnesia	B-DiseaseOrPhenotypicFeature
induced	O
by	O
apomorphine	B-ChemicalEntity
at	O
the	O
10h	O
post	O
-	O
training	O
time	O
and	O
the	O
converse	O
was	O
also	O
true	O
.	O

These	O
effects	O
were	O
not	O
mediated	O
by	O
a	O
dopaminergic	O
mechanism	O
as	O
nefiracetam	B-ChemicalEntity
,	O
at	O
millimolar	O
concentrations	O
,	O
failed	O
to	O
displace	O
either	O
[	O
3H	B-ChemicalEntity
]	O
SCH	B-ChemicalEntity
23390	I-ChemicalEntity
or	O
[	O
3H	B-ChemicalEntity
]	O
spiperone	B-ChemicalEntity
binding	O
from	O
D1	B-GeneOrGeneProduct
or	I-GeneOrGeneProduct
D2	I-GeneOrGeneProduct
dopamine	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
subtypes	O
,	O
respectively	O
.	O

It	O
is	O
suggested	O
that	O
nefiracetam	B-ChemicalEntity
augments	O
molecular	O
processes	O
in	O
the	O
early	O
stages	O
of	O
events	O
which	O
ultimately	O
lead	O
to	O
consolidation	O
of	O
memory	O
.	O
Angiotensin	B-GeneOrGeneProduct
II	I-GeneOrGeneProduct
subtype	I-GeneOrGeneProduct
1a	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
signaling	O
in	O
resident	O
hepatic	O
macrophages	O
induces	O
liver	B-DiseaseOrPhenotypicFeature
metastasis	I-DiseaseOrPhenotypicFeature
formation	O
.	O

Liver	B-DiseaseOrPhenotypicFeature
metastases	I-DiseaseOrPhenotypicFeature
from	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
CRC	B-DiseaseOrPhenotypicFeature
)	O
are	O
a	O
clinically	O
significant	O
problem	O
.	O

The	O
renin	B-GeneOrGeneProduct
-	O
angiotensin	B-GeneOrGeneProduct
system	O
is	O
involved	O
in	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
and	O
metastases	B-DiseaseOrPhenotypicFeature
.	O

This	O
study	O
was	O
designed	O
to	O
evaluate	O
the	O
role	O
of	O
angiotensin	B-GeneOrGeneProduct
II	I-GeneOrGeneProduct
subtype	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
1a	I-GeneOrGeneProduct
(	O
AT1a	B-GeneOrGeneProduct
)	O
in	O
the	O
formation	O
of	O
liver	B-DiseaseOrPhenotypicFeature
metastasis	I-DiseaseOrPhenotypicFeature
in	O
CRC	B-DiseaseOrPhenotypicFeature
.	O

A	O
model	O
of	O
liver	B-DiseaseOrPhenotypicFeature
metastasis	I-DiseaseOrPhenotypicFeature
was	O
developed	O
by	O
intrasplenic	O
injection	O
of	O
mouse	B-OrganismTaxon
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
(	O
CMT	B-CellLine
-	O
93	I-CellLine
)	O
into	O
AT1a	B-GeneOrGeneProduct
knockout	O
mice	B-OrganismTaxon
(	O
AT1aKO	B-GeneOrGeneProduct
)	O
and	O
wild	O
-	O
type	O
(	O
C57BL	B-CellLine
/	O
6	I-CellLine
)	O
mice	B-OrganismTaxon
(	O
WT	O
)	O
.	O

Compared	O
with	O
WT	O
mice	B-OrganismTaxon
,	O
the	O
liver	O
weight	O
and	O
liver	B-DiseaseOrPhenotypicFeature
metastatic	I-DiseaseOrPhenotypicFeature
rate	O
were	O
significantly	O
lower	O
in	O
AT1aKO	B-GeneOrGeneProduct
.	O

The	O
mRNA	O
levels	O
of	O
CD31	B-GeneOrGeneProduct
,	O
transforming	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
b1	I-GeneOrGeneProduct
(	O
TGF	B-GeneOrGeneProduct
-	O
b1	I-GeneOrGeneProduct
)	O
,	O
and	O
F4	B-GeneOrGeneProduct
/	O
80	I-GeneOrGeneProduct
were	O
suppressed	O
in	O
AT1aKO	B-GeneOrGeneProduct
compared	O
with	O
WT	O
.	O

Double	O
immunofluorescence	O
analysis	O
showed	O
that	O
the	O
number	O
of	O
accumulated	O
F4	B-GeneOrGeneProduct
/	O
80	I-GeneOrGeneProduct
(	O
+	O
)	O
cells	O
expressing	O
TGF	B-GeneOrGeneProduct
-	O
b1	I-GeneOrGeneProduct
in	O
metastatic	O
areas	O
was	O
higher	O
in	O
WT	O
than	O
in	O
AT1aKO	B-GeneOrGeneProduct
.	O

The	O
AT1aKO	B-GeneOrGeneProduct
bone	O
marrow	O
(	O
BM	O
)	O
(	O
AT1aKO	B-GeneOrGeneProduct
-	O
BM	O
)	O
>	O
WT	O
showed	O
suppressed	O
formation	O
of	O
liver	B-DiseaseOrPhenotypicFeature
metastasis	I-DiseaseOrPhenotypicFeature
compared	O
with	O
WT	O
-	O
BM	O
>	O
WT	O
.	O

However	O
,	O
the	O
formation	O
of	O
metastasis	B-DiseaseOrPhenotypicFeature
was	O
further	O
suppressed	O
in	O
WT	O
-	O
BM	O
>	O
AT1aKO	B-GeneOrGeneProduct
compared	O
with	O
AT1aKO	B-GeneOrGeneProduct
-	O
BM	O
>	O
WT	O
.	O

In	O
addition	O
,	O
accumulated	O
F4	B-GeneOrGeneProduct
/	O
80	I-GeneOrGeneProduct
(	O
+	O
)	O
cells	O
in	O
the	O
liver	B-DiseaseOrPhenotypicFeature
metastasis	I-DiseaseOrPhenotypicFeature
were	O
not	O
BM	O
-	O
derived	O
F4	B-GeneOrGeneProduct
/	O
80	I-GeneOrGeneProduct
(	O
+	O
)	O
cells	O
,	O
but	O
mainly	O
resident	O
hepatic	O
F4	B-GeneOrGeneProduct
/	O
80	I-GeneOrGeneProduct
(	O
+	O
)	O
cells	O
,	O
and	O
these	O
resident	O
hepatic	O
F4	B-GeneOrGeneProduct
/	O
80	I-GeneOrGeneProduct
(	O
+	O
)	O
cells	O
were	O
positive	O
for	O
TGF	B-GeneOrGeneProduct
-	O
b1	I-GeneOrGeneProduct
.	O

Angiotensin	B-GeneOrGeneProduct
II	I-GeneOrGeneProduct
enhanced	O
TGF	B-GeneOrGeneProduct
-	O
b1	I-GeneOrGeneProduct
expression	O
in	O
Kupffer	O
cells	O
.	O

Treatment	O
of	O
WT	O
with	O
clodronate	B-ChemicalEntity
liposomes	O
suppressed	O
liver	B-DiseaseOrPhenotypicFeature
metastasis	I-DiseaseOrPhenotypicFeature
by	O
diminishing	O
TGF	B-GeneOrGeneProduct
-	O
b1	I-GeneOrGeneProduct
(	O
+	O
)	O
F4	B-GeneOrGeneProduct
/	O
80	I-GeneOrGeneProduct
(	O
+	O
)	O
cells	O
accumulation	O
.	O

The	O
formation	O
of	O
liver	B-DiseaseOrPhenotypicFeature
metastasis	I-DiseaseOrPhenotypicFeature
correlated	O
with	O
collagen	B-GeneOrGeneProduct
deposition	O
in	O
the	O
metastatic	O
area	O
,	O
which	O
was	O
dependent	O
on	O
AT1a	B-GeneOrGeneProduct
signaling	O
.	O

These	O
results	O
suggested	O
that	O
resident	O
hepatic	O
macrophages	O
induced	O
liver	B-DiseaseOrPhenotypicFeature
metastasis	I-DiseaseOrPhenotypicFeature
formation	O
by	O
induction	O
of	O
TGF	B-GeneOrGeneProduct
-	O
b1	I-GeneOrGeneProduct
through	O
AT1a	B-GeneOrGeneProduct
signaling	O
.	O
Isoproterenol	B-ChemicalEntity
induces	O
primary	O
loss	O
of	O
dystrophin	B-GeneOrGeneProduct
in	O
rat	B-OrganismTaxon
hearts	O
:	O
correlation	O
with	O
myocardial	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
.	O

The	O
mechanism	O
of	O
isoproterenol	B-ChemicalEntity
-	O
induced	O
myocardial	B-DiseaseOrPhenotypicFeature
damage	I-DiseaseOrPhenotypicFeature
is	O
unknown	O
,	O
but	O
a	O
mismatch	O
of	O
oxygen	B-ChemicalEntity
supply	O
vs	O
.	O

demand	O
following	O
coronary	O
hypotension	B-DiseaseOrPhenotypicFeature
and	O
myocardial	B-DiseaseOrPhenotypicFeature
hyperactivity	I-DiseaseOrPhenotypicFeature
is	O
the	O
best	O
explanation	O
for	O
the	O
complex	O
morphological	O
alterations	O
observed	O
.	O

Severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
have	O
been	O
demonstrated	O
to	O
be	O
caused	O
by	O
isoproterenol	B-ChemicalEntity
.	O

Taking	O
into	O
account	O
that	O
the	O
sarcolemmal	O
integrity	O
is	O
stabilized	O
by	O
the	O
dystrophin	B-GeneOrGeneProduct
-	O
glycoprotein	B-GeneOrGeneProduct
complex	O
(	O
DGC	O
)	O
that	O
connects	O
actin	B-GeneOrGeneProduct
and	O
laminin	B-GeneOrGeneProduct
in	O
contractile	O
machinery	O
and	O
extracellular	O
matrix	O
and	O
by	O
integrins	O
,	O
this	O
study	O
tests	O
the	O
hypothesis	O
that	O
isoproterenol	B-ChemicalEntity
affects	O
sarcolemmal	O
stability	O
through	O
changes	O
in	O
the	O
DGC	O
and	O
integrins	O
.	O

We	O
found	O
different	O
sensitivity	O
of	O
the	O
DGC	O
and	O
integrin	O
to	O
isoproterenol	B-ChemicalEntity
subcutaneous	O
administration	O
.	O

Immunofluorescent	O
staining	O
revealed	O
that	O
dystrophin	B-GeneOrGeneProduct
is	O
the	O
most	O
sensitive	O
among	O
the	O
structures	O
connecting	O
the	O
actin	B-GeneOrGeneProduct
in	O
the	O
cardiomyocyte	O
cytoskeleton	O
and	O
the	O
extracellular	O
matrix	O
.	O

The	O
sarcomeric	O
actin	B-GeneOrGeneProduct
dissolution	O
occurred	O
after	O
the	O
reduction	O
or	O
loss	O
of	O
dystrophin	B-GeneOrGeneProduct
.	O

Subsequently	O
,	O
after	O
lysis	O
of	O
myofilaments	O
,	O
gamma	B-GeneOrGeneProduct
-	O
sarcoglycan	I-GeneOrGeneProduct
,	O
beta	B-GeneOrGeneProduct
-	O
dystroglycan	I-GeneOrGeneProduct
,	O
beta1	B-GeneOrGeneProduct
-	O
integrin	I-GeneOrGeneProduct
,	O
and	O
laminin	B-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
expressions	O
were	O
reduced	O
followed	O
by	O
their	O
breakdown	O
,	O
as	O
epiphenomena	O
of	O
the	O
myocytolytic	O
process	O
.	O

In	O
conclusion	O
,	O
administration	O
of	O
isoproterenol	B-ChemicalEntity
to	O
rats	B-OrganismTaxon
results	O
in	O
primary	O
loss	O
of	O
dystrophin	B-GeneOrGeneProduct
,	O
the	O
most	O
sensitive	O
among	O
the	O
structural	O
proteins	O
that	O
form	O
the	O
DGC	O
that	O
connects	O
the	O
extracellular	O
matrix	O
and	O
the	O
cytoskeleton	O
in	O
cardiomyocyte	O
.	O

These	O
changes	O
,	O
related	O
to	O
ischaemic	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
,	O
explain	O
the	O
severe	O
alterations	O
in	O
the	O
structural	O
integrity	O
of	O
the	O
sarcolemma	O
of	O
cardiomyocytes	O
and	O
hence	O
severe	O
and	O
irreversible	O
injury	O
induced	O
by	O
isoproterenol	B-ChemicalEntity
.	O
The	O
-	O
930A	I-SequenceVariant
>	O
G	I-SequenceVariant
polymorphism	O
of	O
the	O
CYBA	B-GeneOrGeneProduct
gene	O
is	O
associated	O
with	O
premature	O
coronary	B-DiseaseOrPhenotypicFeature
artery	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

A	O
case	O
-	O
control	O
study	O
and	O
gene	O
-	O
risk	O
factors	O
interactions	O
.	O

Reactive	B-ChemicalEntity
oxygen	I-ChemicalEntity
species	I-ChemicalEntity
(	O
ROS	B-ChemicalEntity
)	O
are	O
involved	O
in	O
the	O
pathogenesis	O
of	O
atherosclerosis	B-DiseaseOrPhenotypicFeature
and	O
coronary	B-DiseaseOrPhenotypicFeature
artery	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
CAD	B-DiseaseOrPhenotypicFeature
)	O
.	O

NADPH	B-GeneOrGeneProduct
oxidases	I-GeneOrGeneProduct
are	O
the	O
main	O
source	O
of	O
ROS	B-ChemicalEntity
in	O
the	O
vasculature	O
.	O

p22phox	B-GeneOrGeneProduct
is	O
a	O
critical	O
component	O
of	O
vascular	O
NADPH	B-GeneOrGeneProduct
oxidases	I-GeneOrGeneProduct
and	O
is	O
encoded	O
by	O
the	O
CYBA	B-GeneOrGeneProduct
(	O
cytochrome	B-GeneOrGeneProduct
b245	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
)	O
gene	O
.	O

The	O
-	O
930A	I-SequenceVariant
>	O
G	I-SequenceVariant
CYBA	B-GeneOrGeneProduct
polymorphism	O
(	O
rs9932581	B-SequenceVariant
:	O
A	B-SequenceVariant
>	O
G	I-SequenceVariant
)	O
modulates	O
the	O
activity	O
of	O
the	O
CYBA	B-GeneOrGeneProduct
promoter	O
,	O
and	O
influences	O
CYBA	B-GeneOrGeneProduct
transcriptional	O
activity	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
analyze	O
a	O
possible	O
association	O
between	O
the	O
-	O
930A	I-SequenceVariant
>	O
G	I-SequenceVariant
polymorphism	O
and	O
CAD	B-DiseaseOrPhenotypicFeature
and	O
to	O
search	O
for	O
gene	O
-	O
traditional	O
risk	O
factors	O
interactions	O
.	O

480	O
subjects	O
were	O
studied	O
:	O
240	O
patients	B-OrganismTaxon
with	O
premature	O
CAD	B-DiseaseOrPhenotypicFeature
,	O
240	O
age	O
and	O
sex	O
matched	O
blood	O
donors	O
.	O

The	O
-	O
930A	I-SequenceVariant
>	O
G	I-SequenceVariant
polymorphism	O
was	O
genotyped	O
using	O
the	O
TaqMan	O
-	O
Pre	O
-	O
designed	O
SNP	O
Genotyping	O
Assay	O
(	O
Applied	O
Biosystems	O
)	O
.	O

The	O
-	O
930G	I-SequenceVariant
allele	O
carrier	O
state	O
was	O
a	O
risk	O
factor	O
for	O
CAD	B-DiseaseOrPhenotypicFeature
(	O
OR	O
2	O
.	O
03	O
,	O
95%	O
CI	O
1	O
.	O
21	O
-	O
3	O
.	O
44	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

A	O
synergistic	O
effect	O
of	O
the	O
-	O
930G	I-SequenceVariant
allele	O
with	O
overweight	B-DiseaseOrPhenotypicFeature
/	O
obesity	B-DiseaseOrPhenotypicFeature
(	O
BMI	O
-	O
-	O
25	O
)	O
and	O
cigarette	O
smoking	O
was	O
found	O
.	O

The	O
estimated	O
CAD	B-DiseaseOrPhenotypicFeature
risk	O
for	O
BMI	O
-	O
-	O
25	O
and	O
the	O
-	O
930G	I-SequenceVariant
allele	O
interaction	O
was	O
about	O
160%	O
greater	O
than	O
that	O
predicted	O
by	O
assuming	O
additivity	O
of	O
the	O
effects	O
,	O
and	O
about	O
40%	O
greater	O
for	O
interaction	O
of	O
cigarette	O
smoking	O
and	O
the	O
-	O
930G	I-SequenceVariant
allele	O
.	O

Overweight	B-DiseaseOrPhenotypicFeature
/	O
obesity	B-DiseaseOrPhenotypicFeature
was	O
a	O
risk	O
factor	O
for	O
CAD	B-DiseaseOrPhenotypicFeature
only	O
in	O
the	O
-	O
930G	I-SequenceVariant
allele	O
carriers	O
(	O
P	O
<	O
10	O
(	O
-	O
10	O
)	O
)	O
but	O
not	O
in	O
the	O
AA	O
homozygotes	O
(	O
P	O
=	O
1	O
.	O
00	O
)	O
.	O

In	O
conclusion	O
the	O
-	O
930A	I-SequenceVariant
>	O
G	I-SequenceVariant
CYBA	B-GeneOrGeneProduct
polymorphism	O
is	O
associated	O
with	O
CAD	B-DiseaseOrPhenotypicFeature
in	O
the	O
Polish	O
population	O
.	O

The	O
-	O
930G	I-SequenceVariant
allele	O
carriers	O
are	O
particularly	O
at	O
risk	O
of	O
consequences	O
of	O
obesity	B-DiseaseOrPhenotypicFeature
and	O
tobacco	B-OrganismTaxon
smoke	O
exposure	O
.	O
Segregation	O
of	O
a	O
M404V	B-SequenceVariant
mutation	O
of	O
the	O
p62	B-GeneOrGeneProduct
/	O
sequestosome	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
p62	B-GeneOrGeneProduct
/	O
SQSTM1	B-GeneOrGeneProduct
)	O
gene	O
with	O
polyostotic	O
Paget	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
bone	I-DiseaseOrPhenotypicFeature
in	O
an	O
Italian	O
family	O
.	O

Mutations	O
of	O
the	O
p62	B-GeneOrGeneProduct
/	O
Sequestosome	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
gene	O
(	O
p62	B-GeneOrGeneProduct
/	O
SQSTM1	B-GeneOrGeneProduct
)	O
account	O
for	O
both	O
sporadic	O
and	O
familial	O
forms	O
of	O
Paget	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
bone	I-DiseaseOrPhenotypicFeature
(	O
PDB	B-DiseaseOrPhenotypicFeature
)	O
.	O

We	O
originally	O
described	O
a	O
methionine	B-SequenceVariant
-	O
-	O
>	O
valine	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
codon	I-SequenceVariant
404	I-SequenceVariant
(	O
M404V	B-SequenceVariant
)	O
of	O
exon	O
8	O
,	O
in	O
the	O
ubiquitin	O
protein	O
-	O
binding	O
domain	O
of	O
p62	B-GeneOrGeneProduct
/	O
SQSTM1	B-GeneOrGeneProduct
gene	O
in	O
an	O
Italian	O
PDB	B-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
.	O

The	O
collection	O
of	O
data	O
from	O
the	O
patient	B-OrganismTaxon
'	O
s	O
pedigree	O
provided	O
evidence	O
for	O
a	O
familial	O
form	O
of	O
PDB	B-DiseaseOrPhenotypicFeature
.	O

Extension	O
of	O
the	O
genetic	O
analysis	O
to	O
other	O
relatives	O
in	O
this	O
family	O
demonstrated	O
segregation	O
of	O
the	O
M404V	B-SequenceVariant
mutation	O
with	O
the	O
polyostotic	O
PDB	B-DiseaseOrPhenotypicFeature
phenotype	O
and	O
provided	O
the	O
identification	O
of	O
six	O
asymptomatic	O
gene	O
carriers	O
.	O

DNA	O
for	O
mutational	O
analysis	O
of	O
the	O
exon	O
8	O
coding	O
sequence	O
was	O
obtained	O
from	O
22	O
subjects	O
,	O
4	O
PDB	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
18	O
clinically	O
unaffected	O
members	O
.	O

Of	O
the	O
five	O
clinically	O
ascertained	O
affected	O
members	O
of	O
the	O
family	O
,	O
four	O
possessed	O
the	O
M404V	B-SequenceVariant
mutation	O
and	O
exhibited	O
the	O
polyostotic	O
form	O
of	O
PDB	B-DiseaseOrPhenotypicFeature
,	O
except	O
one	O
patient	B-OrganismTaxon
with	O
a	O
single	O
X	O
-	O
ray	O
-	O
assessed	O
skeletal	O
localization	O
and	O
one	O
with	O
a	O
polyostotic	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
who	O
had	O
died	O
several	O
years	O
before	O
the	O
DNA	O
analysis	O
.	O

By	O
both	O
reconstitution	O
and	O
mutational	O
analysis	O
of	O
the	O
pedigree	O
,	O
six	O
unaffected	O
subjects	O
were	O
shown	O
to	O
bear	O
the	O
M404V	B-SequenceVariant
mutation	O
,	O
representing	O
potential	O
asymptomatic	O
gene	O
carriers	O
whose	O
circulating	O
levels	O
of	O
alkaline	B-ChemicalEntity
phosphatase	I-ChemicalEntity
were	O
recently	O
assessed	O
as	O
still	O
within	O
the	O
normal	O
range	O
.	O

Taken	O
together	O
,	O
these	O
results	O
support	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
the	O
M404V	B-SequenceVariant
mutation	O
in	O
the	O
p62	B-GeneOrGeneProduct
/	O
SQSTM1	B-GeneOrGeneProduct
gene	O
and	O
a	O
polyostotic	O
form	O
of	O
PDB	B-DiseaseOrPhenotypicFeature
in	O
this	O
family	O
.	O

The	O
high	O
penetrance	O
of	O
the	O
PDB	B-DiseaseOrPhenotypicFeature
trait	O
in	O
this	O
family	O
together	O
with	O
the	O
study	O
of	O
the	O
asymptomatic	O
gene	O
carriers	O
will	O
allow	O
us	O
to	O
confirm	O
the	O
proposed	O
genotype	O
-	O
phenotype	O
correlation	O
and	O
to	O
evaluate	O
the	O
potential	O
use	O
of	O
mutational	O
analysis	O
of	O
the	O
p62	B-GeneOrGeneProduct
/	O
SQSTM1	B-GeneOrGeneProduct
gene	O
in	O
the	O
early	O
detection	O
of	O
relatives	O
at	O
risk	O
for	O
PDB	B-DiseaseOrPhenotypicFeature
.	O
Osteogenesis	B-DiseaseOrPhenotypicFeature
imperfecta	I-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
III	I-DiseaseOrPhenotypicFeature
with	O
intracranial	B-DiseaseOrPhenotypicFeature
hemorrhage	I-DiseaseOrPhenotypicFeature
and	O
brachydactyly	B-DiseaseOrPhenotypicFeature
associated	O
with	O
mutations	O
in	O
exon	O
49	O
of	O
COL1A2	B-GeneOrGeneProduct
.	O

Osteogenesis	B-DiseaseOrPhenotypicFeature
imperfecta	I-DiseaseOrPhenotypicFeature
(	O
OI	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
heritable	O
bone	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
characterized	O
by	O
fractures	B-DiseaseOrPhenotypicFeature
with	O
minimal	O
trauma	B-DiseaseOrPhenotypicFeature
.	O

Intracranial	B-DiseaseOrPhenotypicFeature
hemorrhage	I-DiseaseOrPhenotypicFeature
has	O
been	O
reported	O
in	O
a	O
small	O
number	O
of	O
OI	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

Here	O
we	O
describe	O
three	O
patients	B-OrganismTaxon
,	O
a	O
boy	O
(	O
aged	O
15	O
years	O
)	O
and	O
two	O
girls	O
(	O
aged	O
17	O
and	O
7	O
years	O
)	O
with	O
OI	B-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
III	I-DiseaseOrPhenotypicFeature
who	O
suffered	O
intracranial	B-DiseaseOrPhenotypicFeature
hemorrhage	I-DiseaseOrPhenotypicFeature
and	O
in	O
addition	O
had	O
brachydactyly	B-DiseaseOrPhenotypicFeature
and	O
nail	B-DiseaseOrPhenotypicFeature
hypoplasia	I-DiseaseOrPhenotypicFeature
.	O

In	O
all	O
of	O
these	O
patients	B-OrganismTaxon
,	O
OI	B-DiseaseOrPhenotypicFeature
was	O
caused	O
by	O
glycine	O
mutations	O
affecting	O
exon	O
49	O
of	O
the	O
COL1A2	B-GeneOrGeneProduct
gene	O
,	O
which	O
codes	O
for	O
the	O
most	O
carboxy	O
-	O
terminal	O
part	O
of	O
the	O
triple	O
-	O
helical	O
domain	O
of	O
the	O
collagen	B-GeneOrGeneProduct
type	I-GeneOrGeneProduct
I	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
chain	O
.	O

These	O
observations	O
suggest	O
that	O
mutations	O
in	O
this	O
region	O
of	O
the	O
collagen	B-GeneOrGeneProduct
type	I-GeneOrGeneProduct
I	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
chain	O
carry	O
a	O
high	O
risk	O
of	O
abnormal	B-DiseaseOrPhenotypicFeature
limb	I-DiseaseOrPhenotypicFeature
development	I-DiseaseOrPhenotypicFeature
and	O
intracranial	B-DiseaseOrPhenotypicFeature
bleeding	I-DiseaseOrPhenotypicFeature
.	O
SLURP1	B-GeneOrGeneProduct
mutation	O
-	O
impaired	O
T	O
-	O
cell	O
activation	O
in	O
a	O
family	O
with	O
mal	B-DiseaseOrPhenotypicFeature
de	I-DiseaseOrPhenotypicFeature
Meleda	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Mal	B-DiseaseOrPhenotypicFeature
de	I-DiseaseOrPhenotypicFeature
Meleda	I-DiseaseOrPhenotypicFeature
(	O
MDM	B-DiseaseOrPhenotypicFeature
)	O
is	O
palmoplantar	B-DiseaseOrPhenotypicFeature
erythrokeratoderma	I-DiseaseOrPhenotypicFeature
with	O
an	O
autosomal	O
recessive	O
inheritance	O
and	O
is	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
gene	O
encoding	O
SLURP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
lymphocyte	B-GeneOrGeneProduct
antigen	I-GeneOrGeneProduct
6	I-GeneOrGeneProduct
/	O
urokinase	B-GeneOrGeneProduct
-	O
type	I-GeneOrGeneProduct
plasminogen	I-GeneOrGeneProduct
activator	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
related	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
.	O

SLURP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
is	O
an	O
allosteric	O
agonist	O
to	O
the	O
nicotinic	B-GeneOrGeneProduct
acetylcholine	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
nAchR	B-GeneOrGeneProduct
)	O
and	O
it	O
regulates	O
epidermal	O
homeostasis	O
.	O

In	O
addition	O
,	O
murine	B-OrganismTaxon
studies	O
have	O
shown	O
that	O
nAchR	B-GeneOrGeneProduct
signalling	O
is	O
important	O
for	O
the	O
regulation	O
of	O
T	O
-	O
cell	O
function	O
.	O

Among	O
the	O
family	O
members	O
,	O
patients	B-OrganismTaxon
with	O
the	O
homozygous	O
SLURP1	B-GeneOrGeneProduct
(	O
previously	O
known	O
as	O
ARS	O
component	O
B	O
)	O
mutation	O
are	O
prone	O
to	O
melanoma	B-DiseaseOrPhenotypicFeature
and	O
viral	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
,	O
which	O
might	O
link	O
to	O
defective	O
T	O
-	O
cell	O
function	O
as	O
well	O
as	O
a	O
derangement	O
of	O
epidermal	O
homeostasis	O
.	O

OBJECTIVES	O
:	O
To	O
investigate	O
the	O
association	O
of	O
the	O
SLURP1	B-GeneOrGeneProduct
gene	O
mutation	O
with	O
T	O
-	O
cell	O
activation	O
in	O
a	O
Taiwanese	O
family	O
with	O
MDM	B-DiseaseOrPhenotypicFeature
.	O

To	O
test	O
that	O
SLURP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
is	O
essential	O
for	O
T	O
-	O
cell	O
activation	O
.	O

METHODS	O
:	O
Human	B-OrganismTaxon
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
were	O
isolated	O
from	O
a	O
Taiwanese	O
MDM	B-DiseaseOrPhenotypicFeature
family	O
bearing	O
the	O
G	B-SequenceVariant
to	I-SequenceVariant
A	I-SequenceVariant
substitution	I-SequenceVariant
in	I-SequenceVariant
nucleotide	I-SequenceVariant
256	I-SequenceVariant
in	O
the	O
SLURP1	B-GeneOrGeneProduct
gene	O
,	O
corresponding	O
to	O
a	O
glycine	B-SequenceVariant
to	I-SequenceVariant
arginine	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
86	I-SequenceVariant
(	O
G86R	B-SequenceVariant
)	O
in	O
the	O
SLURP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
protein	O
.	O

PBMCs	O
from	O
homozygotes	O
and	O
wild	O
-	O
type	O
controls	O
were	O
stimulated	O
with	O
anti	O
-	O
CD3	B-GeneOrGeneProduct
/	O
anti	O
-	O
CD28	B-GeneOrGeneProduct
antibodies	O
and	O
the	O
level	O
of	O
T	O
-	O
cell	O
activation	O
was	O
determined	O
by	O
the	O
stimulation	O
index	O
.	O

RESULTS	O
:	O
PBMCs	O
with	O
the	O
heterozygous	O
and	O
homozygous	O
SLURP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
G86R	B-SequenceVariant
mutation	O
had	O
defective	O
T	O
-	O
cell	O
activation	O
.	O

This	O
was	O
restored	O
by	O
the	O
addition	O
of	O
0	O
5	O
ug	O
mL	O
(	O
-	O
1	O
)	O
recombinant	O
human	B-OrganismTaxon
SLURP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
protein	O
.	O

CONCLUSIONS	O
:	O
Patients	B-OrganismTaxon
with	O
MDM	B-DiseaseOrPhenotypicFeature
with	O
the	O
homozygous	O
SLURP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
G86R	B-SequenceVariant
mutation	O
may	O
have	O
an	O
impaired	O
T	O
-	O
cell	O
activation	O
.	O

The	O
presence	O
of	O
wild	O
-	O
type	O
SLURP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
is	O
essential	O
for	O
normal	O
T	O
-	O
cell	O
activation	O
.	O
Molecular	O
diagnosis	O
of	O
46	B-DiseaseOrPhenotypicFeature
,	O
XY	I-DiseaseOrPhenotypicFeature
DSD	I-DiseaseOrPhenotypicFeature
and	O
identification	O
of	O
a	O
novel	O
8	B-SequenceVariant
nucleotide	I-SequenceVariant
deletion	I-SequenceVariant
in	O
exon	O
1	O
of	O
the	O
SRD5A2	B-GeneOrGeneProduct
gene	O
.	O

Phenotypic	O
presentation	O
of	O
46	B-DiseaseOrPhenotypicFeature
,	O
XY	I-DiseaseOrPhenotypicFeature
DSD	I-DiseaseOrPhenotypicFeature
depends	O
on	O
the	O
underlying	O
defects	O
.	O

Defect	O
in	O
androgen	O
action	O
on	O
the	O
target	O
tissues	O
or	O
production	O
of	O
active	O
metabolite	O
share	O
common	O
morphological	O
features	O
.	O

Molecular	O
study	O
may	O
help	O
differentiating	O
these	O
abnormalities	O
with	O
precision	O
.	O

Mutational	O
analysis	O
of	O
androgen	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
AR	B-GeneOrGeneProduct
)	O
and	O
SRD5A2	B-GeneOrGeneProduct
genes	O
was	O
performed	O
in	O
29	O
patients	B-OrganismTaxon
with	O
46	B-DiseaseOrPhenotypicFeature
,	O
XY	I-DiseaseOrPhenotypicFeature
DSD	I-DiseaseOrPhenotypicFeature
,	O
by	O
PCR	O
-	O
SSCP	O
.	O

The	O
amplicons	O
that	O
showed	O
an	O
aberrant	O
migration	O
in	O
SSCP	O
were	O
subjected	O
to	O
sequencing	O
.	O

Interestingly	O
,	O
six	O
patients	B-OrganismTaxon
from	O
4	O
unrelated	O
families	O
(	O
a	O
pair	O
of	O
sibs	O
,	O
uncle	O
/	O
nephew	O
and	O
other	O
two	O
isolated	O
)	O
were	O
identified	O
with	O
mutations	O
in	O
SRD5A2	B-GeneOrGeneProduct
gene	O
.	O

In	O
five	O
patients	B-OrganismTaxon
p	B-SequenceVariant
.	O
R246Q	I-SequenceVariant
missense	O
mutation	O
was	O
detected	O
,	O
of	O
which	O
four	O
were	O
homozygous	O
and	O
one	O
was	O
compound	O
heterozygous	O
:	O
g	B-SequenceVariant
.	O
80_87delT	I-SequenceVariant
CGCGAAG	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
A27fsX132	I-SequenceVariant
)	O
and	O
p	B-SequenceVariant
.	O
R246Q	I-SequenceVariant
.	O

Another	O
patient	B-OrganismTaxon
with	O
isolated	B-DiseaseOrPhenotypicFeature
micropenis	I-DiseaseOrPhenotypicFeature
harbored	O
a	O
heterozygous	O
p	B-SequenceVariant
.	O
G196S	I-SequenceVariant
missense	O
mutation	O
.	O

No	O
AR	B-GeneOrGeneProduct
gene	O
mutation	O
was	O
detected	O
.	O

In	O
conclusion	O
,	O
our	O
study	O
suggests	O
that	O
p	B-SequenceVariant
.	O
R246Q	I-SequenceVariant
mutation	O
is	O
common	O
amongst	O
patients	B-OrganismTaxon
with	O
SRD5A2	B-GeneOrGeneProduct
gene	O
defect	O
from	O
the	O
Northern	O
states	O
of	O
India	O
.	O

Also	O
,	O
it	O
records	O
a	O
novel	O
deletion	O
in	O
exon	O
1	O
of	O
SRD5A2	B-GeneOrGeneProduct
gene	O
in	O
a	O
patient	B-OrganismTaxon
with	O
severe	O
hypospadias	B-DiseaseOrPhenotypicFeature
.	O
People	O
aged	O
over	O
75	O
in	O
atrial	B-DiseaseOrPhenotypicFeature
fibrillation	I-DiseaseOrPhenotypicFeature
on	O
warfarin	B-ChemicalEntity
:	O
the	O
rate	O
of	O
major	O
hemorrhage	B-DiseaseOrPhenotypicFeature
and	O
stroke	B-DiseaseOrPhenotypicFeature
in	O
more	O
than	O
500	O
patient	B-OrganismTaxon
-	O
years	O
of	O
follow	O
-	O
up	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
incidence	O
of	O
major	O
hemorrhage	B-DiseaseOrPhenotypicFeature
and	O
stroke	B-DiseaseOrPhenotypicFeature
in	O
people	O
aged	O
76	O
and	O
older	O
with	O
atrial	B-DiseaseOrPhenotypicFeature
fibrillation	I-DiseaseOrPhenotypicFeature
on	O
adjusted	O
-	O
dose	O
warfarin	B-ChemicalEntity
who	O
had	O
been	O
recently	O
been	O
admitted	O
to	O
hospital	O
.	O

DESIGN	O
:	O
A	O
retrospective	O
observational	O
cohort	O
study	O
.	O

SETTING	O
:	O
A	O
major	O
healthcare	O
network	O
involving	O
four	O
tertiary	O
hospitals	O
.	O

PARTICIPANTS	O
:	O
Two	O
hundred	O
thirty	O
-	O
five	O
patients	B-OrganismTaxon
aged	O
76	O
and	O
older	O
admitted	O
to	O
a	O
major	O
healthcare	O
network	O
between	O
July	O
1	O
,	O
2001	O
,	O
and	O
June	O
30	O
,	O
2002	O
,	O
with	O
atrial	B-DiseaseOrPhenotypicFeature
fibrillation	I-DiseaseOrPhenotypicFeature
on	O
warfarin	B-ChemicalEntity
were	O
enrolled	O
.	O

MEASUREMENTS	O
:	O
Information	O
regarding	O
major	O
bleeding	B-DiseaseOrPhenotypicFeature
episodes	O
,	O
strokes	B-DiseaseOrPhenotypicFeature
,	O
and	O
warfarin	B-ChemicalEntity
use	O
was	O
obtained	O
from	O
patients	B-OrganismTaxon
,	O
relatives	O
,	O
primary	O
physicians	O
,	O
and	O
medical	O
records	O
.	O

RESULTS	O
:	O
Two	O
hundred	O
twenty	O
-	O
eight	O
patients	B-OrganismTaxon
(	O
42%	O
men	B-OrganismTaxon
)	O
with	O
a	O
mean	O
age	O
of	O
81	O
.	O
1	O
(	O
range	O
76	O
-	O
94	O
)	O
were	O
included	O
in	O
the	O
analysis	O
.	O

Total	O
follow	O
-	O
up	O
on	O
warfarin	B-ChemicalEntity
was	O
530	O
years	O
(	O
mean	O
28	O
months	O
)	O
.	O

There	O
were	O
53	O
major	O
hemorrhages	B-DiseaseOrPhenotypicFeature
,	O
for	O
an	O
annual	O
rate	O
of	O
10	O
.	O
0%	O
,	O
including	O
24	O
(	O
45	O
.	O
3%	O
)	O
life	O
-	O
threatening	O
and	O
five	O
(	O
9	O
.	O
4%	O
)	O
fatal	O
bleeds	B-DiseaseOrPhenotypicFeature
.	O

The	O
annual	O
stroke	B-DiseaseOrPhenotypicFeature
rate	O
after	O
initiation	O
of	O
warfarin	B-ChemicalEntity
was	O
2	O
.	O
6%	O
.	O

CONCLUSION	O
:	O
The	O
rate	O
of	O
major	O
hemorrhage	B-DiseaseOrPhenotypicFeature
was	O
high	O
in	O
this	O
old	O
,	O
frail	O
group	O
,	O
but	O
excluding	O
fatalities	O
,	O
resulted	O
in	O
no	O
long	O
-	O
term	O
sequelae	O
,	O
and	O
the	O
stroke	B-DiseaseOrPhenotypicFeature
rate	O
on	O
warfarin	B-ChemicalEntity
was	O
low	O
,	O
demonstrating	O
how	O
effective	O
warfarin	B-ChemicalEntity
treatment	O
is	O
.	O
Apomorphine	B-ChemicalEntity
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

Apomorphine	B-ChemicalEntity
was	O
the	O
first	O
dopaminergic	B-ChemicalEntity
drug	I-ChemicalEntity
ever	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

While	O
powerful	O
antiparkinsonian	O
effects	O
had	O
been	O
observed	O
as	O
early	O
as	O
1951	O
,	O
the	O
potential	O
of	O
treating	O
fluctuating	O
Parkinson	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
by	O
subcutaneous	O
administration	O
of	O
apomorphine	B-ChemicalEntity
has	O
only	O
recently	O
become	O
the	O
subject	O
of	O
systematic	O
study	O
.	O

A	O
number	O
of	O
small	O
scale	O
clinical	O
trials	O
have	O
unequivocally	O
shown	O
that	O
intermittent	O
subcutaneous	O
apomorphine	B-ChemicalEntity
injections	O
produce	O
antiparkinsonian	O
benefit	O
close	O
if	O
not	O
identical	O
to	O
that	O
seen	O
with	O
levodopa	B-ChemicalEntity
and	O
that	O
apomorphine	B-ChemicalEntity
rescue	O
injections	O
can	O
reliably	O
revert	O
off	O
-	O
periods	O
even	O
in	O
patients	B-OrganismTaxon
with	O
complex	O
on	O
-	O
off	O
motor	O
swings	O
.	O

Continuous	O
subcutaneous	O
apomorphine	B-ChemicalEntity
infusions	O
can	O
reduce	O
daily	O
off	O
-	O
time	O
by	O
more	O
than	O
50%	O
in	O
this	O
group	O
of	O
patients	B-OrganismTaxon
,	O
which	O
appears	O
to	O
be	O
a	O
stronger	O
effect	O
than	O
that	O
generally	O
seen	O
with	O
add	O
-	O
on	O
therapy	O
with	O
oral	O
dopamine	B-ChemicalEntity
agonists	I-ChemicalEntity
or	O
COMT	B-ChemicalEntity
inhibitors	I-ChemicalEntity
.	O

Extended	O
follow	O
-	O
up	O
studies	O
of	O
up	O
to	O
8	O
years	O
have	O
demonstrated	O
long	O
-	O
term	O
persistence	O
of	O
apomorphine	B-ChemicalEntity
efficacy	O
.	O

In	O
addition	O
,	O
there	O
is	O
convincing	O
clinical	O
evidence	O
that	O
monotherapy	O
with	O
continuous	O
subcutaneous	O
apomorphine	B-ChemicalEntity
infusions	O
is	O
associated	O
with	O
marked	O
reductions	O
of	O
preexisting	O
levodopa	B-ChemicalEntity
-	O
induced	O
dyskinesias	B-DiseaseOrPhenotypicFeature
.	O

The	O
main	O
side	O
effects	O
of	O
subcutaneous	O
apomorphine	B-ChemicalEntity
treatment	O
are	O
related	O
to	O
cutaneous	O
tolerability	O
problems	O
,	O
whereas	O
sedation	O
and	O
psychiatric	B-DiseaseOrPhenotypicFeature
complications	I-DiseaseOrPhenotypicFeature
play	O
a	O
lesser	O
role	O
.	O

Given	O
the	O
marked	O
degree	O
of	O
efficacy	O
of	O
subcutaneous	O
apomorphine	B-ChemicalEntity
treatment	O
in	O
fluctuating	O
Parkinson	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
,	O
this	O
approach	O
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	O
use	O
.	O
Interleukin	B-GeneOrGeneProduct
-	O
17F	I-GeneOrGeneProduct
gene	O
polymorphism	O
in	O
patients	B-OrganismTaxon
with	O
chronic	B-DiseaseOrPhenotypicFeature
immune	I-DiseaseOrPhenotypicFeature
thrombocytopenia	I-DiseaseOrPhenotypicFeature
.	O

INTRODUCTION	O
:	O
IL	B-GeneOrGeneProduct
-	O
17F	I-GeneOrGeneProduct
is	O
a	O
novel	O
inflammatory	B-GeneOrGeneProduct
cytokine	I-GeneOrGeneProduct
and	O
plays	O
an	O
important	O
role	O
in	O
some	O
autoimmune	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
.	O

We	O
investigated	O
the	O
association	O
between	O
chronic	B-DiseaseOrPhenotypicFeature
ITP	I-DiseaseOrPhenotypicFeature
and	O
the	O
frequency	O
of	O
the	O
single	O
-	O
nucleotide	O
polymorphism	O
rs763780	B-SequenceVariant
(	O
7488T	B-SequenceVariant
/	O
C	I-SequenceVariant
)	O
,	O
which	O
causes	O
a	O
His	B-SequenceVariant
-	O
to	I-SequenceVariant
-	O
Arg	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
amino	I-SequenceVariant
acid	I-SequenceVariant
161	I-SequenceVariant
.	O

PATIENTS	B-OrganismTaxon
AND	O
METHODS	O
:	O
We	O
examined	O
102	O
patients	B-OrganismTaxon
(	O
men	B-OrganismTaxon
/	O
women	B-OrganismTaxon
,	O
40	O
/	O
62	O
;	O
median	O
age	O
,	O
42	O
)	O
diagnosed	O
with	O
chronic	B-DiseaseOrPhenotypicFeature
ITP	I-DiseaseOrPhenotypicFeature
and	O
188	O
healthy	O
controls	O
(	O
men	B-OrganismTaxon
/	O
women	B-OrganismTaxon
,	O
78	O
/	O
110	O
;	O
median	O
age	O
,	O
38	O
)	O
.	O

Genotyping	O
was	O
determined	O
by	O
the	O
polymerase	O
chain	O
reaction	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
(	O
PCR	O
-	O
RFLP	O
)	O
technique	O
.	O

RESULTS	O
:	O
Compared	O
with	O
the	O
control	O
group	O
,	O
patients	B-OrganismTaxon
with	O
chronic	B-DiseaseOrPhenotypicFeature
ITP	I-DiseaseOrPhenotypicFeature
had	O
a	O
significantly	O
lower	O
frequency	O
of	O
the	O
IL	B-GeneOrGeneProduct
-	O
17F	I-GeneOrGeneProduct
7488CC	B-SequenceVariant
genotype	O
(	O
0%	O
vs	O
.	O

4	O
.	O
8%	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
number	O
of	O
IL	B-GeneOrGeneProduct
-	O
17F	I-GeneOrGeneProduct
7488C	B-SequenceVariant
alleles	O
among	O
the	O
patients	B-OrganismTaxon
with	O
chronic	B-DiseaseOrPhenotypicFeature
ITP	I-DiseaseOrPhenotypicFeature
was	O
also	O
significantly	O
lower	O
than	O
in	O
the	O
control	O
group	O
(	O
8	O
.	O
7%	O
vs	O
.	O

15	O
.	O
2%	O
OR	O
=	O
0	O
.	O
48	O
,	O
95%CI	O
=	O
0	O
.	O
27	O
-	O
0	O
.	O
84	O
,	O
P	O
=	O
0	O
.	O
016	O
)	O
.	O

Furthermore	O
,	O
patients	B-OrganismTaxon
with	O
the	O
IL	B-GeneOrGeneProduct
-	O
17F	I-GeneOrGeneProduct
7488TT	B-SequenceVariant
genotype	O
showed	O
a	O
severe	O
thrombocytopenic	B-DiseaseOrPhenotypicFeature
state	O
(	O
platelet	O
count	O
<	O
10	O
10	O
(	O
9	O
)	O
/	O
L	O
)	O
at	O
diagnosis	O
than	O
those	O
with	O
the	O
IL	B-GeneOrGeneProduct
-	O
17F	I-GeneOrGeneProduct
7488TC	B-SequenceVariant
genotype	O
(	O
20	O
.	O
9%	O
vs	O
.	O

0%	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
suggest	O
that	O
the	O
IL	B-GeneOrGeneProduct
-	O
17F	I-GeneOrGeneProduct
7488	B-SequenceVariant
T	I-SequenceVariant
allele	O
is	O
significantly	O
associated	O
with	O
the	O
development	O
of	O
chronic	B-DiseaseOrPhenotypicFeature
ITP	I-DiseaseOrPhenotypicFeature
,	O
suggesting	O
a	O
role	O
for	O
IL	B-GeneOrGeneProduct
-	O
17F	I-GeneOrGeneProduct
in	O
the	O
pathogenesis	O
of	O
chronic	B-DiseaseOrPhenotypicFeature
ITP	I-DiseaseOrPhenotypicFeature
.	O
Identification	O
of	O
the	O
BRAF	B-GeneOrGeneProduct
V600E	B-SequenceVariant
mutation	O
in	O
gastroenteropancreatic	B-DiseaseOrPhenotypicFeature
neuroendocrine	I-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
.	O

Genomic	O
profiles	O
of	O
gastroenteropancreatic	B-DiseaseOrPhenotypicFeature
neuroendocrine	I-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
(	O
GEP	B-DiseaseOrPhenotypicFeature
-	O
NETs	I-DiseaseOrPhenotypicFeature
)	O
are	O
still	O
insufficiently	O
understood	O
,	O
and	O
the	O
genetic	O
alterations	O
associated	O
with	O
drug	O
responses	O
have	O
not	O
been	O
studied	O
.	O

Here	O
,	O
we	O
performed	O
whole	O
exome	O
sequencing	O
of	O
12	O
GEP	B-DiseaseOrPhenotypicFeature
-	O
NETs	I-DiseaseOrPhenotypicFeature
from	O
patients	B-OrganismTaxon
enrolled	O
in	O
a	O
nonrandomized	O
,	O
open	O
-	O
labeled	O
,	O
single	O
-	O
center	O
phase	O
II	O
study	O
for	O
pazopanib	B-ChemicalEntity
,	O
and	O
integrated	O
our	O
results	O
with	O
previously	O
published	O
results	O
on	O
pancreas	O
(	O
n	O
=	O
12	O
)	O
and	O
small	O
intestine	B-DiseaseOrPhenotypicFeature
NETs	I-DiseaseOrPhenotypicFeature
(	O
n	O
=	O
50	O
)	O
.	O

The	O
mean	O
numbers	O
of	O
somatic	O
mutations	O
in	O
each	O
case	O
varied	O
widely	O
from	O
20	O
to	O
4682	O
.	O

Among	O
12	O
GEP	B-DiseaseOrPhenotypicFeature
-	O
NETs	I-DiseaseOrPhenotypicFeature
,	O
eight	O
showed	O
mutations	O
of	O
more	O
than	O
one	O
cancer	B-DiseaseOrPhenotypicFeature
-	O
related	O
gene	O
,	O
including	O
TP53	B-GeneOrGeneProduct
,	O
CNBD1	B-GeneOrGeneProduct
,	O
RB1	B-GeneOrGeneProduct
,	O
APC	B-GeneOrGeneProduct
,	O
BCOR	B-GeneOrGeneProduct
,	O
BRAF	B-GeneOrGeneProduct
,	O
CTNNB1	B-GeneOrGeneProduct
,	O
EGFR	B-GeneOrGeneProduct
,	O
EP300	B-GeneOrGeneProduct
,	O
ERBB3	B-GeneOrGeneProduct
,	O
KDM6A	B-GeneOrGeneProduct
,	O
KRAS	B-GeneOrGeneProduct
,	O
MGA	B-GeneOrGeneProduct
,	O
MLL3	B-GeneOrGeneProduct
,	O
PTEN	B-GeneOrGeneProduct
,	O
RASA1	B-GeneOrGeneProduct
,	O
SMARCB1	B-GeneOrGeneProduct
,	O
SPEN	B-GeneOrGeneProduct
,	O
TBC1D12	B-GeneOrGeneProduct
,	O
and	O
VHL	B-GeneOrGeneProduct
.	O

TP53	B-GeneOrGeneProduct
was	O
recurrently	O
mutated	O
in	O
three	O
cases	O
,	O
whereas	O
CNBD1	B-GeneOrGeneProduct
and	O
RB1	B-GeneOrGeneProduct
mutations	O
were	O
identified	O
in	O
two	O
cases	O
.	O

Three	O
GEP	B-DiseaseOrPhenotypicFeature
-	O
NET	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
with	O
TP53	B-GeneOrGeneProduct
mutations	O
demonstrated	O
a	O
durable	O
response	O
and	O
one	O
small	O
intestinal	B-DiseaseOrPhenotypicFeature
grade	I-DiseaseOrPhenotypicFeature
(	O
G	I-DiseaseOrPhenotypicFeature
)	O
1	I-DiseaseOrPhenotypicFeature
NET	I-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
with	O
BRAF	B-GeneOrGeneProduct
V600E	B-SequenceVariant
mutation	O
showed	O
progression	O
after	O
pazopanib	B-ChemicalEntity
treatment	O
.	O

We	O
found	O
BRAF	B-GeneOrGeneProduct
V600E	B-SequenceVariant
(	O
G1	O
NET	B-DiseaseOrPhenotypicFeature
from	O
rectum	O
and	O
two	O
G3	O
NETs	B-DiseaseOrPhenotypicFeature
from	O
colon	O
)	O
and	O
BRAF	B-GeneOrGeneProduct
G593S	B-SequenceVariant
(	O
G2	O
NET	B-DiseaseOrPhenotypicFeature
from	O
pancreas	O
)	O
missense	O
mutations	O
(	O
9	O
.	O
1%	O
)	O
in	O
an	O
independent	O
cohort	O
of	O
44	O
GEP	B-DiseaseOrPhenotypicFeature
-	O
NETs	I-DiseaseOrPhenotypicFeature
from	O
the	O
rectum	O
(	O
n	O
=	O
26	O
)	O
,	O
colon	O
(	O
n	O
=	O
7	O
)	O
,	O
pancreas	O
(	O
n	O
=	O
4	O
)	O
,	O
small	O
intestine	O
(	O
n	O
=	O
3	O
)	O
,	O
stomach	O
(	O
n	O
=	O
3	O
)	O
and	O
appendix	O
(	O
n	O
=	O
1	O
)	O
by	O
Sanger	O
sequencing	O
.	O

All	O
tumor	B-DiseaseOrPhenotypicFeature
specimens	O
were	O
obtained	O
before	O
chemotherapy	O
.	O

In	O
conclusion	O
,	O
BRAF	B-GeneOrGeneProduct
V600E	B-SequenceVariant
mutation	O
is	O
likely	O
to	O
result	O
in	O
resistance	O
to	O
pazopanib	B-ChemicalEntity
but	O
may	O
be	O
a	O
potentianally	O
actionable	O
mutation	O
in	O
metastatic	O
GEP	B-DiseaseOrPhenotypicFeature
-	O
NETs	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O
A	O
novel	O
apolipoprotein	B-GeneOrGeneProduct
E	I-GeneOrGeneProduct
mutation	O
,	O
ApoE	B-GeneOrGeneProduct
Osaka	O
(	O
Arg158	B-SequenceVariant
Pro	I-SequenceVariant
)	O
,	O
in	O
a	O
dyslipidemic	B-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
with	O
lipoprotein	B-DiseaseOrPhenotypicFeature
glomerulopathy	I-DiseaseOrPhenotypicFeature
.	O

Lipoprotein	B-DiseaseOrPhenotypicFeature
glomerulopathy	I-DiseaseOrPhenotypicFeature
(	O
LPG	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
the	O
presence	O
of	O
thrombuslike	O
deposition	O
in	O
markedly	O
dilated	O
glomerular	O
capillaries	O
and	O
is	O
often	O
accompanied	O
by	O
an	O
increased	O
serum	O
apolipoprotein	B-GeneOrGeneProduct
E	I-GeneOrGeneProduct
(	O
apoE	B-GeneOrGeneProduct
)	O
level	O
.	O

Several	O
gene	O
mutations	O
of	O
apoE	B-GeneOrGeneProduct
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
LPG	B-DiseaseOrPhenotypicFeature
.	O

In	O
the	O
current	O
study	O
,	O
we	O
report	O
an	O
LPG	B-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
with	O
a	O
novel	O
apoE	B-GeneOrGeneProduct
mutation	O
,	O
apoE	B-GeneOrGeneProduct
Osaka	O
.	O

The	O
patient	B-OrganismTaxon
was	O
a	O
45	O
-	O
year	O
-	O
old	O
man	B-OrganismTaxon
who	O
was	O
hospitalized	O
due	O
to	O
nephrotic	B-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Light	O
and	O
electron	O
microscopic	O
observations	O
of	O
renal	O
biopsy	O
clearly	O
showed	O
characteristic	O
findings	O
of	O
LPG	B-DiseaseOrPhenotypicFeature
,	O
including	O
lamellate	B-DiseaseOrPhenotypicFeature
thrombi	I-DiseaseOrPhenotypicFeature
in	O
the	O
lumen	O
of	O
dilated	O
glomerular	O
capillaries	O
.	O

His	O
apoE	B-GeneOrGeneProduct
phenotype	O
was	O
apoE3	B-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
and	O
he	O
had	O
mild	O
dyslipidemia	B-DiseaseOrPhenotypicFeature
with	O
a	O
mid	O
-	O
band	O
on	O
polyacrylamide	B-ChemicalEntity
gel	O
electrophoresis	O
.	O

It	O
is	O
intriguing	O
that	O
the	O
serum	O
apoE	B-GeneOrGeneProduct
level	O
was	O
within	O
normal	O
limits	O
.	O

We	O
determined	O
the	O
sequence	O
of	O
the	O
apoE	B-GeneOrGeneProduct
gene	O
using	O
direct	O
sequencing	O
of	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
products	O
.	O

ApoE	B-GeneOrGeneProduct
gene	O
analysis	O
showed	O
a	O
nucleotide	O
substitution	O
of	O
G	B-SequenceVariant
to	I-SequenceVariant
C	I-SequenceVariant
at	I-SequenceVariant
codon	I-SequenceVariant
158	I-SequenceVariant
of	O
exon	O
4	O
.	O

This	O
mutation	O
denoted	O
an	O
amino	O
acid	O
substitution	O
of	O
arginine	B-SequenceVariant
residue	I-SequenceVariant
for	I-SequenceVariant
the	I-SequenceVariant
proline	I-SequenceVariant
residue	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
158	I-SequenceVariant
of	O
apoE	B-GeneOrGeneProduct
.	O

The	O
result	O
of	O
PCR	O
associated	O
with	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
also	O
suggested	O
that	O
this	O
mutation	O
is	O
heterozygous	O
.	O

It	O
is	O
possible	O
that	O
apoE	B-GeneOrGeneProduct
Osaka	O
mutation	O
causes	O
a	O
conformational	O
change	O
of	O
apoE	B-GeneOrGeneProduct
protein	O
and	O
affects	O
the	O
interaction	O
between	O
abnormal	O
apoE	B-GeneOrGeneProduct
-	O
containing	O
lipoproteins	O
and	O
the	O
endothelial	O
cells	O
of	O
glomerular	O
capillaries	O
.	O

The	O
precise	O
mechanism	O
of	O
LPG	B-DiseaseOrPhenotypicFeature
related	O
with	O
apoE	B-GeneOrGeneProduct
Osaka	O
,	O
however	O
,	O
remains	O
to	O
be	O
elucidated	O
.	O
Hemodynamic	O
parameters	O
and	O
heart	O
rate	O
variability	O
during	O
a	O
tilt	O
test	O
in	O
relation	O
to	O
gene	O
polymorphism	O
of	O
renin	B-GeneOrGeneProduct
-	O
angiotensin	B-GeneOrGeneProduct
and	O
serotonin	B-ChemicalEntity
system	O
.	O

PURPOSE	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
renin	B-GeneOrGeneProduct
-	O
angiotensin	B-GeneOrGeneProduct
system	O
and	O
serotonin	B-GeneOrGeneProduct
transporter	I-GeneOrGeneProduct
gene	O
polymorphisms	O
in	O
relation	O
to	O
hemodynamic	O
parameters	O
and	O
heart	O
rate	O
variability	O
during	O
a	O
head	O
-	O
up	O
tilt	O
test	O
(	O
HUT	O
)	O
in	O
patients	B-OrganismTaxon
with	O
vasovagal	B-DiseaseOrPhenotypicFeature
syncope	I-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
DNA	O
was	O
collected	O
from	O
191	O
patients	B-OrganismTaxon
(	O
mean	O
age	O
44	O
+	O
/	O
-	O
18	O
years	O
,	O
61	O
men	B-OrganismTaxon
,	O
130	O
women	B-OrganismTaxon
)	O
.	O

The	O
following	O
gene	O
polymorphisms	O
were	O
determined	O
in	O
genomic	O
DNA	O
:	O
angiotensin	B-GeneOrGeneProduct
-	O
converting	I-GeneOrGeneProduct
enzyme	I-GeneOrGeneProduct
insertion	O
/	O
deletion	O
polymorphism	O
(	O
I	O
/	O
D	O
ACE	B-GeneOrGeneProduct
)	O
,	O
angiotensinogen	B-GeneOrGeneProduct
gene	O
polymorphism	O
(	O
M	B-SequenceVariant
235	I-SequenceVariant
)	O
,	O
angiotensin	B-GeneOrGeneProduct
II	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
type	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
ATR1	B-GeneOrGeneProduct
)	O
polymorphism	O
(	O
A	B-SequenceVariant
11666C	I-SequenceVariant
)	O
,	O
and	O
polymorphism	O
of	O
serotonin	B-GeneOrGeneProduct
transporter	I-GeneOrGeneProduct
gene	O
(	O
5HTTLPR	B-GeneOrGeneProduct
)	O
.	O
Heart	O
rate	O
variability	O
during	O
HUT	O
was	O
assessed	O
in	O
5	O
-	O
minute	O
intervals	O
by	O
low	O
frequency	O
,	O
high	O
frequency	O
,	O
standard	O
deviation	O
of	O
the	O
normal	O
-	O
to	O
-	O
normal	O
(	O
SDNN	O
)	O
,	O
and	O
root	O
mean	O
square	O
successive	O
difference	O
parameters	O
.	O

RESULTS	O
:	O
AA	O
genotype	O
of	O
A	B-SequenceVariant
1166C	I-SequenceVariant
polymorphism	O
was	O
associated	O
with	O
lower	O
minimal	O
systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
and	O
diastolic	O
blood	O
pressure	O
(	O
DBP	O
)	O
during	O
HUT	O
compared	O
with	O
other	O
genotypes	O
(	O
minimal	O
SBP	O
:	O
AA	O
59	O
.	O
6	O
+	O
/	O
-	O
21	O
,	O
8	O
,	O
AC	O
79	O
.	O
9	O
+	O
/	O
-	O
22	O
.	O
7	O
,	O
CC	O
65	O
.	O
4	O
+	O
/	O
-	O
22	O
.	O
7	O
mmHg	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
,	O
(	O
minimal	O
DBP	O
:	O
AA	O
36	O
.	O
4	O
+	O
/	O
-	O
22	O
.	O
7	O
,	O
AC	O
52	O
.	O
3	O
+	O
/	O
-	O
22	O
.	O
9	O
,	O
CC	O
45	O
.	O
4	O
+	O
/	O
-	O
19	O
.	O
5	O
mmHg	O
,	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O
AA	O
genotype	O
was	O
also	O
associated	O
with	O
higher	O
SDNN	O
compared	O
to	O
other	O
genotypes	O
in	O
the	O
early	O
phase	O
of	O
HUT	O
(	O
SDNN	O
in	O
5	O
minutes	O
of	O
tilt	O
:	O
AA	O
59	O
.	O
7	O
+	O
/	O
-	O
24	O
.	O
6	O
,	O
AC	O
50	O
.	O
6	O
+	O
/	O
-	O
20	O
.	O
6	O
,	O
CC	O
46	O
.	O
0	O
+	O
/	O
-	O
13	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
at	O
syncope	B-DiseaseOrPhenotypicFeature
occurrence	O
(	O
SDNN	O
:	O
AA	O
71	O
.	O
0	O
+	O
/	O
-	O
20	O
.	O
9	O
,	O
AC	O
58	O
.	O
2	O
+	O
/	O
-	O
17	O
.	O
9	O
,	O
CC	O
58	O
+	O
/	O
-	O
10	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
CONCLUSION	O
:	O
AA	O
genotype	O
of	O
A	B-SequenceVariant
1166C	I-SequenceVariant
polymorphism	O
in	O
the	O
ATR1	B-GeneOrGeneProduct
gene	O
may	O
be	O
associated	O
with	O
hypotension	B-DiseaseOrPhenotypicFeature
and	O
decline	O
in	O
sympathetic	O
tone	O
during	O
HUT	O
.	O

Its	O
role	O
in	O
genetic	O
predisposition	O
to	O
vasovagal	B-DiseaseOrPhenotypicFeature
syncope	I-DiseaseOrPhenotypicFeature
cannot	O
be	O
excluded	O
.	O
Founder	O
mutations	O
in	O
the	O
BRCA1	B-GeneOrGeneProduct
gene	O
in	O
Polish	O
families	O
with	O
breast	B-DiseaseOrPhenotypicFeature
-	O
ovarian	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

We	O
have	O
undertaken	O
a	O
hospital	O
-	O
based	O
study	O
,	O
to	O
identify	O
possible	O
BRCA1	B-GeneOrGeneProduct
and	O
BRCA2	B-GeneOrGeneProduct
founder	O
mutations	O
in	O
the	O
Polish	O
population	O
.	O

The	O
study	O
group	O
consisted	O
of	O
66	O
Polish	O
families	O
with	O
cancer	B-DiseaseOrPhenotypicFeature
who	O
have	O
at	O
least	O
three	O
related	O
females	O
affected	O
with	O
breast	B-DiseaseOrPhenotypicFeature
or	I-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
and	O
who	O
had	O
cancer	B-DiseaseOrPhenotypicFeature
diagnosed	O
,	O
in	O
at	O
least	O
one	O
of	O
the	O
three	O
affected	O
females	O
,	O
at	O
age	O
<	O
50	O
years	O
.	O

A	O
total	O
of	O
26	O
families	O
had	O
both	O
breast	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
,	O
4	O
families	O
had	O
ovarian	B-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
only	O
,	O
and	O
36	O
families	O
had	O
breast	B-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
only	O
.	O

Genomic	O
DNA	O
was	O
prepared	O
from	O
the	O
peripheral	O
blood	O
leukocytes	O
of	O
at	O
least	O
one	O
affected	O
woman	B-OrganismTaxon
from	O
each	O
family	O
.	O

The	O
entire	O
coding	O
region	O
of	O
BRCA1	B-GeneOrGeneProduct
and	O
BRCA2	B-GeneOrGeneProduct
was	O
screened	O
for	O
the	O
presence	O
of	O
germline	O
mutations	O
,	O
by	O
use	O
of	O
SSCP	O
followed	O
by	O
direct	O
sequencing	O
of	O
observed	O
variants	O
.	O

Mutations	O
were	O
found	O
in	O
35	O
(	O
53%	O
)	O
of	O
the	O
66	O
families	O
studied	O
.	O

All	O
but	O
one	O
of	O
the	O
mutations	O
were	O
detected	O
within	O
the	O
BRCA1	B-GeneOrGeneProduct
gene	O
.	O

BRCA1	B-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
were	O
identified	O
in	O
all	O
four	O
families	O
with	O
ovarian	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
only	O
,	O
in	O
67%	O
of	O
27	O
families	O
with	O
both	O
breast	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
ovarian	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
,	O
and	O
in	O
34%	O
of	O
35	O
families	O
with	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
only	O
.	O

The	O
single	O
family	O
with	O
a	O
BRCA2	B-GeneOrGeneProduct
mutation	O
had	O
the	O
breast	B-DiseaseOrPhenotypicFeature
-	O
ovarian	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Seven	O
distinct	O
mutations	O
were	O
identified	O
;	O
five	O
of	O
these	O
occurred	O
in	O
two	O
or	O
more	O
families	O
.	O

In	O
total	O
,	O
recurrent	O
mutations	O
were	O
found	O
in	O
33	O
(	O
94%	O
)	O
of	O
the	O
35	O
families	O
with	O
detected	O
mutations	O
.	O

Three	O
BRCA1	B-DiseaseOrPhenotypicFeature
abnormalities	I-DiseaseOrPhenotypicFeature
-	O
5382insC	B-SequenceVariant
,	O
C61G	B-SequenceVariant
,	O
and	O
4153delA	B-SequenceVariant
-	O
accounted	O
for	O
51%	O
,	O
20%	O
,	O
and	O
11%	O
of	O
the	O
identified	O
mutations	O
,	O
respectively	O
.	O
Allelic	O
expression	O
imbalance	O
of	O
human	B-OrganismTaxon
mu	B-GeneOrGeneProduct
opioid	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
OPRM1	B-GeneOrGeneProduct
)	O
caused	O
by	O
variant	O
A118G	B-SequenceVariant
.	O

As	O
a	O
primary	O
target	O
for	O
opioid	O
drugs	O
and	O
peptides	O
,	O
the	O
mu	B-GeneOrGeneProduct
opioid	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
OPRM1	B-GeneOrGeneProduct
)	O
plays	O
a	O
key	O
role	O
in	O
pain	B-DiseaseOrPhenotypicFeature
perception	O
and	O
addiction	O
.	O

Genetic	O
variants	O
of	O
OPRM1	B-GeneOrGeneProduct
have	O
been	O
implicated	O
in	O
predisposition	O
to	O
drug	B-DiseaseOrPhenotypicFeature
addiction	I-DiseaseOrPhenotypicFeature
,	O
in	O
particular	O
the	O
single	O
nucleotide	O
polymorphism	O
A118G	B-SequenceVariant
,	O
leading	O
to	O
an	O
N40D	B-SequenceVariant
substitution	O
,	O
with	O
an	O
allele	O
frequency	O
of	O
10	O
-	O
32%	O
,	O
and	O
uncertain	O
functions	O
.	O

We	O
have	O
measured	O
allele	O
-	O
specific	O
mRNA	O
expression	O
of	O
OPRM1	B-GeneOrGeneProduct
in	O
human	B-OrganismTaxon
autopsy	O
brain	O
tissues	O
,	O
using	O
A118G	B-SequenceVariant
as	O
a	O
marker	O
.	O

In	O
8	O
heterozygous	O
samples	O
measured	O
,	O
the	O
A118	B-SequenceVariant
mRNA	O
allele	O
was	O
1	O
.	O
5	O
-	O
2	O
.	O
5	O
-	O
fold	O
more	O
abundant	O
than	O
the	O
G118	B-SequenceVariant
allele	O
.	O

Transfection	O
into	O
Chinese	B-OrganismTaxon
hamster	I-OrganismTaxon
ovary	O
cells	O
of	O
a	O
cDNA	O
representing	O
only	O
the	O
coding	O
region	O
of	O
OPRM1	B-GeneOrGeneProduct
,	O
carrying	O
adenosine	B-SequenceVariant
,	O
guanosine	I-SequenceVariant
,	O
cytidine	I-SequenceVariant
,	O
and	I-SequenceVariant
thymidine	I-SequenceVariant
in	I-SequenceVariant
position	I-SequenceVariant
118	I-SequenceVariant
,	O
resulted	O
in	O
1	O
.	O
5	O
-	O
fold	O
lower	O
mRNA	O
levels	O
only	O
for	O
OPRM1	B-GeneOrGeneProduct
-	O
G118	B-SequenceVariant
,	O
and	O
more	O
than	O
10	O
-	O
fold	O
lower	O
OPRM1	B-GeneOrGeneProduct
protein	O
levels	O
,	O
measured	O
by	O
Western	O
blotting	O
and	O
receptor	O
binding	O
assay	O
.	O

After	O
transfection	O
and	O
inhibition	O
of	O
transcription	O
with	O
actinomycin	B-ChemicalEntity
D	I-ChemicalEntity
,	O
analysis	O
of	O
mRNA	O
turnover	O
failed	O
to	O
reveal	O
differences	O
in	O
mRNA	O
stability	O
between	O
A118	B-SequenceVariant
and	O
G118	B-SequenceVariant
alleles	O
,	O
indicating	O
a	O
defect	O
in	O
transcription	O
or	O
mRNA	O
maturation	O
.	O

These	O
results	O
indicate	O
that	O
OPRM1	B-GeneOrGeneProduct
-	O
G118	B-SequenceVariant
is	O
a	O
functional	O
variant	O
with	O
deleterious	O
effects	O
on	O
both	O
mRNA	O
and	O
protein	O
yield	O
.	O

Clarifying	O
the	O
functional	O
relevance	O
of	O
polymorphisms	O
associated	O
with	O
susceptibility	O
to	O
a	O
complex	O
disorder	O
such	O
as	O
drug	B-DiseaseOrPhenotypicFeature
addiction	I-DiseaseOrPhenotypicFeature
provides	O
a	O
foundation	O
for	O
clinical	O
association	O
studies	O
.	O
Peroxisomal	B-GeneOrGeneProduct
proliferator	I-GeneOrGeneProduct
activated	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
gamma	I-GeneOrGeneProduct
deficiency	O
in	O
a	O
Canadian	O
kindred	O
with	O
familial	B-DiseaseOrPhenotypicFeature
partial	I-DiseaseOrPhenotypicFeature
lipodystrophy	I-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
3	I-DiseaseOrPhenotypicFeature
(	O
FPLD3	B-DiseaseOrPhenotypicFeature
)	O
.	O

BACKGROUND	O
:	O
Familial	B-DiseaseOrPhenotypicFeature
partial	I-DiseaseOrPhenotypicFeature
lipodystrophy	I-DiseaseOrPhenotypicFeature
(	O
Dunnigan	I-DiseaseOrPhenotypicFeature
)	O
type	I-DiseaseOrPhenotypicFeature
3	I-DiseaseOrPhenotypicFeature
(	O
FPLD3	B-DiseaseOrPhenotypicFeature
,	O
Mendelian	B-DiseaseOrPhenotypicFeature
Inheritance	I-DiseaseOrPhenotypicFeature
in	I-DiseaseOrPhenotypicFeature
Man	I-DiseaseOrPhenotypicFeature
[	O
MIM	I-DiseaseOrPhenotypicFeature
]	O
604367	I-DiseaseOrPhenotypicFeature
)	O
results	O
from	O
heterozygous	O
mutations	O
in	O
PPARG	B-GeneOrGeneProduct
encoding	O
peroxisomal	B-GeneOrGeneProduct
proliferator	I-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
gamma	I-GeneOrGeneProduct
.	O

Both	O
dominant	O
-	O
negative	O
and	O
haploinsufficiency	O
mechanisms	O
have	O
been	O
suggested	O
for	O
this	O
condition	O
.	O

METHODS	O
:	O
We	O
present	O
a	O
Canadian	O
FPLD3	B-DiseaseOrPhenotypicFeature
kindred	O
with	O
an	O
affected	O
mother	O
who	O
had	O
loss	O
of	O
fat	O
on	O
arms	O
and	O
legs	O
,	O
but	O
no	O
increase	O
in	O
facial	O
,	O
neck	O
,	O
suprascapular	O
or	O
abdominal	O
fat	O
.	O

She	O
had	O
profound	O
insulin	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
,	O
diabetes	B-DiseaseOrPhenotypicFeature
,	O
severe	O
hypertriglyceridemia	B-DiseaseOrPhenotypicFeature
and	O
relapsing	O
pancreatitis	B-DiseaseOrPhenotypicFeature
,	O
while	O
her	O
pre	O
-	O
pubescent	O
daughter	O
had	O
normal	O
fat	O
distribution	O
but	O
elevated	O
plasma	O
triglycerides	B-ChemicalEntity
and	O
C	B-ChemicalEntity
-	O
peptide	I-ChemicalEntity
and	O
depressed	O
high	B-ChemicalEntity
-	O
density	I-ChemicalEntity
lipoprotein	I-ChemicalEntity
cholesterol	I-ChemicalEntity
.	O

RESULTS	O
:	O
The	O
mother	O
and	O
daughter	O
were	O
each	O
heterozygous	O
for	O
PPARG	B-GeneOrGeneProduct
nonsense	O
mutation	O
Y355X	B-SequenceVariant
,	O
whose	O
protein	O
product	O
in	O
vitro	O
was	O
transcriptionally	O
inactive	O
with	O
no	O
dominant	O
-	O
negative	O
activity	O
against	O
the	O
wild	O
-	O
type	O
receptor	O
.	O

In	O
addition	O
the	O
mutant	O
protein	O
appeared	O
to	O
be	O
markedly	O
unstable	O
.	O

CONCLUSION	O
:	O
Taken	O
together	O
with	O
previous	O
studies	O
of	O
human	B-OrganismTaxon
PPARG	B-GeneOrGeneProduct
mutations	O
,	O
these	O
findings	O
suggest	O
that	O
PPAR	B-GeneOrGeneProduct
-	O
gamma	I-GeneOrGeneProduct
deficiency	O
due	O
either	O
to	O
haploinsufficiency	O
or	O
to	O
substantial	O
activity	O
loss	O
due	O
to	O
dominant	O
negative	O
interference	O
of	O
the	O
normal	O
allele	O
product	O
'	O
s	O
function	O
can	O
each	O
contribute	O
to	O
the	O
FPLD3	B-DiseaseOrPhenotypicFeature
phenotype	O
.	O
Cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
of	O
temsirolimus	B-ChemicalEntity
in	O
refractory	O
mantle	B-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
.	O

Mantle	B-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
(	O
MCL	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
rare	O
and	O
aggressive	O
type	O
of	O
B	B-DiseaseOrPhenotypicFeature
-	O
cell	I-DiseaseOrPhenotypicFeature
non	I-DiseaseOrPhenotypicFeature
-	O
Hodgkin	I-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
.	O

Patients	B-OrganismTaxon
become	O
progressively	O
refractory	O
to	O
conventional	O
chemotherapy	O
,	O
and	O
their	O
prognosis	O
is	O
poor	O
.	O

However	O
,	O
a	O
38%	O
remission	O
rate	O
has	O
been	O
recently	O
reported	O
in	O
refractory	O
MCL	B-DiseaseOrPhenotypicFeature
treated	O
with	O
temsirolimus	B-ChemicalEntity
,	O
a	O
mTOR	B-GeneOrGeneProduct
inhibitor	O
.	O
Here	O
we	O
had	O
the	O
opportunity	O
to	O
study	O
a	O
case	O
of	O
refractory	O
MCL	B-DiseaseOrPhenotypicFeature
who	O
had	O
tumor	B-DiseaseOrPhenotypicFeature
regression	O
two	O
months	O
after	O
temsirolimus	B-ChemicalEntity
treatment	O
,	O
and	O
a	O
progression	O
-	O
free	O
survival	O
of	O
10	O
months	O
.	O

In	O
this	O
case	O
,	O
lymph	O
node	O
biopsies	O
were	O
performed	O
before	O
and	O
six	O
months	O
after	O
temsirolimus	B-ChemicalEntity
therapy	O
.	O

Comparison	O
of	O
the	O
two	O
biopsies	O
showed	O
that	O
temsirolimus	B-ChemicalEntity
inhibited	O
tumor	B-DiseaseOrPhenotypicFeature
cell	O
proliferation	O
through	O
cell	O
cycle	O
arrest	O
,	O
but	O
did	O
not	O
induce	O
any	O
change	O
in	O
the	O
number	O
of	O
apoptotic	O
tumor	B-DiseaseOrPhenotypicFeature
cells	O
.	O

Apart	O
from	O
this	O
cytostatic	O
effect	O
,	O
temsirolimus	B-ChemicalEntity
had	O
an	O
antiangiogenic	O
effect	O
with	O
decrease	O
of	O
tumor	B-DiseaseOrPhenotypicFeature
microvessel	O
density	O
and	O
of	O
VEGF	B-GeneOrGeneProduct
expression	O
.	O

Moreover	O
,	O
numerous	O
patchy	O
,	O
well	O
-	O
limited	O
fibrotic	O
areas	O
,	O
compatible	O
with	O
post	O
-	O
necrotic	B-DiseaseOrPhenotypicFeature
tissue	O
repair	O
,	O
were	O
found	O
after	O
6	O
-	O
month	O
temsirolimus	B-ChemicalEntity
therapy	O
.	O

Thus	O
,	O
temsirolimus	B-ChemicalEntity
reduced	O
tumor	B-DiseaseOrPhenotypicFeature
burden	O
through	O
associated	O
cytostatic	O
and	O
anti	O
-	O
angiogenic	O
effects	O
.	O
This	O
dual	O
effect	O
of	O
temsirolimus	B-ChemicalEntity
on	O
tumor	B-DiseaseOrPhenotypicFeature
tissue	O
could	O
contribute	O
to	O
its	O
recently	O
reported	O
efficiency	O
in	O
refractory	O
MCL	B-DiseaseOrPhenotypicFeature
resistant	O
to	O
conventional	O
chemotherapy	O
.	O
Rapid	O
reversal	O
of	O
anticoagulation	O
reduces	O
hemorrhage	B-DiseaseOrPhenotypicFeature
volume	O
in	O
a	O
mouse	B-OrganismTaxon
model	O
of	O
warfarin	B-ChemicalEntity
-	O
associated	O
intracerebral	B-DiseaseOrPhenotypicFeature
hemorrhage	I-DiseaseOrPhenotypicFeature
.	O

Warfarin	B-ChemicalEntity
-	O
associated	O
intracerebral	B-DiseaseOrPhenotypicFeature
hemorrhage	I-DiseaseOrPhenotypicFeature
(	O
W	B-ChemicalEntity
-	O
ICH	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
severe	O
type	O
of	O
stroke	B-DiseaseOrPhenotypicFeature
.	O

There	O
is	O
no	O
consensus	O
on	O
the	O
optimal	O
treatment	O
for	O
W	B-ChemicalEntity
-	O
ICH	B-DiseaseOrPhenotypicFeature
.	O

Using	O
a	O
mouse	B-OrganismTaxon
model	O
,	O
we	O
tested	O
whether	O
the	O
rapid	O
reversal	O
of	O
anticoagulation	O
using	O
human	B-OrganismTaxon
prothrombin	B-ChemicalEntity
complex	I-ChemicalEntity
concentrate	I-ChemicalEntity
(	O
PCC	B-ChemicalEntity
)	O
can	O
reduce	O
hemorrhagic	O
blood	O
volume	O
.	O

Male	O
CD	O
-	O
1	O
mice	B-OrganismTaxon
were	O
treated	O
with	O
warfarin	B-ChemicalEntity
(	O
2	O
mg	O
/	O
kg	O
over	O
24	O
h	O
)	O
,	O
resulting	O
in	O
a	O
mean	O
(	O
+	O
/	O
-	O
s	O
.	O
d	O
.	O
)	O
International	O
Normalized	O
Ratio	O
of	O
3	O
.	O
5	O
+	O
/	O
-	O
0	O
.	O
9	O
.	O

First	O
,	O
we	O
showed	O
that	O
an	O
intravenous	O
administration	O
of	O
human	B-OrganismTaxon
PCC	B-ChemicalEntity
rapidly	O
reversed	O
anticoagulation	O
in	O
mice	B-OrganismTaxon
.	O

Second	O
,	O
a	O
stereotactic	O
injection	O
of	O
collagenase	B-ChemicalEntity
was	O
administered	O
to	O
induce	O
hemorrhage	B-DiseaseOrPhenotypicFeature
in	O
the	O
right	O
striatum	O
.	O

Forty	O
-	O
five	O
minutes	O
later	O
,	O
the	O
animals	O
were	O
randomly	O
treated	O
with	O
PCC	B-ChemicalEntity
(	O
100	O
U	O
/	O
kg	O
)	O
or	O
saline	O
i	O
.	O
v	O
.	O

(	O
n	O
=	O
12	O
per	O
group	O
)	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
hemorrhage	B-DiseaseOrPhenotypicFeature
induction	O
,	O
hemorrhagic	O
blood	O
volume	O
was	O
quantified	O
using	O
a	O
photometric	O
hemoglobin	O
assay	O
.	O

The	O
mean	O
hemorrhagic	O
blood	O
volume	O
was	O
reduced	O
in	O
PCC	B-ChemicalEntity
-	O
treated	O
animals	O
(	O
6	O
.	O
5	O
+	O
/	O
-	O
3	O
.	O
1	O
microL	O
)	O
compared	O
with	O
saline	O
controls	O
(	O
15	O
.	O
3	O
+	O
/	O
-	O
11	O
.	O
2	O
microL	O
,	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

In	O
the	O
saline	O
group	O
,	O
45%	O
of	O
the	O
mice	B-OrganismTaxon
developed	O
large	O
hematomas	B-DiseaseOrPhenotypicFeature
(	O
i	O
.	O
e	O
.	O
,	O
>	O
15	O
microL	O
)	O
.	O

In	O
contrast	O
,	O
such	O
extensive	O
lesions	O
were	O
never	O
found	O
in	O
the	O
PCC	B-ChemicalEntity
group	O
.	O

We	O
provide	O
experimental	O
data	O
suggesting	O
PCC	B-ChemicalEntity
to	O
be	O
an	O
effective	O
acute	O
treatment	O
for	O
W	B-ChemicalEntity
-	O
ICH	B-DiseaseOrPhenotypicFeature
in	O
terms	O
of	O
reducing	O
hemorrhagic	O
blood	O
volume	O
.	O

Future	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
therapeutic	O
potential	O
emerging	O
from	O
our	O
finding	O
for	O
human	B-OrganismTaxon
W	B-ChemicalEntity
-	O
ICH	B-DiseaseOrPhenotypicFeature
.	O
Role	O
of	O
stress	O
-	O
activated	O
OCT4A	B-GeneOrGeneProduct
in	O
the	O
cell	O
fate	O
decisions	O
of	O
embryonal	B-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
cells	O
treated	O
with	O
etoposide	B-ChemicalEntity
.	O

Tumor	O
cellular	O
senescence	O
induced	O
by	O
genotoxic	O
treatments	O
has	O
recently	O
been	O
found	O
to	O
be	O
paradoxically	O
linked	O
to	O
the	O
induction	O
of	O
""""	O
stemness	O
.	O
""""	O
This	O
observation	O
is	O
critical	O
as	O
it	O
directly	O
impinges	O
upon	O
the	O
response	O
of	O
tumors	B-DiseaseOrPhenotypicFeature
to	O
current	O
chemo	O
-	O
radio	O
-	O
therapy	O
treatment	O
regimens	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
following	O
etoposide	B-ChemicalEntity
(	O
ETO	B-ChemicalEntity
)	O
treatment	O
embryonal	B-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
PA	B-CellLine
-	O
1	I-CellLine
cells	O
undergo	O
a	O
p53	B-GeneOrGeneProduct
-	O
dependent	O
upregulation	O
of	O
OCT4A	B-GeneOrGeneProduct
and	O
p21Cip1	B-GeneOrGeneProduct
(	O
governing	O
self	O
-	O
renewal	O
and	O
regulating	O
cell	O
cycle	O
inhibition	O
and	O
senescence	O
,	O
respectively	O
)	O
.	O

Here	O
we	O
report	O
further	O
detail	O
on	O
the	O
relationship	O
between	O
these	O
and	O
other	O
critical	O
cell	O
-	O
fate	O
regulators	O
.	O

PA	B-CellLine
-	O
1	I-CellLine
cells	O
treated	O
with	O
ETO	B-ChemicalEntity
display	O
highly	O
heterogeneous	O
increases	O
in	O
OCT4A	B-GeneOrGeneProduct
and	O
p21Cip1	B-GeneOrGeneProduct
indicative	O
of	O
dis	O
-	O
adaptation	O
catastrophe	O
.	O

Silencing	O
OCT4A	B-GeneOrGeneProduct
suppresses	O
p21Cip1	B-GeneOrGeneProduct
,	O
changes	O
cell	O
cycle	O
regulation	O
and	O
subsequently	O
suppresses	O
terminal	O
senescence	O
;	O
p21Cip1	B-GeneOrGeneProduct
-	O
silencing	O
did	O
not	O
affect	O
OCT4A	B-GeneOrGeneProduct
expression	O
or	O
cellular	O
phenotype	O
.	O

SOX2	B-GeneOrGeneProduct
and	O
NANOG	B-GeneOrGeneProduct
expression	O
did	O
not	O
change	O
following	O
ETO	B-ChemicalEntity
treatment	O
suggesting	O
a	O
dissociation	O
of	O
OCT4A	B-GeneOrGeneProduct
from	O
its	O
pluripotency	O
function	O
.	O

Instead	O
,	O
ETO	B-ChemicalEntity
-	O
induced	O
OCT4A	B-GeneOrGeneProduct
was	O
concomitant	O
with	O
activation	O
of	O
AMPK	B-GeneOrGeneProduct
,	O
a	O
key	O
component	O
of	O
metabolic	O
stress	O
and	O
autophagy	O
regulation	O
.	O

p16ink4a	B-GeneOrGeneProduct
,	O
the	O
inducer	O
of	O
terminal	O
senescence	O
,	O
underwent	O
autophagic	O
sequestration	O
in	O
the	O
cytoplasm	O
of	O
ETO	B-ChemicalEntity
-	O
treated	O
cells	O
,	O
allowing	O
alternative	O
cell	O
fates	O
.	O

Accordingly	O
,	O
failure	O
of	O
autophagy	O
was	O
accompanied	O
by	O
an	O
accumulation	O
of	O
p16ink4a	B-GeneOrGeneProduct
,	O
nuclear	O
disintegration	O
,	O
and	O
loss	O
of	O
cell	O
recovery	O
.	O

Together	O
,	O
these	O
findings	O
imply	O
that	O
OCT4A	B-GeneOrGeneProduct
induction	O
following	O
DNA	O
damage	O
in	O
PA	B-CellLine
-	O
1	I-CellLine
cells	O
,	O
performs	O
a	O
cell	O
stress	O
,	O
rather	O
than	O
self	O
-	O
renewal	O
,	O
function	O
by	O
moderating	O
the	O
expression	O
of	O
p21Cip1	B-GeneOrGeneProduct
,	O
which	O
alongside	O
AMPK	B-GeneOrGeneProduct
helps	O
to	O
then	O
regulate	O
autophagy	O
.	O

Moreover	O
,	O
this	O
data	O
indicates	O
that	O
exhaustion	O
of	O
autophagy	O
,	O
through	O
persistent	O
DNA	O
damage	O
,	O
is	O
the	O
cause	O
of	O
terminal	O
cellular	O
senescence	O
.	O
Cisplatin	B-ChemicalEntity
induces	O
tolerogenic	O
dendritic	O
cells	O
in	O
response	O
to	O
TLR	B-GeneOrGeneProduct
agonists	O
via	O
the	O
abundant	O
production	O
of	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
,	O
thereby	O
promoting	O
Th2	O
-	O
and	O
Tr1	O
-	O
biased	O
T	O
-	O
cell	O
immunity	O
.	O

Although	O
many	O
advantageous	O
roles	O
of	O
cisplatin	B-ChemicalEntity
(	O
cis	B-ChemicalEntity
-	O
diamminedichloroplatinum	I-ChemicalEntity
(	O
II	O
)	O
,	O
CDDP	B-ChemicalEntity
)	O
have	O
been	O
reported	O
in	O
cancer	B-DiseaseOrPhenotypicFeature
therapy	O
,	O
the	O
immunomodulatory	O
roles	O
of	O
cisplatin	B-ChemicalEntity
in	O
the	O
phenotypic	O
and	O
functional	O
alterations	O
of	O
dendritic	O
cells	O
(	O
DCs	O
)	O
are	O
poorly	O
understood	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
cisplatin	B-ChemicalEntity
on	O
the	O
functionality	O
of	O
DCs	O
and	O
the	O
changes	O
in	O
signaling	O
pathways	O
activated	O
upon	O
toll	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
TLR	B-GeneOrGeneProduct
)	O
stimulation	O
.	O

Cisplatin	B-ChemicalEntity
-	O
treated	O
DCs	O
down	O
-	O
regulated	O
the	O
expression	O
of	O
cell	O
surface	O
molecules	O
(	O
CD80	B-GeneOrGeneProduct
,	O
CD86	B-GeneOrGeneProduct
,	O
MHC	B-GeneOrGeneProduct
class	I-GeneOrGeneProduct
I	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
)	O
and	O
up	O
-	O
regulated	O
endocytic	O
capacity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Upon	O
stimulation	O
with	O
various	O
TLR	B-GeneOrGeneProduct
agonists	O
,	O
cisplatin	B-ChemicalEntity
-	O
treated	O
DCs	O
showed	O
markedly	O
increased	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
production	O
through	O
activation	O
of	O
the	O
p38	B-GeneOrGeneProduct
MAPK	I-GeneOrGeneProduct
and	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
signaling	O
pathways	O
without	O
altering	O
the	O
levels	O
of	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
and	O
IL	B-GeneOrGeneProduct
-	O
12p70	I-GeneOrGeneProduct
,	O
indicating	O
the	O
cisplatin	B-ChemicalEntity
-	O
mediated	O
induction	O
of	O
tolerogenic	O
DCs	O
.	O

This	O
effect	O
was	O
dependent	O
on	O
the	O
production	O
of	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
from	O
DCs	O
,	O
as	O
neither	O
DCs	O
isolated	O
from	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
-	O
/	O
-	O
mice	B-OrganismTaxon
nor	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
-	O
neutralized	O
DCs	O
generated	O
tolerogenic	O
DCs	O
.	O

Interestingly	O
,	O
DCs	O
that	O
were	O
co	O
-	O
treated	O
with	O
cisplatin	B-ChemicalEntity
and	O
lipopolysaccharide	B-ChemicalEntity
(	O
LPS	B-ChemicalEntity
)	O
exhibited	O
a	O
decreased	O
immunostimulatory	O
capacity	O
for	O
inducing	O
the	O
proliferation	O
of	O
Th1	O
-	O
and	O
Th17	O
-	O
type	O
T	O
cells	O
;	O
instead	O
,	O
these	O
DCs	O
contributed	O
to	O
Th2	O
-	O
type	O
T	O
cell	O
immunity	O
.	O

Furthermore	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
investigations	O
revealed	O
a	O
unique	O
T	O
cell	O
population	O
,	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
-	O
producing	O
CD3	B-GeneOrGeneProduct
+	O
CD4	B-GeneOrGeneProduct
+	O
LAG	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
+	O
CD49b	B-GeneOrGeneProduct
+	O
CD25	B-GeneOrGeneProduct
-	O
Foxp3	B-GeneOrGeneProduct
-	O
Tr1	O
cells	O
,	O
that	O
was	O
significantly	O
increased	O
without	O
altering	O
the	O
Foxp3	B-GeneOrGeneProduct
+	O
regulatory	O
T	O
cell	O
population	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
cisplatin	B-ChemicalEntity
induces	O
immune	O
-	O
suppressive	O
tolerogenic	O
DCs	O
in	O
TLR	B-ChemicalEntity
agonist	I-ChemicalEntity
-	O
induced	O
inflammatory	B-DiseaseOrPhenotypicFeature
conditions	O
via	O
abundant	O
IL	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
production	O
,	O
thereby	O
skewing	O
Th	O
cell	O
differentiation	O
towards	O
Th2	O
and	O
Tr1	O
cells	O
.	O

This	O
relationship	O
may	O
provide	O
cancer	B-DiseaseOrPhenotypicFeature
cells	O
with	O
an	O
opportunity	O
to	O
evade	O
the	O
immune	O
system	O
.	O

Leukemia	B-GeneOrGeneProduct
inhibitory	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
protects	O
the	O
lung	O
during	O
respiratory	B-DiseaseOrPhenotypicFeature
syncytial	I-DiseaseOrPhenotypicFeature
viral	I-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Respiratory	B-OrganismTaxon
syncytial	I-OrganismTaxon
virus	I-OrganismTaxon
(	O
RSV	B-OrganismTaxon
)	O
infects	O
the	O
lung	O
epithelium	O
where	O
it	O
stimulates	O
the	O
production	O
of	O
numerous	O
host	O
cytokines	O
that	O
are	O
associated	O
with	O
disease	O
burden	O
and	O
acute	B-DiseaseOrPhenotypicFeature
lung	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
.	O

Characterizing	O
the	O
host	O
cytokine	O
response	O
to	O
RSV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
,	O
the	O
regulation	O
of	O
host	O
cytokines	O
and	O
the	O
impact	O
of	O
neutralizing	O
an	O
RSV	B-OrganismTaxon
-	O
inducible	O
cytokine	O
during	O
infection	B-DiseaseOrPhenotypicFeature
were	O
undertaken	O
in	O
this	O
study	O
.	O

METHODS	O
:	O
A549	B-CellLine
,	O
primary	O
human	B-OrganismTaxon
small	O
airway	O
epithelial	O
(	O
SAE	B-CellLine
)	O
cells	O
and	O
wild	O
-	O
type	O
,	O
TIR	B-GeneOrGeneProduct
-	O
domain	I-GeneOrGeneProduct
-	O
containing	I-GeneOrGeneProduct
adapter	I-GeneOrGeneProduct
-	O
inducing	I-GeneOrGeneProduct
interferon	I-GeneOrGeneProduct
-	O
b	I-GeneOrGeneProduct
(	O
Trif	B-GeneOrGeneProduct
)	O
and	O
mitochondrial	B-GeneOrGeneProduct
antiviral	I-GeneOrGeneProduct
-	O
signaling	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
Mavs	B-GeneOrGeneProduct
)	O
knockout	O
(	O
KO	O
)	O
mice	B-OrganismTaxon
were	O
infected	O
with	O
RSV	B-OrganismTaxon
and	O
cytokine	O
responses	O
were	O
investigated	O
by	O
ELISA	O
,	O
multiplex	O
analysis	O
and	O
qPCR	O
.	O

Neutralizing	O
anti	O
-	O
leukemia	B-GeneOrGeneProduct
inhibitory	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
LIF	B-GeneOrGeneProduct
)	O
IgG	O
or	O
control	O
IgG	O
was	O
administered	O
to	O
a	O
group	O
of	O
wild	O
-	O
type	O
animals	O
prior	O
to	O
RSV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O

RESULTS	O
AND	O
DISCUSSION	O
:	O
RSV	B-DiseaseOrPhenotypicFeature
-	O
infected	I-DiseaseOrPhenotypicFeature
A549	B-CellLine
and	O
SAE	B-CellLine
cells	O
release	O
a	O
network	O
of	O
cytokines	O
,	O
including	O
newly	O
identified	O
RSV	B-OrganismTaxon
-	O
inducible	O
cytokines	O
LIF	B-GeneOrGeneProduct
,	O
migration	B-GeneOrGeneProduct
inhibitory	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
MIF	B-GeneOrGeneProduct
)	O
,	O
stem	B-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
SCF	B-GeneOrGeneProduct
)	O
,	O
CCL27	B-GeneOrGeneProduct
,	O
CXCL12	B-GeneOrGeneProduct
and	O
stem	B-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
(	O
SCGF	B-GeneOrGeneProduct
-	O
b	I-GeneOrGeneProduct
)	O
.	O

These	O
RSV	B-OrganismTaxon
-	O
inducible	O
cytokines	O
were	O
also	O
observed	O
in	O
the	O
airways	O
of	O
mice	B-OrganismTaxon
during	O
an	O
infection	B-DiseaseOrPhenotypicFeature
.	O

To	O
identify	O
the	O
regulation	O
of	O
RSV	B-OrganismTaxon
inducible	O
cytokines	O
,	O
Mavs	B-GeneOrGeneProduct
and	O
Trif	B-GeneOrGeneProduct
deficient	O
animals	O
were	O
infected	O
with	O
RSV	B-OrganismTaxon
.	O

In	O
vivo	O
induction	O
of	O
airway	O
IL	B-GeneOrGeneProduct
-	O
1b	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
5	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
12	I-GeneOrGeneProduct
(	O
p40	B-GeneOrGeneProduct
)	O
,	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
,	O
CCL2	B-GeneOrGeneProduct
,	O
CCL5	B-GeneOrGeneProduct
,	O
CCL3	B-GeneOrGeneProduct
,	O
CXCL1	B-GeneOrGeneProduct
,	O
IP	B-GeneOrGeneProduct
-	O
10	I-GeneOrGeneProduct
/	O
CXCL10	B-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
22	I-GeneOrGeneProduct
,	O
MIG	B-GeneOrGeneProduct
/	O
CXCL9	B-GeneOrGeneProduct
and	O
MIF	B-GeneOrGeneProduct
were	O
dependent	O
on	O
Mavs	B-GeneOrGeneProduct
expression	O
in	O
mice	B-OrganismTaxon
.	O

Loss	O
of	O
Trif	B-GeneOrGeneProduct
expression	O
in	O
mice	B-OrganismTaxon
altered	O
the	O
RSV	B-OrganismTaxon
induction	O
of	O
IL	B-GeneOrGeneProduct
-	O
1b	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
5	I-GeneOrGeneProduct
,	O
CXCL12	B-GeneOrGeneProduct
,	O
MIF	B-GeneOrGeneProduct
,	O
LIF	B-GeneOrGeneProduct
,	O
CXCL12	B-GeneOrGeneProduct
and	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
.	O

Silencing	O
of	O
retinoic	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
-	O
inducible	I-GeneOrGeneProduct
gene	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
RIG	B-GeneOrGeneProduct
-	O
I	I-GeneOrGeneProduct
)	O
expression	O
in	O
A549	B-CellLine
cells	O
had	O
a	O
greater	O
impact	O
on	O
RSV	B-OrganismTaxon
-	O
inducible	O
cytokines	O
than	O
melanoma	B-GeneOrGeneProduct
differentiation	I-GeneOrGeneProduct
-	O
associated	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
5	I-GeneOrGeneProduct
(	O
MDA5	B-GeneOrGeneProduct
)	O
and	O
laboratory	B-GeneOrGeneProduct
of	I-GeneOrGeneProduct
genetics	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
physiology	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
(	O
LGP2	B-GeneOrGeneProduct
)	O
,	O
and	O
Trif	B-GeneOrGeneProduct
expression	O
.	O

To	O
evaluate	O
the	O
role	O
of	O
LIF	B-GeneOrGeneProduct
in	O
the	O
airways	O
during	O
RSV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
,	O
animals	O
were	O
treated	O
with	O
neutralizing	O
anti	O
-	O
LIF	B-GeneOrGeneProduct
IgG	O
,	O
which	O
enhanced	O
RSV	B-OrganismTaxon
pathology	O
observed	O
with	O
increased	O
airspace	O
protein	O
content	O
,	O
apoptosis	O
and	O
airway	O
hyperresponsiveness	O
compared	O
to	O
control	O
IgG	O
treatment	O
.	O

CONCLUSIONS	O
:	O
RSV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
in	O
the	O
epithelium	O
induces	O
a	O
network	O
of	O
immune	O
factors	O
to	O
counter	O
infection	B-DiseaseOrPhenotypicFeature
,	O
primarily	O
in	O
a	O
RIG	B-GeneOrGeneProduct
-	O
I	I-GeneOrGeneProduct
dependent	O
manner	O
.	O

Expression	O
of	O
LIF	B-GeneOrGeneProduct
protects	O
the	O
lung	O
from	O
lung	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	O
enhanced	O
pathology	O
during	O
RSV	B-DiseaseOrPhenotypicFeature
infection	I-DiseaseOrPhenotypicFeature
.	O
Assessment	O
of	O
a	O
new	O
non	O
-	O
invasive	O
index	O
of	O
cardiac	O
performance	O
for	O
detection	O
of	O
dobutamine	B-ChemicalEntity
-	O
induced	O
myocardial	B-DiseaseOrPhenotypicFeature
ischemia	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Electrocardiography	O
has	O
a	O
very	O
low	O
sensitivity	O
in	O
detecting	O
dobutamine	B-ChemicalEntity
-	O
induced	O
myocardial	B-DiseaseOrPhenotypicFeature
ischemia	I-DiseaseOrPhenotypicFeature
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
added	O
diagnostic	O
value	O
of	O
a	O
new	O
cardiac	O
performance	O
index	O
(	O
dP	O
/	O
dtejc	O
)	O
measurement	O
,	O
based	O
on	O
brachial	O
artery	O
flow	O
changes	O
,	O
as	O
compared	O
to	O
standard	O
12	O
-	O
lead	O
ECG	O
,	O
for	O
detecting	O
dobutamine	B-ChemicalEntity
-	O
induced	O
myocardial	B-DiseaseOrPhenotypicFeature
ischemia	I-DiseaseOrPhenotypicFeature
,	O
using	O
Tc99m	O
-	O
Sestamibi	O
single	O
-	O
photon	O
emission	O
computed	O
tomography	O
as	O
the	O
gold	O
standard	O
of	O
comparison	O
to	O
assess	O
the	O
presence	O
or	O
absence	O
of	O
ischemia	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
The	O
study	O
group	O
comprised	O
40	O
patients	B-OrganismTaxon
undergoing	O
Sestamibi	O
-	O
SPECT	O
/	O
dobutamine	B-ChemicalEntity
stress	O
test	O
.	O

Simultaneous	O
measurements	O
of	O
ECG	O
and	O
brachial	O
artery	O
dP	O
/	O
dtejc	O
were	O
performed	O
at	O
each	O
dobutamine	B-ChemicalEntity
level	O
.	O

In	O
19	O
of	O
the	O
40	O
patients	B-OrganismTaxon
perfusion	O
defects	O
compatible	O
with	O
ischemia	B-DiseaseOrPhenotypicFeature
were	O
detected	O
on	O
SPECT	O
.	O

The	O
increase	O
in	O
dP	O
/	O
dtejc	O
during	O
infusion	O
of	O
dobutamine	B-ChemicalEntity
in	O
this	O
group	O
was	O
severely	O
impaired	O
as	O
compared	O
to	O
the	O
non	O
-	O
ischemic	O
group	O
.	O

dP	O
/	O
dtejc	O
outcome	O
was	O
combined	O
with	O
the	O
ECG	O
results	O
,	O
giving	O
an	O
ECG	O
-	O
enhanced	O
value	O
,	O
and	O
compared	O
to	O
ECG	O
alone	O
.	O

RESULTS	O
:	O
The	O
sensitivity	O
improved	O
dramatically	O
from	O
16%	O
to	O
79%	O
,	O
positive	O
predictive	O
value	O
increased	O
from	O
60%	O
to	O
68%	O
and	O
negative	O
predictive	O
value	O
from	O
54%	O
to	O
78%	O
,	O
and	O
specificity	O
decreased	O
from	O
90%	O
to	O
67%	O
.	O

CONCLUSIONS	O
:	O
If	O
ECG	O
alone	O
is	O
used	O
for	O
specificity	O
,	O
the	O
combination	O
with	O
dP	O
/	O
dtejc	O
improved	O
the	O
sensitivity	O
of	O
the	O
test	O
and	O
could	O
be	O
a	O
cost	O
-	O
savings	O
alternative	O
to	O
cardiac	O
imaging	O
or	O
perfusion	O
studies	O
to	O
detect	O
myocardial	B-DiseaseOrPhenotypicFeature
ischemia	I-DiseaseOrPhenotypicFeature
,	O
especially	O
in	O
patients	B-OrganismTaxon
unable	O
to	O
exercise	O
.	O
Two	O
novel	O
mutations	O
,	O
L490R	B-SequenceVariant
and	O
V561X	B-SequenceVariant
,	O
of	O
the	O
transferrin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
gene	O
in	O
Japanese	O
patients	B-OrganismTaxon
with	O
hemochromatosis	B-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
AND	O
OBJECTIVES	O
:	O
The	O
low	O
prevalence	O
of	O
the	O
C282Y	B-SequenceVariant
mutation	O
of	O
the	O
HFE	B-GeneOrGeneProduct
gene	O
in	O
Japan	O
means	O
that	O
the	O
genetic	O
background	O
of	O
hemochromatosis	B-DiseaseOrPhenotypicFeature
in	O
Japanese	O
patients	B-OrganismTaxon
remains	O
unclear	O
.	O

In	O
a	O
previous	O
report	O
,	O
we	O
showed	O
that	O
3	O
patients	B-OrganismTaxon
from	O
one	O
family	O
had	O
an	O
AVAQ	B-SequenceVariant
594	I-SequenceVariant
-	O
597	I-SequenceVariant
deletion	I-SequenceVariant
of	O
the	O
transferrin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
TfR2	B-GeneOrGeneProduct
)	O
gene	O
.	O

This	O
suggests	O
that	O
the	O
TfR2	B-GeneOrGeneProduct
gene	O
is	O
involved	O
in	O
hemochromatosis	B-DiseaseOrPhenotypicFeature
in	O
Japanese	O
patients	B-OrganismTaxon
.	O

DESIGN	O
AND	O
METHODS	O
:	O
Nine	O
patients	B-OrganismTaxon
clinically	O
diagnosed	O
with	O
hemochromatosis	B-DiseaseOrPhenotypicFeature
were	O
included	O
in	O
the	O
study	O
.	O

DNA	O
was	O
extracted	O
from	O
whole	O
blood	O
samples	O
collected	O
with	O
informed	O
consent	O
.	O

The	O
HFE	B-GeneOrGeneProduct
and	O
TfR2	B-GeneOrGeneProduct
genes	O
were	O
analyzed	O
by	O
sequencing	O
the	O
coding	O
region	O
and	O
splicing	O
sites	O
.	O

RESULTS	O
:	O
There	O
were	O
no	O
mutations	O
in	O
the	O
HFE	B-GeneOrGeneProduct
gene	O
.	O

In	O
the	O
TfR2	B-GeneOrGeneProduct
gene	O
,	O
2	O
novel	O
mutations	O
,	O
1469T	B-SequenceVariant
-	O
>	O
G	I-SequenceVariant
(	O
L490R	B-SequenceVariant
)	O
and	O
1665delC	B-SequenceVariant
(	O
V561X	B-SequenceVariant
)	O
,	O
were	O
found	O
in	O
2	O
patients	B-OrganismTaxon
.	O

A	O
known	O
variation	O
,	O
714C	B-SequenceVariant
-	O
>	O
(	O
I238M	B-SequenceVariant
)	O
,	O
was	O
also	O
found	O
in	O
the	O
patient	B-OrganismTaxon
with	O
L490R	B-SequenceVariant
.	O

The	O
patient	B-OrganismTaxon
homozygous	O
for	O
both	O
L490R	B-SequenceVariant
and	O
I238M	B-SequenceVariant
presented	O
with	O
a	O
mild	O
manifestation	O
of	O
hemochromatosis	B-DiseaseOrPhenotypicFeature
at	O
the	O
age	O
of	O
41	O
years	O
.	O

His	O
liver	O
was	O
cirrhotic	B-DiseaseOrPhenotypicFeature
with	O
parenchymal	O
iron	B-ChemicalEntity
deposits	O
and	O
the	O
result	O
of	O
a	O
glucose	B-ChemicalEntity
tolerance	O
test	O
was	O
compatible	O
with	O
diabetes	B-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
.	O

The	O
patient	B-OrganismTaxon
homozygous	O
for	O
V561X	B-SequenceVariant
had	O
severe	O
iron	B-DiseaseOrPhenotypicFeature
overload	I-DiseaseOrPhenotypicFeature
with	O
the	O
triad	O
of	O
cirrhosis	B-DiseaseOrPhenotypicFeature
,	O
diabetes	B-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
and	O
skin	B-DiseaseOrPhenotypicFeature
pigmentation	I-DiseaseOrPhenotypicFeature
at	O
the	O
age	O
of	O
58	O
years	O
.	O

INTERPRETATION	O
AND	O
CONCLUSIONS	O
:	O
Taken	O
together	O
with	O
the	O
previous	O
report	O
,	O
5	O
of	O
our	O
12	O
patients	B-OrganismTaxon
with	O
hemochromatosis	B-DiseaseOrPhenotypicFeature
manifesting	O
in	O
middle	O
age	O
had	O
mutations	O
in	O
the	O
TfR2	B-GeneOrGeneProduct
gene	O
.	O

Thus	O
,	O
TfR2	B-GeneOrGeneProduct
plays	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
hemochromatosis	B-DiseaseOrPhenotypicFeature
in	O
Japan	O
.	O
Endothelial	O
NADPH	B-GeneOrGeneProduct
oxidase	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
mediates	O
vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
-	O
induced	O
intravitreal	O
neovascularization	O
in	O
a	O
rat	B-OrganismTaxon
model	O
of	O
retinopathy	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
prematurity	I-DiseaseOrPhenotypicFeature
.	O

PURPOSE	O
:	O
NADPH	B-GeneOrGeneProduct
oxidase	I-GeneOrGeneProduct
-	O
generated	O
reactive	B-ChemicalEntity
oxygen	I-ChemicalEntity
species	I-ChemicalEntity
(	O
ROS	B-ChemicalEntity
)	O
are	O
implicated	O
in	O
angiogenesis	O
.	O

Isoforms	O
of	O
NADPH	B-GeneOrGeneProduct
oxidase	I-GeneOrGeneProduct
NOX1	B-GeneOrGeneProduct
,	O
NOX2	B-GeneOrGeneProduct
,	O
and	O
NOX4	B-GeneOrGeneProduct
are	O
reported	O
to	O
be	O
expressed	O
in	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O

Of	O
these	O
,	O
NOX1	B-GeneOrGeneProduct
and	O
NOX2	B-GeneOrGeneProduct
have	O
been	O
reported	O
to	O
contribute	O
to	O
intravitreal	O
neovascularization	O
(	O
IVNV	O
)	O
in	O
oxygen	B-ChemicalEntity
-	O
induced	O
retinopathy	B-DiseaseOrPhenotypicFeature
(	O
OIR	B-DiseaseOrPhenotypicFeature
)	O
models	O
.	O

In	O
this	O
study	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
the	O
isoform	O
NOX4	B-GeneOrGeneProduct
in	O
ECs	O
contributed	O
to	O
vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
VEGF	B-GeneOrGeneProduct
)	O
-	O
induced	O
angiogenesis	O
and	O
IVNV	O
.	O

METHODS	O
:	O
Isoforms	O
of	O
NADPH	B-GeneOrGeneProduct
oxidase	I-GeneOrGeneProduct
MRNA	O
were	O
measured	O
in	O
several	O
types	O
of	O
cultured	O
vascular	O
ecs	O
:	O
human	B-OrganismTaxon
retinal	O
microvascular	O
ECs	O
(	O
hRMVECs	O
)	O
,	O
choroidal	O
ECs	O
(	O
CECs	O
)	O
,	O
and	O
human	B-OrganismTaxon
umbilical	O
vascular	O
ECs	O
(	O
HUVECs	O
)	O
using	O
real	O
-	O
time	O
PCR	O
.	O

Newborn	O
rat	B-OrganismTaxon
pups	O
and	O
dams	O
were	O
placed	O
into	O
an	O
OIR	B-DiseaseOrPhenotypicFeature
model	O
that	O
cycled	O
oxygen	B-ChemicalEntity
concentration	O
between	O
50%	O
and	O
10%	O
every	O
24	O
h	O
for	O
14	O
days	O
,	O
and	O
then	O
were	O
placed	O
in	O
room	O
air	O
(	O
RA	O
)	O
for	O
an	O
additional	O
4	O
days	O
(	O
rat	B-OrganismTaxon
OIR	B-DiseaseOrPhenotypicFeature
model	O
)	O
.	O

NOX4	B-GeneOrGeneProduct
expression	O
in	O
retinal	O
lysates	O
from	O
the	O
RA	O
-	O
raised	O
pups	O
at	O
postnatal	O
day	O
0	O
(	O
P0	O
)	O
,	O
P14	O
,	O
and	O
P18	O
was	O
determined	O
with	O
western	O
blots	O
.	O

STAT3	B-GeneOrGeneProduct
activation	O
was	O
determined	O
as	O
the	O
ratio	O
of	O
phosphorylated	O
STAT3	B-GeneOrGeneProduct
to	O
total	O
STAT3	B-GeneOrGeneProduct
with	O
western	O
blot	O
analysis	O
of	O
retinal	O
lysates	O
from	O
pups	O
raised	O
in	O
RA	O
or	O
from	O
the	O
rat	B-OrganismTaxon
OIR	B-DiseaseOrPhenotypicFeature
model	O
at	O
P18	O
.	O

Semiquantitative	O
assessment	O
of	O
the	O
density	O
of	O
NOX4	B-GeneOrGeneProduct
colabeling	O
with	O
lectin	B-GeneOrGeneProduct
-	O
stained	O
retinal	O
ECs	O
was	O
determined	O
by	O
immunolabeling	O
of	O
retinal	O
cryosections	O
from	O
P18	O
pups	O
in	O
OIR	B-DiseaseOrPhenotypicFeature
or	O
in	O
RA	O
.	O

In	O
hRMVECs	O
transfected	O
with	O
NOX4	B-GeneOrGeneProduct
siRNA	O
and	O
treated	O
with	O
VEGF	B-GeneOrGeneProduct
or	O
control	O
,	O
1	O
)	O
ROS	B-ChemicalEntity
generation	O
was	O
measured	O
using	O
the	O
5	B-ChemicalEntity
-	O
(	O
and	I-ChemicalEntity
-	O
6	I-ChemicalEntity
)	O
-	O
chloromethyl	I-ChemicalEntity
-	O
2	I-ChemicalEntity
'	O
,	O
7	I-ChemicalEntity
'	O
-	O
dichlorodihydrofluorescein	I-ChemicalEntity
diacetate	I-ChemicalEntity
,	O
acetyl	I-ChemicalEntity
ester	I-ChemicalEntity
fluorescence	O
assay	O
and	O
2	O
)	O
phosphorylated	O
VEGF	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
and	O
STAT3	B-GeneOrGeneProduct
,	O
and	O
total	O
VEGFR2	B-GeneOrGeneProduct
and	O
STAT3	B-GeneOrGeneProduct
were	O
measured	O
in	O
western	O
blot	O
analyses	O
.	O

VEGF	B-GeneOrGeneProduct
-	O
stimulated	O
hRMVEC	O
proliferation	O
was	O
measured	O
following	O
transfection	O
with	O
NOX4	B-GeneOrGeneProduct
siRNA	O
or	O
STAT3	B-GeneOrGeneProduct
siRNA	O
,	O
or	O
respective	O
controls	O
.	O

RESULTS	O
:	O
NOX4	B-GeneOrGeneProduct
was	O
the	O
most	O
prevalent	O
isoform	O
of	O
NADPH	B-GeneOrGeneProduct
oxidase	I-GeneOrGeneProduct
in	O
vascular	O
ECs	O
.	O

NOX4	B-GeneOrGeneProduct
expression	O
in	O
retinal	O
lysates	O
was	O
significantly	O
decreased	O
during	O
development	O
in	O
RA	O
.	O

Compared	O
to	O
RA	O
,	O
the	O
expression	O
of	O
retinal	O
NOX4	B-GeneOrGeneProduct
increased	O
at	O
P18	O
.	O

At	O
p18	O
OIR	B-DiseaseOrPhenotypicFeature
,	O
semiquantitative	O
assessment	O
of	O
the	O
density	O
of	O
lectin	B-GeneOrGeneProduct
and	O
NOX4	B-GeneOrGeneProduct
colabeling	O
in	O
retinal	O
vascular	O
ECs	O
was	O
greater	O
in	O
retinal	O
cryosections	O
and	O
activated	O
STAT3	B-GeneOrGeneProduct
was	O
greater	O
in	O
retinal	O
lysates	O
when	O
compared	O
to	O
the	O
RA	O
-	O
raised	O
pups	O
.	O

In	O
cultured	O
hRMVECs	O
,	O
knockdown	O
of	O
NOX4	B-GeneOrGeneProduct
by	O
siRNA	O
transfection	O
inhibited	O
VEGF	B-GeneOrGeneProduct
-	O
induced	O
ROS	B-ChemicalEntity
generation	O
.	O

VEGF	B-GeneOrGeneProduct
induced	O
a	O
physical	O
interaction	O
of	O
phosphorylated	O
-	O
VEGFR2	B-GeneOrGeneProduct
and	O
NOX4	B-GeneOrGeneProduct
.	O

Knockdown	O
of	O
NOX4	B-GeneOrGeneProduct
:	O
1	O
)	O
reduced	O
VEGFR2	B-GeneOrGeneProduct
activation	O
but	O
did	O
not	O
abolish	O
it	O
and	O
2	O
)	O
abolished	O
STAT3	B-GeneOrGeneProduct
activation	O
in	O
response	O
to	O
VEGF	B-GeneOrGeneProduct
.	O

Knockdown	O
of	O
either	O
NOX4	B-GeneOrGeneProduct
or	O
STAT3	B-GeneOrGeneProduct
inhibited	O
VEGF	B-GeneOrGeneProduct
-	O
induced	O
EC	O
proliferation	O
.	O

CONCLUSIONS	O
:	O
Our	O
data	O
suggest	O
that	O
in	O
a	O
model	O
representative	O
of	O
human	B-OrganismTaxon
retinopathy	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
prematurity	I-DiseaseOrPhenotypicFeature
,	O
NOX4	B-GeneOrGeneProduct
was	O
increased	O
at	O
a	O
time	O
point	O
when	O
IVNV	O
developed	O
.	O

VEGF	B-GeneOrGeneProduct
-	O
activated	O
NOX4	B-GeneOrGeneProduct
led	O
to	O
an	O
interaction	O
between	O
VEGF	B-GeneOrGeneProduct
-	O
activated	O
VEGFR2	B-GeneOrGeneProduct
and	O
NOX4	B-GeneOrGeneProduct
that	O
mediated	O
EC	O
proliferation	O
via	O
activation	O
of	O
STAT3	B-GeneOrGeneProduct
.	O

Altogether	O
,	O
our	O
results	O
suggest	O
that	O
NOX4	B-GeneOrGeneProduct
may	O
regulate	O
VEGFR2	B-GeneOrGeneProduct
-	O
mediated	O
IVNV	O
through	O
activated	O
STAT3	B-GeneOrGeneProduct
.	O
MDMA	B-ChemicalEntity
polydrug	O
users	O
show	O
process	O
-	O
specific	O
central	O
executive	O
impairments	O
coupled	O
with	O
impaired	B-DiseaseOrPhenotypicFeature
social	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
emotional	I-DiseaseOrPhenotypicFeature
judgement	I-DiseaseOrPhenotypicFeature
processes	I-DiseaseOrPhenotypicFeature
.	O

In	O
recent	O
years	O
working	O
memory	B-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
have	O
been	O
reported	O
in	O
users	O
of	O
MDMA	B-ChemicalEntity
(	O
3	B-ChemicalEntity
,	O
4	I-ChemicalEntity
-	O
methylenedioxymethamphetamine	I-ChemicalEntity
,	O
ecstasy	B-ChemicalEntity
)	O
.	O

The	O
current	O
study	O
aimed	O
to	O
assess	O
the	O
impact	O
of	O
MDMA	B-ChemicalEntity
use	O
on	O
three	O
separate	O
central	O
executive	O
processes	O
(	O
set	O
shifting	O
,	O
inhibition	O
and	O
memory	O
updating	O
)	O
and	O
also	O
on	O
""""	O
prefrontal	O
""""	O
mediated	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

Fifteen	O
polydrug	O
ecstasy	B-ChemicalEntity
users	O
and	O
15	O
polydrug	O
non	O
-	O
ecstasy	B-ChemicalEntity
user	O
controls	O
completed	O
a	O
general	O
drug	O
use	O
questionnaire	O
,	O
the	O
Brixton	O
Spatial	O
Anticipation	O
task	O
(	O
set	O
shifting	O
)	O
,	O
Backward	O
Digit	O
Span	O
procedure	O
(	O
memory	O
updating	O
)	O
,	O
Inhibition	O
of	O
Return	O
(	O
inhibition	O
)	O
,	O
an	O
emotional	O
intelligence	O
scale	O
,	O
the	O
Tromso	O
Social	O
Intelligence	O
Scale	O
and	O
the	O
Dysexecutive	O
Questionnaire	O
(	O
DEX	O
)	O
.	O

Compared	O
with	O
MDMA	B-ChemicalEntity
-	O
free	O
polydrug	O
controls	O
,	O
MDMA	B-ChemicalEntity
polydrug	O
users	O
showed	O
impairments	O
in	O
set	O
shifting	O
and	O
memory	O
updating	O
,	O
and	O
also	O
in	O
social	O
and	O
emotional	O
judgement	O
processes	O
.	O

The	O
latter	O
two	O
deficits	O
remained	O
significant	O
after	O
controlling	O
for	O
other	O
drug	O
use	O
.	O

These	O
data	O
lend	O
further	O
support	O
to	O
the	O
proposal	O
that	O
cognitive	O
processes	O
mediated	O
by	O
the	O
prefrontal	O
cortex	O
may	O
be	O
impaired	O
by	O
recreational	O
ecstasy	B-ChemicalEntity
use	O
.	O
Successful	O
therapy	O
with	O
argatroban	B-ChemicalEntity
for	O
superior	O
mesenteric	O
vein	B-DiseaseOrPhenotypicFeature
thrombosis	I-DiseaseOrPhenotypicFeature
in	O
a	O
patient	B-OrganismTaxon
with	O
congenital	B-DiseaseOrPhenotypicFeature
antithrombin	I-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
.	O

A	O
38	O
-	O
year	O
-	O
old	O
woman	B-OrganismTaxon
was	O
admitted	O
with	O
superior	B-DiseaseOrPhenotypicFeature
mesenteric	I-DiseaseOrPhenotypicFeature
vein	I-DiseaseOrPhenotypicFeature
(	O
SMV	I-DiseaseOrPhenotypicFeature
)	O
thrombosis	I-DiseaseOrPhenotypicFeature
,	O
which	O
was	O
refractory	O
to	O
anticoagulation	O
therapy	O
.	O

The	O
plasma	O
antithrombin	B-GeneOrGeneProduct
activity	O
was	O
decreased	O
and	O
hardly	O
compensated	O
by	O
concentrated	O
antithrombin	B-GeneOrGeneProduct
preparation	O
due	O
to	O
high	O
consumption	O
rate	O
.	O

However	O
,	O
successful	O
anticoagulation	O
was	O
achieved	O
by	O
administration	O
of	O
direct	O
thrombin	B-GeneOrGeneProduct
inhibitor	O
,	O
argatroban	B-ChemicalEntity
.	O

Family	O
studies	O
of	O
antithrombin	B-GeneOrGeneProduct
activity	O
revealed	O
that	O
she	O
had	O
type	B-DiseaseOrPhenotypicFeature
I	I-DiseaseOrPhenotypicFeature
congenital	I-DiseaseOrPhenotypicFeature
antithrombin	I-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
.	O

A	O
novel	O
heterozygous	O
mutation	O
in	O
the	O
gene	O
for	O
antithrombin	B-GeneOrGeneProduct
(	O
single	O
nucleotide	B-SequenceVariant
T	I-SequenceVariant
insertion	I-SequenceVariant
at	I-SequenceVariant
7916	I-SequenceVariant
and	I-SequenceVariant
7917	I-SequenceVariant
,	O
Glu	B-SequenceVariant
272	I-SequenceVariant
to	I-SequenceVariant
stop	I-SequenceVariant
in	O
exon	O
4	O
)	O
was	O
identified	O
.	O

Argatroban	B-ChemicalEntity
administration	O
would	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
congenital	B-DiseaseOrPhenotypicFeature
antithrombin	I-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
with	O
SMV	B-DiseaseOrPhenotypicFeature
thrombosis	I-DiseaseOrPhenotypicFeature
.	O
Mutational	O
analysis	O
of	O
CYP2C8	B-GeneOrGeneProduct
in	O
hypertensive	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
.	O

WHAT	O
IS	O
KNOWN	O
AND	O
OBJECTIVE	O
:	O
CYP2C8	B-GeneOrGeneProduct
is	O
involved	O
in	O
the	O
cytochrome	B-GeneOrGeneProduct
P450	I-GeneOrGeneProduct
(	O
CYP	I-GeneOrGeneProduct
)	O
epoxygenase	I-GeneOrGeneProduct
pathway	O
.	O

Arachidonic	B-ChemicalEntity
acid	I-ChemicalEntity
metabolites	O
such	O
as	O
epoxyeicosatrienenoic	B-ChemicalEntity
acids	I-ChemicalEntity
and	O
hydroxyeicosatetrenoic	B-ChemicalEntity
acids	I-ChemicalEntity
,	O
produced	O
may	O
have	O
a	O
role	O
in	O
hypertension	B-DiseaseOrPhenotypicFeature
.	O

We	O
aimed	O
to	O
develop	O
a	O
medium	O
through	O
-	O
put	O
method	O
for	O
screening	O
samples	O
of	O
known	O
and	O
new	O
mutations	O
of	O
CYP2C8	B-GeneOrGeneProduct
using	O
denaturing	O
high	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
)	O
.	O

METHODS	O
:	O
DNA	O
samples	O
from	O
200	O
subjects	O
(	O
hypertensive	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
healthy	O
controls	O
)	O
were	O
screened	O
for	O
SNPs	O
in	O
CYP2C8	B-GeneOrGeneProduct
using	O
DHPLC	O
.	O

Genotypes	O
and	O
allelic	O
frequencies	O
of	O
CYP2C8	B-GeneOrGeneProduct
between	O
the	O
healthy	O
controls	O
and	O
patients	B-OrganismTaxon
with	O
hypertension	B-DiseaseOrPhenotypicFeature
were	O
compared	O
.	O

RESULTS	O
AND	O
DISCUSSIONS	O
:	O
Six	O
variants	O
were	O
detected	O
and	O
two	O
were	O
new	O
;	O
T	B-SequenceVariant
deletion	I-SequenceVariant
at	I-SequenceVariant
5063	I-SequenceVariant
and	O
substitution	O
of	O
C	B-SequenceVariant
to	I-SequenceVariant
T	I-SequenceVariant
at	I-SequenceVariant
33468	I-SequenceVariant
in	O
exon	O
8	O
.	O

Differences	O
in	O
variant	O
frequencies	O
were	O
detected	O
between	O
the	O
controls	O
and	O
hypertensive	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

The	O
controls	O
have	O
significantly	O
higher	O
prevalence	O
of	O
C35322C	B-SequenceVariant
compared	O
to	O
the	O
patients	B-OrganismTaxon
.	O

The	O
functional	O
significance	O
of	O
the	O
SNP	O
at	O
35322	O
requires	O
further	O
study	O
.	O

Having	O
homozygous	O
C35322C	B-SequenceVariant
could	O
be	O
a	O
protective	O
factor	O
for	O
hypertension	B-DiseaseOrPhenotypicFeature
.	O

WHAT	O
IS	O
NEW	O
AND	O
CONCLUSION	O
:	O
Denaturing	O
high	O
performance	O
liquid	O
chromatography	O
is	O
useful	O
for	O
population	O
screening	O
to	O
identify	O
new	O
and	O
existing	O
SNPs	O
.	O

A	O
higher	O
frequency	O
of	O
the	O
C35322T	B-SequenceVariant
SNP	O
was	O
observed	O
among	O
hypertensive	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
than	O
control	O
subjects	O
.	O

This	O
potentially	O
important	O
observation	O
requires	O
confirmation	O
and	O
the	O
clinical	O
significance	O
assessed	O
.	O
Voltage	B-GeneOrGeneProduct
-	O
Dependent	I-GeneOrGeneProduct
Anion	I-GeneOrGeneProduct
Channel	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
VDAC1	B-GeneOrGeneProduct
)	O
Participates	O
the	O
Apoptosis	O
of	O
the	O
Mitochondrial	B-DiseaseOrPhenotypicFeature
Dysfunction	I-DiseaseOrPhenotypicFeature
in	O
Desminopathy	B-DiseaseOrPhenotypicFeature
.	O

Desminopathies	B-DiseaseOrPhenotypicFeature
caused	O
by	O
the	O
mutation	O
in	O
the	O
gene	O
coding	O
for	O
desmin	B-GeneOrGeneProduct
are	O
genetically	O
protein	O
aggregation	O
myopathies	B-DiseaseOrPhenotypicFeature
.	O

Mitochondrial	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
is	O
one	O
of	O
pathological	O
changes	O
in	O
the	O
desminopathies	B-DiseaseOrPhenotypicFeature
at	O
the	O
earliest	O
stage	O
.	O

The	O
molecular	O
mechanisms	O
of	O
mitochondria	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
in	O
desminopathies	B-DiseaseOrPhenotypicFeature
remain	O
exclusive	O
.	O

VDAC1	B-GeneOrGeneProduct
regulates	O
mitochondrial	O
uptake	O
across	O
the	O
outer	O
membrane	O
and	O
mitochondrial	O
outer	O
membrane	O
permeabilization	O
(	O
MOMP	O
)	O
.	O

Relationships	O
between	O
desminopathies	B-DiseaseOrPhenotypicFeature
and	O
Voltage	B-GeneOrGeneProduct
-	O
dependent	I-GeneOrGeneProduct
anion	I-GeneOrGeneProduct
channel	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
VDAC1	B-GeneOrGeneProduct
)	O
remain	O
unclear	O
.	O

Here	O
we	O
successfully	O
constructed	O
the	O
desminopathy	B-DiseaseOrPhenotypicFeature
rat	B-OrganismTaxon
model	O
,	O
evaluated	O
with	O
conventional	O
stains	O
,	O
containing	O
hematoxylin	O
and	O
eosin	O
(	O
HE	O
)	O
,	O
Gomori	O
Trichrome	O
(	O
MGT	O
)	O
,	O
(	O
PAS	O
)	O
,	O
red	O
oil	O
(	O
ORO	O
)	O
,	O
NADH	O
-	O
TR	O
,	O
SDH	O
staining	O
and	O
immunohistochemistry	O
.	O

Immunofluorescence	O
results	O
showed	O
that	O
VDAC1	B-GeneOrGeneProduct
was	O
accumulated	O
in	O
the	O
desmin	B-GeneOrGeneProduct
highly	O
stained	O
area	O
of	O
muscle	O
fibers	O
of	O
desminopathy	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
or	O
desminopathy	B-DiseaseOrPhenotypicFeature
rat	B-OrganismTaxon
model	O
compared	O
to	O
the	O
normal	O
ones	O
.	O

Meanwhile	O
apoptosis	O
related	O
proteins	O
bax	B-GeneOrGeneProduct
and	O
ATF2	B-GeneOrGeneProduct
were	O
involved	O
in	O
desminopathy	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
desminopathy	B-DiseaseOrPhenotypicFeature
rat	B-OrganismTaxon
model	O
,	O
but	O
not	O
bcl	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
,	O
bcl	B-GeneOrGeneProduct
-	O
xl	I-GeneOrGeneProduct
or	O
HK2	B-GeneOrGeneProduct
.	O
VDAC1	B-GeneOrGeneProduct
and	O
desmin	B-GeneOrGeneProduct
are	O
closely	O
relevant	O
in	O
the	O
tissue	O
splices	O
of	O
deminopathies	O
patients	B-OrganismTaxon
and	O
rats	B-OrganismTaxon
with	O
desminopathy	B-DiseaseOrPhenotypicFeature
at	O
protein	O
lever	O
.	O

Moreover	O
,	O
apoptotic	O
proteins	O
are	O
also	O
involved	O
in	O
the	O
desminopathies	B-DiseaseOrPhenotypicFeature
,	O
like	O
bax	B-GeneOrGeneProduct
,	O
ATF2	B-GeneOrGeneProduct
,	O
but	O
not	O
bcl	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
,	O
bcl	B-GeneOrGeneProduct
-	O
xl	I-GeneOrGeneProduct
or	O
HK2	B-GeneOrGeneProduct
.	O

This	O
pathological	O
analysis	O
presents	O
the	O
correlation	O
between	O
VDAC1	B-GeneOrGeneProduct
and	O
desmin	B-GeneOrGeneProduct
,	O
and	O
apoptosis	O
related	O
proteins	O
are	O
correlated	O
in	O
the	O
desminopathy	B-DiseaseOrPhenotypicFeature
.	O

Furthermore	O
,	O
we	O
provide	O
a	O
rat	B-OrganismTaxon
model	O
of	O
desminopathy	B-DiseaseOrPhenotypicFeature
for	O
the	O
investigation	O
of	O
desmin	B-GeneOrGeneProduct
related	O
myopathy	B-DiseaseOrPhenotypicFeature
.	O
The	O
cytogenetic	O
action	O
of	O
ifosfamide	B-ChemicalEntity
,	O
mesna	B-ChemicalEntity
,	O
and	O
their	O
combination	O
on	O
peripheral	O
rabbit	B-OrganismTaxon
lymphocytes	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
cytogenetic	O
study	O
.	O

Ifosfamide	B-ChemicalEntity
(	O
IFO	B-ChemicalEntity
)	O
is	O
an	O
alkylating	B-ChemicalEntity
nitrogen	I-ChemicalEntity
mustard	I-ChemicalEntity
,	O
administrated	O
as	O
an	O
antineoplasmic	O
agent	O
.	O

It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action	O
,	O
leading	O
to	O
hemorrhagic	B-DiseaseOrPhenotypicFeature
cystitis	B-DiseaseOrPhenotypicFeature
.	O

This	O
side	O
effect	O
of	O
IFO	B-ChemicalEntity
raises	O
the	O
requirement	O
for	O
the	O
co	O
-	O
administration	O
with	O
sodium	B-ChemicalEntity
2	I-ChemicalEntity
-	O
sulfanylethanesulfonate	I-ChemicalEntity
(	O
Mesna	B-ChemicalEntity
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effect	O
.	O

IFO	B-ChemicalEntity
and	O
Mesna	B-ChemicalEntity
were	O
administrated	O
separately	O
on	O
rabbit	B-OrganismTaxon
'	O
s	O
lymphocytes	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O

Cytogenetic	O
markers	O
for	O
sister	O
chromatid	O
exchanges	O
(	O
SCEs	O
)	O
,	O
proliferation	O
rate	O
index	O
(	O
PRI	O
)	O
and	O
Mitotic	O
Index	O
were	O
recorded	O
.	O

Mesna	B-ChemicalEntity
'	O
s	O
action	O
,	O
in	O
conjunction	O
with	O
IFO	B-ChemicalEntity
reduces	O
the	O
frequency	O
of	O
SCEs	O
,	O
in	O
comparison	O
with	O
the	O
SCEs	O
recordings	O
obtained	O
when	O
IFO	B-ChemicalEntity
is	O
administered	O
alone	O
.	O

In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentrations	O
of	O
Mesna	B-ChemicalEntity
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	B-ChemicalEntity
acting	O
at	O
the	O
same	O
concentration	O
on	O
the	O
lymphocytes	O
.	O

Mesna	B-ChemicalEntity
significantly	O
reduces	O
IFO	B-ChemicalEntity
'	O
s	O
genotoxicity	B-DiseaseOrPhenotypicFeature
,	O
while	O
when	O
administered	O
in	O
high	O
concentrations	O
it	O
acts	O
in	O
an	O
inhibitory	O
fashion	O
on	O
the	O
cytostatic	O
action	O
of	O
the	O
drug	O
.	O
Two	O
novel	O
mutations	O
of	O
the	O
PAX6	B-GeneOrGeneProduct
gene	O
causing	O
different	O
phenotype	O
in	O
a	O
cohort	O
of	O
Chinese	O
patients	B-OrganismTaxon
.	O

PURPOSE	O
:	O
Aniridia	B-DiseaseOrPhenotypicFeature
(	O
AN	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
rare	O
congenital	B-DiseaseOrPhenotypicFeature
panocular	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
caused	O
by	O
the	O
mutations	O
of	O
the	O
paired	B-GeneOrGeneProduct
box	I-GeneOrGeneProduct
homeotic	I-GeneOrGeneProduct
gene	I-GeneOrGeneProduct
6	I-GeneOrGeneProduct
(	O
PAX6	B-GeneOrGeneProduct
)	O
gene	O
.	O

The	O
PAX6	B-GeneOrGeneProduct
gene	O
is	O
also	O
involved	O
in	O
other	O
anterior	B-DiseaseOrPhenotypicFeature
segment	I-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
including	O
Peters	B-DiseaseOrPhenotypicFeature
anomaly	I-DiseaseOrPhenotypicFeature
.	O

We	O
studied	O
the	O
PAX6	B-GeneOrGeneProduct
gene	O
mutations	O
in	O
a	O
cohort	O
of	O
affected	O
individuals	O
with	O
different	O
clinical	O
phenotype	O
including	O
AN	B-DiseaseOrPhenotypicFeature
,	O
coloboma	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
iris	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
choroid	I-DiseaseOrPhenotypicFeature
,	O
or	O
anterior	B-DiseaseOrPhenotypicFeature
segment	I-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
.	O

PATIENTS	B-OrganismTaxon
AND	O
METHODS	O
:	O
Six	O
unrelated	O
families	O
and	O
10	O
sporadic	O
patients	B-OrganismTaxon
were	O
examined	O
clinically	O
.	O

After	O
informed	O
consent	O
was	O
obtained	O
,	O
genomic	O
DNA	O
was	O
extracted	O
from	O
the	O
venous	O
blood	O
of	O
all	O
participants	O
.	O

Mutation	O
screening	O
of	O
all	O
exons	O
of	O
the	O
PAX6	B-GeneOrGeneProduct
gene	O
was	O
performed	O
by	O
direct	O
sequencing	O
of	O
PCR	O
-	O
amplified	O
DNA	O
fragments	O
.	O

Multiplex	O
ligation	O
-	O
dependent	O
probe	O
amplification	O
(	O
MLPA	O
)	O
was	O
performed	O
to	O
detect	O
large	O
deletions	O
.	O

RESULTS	O
:	O
By	O
clinical	O
examination	O
,	O
the	O
patients	B-OrganismTaxon
and	O
the	O
pedigrees	O
were	O
divided	O
into	O
the	O
following	O
three	O
groups	O
:	O
AN	B-DiseaseOrPhenotypicFeature
,	O
coloboma	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
iris	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
choroids	I-DiseaseOrPhenotypicFeature
,	O
and	O
the	O
anterior	B-DiseaseOrPhenotypicFeature
segment	I-DiseaseOrPhenotypicFeature
malformations	I-DiseaseOrPhenotypicFeature
including	O
peters	B-DiseaseOrPhenotypicFeature
anomaly	I-DiseaseOrPhenotypicFeature
.	O

Sequencing	O
of	O
the	O
PAX6	B-GeneOrGeneProduct
gene	O
,	O
three	O
intragenic	O
mutations	O
including	O
a	O
novel	O
heterozygous	O
splicing	O
-	O
site	O
mutations	O
c	B-SequenceVariant
.	O
357	I-SequenceVariant
-	O
3C	I-SequenceVariant
>	O
G	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Ser119fsX	I-SequenceVariant
)	O
were	O
identified	O
in	O
the	O
patients	B-OrganismTaxon
of	O
the	O
AN	B-DiseaseOrPhenotypicFeature
group	O
.	O

A	O
novel	O
missense	O
mutation	O
c	B-SequenceVariant
.	O
643T	I-SequenceVariant
>	O
C	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
S216P	I-SequenceVariant
)	O
was	O
detected	O
in	O
the	O
anterior	B-DiseaseOrPhenotypicFeature
segment	I-DiseaseOrPhenotypicFeature
malformation	I-DiseaseOrPhenotypicFeature
group	O
.	O

The	O
mutation	O
p	B-SequenceVariant
.	O
S216P	I-SequenceVariant
located	O
in	O
the	O
homeodomain	O
region	O
of	O
the	O
PAX6	B-GeneOrGeneProduct
caused	O
the	O
phenotype	O
of	O
Peters	B-DiseaseOrPhenotypicFeature
anomaly	I-DiseaseOrPhenotypicFeature
in	O
family	O
A6	O
with	O
different	O
expressing	O
.	O

Through	O
MLPA	O
analysis	O
,	O
a	O
large	O
deletion	O
including	O
the	O
whole	O
PAX6	B-GeneOrGeneProduct
gene	O
and	O
DKFZ	B-GeneOrGeneProduct
p686k1684	I-GeneOrGeneProduct
gene	O
was	O
detected	O
in	O
one	O
sporadic	O
patient	B-OrganismTaxon
from	O
the	O
AN	B-DiseaseOrPhenotypicFeature
group	O
.	O

Neither	O
intragenic	O
mutation	O
nor	O
large	O
deletion	O
was	O
identified	O
in	O
the	O
group	O
with	O
coloboma	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
iris	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
choroid	I-DiseaseOrPhenotypicFeature
.	O

CONCLUSION	O
:	O
Our	O
findings	O
further	O
confirmed	O
that	O
different	O
kind	O
of	O
mutations	O
might	O
cause	O
different	O
ocular	O
phenotype	O
,	O
and	O
clearly	O
clinical	O
phenotype	O
classification	O
might	O
increase	O
the	O
mutation	O
detection	O
rate	O
of	O
the	O
PAX6	B-GeneOrGeneProduct
gene	O
.	O
Polymorphisms	O
of	O
the	O
DNA	O
mismatch	B-GeneOrGeneProduct
repair	I-GeneOrGeneProduct
gene	O
HMSH2	B-GeneOrGeneProduct
in	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
occurence	O
and	O
progression	O
.	O

The	O
response	O
of	O
the	O
cell	O
to	O
DNA	O
damage	O
and	O
its	O
ability	O
to	O
maintain	O
genomic	O
stability	O
by	O
DNA	O
repair	O
are	O
crucial	O
in	O
preventing	O
cancer	B-DiseaseOrPhenotypicFeature
initiation	I-DiseaseOrPhenotypicFeature
and	O
progression	O
.	O

Therefore	O
,	O
polymorphism	O
of	O
DNA	O
repair	O
genes	O
may	O
affect	O
the	O
process	O
of	O
carcinogenesis	B-DiseaseOrPhenotypicFeature
.	O

The	O
importance	O
of	O
genetic	O
variability	O
of	O
the	O
components	O
of	O
mismatch	B-GeneOrGeneProduct
repair	I-GeneOrGeneProduct
(	O
MMR	B-GeneOrGeneProduct
)	O
genes	O
is	O
well	O
documented	O
in	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
,	O
but	O
little	O
is	O
known	O
about	O
its	O
role	O
in	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

hMSH2	B-GeneOrGeneProduct
is	O
one	O
of	O
the	O
crucial	O
proteins	O
of	O
MMR	B-GeneOrGeneProduct
.	O

We	O
performed	O
a	O
case	O
-	O
control	O
study	O
to	O
test	O
the	O
association	O
between	O
two	O
polymorphisms	O
in	O
the	O
hMSH2	B-GeneOrGeneProduct
gene	O
:	O
an	O
A	B-SequenceVariant
-	O
-	O
>	O
G	I-SequenceVariant
transition	I-SequenceVariant
at	I-SequenceVariant
127	I-SequenceVariant
position	I-SequenceVariant
producing	O
an	O
Asn	B-SequenceVariant
-	O
-	O
>	O
Ser	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
codon	I-SequenceVariant
127	I-SequenceVariant
(	O
the	O
Asn127Ser	B-SequenceVariant
polymorphism	O
)	O
and	O
a	O
G	B-SequenceVariant
-	O
-	O
>	O
A	I-SequenceVariant
transition	I-SequenceVariant
at	I-SequenceVariant
1032	I-SequenceVariant
position	I-SequenceVariant
resulting	O
in	O
a	O
Gly	B-SequenceVariant
-	O
-	O
>	O
Asp	I-SequenceVariant
change	I-SequenceVariant
at	I-SequenceVariant
codon	I-SequenceVariant
322	I-SequenceVariant
(	O
the	O
Gly322Asp	B-SequenceVariant
polymorphism	O
)	O
and	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
and	O
cancer	B-DiseaseOrPhenotypicFeature
progression	O
.	O

Genotypes	O
were	O
determined	O
in	O
DNA	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
150	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
150	O
age	O
-	O
matched	O
women	B-OrganismTaxon
(	O
controls	O
)	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
and	O
allele	O
-	O
specific	O
PCR	O
.	O

We	O
did	O
not	O
observe	O
any	O
correlation	O
between	O
studied	O
polymorphisms	O
and	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
progression	O
evaluated	O
by	O
node	O
-	O
metastasis	O
,	O
tumor	B-DiseaseOrPhenotypicFeature
size	O
and	O
Bloom	O
-	O
Richardson	O
grading	O
.	O

A	O
strong	O
association	O
between	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
occurrence	O
and	O
the	O
Gly	O
/	O
Gly	O
phenotype	O
of	O
the	O
Gly322Asp	B-SequenceVariant
polymorphism	O
(	O
odds	O
ratio	O
8	O
.	O
39	O
;	O
95%	O
confidence	O
interval	O
1	O
.	O
44	O
-	O
48	O
.	O
8	O
)	O
was	O
found	O
.	O

Therefore	O
,	O
MMR	B-GeneOrGeneProduct
may	O
play	O
a	O
role	O
in	O
the	O
breast	B-DiseaseOrPhenotypicFeature
carcinogenesis	I-DiseaseOrPhenotypicFeature
and	O
the	O
Gly322Asp	B-SequenceVariant
polymorphism	O
of	O
the	O
hMSH2	B-GeneOrGeneProduct
gene	O
may	O
be	O
considered	O
as	O
a	O
potential	O
marker	O
in	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O
Vitamin	B-GeneOrGeneProduct
D	I-GeneOrGeneProduct
-	O
binding	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
gene	O
polymorphism	O
association	O
with	O
IA	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
autoantibodies	O
in	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Vitamin	B-GeneOrGeneProduct
D	I-GeneOrGeneProduct
-	O
binding	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
DBP	B-GeneOrGeneProduct
)	O
is	O
the	O
main	O
systemic	O
transporter	O
of	O
1	B-ChemicalEntity
.	O
25	I-ChemicalEntity
(	O
OH	I-ChemicalEntity
)	O
2D3	I-ChemicalEntity
and	O
is	O
essential	O
for	O
its	O
cellular	O
endocytosis	O
.	O

There	O
are	O
two	O
known	O
polymorphisms	O
in	O
exon	O
11	O
of	O
the	O
DBP	B-GeneOrGeneProduct
gene	O
resulting	O
in	O
amino	O
acid	O
variants	O
:	O
GAT	B-SequenceVariant
-	O
-	O
>	O
GAG	I-SequenceVariant
substitution	I-SequenceVariant
replaces	I-SequenceVariant
aspartic	I-SequenceVariant
acid	I-SequenceVariant
by	I-SequenceVariant
glutamic	I-SequenceVariant
acid	I-SequenceVariant
in	I-SequenceVariant
codon	I-SequenceVariant
416	I-SequenceVariant
;	O
and	O
ACG	B-SequenceVariant
-	O
-	O
>	O
AAG	I-SequenceVariant
substitution	I-SequenceVariant
in	I-SequenceVariant
codon	I-SequenceVariant
420	I-SequenceVariant
leads	O
to	O
an	O
exchange	O
of	O
threonine	B-SequenceVariant
for	I-SequenceVariant
lysine	I-SequenceVariant
.	O

These	O
DBP	B-GeneOrGeneProduct
variants	O
lead	O
to	O
differences	O
in	O
the	O
affinity	O
for	O
1	B-ChemicalEntity
.	O
25	I-ChemicalEntity
(	O
OH	I-ChemicalEntity
)	O
2D3	I-ChemicalEntity
.	O

Correlations	O
between	O
DBP	B-GeneOrGeneProduct
alleles	O
and	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
have	O
been	O
described	O
in	O
different	O
populations	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
polymorphism	O
in	O
codon	O
416	O
of	O
the	O
DBP	B-GeneOrGeneProduct
gene	O
for	O
an	O
association	O
with	O
autoimmune	O
markers	O
of	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
.	O

DESIGN	O
AND	O
METHODS	O
:	O
The	O
present	O
analysis	O
was	O
a	O
case	O
control	O
study	O
.	O

110	O
patients	B-OrganismTaxon
,	O
68	O
controls	O
,	O
and	O
115	O
first	O
-	O
degree	O
relatives	O
were	O
genotyped	O
for	O
the	O
DBP	B-GeneOrGeneProduct
polymorphism	O
in	O
codon	O
416	O
.	O

DNA	O
typing	O
of	O
DBP	B-GeneOrGeneProduct
locus	O
was	O
performed	O
by	O
the	O
PCR	O
-	O
restriction	O
fragment	O
length	O
polymorphism	O
method	O
(	O
RFLP	O
)	O
.	O

RESULTS	O
:	O
The	O
frequencies	O
of	O
the	O
Asp	O
/	O
Glu	O
and	O
Glu	O
/	O
Glu	O
were	O
significantly	O
increased	O
in	O
diabetic	B-DiseaseOrPhenotypicFeature
subjects	O
with	O
detectable	O
IA	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
antibodies	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

On	O
the	O
contrary	O
,	O
the	O
DBP	B-GeneOrGeneProduct
Glu	O
-	O
containing	O
genotype	O
was	O
not	O
accompanied	O
by	O
differences	O
in	O
the	O
prevalence	O
of	O
GAD65	B-GeneOrGeneProduct
antibodies	O
.	O

These	O
finding	O
supports	O
a	O
role	O
of	O
the	O
vitamin	B-ChemicalEntity
D	I-ChemicalEntity
endocrine	O
system	O
in	O
the	O
autoimmune	O
process	O
of	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
.	O
Deletion	O
of	O
endothelial	O
cell	O
-	O
specific	O
liver	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
B1	I-GeneOrGeneProduct
increases	O
angiogenesis	O
and	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
via	O
vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
.	O

Liver	B-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
B1	I-GeneOrGeneProduct
(	O
LKB1	B-GeneOrGeneProduct
)	O
is	O
a	O
serine	B-GeneOrGeneProduct
/	O
threonine	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
ubiquitously	O
expressed	O
in	O
mammalian	O
cells	O
.	O

It	O
was	O
first	O
identified	O
in	O
Peutz	B-DiseaseOrPhenotypicFeature
-	O
Jeghers	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
as	O
a	O
tumor	B-DiseaseOrPhenotypicFeature
suppressor	O
gene	O
.	O

Whether	O
endothelial	O
LKB1	B-GeneOrGeneProduct
regulates	O
angiogenesis	O
and	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
is	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
endothelial	O
cell	O
-	O
specific	O
LKB1	B-GeneOrGeneProduct
-	O
knockout	O
(	O
LKB1	B-GeneOrGeneProduct
(	O
endo	O
-	O
/	O
-	O
)	O
)	O
mice	B-OrganismTaxon
by	O
crossbreeding	O
vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
-	O
cadherin	I-GeneOrGeneProduct
-	O
Cre	O
mice	B-OrganismTaxon
with	O
LKB1	B-GeneOrGeneProduct
(	O
flox	O
/	O
flox	O
)	O
mice	B-OrganismTaxon
.	O

Vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
VEGF	B-GeneOrGeneProduct
)	O
level	O
was	O
highly	O
co	O
-	O
stained	O
in	O
endothelial	O
cells	O
but	O
not	O
in	O
macrophages	O
in	O
LKB1	B-GeneOrGeneProduct
(	O
endo	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
.	O

Consistently	O
,	O
LKB1	B-GeneOrGeneProduct
(	O
endo	O
-	O
/	O
-	O
)	O
mouse	B-OrganismTaxon
tissues	O
including	O
the	O
lung	O
,	O
skin	O
,	O
kidney	O
and	O
liver	O
showed	O
increased	O
vascular	O
permeability	O
.	O

Tumors	B-DiseaseOrPhenotypicFeature
implanted	O
in	O
LKB1	B-GeneOrGeneProduct
(	O
endo	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
but	O
not	O
macrophage	O
-	O
specific	O
LKB1	B-GeneOrGeneProduct
-	O
knockout	O
mice	B-OrganismTaxon
grew	O
faster	O
and	O
showed	O
enhanced	O
vascular	O
permeability	O
and	O
increased	O
angiogenesis	O
as	O
compared	O
with	O
those	O
implanted	O
in	O
wild	O
-	O
type	O
mice	B-OrganismTaxon
.	O

Injection	O
of	O
VEGF	B-GeneOrGeneProduct
-	O
neutralizing	O
antibody	O
but	O
not	O
the	O
isotype	O
-	O
matched	O
control	O
antibody	O
decreased	O
endothelial	O
-	O
cell	O
angiogenesis	O
and	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
in	O
vivo	O
.	O

Furthermore	O
,	O
LKB1	B-GeneOrGeneProduct
deletion	O
enhanced	O
mouse	B-OrganismTaxon
retinal	O
and	O
cell	O
angiogenesis	O
,	O
and	O
knockdown	O
of	O
VEGF	B-GeneOrGeneProduct
by	O
small	O
-	O
interfering	O
RNA	O
decreased	O
endothelial	O
cell	O
proliferation	O
and	O
migration	O
.	O

Re	O
-	O
expression	O
of	O
LKB1	B-GeneOrGeneProduct
or	O
knockdown	O
of	O
VEGF	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
decreased	O
the	O
overproliferation	O
and	O
-	O
migration	O
observed	O
in	O
LKB1	B-GeneOrGeneProduct
(	O
endo	O
-	O
/	O
-	O
)	O
cells	O
.	O

Mechanistically	O
,	O
LKB1	B-GeneOrGeneProduct
could	O
bind	O
to	O
the	O
VEGF	B-GeneOrGeneProduct
transcription	O
factor	O
,	O
specificity	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
Sp1	B-GeneOrGeneProduct
)	O
,	O
which	O
then	O
inhibited	O
the	O
binding	O
of	O
Sp1	B-GeneOrGeneProduct
to	O
the	O
VEGF	B-GeneOrGeneProduct
promoter	O
to	O
reduce	O
VEGF	B-GeneOrGeneProduct
expression	O
.	O

Endothelial	O
LKB1	B-GeneOrGeneProduct
may	O
regulate	O
endothelial	O
angiogenesis	O
and	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
by	O
modulating	O
Sp1	B-GeneOrGeneProduct
-	O
mediated	O
VEGF	B-GeneOrGeneProduct
expression	O
.	O
Urinary	B-DiseaseOrPhenotypicFeature
bladder	I-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
in	O
Wegener	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
granulomatosis	I-DiseaseOrPhenotypicFeature
:	O
risks	O
and	O
relation	O
to	O
cyclophosphamide	B-ChemicalEntity
.	O

OBJECTIVE	O
:	O
To	O
assess	O
and	O
characterise	O
the	O
risk	O
of	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
,	O
and	O
its	O
relation	O
to	O
cyclophosphamide	B-ChemicalEntity
,	O
in	O
patients	B-OrganismTaxon
with	O
Wegener	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
granulomatosis	I-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
In	O
the	O
population	O
based	O
,	O
nationwide	O
Swedish	O
Inpatient	B-OrganismTaxon
Register	O
a	O
cohort	O
of	O
1065	O
patients	B-OrganismTaxon
with	O
Wegener	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
granulomatosis	I-DiseaseOrPhenotypicFeature
,	O
1969	O
-	O
95	O
,	O
was	O
identified	O
.	O

Through	O
linkage	O
with	O
the	O
Swedish	O
Cancer	B-DiseaseOrPhenotypicFeature
Register	O
,	O
all	O
subjects	O
in	O
this	O
cohort	O
diagnosed	O
with	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
were	O
identified	O
.	O

Nested	O
within	O
the	O
cohort	O
,	O
a	O
matched	O
case	O
-	O
control	O
study	O
was	O
performed	O
to	O
estimate	O
the	O
association	O
between	O
cyclophosphamide	B-ChemicalEntity
and	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
using	O
odds	O
ratios	O
(	O
ORs	O
)	O
as	O
relative	O
risk	O
.	O

In	O
the	O
cohort	O
the	O
cumulative	O
risk	O
of	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
after	O
Wegener	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
granulomatosis	I-DiseaseOrPhenotypicFeature
,	O
and	O
the	O
relative	O
prevalence	O
of	O
a	O
history	O
of	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
granulomatosis	I-DiseaseOrPhenotypicFeature
,	O
were	O
also	O
estimated	O
.	O

RESULTS	O
:	O
The	O
median	O
cumulative	O
doses	O
of	O
cyclophosphamide	B-ChemicalEntity
among	O
cases	O
(	O
n	O
=	O
11	O
)	O
and	O
controls	O
(	O
n	O
=	O
25	O
)	O
were	O
113	O
g	O
and	O
25	O
g	O
,	O
respectively	O
.	O

The	O
risk	O
of	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
doubled	O
for	O
every	O
10	O
g	O
increment	O
in	O
cyclophosphamide	B-ChemicalEntity
(	O
OR	O
=	O
2	O
.	O
0	O
,	O
95%	O
confidence	O
interval	O
(	O
CI	O
)	O
0	O
.	O
8	O
to	O
4	O
.	O
9	O
)	O
.	O

Treatment	O
duration	O
longer	O
than	O
1	O
year	O
was	O
associated	O
with	O
an	O
eightfold	O
increased	O
risk	O
(	O
OR	O
=	O
7	O
.	O
7	O
,	O
95%	O
CI	O
0	O
.	O
9	O
to	O
69	O
)	O
.	O

The	O
absolute	O
risk	O
for	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
in	O
the	O
cohort	O
reached	O
10%	O
16	O
years	O
after	O
diagnosis	O
of	O
Wegener	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
granulomatosis	I-DiseaseOrPhenotypicFeature
,	O
and	O
a	O
history	O
of	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
was	O
(	O
non	O
-	O
significantly	O
)	O
twice	O
as	O
common	O
as	O
expected	O
at	O
the	O
time	O
of	O
diagnosis	O
of	O
Wegener	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
granulomatosis	I-DiseaseOrPhenotypicFeature
.	O

CONCLUSION	O
:	O
The	O
results	O
indicate	O
a	O
dose	O
-	O
response	O
relationship	O
between	O
cyclophosphamide	B-ChemicalEntity
and	O
the	O
risk	O
of	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
,	O
high	O
cumulative	O
risks	O
in	O
the	O
entire	O
cohort	O
,	O
and	O
also	O
the	O
possibility	O
of	O
risk	O
factors	O
operating	O
even	O
before	O
Wegener	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
granulomatosis	I-DiseaseOrPhenotypicFeature
.	O
Mutation	O
analysis	O
of	O
FOXF2	B-GeneOrGeneProduct
in	O
patients	B-OrganismTaxon
with	O
disorders	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
sex	I-DiseaseOrPhenotypicFeature
development	I-DiseaseOrPhenotypicFeature
(	O
DSD	B-DiseaseOrPhenotypicFeature
)	O
in	O
combination	O
with	O
cleft	B-DiseaseOrPhenotypicFeature
palate	I-DiseaseOrPhenotypicFeature
.	O

In	O
contrast	O
to	O
disorders	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
sexual	I-DiseaseOrPhenotypicFeature
differentiation	I-DiseaseOrPhenotypicFeature
caused	O
by	O
lack	O
of	O
androgen	B-ChemicalEntity
production	O
or	O
inhibited	O
androgen	B-ChemicalEntity
action	O
,	O
defects	O
affecting	O
development	O
of	O
the	O
bipotent	O
genital	O
anlagen	O
have	O
rarely	O
been	O
investigated	O
in	O
humans	B-OrganismTaxon
.	O

We	O
have	O
previously	O
documented	O
that	O
the	O
transcription	O
factor	O
FOXF2	B-GeneOrGeneProduct
is	O
highly	O
expressed	O
in	O
human	B-OrganismTaxon
foreskin	O
.	O

Moreover	O
,	O
Foxf2	B-GeneOrGeneProduct
knockout	O
mice	B-OrganismTaxon
present	O
with	O
cleft	B-DiseaseOrPhenotypicFeature
palate	I-DiseaseOrPhenotypicFeature
in	O
combination	O
with	O
hypoplasia	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
genital	I-DiseaseOrPhenotypicFeature
tubercle	I-DiseaseOrPhenotypicFeature
.	O

We	O
hypothesized	O
that	O
humans	B-OrganismTaxon
with	O
disorders	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
sex	I-DiseaseOrPhenotypicFeature
development	I-DiseaseOrPhenotypicFeature
(	O
DSD	B-DiseaseOrPhenotypicFeature
)	O
in	O
combination	O
with	O
cleft	B-DiseaseOrPhenotypicFeature
palate	I-DiseaseOrPhenotypicFeature
could	O
have	O
mutations	O
in	O
the	O
FOXF2	B-GeneOrGeneProduct
gene	O
.	O

Eighteen	O
children	O
with	O
DSD	B-DiseaseOrPhenotypicFeature
and	O
cleft	B-DiseaseOrPhenotypicFeature
palate	I-DiseaseOrPhenotypicFeature
were	O
identified	O
in	O
the	O
L	O
beck	O
DSD	B-DiseaseOrPhenotypicFeature
database	O
(	O
about	O
1	O
,	O
500	O
entries	O
)	O
.	O

Genomic	O
DNA	O
sequence	O
analysis	O
of	O
the	O
FOXF2	B-GeneOrGeneProduct
gene	O
was	O
performed	O
and	O
compared	O
with	O
10	O
normal	O
female	O
and	O
10	O
normal	O
male	O
controls	O
,	O
respectively	O
.	O

Two	O
heterozygous	O
DNA	O
sequence	O
variations	O
were	O
solely	O
present	O
in	O
one	O
single	O
patient	B-OrganismTaxon
each	O
but	O
in	O
none	O
of	O
the	O
20	O
normal	O
controls	O
:	O
a	O
duplication	B-SequenceVariant
of	I-SequenceVariant
GCC	I-SequenceVariant
(	O
c	B-SequenceVariant
.	O
97GCC	I-SequenceVariant
[	O
9	I-SequenceVariant
]	O
+	O
[	O
10	I-SequenceVariant
]	O
)	O
resulting	O
in	O
an	O
extra	O
alanine	O
within	O
exon	O
1	O
and	O
a	O
25	B-SequenceVariant
*	O
G	I-SequenceVariant
>	O
A	I-SequenceVariant
substitution	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
.	O

Two	O
patients	B-OrganismTaxon
carried	O
a	O
c	B-SequenceVariant
.	O
262G	I-SequenceVariant
>	O
A	I-SequenceVariant
sequence	O
variation	O
predicting	O
for	O
an	O
Ala88Thr	B-SequenceVariant
exchange	O
which	O
was	O
also	O
detected	O
in	O
2	O
normal	O
controls	O
.	O

Two	O
silent	O
mutations	O
,	O
c	B-SequenceVariant
.	O
1272C	I-SequenceVariant
>	O
T	I-SequenceVariant
(	O
Ser424Ser	B-SequenceVariant
)	O
and	O
c	B-SequenceVariant
.	O
1284T	I-SequenceVariant
>	O
C	I-SequenceVariant
(	O
Tyr428Tyr	B-SequenceVariant
)	O
,	O
respectively	O
,	O
occurred	O
in	O
the	O
coding	O
region	O
of	O
exon	O
2	O
,	O
again	O
in	O
both	O
patients	B-OrganismTaxon
and	O
normal	O
controls	O
.	O

In	O
conclusion	O
,	O
the	O
majority	O
of	O
the	O
detected	O
sequence	O
alterations	O
were	O
polymorphisms	O
without	O
obvious	O
functional	O
relevance	O
.	O

However	O
,	O
it	O
cannot	O
be	O
excluded	O
that	O
the	O
2	O
unique	O
DNA	O
sequence	O
alterations	O
could	O
have	O
affected	O
FOXF2	B-GeneOrGeneProduct
on	O
the	O
mRNA	O
or	O
protein	O
level	O
thus	O
contributing	O
to	O
the	O
observed	O
disturbances	O
in	O
genital	O
and	O
palate	O
development	O
.	O
Melanocortin	B-GeneOrGeneProduct
-	O
4	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
activation	O
inhibits	O
c	B-GeneOrGeneProduct
-	O
Jun	I-GeneOrGeneProduct
N	I-GeneOrGeneProduct
-	O
terminal	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
activity	O
and	O
promotes	O
insulin	B-GeneOrGeneProduct
signaling	O
.	O

The	O
melanocortin	B-GeneOrGeneProduct
system	O
is	O
crucial	O
to	O
regulation	O
of	O
energy	O
homeostasis	O
.	O

The	O
melanocortin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
type	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
(	O
MC4R	B-GeneOrGeneProduct
)	O
modulates	O
insulin	B-GeneOrGeneProduct
signaling	O
via	O
effects	O
on	O
c	B-GeneOrGeneProduct
-	O
Jun	I-GeneOrGeneProduct
N	I-GeneOrGeneProduct
-	O
terminal	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
(	O
JNK	B-GeneOrGeneProduct
)	O
.	O

The	O
melanocortin	B-GeneOrGeneProduct
agonist	O
NDP	B-ChemicalEntity
-	O
MSH	I-ChemicalEntity
dose	O
-	O
dependently	O
inhibited	O
JNK	B-GeneOrGeneProduct
activity	O
in	O
HEK293	B-CellLine
cells	O
stably	O
expressing	O
the	O
human	B-OrganismTaxon
MC4R	B-GeneOrGeneProduct
;	O
effects	O
were	O
reversed	O
by	O
melanocortin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
antagonist	O
.	O

NDP	B-ChemicalEntity
-	O
MSH	I-ChemicalEntity
time	O
-	O
and	O
dose	O
-	O
dependently	O
inhibited	O
IRS	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
ser307	B-SequenceVariant
)	O
phosphorylation	O
,	O
effects	O
also	O
reversed	O
by	O
a	O
specific	O
melanocortin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
antagonist	O
.	O

NDP	B-ChemicalEntity
-	O
MSH	I-ChemicalEntity
augmented	O
insulin	B-GeneOrGeneProduct
-	O
stimulated	O
AKT	B-GeneOrGeneProduct
phosphorylation	O
in	O
vitro	O
.	O

The	O
melanocortin	B-GeneOrGeneProduct
agonist	O
melanotan	B-ChemicalEntity
II	I-ChemicalEntity
increased	O
insulin	B-GeneOrGeneProduct
-	O
stimulated	O
AKT	B-GeneOrGeneProduct
phosphorylation	O
in	O
the	O
rat	B-OrganismTaxon
hypothalamus	O
in	O
vivo	O
.	O

NDP	B-ChemicalEntity
-	O
MSH	I-ChemicalEntity
increased	O
insulin	B-GeneOrGeneProduct
-	O
stimulated	O
glucose	B-ChemicalEntity
uptake	O
in	O
hypothalamic	O
GT1	B-CellLine
-	O
1	I-CellLine
cells	O
.	O

The	O
current	O
study	O
shows	O
that	O
the	O
melanocortinergic	O
system	O
interacts	O
with	O
insulin	B-GeneOrGeneProduct
signaling	O
via	O
novel	O
effects	O
on	O
JNK	B-GeneOrGeneProduct
activity	O
.	O
Recovery	O
of	O
tacrolimus	B-ChemicalEntity
-	O
associated	O
brachial	B-DiseaseOrPhenotypicFeature
neuritis	I-DiseaseOrPhenotypicFeature
after	O
conversion	O
to	O
everolimus	B-ChemicalEntity
in	O
a	O
pediatric	O
renal	O
transplant	O
recipient	O
-	O
-	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

TAC	B-ChemicalEntity
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
immunosuppressive	O
agent	O
for	O
solid	O
organ	O
transplantation	O
in	O
pediatrics	O
.	O

Neurotoxicity	B-DiseaseOrPhenotypicFeature
is	O
a	O
potentially	O
serious	O
toxic	O
effect	O
.	O

It	O
is	O
characterized	O
by	O
encephalopathy	B-DiseaseOrPhenotypicFeature
,	O
headaches	B-DiseaseOrPhenotypicFeature
,	O
seizures	B-DiseaseOrPhenotypicFeature
,	O
or	O
neurological	B-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
.	O

Here	O
,	O
we	O
describe	O
an	O
eight	O
-	O
and	O
-	O
a	O
-	O
half	O
-	O
yr	O
-	O
old	O
male	O
renal	O
transplant	O
recipient	O
with	O
right	O
BN	O
.	O

MRI	O
demonstrated	O
hyperintense	O
T2	O
signals	O
in	O
the	O
cervical	O
cord	O
and	O
right	O
brachial	O
plexus	O
roots	O
indicative	O
of	O
both	O
myelitis	B-DiseaseOrPhenotypicFeature
and	O
right	O
brachial	B-DiseaseOrPhenotypicFeature
plexitis	I-DiseaseOrPhenotypicFeature
.	O

Symptoms	O
persisted	O
for	O
three	O
months	O
despite	O
TAC	B-ChemicalEntity
dose	O
reduction	O
,	O
administration	O
of	O
IVIG	O
and	O
four	O
doses	O
of	O
methylprednisolone	B-ChemicalEntity
pulse	O
therapy	O
.	O

Improvement	O
and	O
eventually	O
full	O
recovery	O
only	O
occurred	O
after	O
TAC	B-ChemicalEntity
was	O
completely	O
discontinued	O
and	O
successfully	O
replaced	O
by	O
everolimus	B-ChemicalEntity
.	O
A	O
Taiwanese	O
boy	O
with	O
congenital	B-DiseaseOrPhenotypicFeature
generalized	I-DiseaseOrPhenotypicFeature
lipodystrophy	I-DiseaseOrPhenotypicFeature
caused	O
by	O
homozygous	O
Ile262fs	B-SequenceVariant
mutation	O
in	O
the	O
BSCL2	B-GeneOrGeneProduct
gene	O
.	O

Congenital	B-DiseaseOrPhenotypicFeature
generalized	I-DiseaseOrPhenotypicFeature
lipodystrophy	I-DiseaseOrPhenotypicFeature
(	O
CGL	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
rare	O
autosomal	B-DiseaseOrPhenotypicFeature
recessive	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
that	O
is	O
characterized	O
by	O
a	O
near	O
-	O
complete	O
absence	O
of	O
adipose	O
tissue	O
from	O
birth	O
or	O
early	O
infancy	O
.	O

Mutations	O
in	O
the	O
BSCL2	B-GeneOrGeneProduct
gene	O
are	O
known	O
to	O
result	O
in	O
CGL2	B-DiseaseOrPhenotypicFeature
,	O
a	O
more	O
severe	O
phenotype	O
than	O
CGL1	B-DiseaseOrPhenotypicFeature
,	O
with	O
earlier	O
onset	O
,	O
more	O
extensive	O
fat	O
loss	O
and	O
biochemical	O
changes	O
,	O
more	O
severe	O
intellectual	B-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
,	O
and	O
more	O
severe	O
cardiomyopathy	B-DiseaseOrPhenotypicFeature
.	O

We	O
report	O
a	O
3	O
-	O
month	O
-	O
old	O
Taiwanese	O
boy	O
with	O
initial	O
presentation	O
of	O
a	O
lack	O
of	O
subcutaneous	O
fat	O
,	O
prominent	O
musculature	O
,	O
generalized	O
eruptive	B-DiseaseOrPhenotypicFeature
xanthomas	I-DiseaseOrPhenotypicFeature
,	O
and	O
extreme	O
hypertriglyceridemia	B-DiseaseOrPhenotypicFeature
.	O

Absence	O
of	O
mechanical	O
adipose	O
tissue	O
in	O
the	O
orbits	O
and	O
scalp	O
was	O
revealed	O
by	O
head	O
magnetic	O
resonance	O
imaging	O
.	O

Hepatomegaly	B-DiseaseOrPhenotypicFeature
was	O
noticed	O
,	O
and	O
histological	O
examination	O
of	O
a	O
liver	O
biopsy	O
specimen	O
suggested	O
severe	O
hepatic	B-DiseaseOrPhenotypicFeature
steatosis	I-DiseaseOrPhenotypicFeature
and	O
periportal	O
necrosis	B-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
echocardiography	O
indicated	O
no	O
sign	O
of	O
cardiomyopathy	B-DiseaseOrPhenotypicFeature
and	O
he	O
showed	O
no	O
distinct	O
intellectual	B-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
that	O
interfered	O
with	O
daily	O
life	O
.	O

About	O
1	O
year	O
later	O
,	O
abdominal	O
computed	O
tomography	O
revealed	O
enlargement	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
kidneys	I-DiseaseOrPhenotypicFeature
.	O

He	O
had	O
a	O
homozygous	O
insertion	O
of	O
a	O
nucleotide	O
,	O
783insG	B-SequenceVariant
(	O
Ile262fs	B-SequenceVariant
mutation	O
)	O
,	O
in	O
exon	O
7	O
of	O
the	O
BSCL2	B-GeneOrGeneProduct
gene	O
.	O

We	O
reviewed	O
the	O
genotype	O
of	O
CGL	B-DiseaseOrPhenotypicFeature
cases	O
from	O
Japan	O
,	O
India	O
,	O
China	O
and	O
Taiwan	O
,	O
and	O
found	O
that	O
BSCL2	B-GeneOrGeneProduct
is	O
a	O
major	O
causative	O
gene	O
for	O
CGL	B-DiseaseOrPhenotypicFeature
in	O
Asian	O
.	O
Pleomorphic	B-GeneOrGeneProduct
adenoma	I-GeneOrGeneProduct
gene	I-GeneOrGeneProduct
like	I-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
induces	O
epithelial	O
-	O
mesenchymal	O
transition	O
via	O
Wnt	B-GeneOrGeneProduct
/	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
signaling	O
pathway	O
in	O
human	B-OrganismTaxon
colorectal	B-DiseaseOrPhenotypicFeature
adenocarcinoma	I-DiseaseOrPhenotypicFeature
.	O

Epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
is	O
a	O
critical	O
step	O
in	O
the	O
acquisition	O
of	O
metastatic	O
and	O
invasive	O
power	O
for	O
tumor	B-DiseaseOrPhenotypicFeature
cells	O
.	O

Colorectal	B-DiseaseOrPhenotypicFeature
adenocarcinoma	I-DiseaseOrPhenotypicFeature
(	O
CRC	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
common	O
cancer	B-DiseaseOrPhenotypicFeature
where	O
metastasis	B-DiseaseOrPhenotypicFeature
is	O
directly	O
linked	O
to	O
patient	B-OrganismTaxon
survival	O
.	O

Recent	O
studies	O
show	O
that	O
pleomorphic	B-GeneOrGeneProduct
adenoma	I-GeneOrGeneProduct
gene	I-GeneOrGeneProduct
like	I-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
(	O
PLAGL2	B-GeneOrGeneProduct
)	O
could	O
induce	O
tumor	B-DiseaseOrPhenotypicFeature
EMT	O
and	O
is	O
an	O
independent	O
predictive	O
factor	O
associated	O
with	O
poor	O
prognosis	O
in	O
cancer	B-DiseaseOrPhenotypicFeature
.	O

In	O
the	O
present	O
study	O
,	O
we	O
confirmed	O
the	O
role	O
of	O
PLAGL2	B-GeneOrGeneProduct
in	O
the	O
prognosis	O
of	O
CRC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
provide	O
molecular	O
evidence	O
of	O
PLAGL2	B-GeneOrGeneProduct
promoted	O
EMT	O
in	O
CRC	B-DiseaseOrPhenotypicFeature
cell	O
line	O
SW480	B-CellLine
.	O

We	O
found	O
that	O
PLAGL2	B-GeneOrGeneProduct
expression	O
was	O
upregulated	O
in	O
the	O
paraffin	B-ChemicalEntity
-	O
embedded	O
CRC	B-DiseaseOrPhenotypicFeature
tissues	O
compared	O
to	O
borderline	O
or	O
benign	O
tissues	O
.	O

Experimental	O
EMT	O
induced	O
by	O
PLAGL2	B-GeneOrGeneProduct
plasmid	O
transfection	O
proved	O
PLAGL2	B-GeneOrGeneProduct
protein	O
overexpression	O
could	O
enhance	O
the	O
cell	O
scratch	O
wound	O
-	O
healing	O
and	O
transwell	O
ability	O
and	O
significantly	O
upregulated	O
mesenchymal	O
marker	O
proteins	O
,	O
N	B-GeneOrGeneProduct
-	O
cadherin	I-GeneOrGeneProduct
and	O
vimentin	B-GeneOrGeneProduct
and	O
concurrently	O
downregulated	O
epithelial	O
marker	O
of	O
E	B-GeneOrGeneProduct
-	O
cadherin	I-GeneOrGeneProduct
.	O

Subsequently	O
,	O
through	O
western	O
blot	O
assay	O
,	O
we	O
found	O
that	O
PLAGL2	B-GeneOrGeneProduct
could	O
activate	O
the	O
wnt	B-GeneOrGeneProduct
-	O
signaling	O
component	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
in	O
the	O
nuclei	O
.	O

More	O
CRC	B-DiseaseOrPhenotypicFeature
cell	O
metastasis	B-DiseaseOrPhenotypicFeature
to	O
the	O
lungs	O
was	O
observed	O
when	O
the	O
PLAGL2	B-GeneOrGeneProduct
overexpressing	O
SW480	B-CellLine
cells	O
were	O
injected	O
into	O
the	O
tail	O
vein	O
of	O
rats	B-OrganismTaxon
,	O
compared	O
with	O
the	O
cell	O
control	O
and	O
PLAGL2	B-GeneOrGeneProduct
silence	O
group	O
.	O

Our	O
findings	O
indicated	O
that	O
PLAGL2	B-GeneOrGeneProduct
might	O
be	O
a	O
very	O
upstream	O
key	O
molecule	O
regulating	O
EMT	O
involved	O
in	O
Wnt	B-GeneOrGeneProduct
/	O
b	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
signaling	O
pathway	O
.	O
Calcium	B-GeneOrGeneProduct
sensing	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
protects	O
high	O
glucose	B-ChemicalEntity
-	O
induced	O
energy	O
metabolism	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
via	O
blocking	O
gp78	B-GeneOrGeneProduct
-	O
ubiquitin	O
proteasome	O
pathway	O
.	O

Diabetic	B-DiseaseOrPhenotypicFeature
cardiomyopathy	I-DiseaseOrPhenotypicFeature
(	O
DCM	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
major	O
complication	O
and	O
fatal	O
cause	O
of	O
the	O
patients	B-OrganismTaxon
with	O
diabetes	B-DiseaseOrPhenotypicFeature
.	O

The	O
calcium	B-GeneOrGeneProduct
sensing	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
CaSR	B-GeneOrGeneProduct
)	O
is	O
a	O
G	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
-	O
coupled	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
,	O
which	O
is	O
involved	O
in	O
maintaining	O
calcium	B-ChemicalEntity
homeostasis	O
,	O
regulating	O
cell	O
proliferation	O
and	O
apoptosis	O
,	O
and	O
so	O
on	O
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
found	O
that	O
CaSR	B-GeneOrGeneProduct
expression	O
,	O
intracellular	O
calcium	B-ChemicalEntity
levels	O
and	O
cardiac	O
function	O
were	O
all	O
significantly	O
decreased	O
in	O
DCM	B-DiseaseOrPhenotypicFeature
rats	B-OrganismTaxon
;	O
however	O
,	O
the	O
exact	O
mechanism	O
are	O
not	O
clear	O
yet	O
.	O

The	O
present	O
study	O
revealed	O
the	O
protective	O
role	O
of	O
CaSR	B-GeneOrGeneProduct
in	O
myocardial	B-DiseaseOrPhenotypicFeature
energy	I-DiseaseOrPhenotypicFeature
metabolism	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
induced	O
by	O
high	O
glucose	B-ChemicalEntity
(	O
HG	O
)	O
as	O
well	O
as	O
the	O
underlying	O
mechanism	O
.	O

Here	O
,	O
we	O
demonstrated	O
that	O
HG	O
decreased	O
the	O
expression	O
of	O
CaSR	B-GeneOrGeneProduct
,	O
mitochondrial	O
fusion	O
proteins	O
(	O
Mfn1	B-GeneOrGeneProduct
,	O
Mfn2	B-GeneOrGeneProduct
)	O
,	O
cell	O
gap	O
junction	O
related	O
proteins	O
(	O
Cx43	B-GeneOrGeneProduct
,	O
beta	B-GeneOrGeneProduct
-	O
catenin	I-GeneOrGeneProduct
,	O
N	B-GeneOrGeneProduct
-	O
cadherin	I-GeneOrGeneProduct
)	O
,	O
and	O
intracellular	O
ATP	B-ChemicalEntity
concentration	O
.	O

In	O
contrast	O
,	O
HG	O
increased	O
extracellular	O
ATP	B-ChemicalEntity
concentration	O
,	O
the	O
expression	O
of	O
gp78	B-GeneOrGeneProduct
,	O
mitochondrial	O
fission	O
proteins	O
(	O
Fis1	B-GeneOrGeneProduct
,	O
Drp1	B-GeneOrGeneProduct
)	O
,	O
and	O
the	O
ubiquitination	O
levels	O
of	O
Mfn1	B-GeneOrGeneProduct
,	O
Mfn2	B-GeneOrGeneProduct
and	O
Cx43	B-GeneOrGeneProduct
.	O

Moreover	O
,	O
CaSR	B-GeneOrGeneProduct
agonist	O
and	O
gp78	B-GeneOrGeneProduct
-	O
siRNA	O
significantly	O
reduced	O
the	O
above	O
changes	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
HG	O
induces	O
myocardial	B-DiseaseOrPhenotypicFeature
energy	I-DiseaseOrPhenotypicFeature
metabolism	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
via	O
decrease	O
of	O
CaSR	B-GeneOrGeneProduct
expression	O
,	O
and	O
activation	O
of	O
gp78	B-GeneOrGeneProduct
-	O
ubiquitin	O
proteasome	O
system	O
.	O

In	O
turn	O
,	O
these	O
effects	O
disrupt	O
the	O
structure	O
and	O
function	O
of	O
the	O
mitochondria	O
and	O
the	O
cell	O
gap	O
junction	O
,	O
result	O
in	O
the	O
reduced	O
ATP	B-ChemicalEntity
synthesis	O
and	O
the	O
increased	O
ATP	B-ChemicalEntity
leakage	O
.	O

Stimulation	O
of	O
CaSR	B-GeneOrGeneProduct
significantly	O
attenuates	O
HG	O
-	O
induced	O
abnormal	B-DiseaseOrPhenotypicFeature
myocardial	I-DiseaseOrPhenotypicFeature
energy	I-DiseaseOrPhenotypicFeature
metabolism	I-DiseaseOrPhenotypicFeature
,	O
suggesting	O
CaSR	B-GeneOrGeneProduct
would	O
be	O
a	O
promising	O
potential	O
therapeutic	O
target	O
for	O
DCM	B-DiseaseOrPhenotypicFeature
.	O
Mutations	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
modulate	O
seroreactivity	O
to	O
microbial	O
antigens	O
in	O
patients	B-OrganismTaxon
with	O
inflammatory	B-DiseaseOrPhenotypicFeature
bowel	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
AND	O
AIMS	O
:	O
A	O
number	O
of	O
antibodies	O
against	O
microbial	O
epitopes	O
or	O
self	O
-	O
antigens	O
have	O
been	O
associated	O
with	O
Crohn	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

The	O
development	O
of	O
antibodies	O
reflects	O
a	O
loss	O
of	O
tolerance	O
to	O
intestinal	O
bacteria	B-OrganismTaxon
that	O
underlies	O
Crohn	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
,	O
resulting	O
in	O
an	O
exaggerated	O
adaptive	O
immune	O
response	O
to	O
these	O
bacteria	B-OrganismTaxon
.	O

It	O
was	O
hypothesised	O
that	O
the	O
development	O
of	O
antimicrobial	O
antibodies	O
is	O
influenced	O
by	O
the	O
presence	O
of	O
genetic	O
variants	O
in	O
pattern	O
recognition	O
receptor	O
genes	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
therefore	O
to	O
investigate	O
the	O
influence	O
of	O
mutations	O
in	O
these	O
innate	B-GeneOrGeneProduct
immune	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
genes	O
(	O
nucleotide	B-GeneOrGeneProduct
oligomerisation	I-GeneOrGeneProduct
domain	I-GeneOrGeneProduct
(	O
NOD	I-GeneOrGeneProduct
)	O
2	I-GeneOrGeneProduct
/	O
caspase	B-GeneOrGeneProduct
recruitment	I-GeneOrGeneProduct
domain	I-GeneOrGeneProduct
(	O
CARD	I-GeneOrGeneProduct
)	O
15	I-GeneOrGeneProduct
,	O
NOD1	B-GeneOrGeneProduct
/	O
CARD4	B-GeneOrGeneProduct
,	O
TUCAN	B-GeneOrGeneProduct
/	O
CARDINAL	B-GeneOrGeneProduct
/	O
CARD8	B-GeneOrGeneProduct
,	O
Toll	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
TLR	I-GeneOrGeneProduct
)	O
4	I-GeneOrGeneProduct
,	O
TLR2	B-GeneOrGeneProduct
,	O
TLR1	B-GeneOrGeneProduct
and	O
TLR6	B-GeneOrGeneProduct
)	O
on	O
the	O
development	O
of	O
antimicrobial	O
and	O
antiglycan	O
antibodies	O
in	O
inflammatory	B-DiseaseOrPhenotypicFeature
bowel	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
IBD	B-DiseaseOrPhenotypicFeature
)	O
.	O

Materials	O
and	O
METHODS	O
:	O
A	O
cohort	O
of	O
1163	O
unrelated	O
patients	B-OrganismTaxon
with	O
IBD	B-DiseaseOrPhenotypicFeature
(	O
874	O
Crohn	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
,	O
259	O
ulcerative	B-DiseaseOrPhenotypicFeature
colitis	I-DiseaseOrPhenotypicFeature
,	O
30	O
indeterminate	O
colitis	B-DiseaseOrPhenotypicFeature
)	O
and	O
312	O
controls	O
were	O
analysed	O
for	O
anti	O
-	O
Saccharomyces	B-OrganismTaxon
cerevisiae	I-OrganismTaxon
antibodies	O
(	O
gASCA	O
)	O
IgG	O
,	O
anti	O
-	O
laminaribioside	O
antibodies	O
(	O
ALCA	O
)	O
IgG	O
,	O
anti	O
-	O
chitobioside	O
antibodies	O
(	O
ACCA	O
)	O
IgA	O
,	O
anti	O
-	O
mannobioside	O
antibodies	O
(	O
AMCA	O
)	O
IgG	O
and	O
outer	O
membrane	O
porin	O
(	O
Omp	O
)	O
IgA	O
and	O
were	O
genotyped	O
for	O
variants	O
in	O
NOD2	B-GeneOrGeneProduct
/	O
CARD15	B-GeneOrGeneProduct
,	O
TUCAN	B-GeneOrGeneProduct
/	O
CARDINAL	B-GeneOrGeneProduct
/	O
CARD8	B-GeneOrGeneProduct
,	O
NOD1	B-GeneOrGeneProduct
/	O
CARD4	B-GeneOrGeneProduct
,	O
TLR4	B-GeneOrGeneProduct
,	O
TLR1	B-GeneOrGeneProduct
,	O
TLR2	B-GeneOrGeneProduct
and	O
TLR6	B-GeneOrGeneProduct
.	O

RESULTS	O
:	O
When	O
compared	O
with	O
Crohn	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
without	O
CARD15	B-GeneOrGeneProduct
mutations	O
,	O
the	O
presence	O
of	O
at	O
least	O
one	O
CARD15	B-GeneOrGeneProduct
variant	O
in	O
Crohn	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
more	O
frequently	O
led	O
to	O
gASCA	O
positivity	O
(	O
66	O
.	O
1%	O
versus	O
51	O
.	O
5%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
ALCA	O
positivity	O
(	O
43	O
.	O
3%	O
versus	O
34	O
.	O
9%	O
,	O
p	O
=	O
0	O
.	O
018	O
)	O
and	O
higher	O
gASCA	O
titers	O
(	O
85	O
.	O
7	O
versus	O
51	O
.	O
8	O
ELISA	O
units	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
independent	O
of	O
ileal	O
involvement	O
.	O

A	O
gene	O
dosage	O
effect	O
,	O
with	O
increasing	O
gASCA	O
and	O
ALCA	O
positivity	O
for	O
patients	B-OrganismTaxon
carrying	O
none	O
,	O
one	O
and	O
two	O
CARD15	B-GeneOrGeneProduct
variants	O
,	O
respectively	O
,	O
was	O
seen	O
for	O
both	O
markers	O
.	O

Similarly	O
,	O
Crohn	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
carrying	O
NOD1	B-GeneOrGeneProduct
/	O
CARD4	B-GeneOrGeneProduct
indel	O
had	O
a	O
higher	O
prevalence	O
of	O
gASCA	O
antibodies	O
than	O
wild	O
-	O
type	O
patients	B-OrganismTaxon
(	O
63	O
.	O
8%	O
versus	O
55	O
.	O
2%	O
,	O
p	O
=	O
0	O
.	O
014	O
)	O
,	O
also	O
with	O
a	O
gene	O
dosage	O
effect	O
.	O

An	O
opposite	O
effect	O
was	O
observed	O
for	O
the	O
TLR4	B-GeneOrGeneProduct
D299G	B-SequenceVariant
and	O
TLR2	B-GeneOrGeneProduct
P631H	B-SequenceVariant
variants	O
,	O
with	O
a	O
lower	O
prevalence	O
of	O
ACCA	O
antibodies	O
(	O
23	O
.	O
4%	O
versus	O
35%	O
,	O
p	O
=	O
0	O
.	O
013	O
)	O
and	O
Omp	O
antibodies	O
(	O
20	O
.	O
5%	O
versus	O
34	O
.	O
6%	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
,	O
respectively	O
.	O

CONCLUSION	O
:	O
Variants	O
in	O
innate	B-GeneOrGeneProduct
immune	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
genes	O
were	O
found	O
to	O
influence	O
antibody	O
formation	O
against	O
microbial	O
epitopes	O
.	O

In	O
this	O
respect	O
,	O
it	O
is	O
intriguing	O
that	O
an	O
opposite	O
effect	O
of	O
CARD15	B-GeneOrGeneProduct
and	O
TLR4	B-GeneOrGeneProduct
variants	O
was	O
observed	O
.	O

These	O
findings	O
may	O
contribute	O
to	O
an	O
understanding	O
of	O
the	O
aetiology	O
of	O
the	O
seroreactivity	O
observed	O
in	O
IBD	B-DiseaseOrPhenotypicFeature
.	O
Serotonin	B-GeneOrGeneProduct
6	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
gene	O
is	O
associated	O
with	O
methamphetamine	B-ChemicalEntity
-	O
induced	O
psychosis	B-DiseaseOrPhenotypicFeature
in	O
a	O
Japanese	O
population	O
.	O

BACKGROUND	O
:	O
Altered	O
serotonergic	O
neural	O
transmission	O
is	O
hypothesized	O
to	O
be	O
a	O
susceptibility	O
factor	O
for	O
psychotic	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
such	O
as	O
schizophrenia	B-DiseaseOrPhenotypicFeature
.	O

The	O
serotonin	B-GeneOrGeneProduct
6	I-GeneOrGeneProduct
(	O
5	I-GeneOrGeneProduct
-	O
HT6	I-GeneOrGeneProduct
)	O
receptor	I-GeneOrGeneProduct
is	O
therapeutically	O
targeted	O
by	O
several	O
second	O
generation	O
antipsychotics	B-ChemicalEntity
,	O
such	O
as	O
clozapine	B-ChemicalEntity
and	O
olanzapine	B-ChemicalEntity
,	O
and	O
d	B-ChemicalEntity
-	O
amphetamine	I-ChemicalEntity
-	O
induced	O
hyperactivity	B-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
is	O
corrected	O
with	O
the	O
use	O
of	O
a	O
selective	O
5	B-ChemicalEntity
-	O
HT6	I-ChemicalEntity
receptor	I-ChemicalEntity
antagonist	I-ChemicalEntity
.	O

In	O
addition	O
,	O
the	O
disrupted	O
prepulse	O
inhibition	O
induced	O
by	O
d	B-ChemicalEntity
-	O
amphetamine	I-ChemicalEntity
or	O
phencyclidine	B-ChemicalEntity
was	O
restored	O
by	O
5	B-ChemicalEntity
-	O
HT6	I-ChemicalEntity
receptor	I-ChemicalEntity
antagonist	I-ChemicalEntity
in	O
an	O
animal	O
study	O
using	O
rats	B-OrganismTaxon
.	O

These	O
animal	O
models	O
were	O
considered	O
to	O
reflect	O
the	O
positive	O
symptoms	O
of	O
schizophrenia	B-DiseaseOrPhenotypicFeature
,	O
and	O
the	O
above	O
evidence	O
suggests	O
that	O
altered	O
5	B-GeneOrGeneProduct
-	O
HT6	I-GeneOrGeneProduct
receptors	I-GeneOrGeneProduct
are	O
involved	O
in	O
the	O
pathophysiology	O
of	O
psychotic	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
.	O

The	O
symptoms	O
of	O
methamphetamine	B-ChemicalEntity
(	O
METH	B-ChemicalEntity
)	O
-	O
induced	O
psychosis	B-DiseaseOrPhenotypicFeature
are	O
similar	O
to	O
those	O
of	O
paranoid	B-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
schizophrenia	I-DiseaseOrPhenotypicFeature
.	O

Therefore	O
,	O
we	O
conducted	O
an	O
analysis	O
of	O
the	O
association	O
of	O
the	O
5	B-GeneOrGeneProduct
-	O
HT6	I-GeneOrGeneProduct
gene	O
(	O
HTR6	B-GeneOrGeneProduct
)	O
with	O
METH	B-ChemicalEntity
-	O
induced	O
psychosis	B-DiseaseOrPhenotypicFeature
.	O

METHOD	O
:	O
Using	O
five	O
tagging	O
SNPs	O
(	O
rs6693503	B-SequenceVariant
,	O
rs1805054	B-SequenceVariant
,	O
rs4912138	B-SequenceVariant
,	O
rs3790757	B-SequenceVariant
and	O
rs9659997	B-SequenceVariant
)	O
,	O
we	O
conducted	O
a	O
genetic	O
association	O
analysis	O
of	O
case	O
-	O
control	O
samples	O
(	O
197	O
METH	B-ChemicalEntity
-	O
induced	O
psychosis	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
337	O
controls	O
)	O
in	O
the	O
Japanese	O
population	O
.	O

The	O
age	O
and	O
sex	O
of	O
the	O
control	O
subjects	O
did	O
not	O
differ	O
from	O
those	O
of	O
the	O
methamphetamine	B-ChemicalEntity
dependence	O
patients	B-OrganismTaxon
.	O

RESULTS	O
:	O
rs6693503	B-SequenceVariant
was	O
associated	O
with	O
METH	B-ChemicalEntity
-	O
induced	O
psychosis	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
in	O
the	O
allele	O
/	O
genotype	O
-	O
wise	O
analysis	O
.	O

Moreover	O
,	O
this	O
association	O
remained	O
significant	O
after	O
Bonferroni	O
correction	O
.	O

In	O
the	O
haplotype	O
-	O
wise	O
analysis	O
,	O
we	O
detected	O
an	O
association	O
between	O
two	O
markers	O
(	O
rs6693503	B-SequenceVariant
and	O
rs1805054	B-SequenceVariant
)	O
and	O
three	O
markers	O
(	O
rs6693503	B-SequenceVariant
,	O
rs1805054	B-SequenceVariant
and	O
rs4912138	B-SequenceVariant
)	O
in	O
HTR6	B-GeneOrGeneProduct
and	O
METH	B-ChemicalEntity
-	O
induced	O
psychosis	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
respectively	O
.	O

CONCLUSION	O
:	O
HTR6	B-GeneOrGeneProduct
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
METH	B-ChemicalEntity
-	O
induced	O
psychosis	B-DiseaseOrPhenotypicFeature
in	O
the	O
Japanese	O
population	O
.	O
Growth	B-GeneOrGeneProduct
hormone	I-GeneOrGeneProduct
dose	O
in	O
growth	B-DiseaseOrPhenotypicFeature
hormone	I-DiseaseOrPhenotypicFeature
-	O
deficient	I-DiseaseOrPhenotypicFeature
adults	O
is	O
not	O
associated	O
with	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
gene	O
polymorphisms	O
.	O

AIMS	O
:	O
Several	O
SNPs	O
and	O
a	O
microsatellite	O
cytosine	O
-	O
adenine	O
repeat	O
promoter	O
polymorphism	O
of	O
the	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
gene	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
circulating	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
serum	O
concentrations	O
.	O

Variance	O
in	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
concentrations	O
due	O
to	O
genetic	O
variations	O
may	O
affect	O
different	O
response	O
to	O
growth	B-GeneOrGeneProduct
hormone	I-GeneOrGeneProduct
(	O
GH	B-GeneOrGeneProduct
)	O
treatment	O
,	O
resulting	O
in	O
different	O
individually	O
required	O
GH	B-GeneOrGeneProduct
-	O
doses	O
in	O
GH	B-DiseaseOrPhenotypicFeature
-	O
deficient	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
test	O
if	O
the	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
gene	O
polymorphisms	O
are	O
associated	O
with	O
the	O
GH	B-GeneOrGeneProduct
-	O
dose	O
of	O
GH	B-DiseaseOrPhenotypicFeature
-	O
deficient	I-DiseaseOrPhenotypicFeature
adults	O
.	O

MATERIALS	O
&	O
METHODS	O
:	O
A	O
total	O
of	O
nine	O
tagging	O
SNPs	O
,	O
five	O
additionally	O
selected	O
SNPs	O
and	O
a	O
cytosine	O
-	O
adenine	O
repeat	O
polymorphism	O
were	O
determined	O
in	O
133	O
German	O
adult	O
patients	B-OrganismTaxon
(	O
66	O
men	B-OrganismTaxon
,	O
67	O
women	B-OrganismTaxon
;	O
mean	O
age	O
45	O
.	O
4	O
years	O
+	O
/	O
-	O
13	O
.	O
1	O
standard	O
deviation	O
;	O
majority	O
Caucasian	O
)	O
with	O
GH	B-DiseaseOrPhenotypicFeature
-	O
deficiency	I-DiseaseOrPhenotypicFeature
(	O
GHD	B-DiseaseOrPhenotypicFeature
)	O
of	O
different	O
origin	O
,	O
derived	O
from	O
the	O
prospective	O
Pfizer	O
International	O
Metabolic	O
Study	O
(	O
KIMS	O
)	O
Pharmacogenetics	O
Study	O
.	O

Patients	B-OrganismTaxon
received	O
GH	B-GeneOrGeneProduct
-	O
treatment	O
for	O
12	O
months	O
with	O
finished	O
dose	O
-	O
titration	O
of	O
GH	B-GeneOrGeneProduct
and	O
centralized	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
measurements	O
.	O

GH	B-GeneOrGeneProduct
-	O
dose	O
after	O
1	O
year	O
of	O
treatment	O
,	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
concentrations	O
,	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
-	O
standard	O
deviation	O
score	O
(	O
SDS	O
)	O
,	O
the	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
:	O
GH	B-GeneOrGeneProduct
ratio	O
and	O
anthropometric	O
data	O
were	O
analyzed	O
by	O
genotype	O
.	O

RESULTS	O
:	O
Except	O
for	O
rs1019731	B-SequenceVariant
,	O
which	O
showed	O
a	O
significant	O
difference	O
of	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
-	O
SDS	O
by	O
genotypes	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
,	O
all	O
polymorphisms	O
showed	O
no	O
associations	O
with	O
the	O
GH	B-GeneOrGeneProduct
-	O
doses	O
,	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
concentrations	O
,	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
-	O
SDS	O
and	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
:	O
GH	B-GeneOrGeneProduct
ratio	O
after	O
adjusting	O
for	O
the	O
confounding	O
variables	O
gender	O
,	O
age	O
and	O
BMI	O
.	O

CONCLUSION	O
:	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
gene	O
polymorphisms	O
were	O
not	O
associated	O
with	O
the	O
responsiveness	O
to	O
exogenous	O
GH	B-GeneOrGeneProduct
in	O
GHD	B-DiseaseOrPhenotypicFeature
.	O

Therefore	O
,	O
genetic	O
variations	O
of	O
the	O
IGF	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
gene	O
seem	O
not	O
to	O
be	O
major	O
influencing	O
factors	O
of	O
the	O
GH	B-GeneOrGeneProduct
-	O
IGF	B-GeneOrGeneProduct
-	O
axis	O
causing	O
variable	O
response	O
to	O
exogenous	O
GH	B-GeneOrGeneProduct
-	O
treatment	O
.	O
Fine	O
mapping	O
and	O
identification	O
of	O
a	O
candidate	O
gene	O
SSH1	B-GeneOrGeneProduct
in	O
disseminated	B-DiseaseOrPhenotypicFeature
superficial	I-DiseaseOrPhenotypicFeature
actinic	I-DiseaseOrPhenotypicFeature
porokeratosis	I-DiseaseOrPhenotypicFeature
.	O

Disseminated	B-DiseaseOrPhenotypicFeature
superficial	I-DiseaseOrPhenotypicFeature
actinic	I-DiseaseOrPhenotypicFeature
porokeratosis	I-DiseaseOrPhenotypicFeature
(	O
DSAP	B-DiseaseOrPhenotypicFeature
)	O
is	O
an	O
uncommon	O
autosomal	O
dominant	O
chronic	O
keratinization	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
,	O
characterized	O
by	O
multiple	O
superficial	O
keratotic	B-DiseaseOrPhenotypicFeature
lesions	I-DiseaseOrPhenotypicFeature
surrounded	O
by	O
a	O
slightly	O
raised	O
keratotic	O
border	O
.	O

Thus	O
far	O
,	O
although	O
two	O
loci	O
for	O
DSAP	B-DiseaseOrPhenotypicFeature
have	O
been	O
identified	O
,	O
the	O
genetic	O
basis	O
and	O
pathogenesis	O
of	O
this	O
disorder	O
have	O
not	O
been	O
elucidated	O
yet	O
.	O

In	O
this	O
study	O
,	O
we	O
performed	O
a	O
genome	O
-	O
wide	O
linkage	O
analysis	O
in	O
three	O
Chinese	O
affected	O
families	O
and	O
localized	O
the	O
gene	O
in	O
an	O
8	O
.	O
0	O
cM	O
interval	O
defined	O
by	O
D12S330	O
and	O
D12S354	O
on	O
chromosome	O
12	O
.	O

Upon	O
screening	O
30	O
candidate	O
genes	O
,	O
we	O
identified	O
a	O
missense	O
mutation	O
,	O
p	B-SequenceVariant
.	O
Ser63Asn	I-SequenceVariant
in	O
SSH1	B-GeneOrGeneProduct
in	O
one	O
family	O
,	O
a	O
frameshift	O
mutation	O
,	O
p	B-SequenceVariant
.	O
Ser19CysfsX24	I-SequenceVariant
in	O
an	O
alternative	O
variant	O
(	O
isoform	O
f	O
)	O
of	O
SSH1	B-GeneOrGeneProduct
in	O
another	O
family	O
,	O
and	O
a	O
frameshift	O
mutation	O
,	O
p	B-SequenceVariant
.	O
Pro27ProfsX54	I-SequenceVariant
in	O
the	O
same	O
alternative	O
variant	O
in	O
one	O
non	O
-	O
familial	O
case	O
with	O
DSAP	B-DiseaseOrPhenotypicFeature
.	O

SSH1	B-GeneOrGeneProduct
encodes	O
a	O
phosphatase	O
that	O
plays	O
a	O
pivotal	O
role	O
in	O
actin	O
dynamics	O
.	O

Our	O
data	O
suggested	O
that	O
cytoskeleton	O
disorganization	O
in	O
epidermal	O
cells	O
is	O
likely	O
associated	O
with	O
the	O
pathogenesis	O
of	O
DSAP	B-DiseaseOrPhenotypicFeature
.	O
Atorvastatin	B-ChemicalEntity
protects	O
against	O
contrast	B-DiseaseOrPhenotypicFeature
-	O
induced	I-DiseaseOrPhenotypicFeature
nephropathy	I-DiseaseOrPhenotypicFeature
via	O
anti	O
-	O
apoptosis	O
by	O
the	O
upregulation	O
of	O
Hsp27	B-GeneOrGeneProduct
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Contrast	B-DiseaseOrPhenotypicFeature
-	O
induced	I-DiseaseOrPhenotypicFeature
nephropathy	I-DiseaseOrPhenotypicFeature
(	O
CIN	B-DiseaseOrPhenotypicFeature
)	O
is	O
an	O
iatrogenic	O
acute	B-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
occurring	O
following	O
the	O
intravascular	O
injection	O
of	O
iodinated	O
radiographic	O
contrast	O
medium	O
.	O

However	O
,	O
the	O
regulatory	O
mechanisms	O
for	O
CIN	B-DiseaseOrPhenotypicFeature
remain	O
to	O
be	O
fully	O
elucidated	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
whether	O
atorvastatin	B-ChemicalEntity
protects	O
against	O
CIN	B-DiseaseOrPhenotypicFeature
via	O
anti	O
-	O
apoptotic	O
effects	O
by	O
the	O
upregulation	O
of	O
Hsp27	B-GeneOrGeneProduct
in	O
vivo	O
and	O
in	O
vitro	O
.	O

To	O
determine	O
whether	O
atorvastatin	B-ChemicalEntity
attenuated	O
CIN	B-DiseaseOrPhenotypicFeature
,	O
the	O
inflammatory	B-DiseaseOrPhenotypicFeature
response	O
and	O
apoptosis	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
a	O
rat	B-OrganismTaxon
model	O
of	O
iopamidol	B-ChemicalEntity
-	O
induced	O
CIN	B-DiseaseOrPhenotypicFeature
was	O
used	O
,	O
and	O
human	B-OrganismTaxon
embryonic	O
proximal	O
tubule	O
(	O
HK2	B-CellLine
)	O
cell	O
damage	O
was	O
assessed	O
.	O

The	O
rats	B-OrganismTaxon
were	O
assigned	O
into	O
four	O
groups	O
(	O
n	O
=	O
10	O
per	O
group	O
)	O
,	O
as	O
follows	O
:	O
Control	O
rats	B-OrganismTaxon
;	O
rats	B-OrganismTaxon
+	O
atorvastatin	B-ChemicalEntity
;	O
rats	B-OrganismTaxon
+	O
iopamidol	B-ChemicalEntity
;	O
rats	B-OrganismTaxon
+	O
iopamidol	B-ChemicalEntity
+	O
atorvastatin	B-ChemicalEntity
.	O

In	O
vitro	O
,	O
the	O
HK2	B-CellLine
cells	O
were	O
treated	O
with	O
iopamidol	B-ChemicalEntity
in	O
the	O
presence	O
or	O
absence	O
of	O
atorvastatin	B-ChemicalEntity
,	O
heat	B-GeneOrGeneProduct
shock	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
Hsp	I-GeneOrGeneProduct
)	O
27	I-GeneOrGeneProduct
small	O
interfering	O
(	O
si	O
)	O
RNA	O
or	O
pcDNA3	O
.	O
1	O
-	O
Hsp27	B-GeneOrGeneProduct
.	O

The	O
renal	O
tissues	O
were	O
examined	O
histopathologically	O
and	O
collected	O
for	O
western	O
blot	O
analysis	O
.	O

The	O
results	O
showed	O
that	O
atorvastatin	B-ChemicalEntity
ameliorated	O
the	O
apoptosis	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
deterioration	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
function	I-DiseaseOrPhenotypicFeature
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
atorvastatin	B-ChemicalEntity
reduced	O
the	O
iopamidol	B-ChemicalEntity
-	O
induced	O
activity	O
of	O
B	B-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
lymphoma	I-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
(	O
Bcl	I-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
)	O
-	O
associated	I-GeneOrGeneProduct
X	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
Bax	B-GeneOrGeneProduct
)	O
/	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
and	O
increased	O
the	O
expression	O
of	O
Bcl	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
in	O
vivo	O
and	O
in	O
vitro	O
.	O

Notably	O
,	O
following	O
treatment	O
with	O
Hsp27	B-GeneOrGeneProduct
siRNA	O
or	O
pcDNA3	O
.	O
1	O
-	O
Hsp27	B-GeneOrGeneProduct
,	O
it	O
was	O
found	O
that	O
iopamidol	B-ChemicalEntity
enhanced	O
or	O
weakened	O
the	O
upregulation	O
of	O
Bax	B-GeneOrGeneProduct
/	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
and	O
downregulation	O
of	O
Bcl	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
in	O
the	O
HK2	B-CellLine
cells	O
,	O
respectively	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
atorvastatin	B-ChemicalEntity
protected	O
against	O
contrast	B-DiseaseOrPhenotypicFeature
-	O
induced	I-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
tubular	I-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
apoptosis	I-DiseaseOrPhenotypicFeature
through	O
the	O
upregulation	O
of	O
Hsp27	B-GeneOrGeneProduct
in	O
vivo	O
and	O
in	O
vitro	O
.	O
Possible	O
neuroleptic	B-DiseaseOrPhenotypicFeature
malignant	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
related	O
to	O
concomitant	O
treatment	O
with	O
paroxetine	B-ChemicalEntity
and	O
alprazolam	B-ChemicalEntity
.	O

A	O
74	O
-	O
year	O
-	O
old	O
man	B-OrganismTaxon
with	O
depressive	B-DiseaseOrPhenotypicFeature
symptoms	I-DiseaseOrPhenotypicFeature
was	O
admitted	O
to	O
a	O
psychiatric	B-DiseaseOrPhenotypicFeature
hospital	O
due	O
to	O
insomnia	B-DiseaseOrPhenotypicFeature
,	O
loss	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
appetite	I-DiseaseOrPhenotypicFeature
,	O
exhaustion	O
,	O
and	O
agitation	B-DiseaseOrPhenotypicFeature
.	O

Medical	O
treatment	O
was	O
initiated	O
at	O
a	O
daily	O
dose	O
of	O
20	O
mg	O
paroxetine	B-ChemicalEntity
and	O
1	O
.	O
2	O
mg	O
alprazolam	B-ChemicalEntity
.	O

On	O
the	O
10th	O
day	O
of	O
paroxetine	B-ChemicalEntity
and	O
alprazolam	B-ChemicalEntity
treatment	O
,	O
the	O
patient	B-OrganismTaxon
exhibited	O
marked	O
psychomotor	B-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
,	O
disorientation	O
,	O
and	O
severe	O
muscle	B-DiseaseOrPhenotypicFeature
rigidity	I-DiseaseOrPhenotypicFeature
with	O
tremors	B-DiseaseOrPhenotypicFeature
.	O

The	O
patient	B-OrganismTaxon
had	O
a	O
fever	B-DiseaseOrPhenotypicFeature
(	O
38	O
.	O
2	O
degrees	O
C	O
)	O
,	O
fluctuating	O
blood	O
pressure	O
(	O
between	O
165	O
/	O
90	O
and	O
130	O
/	O
70	O
mg	O
mm	O
Hg	O
)	O
,	O
and	O
severe	O
extrapyramidal	B-DiseaseOrPhenotypicFeature
symptoms	I-DiseaseOrPhenotypicFeature
.	O

Laboratory	O
tests	O
showed	O
an	O
elevation	O
of	O
creatine	B-ChemicalEntity
phosphokinase	I-ChemicalEntity
(	O
2218	O
IU	O
/	O
L	O
)	O
,	O
aspartate	B-ChemicalEntity
aminotransferase	I-ChemicalEntity
(	O
134	O
IU	O
/	O
L	O
)	O
,	O
alanine	B-ChemicalEntity
aminotransferase	I-ChemicalEntity
(	O
78	O
IU	O
/	O
L	O
)	O
,	O
and	O
BUN	O
(	O
27	O
.	O
9	O
mg	O
/	O
ml	O
)	O
levels	O
.	O

The	O
patient	B-OrganismTaxon
received	O
bromocriptine	B-ChemicalEntity
and	O
diazepam	B-ChemicalEntity
to	O
treat	O
his	O
symptoms	O
.	O

7	O
days	O
later	O
,	O
the	O
fever	B-DiseaseOrPhenotypicFeature
disappeared	O
and	O
the	O
patient	B-OrganismTaxon
'	O
s	O
serum	O
CPK	B-ChemicalEntity
levels	O
were	O
normalized	O
(	O
175	O
IU	O
/	O
L	O
)	O
.	O

This	O
patient	B-OrganismTaxon
presented	O
with	O
symptoms	O
of	O
neuroleptic	B-DiseaseOrPhenotypicFeature
malignant	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
NMS	B-DiseaseOrPhenotypicFeature
)	O
,	O
thus	O
demonstrating	O
that	O
NMS	B-DiseaseOrPhenotypicFeature
-	O
like	O
symptoms	O
can	O
occur	O
after	O
combined	O
paroxetine	B-ChemicalEntity
and	O
alprazolam	B-ChemicalEntity
treatment	O
.	O

The	O
adverse	O
drug	O
reaction	O
score	O
obtained	O
by	O
the	O
Naranjo	O
algorithm	O
was	O
6	O
in	O
our	O
case	O
,	O
indicating	O
a	O
probable	O
relationship	O
between	O
the	O
patient	B-OrganismTaxon
'	O
s	O
NMS	B-DiseaseOrPhenotypicFeature
-	O
like	O
adverse	O
symptoms	O
and	O
the	O
combined	O
treatment	O
used	O
in	O
this	O
case	O
.	O

The	O
involvement	O
of	O
physiologic	O
and	O
environmental	O
aspects	O
specific	O
to	O
this	O
patient	B-OrganismTaxon
was	O
suspected	O
.	O

Several	O
risk	O
factors	O
for	O
NMS	B-DiseaseOrPhenotypicFeature
should	O
be	O
noted	O
in	O
elderly	O
depressive	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
whose	O
symptoms	O
often	O
include	O
dehydration	B-DiseaseOrPhenotypicFeature
,	O
agitation	B-DiseaseOrPhenotypicFeature
,	O
malnutrition	B-DiseaseOrPhenotypicFeature
,	O
and	O
exhaustion	O
.	O

Careful	O
therapeutic	O
intervention	O
is	O
necessary	O
in	O
cases	O
involving	O
elderly	O
patients	B-OrganismTaxon
who	O
suffer	O
from	O
depression	B-DiseaseOrPhenotypicFeature
.	O
Whole	O
-	O
Organism	O
Developmental	O
Expression	O
Profiling	O
Identifies	O
RAB	B-GeneOrGeneProduct
-	O
28	I-GeneOrGeneProduct
as	O
a	O
Novel	O
Ciliary	O
GTPase	B-GeneOrGeneProduct
Associated	O
with	O
the	O
BBSome	B-GeneOrGeneProduct
and	O
Intraflagellar	O
Transport	O
.	O

Primary	O
cilia	O
are	O
specialised	O
sensory	O
and	O
developmental	O
signalling	O
devices	O
extending	O
from	O
the	O
surface	O
of	O
most	O
eukaryotic	O
cells	O
.	O

Defects	O
in	O
these	O
organelles	O
cause	O
inherited	B-DiseaseOrPhenotypicFeature
human	I-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
(	O
ciliopathies	B-DiseaseOrPhenotypicFeature
)	O
such	O
as	O
retinitis	B-DiseaseOrPhenotypicFeature
pigmentosa	I-DiseaseOrPhenotypicFeature
and	O
Bardet	B-DiseaseOrPhenotypicFeature
-	O
Biedl	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
BBS	B-DiseaseOrPhenotypicFeature
)	O
,	O
frequently	O
affecting	O
many	O
physiological	O
and	O
developmental	O
processes	O
across	O
multiple	O
organs	O
.	O

Cilium	O
formation	O
,	O
maintenance	O
and	O
function	O
depend	O
on	O
intracellular	O
transport	O
systems	O
such	O
as	O
intraflagellar	O
transport	O
(	O
IFT	O
)	O
,	O
which	O
is	O
driven	O
by	O
kinesin	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
and	O
IFT	O
-	O
dynein	B-GeneOrGeneProduct
motors	O
and	O
regulated	O
by	O
the	O
Bardet	B-GeneOrGeneProduct
-	O
Biedl	I-GeneOrGeneProduct
syndrome	I-GeneOrGeneProduct
(	O
BBS	I-GeneOrGeneProduct
)	O
cargo	I-GeneOrGeneProduct
-	O
adaptor	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
,	O
or	O
BBSome	B-GeneOrGeneProduct
.	O

To	O
identify	O
new	O
cilium	O
-	O
associated	O
genes	O
,	O
we	O
employed	O
the	O
nematode	O
C	B-OrganismTaxon
.	O

elegans	I-OrganismTaxon
,	O
where	O
ciliogenesis	O
occurs	O
within	O
a	O
short	O
timespan	O
during	O
late	O
embryogenesis	O
when	O
most	O
sensory	O
neurons	O
differentiate	O
.	O

Using	O
whole	O
-	O
organism	O
RNA	O
-	O
Seq	O
libraries	O
,	O
we	O
discovered	O
a	O
signature	O
expression	O
profile	O
highly	O
enriched	O
for	O
transcripts	O
of	O
known	O
ciliary	O
proteins	O
,	O
including	O
FAM	B-GeneOrGeneProduct
-	O
161	I-GeneOrGeneProduct
(	O
FAM161A	B-GeneOrGeneProduct
orthologue	O
)	O
,	O
CCDC	B-GeneOrGeneProduct
-	O
104	I-GeneOrGeneProduct
(	O
CCDC104	B-GeneOrGeneProduct
)	O
,	O
and	O
RPI	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
RP1	B-GeneOrGeneProduct
/	O
RP1L1	B-GeneOrGeneProduct
)	O
,	O
which	O
we	O
confirm	O
are	O
cilium	O
-	O
localised	O
in	O
worms	O
.	O

From	O
a	O
list	O
of	O
185	O
candidate	O
ciliary	O
genes	O
,	O
we	O
uncover	O
orthologues	O
of	O
human	B-OrganismTaxon
MAP9	B-GeneOrGeneProduct
,	O
YAP	B-GeneOrGeneProduct
,	O
CCDC149	B-GeneOrGeneProduct
,	O
and	O
RAB28	B-GeneOrGeneProduct
as	O
conserved	O
cilium	O
-	O
associated	O
components	O
.	O

Further	O
analyses	O
of	O
C	B-OrganismTaxon
.	O

elegans	I-OrganismTaxon
RAB	B-GeneOrGeneProduct
-	O
28	I-GeneOrGeneProduct
,	O
recently	O
associated	O
with	O
autosomal	O
-	O
recessive	O
cone	B-DiseaseOrPhenotypicFeature
-	O
rod	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
,	O
reveal	O
that	O
this	O
small	O
GTPase	B-GeneOrGeneProduct
is	O
exclusively	O
expressed	O
in	O
ciliated	O
neurons	O
where	O
it	O
dynamically	O
associates	O
with	O
IFT	O
trains	O
.	O

Whereas	O
inactive	O
GDP	B-ChemicalEntity
-	O
bound	O
RAB	B-GeneOrGeneProduct
-	O
28	I-GeneOrGeneProduct
displays	O
no	O
IFT	O
movement	O
and	O
diffuse	O
localisation	O
,	O
GTP	B-ChemicalEntity
-	O
bound	O
(	O
activated	O
)	O
RAB	B-GeneOrGeneProduct
-	O
28	I-GeneOrGeneProduct
concentrates	O
at	O
the	O
periciliary	O
membrane	O
in	O
a	O
BBSome	B-GeneOrGeneProduct
-	O
dependent	O
manner	O
and	O
undergoes	O
bidirectional	O
IFT	O
.	O

Functional	O
analyses	O
reveal	O
that	O
whilst	O
cilium	O
structure	O
,	O
sensory	O
function	O
and	O
IFT	O
are	O
seemingly	O
normal	O
in	O
a	O
rab	B-GeneOrGeneProduct
-	O
28	I-GeneOrGeneProduct
null	O
allele	O
,	O
overexpression	O
of	O
predicted	O
GDP	B-ChemicalEntity
or	O
GTP	B-ChemicalEntity
locked	O
variants	O
of	O
RAB	B-GeneOrGeneProduct
-	O
28	I-GeneOrGeneProduct
perturbs	O
cilium	O
and	O
sensory	O
pore	O
morphogenesis	O
and	O
function	O
.	O

Collectively	O
,	O
our	O
findings	O
present	O
a	O
new	O
approach	O
for	O
identifying	O
ciliary	O
proteins	O
,	O
and	O
unveil	O
RAB28	B-GeneOrGeneProduct
,	O
a	O
GTPase	B-GeneOrGeneProduct
most	O
closely	O
related	O
to	O
the	O
BBS	B-DiseaseOrPhenotypicFeature
protein	O
RABL4	B-GeneOrGeneProduct
/	O
IFT27	B-GeneOrGeneProduct
,	O
as	O
an	O
IFT	O
-	O
associated	O
cargo	O
with	O
BBSome	B-GeneOrGeneProduct
-	O
dependent	O
cell	O
autonomous	O
and	O
non	O
-	O
autonomous	O
functions	O
at	O
the	O
ciliary	O
base	O
.	O
Compound	O
heterozygous	O
mutations	O
in	O
the	O
SRD5A2	B-GeneOrGeneProduct
gene	O
exon	O
4	O
in	O
a	O
male	B-DiseaseOrPhenotypicFeature
pseudohermaphrodite	I-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
of	O
Chinese	O
origin	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
perform	O
5	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
-	O
reductase	I-GeneOrGeneProduct
type	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
gene	O
(	O
SRD5A2	B-GeneOrGeneProduct
)	O
analysis	O
in	O
a	O
male	B-DiseaseOrPhenotypicFeature
pseudohermaphrodite	I-DiseaseOrPhenotypicFeature
(	O
MPH	B-DiseaseOrPhenotypicFeature
)	O
patient	B-OrganismTaxon
with	O
normal	O
testosterone	B-ChemicalEntity
(	O
T	B-ChemicalEntity
)	O
production	O
and	O
normal	O
androgen	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
AR	B-GeneOrGeneProduct
)	O
gene	O
coding	O
sequences	O
.	O

A	O
patient	B-OrganismTaxon
of	O
Chinese	O
origin	O
with	O
ambiguous	O
genitalia	O
at	O
14	O
months	O
,	O
a	O
46	O
,	O
XY	O
karyotype	O
,	O
and	O
normal	O
T	B-ChemicalEntity
secretion	O
under	O
human	B-ChemicalEntity
chorionic	I-ChemicalEntity
gonadotropin	I-ChemicalEntity
(	O
hCG	B-ChemicalEntity
)	O
stimulation	O
underwent	O
a	O
gonadectomy	O
at	O
20	O
months	O
.	O

Exons	O
1	O
-	O
8	O
of	O
the	O
AR	B-GeneOrGeneProduct
gene	O
and	O
exons	O
1	O
-	O
5	O
of	O
the	O
SRD5A2	B-GeneOrGeneProduct
gene	O
were	O
sequenced	O
from	O
peripheral	O
blood	O
DNA	O
.	O

AR	B-GeneOrGeneProduct
gene	O
coding	O
sequences	O
were	O
normal	O
.	O

SRD5A2	B-GeneOrGeneProduct
gene	O
analysis	O
revealed	O
2	O
consecutive	O
mutations	O
in	O
exon	O
4	O
,	O
each	O
located	O
in	O
a	O
different	O
allele	O
:	O
1	O
)	O
a	O
T	B-SequenceVariant
nucleotide	I-SequenceVariant
deletion	I-SequenceVariant
,	O
which	I-SequenceVariant
predicts	I-SequenceVariant
a	I-SequenceVariant
frameshift	I-SequenceVariant
mutation	I-SequenceVariant
from	I-SequenceVariant
codon	I-SequenceVariant
219	I-SequenceVariant
,	O
and	O
2	O
)	O
a	O
missense	O
mutation	O
at	O
codon	O
227	O
,	O
where	O
the	O
substitution	O
of	O
guanine	B-SequenceVariant
(	O
CGA	I-SequenceVariant
)	O
by	I-SequenceVariant
adenine	I-SequenceVariant
(	O
CAA	I-SequenceVariant
)	O
predicts	O
a	O
glutamine	B-SequenceVariant
replacement	I-SequenceVariant
of	I-SequenceVariant
arginine	I-SequenceVariant
(	O
R227Q	B-SequenceVariant
)	O
.	O

Testes	O
located	O
in	O
the	O
inguinal	O
canal	O
showed	O
a	O
normal	O
morphology	O
for	O
age	O
.	O

The	O
patient	B-OrganismTaxon
was	O
a	O
compound	O
heterozygote	O
for	O
SRD5A2	B-GeneOrGeneProduct
mutations	O
,	O
carrying	O
2	O
mutations	O
in	O
exon	O
4	O
.	O

The	O
patient	B-OrganismTaxon
showed	O
an	O
R227Q	B-SequenceVariant
mutation	O
that	O
has	O
been	O
described	O
in	O
an	O
Asian	O
population	O
and	O
MPH	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
along	O
with	O
a	O
novel	O
frameshift	O
mutation	O
,	O
Tdel219	B-SequenceVariant
.	O

Testis	O
morphology	O
showed	O
that	O
,	O
during	O
early	O
infancy	O
,	O
the	O
5	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
-	O
reductase	I-GeneOrGeneProduct
enzyme	O
deficiency	O
may	O
not	O
have	O
affected	O
interstitial	O
or	O
tubular	O
development	O
.	O
A	O
haplotype	O
-	O
based	O
analysis	O
of	O
the	O
PTPN22	B-GeneOrGeneProduct
locus	O
in	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
.	O

A	O
recent	O
addition	O
to	O
the	O
list	O
of	O
widely	O
confirmed	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
risk	O
loci	O
is	O
the	O
PTPN22	B-GeneOrGeneProduct
gene	O
encoding	O
a	O
lymphoid	B-GeneOrGeneProduct
-	O
specific	I-GeneOrGeneProduct
phosphatase	I-GeneOrGeneProduct
(	O
Lyp	B-GeneOrGeneProduct
)	O
.	O

However	O
,	O
evidence	O
supporting	O
a	O
role	O
for	O
PTPN22	B-GeneOrGeneProduct
in	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
derives	O
entirely	O
from	O
the	O
study	O
of	O
just	O
one	O
coding	O
single	O
nucleotide	O
polymorphism	O
,	O
1858C	B-SequenceVariant
/	O
T	I-SequenceVariant
.	O

In	O
the	O
current	O
study	O
,	O
the	O
haplotype	O
structure	O
of	O
the	O
PTPN22	B-GeneOrGeneProduct
region	O
was	O
determined	O
,	O
and	O
individual	O
haplotypes	O
were	O
tested	O
for	O
association	O
with	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
in	O
family	O
-	O
based	O
tests	O
.	O

The	O
1858T	B-SequenceVariant
risk	O
allele	O
occurred	O
on	O
only	O
a	O
single	O
haplotype	O
that	O
was	O
strongly	O
associated	O
with	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
(	O
P	O
=	O
7	O
.	O
9	O
x	O
10	O
(	O
-	O
5	O
)	O
)	O
.	O

After	O
controlling	O
for	O
the	O
effects	O
of	O
this	O
allele	O
,	O
two	O
other	O
haplotypes	O
were	O
observed	O
to	O
be	O
weakly	O
associated	O
with	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Sequencing	O
of	O
the	O
coding	O
region	O
of	O
PTPN22	B-GeneOrGeneProduct
on	O
these	O
haplotypes	O
revealed	O
a	O
novel	O
variant	O
(	O
2250G	B-SequenceVariant
/	O
C	I-SequenceVariant
)	O
predicted	O
to	O
result	O
in	O
a	O
nonsynonymous	O
amino	O
acid	O
substitution	O
.	O

Analysis	O
of	O
PTPN22	B-GeneOrGeneProduct
transcripts	O
from	O
a	O
subject	O
heterozygous	O
for	O
this	O
variant	O
indicated	O
that	O
it	O
interfered	O
with	O
normal	O
mRNA	O
splicing	O
,	O
resulting	O
in	O
a	O
premature	O
termination	O
codon	O
after	O
exon	O
17	O
.	O

These	O
results	O
support	O
the	O
conclusion	O
that	O
the	O
1858C	B-SequenceVariant
/	O
T	I-SequenceVariant
allele	O
is	O
the	O
major	O
risk	O
variant	O
for	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
in	O
the	O
PTPN22	B-GeneOrGeneProduct
locus	O
,	O
but	O
they	O
suggest	O
that	O
additional	O
infrequent	O
coding	O
variants	O
at	O
PTPN22	B-GeneOrGeneProduct
may	O
also	O
contribute	O
to	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
risk	O
.	O
Sepsis	B-DiseaseOrPhenotypicFeature
-	O
induced	O
changes	O
in	O
amino	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
transporters	I-GeneOrGeneProduct
and	O
leucine	B-ChemicalEntity
signaling	O
via	O
mTOR	B-GeneOrGeneProduct
in	O
skeletal	O
muscle	O
.	O

The	O
present	O
study	O
tested	O
the	O
hypothesis	O
that	O
sepsis	B-DiseaseOrPhenotypicFeature
-	O
induced	O
leucine	B-ChemicalEntity
(	O
Leu	B-ChemicalEntity
)	O
resistance	O
in	O
skeletal	O
muscle	O
is	O
associated	O
with	O
a	O
down	O
-	O
regulation	O
of	O
amino	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
transporters	I-GeneOrGeneProduct
important	O
in	O
regulating	O
Leu	B-ChemicalEntity
flux	O
or	O
an	O
impairment	O
in	O
the	O
formation	O
of	O
the	O
Leu	B-ChemicalEntity
-	O
sensitive	O
mTOR	B-GeneOrGeneProduct
-	O
Ragulator	B-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
.	O

Sepsis	B-DiseaseOrPhenotypicFeature
in	O
adult	O
male	O
rats	B-OrganismTaxon
decreased	O
basal	O
protein	O
synthesis	O
in	O
gastrocnemius	O
,	O
associated	O
with	O
a	O
reduction	O
in	O
mTOR	B-GeneOrGeneProduct
activation	O
as	O
indicated	O
by	O
decreased	O
4E	B-GeneOrGeneProduct
-	O
BP1	I-GeneOrGeneProduct
and	O
S6K1	B-GeneOrGeneProduct
phosphorylation	O
.	O

The	O
ability	O
of	O
oral	O
Leu	B-ChemicalEntity
to	O
increase	O
protein	O
synthesis	O
and	O
mTOR	B-GeneOrGeneProduct
kinase	O
after	O
1	O
h	O
was	O
largely	O
prevented	O
in	O
sepsis	B-DiseaseOrPhenotypicFeature
.	O

Sepsis	B-DiseaseOrPhenotypicFeature
increased	O
CAT1	B-GeneOrGeneProduct
,	O
LAT2	B-GeneOrGeneProduct
and	O
SNAT2	B-GeneOrGeneProduct
mRNA	O
content	O
two	O
-	O
to	O
fourfold	O
,	O
but	O
only	O
the	O
protein	O
content	O
for	O
CAT1	B-GeneOrGeneProduct
(	O
20	O
%	O
decrease	O
)	O
differed	O
significantly	O
.	O

Conversely	O
,	O
sepsis	B-DiseaseOrPhenotypicFeature
decreased	O
the	O
proton	B-GeneOrGeneProduct
-	O
assisted	I-GeneOrGeneProduct
amino	I-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
transporter	I-GeneOrGeneProduct
(	O
PAT	I-GeneOrGeneProduct
)	O
-	O
2	I-GeneOrGeneProduct
mRNA	O
by	O
60	O
%	O
,	O
but	O
without	O
a	O
coordinate	O
change	O
in	O
PAT2	B-GeneOrGeneProduct
protein	O
.	O

There	O
was	O
no	O
sepsis	B-DiseaseOrPhenotypicFeature
or	O
Leu	B-ChemicalEntity
effect	O
on	O
the	O
protein	O
content	O
for	O
RagA	B-GeneOrGeneProduct
-	O
D	I-GeneOrGeneProduct
,	O
LAMTOR	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
,	O
raptor	B-GeneOrGeneProduct
,	O
Rheb	B-GeneOrGeneProduct
or	O
mTOR	B-GeneOrGeneProduct
in	O
muscle	O
.	O

The	O
binding	O
of	O
mTOR	B-GeneOrGeneProduct
,	O
PRAS40	B-GeneOrGeneProduct
and	O
RagC	B-GeneOrGeneProduct
to	O
raptor	B-GeneOrGeneProduct
did	O
not	O
differ	O
for	O
control	O
and	O
septic	O
muscle	O
in	O
the	O
basal	O
condition	O
;	O
however	O
,	O
the	O
Leu	B-ChemicalEntity
-	O
induced	O
decrease	O
in	O
PRAS40	B-GeneOrGeneProduct
raptor	B-GeneOrGeneProduct
and	O
increase	O
in	O
RagC	B-GeneOrGeneProduct
raptor	B-GeneOrGeneProduct
seen	O
in	O
control	O
muscle	O
was	O
absent	O
in	O
sepsis	B-DiseaseOrPhenotypicFeature
.	O

The	O
intracellular	O
Leu	B-ChemicalEntity
concentration	O
was	O
increased	O
in	O
septic	O
muscle	O
,	O
compared	O
to	O
basal	O
control	O
conditions	O
,	O
and	O
oral	O
Leu	B-ChemicalEntity
further	O
increased	O
the	O
intracellular	O
Leu	B-ChemicalEntity
concentration	O
similarly	O
in	O
both	O
control	O
and	O
septic	O
rats	B-OrganismTaxon
.	O

Hence	O
,	O
while	O
alterations	O
in	O
select	O
amino	B-GeneOrGeneProduct
acid	I-GeneOrGeneProduct
transporters	I-GeneOrGeneProduct
are	O
not	O
associated	O
with	O
development	O
of	O
sepsis	B-DiseaseOrPhenotypicFeature
-	O
induced	O
Leu	B-ChemicalEntity
resistance	O
,	O
the	O
Leu	B-ChemicalEntity
-	O
stimulated	O
binding	O
of	O
raptor	B-GeneOrGeneProduct
with	O
RagC	B-GeneOrGeneProduct
and	O
the	O
recruitment	O
of	O
mTOR	B-GeneOrGeneProduct
/	O
raptor	B-GeneOrGeneProduct
to	O
the	O
endosome	O
-	O
lysosomal	O
compartment	O
may	O
partially	O
explain	O
the	O
inability	O
of	O
Leu	B-ChemicalEntity
to	O
fully	O
activate	O
mTOR	B-GeneOrGeneProduct
and	O
muscle	O
protein	O
synthesis	O
.	O
Identification	O
of	O
novel	O
mutations	O
and	O
sequence	O
variants	O
in	O
the	O
SOX2	B-GeneOrGeneProduct
and	O
CHX10	B-GeneOrGeneProduct
genes	O
in	O
patients	B-OrganismTaxon
with	O
anophthalmia	B-DiseaseOrPhenotypicFeature
/	O
microphthalmia	B-DiseaseOrPhenotypicFeature
.	O

PURPOSE	O
:	O
Mutations	O
in	O
the	O
SOX2	B-GeneOrGeneProduct
and	O
CHX10	B-GeneOrGeneProduct
genes	O
have	O
been	O
reported	O
in	O
patients	B-OrganismTaxon
with	O
anophthalmia	B-DiseaseOrPhenotypicFeature
and	O
/	O
or	O
microphthalmia	B-DiseaseOrPhenotypicFeature
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
34	O
anophthalmic	B-DiseaseOrPhenotypicFeature
/	O
microphthalmic	B-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
DNA	O
samples	O
(	O
two	O
sets	O
of	O
siblings	O
included	O
)	O
for	O
mutations	O
and	O
sequence	O
variants	O
in	O
SOX2	B-GeneOrGeneProduct
and	O
CHX10	B-GeneOrGeneProduct
.	O

METHODS	O
:	O
Conformational	O
sensitive	O
gel	O
electrophoresis	O
(	O
CSGE	O
)	O
was	O
used	O
for	O
the	O
initial	O
SOX2	B-GeneOrGeneProduct
and	O
CHX10	B-GeneOrGeneProduct
screening	O
of	O
34	O
affected	O
individuals	O
(	O
two	O
sets	O
of	O
siblings	O
)	O
,	O
five	O
unaffected	O
family	O
members	O
,	O
and	O
80	O
healthy	O
controls	O
.	O

Patient	B-OrganismTaxon
samples	O
containing	O
heteroduplexes	O
were	O
selected	O
for	O
sequence	O
analysis	O
.	O

Base	O
pair	O
changes	O
in	O
SOX2	B-GeneOrGeneProduct
and	O
CHX10	B-GeneOrGeneProduct
were	O
confirmed	O
by	O
sequencing	O
bidirectionally	O
in	O
patient	B-OrganismTaxon
samples	O
.	O

RESULTS	O
:	O
Two	O
novel	O
heterozygous	O
mutations	O
and	O
two	O
sequence	O
variants	O
(	O
one	O
known	O
)	O
in	O
SOX2	B-GeneOrGeneProduct
were	O
identified	O
in	O
this	O
cohort	O
.	O

Mutation	O
c	B-SequenceVariant
.	O
310	I-SequenceVariant
G	I-SequenceVariant
>	O
T	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O

Glu104X	I-SequenceVariant
)	O
,	O
found	O
in	O
one	O
patient	B-OrganismTaxon
,	O
was	O
in	O
the	O
region	O
encoding	O
the	O
high	O
mobility	O
group	O
(	O
HMG	O
)	O
DNA	O
-	O
binding	O
domain	O
and	O
resulted	O
in	O
a	O
change	O
from	O
glutamic	B-SequenceVariant
acid	I-SequenceVariant
to	I-SequenceVariant
a	I-SequenceVariant
stop	I-SequenceVariant
codon	I-SequenceVariant
.	O

The	O
second	O
mutation	O
,	O
noted	O
in	O
two	O
affected	O
siblings	O
,	O
was	O
a	O
single	O
nucleotide	O
deletion	O
c	B-SequenceVariant
.	O
549delC	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O

Pro184ArgfsX19	I-SequenceVariant
)	O
in	O
the	O
region	O
encoding	O
the	O
activation	O
domain	O
,	O
resulting	O
in	O
a	O
frameshift	O
and	O
premature	O
termination	O
of	O
the	O
coding	O
sequence	O
.	O

The	O
shortened	O
protein	O
products	O
may	O
result	O
in	O
the	O
loss	O
of	O
function	O
.	O

In	O
addition	O
,	O
a	O
novel	O
nucleotide	O
substitution	O
c	B-SequenceVariant
.	O
*	O
557G	I-SequenceVariant
>	O
A	I-SequenceVariant
was	O
identified	O
in	O
the	O
3	O
'	O
-	O
untranslated	O
region	O
in	O
one	O
patient	B-OrganismTaxon
.	O

The	O
relationship	O
between	O
the	O
nucleotide	O
change	O
and	O
the	O
protein	O
function	O
is	O
indeterminate	O
.	O

A	O
known	O
single	O
nucleotide	O
polymorphism	O
(	O
c	B-SequenceVariant
.	O

*	O
469	I-SequenceVariant
C	I-SequenceVariant
>	O
A	I-SequenceVariant
,	O
SNP	O
rs11915160	B-SequenceVariant
)	O
was	O
also	O
detected	O
in	O
2	O
of	O
the	O
34	O
patients	B-OrganismTaxon
.	O

Screening	O
of	O
CHX10	B-GeneOrGeneProduct
identified	O
two	O
synonymous	O
sequence	O
variants	O
,	O
c	B-SequenceVariant
.	O
471	I-SequenceVariant
C	I-SequenceVariant
>	O
T	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Ser157Ser	I-SequenceVariant
,	O
rs35435463	B-SequenceVariant
)	O
and	O
c	B-SequenceVariant
.	O
579	I-SequenceVariant
G	I-SequenceVariant
>	O
A	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O

Gln193Gln	I-SequenceVariant
,	O
novel	O
SNP	O
)	O
,	O
and	O
one	O
non	O
-	O
synonymous	O
sequence	O
variant	O
,	O
c	B-SequenceVariant
.	O
871	I-SequenceVariant
G	I-SequenceVariant
>	O
A	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O

Asp291Asn	I-SequenceVariant
,	O
novel	O
SNP	O
)	O
.	O

The	O
non	O
-	O
synonymous	O
polymorphism	O
was	O
also	O
present	O
in	O
healthy	O
controls	O
,	O
suggesting	O
non	O
-	O
causality	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
support	O
the	O
role	O
of	O
SOX2	B-GeneOrGeneProduct
in	O
ocular	O
development	O
.	O

Loss	O
of	O
SOX2	B-GeneOrGeneProduct
function	O
results	O
in	O
severe	O
eye	B-DiseaseOrPhenotypicFeature
malformation	I-DiseaseOrPhenotypicFeature
.	O

CHX10	B-GeneOrGeneProduct
was	O
not	O
implicated	O
with	O
microphthalmia	B-DiseaseOrPhenotypicFeature
/	O
anophthalmia	B-DiseaseOrPhenotypicFeature
in	O
our	O
patient	B-OrganismTaxon
cohort	O
.	O
Combination	O
of	O
the	O
histone	B-GeneOrGeneProduct
deacetylase	I-GeneOrGeneProduct
inhibitor	O
depsipeptide	B-ChemicalEntity
and	O
5	B-ChemicalEntity
-	O
fluorouracil	I-ChemicalEntity
upregulates	O
major	B-GeneOrGeneProduct
histocompatibility	I-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
class	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
and	O
p21	B-GeneOrGeneProduct
genes	O
and	O
activates	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
/	O
7	I-GeneOrGeneProduct
in	O
human	B-OrganismTaxon
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
HCT	B-CellLine
-	O
116	I-CellLine
cells	O
.	O

Epigenetic	O
anticancer	O
drugs	O
such	O
as	O
histone	B-GeneOrGeneProduct
deacetylase	I-GeneOrGeneProduct
(	O
HDAC	B-GeneOrGeneProduct
)	O
inhibitors	O
have	O
been	O
combined	O
with	O
existing	O
anticancer	O
drugs	O
for	O
synergistic	O
or	O
additive	O
effects	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
a	O
very	O
low	O
concentration	O
of	O
depsipeptide	B-ChemicalEntity
,	O
an	O
HDAC	B-GeneOrGeneProduct
inhibitor	O
,	O
potentiated	O
the	O
antitumor	O
activity	O
of	O
5	B-ChemicalEntity
-	O
fluorouracil	I-ChemicalEntity
(	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
)	O
in	O
a	O
human	B-OrganismTaxon
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
model	O
using	O
HCT	B-CellLine
-	O
116	I-CellLine
,	O
HT29	B-CellLine
,	O
and	O
SW48	B-CellLine
cells	O
via	O
the	O
inhibition	O
of	O
colony	O
formation	O
ability	O
or	O
cellular	O
viability	O
.	O

Exposure	O
to	O
a	O
combination	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
(	O
1	O
.	O
75	O
uM	O
)	O
and	O
1	O
nM	O
depsipeptide	B-ChemicalEntity
for	O
24	O
and	O
48	O
h	O
resulted	O
in	O
a	O
3	O
-	O
to	O
4	O
-	O
fold	O
increase	O
in	O
activated	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
/	O
7	I-GeneOrGeneProduct
,	O
while	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
alone	O
failed	O
to	O
activate	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
/	O
7	I-GeneOrGeneProduct
.	O

Microarray	O
and	O
subsequent	O
gene	O
ontology	O
analyses	O
revealed	O
that	O
compared	O
to	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
or	O
depsipeptide	B-ChemicalEntity
alone	O
,	O
the	O
combination	O
treatment	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
and	O
depsipeptide	B-ChemicalEntity
upregulated	O
genes	O
related	O
to	O
cell	O
death	O
and	O
the	O
apoptotic	O
process	O
consistent	O
with	O
the	O
inhibition	O
of	O
colony	O
formation	O
and	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
/	O
7	I-GeneOrGeneProduct
activation	O
.	O

These	O
analyses	O
indicated	O
marked	O
upregulation	O
of	O
antigen	O
processing	O
and	O
presentation	O
of	O
peptide	O
or	O
polysaccharide	B-ChemicalEntity
antigen	O
via	O
major	B-GeneOrGeneProduct
histocompatibility	I-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
(	O
MHC	I-GeneOrGeneProduct
)	O
class	I-GeneOrGeneProduct
(	O
GO	O
:	O
0002504	O
)	O
and	O
MHC	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
(	O
GO	O
:	O
0042611	O
)	O
.	O

Compared	O
with	O
vehicle	O
controls	O
,	O
the	O
cells	O
treated	O
with	O
the	O
combination	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
and	O
depsipeptide	B-ChemicalEntity
showed	O
marked	O
induction	O
(	O
3	O
-	O
to	O
8	O
.	O
5	O
-	O
fold	O
)	O
of	O
expression	O
of	O
MHC	B-GeneOrGeneProduct
class	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
genes	I-GeneOrGeneProduct
,	O
but	O
not	O
of	O
MHC	B-GeneOrGeneProduct
class	I-GeneOrGeneProduct
I	I-GeneOrGeneProduct
genes	I-GeneOrGeneProduct
.	O

Furthermore	O
,	O
our	O
global	O
analysis	O
of	O
gene	O
expression	O
,	O
which	O
was	O
focused	O
on	O
genes	O
involved	O
in	O
the	O
molecular	O
regulation	O
of	O
MHC	B-GeneOrGeneProduct
class	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
genes	I-GeneOrGeneProduct
,	O
showed	O
enhancement	O
of	O
pro	O
-	O
apoptotic	O
PCAF	B-GeneOrGeneProduct
and	O
CIITA	B-GeneOrGeneProduct
after	O
the	O
combination	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
and	O
depsipeptide	B-ChemicalEntity
.	O

These	O
results	O
may	O
indicate	O
a	O
closer	O
relationship	O
between	O
elevation	O
of	O
MHC	B-GeneOrGeneProduct
class	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
expression	O
and	O
cellular	O
apoptosis	O
induced	O
by	O
the	O
combination	O
of	O
depsipeptide	B-ChemicalEntity
and	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
report	O
that	O
the	O
combination	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
and	O
depsipeptide	B-ChemicalEntity
induces	O
human	B-OrganismTaxon
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
apoptosis	O
in	O
a	O
concerted	O
manner	O
with	O
the	O
induction	O
of	O
MHC	B-GeneOrGeneProduct
class	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
gene	O
expression	O
.	O
MOL1	B-GeneOrGeneProduct
is	O
required	O
for	O
cambium	O
homeostasis	O
in	O
Arabidopsis	B-OrganismTaxon
.	O

Plants	O
maintain	O
pools	O
of	O
pluripotent	O
stem	O
cells	O
which	O
allow	O
them	O
to	O
constantly	O
produce	O
new	O
tissues	O
and	O
organs	O
.	O

Stem	O
cell	O
homeostasis	O
in	O
shoot	O
and	O
root	O
tips	O
depends	O
on	O
negative	O
regulation	O
by	O
ligand	O
-	O
receptor	O
pairs	O
of	O
the	O
CLE	B-GeneOrGeneProduct
peptide	I-GeneOrGeneProduct
and	O
leucine	B-GeneOrGeneProduct
-	O
rich	I-GeneOrGeneProduct
repeat	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
(	O
LRR	B-GeneOrGeneProduct
-	O
RLK	I-GeneOrGeneProduct
)	O
families	O
.	O

However	O
,	O
regulation	O
of	O
the	O
cambium	O
,	O
the	O
stem	O
cell	O
niche	O
required	O
for	O
lateral	O
growth	O
of	O
shoots	O
and	O
roots	O
,	O
is	O
poorly	O
characterized	O
.	O

Here	O
we	O
show	O
that	O
the	O
LRR	B-GeneOrGeneProduct
-	O
RLK	I-GeneOrGeneProduct
MOL1	B-GeneOrGeneProduct
is	O
necessary	O
for	O
cambium	O
homeostasis	O
in	O
Arabidopsis	B-OrganismTaxon
thaliana	I-OrganismTaxon
.	O

By	O
employing	O
promoter	O
reporter	O
lines	O
,	O
we	O
reveal	O
that	O
MOL1	B-GeneOrGeneProduct
is	O
active	O
in	O
a	O
domain	O
that	O
is	O
distinct	O
from	O
the	O
domain	O
of	O
the	O
positively	O
acting	O
CLE41	B-GeneOrGeneProduct
/	O
PXY	B-GeneOrGeneProduct
signaling	O
module	O
.	O

In	O
particular	O
,	O
we	O
show	O
that	O
MOL1	B-GeneOrGeneProduct
acts	O
in	O
an	O
opposing	O
manner	O
to	O
the	O
CLE41	B-GeneOrGeneProduct
/	O
PXY	B-GeneOrGeneProduct
module	O
and	O
that	O
changing	O
the	O
domain	O
or	O
level	O
of	O
MOL1	B-GeneOrGeneProduct
expression	O
both	O
result	O
in	O
disturbed	O
cambium	O
organization	O
.	O

Underlining	O
discrete	O
roles	O
of	O
MOL1	B-GeneOrGeneProduct
and	O
PXY	B-GeneOrGeneProduct
,	O
both	O
LRR	B-GeneOrGeneProduct
-	O
RLKs	I-GeneOrGeneProduct
are	O
not	O
able	O
to	O
replace	O
each	O
other	O
when	O
their	O
expression	O
domains	O
are	O
interchanged	O
.	O

Furthermore	O
,	O
MOL1	B-GeneOrGeneProduct
but	O
not	O
PXY	B-GeneOrGeneProduct
is	O
able	O
to	O
rescue	O
CLV1	B-GeneOrGeneProduct
deficiency	O
in	O
the	O
shoot	O
apical	O
meristem	O
.	O

By	O
identifying	O
genes	O
mis	O
-	O
expressed	O
in	O
mol1	B-GeneOrGeneProduct
mutants	O
,	O
we	O
demonstrate	O
that	O
MOL1	B-GeneOrGeneProduct
represses	O
genes	O
associated	O
with	O
stress	O
-	O
related	O
ethylene	B-ChemicalEntity
and	O
jasmonic	B-ChemicalEntity
acid	I-ChemicalEntity
hormone	O
signaling	O
pathways	O
which	O
have	O
known	O
roles	O
in	O
coordinating	O
lateral	O
growth	O
of	O
the	O
Arabidopsis	B-OrganismTaxon
stem	O
.	O

Our	O
findings	O
provide	O
evidence	O
that	O
common	O
regulatory	O
mechanisms	O
in	O
different	O
plant	O
stem	O
cell	O
niches	O
are	O
adapted	O
to	O
specific	O
niche	O
anatomies	O
and	O
emphasize	O
the	O
importance	O
of	O
a	O
complex	O
spatial	O
organization	O
of	O
intercellular	O
signaling	O
cascades	O
for	O
a	O
strictly	O
bidirectional	O
tissue	O
production	O
.	O
R58fs	B-SequenceVariant
mutation	O
in	O
the	O
HGD	B-GeneOrGeneProduct
gene	O
in	O
a	O
family	O
with	O
alkaptonuria	B-DiseaseOrPhenotypicFeature
in	O
the	O
UAE	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
the	O
prevalence	O
of	O
alkaptonuria	B-DiseaseOrPhenotypicFeature
in	O
the	O
UAE	O
population	O
and	O
to	O
identify	O
the	O
genotype	O
of	O
affected	O
individuals	O
.	O

In	O
a	O
3	O
stage	O
sampling	O
technique	O
2981	O
pupils	O
from	O
Government	O
schools	O
in	O
Al	O
Ain	O
and	O
private	O
schools	O
in	O
Dubai	O
were	O
selected	O
to	O
take	O
part	O
in	O
the	O
study	O
,	O
of	O
whom	O
2857	O
provided	O
urine	O
samples	O
.	O

Urine	O
collected	O
was	O
analysed	O
for	O
homogentisic	B-ChemicalEntity
acid	I-ChemicalEntity
by	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
the	O
white	O
blood	O
cells	O
of	O
all	O
family	O
members	O
of	O
the	O
affected	O
case	O
following	O
standard	O
established	O
protocols	O
.	O

Specific	O
PRC	O
primers	O
were	O
designed	O
to	O
amplify	O
all	O
14	O
exons	O
of	O
the	O
HGD	B-GeneOrGeneProduct
gene	O
with	O
the	O
flanking	O
intronic	O
sequences	O
including	O
the	O
splice	O
site	O
sequences	O
.	O

2857	O
children	O
returned	O
a	O
viable	O
urine	O
sample	O
,	O
of	O
which	O
one	O
was	O
highly	O
positive	O
for	O
homogentisic	B-ChemicalEntity
acid	I-ChemicalEntity
.	O

All	O
12	O
members	O
of	O
this	O
girl	O
'	O
s	O
family	O
were	O
studied	O
and	O
one	O
,	O
a	O
22	O
year	O
old	O
brother	O
,	O
was	O
found	O
to	O
excrete	O
HGA	B-ChemicalEntity
.	O

Another	O
,	O
a	O
sister	O
who	O
had	O
not	O
provided	O
a	O
urine	O
sample	O
,	O
was	O
discovered	O
by	O
genetic	O
testing	O
.	O

There	O
were	O
no	O
complaints	O
of	O
joint	B-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
or	O
other	O
symptoms	O
in	O
any	O
member	O
of	O
this	O
family	O
.	O

Parents	O
were	O
first	O
cousins	O
.	O

We	O
found	O
a	O
single	O
nucleotide	O
deletion	O
c	B-SequenceVariant
.	O
342delA	I-SequenceVariant
,	O
located	O
in	O
exon	O
3	O
,	O
which	O
resulted	O
in	O
a	O
frameshift	O
at	O
amino	O
acid	O
position	O
58	O
(	O
p	B-SequenceVariant
.	O
Arg58fs	I-SequenceVariant
or	O
p	B-SequenceVariant
.	O
R58fs	I-SequenceVariant
)	O
.	O

Alkaptonuria	B-DiseaseOrPhenotypicFeature
may	O
be	O
more	O
common	O
than	O
it	O
is	O
thought	O
to	O
be	O
with	O
an	O
allele	O
prevalence	O
estimated	O
at	O
0	O
.	O
0107	O
(	O
95%	O
CI	O
0	O
.	O
000392	O
-	O
0	O
.	O
03473	O
)	O
.	O

The	O
R58fs	B-SequenceVariant
mutation	O
is	O
old	O
,	O
perhaps	O
having	O
occurred	O
several	O
thousand	O
years	O
ago	O
,	O
and	O
has	O
spread	O
over	O
a	O
large	O
geographical	O
area	O
.	O
5	B-ChemicalEntity
-	O
Fluorouracil	I-ChemicalEntity
cardiotoxicity	B-DiseaseOrPhenotypicFeature
induced	O
by	O
alpha	B-ChemicalEntity
-	O
fluoro	I-ChemicalEntity
-	O
beta	I-ChemicalEntity
-	O
alanine	I-ChemicalEntity
.	O

Cardiotoxicity	B-DiseaseOrPhenotypicFeature
is	O
a	O
rare	O
complication	O
occurring	O
during	O
5	B-ChemicalEntity
-	O
fluorouracil	I-ChemicalEntity
(	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
)	O
treatment	O
for	O
malignancies	B-DiseaseOrPhenotypicFeature
.	O

We	O
herein	O
report	O
the	O
case	O
of	O
a	O
70	O
-	O
year	O
-	O
old	O
man	B-OrganismTaxon
with	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
-	O
induced	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
,	O
in	O
whom	O
a	O
high	O
serum	O
level	O
of	O
alpha	B-ChemicalEntity
-	O
fluoro	I-ChemicalEntity
-	O
beta	I-ChemicalEntity
-	O
alanine	I-ChemicalEntity
(	O
FBAL	B-ChemicalEntity
)	O
was	O
observed	O
.	O

The	O
patient	B-OrganismTaxon
,	O
who	O
had	O
unresectable	O
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
metastases	B-DiseaseOrPhenotypicFeature
to	O
the	O
liver	O
and	O
lung	O
,	O
was	O
referred	O
to	O
us	O
for	O
chemotherapy	O
from	O
an	O
affiliated	O
hospital	O
;	O
he	O
had	O
no	O
cardiac	O
history	O
.	O

After	O
admission	O
,	O
the	O
patient	B-OrganismTaxon
received	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
(	O
1000	O
mg	O
/	O
day	O
)	O
,	O
during	O
which	O
precordial	B-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
with	O
right	B-DiseaseOrPhenotypicFeature
bundle	I-DiseaseOrPhenotypicFeature
branch	I-DiseaseOrPhenotypicFeature
block	I-DiseaseOrPhenotypicFeature
occurred	O
concomitantly	O
with	O
a	O
high	O
serum	O
FBAL	B-ChemicalEntity
concentration	O
of	O
1955	O
ng	O
/	O
ml	O
.	O

Both	O
the	O
precordial	B-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
and	O
the	O
electrocardiographic	O
changes	O
disappeared	O
spontaneously	O
after	O
the	O
discontinuation	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
.	O

As	O
the	O
precordial	B-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
in	O
this	O
patient	B-OrganismTaxon
was	O
considered	O
to	O
have	O
been	O
due	O
to	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
-	O
induced	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
,	O
the	O
administration	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
was	O
abandoned	O
.	O

Instead	O
,	O
oral	O
administration	O
of	O
S	B-ChemicalEntity
-	O
1	I-ChemicalEntity
(	O
a	O
derivative	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
)	O
,	O
at	O
200	O
mg	O
/	O
day	O
twice	O
a	O
week	O
,	O
was	O
instituted	O
,	O
because	O
S	B-ChemicalEntity
-	O
1	I-ChemicalEntity
has	O
a	O
strong	O
inhibitory	O
effect	O
on	O
dihydropyrimidine	B-ChemicalEntity
dehydrogenase	O
,	O
which	O
catalyzes	O
the	O
degradative	O
of	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
into	O
FBAL	B-ChemicalEntity
.	O

The	O
serum	O
FBAL	B-ChemicalEntity
concentration	O
subsequently	O
decreased	O
to	O
352	O
ng	O
/	O
ml	O
,	O
the	O
same	O
as	O
the	O
value	O
measured	O
on	O
the	O
first	O
day	O
of	O
S	B-ChemicalEntity
-	O
1	I-ChemicalEntity
administration	O
.	O

Thereafter	O
,	O
no	O
cardiac	B-DiseaseOrPhenotypicFeature
symptoms	I-DiseaseOrPhenotypicFeature
were	O
observed	O
.	O

The	O
patient	B-OrganismTaxon
achieved	O
a	O
partial	O
response	O
6	O
months	O
after	O
the	O
initiation	O
of	O
the	O
S	B-ChemicalEntity
-	O
1	I-ChemicalEntity
treatment	O
.	O

The	O
experience	O
of	O
this	O
case	O
,	O
together	O
with	O
a	O
review	O
of	O
the	O
literature	O
,	O
suggests	O
that	O
FBAL	B-ChemicalEntity
is	O
related	O
to	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
-	O
induced	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
.	O

S	B-ChemicalEntity
-	O
1	I-ChemicalEntity
may	O
be	O
administered	O
safely	O
to	O
patients	B-OrganismTaxon
with	O
5	B-ChemicalEntity
-	O
FU	I-ChemicalEntity
-	O
induced	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
.	O
Hypoglycemic	O
Effect	O
of	O
Combined	O
Ghrelin	B-GeneOrGeneProduct
and	O
Glucagon	B-GeneOrGeneProduct
Receptor	I-GeneOrGeneProduct
Blockade	O
.	O

Glucagon	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
GcgR	B-GeneOrGeneProduct
)	O
blockade	O
has	O
been	O
proposed	O
as	O
an	O
alternative	O
to	O
insulin	B-GeneOrGeneProduct
monotherapy	O
for	O
treating	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
since	O
deletion	O
or	O
inhibition	O
of	O
GcgRs	B-GeneOrGeneProduct
corrects	O
hyperglycemia	B-DiseaseOrPhenotypicFeature
in	O
models	O
of	O
diabetes	B-DiseaseOrPhenotypicFeature
.	O

The	O
factors	O
regulating	O
glycemia	B-ChemicalEntity
in	O
a	O
setting	O
devoid	O
of	O
insulin	B-GeneOrGeneProduct
and	O
glucagon	B-GeneOrGeneProduct
function	O
remain	O
unclear	O
but	O
may	O
include	O
the	O
hormone	O
ghrelin	B-GeneOrGeneProduct
.	O

Not	O
only	O
is	O
ghrelin	B-GeneOrGeneProduct
release	O
controlled	O
by	O
glucose	B-ChemicalEntity
but	O
also	O
ghrelin	B-GeneOrGeneProduct
has	O
many	O
actions	O
that	O
can	O
raise	O
or	O
reduce	O
falls	O
in	O
blood	B-ChemicalEntity
glucose	I-ChemicalEntity
level	O
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
ghrelin	B-GeneOrGeneProduct
rises	O
to	O
prevent	O
hypoglycemia	B-DiseaseOrPhenotypicFeature
in	O
the	O
absence	O
of	O
glucagon	B-GeneOrGeneProduct
function	O
.	O

Both	O
GcgR	B-GeneOrGeneProduct
knockout	O
(	O
Gcgr	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
)	O
mice	B-OrganismTaxon
and	O
db	O
/	O
db	O
mice	B-OrganismTaxon
that	O
were	O
administered	O
GcgR	B-GeneOrGeneProduct
monoclonal	O
antibody	O
displayed	O
lower	O
blood	B-ChemicalEntity
glucose	I-ChemicalEntity
levels	O
accompanied	O
by	O
elevated	O
plasma	O
ghrelin	B-GeneOrGeneProduct
levels	O
.	O

Although	O
treatment	O
with	O
the	O
pancreatic	O
b	O
-	O
cell	O
toxin	O
streptozotocin	B-ChemicalEntity
induced	O
hyperglycemia	B-DiseaseOrPhenotypicFeature
and	O
raised	O
plasma	O
ghrelin	B-GeneOrGeneProduct
levels	O
in	O
wild	O
-	O
type	O
mice	B-OrganismTaxon
,	O
hyperglycemia	B-DiseaseOrPhenotypicFeature
was	O
averted	O
in	O
similarly	O
treated	O
Gcgr	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
and	O
the	O
plasma	O
ghrelin	B-GeneOrGeneProduct
level	O
was	O
further	O
increased	O
.	O

Notably	O
,	O
administration	O
of	O
a	O
ghrelin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
antagonist	O
further	O
reduced	O
blood	B-ChemicalEntity
glucose	I-ChemicalEntity
levels	O
into	O
the	O
markedly	O
hypoglycemic	O
range	O
in	O
overnight	O
-	O
fasted	O
,	O
streptozotocin	B-ChemicalEntity
-	O
treated	O
Gcgr	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
.	O

A	O
lowered	O
blood	B-ChemicalEntity
glucose	I-ChemicalEntity
level	O
also	O
was	O
observed	O
in	O
overnight	O
-	O
fasted	O
,	O
streptozotocin	B-ChemicalEntity
-	O
treated	O
ghrelin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
null	O
mice	B-OrganismTaxon
that	O
were	O
administered	O
GcgR	B-GeneOrGeneProduct
monoclonal	O
antibody	O
.	O

These	O
data	O
suggest	O
that	O
when	O
glucagon	B-GeneOrGeneProduct
activity	O
is	O
blocked	O
in	O
the	O
setting	O
of	O
type	B-DiseaseOrPhenotypicFeature
1	I-DiseaseOrPhenotypicFeature
diabetes	I-DiseaseOrPhenotypicFeature
,	O
the	O
plasma	O
ghrelin	B-GeneOrGeneProduct
level	O
rises	O
,	O
preventing	O
hypoglycemia	B-DiseaseOrPhenotypicFeature
.	O
Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
,	O
a	O
poly	B-GeneOrGeneProduct
(	O
A	I-GeneOrGeneProduct
)	O
polymerase	I-GeneOrGeneProduct
,	O
functions	O
as	O
a	O
tumor	B-DiseaseOrPhenotypicFeature
suppressor	O
in	O
an	O
orthotopic	O
human	B-OrganismTaxon
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
model	O
.	O

Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
is	O
a	O
noncanonical	O
poly	B-GeneOrGeneProduct
(	O
A	I-GeneOrGeneProduct
)	O
polymerase	I-GeneOrGeneProduct
and	O
required	O
for	O
the	O
expression	O
of	O
a	O
select	O
set	O
of	O
mRNAs	O
.	O

However	O
,	O
the	O
pathological	O
role	O
of	O
Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
in	O
cancer	B-DiseaseOrPhenotypicFeature
largely	O
remains	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
decreased	O
expression	O
of	O
Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
in	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
lines	O
and	O
tissues	O
.	O

Ectopic	O
Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
expression	O
inhibited	O
proliferation	O
as	O
well	O
as	O
colony	O
-	O
forming	O
ability	O
of	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
.	O

In	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
high	O
levels	O
of	O
Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
correlated	O
with	O
an	O
improved	O
prognosis	O
.	O

Moreover	O
,	O
by	O
regulating	O
the	O
expression	O
of	O
BIK	B-GeneOrGeneProduct
(	O
BCL2	B-GeneOrGeneProduct
-	O
interacting	I-GeneOrGeneProduct
killer	I-GeneOrGeneProduct
)	O
,	O
Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
induced	O
apoptosis	O
of	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
through	O
the	O
mitochondrial	O
pathway	O
.	O

The	O
growth	O
of	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
xenografts	O
in	O
NOD	O
/	O
SCID	B-DiseaseOrPhenotypicFeature
mice	B-OrganismTaxon
was	O
also	O
inhibited	O
by	O
the	O
doxycycline	B-ChemicalEntity
-	O
induced	O
Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
overexpression	O
.	O

Furthermore	O
,	O
Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
sensitized	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
to	O
chemotherapy	O
drugs	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
mammary	O
epithelial	O
cells	O
,	O
Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
knockdown	O
partially	O
transformed	O
these	O
cells	O
and	O
induced	O
them	O
to	O
undergo	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

These	O
findings	O
suggested	O
that	O
Star	B-GeneOrGeneProduct
-	O
PAP	I-GeneOrGeneProduct
possesses	O
tumor	B-DiseaseOrPhenotypicFeature
-	O
suppressing	O
activity	O
and	O
can	O
be	O
a	O
valuable	O
target	O
for	O
developing	O
new	O
cancer	B-DiseaseOrPhenotypicFeature
therapeutic	O
strategies	O
.	O
Chronic	O
treatment	O
with	O
metformin	B-ChemicalEntity
suppresses	O
toll	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
signaling	O
and	O
attenuates	O
left	B-DiseaseOrPhenotypicFeature
ventricular	I-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
following	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
.	O

Acute	O
treatment	O
with	O
metformin	B-ChemicalEntity
has	O
a	O
protective	O
effect	O
in	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
by	O
suppression	O
of	O
inflammatory	B-DiseaseOrPhenotypicFeature
responses	O
due	O
to	O
activation	O
of	O
AMP	B-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
(	O
AMPK	B-GeneOrGeneProduct
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effect	O
of	O
chronic	O
pre	O
-	O
treatment	O
with	O
metformin	B-ChemicalEntity
on	O
cardiac	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
and	O
toll	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
(	O
TLR4	B-GeneOrGeneProduct
)	O
activities	O
following	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
and	O
their	O
relation	O
with	O
AMPK	B-GeneOrGeneProduct
were	O
assessed	O
.	O

Male	O
Wistar	O
rats	B-OrganismTaxon
were	O
randomly	O
assigned	O
to	O
one	O
of	O
5	O
groups	O
(	O
n	O
=	O
6	O
)	O
:	O
normal	O
control	O
and	O
groups	O
were	O
injected	O
isoproterenol	B-ChemicalEntity
after	O
chronic	O
pre	O
-	O
treatment	O
with	O
0	O
,	O
25	O
,	O
50	O
,	O
or	O
100mg	O
/	O
kg	O
of	O
metformin	B-ChemicalEntity
twice	O
daily	O
for	O
14	O
days	O
.	O

Isoproterenol	B-ChemicalEntity
(	O
100mg	O
/	O
kg	O
)	O
was	O
injected	O
subcutaneously	O
on	O
the	O
13th	O
and	O
14th	O
days	O
to	O
induce	O
acute	B-DiseaseOrPhenotypicFeature
myocardial	I-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
.	O

Isoproterenol	B-ChemicalEntity
alone	O
decreased	O
left	O
ventricular	O
systolic	O
pressure	O
and	O
myocardial	O
contractility	O
indexed	O
as	O
LVdp	O
/	O
dtmax	O
and	O
LVdp	O
/	O
dtmin	O
.	O

The	O
left	B-DiseaseOrPhenotypicFeature
ventricular	I-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
was	O
significantly	O
lower	O
in	O
the	O
groups	O
treated	O
with	O
25	O
and	O
50mg	O
/	O
kg	O
of	O
metformin	B-ChemicalEntity
.	O

Metfromin	B-ChemicalEntity
markedly	O
lowered	O
isoproterenol	B-ChemicalEntity
-	O
induced	O
elevation	O
in	O
the	O
levels	O
of	O
TLR4	B-GeneOrGeneProduct
mRNA	O
,	O
myeloid	B-GeneOrGeneProduct
differentiation	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
88	I-GeneOrGeneProduct
(	O
MyD88	B-GeneOrGeneProduct
)	O
,	O
tumor	B-GeneOrGeneProduct
necrosis	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
(	O
TNF	B-GeneOrGeneProduct
-	O
a	I-GeneOrGeneProduct
)	O
,	O
and	O
interleukin	B-GeneOrGeneProduct
6	I-GeneOrGeneProduct
(	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
)	O
in	O
the	O
heart	O
tissues	O
.	O

Similar	O
changes	O
were	O
also	O
seen	O
in	O
the	O
serum	O
levels	O
of	O
TNF	B-GeneOrGeneProduct
-	O
a	I-GeneOrGeneProduct
and	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
.	O

However	O
,	O
the	O
lower	O
doses	O
of	O
25	O
and	O
50mg	O
/	O
kg	O
were	O
more	O
effective	O
than	O
100mg	O
/	O
kg	O
.	O

Phosphorylated	O
AMPKa	B-GeneOrGeneProduct
(	O
p	O
-	O
AMPK	B-GeneOrGeneProduct
)	O
in	O
the	O
myocardium	O
was	O
significantly	O
elevated	O
by	O
25mg	O
/	O
kg	O
of	O
metformin	B-ChemicalEntity
,	O
slightly	O
by	O
50mg	O
/	O
kg	O
,	O
but	O
not	O
by	O
100mg	O
/	O
kg	O
.	O

Chronic	O
pre	O
-	O
treatment	O
with	O
metformin	B-ChemicalEntity
reduces	O
post	O
-	O
myocardial	B-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
cardiac	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
and	O
suppresses	O
inflammatory	B-DiseaseOrPhenotypicFeature
responses	O
,	O
possibly	O
through	O
inhibition	O
of	O
TLR4	B-GeneOrGeneProduct
activities	O
.	O

This	O
mechanism	O
can	O
be	O
considered	O
as	O
a	O
target	O
to	O
protect	O
infarcted	B-DiseaseOrPhenotypicFeature
myocardium	I-DiseaseOrPhenotypicFeature
.	O
Identification	O
of	O
apolipoprotein	B-GeneOrGeneProduct
E	I-GeneOrGeneProduct
Guangzhou	O
(	O
arginine	B-SequenceVariant
150	I-SequenceVariant
proline	I-SequenceVariant
)	O
,	O
a	O
new	O
variant	O
associated	O
with	O
lipoprotein	B-DiseaseOrPhenotypicFeature
glomerulopathy	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
Lipoprotein	B-DiseaseOrPhenotypicFeature
glomerulopathy	I-DiseaseOrPhenotypicFeature
(	O
LPG	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
rare	O
disease	O
characterized	O
by	O
thrombus	B-DiseaseOrPhenotypicFeature
-	O
like	O
substances	O
in	O
markedly	O
dilated	B-DiseaseOrPhenotypicFeature
glomerular	I-DiseaseOrPhenotypicFeature
capillaries	I-DiseaseOrPhenotypicFeature
and	O
elevated	O
plasma	O
levels	O
of	O
apolipoprotein	B-GeneOrGeneProduct
E	I-GeneOrGeneProduct
(	O
apoE	B-GeneOrGeneProduct
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
genetic	O
disorders	O
of	O
apoE	B-GeneOrGeneProduct
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
LPG	B-DiseaseOrPhenotypicFeature
,	O
but	O
LPG	B-DiseaseOrPhenotypicFeature
may	O
not	O
be	O
caused	O
by	O
apoE	B-GeneOrGeneProduct
gene	O
mutations	O
in	O
Chinese	O
patients	B-OrganismTaxon
.	O

This	O
study	O
investigated	O
the	O
association	O
of	O
a	O
new	O
variant	O
of	O
apoE	B-GeneOrGeneProduct
with	O
LPG	B-DiseaseOrPhenotypicFeature
in	O
a	O
Chinese	O
family	O
.	O

METHODS	O
:	O
The	O
apoE	B-GeneOrGeneProduct
gene	O
in	O
a	O
family	O
with	O
4	O
LPG	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
was	O
sequenced	O
.	O

The	O
polymerase	O
chain	O
reaction	O
product	O
of	O
coding	O
region	O
of	O
apoE	B-GeneOrGeneProduct
exon	O
4	O
was	O
cloned	O
into	O
pMD	O
18	O
-	O
T	O
vector	O
and	O
then	O
sequenced	O
.	O

RESULTS	O
:	O
A	O
novel	O
point	O
mutation	O
in	O
exon	O
4	O
of	O
the	O
apoE	B-GeneOrGeneProduct
gene	O
was	O
identified	O
in	O
all	O
4	O
LPG	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
1	O
asymptomatic	O
family	O
member	O
.	O

Sequence	O
analysis	O
confirmed	O
a	O
nucleotide	O
G	B-SequenceVariant
to	I-SequenceVariant
C	I-SequenceVariant
point	I-SequenceVariant
mutation	I-SequenceVariant
in	I-SequenceVariant
exon	I-SequenceVariant
4	I-SequenceVariant
(	O
base	I-SequenceVariant
308	I-SequenceVariant
)	O
of	O
the	O
apoE	B-GeneOrGeneProduct
gene	O
in	O
all	O
patients	B-OrganismTaxon
and	O
the	O
asymptomatic	O
family	O
member	O
.	O

This	O
missense	O
mutation	O
denotes	O
amino	O
acid	O
substitution	O
of	O
the	O
proline	B-SequenceVariant
residue	I-SequenceVariant
for	I-SequenceVariant
arginine	I-SequenceVariant
residue	I-SequenceVariant
at	I-SequenceVariant
position	I-SequenceVariant
150	I-SequenceVariant
of	O
apoE	B-GeneOrGeneProduct
.	O

Those	O
patients	B-OrganismTaxon
were	O
all	O
heterozygotes	O
with	O
apoE	B-GeneOrGeneProduct
Guangzhou	O
.	O

One	O
of	O
2	O
grandsons	O
was	O
a	O
heterozygous	O
carrier	O
of	O
apoE	B-GeneOrGeneProduct
Guangzhou	O
,	O
although	O
he	O
did	O
not	O
have	O
proteinuria	B-DiseaseOrPhenotypicFeature
.	O

CONCLUSION	O
:	O
The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
apoE	B-GeneOrGeneProduct
(	O
arginine	B-SequenceVariant
150	I-SequenceVariant
proline	I-SequenceVariant
)	O
is	O
a	O
novel	O
apoE	B-GeneOrGeneProduct
variant	O
that	O
etiologically	O
related	O
to	O
LPG	B-DiseaseOrPhenotypicFeature
.	O

This	O
variant	O
(	O
apoE	B-GeneOrGeneProduct
Guangzhou	O
)	O
may	O
cause	O
a	O
marked	O
molecular	O
conformational	O
change	O
of	O
the	O
apoE	B-GeneOrGeneProduct
and	O
thus	O
impair	O
its	O
binding	O
ability	O
to	O
lipids	B-ChemicalEntity
.	O
A	O
two	O
base	O
pair	O
deletion	O
in	O
the	O
PQBP1	B-GeneOrGeneProduct
gene	O
is	O
associated	O
with	O
microphthalmia	B-DiseaseOrPhenotypicFeature
,	O
microcephaly	B-DiseaseOrPhenotypicFeature
,	O
and	O
mental	B-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
.	O

X	B-DiseaseOrPhenotypicFeature
-	O
linked	I-DiseaseOrPhenotypicFeature
mental	I-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
has	O
been	O
traditionally	O
divided	O
into	O
syndromic	O
(	O
S	O
-	O
XLMR	B-DiseaseOrPhenotypicFeature
)	O
and	O
non	O
-	O
syndromic	O
forms	O
(	O
NS	O
-	O
XLMR	B-DiseaseOrPhenotypicFeature
)	O
,	O
although	O
the	O
borderlines	O
between	O
these	O
phenotypes	O
begin	O
to	O
vanish	O
and	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
for	O
example	O
PQBP1	B-GeneOrGeneProduct
,	O
can	O
cause	O
S	O
-	O
XLMR	B-DiseaseOrPhenotypicFeature
as	O
well	O
as	O
NS	O
-	O
XLMR	B-DiseaseOrPhenotypicFeature
.	O

Here	O
,	O
we	O
report	O
two	O
maternal	O
cousins	O
with	O
an	O
apparently	O
X	B-DiseaseOrPhenotypicFeature
-	O
linked	I-DiseaseOrPhenotypicFeature
phenotype	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
mental	I-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
(	O
MR	B-DiseaseOrPhenotypicFeature
)	O
,	O
microphthalmia	B-DiseaseOrPhenotypicFeature
,	O
choroid	B-DiseaseOrPhenotypicFeature
coloboma	I-DiseaseOrPhenotypicFeature
,	O
microcephaly	B-DiseaseOrPhenotypicFeature
,	O
renal	B-DiseaseOrPhenotypicFeature
hypoplasia	I-DiseaseOrPhenotypicFeature
,	O
and	O
spastic	B-DiseaseOrPhenotypicFeature
paraplegia	I-DiseaseOrPhenotypicFeature
.	O

By	O
multipoint	O
linkage	O
analysis	O
with	O
markers	O
spanning	O
the	O
entire	O
X	O
-	O
chromosome	O
we	O
mapped	O
the	O
disease	O
locus	O
to	O
a	O
28	O
-	O
Mb	O
interval	O
between	O
Xp11	O
.	O
4	O
and	O
Xq12	O
,	O
including	O
the	O
BCOR	B-GeneOrGeneProduct
gene	O
.	O

A	O
missense	O
mutation	O
in	O
BCOR	B-GeneOrGeneProduct
was	O
described	O
in	O
a	O
family	O
with	O
Lenz	B-DiseaseOrPhenotypicFeature
microphthalmia	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
,	O
a	O
phenotype	O
showing	O
substantial	O
overlapping	O
features	O
with	O
that	O
described	O
in	O
the	O
two	O
cousins	O
.	O

However	O
,	O
no	O
mutation	O
in	O
the	O
BCOR	B-GeneOrGeneProduct
gene	O
was	O
found	O
in	O
both	O
patients	B-OrganismTaxon
.	O

Subsequent	O
mutation	O
analysis	O
of	O
PQBP1	B-GeneOrGeneProduct
,	O
located	O
within	O
the	O
delineated	O
linkage	O
interval	O
in	O
Xp11	O
.	O
23	O
,	O
revealed	O
a	O
2	O
-	O
bp	O
deletion	O
,	O
c	B-SequenceVariant
.	O
461_462delAG	I-SequenceVariant
,	O
that	O
cosegregated	O
with	O
the	O
disease	O
.	O

Notably	O
,	O
the	O
same	O
mutation	O
is	O
associated	O
with	O
the	O
Hamel	B-DiseaseOrPhenotypicFeature
cerebropalatocardiac	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
,	O
another	O
form	O
of	O
S	O
-	O
XLMR	B-DiseaseOrPhenotypicFeature
.	O

Haplotype	O
analysis	O
suggests	O
a	O
germline	O
mosaicism	O
of	O
the	O
2	O
-	O
bp	O
deletion	O
in	O
the	O
maternal	O
grandmother	O
of	O
both	O
affected	O
individuals	O
.	O

In	O
summary	O
,	O
our	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
mutations	O
in	O
PQBP1	B-GeneOrGeneProduct
are	O
associated	O
with	O
an	O
S	O
-	O
XLMR	B-DiseaseOrPhenotypicFeature
phenotype	O
including	O
microphthalmia	B-DiseaseOrPhenotypicFeature
,	O
thereby	O
further	O
extending	O
the	O
clinical	O
spectrum	O
of	O
phenotypes	O
associated	O
with	O
PQBP1	B-GeneOrGeneProduct
mutations	O
.	O
Genetic	O
investigation	O
of	O
the	O
TSPYL1	B-GeneOrGeneProduct
gene	O
in	O
sudden	B-DiseaseOrPhenotypicFeature
infant	I-DiseaseOrPhenotypicFeature
death	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Sudden	B-DiseaseOrPhenotypicFeature
infant	I-DiseaseOrPhenotypicFeature
death	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
SIDS	B-DiseaseOrPhenotypicFeature
)	O
constitutes	O
the	O
most	O
frequent	O
cause	O
of	O
death	B-DiseaseOrPhenotypicFeature
in	O
the	O
postperinatal	O
period	O
in	O
Germany	O
.	O

Recently	O
,	O
a	O
lethal	O
phenotype	O
characterized	O
by	O
sudden	B-DiseaseOrPhenotypicFeature
infant	I-DiseaseOrPhenotypicFeature
death	I-DiseaseOrPhenotypicFeature
with	I-DiseaseOrPhenotypicFeature
dysgenesis	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
testes	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
SIDDT	B-DiseaseOrPhenotypicFeature
)	O
was	O
identified	O
to	O
be	O
caused	O
by	O
loss	O
of	O
function	O
mutations	O
in	O
the	O
TSPYL1	B-GeneOrGeneProduct
gene	O
.	O

PURPOSE	O
:	O
The	O
study	O
'	O
s	O
purpose	O
was	O
to	O
reveal	O
a	O
possible	O
role	O
of	O
TSPYL1	B-GeneOrGeneProduct
in	O
SIDS	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
DNA	O
samples	O
of	O
126	O
SIDS	B-DiseaseOrPhenotypicFeature
cases	O
and	O
261	O
controls	O
were	O
investigated	O
.	O

RESULTS	O
:	O
We	O
found	O
five	O
sequence	O
variations	O
,	O
each	O
of	O
them	O
causing	O
an	O
amino	O
acid	O
substitution	O
.	O

No	O
Hardy	O
Weinberg	O
disequilibrium	O
and	O
no	O
significant	O
difference	O
in	O
allele	O
frequencies	O
between	O
patients	B-OrganismTaxon
and	O
controls	O
were	O
observed	O
for	O
any	O
variation	O
.	O

In	O
one	O
female	O
patient	B-OrganismTaxon
a	O
p	B-SequenceVariant
.	O
F366L	I-SequenceVariant
amino	O
acid	O
polymorphism	O
was	O
found	O
heterozygous	O
,	O
which	O
could	O
not	O
be	O
displayed	O
in	O
controls	O
.	O

A	O
pathogenic	O
implication	O
of	O
this	O
substitution	O
,	O
which	O
is	O
conserved	O
in	O
primates	O
and	O
rodents	O
,	O
cannot	O
be	O
ruled	O
out	O
completely	O
.	O

Because	O
SIDDT	B-DiseaseOrPhenotypicFeature
is	O
the	O
result	O
of	O
homozygous	O
TSPYL1	B-GeneOrGeneProduct
mutations	O
,	O
this	O
heterozygous	O
exchange	O
cannot	O
solely	O
explain	O
the	O
sudden	B-DiseaseOrPhenotypicFeature
death	I-DiseaseOrPhenotypicFeature
in	O
this	O
child	O
.	O

The	O
reported	O
mutation	O
associated	O
with	O
SIDDT	B-DiseaseOrPhenotypicFeature
(	O
457_458insG	B-SequenceVariant
)	O
was	O
not	O
detectable	O
in	O
our	O
cohort	O
.	O

CONCLUSION	O
:	O
No	O
association	O
of	O
sequence	O
variations	O
in	O
the	O
TSPYL1	B-GeneOrGeneProduct
gene	O
and	O
SIDS	B-DiseaseOrPhenotypicFeature
has	O
been	O
found	O
in	O
a	O
German	O
cohort	O
.	O

Genetic	O
analysis	O
of	O
TSPYL1	B-GeneOrGeneProduct
seems	O
to	O
be	O
of	O
limited	O
significance	O
in	O
the	O
differential	O
diagnosis	O
of	O
SIDS	B-DiseaseOrPhenotypicFeature
without	O
dysgenesis	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
testes	I-DiseaseOrPhenotypicFeature
.	O
High	O
fat	B-ChemicalEntity
diet	O
-	O
fed	O
obese	B-DiseaseOrPhenotypicFeature
rats	B-OrganismTaxon
are	O
highly	O
sensitive	O
to	O
doxorubicin	B-ChemicalEntity
-	O
induced	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
.	O

Often	O
,	O
chemotherapy	O
by	O
doxorubicin	B-ChemicalEntity
(	O
Adriamycin	B-ChemicalEntity
)	O
is	O
limited	O
due	O
to	O
life	O
threatening	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
in	O
patients	O
during	O
and	O
posttherapy	O
.	O

Recently	O
,	O
we	O
have	O
shown	O
that	O
moderate	O
diet	O
restriction	O
remarkably	O
protects	O
against	O
doxorubicin	B-ChemicalEntity
-	O
induced	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
.	O

This	O
cardioprotection	O
is	O
accompanied	O
by	O
decreased	O
cardiac	O
oxidative	O
stress	O
and	O
triglycerides	B-ChemicalEntity
and	O
increased	O
cardiac	O
fatty	B-ChemicalEntity
-	O
acid	I-ChemicalEntity
oxidation	O
,	O
ATP	B-ChemicalEntity
synthesis	O
,	O
and	O
upregulated	O
JAK	B-GeneOrGeneProduct
/	O
STAT3	B-GeneOrGeneProduct
pathway	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
whether	O
a	O
physiological	O
intervention	O
by	O
feeding	O
40%	O
high	O
fat	B-ChemicalEntity
diet	O
(	O
HFD	O
)	O
,	O
which	O
induces	O
obesity	B-DiseaseOrPhenotypicFeature
in	O
male	O
Sprague	O
-	O
Dawley	O
rats	B-OrganismTaxon
(	O
250	O
-	O
275	O
g	O
)	O
,	O
sensitizes	O
to	O
doxorubicin	B-ChemicalEntity
-	O
induced	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
.	O

A	O
LD	O
(	O
10	O
)	O
dose	O
(	O
8	O
mg	O
doxorubicin	B-ChemicalEntity
/	O
kg	O
,	O
ip	O
)	O
administered	O
on	O
day	O
43	O
of	O
the	O
HFD	O
feeding	O
regimen	O
led	O
to	O
higher	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
,	O
cardiac	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
,	O
lipid	B-ChemicalEntity
peroxidation	O
,	O
and	O
80%	O
mortality	O
in	O
the	O
obese	B-DiseaseOrPhenotypicFeature
(	O
OB	B-DiseaseOrPhenotypicFeature
)	O
rats	B-OrganismTaxon
in	O
the	O
absence	O
of	O
any	O
significant	O
renal	B-DiseaseOrPhenotypicFeature
or	I-DiseaseOrPhenotypicFeature
hepatic	I-DiseaseOrPhenotypicFeature
toxicity	I-DiseaseOrPhenotypicFeature
.	O

Doxorubicin	B-ChemicalEntity
toxicokinetics	O
studies	O
revealed	O
no	O
change	O
in	O
accumulation	O
of	O
doxorubicin	B-ChemicalEntity
and	O
doxorubicinol	B-ChemicalEntity
(	O
toxic	O
metabolite	O
)	O
in	O
the	O
normal	O
diet	O
-	O
fed	O
(	O
ND	O
)	O
and	O
OB	B-DiseaseOrPhenotypicFeature
hearts	O
.	O

Mechanistic	O
studies	O
revealed	O
that	O
OB	B-DiseaseOrPhenotypicFeature
rats	B-OrganismTaxon
are	O
sensitized	O
due	O
to	O
:	O
(	O
1	O
)	O
higher	O
oxyradical	O
stress	O
leading	O
to	O
upregulation	O
of	O
uncoupling	B-GeneOrGeneProduct
proteins	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
3	I-GeneOrGeneProduct
,	O
(	O
2	O
)	O
downregulation	O
of	O
cardiac	O
peroxisome	B-GeneOrGeneProduct
proliferators	I-GeneOrGeneProduct
activated	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
,	O
(	O
3	O
)	O
decreased	O
plasma	O
adiponectin	B-GeneOrGeneProduct
levels	O
,	O
(	O
4	O
)	O
decreased	O
cardiac	O
fatty	B-ChemicalEntity
-	O
acid	I-ChemicalEntity
oxidation	O
(	O
666	O
.	O
9	O
+	O
/	O
-	O
14	O
.	O
0	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
ND	O
versus	O
400	O
.	O
2	O
+	O
/	O
-	O
11	O
.	O
8	O
nmol	O
/	O
min	O
/	O
g	O
heart	O
in	O
OB	B-DiseaseOrPhenotypicFeature
)	O
,	O
(	O
5	O
)	O
decreased	O
mitochondrial	O
AMP	B-GeneOrGeneProduct
-	O
alpha2	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
,	O
and	O
(	O
6	O
)	O
86%	O
drop	O
in	O
cardiac	O
ATP	B-ChemicalEntity
levels	O
accompanied	O
by	O
decreased	O
ATP	B-ChemicalEntity
/	O
ADP	B-ChemicalEntity
ratio	O
after	O
doxorubicin	B-ChemicalEntity
administration	O
.	O

Decreased	O
cardiac	O
erythropoietin	B-GeneOrGeneProduct
and	O
increased	O
SOCS3	B-GeneOrGeneProduct
further	O
downregulated	O
the	O
cardioprotective	O
JAK	B-GeneOrGeneProduct
/	O
STAT3	B-GeneOrGeneProduct
pathway	O
.	O

In	O
conclusion	O
,	O
HFD	O
-	O
induced	O
obese	B-DiseaseOrPhenotypicFeature
rats	B-OrganismTaxon
are	O
highly	O
sensitized	O
to	O
doxorubicin	B-ChemicalEntity
-	O
induced	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
by	O
substantially	O
downregulating	O
cardiac	O
mitochondrial	O
ATP	B-ChemicalEntity
generation	O
,	O
increasing	O
oxidative	O
stress	O
and	O
downregulating	O
the	O
JAK	B-GeneOrGeneProduct
/	O
STAT3	B-GeneOrGeneProduct
pathway	O
.	O
Risks	O
and	O
benefits	O
of	O
COX	B-ChemicalEntity
-	O
2	I-ChemicalEntity
inhibitors	I-ChemicalEntity
vs	O
non	O
-	O
selective	O
NSAIDs	B-ChemicalEntity
:	O
does	O
their	O
cardiovascular	O
risk	O
exceed	O
their	O
gastrointestinal	O
benefit?	O
A	O
retrospective	O
cohort	O
study	O
.	O

OBJECTIVES	O
:	O
The	O
risk	O
of	O
acute	B-DiseaseOrPhenotypicFeature
myocardial	I-DiseaseOrPhenotypicFeature
infarction	I-DiseaseOrPhenotypicFeature
(	O
AMI	B-DiseaseOrPhenotypicFeature
)	O
with	O
COX	B-ChemicalEntity
-	O
2	I-ChemicalEntity
inhibitors	I-ChemicalEntity
may	O
offset	O
their	O
gastrointestinal	O
(	O
GI	O
)	O
benefit	O
compared	O
with	O
non	O
-	O
selective	O
(	O
NS	O
)	O
non	B-ChemicalEntity
-	O
steroidal	I-ChemicalEntity
anti	I-ChemicalEntity
-	O
inflammatory	I-ChemicalEntity
drugs	I-ChemicalEntity
(	O
NSAIDs	B-ChemicalEntity
)	O
.	O

We	O
aimed	O
to	O
compare	O
the	O
risks	O
of	O
hospitalization	O
for	O
AMI	B-DiseaseOrPhenotypicFeature
and	O
GI	B-DiseaseOrPhenotypicFeature
bleeding	I-DiseaseOrPhenotypicFeature
among	O
elderly	O
patients	O
using	O
COX	B-ChemicalEntity
-	O
2	I-ChemicalEntity
inhibitors	I-ChemicalEntity
,	O
NS	O
-	O
NSAIDs	B-ChemicalEntity
and	O
acetaminophen	B-ChemicalEntity
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
retrospective	O
cohort	O
study	O
using	O
administrative	O
data	O
of	O
patients	O
>	O
or	O
=	O
65	O
years	O
of	O
age	O
who	O
filled	O
a	O
prescription	O
for	O
NSAID	B-ChemicalEntity
or	O
acetaminophen	B-ChemicalEntity
during	O
1999	O
-	O
2002	O
.	O

Outcomes	O
were	O
compared	O
using	O
Cox	O
regression	O
models	O
with	O
time	O
-	O
dependent	O
exposures	O
.	O

RESULTS	O
:	O
Person	O
-	O
years	O
of	O
exposure	O
among	O
non	O
-	O
users	O
of	O
aspirin	B-ChemicalEntity
were	O
:	O
75	O
,	O
761	O
to	O
acetaminophen	B-ChemicalEntity
,	O
42	O
,	O
671	O
to	O
rofecoxib	B-ChemicalEntity
65	O
,	O
860	O
to	O
celecoxib	B-ChemicalEntity
,	O
and	O
37	O
,	O
495	O
to	O
NS	O
-	O
NSAIDs	B-ChemicalEntity
.	O

Among	O
users	O
of	O
aspirin	B-ChemicalEntity
,	O
they	O
were	O
:	O
14	O
,	O
671	O
to	O
rofecoxib	B-ChemicalEntity
,	O
22	O
,	O
875	O
to	O
celecoxib	B-ChemicalEntity
,	O
9	O
,	O
832	O
to	O
NS	O
-	O
NSAIDs	B-ChemicalEntity
and	O
38	O
,	O
048	O
to	O
acetaminophen	B-ChemicalEntity
.	O

Among	O
non	O
-	O
users	O
of	O
aspirin	B-ChemicalEntity
,	O
the	O
adjusted	O
hazard	O
ratios	O
(	O
95%	O
confidence	O
interval	O
)	O
of	O
hospitalization	O
for	O
AMI	B-DiseaseOrPhenotypicFeature
/	O
GI	O
vs	O
the	O
acetaminophen	B-ChemicalEntity
(	O
with	O
no	O
aspirin	B-ChemicalEntity
)	O
group	O
were	O
:	O
rofecoxib	B-ChemicalEntity
1	O
.	O
27	O
(	O
1	O
.	O
13	O
,	O
1	O
.	O
42	O
)	O
,	O
celecoxib	B-ChemicalEntity
0	O
.	O
93	O
(	O
0	O
.	O
83	O
,	O
1	O
.	O
03	O
)	O
,	O
naproxen	B-ChemicalEntity
1	O
.	O
59	O
(	O
1	O
.	O
31	O
,	O
1	O
.	O
93	O
)	O
,	O
diclofenac	B-ChemicalEntity
1	O
.	O
17	O
(	O
0	O
.	O
99	O
,	O
1	O
.	O
38	O
)	O
and	O
ibuprofen	B-ChemicalEntity
1	O
.	O
05	O
(	O
0	O
.	O
74	O
,	O
1	O
.	O
51	O
)	O
.	O

Among	O
users	O
of	O
aspirin	B-ChemicalEntity
,	O
they	O
were	O
:	O
rofecoxib	B-ChemicalEntity
1	O
.	O
73	O
(	O
1	O
.	O
52	O
,	O
1	O
.	O
98	O
)	O
,	O
celecoxib	B-ChemicalEntity
1	O
.	O
34	O
(	O
1	O
.	O
19	O
,	O
1	O
.	O
52	O
)	O
,	O
ibuprofen	B-ChemicalEntity
1	O
.	O
51	O
(	O
0	O
.	O
95	O
,	O
2	O
.	O
41	O
)	O
,	O
diclofenac	B-ChemicalEntity
1	O
.	O
69	O
(	O
1	O
.	O
35	O
,	O
2	O
.	O
10	O
)	O
,	O
naproxen	B-ChemicalEntity
1	O
.	O
35	O
(	O
0	O
.	O
97	O
,	O
1	O
.	O
88	O
)	O
and	O
acetaminophen	B-ChemicalEntity
1	O
.	O
29	O
(	O
1	O
.	O
17	O
,	O
1	O
.	O
42	O
)	O
.	O

CONCLUSION	O
:	O
Among	O
non	O
-	O
users	O
of	O
aspirin	B-ChemicalEntity
,	O
naproxen	B-ChemicalEntity
seemed	O
to	O
carry	O
the	O
highest	O
risk	O
for	O
AMI	B-DiseaseOrPhenotypicFeature
/	O
GI	B-DiseaseOrPhenotypicFeature
bleeding	I-DiseaseOrPhenotypicFeature
.	O

The	O
AMI	B-DiseaseOrPhenotypicFeature
/	O
GI	B-DiseaseOrPhenotypicFeature
toxicity	I-DiseaseOrPhenotypicFeature
of	O
celecoxib	B-ChemicalEntity
was	O
similar	O
to	O
that	O
of	O
acetaminophen	B-ChemicalEntity
and	O
seemed	O
to	O
be	O
better	O
than	O
those	O
of	O
rofecoxib	B-ChemicalEntity
and	O
NS	O
-	O
NSAIDs	B-ChemicalEntity
.	O

Among	O
users	O
of	O
aspirin	B-ChemicalEntity
,	O
both	O
celecoxib	B-ChemicalEntity
and	O
naproxen	B-ChemicalEntity
seemed	O
to	O
be	O
the	O
least	O
toxic	O
.	O
In	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-ChemicalEntity
A2A	I-ChemicalEntity
/	O
A1	I-ChemicalEntity
receptor	I-ChemicalEntity
antagonist	I-ChemicalEntity
in	O
animal	O
models	O
of	O
Parkinson	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

The	O
in	O
vivo	O
characterization	O
of	O
a	O
dual	O
adenosine	B-ChemicalEntity
A	I-ChemicalEntity
(	O
2A	I-ChemicalEntity
)	O
/	O
A	I-ChemicalEntity
(	O
1	I-ChemicalEntity
)	O
receptor	I-ChemicalEntity
antagonist	I-ChemicalEntity
in	O
several	O
animal	O
models	O
of	O
Parkinson	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
is	O
described	O
.	O

Discovery	O
and	O
scale	O
-	O
up	O
syntheses	O
of	O
compound	O
1	O
are	O
described	O
in	O
detail	O
,	O
highlighting	O
optimization	O
steps	O
that	O
increased	O
the	O
overall	O
yield	O
of	O
1	O
from	O
10	O
.	O
0%	O
to	O
30	O
.	O
5%	O
.	O

Compound	O
1	O
is	O
a	O
potent	O
A	B-ChemicalEntity
(	O
2A	I-ChemicalEntity
)	O
/	O
A	I-ChemicalEntity
(	O
1	I-ChemicalEntity
)	O
receptor	I-ChemicalEntity
antagonist	I-ChemicalEntity
in	O
vitro	O
(	O
A	O
(	O
2A	O
)	O
K	O
(	O
i	O
)	O
=	O
4	O
.	O
1	O
nM	O
;	O
A	O
(	O
1	O
)	O
K	O
(	O
i	O
)	O
=	O
17	O
.	O
0	O
nM	O
)	O
that	O
has	O
excellent	O
activity	O
,	O
after	O
oral	O
administration	O
,	O
across	O
a	O
number	O
of	O
animal	O
models	O
of	O
Parkinson	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
including	O
mouse	B-OrganismTaxon
and	O
rat	B-OrganismTaxon
models	O
of	O
haloperidol	B-ChemicalEntity
-	O
induced	O
catalepsy	B-DiseaseOrPhenotypicFeature
,	O
mouse	B-OrganismTaxon
model	O
of	O
reserpine	B-ChemicalEntity
-	O
induced	O
akinesia	B-DiseaseOrPhenotypicFeature
,	O
rat	B-OrganismTaxon
6	B-ChemicalEntity
-	O
hydroxydopamine	I-ChemicalEntity
(	O
6	B-ChemicalEntity
-	O
OHDA	I-ChemicalEntity
)	O
lesion	O
model	O
of	O
drug	O
-	O
induced	O
rotation	O
,	O
and	O
MPTP	B-ChemicalEntity
-	O
treated	O
non	O
-	O
human	B-OrganismTaxon
primate	O
model	O
.	O
Coincidence	O
of	O
mutations	O
in	O
different	O
connexin	O
genes	O
in	O
Hungarian	O
patients	B-OrganismTaxon
.	O

Mutations	O
in	O
the	O
GJB2	B-GeneOrGeneProduct
gene	O
are	O
the	O
most	O
common	O
cause	O
of	O
hereditary	O
prelingual	O
sensorineural	B-DiseaseOrPhenotypicFeature
hearing	I-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
in	O
Europe	O
.	O

Several	O
studies	O
indicate	O
that	O
different	O
members	O
of	O
the	O
connexin	O
protein	O
family	O
interact	O
to	O
form	O
gap	O
junctions	O
in	O
the	O
inner	O
ear	O
.	O

Mutations	O
in	O
different	O
connexin	O
genes	O
may	O
accumulate	O
and	O
,	O
consequently	O
lead	O
to	O
hearing	B-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
.	O

Therefore	O
,	O
we	O
screened	O
47	O
Hungarian	O
GJB2	B-GeneOrGeneProduct
-	O
heterozygous	O
(	O
one	O
mutation	O
in	O
coding	O
exon	O
of	O
the	O
GJB2	B-GeneOrGeneProduct
gene	O
)	O
patients	B-OrganismTaxon
with	O
hearing	B-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
for	O
DNA	O
changes	O
in	O
two	O
further	O
connexin	O
genes	O
(	O
GJB6	B-GeneOrGeneProduct
and	O
GJB3	B-GeneOrGeneProduct
)	O
and	O
in	O
the	O
5	O
'	O
non	O
-	O
coding	O
region	O
of	O
GJB2	B-GeneOrGeneProduct
including	O
the	O
splice	O
sites	O
.	O

Eleven	O
out	O
of	O
47	O
GJB2	B-GeneOrGeneProduct
-	O
heterozygous	O
patients	B-OrganismTaxon
analyzed	O
carried	O
the	O
splice	O
site	O
mutation	O
-	O
3170G	I-SequenceVariant
>	O
A	I-SequenceVariant
in	O
the	O
5	O
'	O
UTR	O
region	O
of	O
GJB2	B-GeneOrGeneProduct
.	O

One	O
out	O
of	O
these	O
11	O
patients	B-OrganismTaxon
showed	O
homozygous	O
-	O
3170G	I-SequenceVariant
>	O
A	I-SequenceVariant
genotype	O
in	O
combination	O
with	O
p	B-SequenceVariant
.	O
R127H	I-SequenceVariant
.	O

Next	O
to	O
the	O
GJB2	B-GeneOrGeneProduct
mutations	O
we	O
noted	O
2	O
cases	O
of	O
deletion	O
in	O
GJB6	B-GeneOrGeneProduct
[	O
Delta	O
(	O
GJB6	B-GeneOrGeneProduct
-	O
D13S1830	O
)	O
]	O
and	O
3	O
(	O
2	O
new	O
and	O
1	O
described	O
)	O
base	O
substitutions	O
in	O
GJB3	B-GeneOrGeneProduct
[	O
c	B-SequenceVariant
.	O
357C	I-SequenceVariant
>	O
T	I-SequenceVariant
,	O
c	B-SequenceVariant
.	O
798C	I-SequenceVariant
>	O
T	I-SequenceVariant
and	O
c	B-SequenceVariant
.	O
94C	I-SequenceVariant
>	O
T	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
R32W	I-SequenceVariant
)	O
]	O
which	O
are	O
unlikely	O
disease	O
-	O
causing	O
.	O

Our	O
results	O
suggest	O
the	O
importance	O
of	O
routine	O
screening	O
for	O
the	O
rather	O
frequent	O
-	O
3170G	I-SequenceVariant
>	O
A	I-SequenceVariant
mutation	O
(	O
in	O
addition	O
to	O
c	B-SequenceVariant
.	O
35delG	I-SequenceVariant
)	O
in	O
patients	B-OrganismTaxon
with	O
hearing	B-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
.	O
Tumor	B-DiseaseOrPhenotypicFeature
thymidylate	B-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
1494del6	B-SequenceVariant
genotype	O
as	O
a	O
prognostic	O
factor	O
in	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
receiving	O
fluorouracil	B-ChemicalEntity
-	O
based	O
adjuvant	O
treatment	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
value	O
of	O
germline	O
and	O
tumor	B-DiseaseOrPhenotypicFeature
thymidylate	B-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
(	O
TS	B-GeneOrGeneProduct
)	O
genotyping	O
as	O
a	O
prognostic	O
marker	O
in	O
a	O
series	O
of	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
receiving	O
adjuvant	O
fluorouracil	B-ChemicalEntity
(	O
FU	B-ChemicalEntity
)	O
-	O
based	O
treatment	O
.	O

PATIENTS	B-OrganismTaxon
AND	O
METHODS	O
:	O
One	O
hundred	O
twenty	O
-	O
nine	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
homogeneously	O
treated	O
with	O
FU	B-ChemicalEntity
plus	O
levamisole	B-ChemicalEntity
or	O
leucovorin	B-ChemicalEntity
in	O
the	O
adjuvant	O
setting	O
were	O
included	O
.	O

TS	B-GeneOrGeneProduct
enhancer	O
region	O
,	O
3R	O
G	B-SequenceVariant
>	O
C	I-SequenceVariant
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
,	O
and	O
TS	B-GeneOrGeneProduct
1494del6	B-SequenceVariant
polymorphisms	O
were	O
assessed	O
in	O
both	O
fresh	O
-	O
frozen	O
normal	O
mucosa	O
and	O
tumor	B-DiseaseOrPhenotypicFeature
.	O

Mutational	O
analyses	O
of	O
TS	B-GeneOrGeneProduct
and	O
allelic	O
imbalances	O
were	O
studied	O
in	O
all	O
primary	O
tumors	B-DiseaseOrPhenotypicFeature
and	O
in	O
18	O
additional	O
metachronic	O
metastases	B-DiseaseOrPhenotypicFeature
.	O

TS	B-GeneOrGeneProduct
protein	O
immunostaining	O
was	O
assessed	O
in	O
an	O
expanded	O
series	O
of	O
214	O
tumors	B-DiseaseOrPhenotypicFeature
.	O

Multivariate	O
Cox	O
models	O
were	O
adjusted	O
for	O
stage	O
,	O
differentiation	O
,	O
and	O
location	O
.	O

RESULTS	O
:	O
Tumor	B-DiseaseOrPhenotypicFeature
genotyping	O
(	O
frequency	O
of	O
allelic	O
loss	O
,	O
26%	O
)	O
showed	O
that	O
the	O
3R	O
/	O
3R	O
genotype	O
was	O
associated	O
with	O
a	O
better	O
outcome	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
=	O
0	O
.	O
38	O
;	O
95%	O
CI	O
,	O
0	O
.	O
16	O
to	O
0	O
.	O
93	O
;	O
P	O
=	O
.	O
020	O
for	O
the	O
recessive	O
model	O
)	O
.	O

3R	O
G	B-SequenceVariant
>	O
C	I-SequenceVariant
SNP	O
genotyping	O
did	O
not	O
add	O
prognostic	O
information	O
.	O

Tumor	B-DiseaseOrPhenotypicFeature
TS	B-GeneOrGeneProduct
1494del6	B-SequenceVariant
allele	O
(	O
frequency	O
of	O
allelic	O
loss	O
,	O
36%	O
)	O
was	O
protective	O
(	O
for	O
each	O
allele	O
with	O
the	O
deletion	O
,	O
based	O
on	O
an	O
additive	O
model	O
,	O
HR	O
=	O
0	O
.	O
42	O
;	O
95%	O
CI	O
,	O
0	O
.	O
22	O
to	O
0	O
.	O
82	O
;	O
P	O
=	O
.	O
0034	O
)	O
.	O

Both	O
polymorphisms	O
were	O
in	O
strong	O
linkage	O
disequilibrium	O
(	O
D	O
'	O
=	O
0	O
.	O
71	O
,	O
P	O
<	O
.	O
001	O
)	O
,	O
and	O
the	O
3R	O
/	O
-	O
6	O
base	O
pair	O
(	O
bp	O
)	O
haplotype	O
showed	O
a	O
significant	O
overall	O
survival	O
benefit	O
compared	O
with	O
the	O
most	O
prevalent	O
haplotype	O
2R	O
/	O
+	O
6bp	O
(	O
HR	O
=	O
0	O
.	O
42	O
;	O
95%	O
CI	O
,	O
0	O
.	O
20	O
to	O
0	O
.	O
85	O
;	O
P	O
=	O
.	O
017	O
)	O
.	O

No	O
TS	B-GeneOrGeneProduct
point	O
mutation	O
was	O
detected	O
in	O
primary	O
tumors	B-DiseaseOrPhenotypicFeature
or	O
metastases	B-DiseaseOrPhenotypicFeature
.	O

TS	B-GeneOrGeneProduct
protein	O
immunostaining	O
was	O
not	O
associated	O
with	O
survival	O
or	O
any	O
of	O
the	O
genotypes	O
analyzed	O
.	O

CONCLUSION	O
:	O
Tumor	B-DiseaseOrPhenotypicFeature
TS	B-GeneOrGeneProduct
1494del6	B-SequenceVariant
genotype	O
may	O
be	O
a	O
prognostic	O
factor	O
in	O
FU	B-ChemicalEntity
-	O
based	O
adjuvant	O
treatment	O
of	O
colorectal	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O
Permeability	O
,	O
ultrastructural	O
changes	O
,	O
and	O
distribution	O
of	O
novel	O
proteins	O
in	O
the	O
glomerular	O
barrier	O
in	O
early	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
nephrosis	B-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
/	O
AIMS	O
:	O
It	O
is	O
still	O
unclear	O
what	O
happens	O
in	O
the	O
glomerulus	O
when	O
proteinuria	B-DiseaseOrPhenotypicFeature
starts	O
.	O

Using	O
puromycin	B-ChemicalEntity
aminonucleoside	I-ChemicalEntity
nephrosis	B-DiseaseOrPhenotypicFeature
(	O
PAN	B-DiseaseOrPhenotypicFeature
)	O
rats	B-OrganismTaxon
,	O
we	O
studied	O
early	O
ultrastructural	O
and	O
permeability	O
changes	O
in	O
relation	O
to	O
the	O
expression	O
of	O
the	O
podocyte	O
-	O
associated	O
molecules	O
nephrin	B-GeneOrGeneProduct
,	O
a	B-GeneOrGeneProduct
-	O
actinin	I-GeneOrGeneProduct
,	O
dendrin	B-GeneOrGeneProduct
,	O
and	O
plekhh2	B-GeneOrGeneProduct
,	O
the	O
last	O
two	O
of	O
which	O
were	O
only	O
recently	O
discovered	O
in	O
podocytes	O
.	O

METHODS	O
:	O
Using	O
immune	O
stainings	O
,	O
semiquantitative	O
measurement	O
was	O
performed	O
under	O
the	O
electron	O
microscope	O
.	O

Permeability	O
was	O
assessed	O
using	O
isolated	O
kidney	O
perfusion	O
with	O
tracers	O
.	O

Possible	O
effects	O
of	O
ACE	B-GeneOrGeneProduct
inhibition	O
were	O
tested	O
.	O

RESULTS	O
:	O
By	O
day	O
2	O
,	O
some	O
patchy	O
foot	O
process	O
effacement	O
,	O
but	O
no	O
proteinuria	B-DiseaseOrPhenotypicFeature
,	O
appeared	O
.	O

The	O
amount	O
of	O
nephrin	B-GeneOrGeneProduct
was	O
reduced	O
in	O
both	O
diseased	O
and	O
normal	O
areas	O
.	O

The	O
other	O
proteins	O
showed	O
few	O
changes	O
,	O
which	O
were	O
limited	O
to	O
diseased	O
areas	O
.	O

By	O
day	O
4	O
,	O
foot	O
process	O
effacement	O
was	O
complete	O
and	O
proteinuria	B-DiseaseOrPhenotypicFeature
appeared	O
in	O
parallel	O
with	O
signs	O
of	O
size	O
barrier	O
damage	O
.	O

Nephrin	B-GeneOrGeneProduct
decreased	O
further	O
,	O
while	O
dendrin	B-GeneOrGeneProduct
and	O
plekhh2	B-GeneOrGeneProduct
also	O
decreased	O
but	O
a	B-GeneOrGeneProduct
-	O
actinin	I-GeneOrGeneProduct
remained	O
unchanged	O
.	O

ACE	B-GeneOrGeneProduct
inhibition	O
had	O
no	O
significant	O
protective	O
effect	O
.	O

CONCLUSIONS	O
:	O
PAN	B-DiseaseOrPhenotypicFeature
glomeruli	O
already	O
showed	O
significant	O
pathology	O
by	O
day	O
4	O
,	O
despite	O
relatively	O
mild	O
proteinuria	B-DiseaseOrPhenotypicFeature
.	O

This	O
was	O
preceded	O
by	O
altered	O
nephrin	B-GeneOrGeneProduct
expression	O
,	O
supporting	O
its	O
pivotal	O
role	O
in	O
podocyte	O
morphology	O
.	O

The	O
novel	O
proteins	O
dendrin	B-GeneOrGeneProduct
and	O
plekhh2	B-GeneOrGeneProduct
were	O
both	O
reduced	O
,	O
suggesting	O
roles	O
in	O
PAN	B-DiseaseOrPhenotypicFeature
,	O
whereas	O
a	B-GeneOrGeneProduct
-	O
actinin	I-GeneOrGeneProduct
was	O
unchanged	O
.	O
Intronic	O
deletions	O
in	O
the	O
SLC34A3	B-GeneOrGeneProduct
gene	O
cause	O
hereditary	B-DiseaseOrPhenotypicFeature
hypophosphatemic	I-DiseaseOrPhenotypicFeature
rickets	I-DiseaseOrPhenotypicFeature
with	I-DiseaseOrPhenotypicFeature
hypercalciuria	I-DiseaseOrPhenotypicFeature
.	O

CONTEXT	O
:	O
Hereditary	B-DiseaseOrPhenotypicFeature
hypophosphatemic	I-DiseaseOrPhenotypicFeature
rickets	I-DiseaseOrPhenotypicFeature
with	I-DiseaseOrPhenotypicFeature
hypercalciuria	I-DiseaseOrPhenotypicFeature
(	O
HHRH	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
rare	O
metabolic	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
,	O
characterized	O
by	O
hypophosphatemia	B-DiseaseOrPhenotypicFeature
and	O
rickets	B-DiseaseOrPhenotypicFeature
/	O
osteomalacia	B-DiseaseOrPhenotypicFeature
with	O
increased	O
serum	O
1	B-ChemicalEntity
,	O
25	I-ChemicalEntity
-	O
dihydroxyvitamin	I-ChemicalEntity
D	I-ChemicalEntity
[	O
1	B-ChemicalEntity
,	O
25	I-ChemicalEntity
-	O
(	O
OH	I-ChemicalEntity
)	O
(	O
2	I-ChemicalEntity
)	O
D	I-ChemicalEntity
]	O
resulting	O
in	O
hypercalciuria	B-DiseaseOrPhenotypicFeature
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
determine	O
whether	O
mutations	O
in	O
the	O
SLC34A3	B-GeneOrGeneProduct
gene	O
,	O
which	O
encodes	O
sodium	B-GeneOrGeneProduct
-	O
phosphate	I-GeneOrGeneProduct
cotransporter	I-GeneOrGeneProduct
type	I-GeneOrGeneProduct
IIc	I-GeneOrGeneProduct
,	O
are	O
responsible	O
for	O
the	O
occurrence	O
of	O
HHRH	B-DiseaseOrPhenotypicFeature
.	O

DESIGN	O
AND	O
SETTING	O
:	O
Mutation	O
analysis	O
of	O
exons	O
and	O
adjacent	O
introns	O
in	O
the	O
SLC34A3	B-GeneOrGeneProduct
gene	O
was	O
conducted	O
at	O
an	O
academic	O
research	O
laboratory	O
and	O
medical	O
center	O
.	O

PATIENTS	B-OrganismTaxon
OR	O
OTHER	O
PARTICIPANTS	O
:	O
Members	O
of	O
two	O
unrelated	O
families	O
with	O
HHRH	B-DiseaseOrPhenotypicFeature
participated	O
in	O
the	O
study	O
.	O

RESULTS	O
:	O
Two	O
affected	O
siblings	O
in	O
one	O
family	O
were	O
homozygous	O
for	O
a	O
101	B-SequenceVariant
-	O
bp	I-SequenceVariant
deletion	I-SequenceVariant
in	O
intron	O
9	O
.	O

Haplotype	O
analysis	O
of	O
the	O
SLC34A3	B-GeneOrGeneProduct
locus	O
in	O
the	O
family	O
showed	O
that	O
the	O
two	O
deletions	O
are	O
on	O
different	O
haplotypes	O
.	O

An	O
unrelated	O
individual	O
with	O
HHRH	B-DiseaseOrPhenotypicFeature
was	O
a	O
compound	O
heterozygote	O
for	O
an	O
85	B-SequenceVariant
-	O
bp	I-SequenceVariant
deletion	I-SequenceVariant
in	O
intron	O
10	O
and	O
a	O
G	B-SequenceVariant
-	O
to	I-SequenceVariant
-	O
A	I-SequenceVariant
substitution	O
at	O
the	O
last	O
nucleotide	O
in	O
exon	O
7	O
.	O

The	O
intron	O
9	O
deletion	O
(	O
and	O
likely	O
the	O
other	O
two	O
mutations	O
)	O
identified	O
in	O
this	O
study	O
causes	O
aberrant	O
RNA	O
splicing	O
.	O

Sequence	O
analysis	O
of	O
the	O
deleted	O
regions	O
revealed	O
the	O
presence	O
of	O
direct	O
repeats	O
of	O
homologous	O
sequences	O
.	O

CONCLUSION	O
:	O
HHRH	B-DiseaseOrPhenotypicFeature
is	O
caused	O
by	O
biallelic	O
mutations	O
in	O
the	O
SLC34A3	B-GeneOrGeneProduct
gene	O
.	O

Haplotype	O
analysis	O
suggests	O
that	O
the	O
two	O
intron	O
9	O
deletions	O
arose	O
independently	O
.	O

The	O
identification	O
of	O
three	O
independent	O
deletions	O
in	O
introns	O
9	O
and	O
10	O
suggests	O
that	O
the	O
SLC34A3	B-GeneOrGeneProduct
gene	O
may	O
be	O
susceptible	O
to	O
unequal	O
crossing	O
over	O
because	O
of	O
sequence	O
misalignment	O
during	O
meiosis	O
.	O
The	O
association	O
between	O
tranexamic	B-ChemicalEntity
acid	I-ChemicalEntity
and	O
convulsive	B-DiseaseOrPhenotypicFeature
seizures	I-DiseaseOrPhenotypicFeature
after	O
cardiac	O
surgery	O
:	O
a	O
multivariate	O
analysis	O
in	O
11	O
529	O
patients	B-OrganismTaxon
.	O

Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	B-DiseaseOrPhenotypicFeature
after	O
cardiac	O
surgery	O
,	O
we	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
11	O
529	O
patients	B-OrganismTaxon
in	O
whom	O
cardiopulmonary	O
bypass	O
was	O
used	O
from	O
January	O
2004	O
to	O
December	O
2010	O
.	O

A	O
convulsive	B-DiseaseOrPhenotypicFeature
seizure	I-DiseaseOrPhenotypicFeature
was	O
defined	O
as	O
a	O
transient	O
episode	O
of	O
disturbed	O
brain	O
function	O
characterised	O
by	O
abnormal	B-DiseaseOrPhenotypicFeature
involuntary	I-DiseaseOrPhenotypicFeature
motor	I-DiseaseOrPhenotypicFeature
movements	I-DiseaseOrPhenotypicFeature
.	O

Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	B-DiseaseOrPhenotypicFeature
.	O

A	O
total	O
of	O
100	O
(	O
0	O
.	O
9%	O
)	O
patients	B-OrganismTaxon
developed	O
postoperative	O
convulsive	B-DiseaseOrPhenotypicFeature
seizures	I-DiseaseOrPhenotypicFeature
.	O

Generalised	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
focal	I-DiseaseOrPhenotypicFeature
seizures	I-DiseaseOrPhenotypicFeature
were	O
identified	O
in	O
68	O
and	O
32	O
patients	B-OrganismTaxon
,	O
respectively	O
.	O

The	O
median	O
(	O
IQR	O
[	O
range	O
]	O
)	O
time	O
after	O
surgery	O
when	O
the	O
seizure	B-DiseaseOrPhenotypicFeature
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O

Epileptiform	O
findings	O
on	O
electroencephalography	O
were	O
seen	O
in	O
19	O
patients	B-OrganismTaxon
.	O

Independent	O
predictors	O
of	O
postoperative	O
seizures	B-DiseaseOrPhenotypicFeature
included	O
age	O
,	O
female	O
sex	O
,	O
redo	O
cardiac	O
surgery	O
,	O
calcification	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
ascending	I-DiseaseOrPhenotypicFeature
aorta	I-DiseaseOrPhenotypicFeature
,	O
congestive	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
failure	I-DiseaseOrPhenotypicFeature
,	O
deep	O
hypothermic	B-DiseaseOrPhenotypicFeature
circulatory	O
arrest	O
,	O
duration	O
of	O
aortic	O
cross	O
-	O
clamp	O
and	O
tranexamic	B-ChemicalEntity
acid	I-ChemicalEntity
.	O

When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis	O
,	O
tranexamic	B-ChemicalEntity
acid	I-ChemicalEntity
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	B-DiseaseOrPhenotypicFeature
(	O
OR	O
14	O
.	O
3	O
,	O
95%	O
CI	O
5	O
.	O
5	O
-	O
36	O
.	O
7	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Patients	B-OrganismTaxon
with	O
convulsive	B-DiseaseOrPhenotypicFeature
seizures	I-DiseaseOrPhenotypicFeature
had	O
2	O
.	O
5	O
times	O
higher	O
in	O
-	O
hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	B-OrganismTaxon
without	O
convulsive	B-DiseaseOrPhenotypicFeature
seizures	I-DiseaseOrPhenotypicFeature
.	O

Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
patients	B-OrganismTaxon
with	O
convulsive	B-DiseaseOrPhenotypicFeature
seizures	I-DiseaseOrPhenotypicFeature
compared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
patients	B-OrganismTaxon
without	O
seizures	B-DiseaseOrPhenotypicFeature
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Convulsive	B-DiseaseOrPhenotypicFeature
seizures	I-DiseaseOrPhenotypicFeature
are	O
a	O
serious	O
postoperative	B-DiseaseOrPhenotypicFeature
complication	I-DiseaseOrPhenotypicFeature
after	O
cardiac	O
surgery	O
.	O

As	O
tranexamic	B-ChemicalEntity
acid	I-ChemicalEntity
is	O
the	O
only	O
modifiable	O
factor	O
,	O
its	O
administration	O
,	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg	O
.	O
kg	O
(	O
-	O
1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	B-DiseaseOrPhenotypicFeature
.	O
A	O
TSPO	B-GeneOrGeneProduct
ligand	O
attenuates	O
brain	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
after	O
intracerebral	B-DiseaseOrPhenotypicFeature
hemorrhage	I-DiseaseOrPhenotypicFeature
.	O

Intracerebral	B-DiseaseOrPhenotypicFeature
hemorrhage	I-DiseaseOrPhenotypicFeature
(	O
ICH	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
devastating	O
disease	O
without	O
effective	O
treatment	O
.	O

After	O
ICH	B-DiseaseOrPhenotypicFeature
,	O
the	O
immediate	O
infiltration	O
of	O
leukocytes	O
and	O
activation	O
of	O
microglia	O
are	O
accompanied	O
by	O
a	O
rapid	O
up	O
-	O
regulation	O
of	O
the	O
18	O
-	O
kDa	O
translocator	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
TSPO	B-GeneOrGeneProduct
)	O
.	O

TSPO	B-GeneOrGeneProduct
ligands	O
have	O
shown	O
anti	O
-	O
inflammatory	B-DiseaseOrPhenotypicFeature
and	O
neuroprotective	O
properties	O
in	O
models	O
of	O
CNS	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
impact	O
of	O
a	O
TSPO	B-GeneOrGeneProduct
ligand	O
,	O
etifoxine	B-ChemicalEntity
,	O
on	O
brain	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	O
inflammation	B-DiseaseOrPhenotypicFeature
in	O
2	O
mouse	B-OrganismTaxon
models	O
of	O
ICH	B-DiseaseOrPhenotypicFeature
.	O

TSPO	B-GeneOrGeneProduct
was	O
up	O
-	O
regulated	O
in	O
Iba1	B-GeneOrGeneProduct
(	O
+	O
)	O
cells	O
from	O
brains	O
of	O
patients	B-OrganismTaxon
with	O
ICH	B-DiseaseOrPhenotypicFeature
and	O
in	O
CD11b	B-GeneOrGeneProduct
(	O
+	O
)	O
CD45	B-GeneOrGeneProduct
(	O
int	O
)	O
cells	O
from	O
mice	B-OrganismTaxon
subjected	O
to	O
collagenase	B-ChemicalEntity
-	O
induced	O
ICH	B-DiseaseOrPhenotypicFeature
.	O

Etifoxine	B-ChemicalEntity
significantly	O
reduced	O
neurodeficits	B-DiseaseOrPhenotypicFeature
and	O
perihematomal	O
brain	B-DiseaseOrPhenotypicFeature
edema	I-DiseaseOrPhenotypicFeature
after	O
ICH	B-DiseaseOrPhenotypicFeature
induction	O
by	O
injection	O
of	O
either	O
autologous	O
blood	O
or	O
collagenase	B-ChemicalEntity
.	O

In	O
collagenase	B-ChemicalEntity
-	O
induced	O
ICH	B-DiseaseOrPhenotypicFeature
mice	B-OrganismTaxon
,	O
the	O
protection	O
of	O
etifoxine	B-ChemicalEntity
was	O
associated	O
with	O
reduced	O
leukocyte	O
infiltration	O
into	O
the	O
brain	O
and	O
microglial	O
production	O
of	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
and	O
TNF	B-GeneOrGeneProduct
-	O
a	I-GeneOrGeneProduct
.	O

Etifoxine	B-ChemicalEntity
improved	O
blood	O
-	O
brain	O
barrier	O
integrity	O
and	O
diminished	O
cell	O
death	O
.	O

Notably	O
,	O
the	O
protective	O
effect	O
of	O
etifoxine	B-ChemicalEntity
was	O
abolished	O
in	O
mice	B-OrganismTaxon
depleted	O
of	O
microglia	O
by	O
using	O
a	O
colony	B-GeneOrGeneProduct
-	O
stimulating	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
inhibitor	O
.	O

These	O
results	O
indicate	O
that	O
the	O
TSPO	B-GeneOrGeneProduct
ligand	O
etifoxine	B-ChemicalEntity
attenuates	O
brain	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	O
inflammation	B-DiseaseOrPhenotypicFeature
after	O
ICH	B-DiseaseOrPhenotypicFeature
.	O

TSPO	B-GeneOrGeneProduct
may	O
be	O
a	O
viable	O
therapeutic	O
target	O
that	O
requires	O
further	O
investigations	O
in	O
ICH	B-DiseaseOrPhenotypicFeature
.	O
-	O
Li	O
,	O
M	O
.	O
,	O
Ren	O
,	O
H	O
.	O
,	O
Sheth	O
,	O
K	O
.	O

N	O
.	O
,	O
Shi	O
,	O
F	O
.	O
-	O
D	O
.	O
,	O
Liu	O
,	O
Q	O
.	O

A	O
TSPO	B-GeneOrGeneProduct
ligand	O
attenuates	O
brain	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
after	O
intracerebral	B-DiseaseOrPhenotypicFeature
hemorrhage	I-DiseaseOrPhenotypicFeature
.	O
Mechanisms	O
of	O
hypertension	B-DiseaseOrPhenotypicFeature
induced	O
by	O
nitric	B-ChemicalEntity
oxide	I-ChemicalEntity
(	O
NO	B-ChemicalEntity
)	O
deficiency	O
:	O
focus	O
on	O
venous	O
function	O
.	O

Loss	O
of	O
endothelial	O
cell	O
-	O
derived	O
nitric	B-ChemicalEntity
oxide	I-ChemicalEntity
(	O
NO	B-ChemicalEntity
)	O
in	O
hypertension	B-DiseaseOrPhenotypicFeature
is	O
a	O
hallmark	O
of	O
arterial	B-DiseaseOrPhenotypicFeature
dysfunction	I-DiseaseOrPhenotypicFeature
.	O

Experimental	O
hypertension	B-DiseaseOrPhenotypicFeature
created	O
by	O
the	O
removal	O
of	O
NO	B-ChemicalEntity
,	O
however	O
,	O
involves	O
mechanisms	O
in	O
addition	O
to	O
decreased	O
arterial	O
vasodilator	O
activity	O
.	O

These	O
include	O
augmented	O
endothelin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
release	O
,	O
increased	O
sympathetic	O
nervous	O
system	O
activity	O
,	O
and	O
elevated	O
tissue	O
oxidative	O
stress	O
.	O

We	O
hypothesized	O
that	O
increased	O
venous	O
smooth	O
muscle	O
(	O
venomotor	O
)	O
tone	O
plays	O
a	O
role	O
in	O
Nomega	B-ChemicalEntity
-	O
nitro	I-ChemicalEntity
-	O
L	I-ChemicalEntity
-	O
arginine	I-ChemicalEntity
(	O
LNNA	B-ChemicalEntity
)	O
hypertension	B-DiseaseOrPhenotypicFeature
through	O
these	O
mechanisms	O
.	O

Rats	B-OrganismTaxon
were	O
treated	O
with	O
the	O
NO	B-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
inhibitor	O
LNNA	B-ChemicalEntity
(	O
0	O
.	O
5	O
g	O
/	O
L	O
in	O
drinking	O
water	O
)	O
for	O
2	O
weeks	O
.	O

Mean	O
arterial	O
pressure	O
of	O
conscious	O
rats	B-OrganismTaxon
was	O
119	O
+	O
/	O
-	O
2	O
mm	O
Hg	O
in	O
control	O
and	O
194	O
+	O
/	O
-	O
5	O
mm	O
Hg	O
in	O
LNNA	B-ChemicalEntity
rats	B-OrganismTaxon
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Carotid	O
arteries	O
and	O
vena	O
cava	O
were	O
removed	O
for	O
measurement	O
of	O
isometric	O
contraction	O
.	O

Maximal	O
contraction	O
to	O
norepinephrine	B-ChemicalEntity
was	O
modestly	O
reduced	O
in	O
arteries	O
from	O
LNNA	B-ChemicalEntity
compared	O
with	O
control	O
rats	B-OrganismTaxon
whereas	O
the	O
maximum	O
contraction	O
to	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
was	O
significantly	O
reduced	O
(	O
54%	O
control	O
)	O
.	O

Maximum	O
contraction	O
of	O
vena	O
cava	O
to	O
norepinephrine	B-ChemicalEntity
(	O
37%	O
control	O
)	O
also	O
was	O
reduced	O
but	O
no	O
change	O
in	O
response	O
to	O
ET	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
was	O
observed	O
.	O

Mean	O
circulatory	O
filling	O
pressure	O
,	O
an	O
in	O
vivo	O
measure	O
of	O
venomotor	O
tone	O
,	O
was	O
not	O
elevated	O
in	O
LNNA	B-ChemicalEntity
hypertension	B-DiseaseOrPhenotypicFeature
at	O
1	O
or	O
2	O
weeks	O
after	O
LNNA	B-ChemicalEntity
.	O

The	O
superoxide	B-ChemicalEntity
scavenger	O
tempol	B-ChemicalEntity
(	O
30	O
,	O
100	O
,	O
and	O
300	O
micromol	O
kg	O
(	O
-	O
1	O
)	O
,	O
IV	O
)	O
did	O
not	O
change	O
arterial	O
pressure	O
in	O
control	O
rats	B-OrganismTaxon
but	O
caused	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
LNNA	B-ChemicalEntity
rats	B-OrganismTaxon
(	O
-	O
18	O
+	O
/	O
-	O
8	O
,	O
-	O
26	O
+	O
/	O
-	O
15	O
,	O
and	O
-	O
54	O
+	O
/	O
-	O
11	O
mm	O
Hg	O
)	O
.	O

Similarly	O
,	O
ganglionic	O
blockade	O
with	O
hexamethonium	B-ChemicalEntity
caused	O
a	O
significantly	O
greater	O
fall	O
in	O
LNNA	B-ChemicalEntity
hypertensive	B-DiseaseOrPhenotypicFeature
rats	B-OrganismTaxon
(	O
76	O
+	O
/	O
-	O
9	O
mm	O
Hg	O
)	O
compared	O
with	O
control	O
rats	B-OrganismTaxon
(	O
35	O
+	O
/	O
-	O
10	O
mm	O
Hg	O
)	O
.	O

Carotid	O
arteries	O
,	O
vena	O
cava	O
,	O
and	O
sympathetic	O
ganglia	O
from	O
LNNA	B-ChemicalEntity
rats	B-OrganismTaxon
had	O
higher	O
basal	O
levels	O
of	O
superoxide	B-ChemicalEntity
compared	O
with	O
those	O
from	O
control	O
rats	B-OrganismTaxon
.	O

These	O
data	O
suggest	O
that	O
while	O
NO	B-ChemicalEntity
deficiency	O
increases	O
oxidative	O
stress	O
and	O
sympathetic	O
activity	O
in	O
both	O
arterial	O
and	O
venous	O
vessels	O
,	O
the	O
impact	O
on	O
veins	O
does	O
not	O
make	O
a	O
major	O
contribution	O
to	O
this	O
form	O
of	O
hypertension	B-DiseaseOrPhenotypicFeature
.	O
Necrotising	B-DiseaseOrPhenotypicFeature
fasciitis	I-DiseaseOrPhenotypicFeature
after	O
bortezomib	B-ChemicalEntity
and	O
dexamethasone	B-ChemicalEntity
-	O
containing	O
regimen	O
in	O
an	O
elderly	O
patient	B-OrganismTaxon
of	O
Waldenstrom	B-DiseaseOrPhenotypicFeature
macroglobulinaemia	I-DiseaseOrPhenotypicFeature
.	O

Bortezomib	B-ChemicalEntity
and	O
high	O
-	O
dose	O
dexamethasone	B-ChemicalEntity
-	O
containing	O
regimens	O
are	O
considered	O
to	O
be	O
generally	O
tolerable	O
with	O
few	O
severe	O
bacterial	B-DiseaseOrPhenotypicFeature
infections	I-DiseaseOrPhenotypicFeature
in	O
patients	B-OrganismTaxon
with	O
B	O
-	O
cell	O
malignancies	B-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
information	O
is	O
limited	O
concerning	O
the	O
safety	O
of	O
the	O
regimen	O
in	O
elderly	O
patients	B-OrganismTaxon
.	O

We	O
report	O
a	O
case	O
of	O
a	O
76	O
-	O
year	O
-	O
old	O
man	B-OrganismTaxon
with	O
Waldenstrom	B-DiseaseOrPhenotypicFeature
macroglobulinaemia	I-DiseaseOrPhenotypicFeature
who	O
suffered	O
necrotising	B-DiseaseOrPhenotypicFeature
fasciitis	I-DiseaseOrPhenotypicFeature
without	O
neutropenia	B-DiseaseOrPhenotypicFeature
after	O
the	O
combination	O
treatment	O
with	O
bortezomib	B-ChemicalEntity
,	O
high	O
-	O
dose	O
dexamethasone	B-ChemicalEntity
and	O
rituximab	B-ChemicalEntity
.	O

Despite	O
immediate	O
intravenous	O
antimicrobial	O
therapy	O
,	O
he	O
succumbed	O
23	O
h	O
after	O
the	O
onset	O
.	O

Physicians	O
should	O
recognise	O
the	O
possibility	O
of	O
fatal	O
bacterial	B-DiseaseOrPhenotypicFeature
infections	I-DiseaseOrPhenotypicFeature
related	O
to	O
bortezomib	B-ChemicalEntity
plus	O
high	O
-	O
dose	O
dexamethasone	B-ChemicalEntity
in	O
elderly	O
patients	B-OrganismTaxon
,	O
and	O
we	O
believe	O
this	O
case	O
warrants	O
further	O
investigation	O
.	O
The	O
glycine	B-GeneOrGeneProduct
transporter	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
inhibitor	O
SSR103800	B-ChemicalEntity
displays	O
a	O
selective	O
and	O
specific	O
antipsychotic	O
-	O
like	O
profile	O
in	O
normal	O
and	O
transgenic	O
mice	B-OrganismTaxon
.	O

Schizophrenia	B-DiseaseOrPhenotypicFeature
has	O
been	O
initially	O
associated	O
with	O
dysfunction	O
in	O
dopamine	B-ChemicalEntity
neurotransmission	O
.	O

However	O
,	O
the	O
observation	O
that	O
antagonists	O
of	O
the	O
glutamate	B-GeneOrGeneProduct
N	I-GeneOrGeneProduct
-	O
methyl	I-GeneOrGeneProduct
-	O
D	I-GeneOrGeneProduct
-	O
aspartate	I-GeneOrGeneProduct
(	O
NMDA	I-GeneOrGeneProduct
)	O
receptor	I-GeneOrGeneProduct
produce	O
schizophrenic	B-DiseaseOrPhenotypicFeature
-	O
like	O
symptoms	O
in	O
humans	B-OrganismTaxon
has	O
led	O
to	O
the	O
idea	O
of	O
a	O
dysfunctioning	O
of	O
the	O
glutamatergic	O
system	O
via	O
its	O
NMDA	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
.	O

As	O
a	O
result	O
,	O
there	O
is	O
a	O
growing	O
interest	O
in	O
the	O
development	O
of	O
pharmacological	O
agents	O
with	O
potential	O
antipsychotic	O
properties	O
that	O
enhance	O
the	O
activity	O
of	O
the	O
glutamatergic	O
system	O
via	O
a	O
modulation	O
of	O
the	O
NMDA	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
.	O

Among	O
them	O
are	O
glycine	B-GeneOrGeneProduct
transporter	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
GlyT1	B-GeneOrGeneProduct
)	O
inhibitors	O
such	O
as	O
SSR103800	B-ChemicalEntity
,	O
which	O
indirectly	O
enhance	O
NMDA	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
function	O
by	O
increasing	O
the	O
glycine	B-ChemicalEntity
(	O
a	O
co	O
-	O
agonist	O
for	O
the	O
NMDA	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
)	O
levels	O
in	O
the	O
synapse	O
.	O

This	O
study	O
aimed	O
at	O
investigating	O
the	O
potential	O
antipsychotic	O
-	O
like	O
properties	O
of	O
SSR103800	B-ChemicalEntity
,	O
with	O
a	O
particular	O
focus	O
on	O
models	O
of	O
hyperactivity	B-DiseaseOrPhenotypicFeature
,	O
involving	O
either	O
drug	O
challenge	O
(	O
ie	O
,	O
amphetamine	B-ChemicalEntity
and	O
MK	B-ChemicalEntity
-	O
801	I-ChemicalEntity
)	O
or	O
transgenic	O
mice	B-OrganismTaxon
(	O
ie	O
,	O
NMDA	B-GeneOrGeneProduct
Nr1	I-GeneOrGeneProduct
(	O
neo	O
-	O
/	O
-	O
)	O
and	O
DAT	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
)	O
.	O

Results	O
showed	O
that	O
SSR103800	B-ChemicalEntity
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
blocked	O
hyperactivity	B-DiseaseOrPhenotypicFeature
induced	O
by	O
the	O
non	O
-	O
competitive	O
NMDA	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
antagonist	O
,	O
MK	B-ChemicalEntity
-	O
801	I-ChemicalEntity
and	O
partially	O
reversed	O
spontaneous	O
hyperactivity	B-DiseaseOrPhenotypicFeature
of	O
NMDA	B-GeneOrGeneProduct
Nr1	I-GeneOrGeneProduct
(	O
neo	O
-	O
/	O
-	O
)	O
mice	B-OrganismTaxon
.	O

In	O
contrast	O
,	O
SSR103800	B-ChemicalEntity
failed	O
to	O
affect	O
hyperactivity	B-DiseaseOrPhenotypicFeature
induced	O
by	O
amphetamine	B-ChemicalEntity
or	O
naturally	O
observed	O
in	O
dopamine	B-GeneOrGeneProduct
transporter	I-GeneOrGeneProduct
(	O
DAT	B-GeneOrGeneProduct
(	O
-	O
/	O
-	O
)	O
)	O
knockout	O
mice	B-OrganismTaxon
(	O
10	O
-	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O
)	O
.	O

Importantly	O
,	O
both	O
classical	O
(	O
haloperidol	B-ChemicalEntity
)	O
and	O
atypical	O
(	O
olanzapine	B-ChemicalEntity
,	O
clozapine	B-ChemicalEntity
and	O
aripiprazole	B-ChemicalEntity
)	O
antipsychotics	O
were	O
effective	O
in	O
all	O
these	O
models	O
of	O
hyperactivity	B-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
unlike	O
these	O
latter	O
,	O
SSR103800	B-ChemicalEntity
did	O
not	O
produce	O
catalepsy	B-DiseaseOrPhenotypicFeature
(	O
retention	O
on	O
the	O
bar	O
test	O
)	O
up	O
to	O
30	O
mg	O
/	O
kg	O
p	O
.	O
o	O
.	O

Together	O
these	O
findings	O
show	O
that	O
the	O
GlyT1	B-GeneOrGeneProduct
inhibitor	O
,	O
SSR103800	B-ChemicalEntity
,	O
produces	O
antipsychotic	O
-	O
like	O
effects	O
,	O
which	O
differ	O
from	O
those	O
observed	O
with	O
compounds	O
primarily	O
targeting	O
the	O
dopaminergic	B-ChemicalEntity
system	O
,	O
and	O
has	O
a	O
reduced	O
side	O
-	O
effect	O
potential	O
as	O
compared	O
with	O
these	O
latter	O
drugs	O
.	O
Atrial	B-DiseaseOrPhenotypicFeature
fibrillation	I-DiseaseOrPhenotypicFeature
following	O
chemotherapy	O
for	O
stage	O
IIIE	O
diffuse	O
large	O
B	O
-	O
cell	O
gastric	B-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
in	O
a	O
patient	B-OrganismTaxon
with	O
myotonic	B-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
(	O
Steinert	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
)	O
.	O

The	O
authors	O
describe	O
the	O
unusual	O
association	O
between	O
diffuse	O
B	O
-	O
cell	O
gastric	B-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
and	O
myotonic	B-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
,	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
,	O
and	O
sudden	O
atrial	B-DiseaseOrPhenotypicFeature
fibrillation	I-DiseaseOrPhenotypicFeature
following	O
one	O
cycle	O
of	O
doxorubicin	B-ChemicalEntity
-	O
based	O
chemotherapy	O
in	O
the	O
same	O
patient	B-OrganismTaxon
.	O

Atrial	B-DiseaseOrPhenotypicFeature
fibrillation	I-DiseaseOrPhenotypicFeature
or	O
other	O
cardiac	B-DiseaseOrPhenotypicFeature
arrhythmias	I-DiseaseOrPhenotypicFeature
are	O
unusual	O
complications	O
in	O
patients	B-OrganismTaxon
treated	O
with	O
chemotherapy	O
.	O

The	O
cardiac	B-DiseaseOrPhenotypicFeature
toxicity	I-DiseaseOrPhenotypicFeature
intrinsically	O
associated	O
with	O
the	O
aggressive	O
chemotherapy	O
employed	O
could	O
function	O
as	O
a	O
triggering	O
factor	O
for	O
the	O
arrhythmia	B-DiseaseOrPhenotypicFeature
in	O
the	O
predisposed	O
myocardium	O
of	O
this	O
patient	B-OrganismTaxon
.	O
NOTCH1	B-GeneOrGeneProduct
and	O
SOX10	B-GeneOrGeneProduct
are	O
Essential	O
for	O
Proliferation	O
and	O
Radiation	O
Resistance	O
of	O
Cancer	B-DiseaseOrPhenotypicFeature
Stem	O
-	O
Like	O
Cells	O
in	O
Adenoid	B-DiseaseOrPhenotypicFeature
Cystic	I-DiseaseOrPhenotypicFeature
Carcinoma	I-DiseaseOrPhenotypicFeature
.	O

PURPOSE	O
:	O
Although	O
the	O
existence	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
stem	O
cells	O
(	O
CSC	O
)	O
in	O
adenoid	B-DiseaseOrPhenotypicFeature
cystic	I-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
(	O
ACC	B-DiseaseOrPhenotypicFeature
)	O
has	O
been	O
proposed	O
,	O
lack	O
of	O
assays	O
for	O
their	O
propagation	O
and	O
uncertainty	O
about	O
molecular	O
markers	O
prevented	O
their	O
characterization	O
.	O

Our	O
objective	O
was	O
to	O
isolate	O
CSC	O
from	O
ACC	B-DiseaseOrPhenotypicFeature
and	O
provide	O
insight	O
into	O
signaling	O
pathways	O
that	O
support	O
their	O
propagation	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
To	O
isolate	O
CSC	O
from	O
ACC	B-DiseaseOrPhenotypicFeature
and	O
characterize	O
them	O
,	O
we	O
used	O
ROCK	B-GeneOrGeneProduct
inhibitor	O
-	O
supplemented	O
cell	O
culture	O
,	O
immunomagnetic	O
cell	O
sorting	O
,	O
andin	O
vitro	O
/	O
in	O
vivoassays	O
for	O
CSC	O
viability	O
and	O
tumorigenicity	O
.	O

RESULTS	O
:	O
We	O
identified	O
in	O
ACC	B-DiseaseOrPhenotypicFeature
CD133	B-GeneOrGeneProduct
-	O
positive	O
CSC	O
that	O
expressed	O
NOTCH1	B-GeneOrGeneProduct
and	O
SOX10	B-GeneOrGeneProduct
,	O
formed	O
spheroids	O
,	O
and	O
initiated	O
tumors	B-DiseaseOrPhenotypicFeature
in	O
nude	O
mice	B-OrganismTaxon
.	O

CD133	B-GeneOrGeneProduct
(	O
+	O
)	O
ACC	B-DiseaseOrPhenotypicFeature
cells	O
produced	O
activated	O
NOTCH1	B-GeneOrGeneProduct
(	O
N1ICD	B-GeneOrGeneProduct
)	O
and	O
generated	O
CD133	B-GeneOrGeneProduct
(	O
-	O
)	O
cells	O
that	O
expressed	O
JAG1	B-GeneOrGeneProduct
as	O
well	O
as	O
neural	O
differentiation	O
factors	O
NR2F1	B-GeneOrGeneProduct
,	O
NR2F2	B-GeneOrGeneProduct
,	O
and	O
p27Kip1	B-GeneOrGeneProduct
.	O

Knockdowns	O
of	O
NOTCH1	B-GeneOrGeneProduct
,	O
SOX10	B-GeneOrGeneProduct
,	O
and	O
their	O
common	O
effector	O
FABP7	B-GeneOrGeneProduct
had	O
negative	O
effects	O
on	O
each	O
other	O
,	O
inhibited	O
spheroidogenesis	O
,	O
and	O
induced	O
cell	O
death	O
pointing	O
at	O
their	O
essential	O
roles	O
in	O
CSC	O
maintenance	O
.	O

Downstream	O
effects	O
of	O
FABP7	B-GeneOrGeneProduct
knockdown	O
included	O
suppression	O
of	O
a	O
broad	O
spectrum	O
of	O
genes	O
involved	O
in	O
proliferation	O
,	O
ribosome	O
biogenesis	O
,	O
and	O
metabolism	O
.	O

Among	O
proliferation	O
-	O
linked	O
NOTCH1	B-GeneOrGeneProduct
/	O
FABP7	B-GeneOrGeneProduct
targets	O
,	O
we	O
identified	O
SKP2	B-GeneOrGeneProduct
and	O
its	O
substrate	O
p27Kip1	B-GeneOrGeneProduct
.	O

A	O
g	B-GeneOrGeneProduct
-	O
secretase	I-GeneOrGeneProduct
inhibitor	O
,	O
DAPT	B-ChemicalEntity
,	O
selectively	O
depleted	O
CD133	B-GeneOrGeneProduct
(	O
+	O
)	O
cells	O
,	O
suppressed	O
N1ICD	B-GeneOrGeneProduct
and	O
SKP2	B-GeneOrGeneProduct
,	O
induced	O
p27Kip1	B-GeneOrGeneProduct
,	O
inhibited	O
ACC	B-DiseaseOrPhenotypicFeature
growthin	O
vivo	O
,	O
and	O
sensitized	O
CD133	B-GeneOrGeneProduct
(	O
+	O
)	O
cells	O
to	O
radiation	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
establish	O
in	O
the	O
majority	O
of	O
ACC	B-DiseaseOrPhenotypicFeature
the	O
presence	O
of	O
a	O
previously	O
uncharacterized	O
population	O
of	O
CD133	B-GeneOrGeneProduct
(	O
+	O
)	O
cells	O
with	O
neural	O
stem	O
properties	O
,	O
which	O
are	O
driven	O
by	O
SOX10	B-GeneOrGeneProduct
,	O
NOTCH1	B-GeneOrGeneProduct
,	O
and	O
FABP7	B-GeneOrGeneProduct
.	O

Sensitivity	O
of	O
these	O
cells	O
to	O
Notch	B-GeneOrGeneProduct
inhibition	O
and	O
their	O
dependence	O
on	O
SKP2	B-GeneOrGeneProduct
offer	O
new	O
opportunities	O
for	O
targeted	O
ACC	B-DiseaseOrPhenotypicFeature
therapies	O
.	O
The	O
impact	O
of	O
PPARa	B-GeneOrGeneProduct
activation	O
on	O
whole	O
genome	O
gene	O
expression	O
in	O
human	B-OrganismTaxon
precision	O
cut	O
liver	O
slices	O
.	O

BACKGROUND	O
:	O
Studies	O
in	O
mice	B-OrganismTaxon
have	O
shown	O
that	O
PPARa	B-GeneOrGeneProduct
is	O
an	O
important	O
regulator	O
of	O
lipid	B-ChemicalEntity
metabolism	O
in	O
liver	O
and	O
key	O
transcription	O
factor	O
involved	O
in	O
the	O
adaptive	O
response	O
to	O
fasting	O
.	O

However	O
,	O
much	O
less	O
is	O
known	O
about	O
the	O
role	O
of	O
PPARa	B-GeneOrGeneProduct
in	O
human	B-OrganismTaxon
liver	O
.	O

METHODS	O
:	O
Here	O
we	O
set	O
out	O
to	O
study	O
the	O
function	O
of	O
PPARa	B-GeneOrGeneProduct
in	O
human	B-OrganismTaxon
liver	O
via	O
analysis	O
of	O
whole	O
genome	O
gene	O
regulation	O
in	O
human	B-OrganismTaxon
liver	O
slices	O
treated	O
with	O
the	O
PPARa	B-GeneOrGeneProduct
agonist	O
Wy14643	B-ChemicalEntity
.	O

RESULTS	O
:	O
Quantitative	O
PCR	O
indicated	O
that	O
PPARa	B-GeneOrGeneProduct
is	O
well	O
expressed	O
in	O
human	B-OrganismTaxon
liver	O
and	O
human	B-OrganismTaxon
liver	O
slices	O
and	O
that	O
the	O
classical	O
PPARa	B-GeneOrGeneProduct
targets	O
PLIN2	B-GeneOrGeneProduct
,	O
VLDLR	B-GeneOrGeneProduct
,	O
ANGPTL4	B-GeneOrGeneProduct
,	O
CPT1A	B-GeneOrGeneProduct
and	O
PDK4	B-GeneOrGeneProduct
are	O
robustly	O
induced	O
by	O
PPARa	B-GeneOrGeneProduct
activation	O
.	O

Transcriptomics	O
analysis	O
indicated	O
that	O
617	O
genes	O
were	O
upregulated	O
and	O
665	O
genes	O
were	O
downregulated	O
by	O
PPARa	B-GeneOrGeneProduct
activation	O
(	O
q	O
value	O
<	O
0	O
.	O
05	O
)	O
.	O

Many	O
genes	O
induced	O
by	O
PPARa	B-GeneOrGeneProduct
activation	O
were	O
involved	O
in	O
lipid	B-ChemicalEntity
metabolism	O
(	O
ACSL5	B-GeneOrGeneProduct
,	O
AGPAT9	B-GeneOrGeneProduct
,	O
FADS1	B-GeneOrGeneProduct
,	O
SLC27A4	B-GeneOrGeneProduct
)	O
,	O
xenobiotic	O
metabolism	O
(	O
POR	B-GeneOrGeneProduct
,	O
ABCC2	B-GeneOrGeneProduct
,	O
CYP3A5	B-GeneOrGeneProduct
)	O
or	O
the	O
unfolded	O
protein	O
response	O
,	O
whereas	O
most	O
of	O
the	O
downregulated	O
genes	O
were	O
involved	O
in	O
immune	O
-	O
related	O
pathways	O
.	O

Among	O
the	O
most	O
highly	O
repressed	O
genes	O
upon	O
PPARa	B-GeneOrGeneProduct
activation	O
were	O
several	O
chemokines	B-GeneOrGeneProduct
(	O
e	O
.	O
g	O
.	O

CXCL9	B-GeneOrGeneProduct
-	O
11	I-GeneOrGeneProduct
,	O
CCL8	B-GeneOrGeneProduct
,	O
CX3CL1	B-GeneOrGeneProduct
,	O
CXCL6	B-GeneOrGeneProduct
)	O
,	O
interferon	B-GeneOrGeneProduct
g	I-GeneOrGeneProduct
-	O
induced	O
genes	O
(	O
e	O
.	O
g	O
.	O

IFITM1	B-GeneOrGeneProduct
,	O
IFIT1	B-GeneOrGeneProduct
,	O
IFIT2	B-GeneOrGeneProduct
,	O
IFIT3	B-GeneOrGeneProduct
)	O
and	O
numerous	O
other	O
immune	O
-	O
related	O
genes	O
(	O
e	O
.	O
g	O
.	O

TLR3	B-GeneOrGeneProduct
,	O
NOS2	B-GeneOrGeneProduct
,	O
and	O
LCN2	B-GeneOrGeneProduct
)	O
.	O

Comparative	O
analysis	O
of	O
gene	O
regulation	O
by	O
Wy14643	B-ChemicalEntity
between	O
human	B-OrganismTaxon
liver	O
slices	O
and	O
primary	O
human	B-OrganismTaxon
hepatocytes	O
showed	O
that	O
down	O
-	O
regulation	O
of	O
gene	O
expression	O
by	O
PPARa	B-GeneOrGeneProduct
is	O
much	O
better	O
captured	O
by	O
liver	O
slices	O
as	O
compared	O
to	O
primary	O
hepatocytes	O
.	O

In	O
particular	O
,	O
PPARa	B-GeneOrGeneProduct
activation	O
markedly	O
suppressed	O
immunity	O
/	O
inflammation	B-DiseaseOrPhenotypicFeature
-	O
related	O
genes	O
in	O
human	B-OrganismTaxon
liver	O
slices	O
but	O
not	O
in	O
primary	O
hepatocytes	O
.	O

Finally	O
,	O
several	O
putative	O
new	O
target	O
genes	O
of	O
PPARa	B-GeneOrGeneProduct
were	O
identified	O
that	O
were	O
commonly	O
induced	O
by	O
PPARa	B-GeneOrGeneProduct
activation	O
in	O
the	O
two	O
human	B-OrganismTaxon
liver	O
model	O
systems	O
,	O
including	O
TSKU	B-GeneOrGeneProduct
,	O
RHOF	B-GeneOrGeneProduct
,	O
CA12	B-GeneOrGeneProduct
and	O
VSIG10L	B-GeneOrGeneProduct
.	O

CONCLUSION	O
:	O
Our	O
paper	O
demonstrates	O
the	O
suitability	O
and	O
superiority	O
of	O
human	B-OrganismTaxon
liver	O
slices	O
over	O
primary	O
hepatocytes	O
for	O
studying	O
the	O
functional	O
role	O
of	O
PPARa	B-GeneOrGeneProduct
in	O
human	B-OrganismTaxon
liver	O
.	O

Our	O
data	O
underscore	O
the	O
major	O
role	O
of	O
PPARa	B-GeneOrGeneProduct
in	O
regulation	O
of	O
hepatic	O
lipid	B-ChemicalEntity
and	O
xenobiotic	O
metabolism	O
in	O
human	B-OrganismTaxon
liver	O
and	O
reveal	O
a	O
marked	O
immuno	O
-	O
suppressive	O
/	O
anti	O
-	O
inflammatory	B-DiseaseOrPhenotypicFeature
effect	O
of	O
PPARa	B-GeneOrGeneProduct
in	O
human	B-OrganismTaxon
liver	O
slices	O
that	O
may	O
be	O
therapeutically	O
relevant	O
for	O
non	B-DiseaseOrPhenotypicFeature
-	O
alcoholic	I-DiseaseOrPhenotypicFeature
fatty	I-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O
Curcumin	B-ChemicalEntity
decreases	O
specificity	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
expression	O
in	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
.	O

Curcumin	B-ChemicalEntity
is	O
the	O
active	O
component	O
of	O
tumeric	O
,	O
and	O
this	O
polyphenolic	O
compound	O
has	O
been	O
extensively	O
investigated	O
as	O
an	O
anticancer	O
drug	O
that	O
modulates	O
multiple	O
pathways	O
and	O
genes	O
.	O

In	O
this	O
study	O
,	O
10	O
to	O
25	O
micromol	O
/	O
L	O
curcumin	B-ChemicalEntity
inhibited	O
253JB	B-CellLine
-	O
V	I-CellLine
and	O
KU7	B-CellLine
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cell	O
growth	O
,	O
and	O
this	O
was	O
accompanied	O
by	O
induction	O
of	O
apoptosis	O
and	O
decreased	O
expression	O
of	O
the	O
proapoptotic	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
survivin	B-GeneOrGeneProduct
and	O
the	O
angiogenic	B-GeneOrGeneProduct
proteins	I-GeneOrGeneProduct
vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
VEGF	B-GeneOrGeneProduct
)	O
and	O
VEGF	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
VEGFR1	B-GeneOrGeneProduct
)	O
.	O

Because	O
expression	O
of	O
survivin	B-GeneOrGeneProduct
,	O
VEGF	B-GeneOrGeneProduct
,	O
and	O
VEGFR1	B-GeneOrGeneProduct
are	O
dependent	O
on	O
specificity	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
(	O
Sp	I-GeneOrGeneProduct
)	O
transcription	I-GeneOrGeneProduct
factors	I-GeneOrGeneProduct
,	O
we	O
also	O
investigated	O
the	O
effects	O
of	O
curcumin	B-ChemicalEntity
on	O
Sp	B-GeneOrGeneProduct
protein	O
expression	O
as	O
an	O
underlying	O
mechanism	O
for	O
the	O
apoptotic	O
and	O
antiangiogenic	O
activity	O
of	O
this	O
compound	O
.	O

The	O
results	O
show	O
that	O
curcumin	B-ChemicalEntity
induced	O
proteasome	B-GeneOrGeneProduct
-	O
dependent	O
down	O
-	O
regulation	O
of	O
Sp1	B-GeneOrGeneProduct
,	O
Sp3	B-GeneOrGeneProduct
,	O
and	O
Sp4	B-GeneOrGeneProduct
in	O
253JB	B-CellLine
-	O
V	I-CellLine
and	O
KU7	B-CellLine
cells	O
.	O

Moreover	O
,	O
using	O
RNA	O
interference	O
with	O
small	O
inhibitory	O
RNAs	O
for	O
Sp1	B-GeneOrGeneProduct
,	O
Sp3	B-GeneOrGeneProduct
,	O
and	O
Sp4	B-GeneOrGeneProduct
,	O
we	O
observed	O
that	O
curcumin	B-ChemicalEntity
-	O
dependent	O
inhibition	O
of	O
nuclear	B-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
kappaB	I-GeneOrGeneProduct
(	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
)	O
-	O
dependent	O
genes	O
,	O
such	O
as	O
bcl	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
,	O
survivin	B-GeneOrGeneProduct
,	O
and	O
cyclin	B-GeneOrGeneProduct
D1	I-GeneOrGeneProduct
,	O
was	O
also	O
due	O
,	O
in	O
part	O
,	O
to	O
loss	O
of	O
Sp	B-GeneOrGeneProduct
proteins	O
.	O

Curcumin	B-ChemicalEntity
also	O
decreased	O
bladder	B-DiseaseOrPhenotypicFeature
tumor	I-DiseaseOrPhenotypicFeature
growth	O
in	O
athymic	O
nude	O
mice	B-OrganismTaxon
bearing	O
KU7	B-CellLine
cells	O
as	O
xenografts	O
and	O
this	O
was	O
accompanied	O
by	O
decreased	O
Sp1	B-GeneOrGeneProduct
,	O
Sp3	B-GeneOrGeneProduct
,	O
and	O
Sp4	B-GeneOrGeneProduct
protein	O
levels	O
in	O
tumors	B-DiseaseOrPhenotypicFeature
.	O

These	O
results	O
show	O
for	O
the	O
first	O
time	O
that	O
one	O
of	O
the	O
underlying	O
mechanisms	O
of	O
action	O
of	O
curcumin	B-ChemicalEntity
as	O
a	O
cancer	B-DiseaseOrPhenotypicFeature
chemotherapeutic	O
agent	O
is	O
due	O
,	O
in	O
part	O
,	O
to	O
decreased	O
expression	O
of	O
Sp	B-GeneOrGeneProduct
transcription	I-GeneOrGeneProduct
factors	I-GeneOrGeneProduct
in	O
bladder	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cells	O
.	O
Study	O
of	O
a	O
Taiwanese	O
family	O
with	O
oculopharyngeal	B-DiseaseOrPhenotypicFeature
muscular	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
Oculopharyngeal	B-DiseaseOrPhenotypicFeature
muscular	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
(	O
OPMD	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
late	O
onset	O
autosomal	B-DiseaseOrPhenotypicFeature
dominant	I-DiseaseOrPhenotypicFeature
muscle	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
.	O

OPMD	B-DiseaseOrPhenotypicFeature
is	O
caused	O
by	O
a	O
short	O
trinucleotide	O
repeat	O
expansion	O
encoding	O
an	O
expanded	O
polyalanine	B-ChemicalEntity
tract	O
in	O
the	O
polyadenylate	B-GeneOrGeneProduct
binding	I-GeneOrGeneProduct
-	O
protein	I-GeneOrGeneProduct
nuclear	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
PABPN1	B-GeneOrGeneProduct
)	O
gene	O
.	O

We	O
identified	O
and	O
characterized	O
a	O
PABPN1	B-GeneOrGeneProduct
mutation	O
in	O
a	O
Taiwanese	O
family	O
with	O
OPMD	B-DiseaseOrPhenotypicFeature
.	O

METHODS	O
:	O
The	O
phenotypic	O
and	O
genotypic	O
characteristics	O
of	O
all	O
subjects	O
were	O
evaluated	O
in	O
a	O
Taiwanese	O
OPMD	B-DiseaseOrPhenotypicFeature
family	O
.	O

Genetic	O
alterations	O
in	O
the	O
PABPN1	B-GeneOrGeneProduct
gene	O
were	O
identified	O
using	O
PCR	O
and	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Ten	O
subjects	O
with	O
OPMD	B-DiseaseOrPhenotypicFeature
(	O
6	O
symptomatic	O
and	O
4	O
asymptomatic	O
)	O
within	O
the	O
Taiwanese	O
family	O
carried	O
a	O
novel	O
mutation	O
in	O
the	O
PABPN1	B-GeneOrGeneProduct
gene	O
.	O

The	O
normal	O
(	O
GCG	I-SequenceVariant
)	O
6	I-SequenceVariant
(	O
GCA	I-SequenceVariant
)	O
3GCG	I-SequenceVariant
sequence	I-SequenceVariant
was	I-SequenceVariant
replaced	I-SequenceVariant
by	I-SequenceVariant
(	O
GCG	I-SequenceVariant
)	O
6	I-SequenceVariant
(	O
GCA	I-SequenceVariant
)	O
(	O
GCG	I-SequenceVariant
)	O
4	I-SequenceVariant
(	O
GCA	I-SequenceVariant
)	O
3GCG	I-SequenceVariant
due	O
to	O
an	O
insertion	B-SequenceVariant
of	I-SequenceVariant
(	O
GCG	I-SequenceVariant
)	O
4GCA	I-SequenceVariant
into	O
the	O
normal	O
allele	O
in	O
the	O
Taiwanese	O
OPMD	B-DiseaseOrPhenotypicFeature
subjects	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
a	O
single	O
GCG	O
expansion	O
in	O
most	O
of	O
OPMD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
in	O
the	O
literature	O
,	O
an	O
insertion	B-SequenceVariant
of	I-SequenceVariant
(	O
GCG	I-SequenceVariant
)	O
4GCA	I-SequenceVariant
in	O
the	O
PABPN1	B-GeneOrGeneProduct
gene	O
was	O
found	O
in	O
the	O
Taiwanese	O
OPMD	B-DiseaseOrPhenotypicFeature
subjects	O
.	O

The	O
identification	O
of	O
this	O
mutation	O
appears	O
to	O
support	O
the	O
molecular	O
mechanism	O
of	O
unequal	O
cross	O
-	O
over	O
of	O
two	O
PABPN1	B-GeneOrGeneProduct
alleles	O
.	O
A	O
novel	O
mutation	O
(	O
E333D	B-SequenceVariant
)	O
in	O
the	O
thyroid	B-GeneOrGeneProduct
hormone	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
causing	O
resistance	B-DiseaseOrPhenotypicFeature
to	I-DiseaseOrPhenotypicFeature
thyroid	I-DiseaseOrPhenotypicFeature
hormone	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Resistance	B-DiseaseOrPhenotypicFeature
to	I-DiseaseOrPhenotypicFeature
thyroid	I-DiseaseOrPhenotypicFeature
hormone	I-DiseaseOrPhenotypicFeature
(	O
RTH	B-DiseaseOrPhenotypicFeature
)	O
is	O
an	O
inherited	O
syndrome	O
characterized	O
by	O
elevated	O
serum	O
thyroid	B-ChemicalEntity
hormones	I-ChemicalEntity
(	O
TH	B-ChemicalEntity
)	O
,	O
failure	O
to	O
suppress	O
pituitary	O
thyroid	B-GeneOrGeneProduct
stimulating	I-GeneOrGeneProduct
hormone	I-GeneOrGeneProduct
(	O
TSH	B-GeneOrGeneProduct
)	O
secretion	O
,	O
and	O
variable	O
peripheral	O
tissue	O
responsiveness	O
to	O
TH	B-ChemicalEntity
.	O

The	O
disorder	O
is	O
associated	O
with	O
diverse	O
mutations	O
in	O
the	O
thyroid	B-GeneOrGeneProduct
hormone	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
TRbeta	B-GeneOrGeneProduct
)	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
natural	O
RTH	B-DiseaseOrPhenotypicFeature
mutation	O
(	O
E333D	B-SequenceVariant
)	O
located	O
in	O
the	O
large	O
carboxy	O
-	O
terminal	O
ligand	O
binding	O
domain	O
of	O
TRbeta	B-GeneOrGeneProduct
.	O

The	O
mutation	O
was	O
identified	O
in	O
a	O
22	O
-	O
year	O
-	O
old	O
French	O
woman	B-OrganismTaxon
coming	O
to	O
medical	O
attention	O
because	O
of	O
an	O
increasing	O
overweight	B-DiseaseOrPhenotypicFeature
.	O

Biochemical	O
tests	O
showed	O
elevated	O
free	O
thyroxine	B-ChemicalEntity
(	O
T4	B-ChemicalEntity
:	O
20	O
.	O
8	O
pg	O
/	O
ml	O
(	O
normal	O
,	O
8	O
.	O
5	O
-	O
18	O
)	O
)	O
and	O
triiodothyronine	B-ChemicalEntity
(	O
T3	B-ChemicalEntity
:	O
5	O
.	O
7	O
pg	O
/	O
ml	O
(	O
normal	O
,	O
1	O
.	O
4	O
-	O
4	O
)	O
)	O
in	O
the	O
serum	O
,	O
together	O
with	O
an	O
inappropriately	O
nonsuppressed	O
TSH	B-GeneOrGeneProduct
level	O
of	O
4	O
.	O
7	O
mU	O
/	O
ml	O
(	O
normal	O
,	O
0	O
.	O
4	O
-	O
4	O
)	O
.	O

Her	O
father	O
and	O
her	O
brother	O
'	O
s	O
serum	O
tests	O
also	O
showed	O
biochemical	O
abnormalities	O
consistent	O
with	O
RTH	B-DiseaseOrPhenotypicFeature
.	O

Direct	O
sequencing	O
of	O
the	O
TRbeta	B-GeneOrGeneProduct
gene	O
revealed	O
a	O
heterozygous	O
transition	O
1284A	B-SequenceVariant
>	O
C	I-SequenceVariant
in	O
exon	O
9	O
resulting	O
in	O
substitution	O
of	O
glutamic	B-SequenceVariant
acid	I-SequenceVariant
333	I-SequenceVariant
by	I-SequenceVariant
aspartic	I-SequenceVariant
acid	I-SequenceVariant
residue	O
(	O
E333D	B-SequenceVariant
)	O
.	O

Further	O
functional	O
analyses	O
of	O
the	O
novel	O
TRbeta	B-GeneOrGeneProduct
mutant	O
were	O
conducted	O
.	O

We	O
found	O
that	O
the	O
E333D	B-SequenceVariant
mutation	O
neither	O
significantly	O
affected	O
the	O
affinity	O
of	O
the	O
receptor	O
for	O
T3	B-ChemicalEntity
nor	O
modified	O
heterodimer	O
formation	O
with	O
retinoid	B-GeneOrGeneProduct
X	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
RXR	B-GeneOrGeneProduct
)	O
when	O
bound	O
to	O
DNA	O
.	O

However	O
,	O
in	O
transient	O
transfection	O
assays	O
,	O
the	O
E333D	B-SequenceVariant
TRbeta	B-GeneOrGeneProduct
mutant	O
exhibited	O
impaired	O
transcriptional	O
regulation	O
on	O
two	O
distinct	O
positively	O
regulated	O
thyroid	O
response	O
elements	O
(	O
F2	O
-	O
and	O
DR4	O
-	O
TREs	O
)	O
as	O
well	O
as	O
on	O
the	O
negatively	O
regulated	O
human	B-OrganismTaxon
TSHalpha	B-GeneOrGeneProduct
promoter	O
.	O

Moreover	O
,	O
a	O
dominant	O
inhibition	O
of	O
the	O
wild	O
-	O
type	O
TRbeta	B-GeneOrGeneProduct
counterpart	O
transactivation	O
function	O
was	O
observed	O
on	O
both	O
a	O
positive	O
(	O
F2	O
-	O
TRE	O
)	O
and	O
a	O
negative	O
(	O
TSHalpha	B-GeneOrGeneProduct
)	O
promoter	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
E333D	B-SequenceVariant
TRbeta	B-GeneOrGeneProduct
mutation	O
is	O
responsible	O
for	O
the	O
RTH	B-DiseaseOrPhenotypicFeature
phenotype	O
in	O
the	O
proposita	O
'	O
s	O
family	O
.	O
Cloning	O
of	O
human	B-OrganismTaxon
very	B-GeneOrGeneProduct
-	O
long	I-GeneOrGeneProduct
-	O
chain	I-GeneOrGeneProduct
acyl	I-GeneOrGeneProduct
-	O
coenzyme	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
dehydrogenase	I-GeneOrGeneProduct
and	O
molecular	O
characterization	O
of	O
its	O
deficiency	O
in	O
two	O
patients	B-OrganismTaxon
.	O

Two	O
overlapping	O
cDNA	O
clones	O
(	O
1	O
,	O
991	O
bp	O
and	O
736	O
bp	O
,	O
respectively	O
)	O
encoding	O
the	O
precursor	O
of	O
human	B-OrganismTaxon
mitochondrial	O
very	B-GeneOrGeneProduct
-	O
long	I-GeneOrGeneProduct
-	O
chain	I-GeneOrGeneProduct
acyl	I-GeneOrGeneProduct
-	O
coenzyme	I-GeneOrGeneProduct
A	I-GeneOrGeneProduct
dehydrogenase	I-GeneOrGeneProduct
(	O
VLCAD	B-GeneOrGeneProduct
)	O
were	O
cloned	O
and	O
sequenced	O
.	O

The	O
cDNA	O
inserts	O
of	O
these	O
clones	O
together	O
encompass	O
a	O
region	O
of	O
2	O
,	O
177	O
bases	O
,	O
encoding	O
the	O
entire	O
protein	O
of	O
655	O
amino	O
acids	O
,	O
including	O
a	O
40	O
-	O
amino	O
acid	O
leader	O
peptide	O
and	O
a	O
615	O
-	O
amino	O
acid	O
mature	O
polypeptide	O
.	O

PCR	O
-	O
amplified	O
VLCAD	B-GeneOrGeneProduct
cDNAs	O
were	O
sequenced	O
in	O
cultured	O
fibroblasts	O
from	O
two	O
VLCAD	B-DiseaseOrPhenotypicFeature
-	O
deficient	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

In	O
both	O
patients	B-OrganismTaxon
,	O
a	O
105	B-SequenceVariant
-	O
bp	I-SequenceVariant
deletion	I-SequenceVariant
encompassing	I-SequenceVariant
bases	I-SequenceVariant
1078	I-SequenceVariant
-	O
1182	I-SequenceVariant
in	O
VLCAD	B-GeneOrGeneProduct
cDNA	O
was	O
identified	O
.	O

The	O
deletion	O
seems	O
to	O
occur	O
due	O
to	O
exon	O
skipping	O
during	O
processing	O
of	O
VLCAD	B-GeneOrGeneProduct
pre	O
-	O
mRNA	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
a	O
mutation	O
causing	O
VLCAD	B-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
.	O

Quantitative	O
cDNA	O
expression	O
of	O
normal	O
human	B-OrganismTaxon
VLCAD	B-GeneOrGeneProduct
was	O
performed	O
in	O
the	O
patients	B-OrganismTaxon
fibroblasts	O
,	O
using	O
vaccinia	O
viral	O
system	O
,	O
which	O
demonstrated	O
that	O
the	O
deficiency	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
normal	I-DiseaseOrPhenotypicFeature
VLCAD	I-DiseaseOrPhenotypicFeature
protein	I-DiseaseOrPhenotypicFeature
causes	O
impaired	O
long	B-ChemicalEntity
-	O
chain	I-ChemicalEntity
fatty	I-ChemicalEntity
acid	I-ChemicalEntity
beta	O
-	O
oxidation	O
activity	O
in	O
the	O
patients	B-OrganismTaxon
fibroblasts	O
.	O

In	O
patient	B-OrganismTaxon
fibroblasts	O
,	O
raising	O
VLCAD	B-GeneOrGeneProduct
activity	O
to	O
approximately	O
20%	O
of	O
normal	O
control	O
fibroblast	O
activity	O
raised	O
palmitic	B-ChemicalEntity
acid	I-ChemicalEntity
beta	O
-	O
oxidation	O
flux	O
to	O
the	O
level	O
found	O
in	O
control	O
fibroblasts	O
,	O
which	O
may	O
offer	O
important	O
information	O
for	O
the	O
rational	O
design	O
of	O
future	O
somatic	O
gene	O
therapy	O
for	O
VLCAD	B-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
.	O
Haplotype	O
structure	O
of	O
the	O
beta	B-GeneOrGeneProduct
adrenergic	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
genes	O
in	O
US	O
Caucasians	O
and	O
African	O
Americans	O
.	O

The	O
beta	B-GeneOrGeneProduct
-	O
adrenergic	I-GeneOrGeneProduct
receptors	I-GeneOrGeneProduct
(	O
beta	B-GeneOrGeneProduct
-	O
AR	I-GeneOrGeneProduct
)	O
are	O
G	O
protein	O
-	O
coupled	O
receptors	O
activated	O
by	O
epinephrine	B-ChemicalEntity
and	O
norepinephrine	B-ChemicalEntity
and	O
are	O
involved	O
in	O
a	O
variety	O
of	O
their	O
physiological	O
functions	O
.	O

Previously	O
,	O
three	O
beta	B-GeneOrGeneProduct
-	O
AR	I-GeneOrGeneProduct
genes	O
(	O
ADRB1	B-GeneOrGeneProduct
,	O
ADRB2	B-GeneOrGeneProduct
and	O
ADRB3	B-GeneOrGeneProduct
)	O
were	O
resequenced	O
,	O
identifying	O
polymorphisms	O
that	O
were	O
used	O
in	O
genetic	O
association	O
studies	O
of	O
cardiovascular	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
metabolic	I-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
.	O

These	O
studies	O
have	O
produced	O
intriguing	O
but	O
inconsistent	O
results	O
,	O
potentially	O
because	O
the	O
known	O
functional	O
variants	O
:	O
ADRB1	B-GeneOrGeneProduct
Arg389Gly	B-SequenceVariant
and	O
Gly49Ser	B-SequenceVariant
,	O
ADRB2	B-GeneOrGeneProduct
Arg16Gly	B-SequenceVariant
and	O
Gln27Glu	B-SequenceVariant
,	O
and	O
ADRB3	B-GeneOrGeneProduct
Arg64Trp	B-SequenceVariant
provided	O
an	O
incomplete	O
picture	O
of	O
the	O
total	O
functional	O
diversity	O
at	O
these	O
genes	O
.	O

Therefore	O
,	O
we	O
created	O
marker	O
panels	O
for	O
each	O
beta	B-GeneOrGeneProduct
-	O
AR	I-GeneOrGeneProduct
gene	O
that	O
included	O
the	O
known	O
functional	O
markers	O
and	O
also	O
other	O
markers	O
evenly	O
spaced	O
and	O
with	O
sufficient	O
density	O
to	O
identify	O
haplotype	O
block	O
structure	O
and	O
to	O
maximize	O
haplotype	O
diversity	O
.	O

A	O
total	O
of	O
27	O
markers	O
were	O
genotyped	O
in	O
96	O
US	O
Caucasians	O
and	O
96	O
African	O
Americans	O
.	O

In	O
both	O
populations	O
and	O
for	O
each	O
gene	O
,	O
a	O
single	O
block	O
with	O
little	O
evidence	O
of	O
historical	O
recombination	O
was	O
observed	O
.	O

For	O
each	O
gene	O
,	O
haplotype	O
captured	O
most	O
of	O
the	O
information	O
content	O
of	O
each	O
functional	O
locus	O
,	O
even	O
if	O
that	O
locus	O
was	O
not	O
genotyped	O
,	O
and	O
presumably	O
haplotype	O
would	O
capture	O
the	O
signal	O
from	O
unknown	O
functional	O
loci	O
whose	O
alleles	O
are	O
of	O
moderate	O
abundance	O
.	O

This	O
study	O
demonstrates	O
the	O
utility	O
of	O
using	O
beta	B-GeneOrGeneProduct
-	O
AR	I-GeneOrGeneProduct
gene	O
haplotype	O
maps	O
and	O
marker	O
panels	O
as	O
tools	O
for	O
linkage	O
studies	O
on	O
beta	B-GeneOrGeneProduct
-	O
AR	I-GeneOrGeneProduct
function	O
.	O
Association	O
of	O
DNA	O
polymorphisms	O
within	O
the	O
CYP11B2	B-GeneOrGeneProduct
/	O
CYP11B1	B-GeneOrGeneProduct
locus	O
and	O
postoperative	O
hypertension	B-DiseaseOrPhenotypicFeature
risk	O
in	O
the	O
patients	B-OrganismTaxon
with	O
aldosterone	B-DiseaseOrPhenotypicFeature
-	O
producing	I-DiseaseOrPhenotypicFeature
adenomas	I-DiseaseOrPhenotypicFeature
.	O

OBJECTIVES	O
:	O
Hypertension	B-DiseaseOrPhenotypicFeature
often	O
persists	O
after	O
adrenalectomy	O
for	O
primary	O
aldosteronism	O
.	O

Traditional	O
factors	O
associated	O
with	O
postoperative	O
hypertension	B-DiseaseOrPhenotypicFeature
were	O
evaluated	O
,	O
but	O
whether	O
genetic	O
determinants	O
were	O
involved	O
remains	O
poorly	O
understood	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
association	O
of	O
DNA	O
polymorphisms	O
within	O
steroid	B-GeneOrGeneProduct
synthesis	I-GeneOrGeneProduct
genes	I-GeneOrGeneProduct
(	O
CYP11B2	B-GeneOrGeneProduct
,	O
CYP11B1	B-GeneOrGeneProduct
)	O
and	O
the	O
postoperative	O
resolution	O
of	O
hypertension	B-DiseaseOrPhenotypicFeature
in	O
Chinese	O
patients	B-OrganismTaxon
undergoing	O
adrenalectomy	O
for	O
aldosterone	B-DiseaseOrPhenotypicFeature
-	O
producing	I-DiseaseOrPhenotypicFeature
adenomas	I-DiseaseOrPhenotypicFeature
(	O
APA	B-DiseaseOrPhenotypicFeature
)	O
.	O

METHODS	O
:	O
Ninety	O
-	O
three	O
patients	B-OrganismTaxon
with	O
APA	B-DiseaseOrPhenotypicFeature
were	O
assessed	O
for	O
postoperative	O
resolution	O
of	O
hypertension	B-DiseaseOrPhenotypicFeature
.	O

All	O
patients	B-OrganismTaxon
were	O
genotyped	O
for	O
rs1799998	B-SequenceVariant
(	O
C	B-SequenceVariant
-	O
344	I-SequenceVariant
T	I-SequenceVariant
)	O
,	O
intron	O
2	O
conversion	O
,	O
rs4539	B-SequenceVariant
(	O
A2718G	B-SequenceVariant
)	O
within	O
CYP11B2	B-GeneOrGeneProduct
and	O
rs6410	B-SequenceVariant
(	O
G22	B-SequenceVariant
5A	I-SequenceVariant
)	O
,	O
rs6387	B-SequenceVariant
(	O
A2803G	B-SequenceVariant
)	O
within	O
CYP11B1	B-GeneOrGeneProduct
.	O

The	O
associations	O
between	O
CYPB11B2	B-GeneOrGeneProduct
/	O
CYP11B1	B-GeneOrGeneProduct
polymorphisms	O
and	O
persistent	O
postoperative	O
hypertension	B-DiseaseOrPhenotypicFeature
were	O
assessed	O
by	O
multivariate	O
analysis	O
.	O

RESULTS	O
:	O
CYP11B2	B-GeneOrGeneProduct
-	O
CYP11B1	B-GeneOrGeneProduct
haplotype	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	B-DiseaseOrPhenotypicFeature
in	O
Chinese	O
patients	B-OrganismTaxon
undergoing	O
adrenalectomy	O
with	O
APA	B-DiseaseOrPhenotypicFeature
(	O
P	O
=	O
.	O
006	O
)	O
.	O

Specifically	O
,	O
the	O
rs4539	B-SequenceVariant
(	O
AA	O
)	O
polymorphism	O
was	O
associated	O
with	O
persistent	O
postoperative	O
hypertension	B-DiseaseOrPhenotypicFeature
(	O
P	O
=	O
.	O
002	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
revealed	O
the	O
common	O
haplotypes	O
H1	O
(	O
AGACT	O
)	O
,	O
H2	O
(	O
AGAWT	O
)	O
,	O
and	O
H3	O
(	O
AGAWC	O
)	O
were	O
associated	O
with	O
the	O
persistent	O
postoperative	O
hypertension	B-DiseaseOrPhenotypicFeature
(	O
P	O
=	O
.	O
01	O
,	O
0	O
.	O
03	O
,	O
0	O
.	O
005	O
after	O
Bonferroni	O
correction	O
)	O
.	O

Additional	O
predictors	O
of	O
persistent	O
postoperative	O
hypertension	B-DiseaseOrPhenotypicFeature
included	O
duration	O
of	O
hypertension	B-DiseaseOrPhenotypicFeature
(	O
P	O
<	O
.	O
0005	O
)	O
,	O
family	O
history	O
of	O
hypertension	B-DiseaseOrPhenotypicFeature
(	O
P	O
=	O
.	O
001	O
)	O
,	O
and	O
elevated	O
systolic	O
blood	O
pressure	O
(	O
P	O
=	O
.	O
015	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
rs4539	B-SequenceVariant
(	O
AA	O
)	O
,	O
H1	O
,	O
H2	O
,	O
and	O
H3	O
are	O
genetic	O
predictors	O
for	O
postoperative	O
persistence	O
of	O
hypertension	B-DiseaseOrPhenotypicFeature
for	O
Chinese	O
patients	B-OrganismTaxon
treated	O
by	O
adrenalectomy	O
with	O
APA	B-DiseaseOrPhenotypicFeature
.	O

DNA	O
polymorphisms	O
at	O
CYP11B2	B-GeneOrGeneProduct
/	O
B1	I-GeneOrGeneProduct
locus	O
may	O
confer	O
susceptibility	O
to	O
postoperative	O
hypertension	B-DiseaseOrPhenotypicFeature
of	O
patients	B-OrganismTaxon
with	O
APA	B-DiseaseOrPhenotypicFeature
.	O
Analysis	O
of	O
skin	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
factors	O
in	O
immunosuppressed	O
renal	O
transplant	O
patients	B-OrganismTaxon
shows	O
high	O
levels	O
of	O
UV	O
-	O
specific	O
tandem	O
CC	B-SequenceVariant
to	I-SequenceVariant
TT	I-SequenceVariant
mutations	O
of	O
the	O
p53	B-GeneOrGeneProduct
gene	O
.	O

Immunosuppressed	O
renal	O
transplant	O
recipients	O
(	O
RTRs	O
)	O
are	O
predisposed	O
to	O
non	B-DiseaseOrPhenotypicFeature
-	O
melanoma	I-DiseaseOrPhenotypicFeature
skin	I-DiseaseOrPhenotypicFeature
cancers	I-DiseaseOrPhenotypicFeature
(	O
NMSCs	B-DiseaseOrPhenotypicFeature
)	O
,	O
predominantly	O
squamous	B-DiseaseOrPhenotypicFeature
cell	I-DiseaseOrPhenotypicFeature
carcinomas	I-DiseaseOrPhenotypicFeature
(	O
SCCs	B-DiseaseOrPhenotypicFeature
)	O
.	O

We	O
have	O
analyzed	O
skin	B-DiseaseOrPhenotypicFeature
lesions	I-DiseaseOrPhenotypicFeature
from	O
RTRs	O
with	O
aggressive	O
tumors	B-DiseaseOrPhenotypicFeature
for	O
p53	B-GeneOrGeneProduct
gene	O
modifications	O
,	O
the	O
presence	O
of	O
Human	B-OrganismTaxon
Papillomas	I-OrganismTaxon
Virus	I-OrganismTaxon
(	O
HPV	B-OrganismTaxon
)	O
DNA	O
in	O
relation	O
to	O
the	O
p53	B-GeneOrGeneProduct
codon	O
72	O
genotype	O
and	O
polymorphisms	O
of	O
the	O
XPD	B-GeneOrGeneProduct
repair	O
gene	O
.	O

We	O
detected	O
24	O
p53	B-GeneOrGeneProduct
mutations	O
in	O
15	O
/	O
25	O
(	O
60%	O
)	O
NMSCs	B-DiseaseOrPhenotypicFeature
,	O
1	O
deletion	O
and	O
23	O
base	O
substitutions	O
,	O
the	O
majority	O
(	O
78%	O
)	O
being	O
UV	O
-	O
specific	O
C	B-SequenceVariant
to	I-SequenceVariant
T	I-SequenceVariant
transitions	O
at	O
bipyrimidine	O
sites	O
.	O

Importantly	O
,	O
35%	O
(	O
6	O
/	O
17	O
)	O
are	O
tandem	O
mutations	O
,	O
including	O
4	O
UV	O
signature	O
CC	B-SequenceVariant
to	I-SequenceVariant
TT	I-SequenceVariant
transitions	O
possibly	O
linked	O
to	O
modulated	O
DNA	O
repair	O
caused	O
by	O
the	O
immunosuppressive	O
drug	O
cyclosporin	B-ChemicalEntity
A	I-ChemicalEntity
(	O
CsA	B-ChemicalEntity
)	O
.	O

We	O
found	O
8	O
p53	B-GeneOrGeneProduct
mutations	O
in	O
7	O
/	O
17	O
(	O
41%	O
)	O
precancerous	B-DiseaseOrPhenotypicFeature
actinic	B-DiseaseOrPhenotypicFeature
keratosis	I-DiseaseOrPhenotypicFeature
(	O
AK	B-DiseaseOrPhenotypicFeature
)	O
,	O
suggesting	O
that	O
p53	B-GeneOrGeneProduct
mutations	O
are	O
early	O
events	O
in	O
RTR	O
skin	B-DiseaseOrPhenotypicFeature
carcinogenesis	I-DiseaseOrPhenotypicFeature
.	O

Immunohistochemical	O
analysis	O
shows	O
a	O
good	O
correlation	O
between	O
p53	B-GeneOrGeneProduct
accumulation	O
and	O
mutations	O
.	O

HPV	B-OrganismTaxon
DNA	O
was	O
detected	O
in	O
78%	O
of	O
skin	B-DiseaseOrPhenotypicFeature
lesions	I-DiseaseOrPhenotypicFeature
(	O
60%	O
Basal	B-DiseaseOrPhenotypicFeature
Cell	I-DiseaseOrPhenotypicFeature
Carcinomas	I-DiseaseOrPhenotypicFeature
,	O
82%AK	O
and	O
79%	O
SCCs	B-DiseaseOrPhenotypicFeature
)	O
.	O

Thus	O
,	O
immunosuppression	O
has	O
increased	O
the	O
risk	O
of	O
infections	B-DiseaseOrPhenotypicFeature
by	O
HPVs	B-OrganismTaxon
,	O
predominantly	O
epidermodysplasia	B-DiseaseOrPhenotypicFeature
verruciformis	I-DiseaseOrPhenotypicFeature
,	O
speculated	O
to	O
play	O
a	O
role	O
in	O
skin	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
development	O
.	O

No	O
association	O
is	O
found	O
between	O
HPV	B-OrganismTaxon
status	O
and	O
p53	B-GeneOrGeneProduct
mutation	O
.	O

Moreover	O
,	O
p53	B-GeneOrGeneProduct
codon	O
72	O
or	O
frequencies	O
of	O
three	O
XPD	B-GeneOrGeneProduct
genotypes	O
of	O
RTRs	O
are	O
comparable	O
with	O
control	O
populations	O
.	O

The	O
p53	B-GeneOrGeneProduct
mutation	O
spectrum	O
,	O
presenting	O
a	O
high	O
level	O
of	O
CC	B-SequenceVariant
to	I-SequenceVariant
TT	I-SequenceVariant
mutations	O
,	O
shows	O
that	O
the	O
UV	O
component	O
of	O
sunlight	O
is	O
the	O
major	O
risk	O
factor	O
and	O
modulated	O
DNA	O
repair	O
by	O
immunosuppressive	O
drug	O
treatment	O
may	O
be	O
significant	O
in	O
the	O
skin	B-DiseaseOrPhenotypicFeature
carcinogenesis	I-DiseaseOrPhenotypicFeature
of	O
RTRs	O
.	O
Tumor	B-DiseaseOrPhenotypicFeature
associated	O
antigen	O
recognition	O
by	O
autologous	O
serum	O
in	O
patients	B-OrganismTaxon
with	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

Breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
accounts	O
for	O
30	O
-	O
40%	O
of	O
all	O
deaths	O
from	O
cancers	B-DiseaseOrPhenotypicFeature
in	O
females	O
.	O

In	O
an	O
effort	O
to	O
identify	O
tumor	B-DiseaseOrPhenotypicFeature
associated	O
antigens	O
that	O
may	O
be	O
useful	O
for	O
immunotherapy	O
,	O
we	O
utilized	O
serological	O
analysis	O
of	O
recombinant	O
cDNA	O
expression	O
libraries	O
(	O
SEREX	O
)	O
technique	O
to	O
identify	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
-	O
associated	O
antigens	O
.	O

SEREX	O
screening	O
of	O
cDNA	O
expression	O
libraries	O
derived	O
from	O
3	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
identified	O
a	O
total	O
of	O
88	O
positive	O
clones	O
(	O
bcg	O
-	O
1	O
to	O
bcg	O
-	O
88	O
)	O
,	O
including	O
27	O
hitherto	O
unknown	O
sequences	O
.	O

The	O
cDNA	O
sequences	O
and	O
mRNA	O
expression	O
patterns	O
were	O
characterized	O
.	O

Seroreactivity	O
of	O
the	O
SEREX	O
clones	O
were	O
determined	O
in	O
sera	O
from	O
75	O
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
75	O
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
and	O
25	O
healthy	O
donors	O
.	O

Expression	O
analysis	O
on	O
a	O
cDNA	O
panel	O
from	O
17	O
different	O
normal	O
tissues	O
by	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
revealed	O
tissue	O
restricted	O
mRNA	O
expression	O
of	O
2	O
of	O
the	O
27	O
unknown	O
antigens	O
.	O

Bcg	O
-	O
72	O
is	O
expressed	O
only	O
in	O
breast	O
,	O
prostate	O
and	O
thymus	O
,	O
while	O
bcg	O
-	O
84	O
is	O
expressed	O
at	O
moderate	O
levels	O
in	O
testis	O
,	O
spleen	O
and	O
breast	O
.	O

The	O
other	O
25	O
unknown	O
antigens	O
were	O
expressed	O
in	O
most	O
other	O
tissues	O
.	O

Serologic	O
assay	O
revealed	O
that	O
7	O
out	O
of	O
the	O
88	O
clones	O
showed	O
reactivity	O
to	O
at	O
least	O
one	O
serum	O
from	O
either	O
75	O
breast	O
or	O
75	O
colon	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

These	O
clones	O
did	O
not	O
react	O
with	O
sera	O
from	O
a	O
panel	O
of	O
25	O
healthy	O
adult	O
individuals	O
.	O

Our	O
results	O
demonstrate	O
the	O
utility	O
of	O
the	O
SEREX	O
approach	O
for	O
the	O
identification	O
of	O
potential	O
tumor	B-DiseaseOrPhenotypicFeature
associated	O
antigens	O
in	O
human	B-OrganismTaxon
breast	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O
The	O
M235T	B-SequenceVariant
polymorphism	O
of	O
the	O
angiotensinogen	B-GeneOrGeneProduct
gene	O
in	O
South	O
Indian	O
patients	B-OrganismTaxon
of	O
hypertrophic	B-DiseaseOrPhenotypicFeature
cardiomyopathy	I-DiseaseOrPhenotypicFeature
.	O

INTRODUCTION	O
:	O
Hypertrophic	B-DiseaseOrPhenotypicFeature
cardiomyopathy	I-DiseaseOrPhenotypicFeature
(	O
HCM	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
complex	O
disorder	O
and	O
genetically	O
transmitted	O
cardiac	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
with	O
a	O
diverse	O
clinical	O
course	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
association	O
of	O
the	O
T704C	B-SequenceVariant
polymorphism	O
of	O
exon	O
2	O
of	O
the	O
angiotensinogen	B-GeneOrGeneProduct
(	O
AGT	B-GeneOrGeneProduct
)	O
gene	O
with	O
HCM	B-DiseaseOrPhenotypicFeature
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O

Subjects	O
and	O
methods	O
.	O

One	O
-	O
hundred	O
and	O
fifty	O
HCM	B-DiseaseOrPhenotypicFeature
(	O
90	O
sporadic	B-DiseaseOrPhenotypicFeature
hypertrophic	I-DiseaseOrPhenotypicFeature
cardiomyopathy	I-DiseaseOrPhenotypicFeature
[	O
SHCM	B-DiseaseOrPhenotypicFeature
]	O
and	O
60	O
familial	B-DiseaseOrPhenotypicFeature
hypertrophic	I-DiseaseOrPhenotypicFeature
cardiomyopathy	I-DiseaseOrPhenotypicFeature
[	O
FHCM	B-DiseaseOrPhenotypicFeature
]	O
)	O
patients	B-OrganismTaxon
and	O
165	O
age	O
-	O
and	O
sex	O
-	O
matched	O
normal	O
healthy	O
controls	O
without	O
known	O
hypertension	B-DiseaseOrPhenotypicFeature
and	O
left	B-DiseaseOrPhenotypicFeature
ventricular	I-DiseaseOrPhenotypicFeature
hypertrophy	I-DiseaseOrPhenotypicFeature
were	O
included	O
in	O
the	O
study	O
.	O

DNA	O
was	O
isolated	O
from	O
peripheral	O
leukocytes	O
and	O
the	O
region	O
of	O
interest	O
in	O
the	O
AGT	B-GeneOrGeneProduct
gene	O
bearing	O
a	O
missense	O
mutation	O
methionine	B-SequenceVariant
to	I-SequenceVariant
threonine	I-SequenceVariant
substitution	I-SequenceVariant
at	I-SequenceVariant
codon	I-SequenceVariant
235	I-SequenceVariant
(	O
M235T	B-SequenceVariant
)	O
of	O
exon	O
2	O
,	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
.	O

The	O
PCR	O
products	O
were	O
subjected	O
to	O
restriction	O
digestion	O
with	O
the	O
enzyme	O
SfaNI	B-ChemicalEntity
.	O

RESULTS	O
:	O
Significant	O
differences	O
were	O
detected	O
in	O
genotypic	O
distribution	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
as	O
well	O
as	O
the	O
allelic	O
frequency	O
(	O
p	O
=	O
0	O
.	O
003	O
)	O
between	O
the	O
SHCM	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
controls	O
.	O

The	O
polymorphism	O
did	O
not	O
show	O
any	O
association	O
with	O
FHCM	B-DiseaseOrPhenotypicFeature
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
T	O
allele	O
of	O
the	O
AGT	B-GeneOrGeneProduct
gene	O
is	O
significantly	O
associated	O
with	O
SHCM	B-DiseaseOrPhenotypicFeature
in	O
a	O
South	O
Indian	O
population	O
from	O
Andhra	O
Pradesh	O
.	O

However	O
,	O
we	O
did	O
not	O
find	O
significant	O
association	O
of	O
this	O
polymorphism	O
with	O
FHCM	B-DiseaseOrPhenotypicFeature
.	O
Gankyrin	B-GeneOrGeneProduct
induces	O
STAT3	B-GeneOrGeneProduct
activation	O
in	O
tumor	B-DiseaseOrPhenotypicFeature
microenvironment	O
and	O
sorafenib	B-ChemicalEntity
resistance	O
in	O
hepatocellular	B-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
.	O

Most	O
hepatocellular	B-DiseaseOrPhenotypicFeature
carcinomas	I-DiseaseOrPhenotypicFeature
(	O
HCC	B-DiseaseOrPhenotypicFeature
)	O
develop	O
as	O
a	O
result	O
of	O
chronic	B-DiseaseOrPhenotypicFeature
liver	I-DiseaseOrPhenotypicFeature
inflammation	I-DiseaseOrPhenotypicFeature
.	O

We	O
have	O
shown	O
that	O
the	O
oncoprotein	B-GeneOrGeneProduct
gankyrin	B-GeneOrGeneProduct
is	O
critical	O
for	O
inflammation	B-DiseaseOrPhenotypicFeature
-	O
induced	O
tumorigenesis	B-DiseaseOrPhenotypicFeature
in	O
the	O
colon	O
.	O

Although	O
the	O
in	O
vitro	O
function	O
of	O
gankyrin	B-GeneOrGeneProduct
is	O
well	O
known	O
,	O
its	O
role	O
in	O
vivo	O
remains	O
to	O
be	O
elucidated	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
gankyrin	B-GeneOrGeneProduct
in	O
the	O
tumor	B-DiseaseOrPhenotypicFeature
microenvironment	O
of	O
mice	B-OrganismTaxon
with	O
liver	O
parenchymal	O
cell	O
-	O
specific	O
gankyrin	B-GeneOrGeneProduct
ablation	O
(	O
Alb	B-GeneOrGeneProduct
-	O
Cre	O
;	O
gankyrin	B-GeneOrGeneProduct
(	O
f	O
/	O
f	O
)	O
)	O
and	O
gankyrin	B-GeneOrGeneProduct
deletion	O
both	O
in	O
liver	O
parenchymal	O
and	O
non	O
-	O
parenchymal	O
cells	O
(	O
Mx1	B-GeneOrGeneProduct
-	O
Cre	O
;	O
gankyrin	B-GeneOrGeneProduct
(	O
f	O
/	O
f	O
)	O
)	O
.	O

Gankyrin	B-GeneOrGeneProduct
upregulates	O
vascular	B-GeneOrGeneProduct
endothelial	I-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
expression	O
in	O
tumor	B-DiseaseOrPhenotypicFeature
cells	O
.	O

Gankyrin	B-GeneOrGeneProduct
binds	O
to	O
Src	B-GeneOrGeneProduct
homology	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
domain	I-GeneOrGeneProduct
-	O
containing	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
tyrosine	I-GeneOrGeneProduct
phosphatase	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
SHP	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
,	O
mainly	O
expressed	O
in	O
liver	O
non	O
-	O
parenchymal	O
cells	O
,	O
resulting	O
in	O
phosphorylation	O
and	O
activation	O
of	O
signal	B-GeneOrGeneProduct
transducer	I-GeneOrGeneProduct
and	I-GeneOrGeneProduct
activator	I-GeneOrGeneProduct
of	I-GeneOrGeneProduct
transcription	I-GeneOrGeneProduct
3	I-GeneOrGeneProduct
(	O
STAT3	B-GeneOrGeneProduct
)	O
.	O

Gankyrin	B-GeneOrGeneProduct
deficiency	O
in	O
non	O
-	O
parenchymal	O
cells	O
,	O
but	O
not	O
in	O
parenchymal	O
cells	O
,	O
reduced	O
STAT3	B-GeneOrGeneProduct
activity	O
,	O
interleukin	B-GeneOrGeneProduct
(	O
IL	I-GeneOrGeneProduct
)	O
-	O
6	I-GeneOrGeneProduct
production	O
,	O
and	O
cancer	B-DiseaseOrPhenotypicFeature
stem	O
cell	O
marker	O
(	O
Bmi1	B-GeneOrGeneProduct
and	O
epithelial	B-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
adhesion	I-GeneOrGeneProduct
molecule	I-GeneOrGeneProduct
[	O
EpCAM	B-GeneOrGeneProduct
]	O
)	O
expression	O
,	O
leading	O
to	O
attenuated	O
tumorigenic	B-DiseaseOrPhenotypicFeature
potential	O
.	O

Chronic	B-DiseaseOrPhenotypicFeature
inflammation	I-DiseaseOrPhenotypicFeature
enhances	O
gankyrin	B-GeneOrGeneProduct
expression	O
in	O
the	O
human	B-OrganismTaxon
liver	O
.	O

Gankyrin	B-GeneOrGeneProduct
expression	O
in	O
the	O
tumor	B-DiseaseOrPhenotypicFeature
microenvironment	O
is	O
negatively	O
correlated	O
with	O
progression	O
-	O
free	O
survival	O
in	O
patients	B-OrganismTaxon
undergoing	O
sorafenib	B-ChemicalEntity
treatment	O
for	O
HCC	B-DiseaseOrPhenotypicFeature
.	O

Thus	O
,	O
gankyrin	B-GeneOrGeneProduct
appears	O
to	O
play	O
a	O
critical	O
oncogenic	O
function	O
in	O
tumor	B-DiseaseOrPhenotypicFeature
microenvironment	O
and	O
may	O
be	O
a	O
potential	O
target	O
for	O
developing	O
therapeutic	O
and	O
preventive	O
strategies	O
against	O
HCC	B-DiseaseOrPhenotypicFeature
.	O
Effects	O
of	O
the	O
cyclooxygenase	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
specific	O
inhibitor	O
valdecoxib	B-ChemicalEntity
versus	O
nonsteroidal	B-ChemicalEntity
antiinflammatory	I-ChemicalEntity
agents	I-ChemicalEntity
and	O
placebo	O
on	O
cardiovascular	O
thrombotic	B-DiseaseOrPhenotypicFeature
events	O
in	O
patients	B-OrganismTaxon
with	O
arthritis	B-DiseaseOrPhenotypicFeature
.	O

There	O
have	O
been	O
concerns	O
that	O
the	O
risk	O
of	O
cardiovascular	O
thrombotic	B-DiseaseOrPhenotypicFeature
events	O
may	O
be	O
higher	O
with	O
cyclooxygenase	B-GeneOrGeneProduct
(	O
COX	I-GeneOrGeneProduct
)	O
-	O
2	I-GeneOrGeneProduct
-	O
specific	O
inhibitors	O
than	O
nonselective	O
nonsteroidal	B-ChemicalEntity
antiinflammatory	I-ChemicalEntity
drugs	I-ChemicalEntity
(	O
NSAIDs	B-ChemicalEntity
)	O
.	O

We	O
evaluated	O
cardiovascular	O
event	O
data	O
for	O
valdecoxib	B-ChemicalEntity
,	O
a	O
new	O
COX	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
-	O
specific	O
inhibitor	O
in	O
approximately	O
8000	O
patients	B-OrganismTaxon
with	O
osteoarthritis	B-DiseaseOrPhenotypicFeature
and	O
rheumatoid	B-DiseaseOrPhenotypicFeature
arthritis	I-DiseaseOrPhenotypicFeature
treated	O
with	O
this	O
agent	O
in	O
randomized	O
clinical	O
trials	O
.	O

The	O
incidence	O
of	O
cardiovascular	O
thrombotic	B-DiseaseOrPhenotypicFeature
events	O
(	O
cardiac	O
,	O
cerebrovascular	O
and	O
peripheral	O
vascular	O
,	O
or	O
arterial	O
thrombotic	B-DiseaseOrPhenotypicFeature
)	O
was	O
determined	O
by	O
analyzing	O
pooled	O
valdecoxib	B-ChemicalEntity
(	O
10	O
-	O
80	O
mg	O
daily	O
)	O
,	O
nonselective	O
NSAID	B-ChemicalEntity
(	O
diclofenac	B-ChemicalEntity
75	O
mg	O
bid	O
,	O
ibuprofen	B-ChemicalEntity
800	O
mg	O
tid	O
,	O
or	O
naproxen	B-ChemicalEntity
500	O
mg	O
bid	O
)	O
and	O
placebo	O
data	O
from	O
10	O
randomized	O
osteoarthritis	B-DiseaseOrPhenotypicFeature
and	O
rheumatoid	B-DiseaseOrPhenotypicFeature
arthritis	I-DiseaseOrPhenotypicFeature
trials	O
that	O
were	O
6	O
-	O
52	O
weeks	O
in	O
duration	O
.	O

The	O
incidence	O
rates	O
of	O
events	O
were	O
determined	O
in	O
all	O
patients	B-OrganismTaxon
(	O
n	O
=	O
7934	O
)	O
and	O
in	O
users	O
of	O
low	O
-	O
dose	O
(	O
<	O
or	O
=	O
325	O
mg	O
daily	O
)	O
aspirin	B-ChemicalEntity
(	O
n	O
=	O
1051	O
)	O
and	O
nonusers	O
of	O
aspirin	B-ChemicalEntity
(	O
n	O
=	O
6883	O
)	O
.	O

Crude	O
and	O
exposure	O
-	O
adjusted	O
incidences	O
of	O
thrombotic	B-DiseaseOrPhenotypicFeature
events	O
were	O
similar	O
for	O
valdecoxib	B-ChemicalEntity
,	O
NSAIDs	B-ChemicalEntity
,	O
and	O
placebo	O
.	O

The	O
risk	O
of	O
serious	O
thrombotic	B-DiseaseOrPhenotypicFeature
events	O
was	O
also	O
similar	O
for	O
each	O
valdecoxib	B-ChemicalEntity
dose	O
.	O

Thrombotic	B-DiseaseOrPhenotypicFeature
risk	O
was	O
consistently	O
higher	O
for	O
users	O
of	O
aspirin	B-ChemicalEntity
users	O
than	O
nonusers	O
of	O
aspirin	B-ChemicalEntity
(	O
placebo	O
,	O
1	O
.	O
4%	O
vs	O
.	O

0%	O
;	O
valdecoxib	B-ChemicalEntity
,	O
1	O
.	O
7%	O
vs	O
.	O

0	O
.	O
2%	O
;	O
NSAIDs	B-ChemicalEntity
,	O
1	O
.	O
9%	O
vs	O
.	O

0	O
.	O
5%	O
)	O
.	O

The	O
rates	O
of	O
events	O
in	O
users	O
of	O
aspirin	B-ChemicalEntity
were	O
similar	O
for	O
all	O
3	O
treatment	O
groups	O
and	O
across	O
valdecoxib	B-ChemicalEntity
doses	O
.	O

Short	O
-	O
and	O
intermediate	O
-	O
term	O
treatment	O
with	O
therapeutic	O
(	O
10	O
or	O
20	O
mg	O
daily	O
)	O
and	O
supratherapeutic	O
(	O
40	O
or	O
80	O
mg	O
daily	O
)	O
valdecoxib	B-ChemicalEntity
doses	O
was	O
not	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
thrombotic	B-DiseaseOrPhenotypicFeature
events	O
relative	O
to	O
nonselective	O
NSAIDs	B-ChemicalEntity
or	O
placebo	O
in	O
osteoarthritis	B-DiseaseOrPhenotypicFeature
and	O
rheumatoid	B-DiseaseOrPhenotypicFeature
arthritis	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
in	O
controlled	O
clinical	O
trials	O
.	O
Metallothionein	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
as	O
a	O
biomarker	O
of	O
altered	O
redox	O
metabolism	O
in	O
hepatocellular	B-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
cells	O
exposed	O
to	O
sorafenib	B-ChemicalEntity
.	O

BACKGROUND	O
:	O
Sorafenib	B-ChemicalEntity
,	O
a	O
kinase	O
inhibitor	O
active	O
against	O
various	O
solid	O
tumours	B-DiseaseOrPhenotypicFeature
,	O
induces	O
oxidative	O
stress	O
and	O
ferroptosis	O
,	O
a	O
new	O
form	O
of	O
oxidative	O
necrosis	B-DiseaseOrPhenotypicFeature
,	O
in	O
some	O
cancer	B-DiseaseOrPhenotypicFeature
cells	O
.	O

Clinically	O
-	O
applicable	O
biomarkers	O
that	O
reflect	O
the	O
impact	O
of	O
sorafenib	B-ChemicalEntity
on	O
the	O
redox	O
metabolism	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
cells	O
are	O
lacking	O
.	O

METHODS	O
:	O
We	O
used	O
gene	O
expression	O
microarrays	O
,	O
real	O
-	O
time	O
PCR	O
,	O
immunoblot	O
,	O
protein	O
-	O
specific	O
ELISA	O
,	O
and	O
gene	O
reporter	O
constructs	O
encoding	O
the	O
enzyme	O
luciferase	O
to	O
study	O
the	O
response	O
of	O
a	O
panel	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
cells	O
to	O
sorafenib	B-ChemicalEntity
.	O

Tumour	B-DiseaseOrPhenotypicFeature
explants	O
prepared	O
from	O
surgical	O
hepatocellular	B-DiseaseOrPhenotypicFeature
carcinoma	I-DiseaseOrPhenotypicFeature
(	O
HCC	B-DiseaseOrPhenotypicFeature
)	O
samples	O
and	O
serum	O
samples	O
obtained	O
from	O
HCC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
receiving	O
sorafenib	B-ChemicalEntity
were	O
also	O
used	O
.	O

RESULTS	O
:	O
We	O
observed	O
that	O
genes	O
of	O
the	O
metallothionein	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
MT1	B-GeneOrGeneProduct
)	O
family	O
are	O
induced	O
in	O
the	O
HCC	B-DiseaseOrPhenotypicFeature
cell	O
line	O
Huh7	B-CellLine
exposed	O
to	O
sorafenib	B-ChemicalEntity
.	O

Sorafenib	B-ChemicalEntity
increased	O
the	O
expression	O
of	O
MT1G	B-GeneOrGeneProduct
mRNA	O
in	O
a	O
panel	O
of	O
human	B-OrganismTaxon
cancer	B-DiseaseOrPhenotypicFeature
cells	O
,	O
an	O
effect	O
that	O
was	O
not	O
observed	O
with	O
eight	O
other	O
clinically	O
-	O
approved	O
kinase	O
inhibitors	O
.	O

We	O
identified	O
the	O
minimal	O
region	O
of	O
the	O
MT1G	B-GeneOrGeneProduct
promoter	O
that	O
confers	O
inducibility	O
by	O
sorafenib	B-ChemicalEntity
to	O
a	O
133	O
base	O
pair	O
region	O
containing	O
an	O
Anti	O
-	O
oxidant	O
Response	O
Element	O
(	O
ARE	O
)	O
and	O
showed	O
the	O
essential	O
role	O
of	O
the	O
transcription	O
factor	O
NRF2	B-GeneOrGeneProduct
(	O
Nuclear	B-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
erythroid	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
-	O
Related	I-GeneOrGeneProduct
Factor	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
)	O
.	O

We	O
examined	O
the	O
clinical	O
relevance	O
of	O
our	O
findings	O
by	O
analysing	O
the	O
regulation	O
of	O
MT1G	B-GeneOrGeneProduct
in	O
five	O
tumour	B-DiseaseOrPhenotypicFeature
explants	O
prepared	O
from	O
surgical	O
HCC	B-DiseaseOrPhenotypicFeature
samples	O
.	O

Finally	O
,	O
we	O
showed	O
that	O
the	O
protein	O
levels	O
of	O
MT1	B-GeneOrGeneProduct
increase	O
in	O
the	O
serum	O
of	O
some	O
HCC	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
receiving	O
sorafenib	B-ChemicalEntity
,	O
and	O
found	O
an	O
association	O
with	O
reduced	O
overall	O
survival	O
.	O

CONCLUSION	O
:	O
These	O
findings	O
indicate	O
that	O
MT1	B-GeneOrGeneProduct
constitute	O
a	O
biomarker	O
adapted	O
for	O
exploring	O
the	O
impact	O
of	O
sorafenib	B-ChemicalEntity
on	O
the	O
redox	O
metabolism	O
of	O
cancer	B-DiseaseOrPhenotypicFeature
cells	O
.	O
Familial	O
glucocorticoid	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
haploinsufficiency	O
by	O
non	O
-	O
sense	O
mediated	O
mRNA	O
decay	O
,	O
adrenal	B-DiseaseOrPhenotypicFeature
hyperplasia	I-DiseaseOrPhenotypicFeature
and	O
apparent	B-DiseaseOrPhenotypicFeature
mineralocorticoid	I-DiseaseOrPhenotypicFeature
excess	I-DiseaseOrPhenotypicFeature
.	O

Primary	O
glucocorticoid	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
(	O
OMIM	B-DiseaseOrPhenotypicFeature
138040	I-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
rare	O
hereditary	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
that	O
causes	O
a	O
generalized	O
partial	O
insensitivity	O
to	O
glucocorticoid	B-ChemicalEntity
action	O
,	O
due	O
to	O
genetic	O
alterations	O
of	O
the	O
glucocorticoid	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
GR	B-GeneOrGeneProduct
)	O
.	O

Investigation	O
of	O
adrenal	B-DiseaseOrPhenotypicFeature
incidentalomas	I-DiseaseOrPhenotypicFeature
led	O
to	O
the	O
discovery	O
of	O
a	O
family	O
(	O
eight	O
affected	O
individuals	O
spanning	O
three	O
generations	O
)	O
,	O
prone	O
to	O
cortisol	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
,	O
bilateral	B-DiseaseOrPhenotypicFeature
adrenal	I-DiseaseOrPhenotypicFeature
hyperplasia	I-DiseaseOrPhenotypicFeature
,	O
arterial	O
hypertension	B-DiseaseOrPhenotypicFeature
and	O
hypokalemia	B-DiseaseOrPhenotypicFeature
.	O

This	O
phenotype	O
exacerbated	O
over	O
time	O
,	O
cosegregates	O
with	O
the	O
first	O
heterozygous	O
nonsense	O
mutation	O
p	B-SequenceVariant
.	O
R469	I-SequenceVariant
[	O
R	I-SequenceVariant
,	O
X	I-SequenceVariant
]	O
reported	O
to	O
date	O
for	O
the	O
GR	B-GeneOrGeneProduct
,	O
replacing	O
an	O
arginine	B-SequenceVariant
(	O
CGA	I-SequenceVariant
)	O
by	I-SequenceVariant
a	I-SequenceVariant
stop	I-SequenceVariant
(	O
TGA	I-SequenceVariant
)	O
at	I-SequenceVariant
amino	I-SequenceVariant
-	O
acid	I-SequenceVariant
469	I-SequenceVariant
in	O
the	O
second	O
zinc	O
finger	O
of	O
the	O
DNA	O
-	O
binding	O
domain	O
of	O
the	O
receptor	O
.	O

In	O
vitro	O
,	O
this	O
mutation	O
leads	O
to	O
a	O
truncated	O
50	O
-	O
kDa	O
GR	B-GeneOrGeneProduct
lacking	O
hormone	O
and	O
DNA	O
binding	O
capacity	O
,	O
devoid	O
of	O
hormone	O
-	O
dependent	O
nuclear	O
translocation	O
and	O
transactivation	O
properties	O
.	O

In	O
the	O
proband	O
'	O
s	O
fibroblasts	O
,	O
we	O
provided	O
evidence	O
for	O
the	O
lack	O
of	O
expression	O
of	O
the	O
defective	O
allele	O
in	O
vivo	O
.	O

The	O
absence	O
of	O
detectable	O
mutated	O
GR	B-GeneOrGeneProduct
mRNA	O
was	O
accompanied	O
by	O
a	O
50%	O
reduction	O
in	O
wild	O
type	O
GR	B-GeneOrGeneProduct
transcript	O
and	O
protein	O
.	O

This	O
reduced	O
GR	B-GeneOrGeneProduct
expression	O
leads	O
to	O
a	O
significantly	O
below	O
-	O
normal	O
induction	O
of	O
glucocorticoid	B-ChemicalEntity
-	O
induced	O
target	O
genes	O
,	O
FKBP5	B-GeneOrGeneProduct
in	O
fibroblasts	O
.	O

We	O
demonstrated	O
that	O
the	O
molecular	O
mechanisms	O
of	O
glucocorticoid	B-ChemicalEntity
signaling	O
dysfunction	O
involved	O
GR	B-GeneOrGeneProduct
haploinsufficiency	O
due	O
to	O
the	O
selective	O
degradation	O
of	O
the	O
mutated	O
GR	B-GeneOrGeneProduct
transcript	O
through	O
a	O
nonsense	O
-	O
mediated	O
mRNA	O
Decay	O
that	O
was	O
experimentally	O
validated	O
on	O
emetine	B-ChemicalEntity
-	O
treated	O
propositus	O
'	O
fibroblasts	O
.	O

GR	B-GeneOrGeneProduct
haploinsufficiency	O
leads	O
to	O
hypertension	B-DiseaseOrPhenotypicFeature
due	O
to	O
illicit	O
occupation	O
of	O
renal	O
mineralocorticoid	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
by	O
elevated	O
cortisol	B-ChemicalEntity
rather	O
than	O
to	O
increased	O
mineralocorticoid	B-ChemicalEntity
production	O
reported	O
in	O
primary	O
glucocorticoid	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
.	O

Indeed	O
,	O
apparent	B-DiseaseOrPhenotypicFeature
mineralocorticoid	I-DiseaseOrPhenotypicFeature
excess	I-DiseaseOrPhenotypicFeature
was	O
demonstrated	O
by	O
a	O
decrease	O
in	O
urinary	O
tetrahydrocortisone	B-ChemicalEntity
-	O
tetrahydrocortisol	B-ChemicalEntity
ratio	O
in	O
affected	O
patients	B-OrganismTaxon
,	O
revealing	O
reduced	O
glucocorticoid	B-ChemicalEntity
degradation	O
by	O
renal	O
activity	O
of	O
the	O
11b	B-GeneOrGeneProduct
-	O
hydroxysteroid	I-GeneOrGeneProduct
dehydrogenase	I-GeneOrGeneProduct
type	I-GeneOrGeneProduct
2	I-GeneOrGeneProduct
,	O
a	O
GR	B-GeneOrGeneProduct
regulated	O
gene	O
.	O

We	O
propose	O
thus	O
that	O
GR	B-GeneOrGeneProduct
haploinsufficiency	O
compromises	O
glucocorticoid	B-ChemicalEntity
sensitivity	O
and	O
may	O
represent	O
a	O
novel	O
genetic	O
cause	O
of	O
subclinical	O
hypercortisolism	B-DiseaseOrPhenotypicFeature
,	O
incidentally	O
revealed	O
bilateral	B-DiseaseOrPhenotypicFeature
adrenal	I-DiseaseOrPhenotypicFeature
hyperplasia	I-DiseaseOrPhenotypicFeature
and	O
mineralocorticoid	B-ChemicalEntity
-	O
independent	O
hypertension	B-DiseaseOrPhenotypicFeature
.	O
Genetic	O
alterations	O
in	O
primary	O
glioblastomas	B-DiseaseOrPhenotypicFeature
in	O
Japan	O
.	O

Current	O
knowledge	O
of	O
genetic	O
alterations	O
in	O
glioblastomas	B-DiseaseOrPhenotypicFeature
is	O
based	O
largely	O
on	O
genetic	O
analyses	O
of	O
tumors	B-DiseaseOrPhenotypicFeature
from	O
mainly	O
caucasian	O
patients	B-OrganismTaxon
in	O
the	O
United	O
States	O
and	O
Europe	O
.	O

In	O
the	O
present	O
study	O
,	O
screening	O
for	O
several	O
key	O
genetic	O
alterations	O
was	O
performed	O
on	O
77	O
primary	O
(	O
de	O
novo	O
)	O
glioblastomas	B-DiseaseOrPhenotypicFeature
in	O
Japanese	O
patients	B-OrganismTaxon
.	O

SSCP	O
followed	O
by	O
DNA	O
sequencing	O
revealed	O
TP53	B-GeneOrGeneProduct
mutations	O
in	O
16	O
of	O
73	O
(	O
22%	O
)	O
glioblastomas	B-DiseaseOrPhenotypicFeature
and	O
PTEN	B-GeneOrGeneProduct
mutations	O
in	O
13	O
of	O
63	O
(	O
21%	O
)	O
cases	O
analyzed	O
.	O

Polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
showed	O
EGFR	B-GeneOrGeneProduct
amplification	O
in	O
25	O
of	O
77	O
(	O
32%	O
)	O
cases	O
and	O
p16	B-GeneOrGeneProduct
homozygous	O
deletion	O
in	O
32	O
of	O
77	O
(	O
42%	O
)	O
cases	O
.	O

Quantitative	O
microsatellite	O
analysis	O
revealed	O
LOH	O
10q	O
in	O
41	O
of	O
59	O
(	O
69%	O
)	O
glioblastomas	B-DiseaseOrPhenotypicFeature
.	O

The	O
frequencies	O
of	O
these	O
genetic	O
alterations	O
were	O
similar	O
to	O
those	O
reported	O
for	O
primary	O
glioblastomas	B-DiseaseOrPhenotypicFeature
at	O
the	O
population	O
level	O
in	O
Switzerland	O
.	O

As	O
previously	O
observed	O
for	O
glioblastomas	B-DiseaseOrPhenotypicFeature
in	O
Europe	O
,	O
there	O
was	O
a	O
positive	O
association	O
between	O
EGFR	B-GeneOrGeneProduct
amplification	O
and	O
p16	B-GeneOrGeneProduct
deletion	O
(	O
p	O
=	O
0	O
.	O
009	O
)	O
,	O
whereas	O
there	O
was	O
an	O
inverse	O
association	O
between	O
TP53	B-GeneOrGeneProduct
mutations	O
and	O
p16	B-GeneOrGeneProduct
deletion	O
(	O
p	O
=	O
0	O
.	O
049	O
)	O
in	O
glioblastomas	B-DiseaseOrPhenotypicFeature
in	O
Japan	O
.	O

Multivariate	O
analyses	O
showed	O
that	O
radiotherapy	O
was	O
significantly	O
predictive	O
for	O
longer	O
survival	O
of	O
glioblastoma	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
(	O
p	O
=	O
0	O
.	O
002	O
)	O
.	O

SSCP	O
followed	O
by	O
DNA	O
sequencing	O
of	O
the	O
kinase	O
domain	O
(	O
exons	O
18	O
-	O
21	O
)	O
of	O
the	O
EGFR	B-GeneOrGeneProduct
gene	O
revealed	O
mutations	O
in	O
2	O
ou	O
of	O
69	O
(	O
3%	O
)	O
glioblastomas	B-DiseaseOrPhenotypicFeature
in	O
Japan	O
and	O
in	O
4	O
of	O
81	O
(	O
5%	O
)	O
glioblastomas	B-DiseaseOrPhenotypicFeature
in	O
Switzerland	O
.	O

The	O
allele	O
frequencies	O
of	O
polymorphisms	O
at	O
codon	B-SequenceVariant
787	I-SequenceVariant
CAG	I-SequenceVariant
/	O
CAA	I-SequenceVariant
(	O
Gln	B-SequenceVariant
/	O
Gln	I-SequenceVariant
)	O
in	O
glioblastomas	B-DiseaseOrPhenotypicFeature
in	O
Japan	O
were	O
G	O
/	O
G	O
(	O
82	O
.	O
4%	O
)	O
,	O
G	O
/	O
A	O
(	O
10	O
.	O
8%	O
)	O
,	O
A	O
/	O
A	O
(	O
6	O
.	O
8%	O
)	O
,	O
corresponding	O
to	O
G	O
0	O
.	O
878	O
versus	O
A	O
0	O
.	O
122	O
,	O
significantly	O
different	O
from	O
those	O
in	O
glioblastomas	B-DiseaseOrPhenotypicFeature
in	O
Switzerland	O
:	O
G	O
/	O
G	O
(	O
27	O
.	O
2%	O
)	O
,	O
G	O
/	O
A	O
(	O
28	O
.	O
4%	O
)	O
,	O
A	O
/	O
A	O
(	O
44	O
.	O
4%	O
)	O
,	O
corresponding	O
to	O
G	O
0	O
.	O
414	O
versus	O
A	O
0	O
.	O
586	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

These	O
results	O
suggest	O
that	O
primary	O
glioblastomas	B-DiseaseOrPhenotypicFeature
in	O
Japan	O
show	O
genetic	O
alterations	O
similar	O
to	O
those	O
in	O
Switzerland	O
,	O
suggesting	O
a	O
similar	O
molecular	O
basis	O
in	O
caucasians	O
and	O
Asians	O
,	O
despite	O
different	O
genetic	O
backgrounds	O
,	O
including	O
different	O
status	O
of	O
a	O
polymorphism	O
in	O
the	O
EGFR	B-GeneOrGeneProduct
gene	O
.	O
Large	O
deletion	O
involving	O
exon	O
5	O
of	O
the	O
arylsulfatase	B-GeneOrGeneProduct
B	I-GeneOrGeneProduct
gene	O
caused	O
apparent	O
homozygosity	O
in	O
a	O
mucopolysaccharidosis	B-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
VI	I-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
.	O

Apparent	O
homozygosity	O
for	O
the	O
mutation	O
p	B-SequenceVariant
.	O
R315X	I-SequenceVariant
present	O
on	O
exon	O
5	O
of	O
the	O
arylsulfatase	B-GeneOrGeneProduct
B	I-GeneOrGeneProduct
(	O
ARSB	B-GeneOrGeneProduct
)	O
gene	O
in	O
a	O
mucopolysaccharidosis	B-DiseaseOrPhenotypicFeature
type	I-DiseaseOrPhenotypicFeature
VI	I-DiseaseOrPhenotypicFeature
patient	B-OrganismTaxon
was	O
solved	O
in	O
this	O
study	O
by	O
further	O
testing	O
for	O
a	O
second	O
mutation	O
.	O

Patient	B-OrganismTaxon
cDNA	O
analysis	O
revealed	O
that	O
the	O
entire	O
exon	O
5	O
of	O
the	O
ARSB	B-GeneOrGeneProduct
gene	O
was	O
lacking	O
;	O
this	O
new	O
mutation	O
was	O
identified	O
as	O
c	B-SequenceVariant
.	O
899	I-SequenceVariant
-	O
1142del	I-SequenceVariant
.	O

As	O
the	O
genomic	O
DNA	O
sequencing	O
excluded	O
the	O
presence	O
of	O
splicing	O
mutations	O
,	O
polymerase	O
chain	O
reaction	O
analysis	O
was	O
performed	O
for	O
polymorphisms	O
listed	O
in	O
the	O
NCBI	O
SNP	O
database	O
for	O
the	O
ARSB	B-GeneOrGeneProduct
gene	O
.	O

This	O
allowed	O
the	O
mutation	O
at	O
the	O
genomic	O
DNA	O
level	O
to	O
be	O
identified	O
as	O
g	B-SequenceVariant
.	O
99367	I-SequenceVariant
-	O
102002del	I-SequenceVariant
;	O
this	O
gross	O
deletion	O
,	O
involving	O
the	O
entire	O
exon	O
5	O
of	O
the	O
gene	O
and	O
parts	O
of	O
introns	O
4	O
and	O
5	O
led	O
to	O
a	O
frameshift	O
starting	O
at	O
amino	O
acid	O
300	O
and	O
resulting	O
in	O
a	O
protein	O
with	O
39%	O
amino	O
acids	O
different	O
from	O
the	O
normal	O
enzyme	O
.	O

We	O
stress	O
that	O
extensive	O
DNA	O
analysis	O
needs	O
to	O
be	O
performed	O
in	O
case	O
of	O
apparent	O
homozygosity	O
to	O
avoid	O
potential	O
errors	O
in	O
genetic	O
counseling	O
.	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
in	O
13%	O
of	O
age	O
-	O
matched	O
Czech	O
children	O
with	O
primary	B-DiseaseOrPhenotypicFeature
microcephaly	I-DiseaseOrPhenotypicFeature
.	O

The	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
is	O
a	O
rare	O
autosomal	B-DiseaseOrPhenotypicFeature
recessive	I-DiseaseOrPhenotypicFeature
chromosomal	I-DiseaseOrPhenotypicFeature
instability	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
characterized	O
by	O
early	O
growth	B-DiseaseOrPhenotypicFeature
retardation	I-DiseaseOrPhenotypicFeature
,	O
congenital	B-DiseaseOrPhenotypicFeature
microcephaly	I-DiseaseOrPhenotypicFeature
,	O
immunodeficiency	B-DiseaseOrPhenotypicFeature
,	O
borderline	O
mental	O
development	O
,	O
and	O
a	O
high	O
tendency	O
to	O
lymphoreticular	B-DiseaseOrPhenotypicFeature
malignancies	I-DiseaseOrPhenotypicFeature
.	O

Most	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
are	O
of	O
Slavonic	O
origin	O
,	O
and	O
all	O
of	O
them	O
known	O
so	O
far	O
carry	O
a	O
founder	O
homozygous	O
5	B-SequenceVariant
nucleotide	I-SequenceVariant
deletion	I-SequenceVariant
in	O
the	O
NBS1	B-GeneOrGeneProduct
gene	O
.	O

Microcephaly	B-DiseaseOrPhenotypicFeature
was	O
present	O
in	O
100%	O
of	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
in	O
a	O
recent	O
large	O
international	O
cooperative	O
study	O
.	O

The	O
frequency	O
of	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
among	O
children	O
with	O
primary	B-DiseaseOrPhenotypicFeature
microcephaly	I-DiseaseOrPhenotypicFeature
was	O
not	O
known	O
.	O

Early	O
correct	O
diagnosis	O
of	O
the	O
syndrome	O
is	O
crucial	O
for	O
appropriate	O
preventive	O
care	O
and	O
therapy	O
.	O

We	O
tested	O
67	O
Czech	O
patients	B-OrganismTaxon
of	O
different	O
ages	O
with	O
simple	O
microcephaly	O
for	O
the	O
presence	O
of	O
the	O
most	O
common	O
mutation	O
in	O
the	O
NBS1	B-GeneOrGeneProduct
gene	O
.	O

Three	O
new	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
cases	O
were	O
detected	O
in	O
this	O
cohort	O
,	O
representing	O
4	O
.	O
5%	O
of	O
the	O
cohort	O
.	O

All	O
these	O
newly	O
diagnosed	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
were	O
younger	O
than	O
10	O
months	O
at	O
the	O
time	O
of	O
diagnosis	O
.	O

They	O
were	O
all	O
born	O
within	O
a	O
2	O
.	O
5	O
-	O
year	O
period	O
.	O

Twenty	O
-	O
three	O
of	O
the	O
67	O
children	O
in	O
the	O
cohort	O
were	O
born	O
within	O
this	O
2	O
.	O
5	O
-	O
year	O
period	O
,	O
representing	O
a	O
13%	O
incidence	O
of	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
.	O

Frequency	O
of	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
heterozygotes	O
among	O
infants	O
in	O
the	O
Czech	O
Republic	O
is	O
1	O
:	O
130	O
-	O
158	O
and	O
the	O
birth	O
rate	O
is	O
90	O
,	O
000	O
per	O
year	O
,	O
therefore	O
in	O
the	O
time	O
span	O
of	O
2	O
.	O
5	O
years	O
,	O
three	O
new	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
homozygotes	O
are	O
expected	O
to	O
be	O
born	O
.	O

Therefore	O
we	O
assume	O
that	O
by	O
DNA	O
testing	O
of	O
Czech	O
primary	O
microcephalic	O
children	O
it	O
is	O
possible	O
to	O
detect	O
all	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
to	O
be	O
expected	O
.	O

The	O
age	O
at	O
correct	O
diagnosis	O
was	O
lowered	O
from	O
7	O
.	O
1	O
years	O
at	O
the	O
time	O
before	O
DNA	O
testing	O
,	O
to	O
well	O
under	O
1	O
year	O
of	O
age	O
.	O

All	O
new	O
Nijmegen	B-DiseaseOrPhenotypicFeature
breakage	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
could	O
receive	O
appropriate	O
preventive	O
care	O
,	O
which	O
should	O
significantly	O
improve	O
their	O
life	O
expectancy	O
and	O
prognosis	O
.	O
CTR9	B-GeneOrGeneProduct
/	O
PAF1c	B-GeneOrGeneProduct
regulates	O
molecular	O
lineage	O
identity	O
,	O
histone	B-GeneOrGeneProduct
H3K36	I-GeneOrGeneProduct
trimethylation	O
and	O
genomic	O
imprinting	O
during	O
preimplantation	O
development	O
.	O

Genome	O
-	O
wide	O
epigenetic	O
reprogramming	O
is	O
required	O
for	O
successful	O
preimplantation	O
development	O
.	O

Inappropriate	O
or	O
deficient	O
chromatin	O
regulation	O
can	O
result	O
in	O
defective	O
lineage	O
specification	O
and	O
loss	O
of	O
genomic	O
imprinting	O
,	O
compromising	O
normal	O
development	O
.	O

Here	O
we	O
report	O
that	O
two	O
members	O
of	O
the	O
RNA	B-GeneOrGeneProduct
polymerase	I-GeneOrGeneProduct
II	I-GeneOrGeneProduct
associated	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
,	O
homolog	I-GeneOrGeneProduct
(	O
Saccharomyces	I-GeneOrGeneProduct
cerevisiae	I-GeneOrGeneProduct
)	O
complex	I-GeneOrGeneProduct
(	O
PAF1	B-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
)	O
components	O
,	O
Ctr9	B-GeneOrGeneProduct
and	O
Rtf1	B-GeneOrGeneProduct
,	O
are	O
required	O
during	O
mammalian	O
preimplantation	O
development	O
.	O

We	O
demonstrate	O
that	O
Ctr9	B-GeneOrGeneProduct
-	O
deficient	O
embryos	O
fail	O
to	O
correctly	O
specify	O
lineages	O
at	O
the	O
blastocyst	O
stage	O
.	O

Expression	O
of	O
some	O
lineage	O
specific	O
factors	O
is	O
markedly	O
reduced	O
in	O
Ctr9	B-GeneOrGeneProduct
knockdown	O
embryos	O
,	O
including	O
Eomes	B-GeneOrGeneProduct
,	O
Elf5	B-GeneOrGeneProduct
and	O
Sox2	B-GeneOrGeneProduct
,	O
while	O
others	O
are	O
inappropriately	O
expressed	O
(	O
Oct4	B-GeneOrGeneProduct
,	O
Nanog	B-GeneOrGeneProduct
,	O
Gata6	B-GeneOrGeneProduct
,	O
Fgf4	B-GeneOrGeneProduct
and	O
Sox17	B-GeneOrGeneProduct
)	O
.	O

We	O
also	O
show	O
that	O
several	O
imprinted	O
genes	O
(	O
Mest	B-GeneOrGeneProduct
,	O
Peg3	B-GeneOrGeneProduct
,	O
Snrpn	B-GeneOrGeneProduct
and	O
Meg3	B-GeneOrGeneProduct
)	O
are	O
aberrantly	O
expressed	O
although	O
allele	O
specific	O
DNA	O
methylation	O
is	O
not	O
altered	O
.	O

We	O
document	O
a	O
loss	O
of	O
histone	B-GeneOrGeneProduct
H3	I-GeneOrGeneProduct
lysine	B-SequenceVariant
36	I-SequenceVariant
trimethylation	O
(	O
H3K36me3	B-GeneOrGeneProduct
)	O
in	O
Ctr9	B-GeneOrGeneProduct
-	O
deficient	O
embryos	O
and	O
confirm	O
that	O
knockdown	O
of	O
either	O
Setd2	B-GeneOrGeneProduct
or	O
Rtf1	B-GeneOrGeneProduct
results	O
in	O
similar	O
phenotypes	O
.	O

These	O
findings	O
show	O
that	O
the	O
PAF1	B-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
is	O
required	O
for	O
mammalian	O
development	O
,	O
likely	O
through	O
regulation	O
of	O
H3K36me3	B-GeneOrGeneProduct
,	O
and	O
indicate	O
functional	O
conservation	O
of	O
the	O
PAF1	B-GeneOrGeneProduct
complex	I-GeneOrGeneProduct
from	O
yeast	B-OrganismTaxon
to	O
mammals	O
in	O
vivo	O
.	O
Salidroside	B-ChemicalEntity
Ameliorates	O
Renal	B-DiseaseOrPhenotypicFeature
Interstitial	I-DiseaseOrPhenotypicFeature
Fibrosis	I-DiseaseOrPhenotypicFeature
by	O
Inhibiting	O
the	O
TLR4	B-GeneOrGeneProduct
/	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
and	O
MAPK	B-GeneOrGeneProduct
Signaling	O
Pathways	O
.	O

Salidroside	B-ChemicalEntity
(	O
Sal	B-ChemicalEntity
)	O
is	O
an	O
active	O
ingredient	O
that	O
is	O
isolated	O
from	O
Rhodiola	B-OrganismTaxon
rosea	I-OrganismTaxon
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
anti	O
-	O
inflammatory	B-DiseaseOrPhenotypicFeature
activities	O
and	O
a	O
renal	O
protective	O
effect	O
.	O

However	O
,	O
the	O
role	O
of	O
Sal	B-ChemicalEntity
on	O
renal	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
has	O
not	O
yet	O
been	O
elucidated	O
.	O

Here	O
,	O
the	O
purpose	O
of	O
the	O
current	O
study	O
is	O
to	O
test	O
the	O
protective	O
effects	O
of	O
Sal	B-ChemicalEntity
against	O
renal	B-DiseaseOrPhenotypicFeature
interstitial	I-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
(	O
RIF	B-DiseaseOrPhenotypicFeature
)	O
,	O
and	O
to	O
explore	O
the	O
underlying	O
mechanisms	O
using	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
models	O
.	O

In	O
this	O
study	O
,	O
we	O
establish	O
the	O
unilateral	B-DiseaseOrPhenotypicFeature
ureteric	I-DiseaseOrPhenotypicFeature
obstruction	I-DiseaseOrPhenotypicFeature
(	O
UUO	B-DiseaseOrPhenotypicFeature
)	O
or	O
folic	B-ChemicalEntity
acid	I-ChemicalEntity
(	O
FA	B-ChemicalEntity
)	O
-	O
induced	O
mice	B-OrganismTaxon
renal	B-DiseaseOrPhenotypicFeature
interstitial	I-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
in	O
vivo	O
and	O
the	O
transforming	B-GeneOrGeneProduct
growth	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
(	O
TGF	I-GeneOrGeneProduct
)	O
-	O
beta1	I-GeneOrGeneProduct
-	O
stimulated	O
human	B-OrganismTaxon
proximal	O
tubular	O
epithelial	O
cell	O
(	O
HK	B-CellLine
-	O
2	I-CellLine
)	O
model	O
in	O
vitro	O
.	O

The	O
levels	O
of	O
kidney	O
functional	O
parameters	O
and	O
inflammatory	B-DiseaseOrPhenotypicFeature
cytokines	O
in	O
serum	O
are	O
examined	O
.	O

The	O
degree	O
of	O
renal	B-DiseaseOrPhenotypicFeature
damage	I-DiseaseOrPhenotypicFeature
and	O
fibrosis	B-DiseaseOrPhenotypicFeature
is	O
determined	O
by	O
histological	O
assessment	O
.	O

Immunohistochemistry	O
and	O
western	O
blotting	O
are	O
used	O
to	O
determine	O
the	O
mechanisms	O
of	O
Sal	B-ChemicalEntity
against	O
RIF	B-DiseaseOrPhenotypicFeature
.	O

Our	O
results	O
show	O
that	O
treatment	O
with	O
Sal	B-ChemicalEntity
can	O
ameliorate	O
tubular	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	O
deposition	O
of	O
the	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
components	O
(	O
including	O
collagen	B-GeneOrGeneProduct
SH	I-GeneOrGeneProduct
and	O
collagen	B-GeneOrGeneProduct
I	I-GeneOrGeneProduct
)	O
.	O

Furthermore	O
,	O
Sal	B-ChemicalEntity
administration	O
significantly	O
suppresses	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
,	O
as	O
evidenced	O
by	O
a	O
decreased	O
expression	O
of	O
alpha	B-GeneOrGeneProduct
-	O
SMA	I-GeneOrGeneProduct
,	O
vimentin	B-GeneOrGeneProduct
,	O
TGF	B-GeneOrGeneProduct
-	O
beta1	I-GeneOrGeneProduct
,	O
snail	B-GeneOrGeneProduct
,	O
slug	B-GeneOrGeneProduct
,	O
and	O
a	O
largely	O
restored	O
expression	O
of	O
E	B-GeneOrGeneProduct
-	O
cadherin	I-GeneOrGeneProduct
.	O

Additionally	O
,	O
Sal	B-ChemicalEntity
also	O
reduces	O
the	O
levels	O
of	O
serum	O
biochemical	O
markers	O
(	O
serum	O
creatinine	B-ChemicalEntity
,	O
Scr	O
;	O
blood	O
urea	B-ChemicalEntity
nitrogen	B-ChemicalEntity
,	O
BUN	O
;	O
and	O
uric	B-ChemicalEntity
acid	I-ChemicalEntity
,	O
UA	B-ChemicalEntity
)	O
and	O
decreases	O
the	O
release	O
of	O
inflammatory	B-DiseaseOrPhenotypicFeature
cytokines	O
(	O
IL	B-GeneOrGeneProduct
-	O
1beta	I-GeneOrGeneProduct
,	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
,	O
TNF	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
)	O
.	O

Further	O
study	O
revealed	O
that	O
the	O
effect	O
of	O
Sal	B-ChemicalEntity
on	O
renal	B-DiseaseOrPhenotypicFeature
interstitial	I-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
is	O
associated	O
with	O
the	O
lower	O
expression	O
of	O
TLR4	B-GeneOrGeneProduct
,	O
p	O
-	O
IkappaBalpha	B-GeneOrGeneProduct
,	O
p	O
-	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
and	O
mitogen	B-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinases	I-GeneOrGeneProduct
(	O
MAPK	B-GeneOrGeneProduct
)	O
,	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

In	O
conclusion	O
,	O
Sal	B-ChemicalEntity
treatment	O
improves	O
kidney	O
function	O
,	O
ameliorates	O
the	O
deposition	O
of	O
the	O
ECM	O
components	O
and	O
relieves	O
the	O
protein	O
levels	O
of	O
EMT	O
markers	O
in	O
mouse	B-OrganismTaxon
kidneys	O
and	O
HK	B-CellLine
-	O
2	I-CellLine
cells	O
.	O

Furthermore	O
,	O
Sal	B-ChemicalEntity
treatment	O
significantly	O
decreases	O
the	O
release	O
of	O
inflammatory	B-DiseaseOrPhenotypicFeature
cytokines	O
and	O
inhibits	O
the	O
TLR4	B-GeneOrGeneProduct
/	O
NF	B-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
and	O
MAPK	B-GeneOrGeneProduct
signaling	O
pathways	O
.	O

Collectively	O
,	O
these	O
results	O
suggest	O
that	O
the	O
administration	O
of	O
Sal	B-ChemicalEntity
could	O
be	O
a	O
novel	O
therapeutic	O
strategy	O
in	O
treating	O
renal	B-DiseaseOrPhenotypicFeature
fibrosis	I-DiseaseOrPhenotypicFeature
.	O
Neuregulin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
and	O
neuregulin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
differentially	O
affect	O
the	O
migration	O
and	O
invasion	O
of	O
malignant	B-DiseaseOrPhenotypicFeature
peripheral	I-DiseaseOrPhenotypicFeature
nerve	I-DiseaseOrPhenotypicFeature
sheath	I-DiseaseOrPhenotypicFeature
tumor	I-DiseaseOrPhenotypicFeature
cells	O
.	O

Malignant	B-DiseaseOrPhenotypicFeature
peripheral	I-DiseaseOrPhenotypicFeature
nerve	I-DiseaseOrPhenotypicFeature
sheath	I-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
(	O
MPNSTs	B-DiseaseOrPhenotypicFeature
)	O
are	O
the	O
most	O
common	O
malignancy	B-DiseaseOrPhenotypicFeature
associated	O
with	O
neurofibromatosis	B-GeneOrGeneProduct
Type	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
NF1	B-GeneOrGeneProduct
)	O
.	O

These	O
Schwann	O
cell	O
lineage	O
-	O
derived	O
sarcomas	B-DiseaseOrPhenotypicFeature
aggressively	O
invade	O
adjacent	O
nerve	O
and	O
soft	O
tissue	O
,	O
frequently	O
precluding	O
surgical	O
resection	O
.	O

Little	O
is	O
known	O
regarding	O
the	O
mechanisms	O
underlying	O
this	O
invasive	O
behavior	O
.	O

We	O
have	O
shown	O
that	O
MPNSTs	B-DiseaseOrPhenotypicFeature
express	O
neuregulin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
NRG	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
)	O
beta	I-GeneOrGeneProduct
isoforms	O
,	O
which	O
promote	O
Schwann	O
cell	O
migration	O
during	O
development	O
,	O
and	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
isoforms	O
,	O
whose	O
effects	O
on	O
Schwann	O
cells	O
are	O
poorly	O
understood	O
.	O

Hypothesizing	O
that	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
and	O
/	O
or	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
promote	O
MPNST	B-DiseaseOrPhenotypicFeature
invasion	O
,	O
we	O
found	O
that	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
promoted	O
MPNST	B-DiseaseOrPhenotypicFeature
migration	O
in	O
a	O
substrate	O
-	O
specific	O
manner	O
,	O
markedly	O
enhancing	O
migration	O
on	O
laminin	B-GeneOrGeneProduct
but	O
not	O
on	O
collagen	B-GeneOrGeneProduct
type	I-GeneOrGeneProduct
I	I-GeneOrGeneProduct
or	O
fibronectin	B-GeneOrGeneProduct
.	O

The	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
receptors	O
erbB3	B-GeneOrGeneProduct
and	O
erbB4	B-GeneOrGeneProduct
were	O
present	O
in	O
MPNST	B-DiseaseOrPhenotypicFeature
invadopodia	O
(	O
processes	O
mediating	O
invasion	O
)	O
,	O
partially	O
colocalized	O
with	O
focal	B-GeneOrGeneProduct
adhesion	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
and	O
the	O
laminin	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
beta	B-GeneOrGeneProduct
(	O
1	I-GeneOrGeneProduct
)	O
-	O
integrin	I-GeneOrGeneProduct
and	O
coimmunoprecipitated	O
with	O
beta	B-GeneOrGeneProduct
(	O
1	I-GeneOrGeneProduct
)	O
-	O
integrin	I-GeneOrGeneProduct
.	O

NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
stimulated	O
human	B-OrganismTaxon
and	O
murine	B-OrganismTaxon
MPNST	B-DiseaseOrPhenotypicFeature
cell	O
migration	O
and	O
invasion	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
in	O
three	O
-	O
dimensional	O
migration	O
assays	O
,	O
acting	O
as	O
a	O
chemotactic	O
factor	O
.	O

Both	O
baseline	O
and	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
-	O
induced	O
migration	O
were	O
erbB	B-GeneOrGeneProduct
-	O
dependent	O
and	O
required	O
the	O
action	O
of	O
MEK	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
,	O
SAPK	B-GeneOrGeneProduct
/	O
JNK	B-GeneOrGeneProduct
,	O
PI	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
,	O
Src	B-GeneOrGeneProduct
family	I-GeneOrGeneProduct
kinases	I-GeneOrGeneProduct
and	O
ROCK	B-GeneOrGeneProduct
-	O
I	I-GeneOrGeneProduct
/	O
II	I-GeneOrGeneProduct
.	O

In	O
contrast	O
,	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
had	O
no	O
effect	O
on	O
the	O
migration	O
and	O
invasion	O
of	O
some	O
MPNST	B-DiseaseOrPhenotypicFeature
lines	O
and	O
inhibited	O
the	O
migration	O
of	O
others	O
.	O

While	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
potently	O
and	O
persistently	O
activated	O
Erk	B-GeneOrGeneProduct
1	I-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
,	O
SAPK	B-GeneOrGeneProduct
/	O
JNK	B-GeneOrGeneProduct
,	O
Akt	B-GeneOrGeneProduct
and	O
Src	B-GeneOrGeneProduct
family	I-GeneOrGeneProduct
kinases	I-GeneOrGeneProduct
,	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
did	O
not	O
activate	O
Akt	B-GeneOrGeneProduct
and	O
activated	O
these	O
other	O
kinases	O
with	O
kinetics	O
distinct	O
from	O
those	O
evident	O
in	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
-	O
stimulated	O
cells	O
.	O

These	O
findings	O
suggest	O
that	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
enhances	O
MPNST	B-DiseaseOrPhenotypicFeature
migration	O
and	O
that	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
and	O
NRG	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
alpha	I-GeneOrGeneProduct
differentially	O
modulate	O
this	O
process	O
.	O
Critical	O
role	O
of	O
neuronal	B-GeneOrGeneProduct
pentraxin	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
in	O
mitochondria	O
-	O
mediated	O
hypoxic	B-DiseaseOrPhenotypicFeature
-	O
ischemic	I-DiseaseOrPhenotypicFeature
neuronal	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
.	O

Developing	O
brain	O
is	O
highly	O
susceptible	O
to	O
hypoxic	B-DiseaseOrPhenotypicFeature
-	O
ischemic	I-DiseaseOrPhenotypicFeature
(	O
HI	I-DiseaseOrPhenotypicFeature
)	O
injury	I-DiseaseOrPhenotypicFeature
leading	O
to	O
severe	O
neurological	B-DiseaseOrPhenotypicFeature
disabilities	I-DiseaseOrPhenotypicFeature
in	O
surviving	O
infants	O
and	O
children	O
.	O

Previously	O
,	O
we	O
have	O
reported	O
induction	O
of	O
neuronal	B-GeneOrGeneProduct
pentraxin	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
(	O
NP1	B-GeneOrGeneProduct
)	O
,	O
a	O
novel	O
neuronal	O
protein	O
of	O
long	O
-	O
pentraxin	O
family	O
,	O
following	O
HI	B-DiseaseOrPhenotypicFeature
neuronal	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
.	O

Here	O
,	O
we	O
investigated	O
how	O
this	O
specific	O
signal	O
is	O
propagated	O
to	O
cause	O
the	O
HI	B-DiseaseOrPhenotypicFeature
neuronal	I-DiseaseOrPhenotypicFeature
death	I-DiseaseOrPhenotypicFeature
.	O

We	O
used	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
NP1	B-GeneOrGeneProduct
knockout	O
(	O
NP1	B-GeneOrGeneProduct
-	O
KO	O
)	O
mouse	B-OrganismTaxon
hippocampal	O
cultures	O
,	O
modeled	O
in	O
vitro	O
following	O
exposure	O
to	O
oxygen	B-ChemicalEntity
glucose	B-ChemicalEntity
deprivation	O
(	O
OGD	O
)	O
,	O
and	O
in	O
vivo	O
neonatal	O
(	O
P9	O
-	O
10	O
)	O
mouse	B-OrganismTaxon
model	O
of	O
HI	B-DiseaseOrPhenotypicFeature
brain	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
.	O

Our	O
results	O
show	O
induction	O
of	O
NP1	B-GeneOrGeneProduct
in	O
primary	O
hippocampal	O
neurons	O
following	O
OGD	O
exposure	O
(	O
4	O
-	O
8	O
h	O
)	O
and	O
in	O
the	O
ipsilateral	O
hippocampal	O
CA1	B-GeneOrGeneProduct
and	O
CA3	B-GeneOrGeneProduct
regions	O
at	O
24	O
-	O
48	O
h	O
post	O
-	O
HI	O
compared	O
to	O
the	O
contralateral	O
side	O
.	O

We	O
also	O
found	O
increased	O
PTEN	B-GeneOrGeneProduct
activity	O
concurrent	O
with	O
OGD	O
time	O
-	O
dependent	O
(	O
4	O
-	O
8	O
h	O
)	O
dephosphorylation	O
of	O
Akt	B-GeneOrGeneProduct
(	O
Ser473	B-SequenceVariant
)	O
and	O
GSK	B-GeneOrGeneProduct
-	O
3b	I-GeneOrGeneProduct
(	O
Ser9	B-SequenceVariant
)	O
.	O

OGD	O
also	O
caused	O
a	O
time	O
-	O
dependent	O
decrease	O
in	O
the	O
phosphorylation	O
of	O
Bad	B-GeneOrGeneProduct
(	O
Ser136	B-SequenceVariant
)	O
,	O
and	O
Bax	B-GeneOrGeneProduct
protein	O
levels	O
.	O

Immunofluorescence	O
staining	O
and	O
subcellular	O
fractionation	O
analyses	O
revealed	O
increased	O
mitochondrial	O
translocation	O
of	O
Bad	B-GeneOrGeneProduct
and	O
Bax	B-GeneOrGeneProduct
proteins	O
from	O
cytoplasm	O
following	O
OGD	O
(	O
4	O
h	O
)	O
and	O
simultaneously	O
increased	O
release	O
of	O
Cyt	B-GeneOrGeneProduct
C	I-GeneOrGeneProduct
from	O
mitochondria	O
followed	O
by	O
activation	O
of	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
.	O

NP1	B-GeneOrGeneProduct
protein	O
was	O
immunoprecipitated	O
with	O
Bad	B-GeneOrGeneProduct
and	O
Bax	B-GeneOrGeneProduct
proteins	O
;	O
OGD	O
caused	O
increased	O
interactions	O
of	O
NP1	B-GeneOrGeneProduct
with	O
Bad	B-GeneOrGeneProduct
and	O
Bax	B-GeneOrGeneProduct
,	O
thereby	O
,	O
facilitating	O
their	O
mitochondrial	O
translocation	O
and	O
dissipation	O
of	O
mitochondrial	O
membrane	O
potential	O
(	O
D	O
(	O
m	O
)	O
)	O
.	O

This	O
NP1	B-GeneOrGeneProduct
induction	O
preceded	O
the	O
increased	O
mitochondrial	O
release	O
of	O
cytochrome	B-GeneOrGeneProduct
C	I-GeneOrGeneProduct
(	O
Cyt	B-GeneOrGeneProduct
C	I-GeneOrGeneProduct
)	O
into	O
the	O
cytosol	O
,	O
activation	O
of	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
and	O
OGD	O
time	O
-	O
dependent	O
cell	O
death	O
in	O
WT	O
primary	O
hippocampal	O
neurons	O
.	O

In	O
contrast	O
,	O
in	O
NP1	B-GeneOrGeneProduct
-	O
KO	O
neurons	O
there	O
was	O
no	O
translocation	O
of	O
Bad	B-GeneOrGeneProduct
and	O
Bax	B-GeneOrGeneProduct
from	O
cytosol	O
to	O
the	O
mitochondria	O
,	O
and	O
no	O
evidence	O
of	O
D	O
(	O
m	O
)	O
loss	O
,	O
increased	O
Cyt	B-GeneOrGeneProduct
C	I-GeneOrGeneProduct
release	O
and	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
activation	O
following	O
OGD	O
;	O
which	O
resulted	O
in	O
significantly	O
reduced	O
neuronal	B-DiseaseOrPhenotypicFeature
death	I-DiseaseOrPhenotypicFeature
.	O

Our	O
results	O
indicate	O
a	O
regulatory	O
role	O
of	O
NP1	B-GeneOrGeneProduct
in	O
Bad	B-GeneOrGeneProduct
/	O
Bax	B-GeneOrGeneProduct
-	O
dependent	O
mitochondrial	O
release	O
of	O
Cyt	B-GeneOrGeneProduct
C	I-GeneOrGeneProduct
and	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
activation	O
.	O

Together	O
our	O
findings	O
demonstrate	O
a	O
novel	O
mechanism	O
by	O
which	O
NP1	B-GeneOrGeneProduct
regulates	O
mitochondria	O
-	O
driven	O
hippocampal	O
cell	O
death	O
;	O
suggesting	O
NP1	B-GeneOrGeneProduct
as	O
a	O
potential	O
therapeutic	O
target	O
against	O
HI	B-DiseaseOrPhenotypicFeature
brain	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
in	O
neonates	O
.	O
Repeated	O
otilonium	B-ChemicalEntity
bromide	I-ChemicalEntity
administration	O
prevents	O
neurotransmitter	B-ChemicalEntity
changes	O
in	O
colon	O
of	O
rats	B-OrganismTaxon
underwent	O
to	O
wrap	O
restraint	O
stress	O
.	O

Otilonium	B-ChemicalEntity
bromide	I-ChemicalEntity
(	O
OB	B-ChemicalEntity
)	O
is	O
a	O
spasmolytic	O
drug	O
successfully	O
used	O
for	O
the	O
treatment	O
of	O
irritable	B-DiseaseOrPhenotypicFeature
bowel	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
IBS	B-DiseaseOrPhenotypicFeature
)	O
.	O

Its	O
efficacy	O
has	O
been	O
attributed	O
to	O
the	O
block	O
of	O
L	B-GeneOrGeneProduct
-	O
and	I-GeneOrGeneProduct
T	I-GeneOrGeneProduct
-	O
type	I-GeneOrGeneProduct
Ca	I-GeneOrGeneProduct
(	O
2	I-GeneOrGeneProduct
+	O
)	O
channels	I-GeneOrGeneProduct
and	O
muscarinic	B-GeneOrGeneProduct
and	I-GeneOrGeneProduct
tachykinin	I-GeneOrGeneProduct
receptors	I-GeneOrGeneProduct
in	O
the	O
smooth	O
muscle	O
.	O

Furthermore	O
,	O
in	O
healthy	O
rats	B-OrganismTaxon
,	O
repeated	O
OB	B-ChemicalEntity
administration	O
modified	O
neurotransmitter	B-ChemicalEntity
expression	O
and	O
function	O
suggesting	O
other	O
mechanisms	O
of	O
action	O
.	O

On	O
this	O
basis	O
,	O
we	O
investigated	O
whether	O
repeated	O
OB	B-ChemicalEntity
treatment	O
prevented	O
the	O
functional	O
and	O
neurochemical	O
changes	O
observed	O
in	O
the	O
colon	O
of	O
rats	B-OrganismTaxon
underwent	O
to	O
wrap	O
restrain	O
stress	O
(	O
WRS	O
)	O
a	O
psychosocial	O
stressor	O
considered	O
suitable	O
to	O
reproduce	O
the	O
main	O
IBS	B-DiseaseOrPhenotypicFeature
signs	O
and	O
symptoms	O
.	O

In	O
control	O
,	O
WRS	O
and	O
OB	B-ChemicalEntity
/	O
WRS	O
rats	B-OrganismTaxon
functional	O
parameters	O
were	O
measured	O
in	O
vivo	O
and	O
morphological	O
investigations	O
were	O
done	O
ex	O
vivo	O
in	O
the	O
colon	O
.	O

The	O
results	O
showed	O
that	O
OB	B-ChemicalEntity
counteracts	O
most	O
of	O
the	O
neurotransmitters	B-ChemicalEntity
changes	O
caused	O
by	O
WRS	O
.	O

In	O
particular	O
,	O
the	O
drug	O
prevents	O
the	O
decrease	O
in	O
SP	B-GeneOrGeneProduct
-	O
,	O
NK1r	B-GeneOrGeneProduct
-	O
,	O
nNOS	B-GeneOrGeneProduct
-	O
,	O
VIP	B-GeneOrGeneProduct
-	O
,	O
and	O
S100b	B-GeneOrGeneProduct
-	O
immunoreactivity	O
(	O
IR	O
)	O
and	O
the	O
increase	O
in	O
CGRP	B-GeneOrGeneProduct
-	O
,	O
and	O
CRF1r	B-GeneOrGeneProduct
-	O
IR	O
.	O

On	O
the	O
contrary	O
,	O
OB	B-ChemicalEntity
does	O
not	O
affect	O
the	O
increase	O
in	O
CRF2r	B-GeneOrGeneProduct
-	O
IR	O
neurons	O
observed	O
in	O
WRS	O
rats	B-OrganismTaxon
and	O
does	O
not	O
interfere	O
with	O
the	O
mild	O
mucosal	B-DiseaseOrPhenotypicFeature
inflammation	I-DiseaseOrPhenotypicFeature
due	O
to	O
WRS	O
.	O

Finally	O
,	O
OB	B-ChemicalEntity
per	O
se	O
increases	O
the	O
Mr2	B-GeneOrGeneProduct
expression	O
in	O
the	O
muscle	O
wall	O
and	O
decreases	O
the	O
number	O
of	O
the	O
myenteric	O
ChAT	B-GeneOrGeneProduct
-	O
IR	O
neurons	O
.	O

Functional	O
findings	O
show	O
a	O
significantly	O
reduction	O
in	O
the	O
number	O
of	O
spontaneous	O
abdominal	O
contraction	O
in	O
OB	B-ChemicalEntity
treated	O
rats	B-OrganismTaxon
.	O

The	O
ability	O
of	O
OB	B-ChemicalEntity
to	O
block	O
L	B-GeneOrGeneProduct
-	O
type	I-GeneOrGeneProduct
Ca	I-GeneOrGeneProduct
(	O
2	I-GeneOrGeneProduct
+	O
)	O
channels	I-GeneOrGeneProduct
,	O
also	O
expressed	O
by	O
enteric	O
neurons	O
,	O
might	O
represent	O
a	O
possible	O
mechanism	O
through	O
which	O
OB	B-ChemicalEntity
exerts	O
its	O
actions	O
.	O
Lack	O
of	O
association	O
of	O
C	B-GeneOrGeneProduct
-	O
C	I-GeneOrGeneProduct
chemokine	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
5	I-GeneOrGeneProduct
DD32	B-SequenceVariant
deletion	I-SequenceVariant
status	O
with	O
rheumatoid	B-DiseaseOrPhenotypicFeature
arthritis	I-DiseaseOrPhenotypicFeature
,	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
,	O
lupus	B-DiseaseOrPhenotypicFeature
nephritis	I-DiseaseOrPhenotypicFeature
,	O
and	O
disease	O
severity	O
.	O

OBJECTIVE	O
:	O
C	B-GeneOrGeneProduct
-	O
C	I-GeneOrGeneProduct
chemokine	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
5	I-GeneOrGeneProduct
(	O
CCR5	B-GeneOrGeneProduct
)	O
plays	O
an	O
important	O
role	O
in	O
inflammation	B-DiseaseOrPhenotypicFeature
.	O

A	O
32	B-SequenceVariant
base	I-SequenceVariant
-	O
pair	I-SequenceVariant
(	O
DD32	I-SequenceVariant
)	O
deletion	I-SequenceVariant
in	O
the	O
CCR5	B-GeneOrGeneProduct
gene	O
leads	O
to	O
a	O
nonfunctional	O
receptor	O
.	O

This	O
deletion	O
has	O
been	O
reported	O
to	O
have	O
a	O
protective	O
effect	O
on	O
the	O
development	O
and	O
progression	O
of	O
several	O
autoimmune	B-DiseaseOrPhenotypicFeature
diseases	I-DiseaseOrPhenotypicFeature
.	O

We	O
investigated	O
whether	O
the	O
DD32	B-SequenceVariant
deletion	I-SequenceVariant
is	O
associated	O
with	O
disease	O
susceptibility	O
in	O
a	O
population	O
of	O
patients	B-OrganismTaxon
with	O
rheumatoid	B-DiseaseOrPhenotypicFeature
arthritis	I-DiseaseOrPhenotypicFeature
(	O
RA	B-DiseaseOrPhenotypicFeature
)	O
,	O
systemic	B-DiseaseOrPhenotypicFeature
lupus	I-DiseaseOrPhenotypicFeature
erythematosus	I-DiseaseOrPhenotypicFeature
(	O
SLE	B-DiseaseOrPhenotypicFeature
)	O
,	O
and	O
lupus	B-DiseaseOrPhenotypicFeature
nephritis	I-DiseaseOrPhenotypicFeature
(	O
LN	B-DiseaseOrPhenotypicFeature
)	O
;	O
and	O
whether	O
it	O
is	O
associated	O
with	O
disease	O
severity	O
.	O

METHODS	O
:	O
DNA	O
samples	O
from	O
405	O
RA	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
97	O
SLE	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
113	O
LN	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
and	O
431	O
healthy	O
controls	O
were	O
genotyped	O
for	O
the	O
CCR5	B-GeneOrGeneProduct
DD32	B-SequenceVariant
deletion	I-SequenceVariant
.	O

Differences	O
in	O
genotype	O
frequencies	O
were	O
tested	O
between	O
patients	B-OrganismTaxon
and	O
controls	O
.	O

Association	O
of	O
genotypes	O
with	O
disease	O
severity	O
was	O
analyzed	O
.	O

RESULTS	O
:	O
Genotype	O
frequencies	O
of	O
each	O
group	O
were	O
in	O
Hardy	O
-	O
Weinberg	O
equilibrium	O
.	O

The	O
genotype	O
frequencies	O
of	O
patients	B-OrganismTaxon
did	O
not	O
differ	O
significantly	O
from	O
controls	O
(	O
CCR5	B-GeneOrGeneProduct
/	O
DD32	B-SequenceVariant
,	O
DD32	B-SequenceVariant
/	O
DD32	B-SequenceVariant
:	O
RA	B-DiseaseOrPhenotypicFeature
18	O
.	O
3%	O
and	O
1	O
.	O
2%	O
,	O
respectively	O
;	O
SLE	B-DiseaseOrPhenotypicFeature
17	O
.	O
5%	O
and	O
2	O
.	O
1%	O
;	O
LN	B-DiseaseOrPhenotypicFeature
13	O
.	O
3%	O
and	O
1	O
.	O
8%	O
;	O
controls	O
20	O
.	O
0%	O
and	O
2	O
.	O
8%	O
)	O
.	O

However	O
,	O
there	O
was	O
a	O
trend	O
for	O
lower	O
DD32	B-SequenceVariant
deletion	I-SequenceVariant
allele	O
frequency	O
in	O
LN	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
compared	O
to	O
controls	O
(	O
p	O
=	O
0	O
.	O
08	O
)	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
the	O
CCR5	B-GeneOrGeneProduct
status	O
and	O
disease	O
severity	O
in	O
RA	B-DiseaseOrPhenotypicFeature
,	O
SLE	B-DiseaseOrPhenotypicFeature
,	O
or	O
LN	B-DiseaseOrPhenotypicFeature
.	O

CONCLUSION	O
:	O
Although	O
an	O
association	O
with	O
LN	B-DiseaseOrPhenotypicFeature
cannot	O
be	O
excluded	O
,	O
the	O
CCR5	B-GeneOrGeneProduct
DD32	B-SequenceVariant
deletion	I-SequenceVariant
does	O
not	O
seem	O
to	O
be	O
a	O
disease	O
susceptibility	O
genotype	O
for	O
RA	B-DiseaseOrPhenotypicFeature
,	O
SLE	B-DiseaseOrPhenotypicFeature
,	O
or	O
LN	B-DiseaseOrPhenotypicFeature
.	O

No	O
significant	O
effect	O
of	O
the	O
DD32	B-SequenceVariant
deletion	I-SequenceVariant
on	O
disease	O
severity	O
was	O
demonstrated	O
.	O
Cocaine	B-ChemicalEntity
causes	O
memory	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
learning	I-DiseaseOrPhenotypicFeature
impairments	I-DiseaseOrPhenotypicFeature
in	O
rats	B-OrganismTaxon
:	O
involvement	O
of	O
nuclear	B-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
kappa	I-GeneOrGeneProduct
B	I-GeneOrGeneProduct
and	O
oxidative	O
stress	O
,	O
and	O
prevention	O
by	O
topiramate	B-ChemicalEntity
.	O

Different	O
mechanisms	O
have	O
been	O
suggested	O
for	O
cocaine	B-ChemicalEntity
toxicity	B-DiseaseOrPhenotypicFeature
including	O
an	O
increase	O
in	O
oxidative	O
stress	O
but	O
the	O
association	O
between	O
oxidative	O
status	O
in	O
the	O
brain	O
and	O
cocaine	B-ChemicalEntity
induced	O
-	O
behaviour	O
is	O
poorly	O
understood	O
.	O

Nuclear	B-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
kappa	I-GeneOrGeneProduct
B	I-GeneOrGeneProduct
(	O
NFkappaB	B-GeneOrGeneProduct
)	O
is	O
a	O
sensor	O
of	O
oxidative	O
stress	O
and	O
participates	O
in	O
memory	O
formation	O
that	O
could	O
be	O
involved	O
in	O
drug	O
toxicity	B-DiseaseOrPhenotypicFeature
and	O
addiction	O
mechanisms	O
.	O

Therefore	O
NFkappaB	B-GeneOrGeneProduct
activity	O
,	O
oxidative	O
stress	O
,	O
neuronal	B-GeneOrGeneProduct
nitric	I-GeneOrGeneProduct
oxide	I-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
(	O
nNOS	B-GeneOrGeneProduct
)	O
activity	O
,	O
spatial	O
learning	O
and	O
memory	O
as	O
well	O
as	O
the	O
effect	O
of	O
topiramate	B-ChemicalEntity
,	O
a	O
previously	O
proposed	O
therapy	O
for	O
cocaine	B-DiseaseOrPhenotypicFeature
addiction	I-DiseaseOrPhenotypicFeature
,	O
were	O
evaluated	O
in	O
an	O
experimental	O
model	O
of	O
cocaine	B-ChemicalEntity
administration	O
in	O
rats	B-OrganismTaxon
.	O

NFkappaB	B-GeneOrGeneProduct
activity	O
was	O
decreased	O
in	O
the	O
frontal	O
cortex	O
of	O
cocaine	B-ChemicalEntity
treated	O
rats	B-OrganismTaxon
,	O
as	O
well	O
as	O
GSH	B-ChemicalEntity
concentration	O
and	O
glutathione	B-ChemicalEntity
peroxidase	O
activity	O
in	O
the	O
hippocampus	O
,	O
whereas	O
nNOS	B-GeneOrGeneProduct
activity	O
in	O
the	O
hippocampus	O
was	O
increased	O
.	O

Memory	O
retrieval	O
of	O
experiences	O
acquired	O
prior	O
to	O
cocaine	B-ChemicalEntity
administration	O
was	O
impaired	O
and	O
negatively	O
correlated	O
with	O
NFkappaB	B-GeneOrGeneProduct
activity	O
in	O
the	O
frontal	O
cortex	O
.	O

In	O
contrast	O
,	O
learning	O
of	O
new	O
tasks	O
was	O
enhanced	O
and	O
correlated	O
with	O
the	O
increase	O
of	O
nNOS	B-GeneOrGeneProduct
activity	O
and	O
the	O
decrease	O
of	O
glutathione	B-ChemicalEntity
peroxidase	O
.	O

These	O
results	O
provide	O
evidence	O
for	O
a	O
possible	O
mechanistic	O
role	O
of	O
oxidative	O
and	O
nitrosative	O
stress	O
and	O
NFkappaB	B-GeneOrGeneProduct
in	O
the	O
alterations	O
induced	O
by	O
cocaine	B-ChemicalEntity
.	O

Topiramate	B-ChemicalEntity
prevented	O
all	O
the	O
alterations	O
observed	O
,	O
showing	O
novel	O
neuroprotective	O
properties	O
.	O
D90A	B-SequenceVariant
-	O
SOD1	B-GeneOrGeneProduct
mediated	O
amyotrophic	B-DiseaseOrPhenotypicFeature
lateral	I-DiseaseOrPhenotypicFeature
sclerosis	I-DiseaseOrPhenotypicFeature
:	O
a	O
single	O
founder	O
for	O
all	O
cases	O
with	O
evidence	O
for	O
a	O
Cis	O
-	O
acting	O
disease	O
modifier	O
in	O
the	O
recessive	O
haplotype	O
.	O

More	O
than	O
100	O
different	O
heterozygous	O
mutations	O
in	O
copper	B-GeneOrGeneProduct
/	O
zinc	I-GeneOrGeneProduct
superoxide	I-GeneOrGeneProduct
dismutase	I-GeneOrGeneProduct
(	O
SOD1	B-GeneOrGeneProduct
)	O
have	O
been	O
found	O
in	O
patients	B-OrganismTaxon
with	O
amyotrophic	B-DiseaseOrPhenotypicFeature
lateral	I-DiseaseOrPhenotypicFeature
sclerosis	I-DiseaseOrPhenotypicFeature
(	O
ALS	B-DiseaseOrPhenotypicFeature
)	O
,	O
a	O
fatal	O
neurodegenerative	B-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

Uniquely	O
,	O
D90A	B-SequenceVariant
-	O
SOD1	B-GeneOrGeneProduct
has	O
been	O
identified	O
in	O
recessive	O
,	O
dominant	O
and	O
apparently	O
sporadic	O
pedigrees	O
.	O

The	O
phenotype	O
of	O
homozygotes	O
is	O
stereotyped	O
with	O
an	O
extended	O
survival	O
,	O
whereas	O
that	O
of	O
affected	O
heterozygotes	O
varies	O
.	O

The	O
frequency	O
of	O
D90A	B-SequenceVariant
-	O
SOD1	B-GeneOrGeneProduct
is	O
50	O
times	O
higher	O
in	O
Scandinavia	O
(	O
2	O
.	O
5%	O
)	O
than	O
elsewhere	O
,	O
though	O
ALS	B-DiseaseOrPhenotypicFeature
prevalence	O
is	O
not	O
raised	O
there	O
.	O

Our	O
earlier	O
study	O
indicated	O
separate	O
founders	O
for	O
recessive	O
and	O
dominant	O
/	O
sporadic	O
ALS	B-DiseaseOrPhenotypicFeature
and	O
we	O
proposed	O
a	O
disease	O
-	O
modifying	O
factor	O
linked	O
to	O
the	O
recessive	O
mutation	O
.	O

Here	O
we	O
have	O
doubled	O
our	O
sample	O
set	O
and	O
employed	O
novel	O
markers	O
to	O
characterise	O
the	O
mutation	O
'	O
s	O
origin	O
and	O
localise	O
any	O
modifying	O
factor	O
.	O

Linkage	O
disequilibrium	O
analysis	O
indicates	O
that	O
D90A	B-SequenceVariant
homozygotes	O
and	O
heterozygotes	O
share	O
a	O
rare	O
haplotype	O
and	O
are	O
all	O
descended	O
from	O
a	O
single	O
ancient	O
founder	O
(	O
alpha	O
0	O
.	O
974	O
)	O
c	O
.	O
895	O
generations	O
ago	O
.	O

Homozygotes	O
arose	O
subsequently	O
only	O
c	O
.	O
63	O
generations	O
ago	O
(	O
alpha	O
0	O
.	O
878	O
)	O
.	O

Recombination	O
has	O
reduced	O
the	O
region	O
shared	O
by	O
recessive	O
kindreds	O
to	O
97	O
-	O
265	O
kb	O
around	O
SOD1	B-GeneOrGeneProduct
,	O
excluding	O
all	O
neighbouring	O
genes	O
.	O

We	O
propose	O
that	O
a	O
cis	O
-	O
acting	O
regulatory	O
polymorphism	O
has	O
arisen	O
close	O
to	O
D90A	B-SequenceVariant
-	O
SOD1	B-GeneOrGeneProduct
in	O
the	O
recessive	O
founder	O
,	O
which	O
decreases	O
ALS	B-DiseaseOrPhenotypicFeature
susceptibility	O
in	O
heterozygotes	O
and	O
slows	O
disease	O
progression	O
.	O
Spirulina	B-OrganismTaxon
lipopolysaccharides	B-ChemicalEntity
inhibit	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
in	O
a	O
Toll	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
-	O
dependent	O
manner	O
by	O
altering	O
the	O
cytokine	O
milieu	O
from	O
interleukin	B-GeneOrGeneProduct
-	O
17	I-GeneOrGeneProduct
/	O
interleukin	B-GeneOrGeneProduct
-	O
23	I-GeneOrGeneProduct
to	O
interferon	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
.	O

Th17	O
cells	O
and	O
the	O
cytokine	O
they	O
produce	O
,	O
interleukin	B-GeneOrGeneProduct
(	O
IL	I-GeneOrGeneProduct
)	O
-	O
17	I-GeneOrGeneProduct
,	O
play	O
an	O
important	O
role	O
in	O
tumor	B-DiseaseOrPhenotypicFeature
progression	O
in	O
humans	B-OrganismTaxon
and	O
in	O
mice	B-OrganismTaxon
.	O

IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
and	O
IL	B-GeneOrGeneProduct
-	O
23	I-GeneOrGeneProduct
are	O
critical	O
cytokines	O
for	O
the	O
differentiation	O
and	O
propagation	O
of	O
Th17	O
cells	O
,	O
respectively	O
.	O

Bacterial	O
lipopolysaccharides	B-ChemicalEntity
(	O
LPS	B-ChemicalEntity
)	O
are	O
known	O
to	O
stimulate	O
immune	O
cells	O
to	O
produce	O
such	O
inflammatory	B-GeneOrGeneProduct
cytokines	I-GeneOrGeneProduct
.	O

Contrary	O
to	O
Escherichia	B-OrganismTaxon
coli	I-OrganismTaxon
(	O
E	B-OrganismTaxon
.	O

coli	I-OrganismTaxon
)	O
LPS	B-ChemicalEntity
,	O
LPS	B-ChemicalEntity
from	O
Spirulina	B-OrganismTaxon
has	O
low	O
toxicity	B-DiseaseOrPhenotypicFeature
and	O
barely	O
induces	O
in	O
vivo	O
production	O
of	O
IL	B-GeneOrGeneProduct
-	O
6	I-GeneOrGeneProduct
and	O
IL	B-GeneOrGeneProduct
-	O
23	I-GeneOrGeneProduct
in	O
mice	B-OrganismTaxon
.	O

We	O
examined	O
the	O
antitumor	O
effects	O
of	O
Spirulina	B-OrganismTaxon
LPS	B-ChemicalEntity
compared	O
to	O
E	B-OrganismTaxon
.	O

coli	I-OrganismTaxon
LPS	B-ChemicalEntity
in	O
an	O
MH134	B-CellLine
hepatoma	B-DiseaseOrPhenotypicFeature
model	O
.	O

Administration	O
of	O
Spirulina	B-OrganismTaxon
LPS	B-ChemicalEntity
suppressed	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
in	O
C3H	O
/	O
HeN	O
mice	B-OrganismTaxon
,	O
but	O
not	O
in	O
Toll	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
4	I-GeneOrGeneProduct
(	O
TLR4	B-GeneOrGeneProduct
)	O
-	O
mutant	O
C3H	O
/	O
HeJ	O
mice	B-OrganismTaxon
,	O
by	O
reducing	O
serum	O
levels	O
of	O
IL	B-GeneOrGeneProduct
-	O
17	I-GeneOrGeneProduct
and	O
IL	B-GeneOrGeneProduct
-	O
23	I-GeneOrGeneProduct
,	O
while	O
increasing	O
interferon	B-GeneOrGeneProduct
(	O
IFN	I-GeneOrGeneProduct
)	O
-	O
g	I-GeneOrGeneProduct
levels	O
.	O

The	O
antitumor	O
activity	O
and	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
production	O
were	O
mediated	O
by	O
T	O
cells	O
.	O

Moreover	O
,	O
in	O
vitro	O
experiments	O
showed	O
that	O
Spirulina	B-OrganismTaxon
LPS	B-ChemicalEntity
impaired	O
the	O
antigen	O
-	O
presenting	O
function	O
that	O
supports	O
the	O
generation	O
of	O
IL	B-GeneOrGeneProduct
-	O
17	I-GeneOrGeneProduct
-	O
producing	O
cells	O
in	O
a	O
toll	B-GeneOrGeneProduct
-	O
like	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
TLR	I-GeneOrGeneProduct
)	O
4	I-GeneOrGeneProduct
-	O
dependent	O
manner	O
.	O

Of	O
note	O
,	O
injection	O
of	O
anti	O
-	O
IL	B-GeneOrGeneProduct
-	O
17	I-GeneOrGeneProduct
antibody	O
in	O
tumor	B-DiseaseOrPhenotypicFeature
-	O
bearing	O
C3H	O
/	O
HeN	O
mice	B-OrganismTaxon
in	O
the	O
absence	O
of	O
Spirulina	B-OrganismTaxon
LPS	B-ChemicalEntity
markedly	O
suppressed	O
tumor	B-DiseaseOrPhenotypicFeature
growth	O
and	O
augmented	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
responses	O
.	O

Thus	O
,	O
our	O
results	O
support	O
the	O
notion	O
that	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
and	O
IL	B-GeneOrGeneProduct
-	O
17	I-GeneOrGeneProduct
/	O
IL	B-GeneOrGeneProduct
-	O
23	I-GeneOrGeneProduct
mutually	O
regulate	O
Th17	O
and	O
Th1	O
responses	O
in	O
tumor	B-DiseaseOrPhenotypicFeature
-	O
bearing	O
hosts	O
,	O
and	O
Spirulina	B-OrganismTaxon
LPS	B-ChemicalEntity
modulates	O
the	O
balance	O
of	O
the	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
-	O
IL	B-GeneOrGeneProduct
-	O
17	I-GeneOrGeneProduct
/	O
IL	B-GeneOrGeneProduct
-	O
23	I-GeneOrGeneProduct
axis	O
towards	O
IFN	B-GeneOrGeneProduct
-	O
g	I-GeneOrGeneProduct
production	O
,	O
which	O
leads	O
to	O
tumor	B-DiseaseOrPhenotypicFeature
inhibition	O
.	O

Furthermore	O
,	O
Spirulina	B-OrganismTaxon
LPS	B-ChemicalEntity
effectively	O
inhibited	O
the	O
spontaneous	O
development	O
of	O
mammary	B-DiseaseOrPhenotypicFeature
tumors	I-DiseaseOrPhenotypicFeature
.	O

This	O
study	O
has	O
important	O
implications	O
for	O
the	O
exploitation	O
of	O
TLR	B-GeneOrGeneProduct
-	O
based	O
immunomodulators	O
for	O
cancer	B-DiseaseOrPhenotypicFeature
immunotherapy	O
.	O
Myotonic	B-GeneOrGeneProduct
dystrophy	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
is	O
involved	O
in	O
the	O
modulation	O
of	O
the	O
Ca2	B-ChemicalEntity
+	O
homeostasis	O
in	O
skeletal	O
muscle	O
cells	O
.	O

Myotonic	B-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
(	O
DM	B-DiseaseOrPhenotypicFeature
)	O
,	O
the	O
most	O
prevalent	O
muscular	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
in	O
adults	O
,	O
is	O
caused	O
by	O
(	O
CTG	O
)	O
n	O
-	O
repeat	O
expansion	O
in	O
a	O
gene	O
encoding	O
a	O
protein	O
kinase	O
(	O
DM	B-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
;	O
DMPK	B-GeneOrGeneProduct
)	O
and	O
involves	O
changes	O
in	O
cytoarchitecture	O
and	O
ion	O
homeostasis	O
.	O

To	O
obtain	O
clues	O
to	O
the	O
normal	O
biological	O
role	O
of	O
DMPK	B-GeneOrGeneProduct
in	O
cellular	O
ion	O
homeostasis	O
,	O
we	O
have	O
compared	O
the	O
resting	O
[	O
Ca2	B-ChemicalEntity
+	O
]	O
i	O
,	O
the	O
amplitude	O
and	O
shape	O
of	O
depolarization	O
-	O
induced	O
Ca2	B-ChemicalEntity
+	O
transients	O
,	O
and	O
the	O
content	O
of	O
ATP	B-ChemicalEntity
-	O
driven	O
ion	O
pumps	O
in	O
cultured	O
skeletal	O
muscle	O
cells	O
of	O
wild	O
-	O
type	O
and	O
DMPK	B-GeneOrGeneProduct
[	O
-	O
/	O
-	O
]	O
knockout	O
mice	B-OrganismTaxon
.	O

In	O
vitro	O
-	O
differentiated	O
DMPK	B-GeneOrGeneProduct
[	O
-	O
/	O
-	O
]	O
myotubes	O
exhibit	O
a	O
higher	O
resting	O
[	O
Ca2	B-ChemicalEntity
+	O
]	O
i	O
than	O
do	O
wild	O
-	O
type	O
myotubes	O
because	O
of	O
an	O
altered	O
open	O
probability	O
of	O
voltage	O
-	O
dependent	O
l	O
-	O
type	O
Ca2	B-ChemicalEntity
+	O
and	O
Na	B-ChemicalEntity
+	O
channels	O
.	O

The	O
mutant	O
myotubes	O
exhibit	O
smaller	O
and	O
slower	O
Ca2	B-ChemicalEntity
+	O
responses	O
upon	O
triggering	O
by	O
acetylcholine	B-ChemicalEntity
or	O
high	O
external	O
K	B-ChemicalEntity
+	O
.	O

In	O
addition	O
,	O
we	O
observed	O
that	O
these	O
Ca2	B-ChemicalEntity
+	O
transients	O
partially	O
result	O
from	O
an	O
influx	O
of	O
extracellular	O
Ca2	B-ChemicalEntity
+	O
through	O
the	O
l	O
-	O
type	O
Ca2	B-ChemicalEntity
+	O
channel	O
.	O

Neither	O
the	O
content	O
nor	O
the	O
activity	O
of	O
Na	B-ChemicalEntity
+	O
/	O
K	I-ChemicalEntity
+	O
ATPase	I-ChemicalEntity
and	O
sarcoplasmic	B-ChemicalEntity
reticulum	I-ChemicalEntity
Ca2	I-ChemicalEntity
+	O
-	O
ATPase	I-ChemicalEntity
are	O
affected	O
by	O
DMPK	B-GeneOrGeneProduct
absence	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
DMPK	B-GeneOrGeneProduct
is	O
involved	O
in	O
modulating	O
the	O
initial	O
events	O
of	O
excitation	O
-	O
contraction	O
coupling	O
in	O
skeletal	O
muscle	O
.	O
Mutations	O
associated	O
with	O
variant	O
phenotypes	O
in	O
ataxia	B-DiseaseOrPhenotypicFeature
-	O
telangiectasia	I-DiseaseOrPhenotypicFeature
.	O

We	O
have	O
identified	O
14	O
families	O
with	O
ataxia	B-DiseaseOrPhenotypicFeature
-	O
telangiectasia	I-DiseaseOrPhenotypicFeature
(	O
A	B-DiseaseOrPhenotypicFeature
-	O
T	I-DiseaseOrPhenotypicFeature
)	O
in	O
which	O
mutation	O
of	O
the	O
ATM	B-GeneOrGeneProduct
gene	O
is	O
associated	O
with	O
a	O
less	O
severe	O
clinical	O
and	O
cellular	O
phenotype	O
(	O
approximately	O
10%	O
-	O
15%	O
of	O
A	B-DiseaseOrPhenotypicFeature
-	O
T	I-DiseaseOrPhenotypicFeature
families	O
identified	O
in	O
the	O
United	O
Kingdom	O
)	O
.	O

In	O
10	O
of	O
these	O
families	O
,	O
all	O
the	O
homozygotes	O
have	O
a	O
137	B-SequenceVariant
-	O
bp	I-SequenceVariant
insertion	I-SequenceVariant
in	O
their	O
cDNA	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
a	O
sequence	O
resembling	O
a	O
splice	O
-	O
donor	O
site	O
.	O

The	O
second	O
A	B-DiseaseOrPhenotypicFeature
-	O
T	I-DiseaseOrPhenotypicFeature
allele	O
has	O
a	O
different	O
mutation	O
in	O
each	O
patient	B-OrganismTaxon
.	O

We	O
show	O
that	O
the	O
less	O
severe	O
phenotype	O
in	O
these	O
patients	B-OrganismTaxon
is	O
caused	O
by	O
some	O
degree	O
of	O
normal	O
splicing	O
,	O
which	O
occurs	O
as	O
an	O
alternative	O
product	O
from	O
the	O
insertion	O
-	O
containing	O
allele	O
.	O

The	O
level	O
of	O
the	O
137	O
-	O
bp	O
PCR	O
product	O
containing	O
the	O
insertion	O
was	O
lowest	O
in	O
two	O
patients	B-OrganismTaxon
who	O
showed	O
a	O
later	O
onset	O
of	O
cerebellar	B-DiseaseOrPhenotypicFeature
ataxia	I-DiseaseOrPhenotypicFeature
.	O

A	O
further	O
four	O
families	O
who	O
do	O
not	O
have	O
this	O
insertion	O
have	O
been	O
identified	O
.	O

Mutations	O
detected	O
in	O
two	O
of	O
four	O
of	O
these	O
are	O
missense	O
mutations	O
,	O
normally	O
rare	O
in	O
A	B-DiseaseOrPhenotypicFeature
-	O
T	I-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
.	O

The	O
demonstration	O
of	O
mutations	O
giving	O
rise	O
to	O
a	O
slightly	O
milder	O
phenotype	O
in	O
A	B-DiseaseOrPhenotypicFeature
-	O
T	I-DiseaseOrPhenotypicFeature
raises	O
the	O
interesting	O
question	O
of	O
what	O
range	O
of	O
phenotypes	O
might	O
occur	O
in	O
individuals	O
in	O
whom	O
both	O
mutations	O
are	O
milder	O
.	O

One	O
possibility	O
might	O
be	O
that	O
individuals	O
who	O
are	O
compound	O
heterozygotes	O
for	O
ATM	B-GeneOrGeneProduct
mutations	O
are	O
more	O
common	O
than	O
we	O
realize	O
.	O
Omitting	O
fentanyl	B-ChemicalEntity
reduces	O
nausea	B-DiseaseOrPhenotypicFeature
and	O
vomiting	B-DiseaseOrPhenotypicFeature
,	O
without	O
increasing	O
pain	B-DiseaseOrPhenotypicFeature
,	O
after	O
sevoflurane	B-ChemicalEntity
for	O
day	O
surgery	O
.	O

BACKGROUND	O
AND	O
OBJECTIVE	O
:	O
Despite	O
advantages	O
of	O
induction	O
and	O
maintenance	O
of	O
anaesthesia	O
with	O
sevoflurane	B-ChemicalEntity
,	O
postoperative	B-DiseaseOrPhenotypicFeature
nausea	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
vomiting	I-DiseaseOrPhenotypicFeature
occurs	O
frequently	O
.	O

Fentanyl	B-ChemicalEntity
is	O
a	O
commonly	O
used	O
supplement	O
that	O
may	O
contribute	O
to	O
this	O
,	O
although	O
it	O
may	O
also	O
improve	O
analgesia	O
.	O

METHODS	O
:	O
This	O
double	O
-	O
blind	O
study	O
examined	O
the	O
incidence	O
and	O
severity	O
of	O
postoperative	B-DiseaseOrPhenotypicFeature
nausea	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
vomiting	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
in	O
the	O
first	O
24	O
h	O
after	O
sevoflurane	B-ChemicalEntity
anaesthesia	O
in	O
216	O
adult	O
day	O
surgery	O
patients	O
.	O

Patients	O
were	O
randomly	O
allocated	O
to	O
either	O
receive	O
or	O
not	O
receive	O
1	O
1	O
fentanyl	B-ChemicalEntity
,	O
while	O
a	O
third	O
group	O
received	O
dexamethasone	B-ChemicalEntity
in	O
addition	O
to	O
fentanyl	B-ChemicalEntity
.	O

RESULTS	O
:	O
Omission	O
of	O
fentanyl	B-ChemicalEntity
did	O
not	O
reduce	O
the	O
overall	O
incidence	O
of	O
postoperative	B-DiseaseOrPhenotypicFeature
nausea	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
vomiting	I-DiseaseOrPhenotypicFeature
,	O
but	O
did	O
reduce	O
the	O
incidence	O
of	O
vomiting	B-DiseaseOrPhenotypicFeature
and	O
/	O
or	O
moderate	O
to	O
severe	O
nausea	B-DiseaseOrPhenotypicFeature
prior	O
to	O
discharge	O
from	O
20%	O
and	O
17%	O
with	O
fentanyl	B-ChemicalEntity
and	O
fentanyl	B-ChemicalEntity
-	O
dexamethasone	B-ChemicalEntity
,	O
respectively	O
,	O
to	O
5%	O
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Antiemetic	O
requirements	O
were	O
reduced	O
from	O
24%	O
and	O
31%	O
to	O
7%	O
(	O
P	O
=	O
0	O
.	O
0012	O
)	O
.	O

Dexamethasone	B-ChemicalEntity
had	O
no	O
significant	O
effect	O
on	O
the	O
incidence	O
or	O
severity	O
of	O
postoperative	B-DiseaseOrPhenotypicFeature
nausea	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
vomiting	I-DiseaseOrPhenotypicFeature
.	O

Combining	O
the	O
two	O
fentanyl	B-ChemicalEntity
groups	O
revealed	O
further	O
significant	O
benefits	O
from	O
the	O
avoidance	O
of	O
opioids	O
,	O
reducing	O
postoperative	B-DiseaseOrPhenotypicFeature
nausea	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
vomiting	I-DiseaseOrPhenotypicFeature
and	O
nausea	B-DiseaseOrPhenotypicFeature
prior	O
to	O
discharge	O
from	O
35%	O
and	O
33%	O
to	O
22%	O
and	O
19%	O
(	O
P	O
=	O
0	O
.	O
049	O
and	O
P	O
=	O
0	O
.	O
035	O
)	O
,	O
respectively	O
,	O
while	O
nausea	B-DiseaseOrPhenotypicFeature
in	O
the	O
first	O
24	O
h	O
was	O
decreased	O
from	O
42%	O
to	O
27%	O
(	O
P	O
=	O
0	O
.	O
034	O
)	O
.	O

Pain	B-DiseaseOrPhenotypicFeature
severity	O
and	O
analgesic	O
requirements	O
were	O
unaffected	O
by	O
the	O
omission	O
of	O
fentanyl	B-ChemicalEntity
.	O

Fentanyl	B-ChemicalEntity
did	O
reduce	O
minor	O
intraoperative	O
movement	O
but	O
had	O
no	O
sevoflurane	B-ChemicalEntity
-	O
sparing	O
effect	O
and	O
increased	O
respiratory	B-DiseaseOrPhenotypicFeature
depression	I-DiseaseOrPhenotypicFeature
,	O
hypotension	B-DiseaseOrPhenotypicFeature
and	O
bradycardia	B-DiseaseOrPhenotypicFeature
.	O

CONCLUSION	O
:	O
As	O
fentanyl	B-ChemicalEntity
exacerbated	O
postoperative	B-DiseaseOrPhenotypicFeature
nausea	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
vomiting	I-DiseaseOrPhenotypicFeature
without	O
an	O
improvement	O
in	O
postoperative	B-DiseaseOrPhenotypicFeature
pain	I-DiseaseOrPhenotypicFeature
and	O
also	O
had	O
adverse	O
cardiorespiratory	O
effects	O
,	O
it	O
appears	O
to	O
be	O
an	O
unnecessary	O
and	O
possibly	O
detrimental	O
supplement	O
to	O
sevoflurane	B-ChemicalEntity
in	O
day	O
surgery	O
.	O
Aconitine	B-ChemicalEntity
-	O
induced	O
Ca2	B-ChemicalEntity
+	O
overload	O
causes	O
arrhythmia	B-DiseaseOrPhenotypicFeature
and	O
triggers	O
apoptosis	O
through	O
p38	B-GeneOrGeneProduct
MAPK	I-GeneOrGeneProduct
signaling	O
pathway	O
in	O
rats	B-OrganismTaxon
.	O

Aconitine	B-ChemicalEntity
is	O
a	O
major	O
bioactive	O
diterpenoid	B-ChemicalEntity
alkaloid	I-ChemicalEntity
with	O
high	O
content	O
derived	O
from	O
herbal	O
aconitum	O
plants	O
.	O

Emerging	O
evidence	O
indicates	O
that	O
voltage	O
-	O
dependent	O
Na	B-ChemicalEntity
(	O
+	O
)	O
channels	O
have	O
pivotal	O
roles	O
in	O
the	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
of	O
aconitine	B-ChemicalEntity
.	O

However	O
,	O
no	O
reports	O
are	O
available	O
on	O
the	O
role	O
of	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
in	O
aconitine	B-ChemicalEntity
poisoning	B-DiseaseOrPhenotypicFeature
.	O

In	O
this	O
study	O
,	O
we	O
explored	O
the	O
importance	O
of	O
pathological	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
signaling	O
in	O
aconitine	B-ChemicalEntity
poisoning	B-DiseaseOrPhenotypicFeature
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
found	O
that	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
overload	O
lead	O
to	O
accelerated	O
beating	O
rhythm	O
in	O
adult	O
rat	B-OrganismTaxon
ventricular	O
myocytes	O
and	O
caused	O
arrhythmia	B-DiseaseOrPhenotypicFeature
in	O
conscious	O
freely	O
moving	O
rats	B-OrganismTaxon
.	O

To	O
investigate	O
effects	O
of	O
aconitine	B-ChemicalEntity
on	O
myocardial	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
,	O
we	O
performed	O
cytotoxicity	B-DiseaseOrPhenotypicFeature
assay	O
in	O
neonatal	O
rat	B-OrganismTaxon
ventricular	O
myocytes	O
(	O
NRVMs	O
)	O
,	O
as	O
well	O
as	O
measured	O
lactate	B-GeneOrGeneProduct
dehydrogenase	I-GeneOrGeneProduct
level	O
in	O
the	O
culture	O
medium	O
of	O
NRVMs	O
and	O
activities	O
of	O
serum	O
cardiac	O
enzymes	O
in	O
rats	B-OrganismTaxon
.	O

The	O
results	O
showed	O
that	O
aconitine	B-ChemicalEntity
resulted	O
in	O
myocardial	B-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
and	O
reduced	O
NRVMs	O
viability	O
dose	O
-	O
dependently	O
.	O

To	O
confirm	O
the	O
pro	O
-	O
apoptotic	O
effects	O
,	O
we	O
performed	O
flow	O
cytometric	O
detection	O
,	O
cardiac	O
histology	O
,	O
transmission	O
electron	O
microscopy	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	B-ChemicalEntity
-	O
biotin	B-ChemicalEntity
nick	O
end	O
labeling	O
assay	O
.	O

The	O
results	O
showed	O
that	O
aconitine	B-ChemicalEntity
stimulated	O
apoptosis	O
time	O
-	O
dependently	O
.	O

The	O
expression	O
analysis	O
of	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
handling	O
proteins	O
demonstrated	O
that	O
aconitine	B-ChemicalEntity
promoted	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
overload	O
through	O
the	O
expression	O
regulation	O
of	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
handling	O
proteins	O
.	O

The	O
expression	O
analysis	O
of	O
apoptosis	O
-	O
related	O
proteins	O
revealed	O
that	O
pro	O
-	O
apoptotic	O
protein	O
expression	O
was	O
upregulated	O
,	O
and	O
anti	O
-	O
apoptotic	O
protein	O
BCL	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
expression	O
was	O
downregulated	O
.	O

Furthermore	O
,	O
increased	O
phosphorylation	O
of	O
MAPK	B-GeneOrGeneProduct
family	O
members	O
,	O
especially	O
the	O
P	O
-	O
P38	B-GeneOrGeneProduct
/	O
P38	B-GeneOrGeneProduct
ratio	O
was	O
found	O
in	O
cardiac	O
tissues	O
.	O

Hence	O
,	O
our	O
results	O
suggest	O
that	O
aconitine	B-ChemicalEntity
significantly	O
aggravates	O
Ca	B-ChemicalEntity
(	O
2	I-ChemicalEntity
+	O
)	O
overload	O
and	O
causes	O
arrhythmia	B-DiseaseOrPhenotypicFeature
and	O
finally	O
promotes	O
apoptotic	O
development	O
via	O
phosphorylation	O
of	O
P38	B-GeneOrGeneProduct
mitogen	I-GeneOrGeneProduct
-	O
activated	I-GeneOrGeneProduct
protein	I-GeneOrGeneProduct
kinase	I-GeneOrGeneProduct
.	O
Coenzyme	B-ChemicalEntity
Q10	I-ChemicalEntity
treatment	O
ameliorates	O
acute	O
cisplatin	B-ChemicalEntity
nephrotoxicity	B-DiseaseOrPhenotypicFeature
in	O
mice	B-OrganismTaxon
.	O

The	O
nephroprotective	O
effect	O
of	O
coenzyme	B-ChemicalEntity
Q10	I-ChemicalEntity
was	O
investigated	O
in	O
mice	B-OrganismTaxon
with	O
acute	B-DiseaseOrPhenotypicFeature
renal	I-DiseaseOrPhenotypicFeature
injury	I-DiseaseOrPhenotypicFeature
induced	O
by	O
a	O
single	O
i	O
.	O
p	O
.	O

injection	O
of	O
cisplatin	B-ChemicalEntity
(	O
5	O
mg	O
/	O
kg	O
)	O
.	O

Coenzyme	B-ChemicalEntity
Q10	I-ChemicalEntity
treatment	O
(	O
10	O
mg	O
/	O
kg	O
/	O
day	O
,	O
i	O
.	O
p	O
.	O
)	O
was	O
applied	O
for	O
6	O
consecutive	O
days	O
,	O
starting	O
1	O
day	O
before	O
cisplatin	B-ChemicalEntity
administration	O
.	O

Coenzyme	B-ChemicalEntity
Q10	I-ChemicalEntity
significantly	O
reduced	O
blood	B-ChemicalEntity
urea	I-ChemicalEntity
nitrogen	I-ChemicalEntity
and	O
serum	O
creatinine	B-ChemicalEntity
levels	O
which	O
were	O
increased	O
by	O
cisplatin	B-ChemicalEntity
.	O

Coenzyme	B-ChemicalEntity
Q10	I-ChemicalEntity
significantly	O
compensated	O
deficits	O
in	O
the	O
antioxidant	O
defense	O
mechanisms	O
(	O
reduced	O
glutathione	B-ChemicalEntity
level	O
and	O
superoxide	B-GeneOrGeneProduct
dismutase	I-GeneOrGeneProduct
activity	O
)	O
,	O
suppressed	O
lipid	B-ChemicalEntity
peroxidation	O
,	O
decreased	O
the	O
elevations	O
of	O
tumor	B-GeneOrGeneProduct
necrosis	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
,	O
nitric	B-ChemicalEntity
oxide	I-ChemicalEntity
and	O
platinum	B-ChemicalEntity
ion	O
concentration	O
,	O
and	O
attenuated	O
the	O
reductions	O
of	O
selenium	B-ChemicalEntity
and	O
zinc	B-ChemicalEntity
ions	O
in	O
renal	O
tissue	O
resulted	O
from	O
cisplatin	B-ChemicalEntity
administration	O
.	O

Also	O
,	O
histopathological	O
renal	B-DiseaseOrPhenotypicFeature
tissue	I-DiseaseOrPhenotypicFeature
damage	I-DiseaseOrPhenotypicFeature
mediated	O
by	O
cisplatin	B-ChemicalEntity
was	O
ameliorated	O
by	O
coenzyme	B-ChemicalEntity
Q10	I-ChemicalEntity
treatment	O
.	O

Immunohistochemical	O
analysis	O
revealed	O
that	O
coenzyme	B-ChemicalEntity
Q10	I-ChemicalEntity
significantly	O
decreased	O
the	O
cisplatin	B-ChemicalEntity
-	O
induced	O
overexpression	O
of	O
inducible	O
nitric	B-GeneOrGeneProduct
oxide	I-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
,	O
nuclear	B-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
-	O
kappaB	I-GeneOrGeneProduct
,	O
caspase	B-GeneOrGeneProduct
-	O
3	I-GeneOrGeneProduct
and	O
p53	B-GeneOrGeneProduct
in	O
renal	O
tissue	O
.	O

It	O
was	O
concluded	O
that	O
coenzyme	B-ChemicalEntity
Q10	I-ChemicalEntity
represents	O
a	O
potential	O
therapeutic	O
option	O
to	O
protect	O
against	O
acute	O
cisplatin	B-ChemicalEntity
nephrotoxicity	B-DiseaseOrPhenotypicFeature
commonly	O
encountered	O
in	O
clinical	O
practice	O
.	O
U87MG	B-CellLine
decoded	O
:	O
the	O
genomic	O
sequence	O
of	O
a	O
cytogenetically	O
aberrant	O
human	B-OrganismTaxon
cancer	B-DiseaseOrPhenotypicFeature
cell	O
line	O
.	O

U87MG	B-CellLine
is	O
a	O
commonly	O
studied	O
grade	B-DiseaseOrPhenotypicFeature
IV	I-DiseaseOrPhenotypicFeature
glioma	I-DiseaseOrPhenotypicFeature
cell	O
line	O
that	O
has	O
been	O
analyzed	O
in	O
at	O
least	O
1	O
,	O
700	O
publications	O
over	O
four	O
decades	O
.	O

In	O
order	O
to	O
comprehensively	O
characterize	O
the	O
genome	O
of	O
this	O
cell	O
line	O
and	O
to	O
serve	O
as	O
a	O
model	O
of	O
broad	O
cancer	B-DiseaseOrPhenotypicFeature
genome	O
sequencing	O
,	O
we	O
have	O
generated	O
greater	O
than	O
30x	O
genomic	O
sequence	O
coverage	O
using	O
a	O
novel	O
50	O
-	O
base	O
mate	O
paired	O
strategy	O
with	O
a	O
1	O
.	O
4kb	O
mean	O
insert	O
library	O
.	O

A	O
total	O
of	O
1	O
,	O
014	O
,	O
984	O
,	O
286	O
mate	O
-	O
end	O
and	O
120	O
,	O
691	O
,	O
623	O
single	O
-	O
end	O
two	O
-	O
base	O
encoded	O
reads	O
were	O
generated	O
from	O
five	O
slides	O
.	O

All	O
data	O
were	O
aligned	O
using	O
a	O
custom	O
designed	O
tool	O
called	O
BFAST	O
,	O
allowing	O
optimal	O
color	O
space	O
read	O
alignment	O
and	O
accurate	O
identification	O
of	O
DNA	O
variants	O
.	O

The	O
aligned	O
sequence	O
reads	O
and	O
mate	O
-	O
pair	O
information	O
identified	O
35	O
interchromosomal	O
translocation	O
events	O
,	O
1	O
,	O
315	O
structural	O
variations	O
(	O
>	O
100	O
bp	O
)	O
,	O
191	O
,	O
743	O
small	O
(	O
<	O
21	O
bp	O
)	O
insertions	O
and	O
deletions	O
(	O
indels	O
)	O
,	O
and	O
2	O
,	O
384	O
,	O
470	O
single	O
nucleotide	O
variations	O
(	O
SNVs	O
)	O
.	O

Among	O
these	O
observations	O
,	O
the	O
known	O
homozygous	O
mutation	O
in	O
PTEN	B-GeneOrGeneProduct
was	O
robustly	O
identified	O
,	O
and	O
genes	O
involved	O
in	O
cell	O
adhesion	O
were	O
overrepresented	O
in	O
the	O
mutated	O
gene	O
list	O
.	O

Data	O
were	O
compared	O
to	O
219	O
,	O
187	O
heterozygous	O
single	O
nucleotide	O
polymorphisms	O
assayed	O
by	O
Illumina	O
1M	O
Duo	O
genotyping	O
array	O
to	O
assess	O
accuracy	O
:	O
93	O
.	O
83%	O
of	O
all	O
SNPs	O
were	O
reliably	O
detected	O
at	O
filtering	O
thresholds	O
that	O
yield	O
greater	O
than	O
99	O
.	O
99%	O
sequence	O
accuracy	O
.	O

Protein	O
coding	O
sequences	O
were	O
disrupted	O
predominantly	O
in	O
this	O
cancer	B-DiseaseOrPhenotypicFeature
cell	O
line	O
due	O
to	O
small	O
indels	O
,	O
large	O
deletions	O
,	O
and	O
translocations	O
.	O

In	O
total	O
,	O
512	O
genes	O
were	O
homozygously	O
mutated	O
,	O
including	O
154	O
by	O
SNVs	O
,	O
178	O
by	O
small	O
indels	O
,	O
145	O
by	O
large	O
microdeletions	O
,	O
and	O
35	O
by	O
interchromosomal	O
translocations	O
to	O
reveal	O
a	O
highly	O
mutated	O
cell	O
line	O
genome	O
.	O

Of	O
the	O
small	O
homozygously	O
mutated	O
variants	O
,	O
8	O
SNVs	O
and	O
99	O
indels	O
were	O
novel	O
events	O
not	O
present	O
in	O
dbSNP	O
.	O

These	O
data	O
demonstrate	O
that	O
routine	O
generation	O
of	O
broad	O
cancer	B-DiseaseOrPhenotypicFeature
genome	O
sequence	O
is	O
possible	O
outside	O
of	O
genome	O
centers	O
.	O

The	O
sequence	O
analysis	O
of	O
U87MG	B-CellLine
provides	O
an	O
unparalleled	O
level	O
of	O
mutational	O
resolution	O
compared	O
to	O
any	O
cell	O
line	O
to	O
date	O
.	O
A	O
single	O
-	O
nucleotide	O
polymorphism	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
of	O
the	O
hPER2	B-GeneOrGeneProduct
gene	O
is	O
associated	O
with	O
diurnal	O
preference	O
.	O

The	O
PERIOD2	B-GeneOrGeneProduct
(	O
PER2	B-GeneOrGeneProduct
)	O
gene	O
is	O
a	O
key	O
component	O
of	O
the	O
molecular	O
mechanism	O
that	O
generates	O
circadian	O
rhythms	O
in	O
mammals	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
human	B-OrganismTaxon
PER2	B-GeneOrGeneProduct
gene	O
has	O
previously	O
been	O
linked	O
to	O
advanced	B-DiseaseOrPhenotypicFeature
sleep	I-DiseaseOrPhenotypicFeature
phase	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
ASPS	B-DiseaseOrPhenotypicFeature
)	O
.	O

We	O
have	O
investigated	O
three	O
other	O
single	O
-	O
nucleotide	O
polymorphisms	O
in	O
the	O
hPER2	B-GeneOrGeneProduct
gene	O
,	O
one	O
downstream	O
of	O
the	O
transcription	O
start	O
site	O
(	O
C	B-SequenceVariant
-	O
1228T	I-SequenceVariant
)	O
,	O
one	O
in	O
exon	O
2	O
in	O
the	O
5	O
'	O
-	O
untranslated	O
region	O
(	O
5	O
'	O
-	O
UTR	O
)	O
(	O
C111G	B-SequenceVariant
)	O
,	O
and	O
one	O
missense	O
mutation	O
(	O
G3853A	B-SequenceVariant
)	O
causing	O
a	O
glycine	B-SequenceVariant
to	I-SequenceVariant
glutamine	I-SequenceVariant
substitution	O
in	O
the	O
predicted	O
protein	O
.	O

Subjects	O
selected	O
from	O
a	O
group	O
of	O
484	O
volunteers	O
for	O
extreme	O
morning	O
or	O
evening	O
preference	O
,	O
or	O
intermediate	O
diurnal	O
preference	O
were	O
genotyped	O
with	O
regard	O
to	O
the	O
three	O
polymorphisms	O
(	O
n	O
=	O
35	O
for	O
each	O
group	O
)	O
.	O

Whereas	O
allele	O
frequencies	O
for	O
the	O
other	O
two	O
polymorphisms	O
did	O
not	O
differ	O
significantly	O
between	O
any	O
of	O
the	O
groups	O
,	O
the	O
111G	B-SequenceVariant
allele	O
frequency	O
was	O
significantly	O
higher	O
in	O
subjects	O
with	O
extreme	O
morning	O
preference	O
(	O
0	O
.	O
14	O
)	O
than	O
in	O
subjects	O
with	O
extreme	O
evening	O
preference	O
(	O
0	O
.	O
03	O
)	O
(	O
Fisher	O
'	O
s	O
exact	O
test	O
,	O
two	O
-	O
sided	O
P	O
value	O
=	O
0	O
.	O
031	O
,	O
odds	O
ratio	O
=	O
5	O
.	O
67	O
)	O
.	O

No	O
significant	O
difference	O
in	O
111G	B-SequenceVariant
allele	O
frequency	O
was	O
observed	O
between	O
either	O
of	O
these	O
groups	O
and	O
subjects	O
with	O
intermediate	O
diurnal	O
preference	O
.	O

Computer	O
prediction	O
indicated	O
that	O
the	O
C111G	B-SequenceVariant
polymorphism	O
,	O
which	O
occurs	O
12	O
bases	O
upstream	O
from	O
the	O
translation	O
start	O
codon	O
,	O
might	O
alter	O
the	O
secondary	O
structure	O
of	O
the	O
transcript	O
.	O

The	O
PER2	B-GeneOrGeneProduct
111G	B-SequenceVariant
allele	O
associates	O
with	O
morning	O
preference	O
and	O
is	O
a	O
potential	O
candidate	O
allele	O
for	O
ASPS	B-DiseaseOrPhenotypicFeature
.	O
RNASEL	B-GeneOrGeneProduct
and	O
RNASEL	B-GeneOrGeneProduct
-	O
inhibitor	O
variation	O
and	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
in	O
Afro	O
-	O
Caribbeans	O
.	O

BACKGROUND	O
:	O
Afro	O
-	O
Caribbeans	O
from	O
Tobago	O
are	O
at	O
high	O
risk	O
of	O
developing	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

This	O
elevated	O
risk	O
of	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
is	O
shared	O
by	O
populations	O
of	O
African	O
ancestry	O
living	O
in	O
diverse	O
environments	O
in	O
the	O
Western	O
hemisphere	O
.	O

Variation	O
in	O
the	O
ribonuclease	B-GeneOrGeneProduct
L	I-GeneOrGeneProduct
(	O
RNASEL	B-GeneOrGeneProduct
)	O
gene	O
has	O
recently	O
been	O
reported	O
to	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
whether	O
RNASEL	B-GeneOrGeneProduct
variation	O
contributes	O
to	O
the	O
increased	O
risk	O
of	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
observed	O
in	O
populations	O
of	O
African	O
ancestry	O
remains	O
unclear	O
.	O

METHODS	O
:	O
We	O
resequenced	O
the	O
positional	O
candidate	O
gene	O
RNASEL	B-GeneOrGeneProduct
in	O
48	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cases	O
and	O
genotyped	O
the	O
previously	O
reported	O
R462Q	B-SequenceVariant
and	O
D541E	B-SequenceVariant
polymorphisms	O
in	O
230	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
cases	O
and	O
458	O
controls	O
.	O

We	O
also	O
examined	O
the	O
inhibitor	O
of	O
RNASEL	B-GeneOrGeneProduct
(	O
ABCE1	B-GeneOrGeneProduct
)	O
for	O
variation	O
associated	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
.	O

RESULTS	O
:	O
We	O
found	O
no	O
evidence	O
of	O
association	O
between	O
R462Q	B-SequenceVariant
and	O
D541E	B-SequenceVariant
polymorphisms	O
and	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
in	O
our	O
case	O
/	O
control	O
analysis	O
.	O

A	O
novel	O
variant	O
(	O
K294E	B-SequenceVariant
)	O
was	O
identified	O
in	O
a	O
single	O
heterozygous	O
individual	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

We	O
also	O
observed	O
a	O
20	B-SequenceVariant
bp	I-SequenceVariant
insertion	I-SequenceVariant
/	O
deletion	I-SequenceVariant
polymorphism	I-SequenceVariant
1	I-SequenceVariant
,	O
109	I-SequenceVariant
bp	I-SequenceVariant
upstream	I-SequenceVariant
of	I-SequenceVariant
the	I-SequenceVariant
initiation	I-SequenceVariant
codon	I-SequenceVariant
,	O
but	O
this	O
variant	O
was	O
not	O
associated	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

We	O
identified	O
16	O
single	O
nucleotide	O
polymorphisms	O
in	O
the	O
ABCE1	B-GeneOrGeneProduct
gene	O
,	O
only	O
3	O
of	O
which	O
had	O
a	O
minor	O
allele	O
frequency	O
>	O
5%	O
.	O

A	O
common	O
A	B-SequenceVariant
/	O
G	I-SequenceVariant
transition	I-SequenceVariant
-	O
1	I-SequenceVariant
,	O
071	I-SequenceVariant
bp	I-SequenceVariant
from	O
the	O
transcriptional	O
start	O
site	O
was	O
genotyped	O
and	O
showed	O
no	O
evidence	O
of	O
association	O
with	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
common	O
variation	O
in	O
the	O
putative	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
susceptibility	O
gene	O
,	O
RNASEL	B-GeneOrGeneProduct
,	O
or	O
its	O
inhibitor	O
does	O
not	O
contribute	O
significantly	O
to	O
prostate	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
in	O
this	O
Afro	O
-	O
Caribbean	O
population	O
.	O
Hepatic	O
but	O
not	O
brain	O
iron	B-ChemicalEntity
is	O
rapidly	O
chelated	O
by	O
deferasirox	B-ChemicalEntity
in	O
aceruloplasminemia	B-DiseaseOrPhenotypicFeature
due	O
to	O
a	O
novel	O
gene	O
mutation	O
.	O

BACKGROUND	O
_	O
#	O
38	O
;	O
AIMS	O
:	O
Aceruloplasminemia	B-DiseaseOrPhenotypicFeature
is	O
a	O
rare	O
autosomal	B-DiseaseOrPhenotypicFeature
recessive	I-DiseaseOrPhenotypicFeature
neurodegenerative	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
associated	O
with	O
brain	O
and	O
liver	O
iron	B-ChemicalEntity
accumulation	O
which	O
typically	O
presents	O
with	O
movement	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
,	O
retinal	B-DiseaseOrPhenotypicFeature
degeneration	I-DiseaseOrPhenotypicFeature
,	O
and	O
diabetes	B-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
.	O

Ceruloplasmin	B-GeneOrGeneProduct
is	O
a	O
multi	O
-	O
copper	O
ferroxidase	B-ChemicalEntity
that	O
is	O
secreted	O
into	O
plasma	O
and	O
facilitates	O
cellular	O
iron	B-ChemicalEntity
export	O
and	O
iron	B-ChemicalEntity
binding	O
to	O
transferrin	B-GeneOrGeneProduct
.	O

RESULTS	O
:	O
A	O
novel	O
homozygous	O
ceruloplasmin	B-GeneOrGeneProduct
gene	O
mutation	O
,	O
c	B-SequenceVariant
.	O
2554	I-SequenceVariant
+	O
1G	I-SequenceVariant
>	O
T	I-SequenceVariant
,	O
was	O
identified	O
as	O
the	O
cause	O
of	O
aceruloplasminemia	B-DiseaseOrPhenotypicFeature
in	O
three	O
affected	O
siblings	O
.	O

Two	O
siblings	O
presented	O
with	O
movement	B-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
and	O
diabetes	B-DiseaseOrPhenotypicFeature
.	O

Complementary	O
DNA	O
sequencing	O
showed	O
that	O
this	O
mutation	O
causes	O
skipping	O
of	O
exon	O
14	O
and	O
deletion	B-SequenceVariant
of	I-SequenceVariant
amino	I-SequenceVariant
acids	I-SequenceVariant
809	I-SequenceVariant
-	O
852	I-SequenceVariant
while	O
preserving	O
the	O
open	O
reading	O
frame	O
.	O

Western	O
blotting	O
of	O
liver	O
extracts	O
and	O
sera	O
of	O
affected	O
patients	B-OrganismTaxon
showed	O
retention	O
of	O
the	O
abnormal	O
protein	O
in	O
the	O
liver	O
.	O

Aceruloplasminemia	B-DiseaseOrPhenotypicFeature
was	O
associated	O
with	O
severe	O
brain	O
and	O
liver	O
iron	B-DiseaseOrPhenotypicFeature
overload	I-DiseaseOrPhenotypicFeature
,	O
where	O
hepatic	O
mRNA	O
expression	O
of	O
the	O
iron	B-ChemicalEntity
hormone	O
hepcidin	B-GeneOrGeneProduct
was	O
increased	O
,	O
corresponding	O
to	O
the	O
degree	O
of	O
iron	B-DiseaseOrPhenotypicFeature
overload	I-DiseaseOrPhenotypicFeature
.	O

Hepatic	O
iron	B-ChemicalEntity
concentration	O
normalized	O
after	O
3	O
and	O
5months	O
of	O
iron	B-ChemicalEntity
chelation	O
therapy	O
with	O
deferasirox	B-ChemicalEntity
,	O
which	O
was	O
also	O
associated	O
with	O
reduced	O
insulin	B-GeneOrGeneProduct
demands	O
.	O

During	O
short	O
term	O
treatment	O
there	O
was	O
no	O
clinical	O
or	O
imaging	O
evidence	O
for	O
significant	O
effects	O
on	O
brain	O
iron	B-DiseaseOrPhenotypicFeature
overload	I-DiseaseOrPhenotypicFeature
.	O

CONCLUSIONS	O
:	O
Aceruloplasminemia	B-DiseaseOrPhenotypicFeature
can	O
show	O
an	O
incomplete	O
clinical	O
penetrance	O
but	O
is	O
invariably	O
associated	O
with	O
iron	B-ChemicalEntity
accumulation	O
in	O
the	O
liver	O
and	O
in	O
the	O
brain	O
.	O

Iron	B-ChemicalEntity
accumulation	O
in	O
aceruloplasminemia	B-DiseaseOrPhenotypicFeature
is	O
a	O
result	O
of	O
defective	O
cellular	O
iron	B-ChemicalEntity
export	O
,	O
where	O
hepcidin	B-GeneOrGeneProduct
regulation	O
is	O
appropriate	O
for	O
the	O
degree	O
of	O
iron	B-DiseaseOrPhenotypicFeature
overload	I-DiseaseOrPhenotypicFeature
.	O

Iron	B-ChemicalEntity
chelation	O
with	O
deferasirox	B-ChemicalEntity
was	O
effective	O
in	O
mobilizing	O
hepatic	O
iron	B-ChemicalEntity
but	O
has	O
no	O
effect	O
on	O
brain	O
iron	B-ChemicalEntity
.	O
Aberrant	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
-	O
mediated	O
Smad	B-GeneOrGeneProduct
signaling	O
and	O
proliferation	O
identified	O
by	O
analysis	O
of	O
adenine	B-SequenceVariant
474	I-SequenceVariant
deletion	I-SequenceVariant
mutation	O
(	O
c	B-SequenceVariant
.	O
474delA	I-SequenceVariant
)	O
in	O
patient	B-OrganismTaxon
fibroblasts	O
:	O
a	O
new	O
perspective	O
on	O
the	O
mechanism	O
of	O
pulmonary	B-DiseaseOrPhenotypicFeature
hypertension	I-DiseaseOrPhenotypicFeature
.	O

A	O
heterozygous	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
c	B-SequenceVariant
.	O
474delA	I-SequenceVariant
mutation	O
has	O
been	O
identified	O
in	O
a	O
family	O
with	O
heritable	O
pulmonary	B-DiseaseOrPhenotypicFeature
arterial	I-DiseaseOrPhenotypicFeature
hypertension	I-DiseaseOrPhenotypicFeature
(	O
PAH	B-DiseaseOrPhenotypicFeature
)	O
.	O

This	O
frameshift	O
mutation	O
leads	O
to	O
a	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
protein	O
that	O
contains	O
all	O
known	O
functional	O
domains	O
but	O
has	O
a	O
change	O
in	O
only	O
the	O
final	O
20	O
amino	O
acids	O
of	O
the	O
C	O
-	O
terminus	O
.	O

Here	O
we	O
studied	O
how	O
this	O
mutation	O
alters	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
function	O
,	O
using	O
patient	B-OrganismTaxon
-	O
derived	O
fibroblasts	O
.	O

Transmission	O
electron	O
microscopy	O
showed	O
that	O
fibroblasts	O
carrying	O
the	O
c	B-SequenceVariant
.	O
474delA	I-SequenceVariant
mutation	O
form	O
typical	O
caveolae	O
.	O

Expression	O
of	O
mutated	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
in	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
-	O
null	O
mouse	B-OrganismTaxon
fibroblasts	O
failed	O
to	O
induce	O
formation	O
of	O
caveolae	O
due	O
to	O
retention	O
of	O
the	O
mutated	O
protein	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

However	O
,	O
coexpression	O
of	O
wild	O
-	O
type	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
with	O
mutated	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
restored	O
the	O
ability	O
to	O
form	O
caveolae	O
.	O

Importantly	O
,	O
fibroblasts	O
carrying	O
the	O
mutation	O
showed	O
twofold	O
increase	O
in	O
proliferation	O
rate	O
associated	O
with	O
hyperphosphorylation	O
of	O
Smad1	B-GeneOrGeneProduct
/	O
5	I-GeneOrGeneProduct
/	O
8	I-GeneOrGeneProduct
.	O

This	O
mutation	O
impaired	O
the	O
antiproliferative	O
function	O
of	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
.	O

Inhibition	O
of	O
type	B-GeneOrGeneProduct
I	I-GeneOrGeneProduct
TGFb	I-GeneOrGeneProduct
receptors	I-GeneOrGeneProduct
ALK1	B-GeneOrGeneProduct
/	O
2	I-GeneOrGeneProduct
/	O
3	I-GeneOrGeneProduct
/	O
6	I-GeneOrGeneProduct
responsible	O
for	O
phosphorylation	O
of	O
Smad1	B-GeneOrGeneProduct
/	O
5	I-GeneOrGeneProduct
/	O
8	I-GeneOrGeneProduct
reduced	O
the	O
hyperproliferation	O
seen	O
in	O
c	B-SequenceVariant
.	O
474delA	I-SequenceVariant
fibroblasts	O
.	O

These	O
results	O
demonstrate	O
the	O
critical	O
role	O
of	O
the	O
final	O
20	O
amino	O
acids	O
of	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
in	O
modulating	O
fibroblast	O
proliferation	O
by	O
dampening	O
Smad	B-GeneOrGeneProduct
signaling	O
and	O
suggest	O
that	O
augmented	O
Smad	B-GeneOrGeneProduct
signaling	O
and	O
fibroblast	O
hyperproliferation	O
are	O
contributing	O
factors	O
in	O
the	O
pathogenesis	O
of	O
PAH	B-DiseaseOrPhenotypicFeature
in	O
patients	B-OrganismTaxon
with	O
caveolin	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
c	B-SequenceVariant
.	O
474delA	I-SequenceVariant
mutation	O
.	O
Mutations	O
in	O
N	B-GeneOrGeneProduct
-	O
acetylglucosamine	I-GeneOrGeneProduct
(	O
O	I-GeneOrGeneProduct
-	O
GlcNAc	I-GeneOrGeneProduct
)	O
transferase	I-GeneOrGeneProduct
in	O
patients	B-OrganismTaxon
with	O
X	B-DiseaseOrPhenotypicFeature
-	O
linked	I-DiseaseOrPhenotypicFeature
intellectual	I-DiseaseOrPhenotypicFeature
disability	I-DiseaseOrPhenotypicFeature
.	O

N	B-GeneOrGeneProduct
-	O
Acetylglucosamine	I-GeneOrGeneProduct
(	O
O	I-GeneOrGeneProduct
-	O
GlcNAc	I-GeneOrGeneProduct
)	O
transferase	I-GeneOrGeneProduct
(	O
OGT	B-GeneOrGeneProduct
)	O
regulates	O
protein	O
O	B-GeneOrGeneProduct
-	O
GlcNAcylation	I-GeneOrGeneProduct
,	O
an	O
essential	O
and	O
dynamic	O
post	O
-	O
translational	O
modification	O
.	O

The	O
O	B-GeneOrGeneProduct
-	O
GlcNAc	I-GeneOrGeneProduct
modification	O
is	O
present	O
on	O
numerous	O
nuclear	O
and	O
cytosolic	O
proteins	O
and	O
has	O
been	O
implicated	O
in	O
essential	O
cellular	O
functions	O
such	O
as	O
signaling	O
and	O
gene	O
expression	O
.	O

Accordingly	O
,	O
altered	O
levels	O
of	O
protein	O
O	B-GeneOrGeneProduct
-	O
GlcNAcylation	I-GeneOrGeneProduct
have	O
been	O
associated	O
with	O
developmental	B-DiseaseOrPhenotypicFeature
defects	I-DiseaseOrPhenotypicFeature
and	O
neurodegeneration	B-DiseaseOrPhenotypicFeature
.	O

However	O
,	O
mutations	O
in	O
the	O
OGT	B-GeneOrGeneProduct
gene	O
have	O
not	O
yet	O
been	O
functionally	O
confirmed	O
in	O
humans	B-OrganismTaxon
.	O

Here	O
,	O
we	O
report	O
on	O
two	O
hemizygous	O
mutations	O
in	O
OGT	B-GeneOrGeneProduct
in	O
individuals	O
with	O
X	B-DiseaseOrPhenotypicFeature
-	O
linked	I-DiseaseOrPhenotypicFeature
intellectual	I-DiseaseOrPhenotypicFeature
disability	I-DiseaseOrPhenotypicFeature
(	O
XLID	B-DiseaseOrPhenotypicFeature
)	O
and	O
dysmorphic	O
features	O
:	O
one	O
missense	O
mutation	O
(	O
p	B-SequenceVariant
.	O
Arg284Pro	I-SequenceVariant
)	O
and	O
one	O
mutation	O
leading	O
to	O
a	O
splicing	O
defect	O
(	O
c	B-SequenceVariant
.	O
463	I-SequenceVariant
-	O
6T	I-SequenceVariant
>	O
G	I-SequenceVariant
)	O
.	O

Both	O
mutations	O
reside	O
in	O
the	O
tetratricopeptide	O
repeats	O
of	O
OGT	B-GeneOrGeneProduct
that	O
are	O
essential	O
for	O
substrate	O
recognition	O
.	O

We	O
observed	O
slightly	O
reduced	O
levels	O
of	O
OGT	B-GeneOrGeneProduct
protein	O
and	O
reduced	O
levels	O
of	O
its	O
opposing	O
enzyme	O
O	B-GeneOrGeneProduct
-	O
GlcNAcase	I-GeneOrGeneProduct
in	O
both	O
patient	B-OrganismTaxon
-	O
derived	O
fibroblasts	O
,	O
but	O
global	O
O	B-GeneOrGeneProduct
-	O
GlcNAc	I-GeneOrGeneProduct
levels	O
appeared	O
to	O
be	O
unaffected	O
.	O

Our	O
data	O
suggest	O
that	O
mutant	O
cells	O
attempt	O
to	O
maintain	O
global	O
O	B-GeneOrGeneProduct
-	O
GlcNAcylation	I-GeneOrGeneProduct
by	O
down	O
-	O
regulating	O
O	B-GeneOrGeneProduct
-	O
GlcNAcase	I-GeneOrGeneProduct
expression	O
.	O

We	O
also	O
found	O
that	O
the	O
c	B-SequenceVariant
.	O
463	I-SequenceVariant
-	O
6T	I-SequenceVariant
>	O
G	I-SequenceVariant
mutation	O
leads	O
to	O
aberrant	O
mRNA	O
splicing	O
,	O
but	O
no	O
stable	O
truncated	O
protein	O
was	O
detected	O
in	O
the	O
corresponding	O
patient	B-OrganismTaxon
-	O
derived	O
fibroblasts	O
.	O

Recombinant	O
OGT	B-GeneOrGeneProduct
bearing	O
the	O
p	B-SequenceVariant
.	O
Arg284Pro	I-SequenceVariant
mutation	O
was	O
prone	O
to	O
unfolding	O
and	O
exhibited	O
reduced	O
glycosylation	O
activity	O
against	O
a	O
complex	O
array	O
of	O
glycosylation	O
substrates	O
and	O
proteolytic	O
processing	O
of	O
the	O
transcription	O
factor	O
host	B-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
,	O
which	O
is	O
also	O
encoded	O
by	O
an	O
XLID	B-DiseaseOrPhenotypicFeature
-	O
associated	O
gene	O
.	O

We	O
conclude	O
that	O
defects	O
in	O
O	B-GeneOrGeneProduct
-	O
GlcNAc	I-GeneOrGeneProduct
homeostasis	O
and	O
host	B-GeneOrGeneProduct
cell	I-GeneOrGeneProduct
factor	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
proteolysis	O
may	O
play	O
roles	O
in	O
mediation	O
of	O
XLID	B-DiseaseOrPhenotypicFeature
in	O
individuals	O
with	O
OGT	B-GeneOrGeneProduct
mutations	O
.	O
Cardiovascular	B-DiseaseOrPhenotypicFeature
complications	I-DiseaseOrPhenotypicFeature
associated	O
with	O
terbutaline	B-ChemicalEntity
treatment	O
for	O
preterm	B-DiseaseOrPhenotypicFeature
labor	I-DiseaseOrPhenotypicFeature
.	O

Severe	O
cardiovascular	B-DiseaseOrPhenotypicFeature
complications	I-DiseaseOrPhenotypicFeature
occurred	O
in	O
eight	O
of	O
160	O
patients	B-OrganismTaxon
treated	O
with	O
terbutaline	B-ChemicalEntity
for	O
preterm	B-DiseaseOrPhenotypicFeature
labor	I-DiseaseOrPhenotypicFeature
.	O

Associated	O
corticosteroid	B-ChemicalEntity
therapy	O
and	O
twin	O
gestations	O
appear	O
to	O
be	O
predisposing	O
factors	O
.	O

Potential	O
mechanisms	O
of	O
the	O
pathophysiology	O
are	O
briefly	O
discussed	O
.	O
Long	O
-	O
term	O
oral	O
galactose	B-ChemicalEntity
treatment	O
prevents	O
cognitive	B-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
in	O
male	O
Wistar	O
rats	B-OrganismTaxon
treated	O
intracerebroventricularly	O
with	O
streptozotocin	B-ChemicalEntity
.	O

Basic	O
and	O
clinical	O
research	O
has	O
demonstrated	O
that	O
dementia	B-DiseaseOrPhenotypicFeature
of	O
sporadic	O
Alzheimer	B-DiseaseOrPhenotypicFeature
'	O
s	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
sAD	B-DiseaseOrPhenotypicFeature
)	O
type	O
is	O
associated	O
with	O
dysfunction	O
of	O
the	O
insulin	B-GeneOrGeneProduct
-	O
receptor	I-GeneOrGeneProduct
(	O
IR	B-GeneOrGeneProduct
)	O
system	O
followed	O
by	O
decreased	O
glucose	B-ChemicalEntity
transport	O
via	O
glucose	B-ChemicalEntity
transporter	O
GLUT4	B-GeneOrGeneProduct
and	O
decreased	O
glucose	B-ChemicalEntity
metabolism	O
in	O
brain	O
cells	O
.	O

An	O
alternative	O
source	O
of	O
energy	O
is	O
d	B-ChemicalEntity
-	O
galactose	I-ChemicalEntity
(	O
the	O
C	O
-	O
4	O
-	O
epimer	O
of	O
d	B-ChemicalEntity
-	O
glucose	I-ChemicalEntity
)	O
which	O
is	O
transported	O
into	O
the	O
brain	O
by	O
insulin	B-GeneOrGeneProduct
-	O
independent	O
GLUT3	B-GeneOrGeneProduct
transporter	O
where	O
it	O
might	O
be	O
metabolized	O
to	O
glucose	B-ChemicalEntity
via	O
the	O
Leloir	O
pathway	O
.	O

Exclusively	O
parenteral	O
daily	O
injections	O
of	O
galactose	B-ChemicalEntity
induce	O
memory	B-DiseaseOrPhenotypicFeature
deterioration	I-DiseaseOrPhenotypicFeature
in	O
rodents	O
and	O
are	O
used	O
to	O
generate	O
animal	O
aging	O
model	O
,	O
but	O
the	O
effects	O
of	O
oral	O
galactose	B-ChemicalEntity
treatment	O
on	O
cognitive	O
functions	O
have	O
never	O
been	O
tested	O
.	O

We	O
have	O
investigated	O
the	O
effects	O
of	O
continuous	O
daily	O
oral	O
galactose	B-ChemicalEntity
(	O
200	O
mg	O
/	O
kg	O
/	O
day	O
)	O
treatment	O
on	O
cognitive	B-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
in	O
streptozotocin	B-ChemicalEntity
-	O
induced	O
(	O
STZ	B-ChemicalEntity
-	O
icv	O
)	O
rat	B-OrganismTaxon
model	O
of	O
sAD	B-DiseaseOrPhenotypicFeature
,	O
tested	O
by	O
Morris	O
Water	O
Maze	O
and	O
Passive	O
Avoidance	O
test	O
,	O
respectively	O
.	O

One	O
month	O
of	O
oral	O
galactose	B-ChemicalEntity
treatment	O
initiated	O
immediately	O
after	O
the	O
STZ	B-ChemicalEntity
-	O
icv	O
administration	O
,	O
successfully	O
prevented	O
development	O
of	O
the	O
STZ	B-ChemicalEntity
-	O
icv	O
-	O
induced	O
cognitive	B-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
.	O

Beneficial	O
effect	O
of	O
oral	O
galactose	B-ChemicalEntity
was	O
independent	O
of	O
the	O
rat	B-OrganismTaxon
age	O
and	O
of	O
the	O
galactose	B-ChemicalEntity
dose	O
ranging	O
from	O
100	O
to	O
300	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Additionally	O
,	O
oral	O
galactose	B-ChemicalEntity
administration	O
led	O
to	O
the	O
appearance	O
of	O
galactose	B-ChemicalEntity
in	O
the	O
blood	O
.	O

The	O
increase	O
of	O
galactose	B-ChemicalEntity
concentration	O
in	O
the	O
cerebrospinal	O
fluid	O
was	O
several	O
times	O
lower	O
after	O
oral	O
than	O
after	O
parenteral	O
administration	O
of	O
the	O
same	O
galactose	B-ChemicalEntity
dose	O
.	O

Oral	O
galactose	B-ChemicalEntity
exposure	O
might	O
have	O
beneficial	O
effects	O
on	O
learning	O
and	O
memory	O
ability	O
and	O
could	O
be	O
worth	O
investigating	O
for	O
improvement	O
of	O
cognitive	B-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
associated	O
with	O
glucose	B-DiseaseOrPhenotypicFeature
hypometabolism	I-DiseaseOrPhenotypicFeature
in	O
AD	B-DiseaseOrPhenotypicFeature
.	O
Biophysical	O
and	O
functional	O
characterization	O
of	O
hippocalcin	B-GeneOrGeneProduct
mutants	O
responsible	O
for	O
human	B-OrganismTaxon
dystonia	B-DiseaseOrPhenotypicFeature
.	O

Dystonia	B-DiseaseOrPhenotypicFeature
is	O
a	O
neurological	B-DiseaseOrPhenotypicFeature
movement	I-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
that	O
forces	O
the	O
body	O
into	O
twisting	O
,	O
repetitive	O
movements	O
or	O
sometimes	O
painful	O
abnormal	O
postures	O
.	O

With	O
the	O
advent	O
of	O
next	O
-	O
generation	O
sequencing	O
technologies	O
,	O
the	O
homozygous	O
mutations	O
T71N	B-SequenceVariant
and	O
A190T	B-SequenceVariant
in	O
the	O
neuronal	B-GeneOrGeneProduct
calcium	I-GeneOrGeneProduct
sensor	I-GeneOrGeneProduct
(	O
NCS	B-GeneOrGeneProduct
)	O
hippocalcin	B-GeneOrGeneProduct
were	O
identified	O
as	O
the	O
genetic	O
cause	O
of	O
primary	B-DiseaseOrPhenotypicFeature
isolated	I-DiseaseOrPhenotypicFeature
dystonia	I-DiseaseOrPhenotypicFeature
(	O
DYT2	B-GeneOrGeneProduct
dystonia	B-DiseaseOrPhenotypicFeature
)	O
.	O

However	O
,	O
the	O
effect	O
of	O
these	O
mutations	O
on	O
the	O
physiological	O
role	O
of	O
hippocalcin	B-GeneOrGeneProduct
has	O
not	O
yet	O
been	O
elucidated	O
.	O

Using	O
a	O
multidisciplinary	O
approach	O
,	O
we	O
demonstrated	O
that	O
hippocalcin	B-GeneOrGeneProduct
oligomerises	O
in	O
a	O
calcium	B-ChemicalEntity
-	O
dependent	O
manner	O
and	O
binds	O
to	O
voltage	B-GeneOrGeneProduct
-	O
gated	I-GeneOrGeneProduct
calcium	I-GeneOrGeneProduct
channels	I-GeneOrGeneProduct
.	O

Mutations	O
T71N	B-SequenceVariant
and	O
A190T	B-SequenceVariant
in	O
hippocalcin	B-GeneOrGeneProduct
did	O
not	O
affect	O
stability	O
,	O
calcium	B-ChemicalEntity
-	O
binding	O
affinity	O
or	O
translocation	O
to	O
cellular	O
membranes	O
(	O
Ca2	B-ChemicalEntity
+	O
/	O
myristoyl	O
switch	O
)	O
.	O

We	O
obtained	O
the	O
first	O
crystal	O
structure	O
of	O
hippocalcin	B-GeneOrGeneProduct
and	O
alignment	O
with	O
other	O
NCS	B-GeneOrGeneProduct
proteins	O
showed	O
significant	O
variability	O
in	O
the	O
orientation	O
of	O
the	O
C	O
-	O
terminal	O
part	O
of	O
the	O
molecule	O
,	O
the	O
region	O
expected	O
to	O
be	O
important	O
for	O
target	O
binding	O
.	O

We	O
demonstrated	O
that	O
the	O
disease	O
-	O
causing	O
mutations	O
did	O
not	O
affect	O
the	O
structure	O
of	O
the	O
protein	O
,	O
however	O
both	O
mutants	O
showed	O
a	O
defect	O
in	O
oligomerisation	O
.	O

In	O
addition	O
,	O
we	O
observed	O
an	O
increased	O
calcium	B-ChemicalEntity
influx	O
in	O
KCl	B-ChemicalEntity
-	O
depolarised	O
cells	O
expressing	O
mutated	O
hippocalcin	B-GeneOrGeneProduct
,	O
mostly	O
driven	O
by	O
N	B-GeneOrGeneProduct
-	O
type	I-GeneOrGeneProduct
voltage	I-GeneOrGeneProduct
-	O
gated	I-GeneOrGeneProduct
calcium	I-GeneOrGeneProduct
channels	I-GeneOrGeneProduct
.	O

Our	O
data	O
demonstrate	O
that	O
the	O
dystonia	B-DiseaseOrPhenotypicFeature
-	O
causing	O
mutations	O
strongly	O
affect	O
hippocalcin	B-GeneOrGeneProduct
cellular	O
functions	O
which	O
suggest	O
a	O
central	O
role	O
for	O
perturbed	O
calcium	B-ChemicalEntity
signalling	O
in	O
DYT2	B-GeneOrGeneProduct
dystonia	B-DiseaseOrPhenotypicFeature
.	O
Primary	B-DiseaseOrPhenotypicFeature
malignant	I-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
the	I-DiseaseOrPhenotypicFeature
brain	I-DiseaseOrPhenotypicFeature
:	O
frequent	O
abnormalities	O
and	O
inactivation	O
of	O
p14	B-GeneOrGeneProduct
tumor	B-DiseaseOrPhenotypicFeature
suppressor	O
gene	O
.	O

Ten	O
primary	B-DiseaseOrPhenotypicFeature
central	I-DiseaseOrPhenotypicFeature
nervous	I-DiseaseOrPhenotypicFeature
system	I-DiseaseOrPhenotypicFeature
lymphomas	I-DiseaseOrPhenotypicFeature
(	O
PCNSL	B-DiseaseOrPhenotypicFeature
,	O
brain	B-DiseaseOrPhenotypicFeature
lymphomas	I-DiseaseOrPhenotypicFeature
)	O
were	O
examined	O
for	O
p14	B-GeneOrGeneProduct
gene	O
exon	O
1beta	O
deletion	O
,	O
mutation	O
and	O
methylation	O
by	O
Southern	O
blot	O
analysis	O
,	O
nucleotide	O
analysis	O
of	O
polymerase	O
chain	O
reaction	O
clones	O
and	O
Southern	O
blot	O
-	O
based	O
methylation	O
assay	O
.	O

In	O
Southern	O
blot	O
analysis	O
,	O
from	O
the	O
signal	O
densities	O
of	O
the	O
hybridized	O
bands	O
and	O
their	O
similarities	O
to	O
those	O
of	O
exons	O
2	O
and	O
3	O
in	O
our	O
previous	O
quantitative	O
study	O
,	O
we	O
found	O
that	O
exon	O
1beta	O
was	O
homozygously	O
deleted	O
in	O
four	O
cases	O
,	O
hemizygously	O
deleted	O
in	O
five	O
cases	O
and	O
not	O
deleted	O
in	O
one	O
case	O
.	O

Thus	O
,	O
the	O
same	O
deletion	O
patterns	O
covered	O
the	O
entire	O
p14	B-GeneOrGeneProduct
gene	O
for	O
all	O
cases	O
except	O
for	O
one	O
case	O
,	O
which	O
suggested	O
the	O
hemizygous	O
deletion	O
of	O
exons	O
1beta	O
and	O
2	O
and	O
homozygous	O
deletion	O
of	O
exon	O
3	O
.	O

In	O
addition	O
,	O
although	O
exon	O
1beta	O
mutation	O
is	O
rare	O
in	O
various	O
tumors	B-DiseaseOrPhenotypicFeature
,	O
we	O
detected	O
a	O
missense	O
mutation	O
(	O
L50R	B-SequenceVariant
)	O
in	O
one	O
case	O
with	O
a	O
hemizygous	O
deletion	O
.	O

Methylation	O
of	O
the	O
5	O
'	O
CpG	O
island	O
of	O
the	O
p14	B-GeneOrGeneProduct
gene	O
was	O
not	O
suggested	O
for	O
any	O
case	O
without	O
homozygous	O
deletion	O
.	O

Our	O
observation	O
of	O
frequent	O
p14	B-GeneOrGeneProduct
gene	O
abnormalities	O
(	O
90%	O
)	O
and	O
inactivation	O
(	O
40	O
-	O
60%	O
)	O
was	O
in	O
striking	O
contrast	O
to	O
the	O
same	O
pathological	O
subtype	O
of	O
systemic	B-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
in	O
which	O
p14	B-GeneOrGeneProduct
gene	O
abnormalities	O
and	O
inactivation	O
were	O
infrequent	O
,	O
suggesting	O
a	O
difference	O
in	O
carcinogenesis	B-DiseaseOrPhenotypicFeature
between	O
PCNSL	B-DiseaseOrPhenotypicFeature
and	O
systemic	B-DiseaseOrPhenotypicFeature
lymphoma	I-DiseaseOrPhenotypicFeature
.	O
Learning	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
memory	I-DiseaseOrPhenotypicFeature
deficits	I-DiseaseOrPhenotypicFeature
in	O
ecstasy	B-ChemicalEntity
users	O
and	O
their	O
neural	O
correlates	O
during	O
a	O
face	O
-	O
learning	O
task	O
.	O

It	O
has	O
been	O
consistently	O
shown	O
that	O
ecstasy	B-ChemicalEntity
users	O
display	O
impairments	B-DiseaseOrPhenotypicFeature
in	I-DiseaseOrPhenotypicFeature
learning	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
memory	I-DiseaseOrPhenotypicFeature
performance	O
.	O

In	O
addition	O
,	O
working	O
memory	O
processing	O
in	O
ecstasy	B-ChemicalEntity
users	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
neural	O
alterations	O
in	O
hippocampal	O
and	O
/	O
or	O
cortical	O
regions	O
as	O
measured	O
by	O
functional	O
magnetic	O
resonance	O
imaging	O
(	O
fMRI	O
)	O
.	O

Using	O
functional	O
imaging	O
and	O
a	O
face	O
-	O
learning	O
task	O
,	O
we	O
investigated	O
neural	O
correlates	O
of	O
encoding	O
and	O
recalling	O
face	O
-	O
name	O
associations	O
in	O
20	O
recreational	O
drug	O
users	O
whose	O
predominant	O
drug	O
use	O
was	O
ecstasy	B-ChemicalEntity
and	O
20	O
controls	O
.	O

To	O
address	O
the	O
potential	O
confounding	O
effects	O
of	O
the	O
cannabis	B-ChemicalEntity
use	O
of	O
the	O
ecstasy	B-ChemicalEntity
using	O
group	O
,	O
a	O
second	O
analysis	O
included	O
14	O
previously	O
tested	O
cannabis	B-ChemicalEntity
users	O
(	O
Nestor	O
,	O
L	O
.	O
,	O
Roberts	O
,	O
G	O
.	O
,	O
Garavan	O
,	O
H	O
.	O
,	O
Hester	O
,	O
R	O
.	O
,	O
2008	O
.	O

Deficits	B-DiseaseOrPhenotypicFeature
in	I-DiseaseOrPhenotypicFeature
learning	I-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
memory	I-DiseaseOrPhenotypicFeature
:	O
parahippocampal	O
hyperactivity	B-DiseaseOrPhenotypicFeature
and	O
frontocortical	O
hypoactivity	O
in	O
cannabis	B-ChemicalEntity
users	O
.	O

Neuroimage	O
40	O
,	O
1328	O
-	O
1339	O
)	O
.	O

Ecstasy	B-ChemicalEntity
users	O
performed	O
significantly	O
worse	O
in	O
learning	O
and	O
memory	O
compared	O
to	O
controls	O
and	O
cannabis	B-ChemicalEntity
users	O
.	O

A	O
conjunction	O
analysis	O
of	O
the	O
encode	O
and	O
recall	O
phases	O
of	O
the	O
task	O
revealed	O
ecstasy	B-ChemicalEntity
-	O
specific	O
hyperactivity	B-DiseaseOrPhenotypicFeature
in	O
bilateral	O
frontal	O
regions	O
,	O
left	O
temporal	O
,	O
right	O
parietal	O
,	O
bilateral	O
temporal	O
,	O
and	O
bilateral	O
occipital	O
brain	O
regions	O
.	O

Ecstasy	B-ChemicalEntity
-	O
specific	O
hypoactivity	O
was	O
evident	O
in	O
the	O
right	O
dorsal	O
anterior	O
cingulated	O
cortex	O
(	O
ACC	O
)	O
and	O
left	O
posterior	O
cingulated	O
cortex	O
.	O

In	O
both	O
ecstasy	B-ChemicalEntity
and	O
cannabis	B-ChemicalEntity
groups	O
brain	O
activation	O
was	O
decreased	O
in	O
the	O
right	O
medial	O
frontal	O
gyrus	O
,	O
left	O
parahippocampal	O
gyrus	O
,	O
left	O
dorsal	O
cingulate	O
gyrus	O
,	O
and	O
left	O
caudate	O
.	O

These	O
results	O
elucidated	O
ecstasy	B-ChemicalEntity
-	O
related	O
deficits	O
,	O
only	O
some	O
of	O
which	O
might	O
be	O
attributed	O
to	O
cannabis	B-ChemicalEntity
use	O
.	O

These	O
ecstasy	B-ChemicalEntity
-	O
specific	O
effects	O
may	O
be	O
related	O
to	O
the	O
vulnerability	O
of	O
isocortical	O
and	O
allocortical	O
regions	O
to	O
the	O
neurotoxic	B-DiseaseOrPhenotypicFeature
effects	O
of	O
ecstasy	B-ChemicalEntity
.	O
Variation	O
in	O
the	O
CXCR1	B-GeneOrGeneProduct
gene	O
(	O
IL8RA	B-GeneOrGeneProduct
)	O
is	O
not	O
associated	O
with	O
susceptibility	O
to	O
chronic	B-DiseaseOrPhenotypicFeature
periodontitis	I-DiseaseOrPhenotypicFeature
.	O

BACKGROUND	O
:	O
The	O
chemokine	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
1	I-GeneOrGeneProduct
CXCR	I-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
(	O
or	O
IL8R	B-GeneOrGeneProduct
-	O
alpha	I-GeneOrGeneProduct
)	O
is	O
a	O
specific	O
receptor	O
for	O
the	O
interleukin	B-GeneOrGeneProduct
8	I-GeneOrGeneProduct
(	O
IL	B-GeneOrGeneProduct
-	O
8	I-GeneOrGeneProduct
)	O
,	O
which	O
is	O
chemoattractant	O
for	O
neutrophils	O
and	O
has	O
an	O
important	O
role	O
in	O
the	O
inflammatory	B-DiseaseOrPhenotypicFeature
response	O
.	O

The	O
polymorphism	O
rs2234671	B-SequenceVariant
at	O
position	O
Ex2	B-SequenceVariant
+	O
860G	I-SequenceVariant
>	O
C	I-SequenceVariant
of	O
the	O
CXCR1	B-GeneOrGeneProduct
gene	O
causes	O
a	O
conservative	O
amino	O
acid	O
substitution	O
(	O
S276T	B-SequenceVariant
)	O
.	O

This	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
seemed	O
to	O
be	O
functional	O
as	O
it	O
was	O
associated	O
with	O
decreased	O
lung	B-DiseaseOrPhenotypicFeature
cancer	I-DiseaseOrPhenotypicFeature
risk	O
.	O

Previous	O
studies	O
of	O
our	O
group	O
found	O
association	O
of	O
haplotypes	O
in	O
the	O
IL8	B-GeneOrGeneProduct
and	O
in	O
the	O
CXCR2	B-GeneOrGeneProduct
genes	O
with	O
the	O
multifactorial	O
disease	O
chronic	B-DiseaseOrPhenotypicFeature
periodontitis	I-DiseaseOrPhenotypicFeature
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
polymorphism	O
rs2234671	B-SequenceVariant
in	O
395	O
Brazilian	O
subjects	O
with	O
and	O
without	O
chronic	B-DiseaseOrPhenotypicFeature
periodontitis	I-DiseaseOrPhenotypicFeature
.	O

FINDINGS	O
:	O
Similar	O
distribution	O
of	O
the	O
allelic	O
and	O
genotypic	O
frequencies	O
were	O
observed	O
between	O
the	O
groups	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
polymorphism	O
rs2234671	B-SequenceVariant
in	O
the	O
CXCR1	B-GeneOrGeneProduct
gene	O
was	O
not	O
associated	O
with	O
the	O
susceptibility	O
to	O
chronic	B-DiseaseOrPhenotypicFeature
periodontitis	I-DiseaseOrPhenotypicFeature
in	O
the	O
studied	O
Brazilian	O
population	O
.	O
Disease	O
-	O
associated	O
mutations	O
in	O
human	B-OrganismTaxon
BICD2	B-GeneOrGeneProduct
hyperactivate	O
motility	O
of	O
dynein	B-GeneOrGeneProduct
-	O
dynactin	B-GeneOrGeneProduct
.	O

Bicaudal	B-GeneOrGeneProduct
D2	I-GeneOrGeneProduct
(	O
BICD2	B-GeneOrGeneProduct
)	O
joins	O
dynein	B-GeneOrGeneProduct
with	O
dynactin	B-GeneOrGeneProduct
into	O
a	O
ternary	O
complex	O
(	O
termed	O
DDB	B-GeneOrGeneProduct
)	O
capable	O
of	O
processive	O
movement	O
.	O

Point	O
mutations	O
in	O
the	O
BICD2	B-GeneOrGeneProduct
gene	O
have	O
been	O
identified	O
in	O
patients	B-OrganismTaxon
with	O
a	O
dominant	O
form	O
of	O
spinal	B-DiseaseOrPhenotypicFeature
muscular	I-DiseaseOrPhenotypicFeature
atrophy	I-DiseaseOrPhenotypicFeature
,	O
but	O
how	O
these	O
mutations	O
cause	O
disease	O
is	O
unknown	O
.	O

To	O
investigate	O
this	O
question	O
,	O
we	O
have	O
developed	O
in	O
vitro	O
motility	O
assays	O
with	O
purified	O
DDB	B-GeneOrGeneProduct
and	O
BICD2	B-GeneOrGeneProduct
'	O
s	O
membrane	O
vesicle	O
partner	O
,	O
the	O
GTPase	B-GeneOrGeneProduct
Rab6a	I-GeneOrGeneProduct
.	O

Rab6a	B-GeneOrGeneProduct
-	O
GTP	I-GeneOrGeneProduct
,	O
either	O
in	O
solution	O
or	O
bound	O
to	O
artificial	O
liposomes	O
,	O
released	O
BICD2	B-GeneOrGeneProduct
from	O
an	O
autoinhibited	O
state	O
and	O
promoted	O
robust	O
dynein	B-GeneOrGeneProduct
-	O
dynactin	B-GeneOrGeneProduct
transport	O
.	O

In	O
these	O
assays	O
,	O
BICD2	B-GeneOrGeneProduct
mutants	O
showed	O
an	O
enhanced	O
ability	O
to	O
form	O
motile	O
DDB	B-GeneOrGeneProduct
complexes	O
.	O

Increased	O
retrograde	O
transport	O
by	O
BICD2	B-GeneOrGeneProduct
mutants	O
also	O
was	O
observed	O
in	O
cells	O
using	O
an	O
inducible	O
organelle	O
transport	O
assay	O
.	O

When	O
overexpressed	O
in	O
rat	B-OrganismTaxon
hippocampal	O
neurons	O
,	O
the	O
hyperactive	O
BICD2	B-GeneOrGeneProduct
mutants	O
decreased	O
neurite	O
growth	O
.	O

Our	O
results	O
reveal	O
that	O
dominant	O
mutations	O
in	O
BICD2	B-GeneOrGeneProduct
hyperactivate	O
DDB	B-GeneOrGeneProduct
motility	O
and	O
suggest	O
that	O
an	O
imbalance	O
of	O
minus	O
versus	O
plus	O
end	O
-	O
directed	O
microtubule	O
motility	O
in	O
neurons	O
may	O
underlie	O
spinal	B-DiseaseOrPhenotypicFeature
muscular	I-DiseaseOrPhenotypicFeature
atrophy	I-DiseaseOrPhenotypicFeature
.	O
Glucose	B-ChemicalEntity
metabolism	O
in	O
patients	O
with	O
schizophrenia	B-DiseaseOrPhenotypicFeature
treated	O
with	O
atypical	O
antipsychotic	B-ChemicalEntity
agents	I-ChemicalEntity
:	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-ChemicalEntity
tolerance	O
test	O
and	O
minimal	O
model	O
analysis	O
.	O

BACKGROUND	O
:	O
While	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
diabetes	B-DiseaseOrPhenotypicFeature
mellitus	I-DiseaseOrPhenotypicFeature
may	O
be	O
increasing	O
in	O
patients	O
with	O
schizophrenia	B-DiseaseOrPhenotypicFeature
treated	O
with	O
certain	O
atypical	O
antipsychotic	B-ChemicalEntity
agents	I-ChemicalEntity
,	O
it	O
remains	O
unclear	O
whether	O
atypical	O
agents	O
are	O
directly	O
affecting	O
glucose	B-ChemicalEntity
metabolism	O
or	O
simply	O
increasing	O
known	O
risk	O
factors	O
for	O
diabetes	B-DiseaseOrPhenotypicFeature
.	O

OBJECTIVE	O
:	O
To	O
study	O
the	O
2	O
drugs	O
most	O
clearly	O
implicated	O
(	O
clozapine	B-ChemicalEntity
and	O
olanzapine	B-ChemicalEntity
)	O
and	O
risperidone	B-ChemicalEntity
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-ChemicalEntity
tolerance	O
test	O
.	O

DESIGN	O
:	O
A	O
cross	O
-	O
sectional	O
design	O
in	O
stable	O
,	O
treated	O
patients	O
with	O
schizophrenia	B-DiseaseOrPhenotypicFeature
evaluated	O
using	O
a	O
frequently	O
sampled	O
intravenous	O
glucose	B-ChemicalEntity
tolerance	O
test	O
and	O
the	O
Bergman	O
minimal	O
model	O
analysis	O
.	O

SETTING	O
:	O
Subjects	O
were	O
recruited	O
from	O
an	O
urban	O
community	O
mental	O
health	O
clinic	O
and	O
were	O
studied	O
at	O
a	O
general	O
clinical	O
research	O
center	O
.	O

Patients	O
Fifty	O
subjects	O
signed	O
informed	O
consent	O
and	O
41	O
underwent	O
the	O
frequently	O
sampled	O
intravenous	O
glucose	B-ChemicalEntity
tolerance	O
test	O
.	O

Thirty	O
-	O
six	O
nonobese	O
subjects	O
with	O
schizophrenia	B-DiseaseOrPhenotypicFeature
or	O
schizoaffective	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
,	O
matched	O
by	O
body	O
mass	O
index	O
and	O
treated	O
with	O
either	O
clozapine	B-ChemicalEntity
,	O
olanzapine	B-ChemicalEntity
,	O
or	O
risperidone	B-ChemicalEntity
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
:	O
Fasting	O
plasma	O
glucose	B-ChemicalEntity
and	O
fasting	O
serum	O
insulin	B-ChemicalEntity
levels	O
,	O
insulin	O
sensitivity	O
index	O
,	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
,	O
and	O
glucose	B-ChemicalEntity
effectiveness	O
.	O

RESULTS	O
:	O
The	O
mean	O
+	O
/	O
-	O
SD	O
duration	O
of	O
treatment	O
with	O
the	O
identified	O
atypical	O
antipsychotic	B-ChemicalEntity
agent	I-ChemicalEntity
was	O
68	O
.	O
3	O
+	O
/	O
-	O
28	O
.	O
9	O
months	O
(	O
clozapine	B-ChemicalEntity
)	O
,	O
29	O
.	O
5	O
+	O
/	O
-	O
17	O
.	O
5	O
months	O
(	O
olanzapine	B-ChemicalEntity
)	O
,	O
and	O
40	O
.	O
9	O
+	O
/	O
-	O
33	O
.	O
7	O
(	O
risperidone	B-ChemicalEntity
)	O
.	O

Fasting	O
serum	O
insulin	B-ChemicalEntity
concentrations	O
differed	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
3	O
.	O
35	O
;	O
P	O
=	O
.	O
047	O
)	O
(	O
clozapine	B-ChemicalEntity
>	O
olanzapine	B-ChemicalEntity
>	O
risperidone	B-ChemicalEntity
)	O
with	O
significant	O
differences	O
between	O
clozapine	B-ChemicalEntity
and	O
risperidone	B-ChemicalEntity
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
32	O
;	O
P	O
=	O
.	O
03	O
)	O
and	O
olanzapine	B-ChemicalEntity
and	O
risperidone	B-ChemicalEntity
(	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
15	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
in	O
insulin	O
sensitivity	O
index	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
10	O
.	O
66	O
;	O
P	O
<	O
.	O
001	O
)	O
(	O
clozapine	B-ChemicalEntity
<	O
olanzapine	B-ChemicalEntity
<	O
risperidone	B-ChemicalEntity
)	O
,	O
with	O
subjects	O
who	O
received	O
clozapine	B-ChemicalEntity
and	O
olanzapine	B-ChemicalEntity
exhibiting	O
significant	O
insulin	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
compared	O
with	O
subjects	O
who	O
were	O
treated	O
with	O
risperidone	B-ChemicalEntity
(	O
clozapine	B-ChemicalEntity
vs	O
risperidone	B-ChemicalEntity
,	O
t	O
(	O
33	O
)	O
=	O
-	O
4	O
.	O
29	O
;	O
P	O
<	O
.	O
001	O
;	O
olanzapine	B-ChemicalEntity
vs	O
risperidone	B-ChemicalEntity
,	O
t	O
(	O
33	O
)	O
=	O
-	O
3	O
.	O
62	O
;	O
P	O
=	O
.	O
001	O
[	O
P	O
<	O
.	O
001	O
]	O
)	O
.	O

The	O
homeostasis	O
model	O
assessment	O
of	O
insulin	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
also	O
differed	O
significantly	O
among	O
groups	O
(	O
F	O
(	O
33	O
)	O
=	O
4	O
.	O
92	O
;	O
P	O
=	O
.	O
01	O
)	O
(	O
clozapine	B-ChemicalEntity
>	O
olanzapine	B-ChemicalEntity
>	O
risperidone	B-ChemicalEntity
)	O
(	O
clozapine	B-ChemicalEntity
vs	O
risperidone	B-ChemicalEntity
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
94	O
;	O
P	O
=	O
.	O
006	O
;	O
olanzapine	B-ChemicalEntity
vs	O
risperidone	B-ChemicalEntity
,	O
t	O
(	O
33	O
)	O
=	O
2	O
.	O
42	O
;	O
P	O
=	O
.	O
02	O
)	O
.	O

There	O
was	O
a	O
significant	O
difference	O
among	O
groups	O
in	O
glucose	B-ChemicalEntity
effectiveness	O
(	O
F	O
(	O
30	O
)	O
=	O
4	O
.	O
18	O
;	O
P	O
=	O
.	O
02	O
)	O
(	O
clozapine	B-ChemicalEntity
<	O
olanzapine	B-ChemicalEntity
<	O
risperidone	B-ChemicalEntity
)	O
with	O
significant	O
differences	O
between	O
clozapine	B-ChemicalEntity
and	O
risperidone	B-ChemicalEntity
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
59	O
;	O
P	O
=	O
.	O
02	O
)	O
and	O
olanzapine	B-ChemicalEntity
and	O
risperidone	B-ChemicalEntity
(	O
t	O
(	O
30	O
)	O
=	O
-	O
2	O
.	O
34	O
,	O
P	O
=	O
.	O
03	O
)	O
.	O

CONCLUSIONS	O
:	O
Both	O
nonobese	O
clozapine	B-ChemicalEntity
-	O
and	O
olanzapine	B-ChemicalEntity
-	O
treated	O
groups	O
displayed	O
significant	O
insulin	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
and	O
impairment	O
of	O
glucose	B-ChemicalEntity
effectiveness	O
compared	O
with	O
risperidone	B-ChemicalEntity
-	O
treated	O
subjects	O
.	O

Patients	O
taking	O
clozapine	B-ChemicalEntity
and	O
olanzapine	B-ChemicalEntity
must	O
be	O
examined	O
for	O
insulin	B-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
and	O
its	O
consequences	O
.	O
Debrisoquine	B-ChemicalEntity
phenotype	O
and	O
the	O
pharmacokinetics	O
and	O
beta	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
pharmacodynamics	O
of	O
metoprolol	B-ChemicalEntity
and	O
its	O
enantiomers	O
.	O

The	O
metabolism	O
of	O
the	O
cardioselective	O
beta	O
-	O
blocker	O
metoprolol	B-ChemicalEntity
is	O
under	O
genetic	O
control	O
of	O
the	O
debrisoquine	B-ChemicalEntity
/	O
sparteine	B-ChemicalEntity
type	O
.	O

The	O
two	O
metabolic	O
phenotypes	O
,	O
extensive	O
(	O
EM	O
)	O
and	O
poor	O
metabolizers	O
(	O
PM	O
)	O
,	O
show	O
different	O
stereoselective	O
metabolism	O
,	O
resulting	O
in	O
apparently	O
higher	O
beta	B-GeneOrGeneProduct
-	O
1	I-GeneOrGeneProduct
adrenoceptor	I-GeneOrGeneProduct
antagonistic	O
potency	O
of	O
racemic	O
metoprolol	B-ChemicalEntity
in	O
EMs	O
.	O

We	O
investigated	O
if	O
the	O
latter	O
also	O
applies	O
to	O
the	O
beta	B-GeneOrGeneProduct
-	O
2	I-GeneOrGeneProduct
adrenoceptor	I-GeneOrGeneProduct
antagonism	O
by	O
metoprolol	B-ChemicalEntity
.	O

The	O
drug	O
effect	O
studied	O
was	O
the	O
antagonism	O
by	O
metoprolol	B-ChemicalEntity
of	O
terbutaline	B-ChemicalEntity
-	O
induced	O
hypokalemia	B-DiseaseOrPhenotypicFeature
.	O

By	O
using	O
pharmacokinetic	O
pharmacodynamic	O
modeling	O
the	O
pharmacodynamics	O
of	O
racemic	O
metoprolol	B-ChemicalEntity
and	O
the	O
active	O
S	O
-	O
isomer	O
,	O
were	O
quantitated	O
in	O
EMs	O
and	O
PMs	O
in	O
terms	O
of	O
IC50	O
values	O
,	O
representing	O
metoprolol	B-ChemicalEntity
plasma	O
concentrations	O
resulting	O
in	O
half	O
-	O
maximum	O
receptor	O
occupancy	O
.	O

Six	O
EMs	O
received	O
0	O
.	O
5	O
mg	O
of	O
terbutaline	B-ChemicalEntity
s	O
.	O
c	O
.	O

on	O
two	O
different	O
occasions	O
:	O
1	O
)	O
1	O
hr	O
after	O
administration	O
of	O
a	O
placebo	O
and	O
2	O
)	O
1	O
hr	O
after	O
150	O
mg	O
of	O
metoprolol	B-ChemicalEntity
p	O
.	O
o	O
.	O

Five	O
PMs	O
were	O
studied	O
according	O
to	O
the	O
same	O
protocol	O
,	O
except	O
for	O
a	O
higher	O
terbutaline	B-ChemicalEntity
dose	O
(	O
0	O
.	O
75	O
mg	O
)	O
on	O
day	O
2	O
.	O

Blood	O
samples	O
for	O
the	O
analysis	O
of	O
plasma	O
potassium	B-ChemicalEntity
,	O
terbutaline	B-ChemicalEntity
,	O
metoprolol	B-ChemicalEntity
(	O
racemic	O
,	O
R	O
-	O
and	O
S	O
-	O
isomer	O
)	O
,	O
and	O
alpha	B-ChemicalEntity
-	O
hydroxymetoprolol	I-ChemicalEntity
concentrations	O
were	O
taken	O
at	O
regular	O
time	O
intervals	O
,	O
during	O
8	O
hr	O
after	O
metoprolol	B-ChemicalEntity
.	O

In	O
PMs	O
,	O
metoprolol	B-ChemicalEntity
increased	O
the	O
terbutaline	B-ChemicalEntity
area	O
under	O
the	O
plasma	O
concentration	O
vs	O
.	O

time	O
curve	O
(	O
+	O
67%	O
)	O
.	O

Higher	O
metoprolol	B-ChemicalEntity
/	O
alpha	B-ChemicalEntity
-	O
hydroxymetoprolol	I-ChemicalEntity
ratios	O
in	O
PMs	O
were	O
predictive	O
for	O
higher	O
R	O
-	O
/	O
S	O
-	O
isomer	O
ratios	O
of	O
unchanged	O
drug	O
.	O

There	O
was	O
a	O
difference	O
in	O
metoprolol	B-ChemicalEntity
potency	O
with	O
higher	O
racemic	O
metoprolol	B-ChemicalEntity
IC50	O
values	O
in	O
PMs	O
(	O
72	O
+	O
/	O
-	O
7	O
ng	O
.	O
ml	O
-	O
1	O
)	O
than	O
EMs	O
(	O
42	O
+	O
/	O
-	O
8	O
ng	O
.	O
ml	O
-	O
1	O
,	O
P	O
less	O
than	O
.	O
001	O
)	O
.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Dexrazoxane	B-ChemicalEntity
protects	O
against	O
myelosuppression	B-DiseaseOrPhenotypicFeature
from	O
the	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
etoposide	B-ChemicalEntity
and	O
daunorubicin	B-ChemicalEntity
but	O
not	O
doxorubicin	B-ChemicalEntity
.	O

PURPOSE	O
:	O
The	O
anthracyclines	B-ChemicalEntity
daunorubicin	B-ChemicalEntity
and	O
doxorubicin	B-ChemicalEntity
and	O
the	O
epipodophyllotoxin	B-ChemicalEntity
etoposide	B-ChemicalEntity
are	O
potent	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
;	O
however	O
,	O
myelosuppression	B-DiseaseOrPhenotypicFeature
and	O
cardiac	B-DiseaseOrPhenotypicFeature
toxicity	I-DiseaseOrPhenotypicFeature
limit	O
their	O
use	O
.	O

Dexrazoxane	B-ChemicalEntity
(	O
ICRF	B-ChemicalEntity
-	O
187	I-ChemicalEntity
)	O
is	O
recommended	O
for	O
protection	O
against	O
anthracycline	B-ChemicalEntity
-	O
induced	O
cardiotoxicity	B-DiseaseOrPhenotypicFeature
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Because	O
of	O
their	O
widespread	O
use	O
,	O
the	O
hematologic	B-DiseaseOrPhenotypicFeature
toxicity	I-DiseaseOrPhenotypicFeature
following	O
coadministration	O
of	O
dexrazoxane	B-ChemicalEntity
and	O
these	O
three	O
structurally	O
different	O
DNA	O
cleavage	O
enhancers	O
was	O
investigated	O
:	O
Sensitivity	O
of	O
human	B-OrganismTaxon
and	O
murine	B-OrganismTaxon
blood	O
progenitor	O
cells	O
to	O
etoposide	B-ChemicalEntity
,	O
daunorubicin	B-ChemicalEntity
,	O
and	O
doxorubicin	B-ChemicalEntity
+	O
/	O
-	O
dexrazoxane	B-ChemicalEntity
was	O
determined	O
in	O
granulocyte	O
-	O
macrophage	O
colony	O
forming	O
assays	O
.	O

Likewise	O
,	O
in	O
vivo	O
,	O
B6D2F1	O
mice	B-OrganismTaxon
were	O
treated	O
with	O
etoposide	B-ChemicalEntity
,	O
daunorubicin	B-ChemicalEntity
,	O
and	O
doxorubicin	B-ChemicalEntity
,	O
with	O
or	O
without	O
dexrazoxane	B-ChemicalEntity
over	O
a	O
wide	O
range	O
of	O
doses	O
:	O
posttreatment	O
,	O
a	O
full	O
hematologic	O
evaluation	O
was	O
done	O
.	O

RESULTS	O
:	O
Nontoxic	O
doses	O
of	O
dexrazoxane	B-ChemicalEntity
reduced	O
myelosuppression	B-DiseaseOrPhenotypicFeature
and	O
weight	B-DiseaseOrPhenotypicFeature
loss	I-DiseaseOrPhenotypicFeature
from	O
daunorubicin	B-ChemicalEntity
and	O
etoposide	B-ChemicalEntity
in	O
mice	B-OrganismTaxon
and	O
antagonized	O
their	O
antiproliferative	O
effects	O
in	O
the	O
colony	O
assay	O
;	O
however	O
,	O
dexrazoxane	B-ChemicalEntity
neither	O
reduced	O
myelosuppression	B-DiseaseOrPhenotypicFeature
,	O
weight	B-DiseaseOrPhenotypicFeature
loss	I-DiseaseOrPhenotypicFeature
,	O
nor	O
the	O
in	O
vitro	O
cytotoxicity	B-DiseaseOrPhenotypicFeature
from	O
doxorubicin	B-ChemicalEntity
.	O

CONCLUSION	O
:	O
Although	O
our	O
findings	O
support	O
the	O
observation	O
that	O
dexrazoxane	B-ChemicalEntity
reduces	O
neither	O
hematologic	O
activity	O
nor	O
antitumor	O
activity	O
from	O
doxorubicin	B-ChemicalEntity
clinically	O
,	O
the	O
potent	O
antagonism	O
of	O
daunorubicin	B-ChemicalEntity
activity	O
raises	O
concern	O
;	O
a	O
possible	O
interference	O
with	O
anticancer	O
efficacy	O
certainly	O
would	O
call	O
for	O
renewed	O
attention	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
significant	O
etoposide	B-ChemicalEntity
dose	O
escalation	O
is	O
perhaps	O
possible	O
by	O
the	O
use	O
of	O
dexrazoxane	B-ChemicalEntity
.	O

Clinical	O
trials	O
in	O
patients	O
with	O
brain	O
metastases	B-DiseaseOrPhenotypicFeature
combining	O
dexrazoxane	B-ChemicalEntity
and	O
high	O
doses	O
of	O
etoposide	B-ChemicalEntity
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
without	O
aggravating	O
hematologic	B-DiseaseOrPhenotypicFeature
toxicity	I-DiseaseOrPhenotypicFeature
.	O

If	O
successful	O
,	O
this	O
represents	O
an	O
exciting	O
mechanism	O
for	O
pharmacologic	O
regulation	O
of	O
side	O
effects	O
from	O
cytotoxic	B-DiseaseOrPhenotypicFeature
chemotherapy	O
.	O
GATA4	B-GeneOrGeneProduct
mutations	O
in	O
486	O
Chinese	O
patients	B-OrganismTaxon
with	O
congenital	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
.	O

Recent	O
studies	O
have	O
reported	O
germline	O
mutations	O
in	O
GATA4	B-GeneOrGeneProduct
gene	O
in	O
some	O
types	O
of	O
congenital	B-DiseaseOrPhenotypicFeature
heart	I-DiseaseOrPhenotypicFeature
disease	I-DiseaseOrPhenotypicFeature
(	O
CHD	B-DiseaseOrPhenotypicFeature
)	O
.	O

However	O
,	O
the	O
prevalence	O
of	O
GATA4	B-GeneOrGeneProduct
mutations	O
in	O
CHD	B-DiseaseOrPhenotypicFeature
and	O
the	O
correlation	O
between	O
the	O
GATA4	B-GeneOrGeneProduct
genotype	O
and	O
CHD	B-DiseaseOrPhenotypicFeature
phenotype	O
have	O
not	O
been	O
extensively	O
studied	O
.	O

We	O
screened	O
germline	O
mutations	O
in	O
the	O
coding	O
exons	O
and	O
the	O
flanking	O
intron	O
sequences	O
of	O
the	O
GATA4	B-GeneOrGeneProduct
gene	O
in	O
486	O
CHD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
by	O
denaturing	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
DHPLC	O
)	O
,	O
and	O
confirmed	O
the	O
mutations	O
by	O
sequencing	O
.	O

Nine	O
distinct	O
mutations	O
including	O
one	O
small	O
deletion	O
mutation	O
(	O
46delS	B-SequenceVariant
)	O
,	O
two	O
small	O
insertion	O
mutations	O
(	O
118	B-SequenceVariant
-	O
119insA	I-SequenceVariant
and	O
125	B-SequenceVariant
-	O
126insAA	I-SequenceVariant
)	O
,	O
and	O
six	O
non	O
-	O
synonymous	O
mutations	O
(	O
A6V	B-SequenceVariant
,	O
P163S	B-SequenceVariant
,	O
E359K	B-SequenceVariant
,	O
P407Q	B-SequenceVariant
,	O
S429T	B-SequenceVariant
and	O
A442V	B-SequenceVariant
)	O
were	O
identified	O
in	O
12	O
of	O
the	O
486	O
patients	B-OrganismTaxon
(	O
nine	O
with	O
ventricular	B-DiseaseOrPhenotypicFeature
septal	I-DiseaseOrPhenotypicFeature
defect	I-DiseaseOrPhenotypicFeature
,	O
two	O
with	O
Tetralogy	B-DiseaseOrPhenotypicFeature
of	I-DiseaseOrPhenotypicFeature
Fallot	I-DiseaseOrPhenotypicFeature
,	O
and	O
one	O
with	O
endocardial	B-DiseaseOrPhenotypicFeature
cushion	I-DiseaseOrPhenotypicFeature
defect	I-DiseaseOrPhenotypicFeature
)	O
.	O

Of	O
them	O
,	O
two	O
patients	B-OrganismTaxon
carrying	O
E359K	B-SequenceVariant
mutation	O
were	O
from	O
two	O
generations	O
in	O
one	O
family	O
with	O
ventricular	B-DiseaseOrPhenotypicFeature
septal	I-DiseaseOrPhenotypicFeature
defect	I-DiseaseOrPhenotypicFeature
(	O
VSD	B-DiseaseOrPhenotypicFeature
)	O
.	O

Interestingly	O
,	O
a	O
nucleotide	O
insertion	O
of	O
c	B-SequenceVariant
.	O
1146	I-SequenceVariant
+	O
25insA	I-SequenceVariant
in	O
exon	O
6	O
was	O
detected	O
in	O
five	O
VSD	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
but	O
not	O
in	O
486	O
normal	O
healthy	O
controls	O
.	O

Our	O
findings	O
are	O
useful	O
in	O
understanding	O
the	O
prevalence	O
of	O
GATA4	B-GeneOrGeneProduct
mutations	O
and	O
the	O
correlation	O
between	O
the	O
GATA4	B-GeneOrGeneProduct
genotype	O
and	O
the	O
CHD	B-DiseaseOrPhenotypicFeature
phenotype	O
in	O
Chinese	O
patients	B-OrganismTaxon
.	O
Two	O
novel	O
mutations	O
of	O
the	O
TSH	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
subunit	O
gene	O
underlying	O
congenital	B-DiseaseOrPhenotypicFeature
central	I-DiseaseOrPhenotypicFeature
hypothyroidism	I-DiseaseOrPhenotypicFeature
undetectable	O
in	O
neonatal	O
TSH	B-GeneOrGeneProduct
screening	O
.	O

CONTEXT	O
:	O
Patients	B-OrganismTaxon
with	O
TSH	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
subunit	O
defects	O
and	O
congenital	B-DiseaseOrPhenotypicFeature
hypothyroidism	I-DiseaseOrPhenotypicFeature
are	O
missed	O
by	O
TSH	B-GeneOrGeneProduct
-	O
based	O
neonatal	O
screening	O
.	O

OBJECTIVE	O
:	O
Our	O
objective	O
was	O
to	O
report	O
the	O
molecular	O
consequences	O
of	O
a	O
novel	O
splice	O
-	O
junction	O
mutation	O
and	O
a	O
novel	O
missense	O
mutation	O
in	O
the	O
TSH	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
subunit	O
gene	O
found	O
in	O
two	O
patients	B-OrganismTaxon
with	O
congenital	B-DiseaseOrPhenotypicFeature
central	I-DiseaseOrPhenotypicFeature
hypothyroidism	I-DiseaseOrPhenotypicFeature
and	O
conventional	O
treatment	O
-	O
resistant	O
anemia	B-DiseaseOrPhenotypicFeature
.	O

RESULTS	O
:	O
Patient	B-OrganismTaxon
1	O
had	O
a	O
homozygous	O
G	B-SequenceVariant
to	I-SequenceVariant
A	I-SequenceVariant
nucleotide	O
change	O
at	O
the	O
5	O
'	O
donor	O
splice	O
site	O
of	O
exon	O
/	O
intron	O
2	O
.	O

This	O
resulted	O
in	O
a	O
silent	O
change	O
at	O
codon	O
34	O
of	O
the	O
mature	O
protein	O
.	O

In	O
vitro	O
splicing	O
assays	O
showed	O
that	O
the	O
mutant	O
minigene	O
dramatically	O
affected	O
pre	O
-	O
mRNA	O
processing	O
,	O
causing	O
exon	O
2	O
to	O
be	O
completely	O
skipped	O
.	O

The	O
putative	O
product	O
from	O
a	O
new	O
out	O
-	O
of	O
-	O
frame	O
translational	O
start	O
point	O
in	O
exon	O
3	O
is	O
expected	O
to	O
yield	O
a	O
nonsense	O
25	O
-	O
amino	O
-	O
acid	O
peptide	O
.	O

In	O
patient	B-OrganismTaxon
2	O
,	O
sequence	O
analysis	O
revealed	O
a	O
compound	O
heterozygosis	O
for	O
the	O
already	O
reported	O
313delT	B-SequenceVariant
(	O
C105Vfs114X	B-SequenceVariant
)	O
mutation	O
and	O
for	O
a	O
second	O
novel	O
mutation	O
in	O
exon	O
3	O
,	O
substituting	O
G	B-SequenceVariant
for	I-SequenceVariant
A	I-SequenceVariant
at	I-SequenceVariant
cDNA	I-SequenceVariant
nucleotide	I-SequenceVariant
position	I-SequenceVariant
323	I-SequenceVariant
,	O
resulting	O
in	O
a	O
C88Y	B-SequenceVariant
change	O
.	O

This	O
cysteine	O
residue	O
is	O
conserved	O
among	O
all	O
dimeric	O
pituitary	O
and	O
placental	O
glycoprotein	B-GeneOrGeneProduct
hormone	I-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
subunits	I-GeneOrGeneProduct
.	O

Data	O
from	O
in	O
silico	O
analysis	O
confirmed	O
that	O
the	O
C88Y	B-SequenceVariant
mutation	O
would	O
affect	O
subunit	O
conformation	O
.	O

Indeed	O
,	O
two	O
different	O
bioinformatics	O
approaches	O
,	O
PolyPhen	O
and	O
SIFT	O
analysis	O
,	O
predicted	O
C88Y	B-SequenceVariant
to	O
be	O
a	O
damaging	O
substitution	O
.	O

CONCLUSIONS	O
:	O
In	O
isolated	O
TSH	B-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
,	O
the	O
exact	O
molecular	O
diagnosis	O
is	O
mandatory	O
for	O
diagnosis	O
of	O
isolated	B-DiseaseOrPhenotypicFeature
pituitary	I-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
,	O
delineation	O
of	O
prognosis	O
,	O
and	O
genetic	O
counseling	O
.	O

Moreover	O
,	O
diagnosis	O
of	O
central	B-DiseaseOrPhenotypicFeature
hypothyroidism	I-DiseaseOrPhenotypicFeature
should	O
be	O
considered	O
in	O
the	O
face	O
of	O
severe	O
infant	O
anemia	B-DiseaseOrPhenotypicFeature
of	O
uncertain	O
etiology	O
.	O
Characterization	O
of	O
a	O
novel	O
BCHE	B-GeneOrGeneProduct
""""	O
silent	O
""""	O
allele	O
:	O
point	O
mutation	O
(	O
p	B-SequenceVariant
.	O
Val204Asp	I-SequenceVariant
)	O
causes	O
loss	O
of	O
activity	O
and	O
prolonged	O
apnea	B-DiseaseOrPhenotypicFeature
with	O
suxamethonium	B-ChemicalEntity
.	O

Butyrylcholinesterase	B-DiseaseOrPhenotypicFeature
deficiency	I-DiseaseOrPhenotypicFeature
is	O
characterized	O
by	O
prolonged	O
apnea	B-DiseaseOrPhenotypicFeature
after	O
the	O
use	O
of	O
muscle	B-ChemicalEntity
relaxants	I-ChemicalEntity
(	O
suxamethonium	B-ChemicalEntity
or	O
mivacurium	B-ChemicalEntity
)	O
in	O
patients	B-OrganismTaxon
who	O
have	O
mutations	O
in	O
the	O
BCHE	B-GeneOrGeneProduct
gene	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
prolonged	O
neuromuscular	B-DiseaseOrPhenotypicFeature
block	I-DiseaseOrPhenotypicFeature
after	O
administration	O
of	O
suxamethonium	B-ChemicalEntity
leading	O
to	O
the	O
discovery	O
of	O
a	O
novel	O
BCHE	B-GeneOrGeneProduct
variant	O
(	O
c	B-SequenceVariant
.	O
695T	I-SequenceVariant
>	O
A	I-SequenceVariant
,	O
p	B-SequenceVariant
.	O
Val204Asp	I-SequenceVariant
)	O
.	O

Inhibition	O
studies	O
,	O
kinetic	O
analysis	O
and	O
molecular	O
dynamics	O
were	O
undertaken	O
to	O
understand	O
how	O
this	O
mutation	O
disrupts	O
the	O
catalytic	O
triad	O
and	O
determines	O
a	O
""""	O
silent	O
""""	O
phenotype	O
.	O

Low	O
activity	O
of	O
patient	B-OrganismTaxon
plasma	O
butyrylcholinesterase	B-GeneOrGeneProduct
with	O
butyrylthiocholine	B-ChemicalEntity
(	O
BTC	B-ChemicalEntity
)	O
and	O
benzoylcholine	B-ChemicalEntity
,	O
and	O
values	O
of	O
dibucaine	B-ChemicalEntity
and	O
fluoride	B-ChemicalEntity
numbers	O
fit	O
with	O
heterozygous	O
atypical	O
silent	O
genotype	O
.	O

Electrophoretic	O
analysis	O
of	O
plasma	O
BChE	B-GeneOrGeneProduct
of	O
the	O
proband	O
and	O
his	O
mother	O
showed	O
that	O
patient	B-OrganismTaxon
has	O
a	O
reduced	O
amount	O
of	O
tetrameric	O
enzyme	O
in	O
plasma	O
and	O
that	O
minor	O
fast	O
-	O
moving	O
BChE	B-GeneOrGeneProduct
components	O
:	O
monomer	O
,	O
dimer	O
,	O
and	O
monomer	O
-	O
albumin	O
conjugate	O
are	O
missing	O
.	O

Kinetic	O
analysis	O
showed	O
that	O
the	O
p	B-SequenceVariant
.	O
Val204Asp	I-SequenceVariant
/	O
p	B-SequenceVariant
.	O
Asp70Gly	I-SequenceVariant
-	O
p	B-SequenceVariant
.	O
Ala539Thr	I-SequenceVariant
BChE	B-GeneOrGeneProduct
displays	O
a	O
pure	O
Michaelian	O
behavior	O
with	O
BTC	B-ChemicalEntity
as	O
the	O
substrate	O
.	O

Both	O
catalytic	O
parameters	O
Km	O
=	O
265	O
uM	O
for	O
BTC	B-ChemicalEntity
,	O
two	O
times	O
higher	O
than	O
that	O
of	O
the	O
atypical	O
enzyme	O
,	O
and	O
a	O
low	O
Vmax	O
are	O
consistent	O
with	O
the	O
absence	O
of	O
activity	O
against	O
suxamethonium	B-ChemicalEntity
.	O

Molecular	O
dynamic	O
(	O
MD	O
)	O
simulations	O
showed	O
that	O
the	O
overall	O
effect	O
of	O
the	O
mutation	O
p	B-SequenceVariant
.	O
Val204Asp	I-SequenceVariant
is	O
disruption	O
of	O
hydrogen	O
bonding	O
between	O
Gln223	B-SequenceVariant
and	O
Glu441	B-SequenceVariant
,	O
leading	O
Ser198	B-SequenceVariant
and	O
His438	B-SequenceVariant
to	O
move	O
away	O
from	O
each	O
other	O
with	O
subsequent	O
disruption	O
of	O
the	O
catalytic	O
triad	O
functionality	O
regardless	O
of	O
the	O
type	O
of	O
substrate	O
.	O

MD	O
also	O
showed	O
that	O
the	O
enzyme	O
volume	O
is	O
increased	O
,	O
suggesting	O
a	O
pre	O
-	O
denaturation	O
state	O
.	O

This	O
fits	O
with	O
the	O
reduced	O
concentration	O
of	O
p	B-SequenceVariant
.	O
Ala204Asp	I-SequenceVariant
/	O
p	B-SequenceVariant
.	O
Asp70Gly	I-SequenceVariant
-	O
p	B-SequenceVariant
.	O
Ala539Thr	I-SequenceVariant
tetrameric	O
enzyme	O
in	O
the	O
plasma	O
and	O
non	O
-	O
detectable	O
fast	O
moving	O
-	O
bands	O
on	O
electrophoresis	O
gels	O
.	O
The	O
promoter	O
of	O
inducible	O
nitric	B-GeneOrGeneProduct
oxide	I-GeneOrGeneProduct
synthase	I-GeneOrGeneProduct
implicated	O
in	O
glaucoma	B-DiseaseOrPhenotypicFeature
based	O
on	O
genetic	O
analysis	O
and	O
nuclear	O
factor	O
binding	O
.	O

PURPOSE	O
:	O
Nitric	B-ChemicalEntity
oxide	I-ChemicalEntity
has	O
many	O
beneficial	O
functions	O
in	O
the	O
human	B-OrganismTaxon
body	O
at	O
the	O
right	O
amounts	O
,	O
but	O
it	O
can	O
also	O
be	O
hazardous	O
if	O
it	O
is	O
produced	O
in	O
amounts	O
more	O
than	O
needed	O
and	O
has	O
therefore	O
been	O
studied	O
in	O
relation	O
to	O
several	O
neurological	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
non	I-DiseaseOrPhenotypicFeature
-	O
neurological	I-DiseaseOrPhenotypicFeature
disorders	I-DiseaseOrPhenotypicFeature
.	O

In	O
vitro	O
and	O
in	O
vivo	O
studies	O
demonstrate	O
a	O
connection	O
between	O
the	O
inducible	O
form	O
of	O
Nitric	B-GeneOrGeneProduct
Oxide	I-GeneOrGeneProduct
Synthase	I-GeneOrGeneProduct
,	O
iNOS	B-GeneOrGeneProduct
,	O
and	O
the	O
neuropathological	B-DiseaseOrPhenotypicFeature
disorder	I-DiseaseOrPhenotypicFeature
glaucoma	I-DiseaseOrPhenotypicFeature
,	O
one	O
of	O
the	O
major	O
causes	O
of	O
blindness	B-DiseaseOrPhenotypicFeature
in	O
the	O
world	O
.	O

In	O
this	O
study	O
,	O
we	O
sought	O
to	O
establish	O
the	O
genetic	O
association	O
between	O
iNOS	B-GeneOrGeneProduct
and	O
primary	B-DiseaseOrPhenotypicFeature
open	I-DiseaseOrPhenotypicFeature
angle	I-DiseaseOrPhenotypicFeature
glaucoma	I-DiseaseOrPhenotypicFeature
,	O
POAG	B-DiseaseOrPhenotypicFeature
,	O
and	O
to	O
find	O
the	O
functional	O
element	O
(	O
s	O
)	O
connected	O
with	O
the	O
pathogenesis	O
of	O
the	O
disease	O
.	O

METHODS	O
:	O
Two	O
microsatellites	O
,	O
1	O
insertion	O
/	O
deletion	O
,	O
and	O
8	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNPs	O
)	O
in	O
the	O
regulatory	O
region	O
of	O
iNOS	B-GeneOrGeneProduct
were	O
genotyped	O
in	O
200	O
POAG	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
and	O
200	O
age	O
-	O
matched	O
controls	O
.	O

Also	O
,	O
the	O
CCTTT	O
-	O
microsatellite	O
was	O
examined	O
for	O
its	O
protein	O
-	O
binding	O
capability	O
in	O
an	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
EMSA	O
.	O

RESULTS	O
:	O
There	O
was	O
a	O
significant	O
difference	O
in	O
allele	O
distribution	O
of	O
the	O
CCTTT	O
-	O
microsatellite	O
,	O
between	O
patients	B-OrganismTaxon
and	O
controls	O
.	O

(	O
CCTTT	I-SequenceVariant
)	O
14	I-SequenceVariant
,	O
which	O
has	O
been	O
reported	O
to	O
have	O
a	O
higher	O
activity	O
in	O
a	O
reporter	O
-	O
construct	O
,	O
was	O
significantly	O
more	O
abundant	O
in	O
POAG	B-DiseaseOrPhenotypicFeature
patients	B-OrganismTaxon
,	O
while	O
(	O
CCTTT	I-SequenceVariant
)	O
10	I-SequenceVariant
and	O
(	O
CCTTT	I-SequenceVariant
)	O
13	I-SequenceVariant
were	O
less	O
common	O
.	O

In	O
EMSA	O
,	O
the	O
(	O
CCTTT	I-SequenceVariant
)	O
14	I-SequenceVariant
allele	O
exhibited	O
specific	O
binding	O
of	O
nuclear	O
proteins	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
,	O
together	O
with	O
other	O
studies	O
on	O
this	O
gene	O
and	O
the	O
CCTTT	O
-	O
microsatellite	O
,	O
establish	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
genetic	O
association	O
of	O
iNOS	B-GeneOrGeneProduct
with	O
POAG	B-DiseaseOrPhenotypicFeature
and	O
suggest	O
a	O
regulatory	O
function	O
for	O
the	O
microsatellite	O
.	O
Severe	O
form	O
of	O
thyroid	B-DiseaseOrPhenotypicFeature
hormone	I-DiseaseOrPhenotypicFeature
resistance	I-DiseaseOrPhenotypicFeature
in	O
a	O
patient	B-OrganismTaxon
with	O
homozygous	O
/	O
hemizygous	O
mutation	O
of	O
T3	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
gene	O
.	O

Resistance	B-DiseaseOrPhenotypicFeature
to	I-DiseaseOrPhenotypicFeature
thyroid	I-DiseaseOrPhenotypicFeature
hormone	I-DiseaseOrPhenotypicFeature
syndrome	I-DiseaseOrPhenotypicFeature
(	O
RTH	B-DiseaseOrPhenotypicFeature
)	O
is	O
a	O
rare	O
disorder	O
,	O
usually	O
inherited	O
as	O
an	O
autosomal	O
dominant	O
trait	O
.	O

Patients	B-OrganismTaxon
with	O
RTH	B-DiseaseOrPhenotypicFeature
are	O
usually	O
euthyroid	O
but	O
can	O
occasionally	O
present	O
with	O
signs	O
and	O
symptoms	O
of	O
thyrotoxicosis	B-DiseaseOrPhenotypicFeature
or	O
rarely	O
with	O
hypothyroidism	B-DiseaseOrPhenotypicFeature
.	O

Affected	O
individuals	O
are	O
usually	O
heterozygous	O
for	O
mutations	O
in	O
the	O
thyroid	B-GeneOrGeneProduct
hormone	I-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
beta	I-GeneOrGeneProduct
gene	O
(	O
TR	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
)	O
.	O

We	O
present	O
a	O
patient	B-OrganismTaxon
with	O
RTH	B-DiseaseOrPhenotypicFeature
found	O
to	O
be	O
homo	O
-	O
/	O
hemizygous	O
for	O
a	O
mutation	O
in	O
the	O
TR	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
gene	O
.	O

The	O
single	O
nucleotide	O
substitution	O
I280S	B-SequenceVariant
(	O
1123T	B-SequenceVariant
-	O
-	O
>	O
G	I-SequenceVariant
)	O
was	O
present	O
either	O
on	O
both	O
alleles	O
or	O
in	O
a	O
hemizygous	O
form	O
with	O
complete	O
deletion	O
of	O
the	O
second	O
allele	O
.	O

The	O
I280S	B-SequenceVariant
mutation	O
was	O
recently	O
reported	O
in	O
a	O
heterozygous	O
patient	B-OrganismTaxon
.	O

The	O
severe	O
phenotype	O
with	O
seriously	O
impaired	B-DiseaseOrPhenotypicFeature
intellectual	I-DiseaseOrPhenotypicFeature
development	I-DiseaseOrPhenotypicFeature
,	O
hyperkinetic	B-DiseaseOrPhenotypicFeature
behaviour	O
,	O
tachycardia	B-DiseaseOrPhenotypicFeature
,	O
hearing	B-DiseaseOrPhenotypicFeature
and	I-DiseaseOrPhenotypicFeature
visual	I-DiseaseOrPhenotypicFeature
impairment	I-DiseaseOrPhenotypicFeature
is	O
probably	O
due	O
to	O
the	O
dominant	O
negative	O
effect	O
of	O
the	O
I280S	B-SequenceVariant
mutant	O
protein	O
and	O
the	O
absence	O
of	O
any	O
functional	O
TR	B-GeneOrGeneProduct
-	O
beta	I-GeneOrGeneProduct
.	O
The	O
androgen	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
confers	O
protection	O
against	O
diet	O
-	O
induced	O
atherosclerosis	B-DiseaseOrPhenotypicFeature
,	O
obesity	B-DiseaseOrPhenotypicFeature
,	O
and	O
dyslipidemia	B-DiseaseOrPhenotypicFeature
in	O
female	O
mice	B-OrganismTaxon
.	O

Androgens	B-ChemicalEntity
have	O
important	O
cardiometabolic	O
actions	O
in	O
males	O
,	O
but	O
their	O
metabolic	O
role	O
in	O
females	O
is	O
unclear	O
.	O

To	O
determine	O
the	O
physiologic	O
androgen	B-GeneOrGeneProduct
receptor	I-GeneOrGeneProduct
(	O
AR	B-GeneOrGeneProduct
)	O
-	O
dependent	O
actions	O
of	O
androgens	B-ChemicalEntity
on	O
atherogenesis	B-DiseaseOrPhenotypicFeature
in	O
female	O
mice	B-OrganismTaxon
,	O
we	O
generated	O
female	O
AR	B-GeneOrGeneProduct
-	O
knockout	O
(	O
ARKO	B-GeneOrGeneProduct
)	O
mice	B-OrganismTaxon
on	O
an	O
atherosclerosis	B-DiseaseOrPhenotypicFeature
-	O
prone	O
apolipoprotein	B-GeneOrGeneProduct
E	I-GeneOrGeneProduct
(	O
apoE	B-GeneOrGeneProduct
)	O
-	O
deficient	O
background	O
.	O

After	O
8	O
weeks	O
on	O
a	O
high	O
-	O
fat	O
diet	O
,	O
but	O
not	O
on	O
a	O
normal	O
chow	O
diet	O
,	O
atherosclerosis	B-DiseaseOrPhenotypicFeature
in	O
aorta	O
was	O
increased	O
in	O
ARKO	B-GeneOrGeneProduct
females	O
(	O
+	O
59%	O
vs	O
.	O

control	O
apoE	B-GeneOrGeneProduct
-	O
deficient	O
mice	B-OrganismTaxon
with	O
intact	O
AR	B-GeneOrGeneProduct
gene	O
)	O
.	O

They	O
also	O
displayed	O
increased	O
body	O
weight	O
(	O
+	O
18%	O
)	O
,	O
body	O
fat	O
percentage	O
(	O
+	O
62%	O
)	O
,	O
and	O
hepatic	O
triglyceride	B-GeneOrGeneProduct
levels	O
,	O
reduced	O
insulin	B-GeneOrGeneProduct
sensitivity	O
,	O
and	O
a	O
marked	O
atherogenic	B-DiseaseOrPhenotypicFeature
dyslipidemia	B-DiseaseOrPhenotypicFeature
(	O
serum	O
cholesterol	B-ChemicalEntity
,	O
+	O
52%	O
)	O
.	O

Differences	O
in	O
atherosclerosis	B-DiseaseOrPhenotypicFeature
,	O
body	O
weight	O
,	O
and	O
lipid	B-ChemicalEntity
levels	O
between	O
ARKO	B-GeneOrGeneProduct
and	O
control	O
mice	B-OrganismTaxon
were	O
abolished	O
in	O
mice	B-OrganismTaxon
that	O
were	O
ovariectomized	O
before	O
puberty	O
,	O
consistent	O
with	O
a	O
protective	O
action	O
of	O
ovarian	O
androgens	B-ChemicalEntity
mediated	O
via	O
the	O
AR	B-GeneOrGeneProduct
.	O

Furthermore	O
,	O
the	O
AR	B-GeneOrGeneProduct
agonist	O
dihydrotestosterone	B-ChemicalEntity
reduced	O
atherosclerosis	B-DiseaseOrPhenotypicFeature
(	O
-	O
41%	O
;	O
thoracic	O
aorta	O
)	O
,	O
subcutaneous	O
fat	O
mass	O
(	O
-	O
44%	O
)	O
,	O
and	O
cholesterol	B-ChemicalEntity
levels	O
(	O
-	O
35%	O
)	O
in	O
ovariectomized	O
mice	B-OrganismTaxon
,	O
reduced	O
hepatocyte	O
lipid	B-ChemicalEntity
accumulation	O
in	O
hepatoma	B-DiseaseOrPhenotypicFeature
cells	O
in	O
vitro	O
,	O
and	O
regulated	O
mRNA	O
expression	O
of	O
hepatic	O
genes	O
pivotal	O
for	O
lipid	B-ChemicalEntity
homeostasis	O
.	O

In	O
conclusion	O
,	O
we	O
demonstrate	O
that	O
the	O
AR	B-GeneOrGeneProduct
protects	O
against	O
diet	O
-	O
induced	O
atherosclerosis	B-DiseaseOrPhenotypicFeature
in	O
female	O
mice	B-OrganismTaxon
and	O
propose	O
that	O
this	O
is	O
mediated	O
by	O
modulation	O
of	O
body	O
composition	O
and	O
lipid	B-ChemicalEntity
metabolism	O
.	O
Macular	B-DiseaseOrPhenotypicFeature
corneal	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
in	O
a	O
Chinese	O
family	O
related	O
with	O
novel	O
mutations	O
of	O
CHST6	B-GeneOrGeneProduct
.	O

PURPOSE	O
:	O
To	O
identify	O
mutations	O
in	O
the	O
carbohydrate	B-GeneOrGeneProduct
sulfotransferase	I-GeneOrGeneProduct
gene	I-GeneOrGeneProduct
(	O
CHST6	B-GeneOrGeneProduct
)	O
for	O
a	O
Chinese	O
family	O
with	O
macular	B-DiseaseOrPhenotypicFeature
corneal	I-DiseaseOrPhenotypicFeature
dystrophy	I-DiseaseOrPhenotypicFeature
(	O
MCD	B-DiseaseOrPhenotypicFeature
)	O
and	O
to	O
investigate	O
the	O
histopathological	O
changes	O
in	O
the	O
affected	O
cornea	O
.	O

METHODS	O
:	O
A	O
corneal	O
button	O
of	O
the	O
proband	O
was	O
obtained	O
by	O
penetrating	O
keratoplasty	O
.	O

The	O
half	O
button	O
and	O
ultrathin	O
sections	O
from	O
the	O
other	O
half	O
button	O
were	O
examined	O
with	O
special	O
stains	O
under	O
a	O
light	O
microscope	O
(	O
LM	O
)	O
and	O
an	O
electron	O
microscope	O
(	O
EM	O
)	O
separately	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
peripheral	O
blood	O
of	O
11	O
family	O
members	O
,	O
and	O
the	O
coding	O
region	O
of	O
CHST6	B-GeneOrGeneProduct
was	O
amplified	O
by	O
the	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
method	O
.	O

The	O
PCR	O
products	O
were	O
analyzed	O
by	O
direct	O
sequencing	O
and	O
restriction	O
enzyme	O
digestion	O
.	O

RESULTS	O
:	O
The	O
positive	O
reaction	O
to	O
colloidal	O
iron	B-ChemicalEntity
stain	O
(	O
extracellular	O
blue	O
accumulations	O
in	O
the	O
stroma	O
)	O
was	O
detected	O
under	O
light	O
microscopy	O
.	O

Transmission	O
electron	O
microscopy	O
revealed	O
the	O
enlargement	O
of	O
smooth	O
endoplasmic	O
reticulum	O
and	O
the	O
presence	O
of	O
intracytoplasmic	O
vacuoles	O
.	O

The	O
compound	O
heterozygous	O
mutations	O
,	O
c	B-SequenceVariant
.	O
892C	I-SequenceVariant
>	O
T	I-SequenceVariant
and	O
c	B-SequenceVariant
.	O
1072T	I-SequenceVariant
>	O
C	I-SequenceVariant
,	O
were	O
identified	O
in	O
exon	O
3	O
of	O
CHST6	B-GeneOrGeneProduct
in	O
three	O
patients	B-OrganismTaxon
.	O

The	O
two	O
transversions	O
resulted	O
in	O
the	O
substitution	O
of	O
a	O
stop	B-SequenceVariant
codon	I-SequenceVariant
for	I-SequenceVariant
glutamine	I-SequenceVariant
at	I-SequenceVariant
codon	I-SequenceVariant
298	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Q298X	I-SequenceVariant
)	O
and	O
a	O
missense	O
mutation	O
at	O
codon	B-SequenceVariant
358	I-SequenceVariant
,	O
tyrosine	I-SequenceVariant
to	I-SequenceVariant
histidine	I-SequenceVariant
(	O
p	B-SequenceVariant
.	O
Y358H	I-SequenceVariant
)	O
.	O

The	O
six	O
unaffected	O
family	O
individuals	O
carried	O
alternative	O
heterozygous	O
mutations	O
.	O

These	O
two	O
mutations	O
were	O
not	O
detected	O
in	O
any	O
of	O
the	O
100	O
control	O
subjects	O
.	O

CONCLUSIONS	O
:	O
Those	O
novel	O
compound	O
heterozygous	O
mutations	O
were	O
thought	O
to	O
contribute	O
to	O
the	O
loss	O
of	O
CHST6	B-GeneOrGeneProduct
function	O
,	O
which	O
induced	O
the	O
abnormal	O
metabolism	O
of	O
keratan	B-ChemicalEntity
sulfate	I-ChemicalEntity
(	O
KS	B-ChemicalEntity
)	O
that	O
deposited	O
in	O
the	O
corneal	O
stroma	O
.	O

It	O
could	O
be	O
proved	O
by	O
the	O
observation	O
of	O
a	O
positive	O
stain	O
reaction	O
and	O
the	O
enlarged	O
collagen	B-GeneOrGeneProduct
fibers	O
as	O
well	O
as	O
hyperplastic	O
fibroblasts	O
under	O
microscopes	O
.	O
